<?xml version='1.0' encoding='ASCII'?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:slxn="http://www.silexion.com/20240630" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
  <title>Silexion Therapeutics Corp - 2022416 - 2024</title>
</head>
<body><div style="font-size: 10pt;"><div style="font-size: 10pt;">

<div style="display:none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20230630_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToIPOMember" id="Fxbrl_20241004173820946">P0Y</ix:nonNumeric>
    <ix:nonNumeric name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermGranted" contextRef="C_20230101to20231231" id="Fxbrl_20241004180444170">P0Y</ix:nonNumeric>
    <ix:nonNumeric name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExercised" contextRef="C_20230101to20231231" id="Fxbrl_20241004180513328">P0Y</ix:nonNumeric>
    <ix:nonNumeric name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermForfeited" contextRef="C_20230101to20231231" id="Fxbrl_20241004180602489">P0Y</ix:nonNumeric>
    <ix:nonNumeric name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExpired" contextRef="C_20230101to20231231" id="Fxbrl_20241004180730561">P0Y</ix:nonNumeric>
    <ix:nonNumeric name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExpired" contextRef="C_20220101to20221231" id="Fxbrl_20241004180813329">P0Y</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20240101to20240630" id="Fxbrl_20241004172251986" unitRef="usd" scale="3" decimals="-3">0</ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20240101to20240630" id="Fxbrl_20241004172316778" unitRef="usd" scale="3" decimals="-3">0</ix:nonFraction>
    <ix:footnote id="FN20241004172411305" xml:lang="en-US">Represents an amount less than $1</ix:footnote>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fhidden-fact-88" unitRef="usd" scale="0" decimals="0">0</ix:nonFraction>
    <ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20240101to20240630" id="Fixv-39817">false</ix:nonNumeric>
    <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20240101to20240630" id="Fixv-39818">0002022416</ix:nonNumeric>
    <ix:footnote id="FN20241004135506058" xml:lang="en-US">Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.</ix:footnote>
    <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToIPOMember" id="Fxbrl_20241004181424317">P0Y</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" id="Fxbrl_20241004054608864_hidden-fact-3" unitRef="usd" scale="3" decimals="-3">0</ix:nonFraction>
    <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" id="Fxbrl_20241004054608864_hidden-fact-2" unitRef="usd" scale="3" decimals="-3">0</ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fhidden-fact-70" unitRef="usd" scale="0" decimals="0">0</ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fhidden-fact-71" unitRef="usd" scale="0" decimals="0">0</ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fhidden-fact-72" unitRef="usd" scale="0" decimals="0">0</ix:nonFraction>
    <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" id="Fhidden-fact-12" unitRef="usd" scale="3" decimals="-3">0</ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fhidden-fact-92" unitRef="usd" scale="3" decimals="-3">0</ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" id="Fhidden-fact-93" unitRef="usd" scale="3" decimals="-3">0</ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapParentMember" id="Fhidden-fact-94" unitRef="usd" scale="3" decimals="-3">0</ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20240630" id="Fhidden-fact-95" unitRef="usd" scale="3" decimals="-3">0</ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fhidden-fact-104" unitRef="usd" scale="3" decimals="-3">0</ix:nonFraction>
    </ix:hidden>
  <ix:references> <link:schemaRef xlink:type="simple" xlink:href="slxn-20240630.xsd"/>
    </ix:references>
  <ix:resources>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ClassAOrdinaryShareSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ClassAOrdinaryShareSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:NonredeemableClassAandBOrdinaryShareMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:NonredeemableClassAandBOrdinaryShareMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapMeasurementInputTypeAxis_slxnProbabilityOfAnIPOScenarioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ProbabilityOfAnIPOScenarioMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedTimeToIPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapMeasurementInputTypeAxis_slxnProbabilityOfOtherLiquidationEventsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ProbabilityOfOtherLiquidationEventsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapMeasurementInputTypeAxis_slxnProbabilityOfOtherLiquidationEventsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ProbabilityOfOtherLiquidationEventsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToLiquidationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedTimeToLiquidationMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToLiquidationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedTimeToLiquidationMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapMeasurementInputTypeAxis_slxnExpectedReturnOnEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedReturnOnEquityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapMeasurementInputTypeAxis_slxnExpectedReturnOnEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedReturnOnEquityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapMeasurementInputTypeAxis_slxnProbabilityOfAnIPOScenarioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ProbabilityOfAnIPOScenarioMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedTimeToIPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtOwnershipAxis_slxnSilexionEquityFinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">slxn:SilexionEquityFinancingMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtStatementGeographicalAxis_countryCN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtStatementGeographicalAxis_countryIL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtStatementGeographicalAxis_countryIL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtStatementGeographicalAxis_slxnSubsidiaryOutsideOfIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">slxn:SubsidiaryOutsideOfIsraelMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtStatementGeographicalAxis_slxnSubsidiaryOutsideOfIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">slxn:SubsidiaryOutsideOfIsraelMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ClassAOrdinaryShareSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ClassAOrdinaryShareSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ClassAOrdinaryShareSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ClassAOrdinaryShareSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:NonredeemableClassAandBOrdinaryShareMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:NonredeemableClassAandBOrdinaryShareMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:NonredeemableClassAandBOrdinaryShareMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:NonredeemableClassAandBOrdinaryShareMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAPreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAOnePreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAOnePreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesA2PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesA2PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAThreePreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAThreePreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAFourPreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAFourPreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAPreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFinancialInstrumentAxis_slxnTenthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">slxn:TenthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFinancialInstrumentAxis_slxnEighthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">slxn:EighthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240806_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtStatementScenarioAxis_srtScenarioForecastMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinarySharesSubjectToPossibleRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ClassAOrdinarySharesSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-08-06</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240806_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtStatementScenarioAxis_srtScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-08-06</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnLaboratoryAndElectronicEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">slxn:LaboratoryAndElectronicEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-01-01</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210809_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSecondPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SecondPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-08-09</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnThirdAndFourthPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:ThirdAndFourthPromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230208_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnFifthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:FifthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-02-08</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFinancialInstrumentAxis_slxnPrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">slxn:PrivateWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230209_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SixthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-02-09</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SixthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-02-19</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230614_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSeventhPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SeventhPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-14</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230614to20230614_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSeventhPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SeventhPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-14</xbrli:startDate>
        <xbrli:endDate>2023-06-14</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSeventhPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SeventhPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230818_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnEighthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:EighthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-08-18</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230819to20230819_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnEighthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:EighthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-19</xbrli:startDate>
        <xbrli:endDate>2023-08-19</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201216_slxnTypeOfAgreementAxis_slxnAdministrativeServicesAgreementMember_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="slxn:TypeOfAgreementAxis">slxn:AdministrativeServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-12-16</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:PromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:PromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapAssetManagementArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:AssetManagementArrangementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapAssetManagementArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:AssetManagementArrangementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">slxn:SAFEMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">slxn:SAFEMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfAnIPOScenarioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ProbabilityOfAnIPOScenarioMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedTimeToIPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfOtherLiquidationEventsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ProbabilityOfOtherLiquidationEventsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfOtherLiquidationEventsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ProbabilityOfOtherLiquidationEventsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToLiquidationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedTimeToLiquidationMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToLiquidationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedTimeToLiquidationMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnExpectedReturnOnEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedReturnOnEquityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnExpectedReturnOnEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedReturnOnEquityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">slxn:SAFEMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfAnIPOScenarioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ProbabilityOfAnIPOScenarioMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedTimeToIPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapClassOfWarrantOrRightAxis_slxnPublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">slxn:PublicWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapClassOfWarrantOrRightAxis_slxnPrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">slxn:PrivateWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtTitleOfIndividualAxis_slxnSecondThirdForthAndFifthPromissoryNotesMember_usgaapDerivativeInstrumentRiskAxis_slxnPrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">slxn:SecondThirdForthAndFifthPromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">slxn:PrivateWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtTitleOfIndividualAxis_slxnSecondThirdForthAndFifthPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">slxn:SecondThirdForthAndFifthPromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220114">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-01-14</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220114_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-01-14</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230530to20230530">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-30</xbrli:startDate>
        <xbrli:endDate>2023-05-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230530_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-05-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230530to20230530_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-30</xbrli:startDate>
        <xbrli:endDate>2023-05-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230530to20230530_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtSubsidiariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-30</xbrli:startDate>
        <xbrli:endDate>2023-05-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230530">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-05-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210315to20210315_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-15</xbrli:startDate>
        <xbrli:endDate>2021-03-15</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">slxn:SAFEMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220114to20220114">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-14</xbrli:startDate>
        <xbrli:endDate>2022-01-14</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220114_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-01-14</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240704_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-07-04</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240704to20240704_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-04</xbrli:startDate>
        <xbrli:endDate>2024-07-04</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240805to20240805_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnGuangzhouSinoIsraelBiotechInvestmentFundMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:GuangzhouSinoIsraelBiotechInvestmentFundMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-05</xbrli:startDate>
        <xbrli:endDate>2024-08-05</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240831_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-08-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240831_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-08-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-11-20</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-19</xbrli:startDate>
        <xbrli:endDate>2021-02-19</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-03</xbrli:startDate>
        <xbrli:endDate>2021-03-03</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-02-19</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-03-03</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_slxnPublicOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">slxn:PublicOfferingMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-19</xbrli:startDate>
        <xbrli:endDate>2021-02-19</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-03</xbrli:startDate>
        <xbrli:endDate>2021-03-03</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnFirstExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:FirstExtensionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnSecondExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:SecondExtensionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-11-20</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201120to20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-20</xbrli:startDate>
        <xbrli:endDate>2020-11-20</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapAwardTypeAxis_slxnPreFundedOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">slxn:PreFundedOptionsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapAwardTypeAxis_slxnPreFundedOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">slxn:PreFundedOptionsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230615_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-15</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240221_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-02-21</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtOwnershipAxis_slxnSilexionEquityFinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">slxn:SilexionEquityFinancingMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapBusinessAcquisitionAxis_slxnNewPubcoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">slxn:NewPubcoMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240618_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSilexionEquityFinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">slxn:SilexionEquityFinancingMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-18</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240618to20240618_srtRangeAxis_srtMinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-18</xbrli:startDate>
        <xbrli:endDate>2024-06-18</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240618to20240618_srtRangeAxis_srtMaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-18</xbrli:startDate>
        <xbrli:endDate>2024-06-18</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240618">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-18</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240618to20240618_srtRangeAxis_srtMinimumMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnNewPubcoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">slxn:NewPubcoMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-18</xbrli:startDate>
        <xbrli:endDate>2024-06-18</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240618to20240618_srtRangeAxis_srtMaximumMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnNewPubcoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">slxn:NewPubcoMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-18</xbrli:startDate>
        <xbrli:endDate>2024-06-18</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240618to20240618">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-18</xbrli:startDate>
        <xbrli:endDate>2024-06-18</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSPACMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SPACMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnNewPubcoMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:NewPubcoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnNewPubcoMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:NewPubcoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnLegalExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:LegalExpensesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnLegalExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:LegalExpensesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnAuditBookkeepingAndAccountingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:AuditBookkeepingAndAccountingMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnAuditBookkeepingAndAccountingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:AuditBookkeepingAndAccountingMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnProfessionalServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:ProfessionalServicesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnProfessionalServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:ProfessionalServicesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnManagementFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:ManagementFeesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnManagementFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:ManagementFeesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnInsuranceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:InsuranceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnInsuranceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:InsuranceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnNasdaqFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:NasdaqFeesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnNasdaqFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:NasdaqFeesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnOtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:OtherExpensesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnOtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:OtherExpensesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnFirstExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:FirstExtensionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnSecondExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:SecondExtensionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_slxnMeasurementInputStrikevPriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:MeasurementInputStrikevPriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_slxnMeasurementInputStrikevPriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:MeasurementInputStrikevPriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDerivativeInstrumentRiskAxis_slxnPublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">slxn:PublicWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDerivativeInstrumentRiskAxis_slxnPrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">slxn:PrivateWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtTitleOfIndividualAxis_slxnSecondThirdForthAndFifthPromissoryNotesMember_usgaapDerivativeInstrumentRiskAxis_slxnPrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">slxn:SecondThirdForthAndFifthPromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">slxn:PrivateWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_slxnMeasurementInputStrikevPriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:MeasurementInputStrikevPriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputCommodityMarketPriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCommodityMarketPriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputCommodityMarketPriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCommodityMarketPriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCostMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">slxn:CostMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCostMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">slxn:CostMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnLaboratoryAndElectronicEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">slxn:LaboratoryAndElectronicEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCommunicationEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">slxn:CommunicationEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCommunicationEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">slxn:CommunicationEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-19</xbrli:startDate>
        <xbrli:endDate>2021-02-19</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-03</xbrli:startDate>
        <xbrli:endDate>2021-03-03</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-03-03</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-03-03</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAPreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAOnePreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesA2PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAThreePreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAFourPreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_usgaapAwardTypeAxis_slxnPreFundedOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">slxn:PreFundedOptionsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapAwardTypeAxis_slxnPreFundedOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">slxn:PreFundedOptionsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRestatementAxis_srtScenarioPreviouslyReportedMember_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRestatementAxis_srtScenarioPreviouslyReportedMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRestatementAxis_srtScenarioPreviouslyReportedMember_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRestatementAxis_srtScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapResearchAndDevelopmentArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtRangeAxis_srtMinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtRangeAxis_srtMaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSupportGrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SupportGrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210809to20210809_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSecondPromissoryNoteMember_usgaapRelatedPartyTransactionAxis_slxnSponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SecondPromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:SponsorMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-09</xbrli:startDate>
        <xbrli:endDate>2021-08-09</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnThirdAndFourthPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:ThirdAndFourthPromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-31</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230208to20230208_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnFifthPromissoryNoteMember_usgaapRelatedPartyTransactionAxis_slxnSponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:FifthPromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:SponsorMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-08</xbrli:startDate>
        <xbrli:endDate>2023-02-08</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230209to20230209_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SixthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-09</xbrli:startDate>
        <xbrli:endDate>2023-02-09</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230219to20230219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SixthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-19</xbrli:startDate>
        <xbrli:endDate>2023-02-19</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230818to20230818_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnEighthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:EighthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-18</xbrli:startDate>
        <xbrli:endDate>2023-08-18</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240327to20240327_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-27</xbrli:startDate>
        <xbrli:endDate>2024-03-27</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240627to20240627_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-27</xbrli:startDate>
        <xbrli:endDate>2024-06-27</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201216to20201216_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnSponsorMember_usgaapTypeOfArrangementAxis_slxnAdministrativeServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slxn:AdministrativeServicesAgreementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-16</xbrli:startDate>
        <xbrli:endDate>2020-12-16</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:PromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapAssetManagementArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:AssetManagementArrangementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:unit id="Segment">
      <xbrli:measure>slxn:Segment</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="ilsPershares"><xbrli:divide>
      <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator>
      <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide>
      </xbrli:unit>
    <xbrli:unit id="pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="usd">
      <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="usdPershares"><xbrli:divide>
      <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator>
      <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide>
      </xbrli:unit>
    <ix:relationship fromRefs="Fxbrl_20241004172251986" toRefs="FN20241004172411305"/>
    <ix:relationship fromRefs="Fxbrl_20241004172316778" toRefs="FN20241004172411305"/>
    <ix:relationship fromRefs="Fix_7_fact" toRefs="FN20241004135506058"/>
    <ix:relationship fromRefs="Fix_8_fact" toRefs="FN20241004135506058"/>
    </ix:resources>
  </ix:header></div>

<div>

<div>

<div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">As filed with
the United States Securities and Exchange Commission on <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">October
31, 2024</span></span>.</div>

<div>

<div>

<div style="text-align:right;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-weight:bold;font-family:'Times New Roman',Times,serif">Registration
No. 333-&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">&#160;</span>
<hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center"/>
</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">UNITED STATES</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold">SECURITIES AND
EXCHANGE COMMISSION</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">Washington,
D.C. 20549</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold">FORM <ix:nonNumeric id="Fixv-37588" name="dei:DocumentType" contextRef="C_20240101to20240630">S-1</ix:nonNumeric></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">REGISTRATION
STATEMENT</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-style:normal;font-weight:bold">UNDER</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-style:normal;font-weight:bold">THE
SECURITIES ACT OF 1933</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:16pt;font-weight:bold"><ix:nonNumeric id="Fixv-64" name="dei:EntityRegistrantName" contextRef="C_20240101to20240630">Silexion
Therapeutics Corp</ix:nonNumeric></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">(Exact name of registrant as
specified in its charter)</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:32.01%;vertical-align:top;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif"><ix:nonNumeric id="Fixv-81" name="dei:EntityIncorporationStateCountryCode" contextRef="C_20240101to20240630" format="ixt-sec:edgarprovcountryen">Cayman
        Islands</ix:nonNumeric></div> </td>
    <td style="width:2%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td>
    <td style="width:32%;vertical-align:top;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif">8731</div> </td>
    <td style="width:2%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td>
    <td style="width:32%;vertical-align:top;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif">N/A</div> </td> </tr>
  <tr>
    <td style="width:32.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">(State or other jurisdiction of</div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">incorporation or organization)</div> </td>
    <td style="width:2%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td>
    <td style="width:32%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">(Primary Standard Industrial<br/>Classification
        Code Number)</div> </td>
    <td style="width:2%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td>
    <td style="width:32%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">(I.R.S. Employer</div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">Identification Number)</div> </td> </tr>
  </table>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">12 Abba Hillel
Road</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">Ramat Gan,
Israel 5250606</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="text-decoration:underline">+972-8-6286005</span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">(Address, Including Zip Code,
and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-family:'Times New Roman',Times,serif">Puglisi&#160;&amp;
Associates<br/>850 Library Avenue, Suite 204<br/>Newark, DE&#160;19711</span><br/><span style="font-family:Times New Roman, Times, serif;text-decoration:underline">Telephone:
(302)&#160;738-6680</span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div>

<div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Name,
Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Copies
to:</span></span></div>

<div>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:49.02%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">J.&#160;David
        Chertok, Adv.<br/>Jonathan M.&#160;Nathan, Adv.<br/>Meitar Law Offices<br/>16 Abba Hillel Road<br/>Ramat Gan, Israel 5251608<br/>Tel:
        +972-3-610-3100</span></span></div> </td>
    <td style="width:50.98%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Mark&#160;S.&#160;Selinger,&#160;Esq.<br/>Gary
        Emmanuel, Esq.</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Greenberg
        Traurig, LLP</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">One&#160;Vanderbilt&#160;Avenue<br/>New&#160;York,&#160;New&#160;York&#160;10017-5404<br/>Tel:&#160;(212)&#160;801-9200</span></span></div>
        </td> </tr>
  </table> </div>

<div>&#160;</div>

<div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Approximate
date of commencement of proposed sale to the public:</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
soon as practicable after the effective date of this registration statement becomes effective.</span></span></div> </div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>
</div> </div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">If any of the
securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933, check the following box. &#9746;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">If this Form
is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">If this Form
is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">If this Form
is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,
or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Large accelerated filer</div> </td>
    <td style="width:30%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#9744;</div> </td>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Accelerated filer</div> </td>
    <td style="width:30%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#9744;</div> </td> </tr>
  <tr>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonNumeric id="Fixv-208" name="dei:EntityFilerCategory" contextRef="C_20240101to20240630" format="ixt-sec:entityfilercategoryen">Non-accelerated
        filer</ix:nonNumeric></div> </td>
    <td style="width:30%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#9746;</div> </td>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Smaller reporting company</div> </td>
    <td style="width:30%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonNumeric id="Fixv-215" name="dei:EntitySmallBusiness" contextRef="C_20240101to20240630" format="ixt:fixed-true">&#9746;</ix:nonNumeric></div>
        </td> </tr>
  <tr>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td>
    <td style="width:30%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Emerging growth company</div> </td>
    <td style="width:30%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonNumeric id="Fixv-223" name="dei:EntityEmergingGrowthCompany" contextRef="C_20240101to20240630" format="ixt:fixed-true">&#9746;</ix:nonNumeric></div>
        </td> </tr>
  </table>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <ix:nonNumeric id="Fixv-229" name="dei:EntityExTransitionPeriod" contextRef="C_20240101to20240630" format="ixt:fixed-false">&#9744;</ix:nonNumeric></div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance
with Section&#160;8(a)&#160;of the Securities Act&#160;of&#160;1933, as amended (&#8220;Securities Act&#8221;), or until the Registration
Statement shall become effective on such date as the SEC, acting pursuant to Section&#160;8(a), may determine.</div> </div> </div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
</div> </div> </div> <!-- Field: Include-Text; File: body.htm; Date: 2024%2D10%2D31T22:17:24; Size: 0x002459E0; Options: XMLPreprocess -->
<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman,Times,serif"> </span></p>

<div><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold; color: rgb(255, 0, 0)">The information in
this preliminary prospectus is not complete and may be changed. The securities described herein may not be sold until the registration
statement filed with the U.S. Securities and Exchange Commission is declared effective. This preliminary prospectus is not an offer to
sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold; color: rgb(255, 0, 0)">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold; color: rgb(255, 0, 0)">PRELIMINARY
PROSPECTUS</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold; color: rgb(255, 0, 0)">

<div style="line-height: 1.25; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">SUBJECT TO COMPLETION, DATED OCTOBER 31,
2024</div> </div> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image0.jpg" alt="" style="width: 199px; height: 76px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Up to &#160; &#160; &#160;
&#160; &#160; &#160; Ordinary Shares and accompanying</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Ordinary Warrants to Purchase
up to&#160; &#160; &#160; &#160; &#160; &#160;&#160; Ordinary Shares</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="font-weight: bold">Up to &#160;
&#160; &#160; &#160; &#160; &#160; Pre-funded Warrants<span style="font-weight: bold"> </span>to Purchase up to&#160; &#160; &#160; &#160;
&#160; Ordinary Shares</span></div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">and accompanying Ordinary
Warrants to Purchase up to&#160; &#160; &#160; &#160; &#160; &#160; &#160; Ordinary Shares</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Placement Agent Warrants
to Purchase up to&#160; &#160; &#160; &#160; &#160; &#160; Ordinary Shares</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Up to&#160; &#160; &#160; &#160; &#160;&#160;
Ordinary Shares Issuable Upon Exercise of the Ordinary Warrants, Pre-funded Warrants and Placement Agent Warrants</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">We are offering in a best-efforts offering up to&#160; &#160; &#160; &#160; &#160; &#160;
&#160; &#160; &#160;&#160; ordinary shares, par value $0.0001 per share of Silexion Therapeutics Corp, a Cayman Islands exempted company
(&#8220;New Silexion&#8221;, the &#8220;Company&#8221;, &#8220;our company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;), together with
ordinary warrants to purchase up to&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ordinary shares
at an assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share and ordinary warrant pursuant to this prospectus.
The ordinary shares and ordinary warrants will be sold in a fixed combination, with each ordinary share accompanied by one warrant to
purchase one ordinary share.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">We are also offering to those purchasers, if any, whose purchase of our ordinary shares
in this offering would otherwise result in such purchaser, together with its affiliates and certain related parties, beneficially owning
more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding ordinary shares immediately following the consummation
of this offering, the opportunity, in lieu of purchasing ordinary shares, to purchase pre-funded warrants to purchase ordinary shares.
Each pre-funded warrant will be immediately exercisable for one ordinary share at any time at the option of the holder until such pre-funded
warrant is exercised in full, provided that the holder will be prohibited from exercising pre-funded warrants for ordinary shares if,
as a result of such exercise, the holder, together with its affiliates and certain related parties, would own more than 4.99% (or, at
the election of the purchaser, 9.99%) of the total number of ordinary shares then issued and outstanding.&#160;The purchase price of each
pre-funded warrant is $&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; (which is equal to the assumed public offering price
per ordinary share and ordinary warrant to be sold in this offering minus $0.0001, the exercise price per ordinary share of each pre-funded
warrant). For each pre-funded warrant we sell, the number of ordinary shares we are offering will be decreased on a one-for-one basis.
The pre-funded warrants will be sold together with ordinary warrants in a fixed combination, with each pre-funded warrant to purchase
one ordinary share accompanied by one ordinary warrant to purchase one ordinary share.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Each ordinary warrant will have an exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per
share (which will be no less than&#160; &#160; &#160; &#160; &#160; % of the assumed public offering price per ordinary share to be sold
in this offering), will be exercisable upon issuance and will expire on&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; , 2029.
Because we will issue an ordinary warrant for each ordinary share and for each pre-funded warrant sold in this offering, the number of
ordinary warrants sold in this offering will not change as a result of a change in the mix of ordinary shares and pre-funded warrants
sold.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25">We are also registering the ordinary shares issuable from time to time upon the exercise
of the pre-funded warrants, ordinary warrants and placement agent warrants offered hereby.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Our ordinary shares and warrants are listed on The Nasdaq Global Market under the symbols
&#8220;SLXN&#8221; and &#8220;SLXNW,&#8221; respectively. On October 30, 2024, the last reported sales price of our ordinary shares was
$0.294 per share and the last reported sales price of our warrants was $0.069 per warrant. There is no established public trading market
for the ordinary shares being offered and the&#160; pre-funded warrants and we do not expect a market to develop. Without an active trading
market, the liquidity of those warrants will be limited. In addition, we do not intend to list the pre-funded warrants or the ordinary
warrants on The Nasdaq Global Market, any other national securities exchange or any other trading system.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">The public offering price per ordinary share and any pre-funded warrant will be determined
at the time of pricing, and may be at a discount to the then current market price. The recent market price used throughout this prospectus
may not be indicative of the final offering price. The final public offering price will be a fixed price determined through negotiation
between us and investors based upon a number of factors, including our history and our prospects, the state of the biotechnology industry
in which we operate, our recent operating results, including results of our pre-clinical studies and clinical trials, and the general
condition of the securities markets at the time of this offering.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">This offering will terminate on&#160;&#160; &#160; &#160; &#160; &#160; &#160; &#160;
&#160; , 2024, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will
have one closing for all the securities purchased in this offering. The combined public offering price per ordinary share (or pre-funded
warrant) and accompanying ordinary warrants will be fixed for the duration of this offering.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">We have engaged&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;
&#160; &#160; &#160; &#160; &#160;&#160; (&#8220;Placement Agent&#8221;), to act as our exclusive placement agent in connection with this
offering. The Placement Agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this
prospectus. The Placement Agent is not purchasing or selling any of the securities we are offering and the Placement Agent is not required
to arrange the purchase or sale of any specific number of securities or dollar amount. We have agreed to pay to the Placement Agent the
placement agent fees set forth in the table, which assumes that we sell all of the securities offered by this prospectus. There is no
minimum offering requirement as a condition of closing of this offering. Because there is no minimum offering amount required as a condition
to closing this offering, we may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds
received by us. We will bear all costs associated with the offering and investors in this offering will not receive a refund in the event
that we do not sell an amount of securities sufficient to pursue our business goals described in this prospectus. In addition, because
there is no escrow account and no minimum offering amount, investors could be in a position where they have invested in our company, but
we are unable to fulfill all of our contemplated objectives due to a lack of interest in this offering. Further, any proceeds from the
sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such
funds to effectively implement our business plan. See &#8220;<span style="font-style: italic">Plan of Distribution</span>&#8221; on page
145 of this prospectus for more information regarding these arrangements.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">Effective November&#160; &#160; &#160; &#160; , 2024, we effected a 1-for-&#160; &#160;
&#160; &#160;&#160; reverse share split of our authorized ordinary shares, including our issued and outstanding ordinary shares. Unless
specifically provided otherwise herein, the share and per share information that follows in this prospectus, other than in the historical
financial statements and related notes included elsewhere in this prospectus, assumes the effect of the reverse share split.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">We are an &#8220;emerging growth company&#8221; as defined under U.S. federal securities
laws and, as such, have elected to comply with reduced public company reporting requirements. This prospectus complies with the requirements
that apply to an issuer that is an emerging growth company.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="zb7b688609d8b426a9537b47da5ca35e4" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Per Ordinary Share and<br/> Accompanying Ordinary<br/> Warrant</div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Per Pre-Funded<br/> Warrant and Accompanying</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Ordinary Warrant</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Total</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Public offering price</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 64%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Placement agent fees (1)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Proceeds to us, before expenses (2) (3)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcf9aebccbeb34cc783fab6eb2948cd9f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 18pt; vertical-align: top">(1)</td>
    <td style="width: auto; vertical-align: top">
        <div>We have agreed to pay the Placement Agent cash fee equal to 7.0% of the gross proceeds raised in this offering. We have also agreed
        to reimburse the Placement Agent for certain of its offering-related expenses, including a management fee of 1.0% of the gross proceeds
        raised in this offering, to reimburse the Placement Agent for its non-accountable expenses in the amount of $25,000, for its legal fees
        and expenses and other out-of-pocket expenses in an amount up to $100,000, and for its clearing expenses in the amount of up to $15,950.
        In addition, we have agreed to issue to the Placement Agent warrants to purchase up to a number of ordinary shares equal to 7% of the
        aggregate number of our ordinary shares and pre-funded warrants being offered, at an exercise price equal to 125% of the public offering
        price of our ordinary shares. See &#8220;<span style="font-style: italic">Plan of Distribution</span>&#8221; for additional information
        and a description of the compensation payable to the Placement Agent.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9c90f6331dd740ab92c463ccb9839fa1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 18pt; vertical-align: top">(2)</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>We estimate the total expenses of this offering payable by us, excluding the placement agent fee, will be approximately $&#160; &#160;
        &#160; &#160; &#160; &#160;&#160; . Because there is no minimum number of securities or amount of proceeds required as a condition to
        closing in this offering, the actual public offering amount, Placement Agent fees, and proceeds to us, if any, are not presently determinable
        and may be substantially less than the total maximum offering amounts set forth above.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6bf6877dc64d4afca17dc379563f8a8e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 18pt; vertical-align: top">(3)</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Does not include proceeds from the cash exercise of the pre-funded warrants or ordinary warrants, if any. Assumes no pre-funded warrants
        are issued.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold">Investing in our securities involves a high degree of risk. You should
review carefully the risks and uncertainties described in the section titled &#8220;Risk Factors&#8221; beginning on page 7 of this prospectus,
and under similar headings in any amendments or supplements to this prospectus.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold">Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus. Any representation
to the contrary is a criminal offense.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25">We expect to deliver the securities to the purchasers in the offering
on or about&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; , 2024, subject to satisfaction of certain conditions.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160; </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Prospectus dated &#160;
&#160; &#160; &#160; &#160;&#160; , 2024</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"> <span style="font-family: Times New Roman,Times,serif"><br/> </span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">

<div style="line-height: 1.25; font-weight: bold">PRELIMINARY NOTES REGARDING<span style="font-family: Times New Roman,Times,serif"> THIS
PROSPECTUS</span></div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Unless the context indicates otherwise, references
in this prospectus to &#8220;<span style="font-weight: bold">New Silexion</span>&#8221;, &#8220;<span style="font-weight: bold">we</span>&#8221;,
&#8220;<span style="font-weight: bold">us,</span>&#8221; &#8220;<span style="font-weight: bold">our</span>,&#8221; &#8220;<span style="font-weight: bold">the
Company</span>&#8221;, &#8220;<span style="font-weight: bold">our company</span>&#8221; and similar terms refer to Silexion Therapeutics
Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company, and its consolidated subsidiaries. References to &#8220;<span style="font-weight: bold">Silexion</span>&#8221;
refer to Silexion Therapeutics Ltd., an Israeli company and wholly-owned subsidiary of the Company, and references to &#8220;<span style="font-weight: bold">Moringa</span>&#8221;
refer to Moringa Acquisition Corp, a Cayman Islands exempted company and wholly-owned subsidiary of the Company. References to the &#8220;<span style="font-weight: bold">Business
Combination</span>&#8221; refer collectively to the transactions completed on August 15, 2024 pursuant to that certain Amended and Restated
Business Combination Agreement, dated as of April 3, 2024 (as amended, the &#8220;<span style="font-weight: bold">Business Combination
Agreement</span>&#8221;), by and among New Silexion, August M.S.&#160;Ltd., an Israeli company and a wholly-owned&#160;subsidiary of New
Silexion (&#8220;<span style="font-weight: bold">Merger Sub 1</span>&#8221;), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted
company and a wholly-owned&#160;subsidiary of New Silexion (&#8220;<span style="font-weight: bold">Merger Sub 2</span>&#8221;), Moringa
and Silexion. Pursuant to the Business Combination Agreement, among other things, (i) Merger Sub 2 merged with and into Moringa, with
Moringa continuing as the surviving company and a wholly-owned subsidiary of New Silexion (the &#8220;<span style="font-weight: bold">SPAC
Merger</span>&#8221;) and (ii) Merger Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company and a wholly-owned
subsidiary of New Silexion (the &#8220;<span style="font-weight: bold">Acquisition Merger</span>&#8221;). In connection with the consummation
of the Business Combination (the &#8220;<span style="font-weight: bold">Closing</span>&#8221;), New Silexion changed its name from &#8220;Biomotion
Sciences&#8221; to &#8220;Silexion Therapeutics Corp&#8221;, and the ordinary shares and warrants of New Silexion commenced trading on
the Nasdaq Global Market (&#8220;<span style="font-weight: bold">Nasdaq</span>&#8221;) under the symbols &#8220;SLXN&#8221; and &#8220;SLXNW&#8221;,
respectively, on August 16, 2024.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">We and the Placement Agent have not authorized anyone to provide
any information or to make any representations other than those contained in or incorporated by reference in this prospectus or in any
free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for and can provide
no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares
offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in or incorporated
by reference in this prospectus is accurate only as of its date regardless of the time of delivery of this prospectus or of any sale of
ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">To the extent there is a conflict between the information contained
in this prospectus, on the one hand, and the information contained in any document incorporated by reference filed with the U.S. Securities
and Exchange Commission (the &#8220;SEC&#8221;) before the date of this prospectus, on the other hand, you should rely on the information
in this prospectus. If any statement in a document incorporated by reference is inconsistent with a statement in another document incorporated
by reference having a later date, the statement in the document having the later date modifies or supersedes the earlier statement.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Neither we nor the Placement Agent have done anything that would
permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other
than in the United States. Persons who come into possession of this prospectus and any free writing prospectus in jurisdictions outside
the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of
this prospectus and any free writing prospectus applicable to that jurisdiction.&#160;We will not make an offer to sell these ordinary
shares in any jurisdiction where the offer or sale is not permitted.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">This prospectus contains market data and industry statistics
and forecasts that are based on independent industry publications and other publicly available information. Although we believe that these
sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this
information. Although we are not aware of any misstatements regarding the market and industry data presented or incorporated by reference
in this prospectus, these estimates involve risks and uncertainties and are subject to change based on various factors, including those
discussed under the heading &#8220;Risk Factors&#8221; and any related free writing prospectus. These and other factors could cause our
future performance to differ materially from our assumptions and estimates. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;
Accordingly, investors should not place undue reliance on this information.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">This prospectus contains summaries of certain
provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information.
All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have
been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a
part, and you may obtain copies of those documents as described below under &#8220;<span style="font-style: italic">Where You Can Find
More Information</span>&#8221;.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The statements contained in this prospectus
that are not purely historical are forward-looking statements. Certain statements in this prospectus may constitute &#8220;forward-looking
statements&#8221; for purposes of the federal securities laws. These forward-looking statements include, but are not limited to, statements
regarding the Company&#8217;s and the Company&#8217;s management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding
the future, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives
of management for future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future
events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221;
&#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221;
&#8220;will,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words
does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements
about:&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;

<table cellspacing="0" cellpadding="0" id="ze0711c706c3e4b46abca09da16db54ba" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">the ability to maintain the listing of our ordinary shares and our warrants on Nasdaq;</div> </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">our future performance, including our projected timeline for regulatory approvals of its product candidates;</div>
        </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdb8994fd65dd4ffb9fde5b4b985d9d3f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">our market opportunity;</div> </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd58bec60967b4c8c91cb21513bcd15ee" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">our strategy, future operations, financial position, projected costs, prospects and plans;</div> </td>
        </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd3b61659cefd4a65848b820925f8dfca" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">expectations regarding the time during which we will be an emerging growth company under the JOBS Act;</div>
        </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z34770608169e419ca996f602360c6356" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">our ability to retain or recruit officers, key employees and directors;</div> </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1b7a0be74eb1420393a71cf06edbe3ba" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">the impact of the regulatory environment and complexities with compliance related to such environment;</div>
        </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zccc4f852b94a4db1ba0913de8fc07e4e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">expectations regarding future partnerships or other relationships with third parties; and</div> </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z146db67359fe4cf1a8c668d8e81015d4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">our future capital requirements and sources and uses of cash, including the our ability to obtain additional
        capital in the future.</div> </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The forward-looking statements contained
in this prospectus and in any document incorporated by reference are based on current expectations, forecasts and beliefs concerning future
developments and their potential effects on us. There can be no assurance that future developments affecting we will be those that we
have anticipated. These forward-looking statements involve a number of risks, uncertainties, some of which are beyond our control, or
other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not limited to, the following factors:</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z89c5a3d2b3564ca38f68ab21ed3816d7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">
        <div style="line-height: 1.25">we are a development-stage company and have a limited operating history on which to assess its business;</div>
        </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb3b7309ea37b4113a7460b2429620888" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">we have never generated any revenue from product sales and
        may never be profitable;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb750f986c1c14b289beeecc857692c7f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">we will need to raise substantial additional funding, which
        may not be available on acceptable terms, or at all, and which will cause dilution to its shareholders;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd42371efcaa74f23a6f9f9de7a07a722" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the approach we are taking to discover and develop novel RNAi
        therapeutics is unproven for oncology and may never lead to marketable products;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" id="zc876b67e337f4dbf83bab24afccd7c0f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">we do not have experience producing our product candidates at commercial levels, currently have no marketing
        and sales organization, have an uncertain market receptiveness to our product candidates, and are uncertain as to whether there will be
        insurance coverage and reimbursement for its potential products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z41891933d3814a349c2fd7311e2f5dd9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">we may be unable to attract, develop and/or retain its key personnel or additional employees required for
        our development and future success;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z13dfd96cbb0449dc82582d1181d17653" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">we may issue additional our ordinary shares or other equity securities without your approval, including:
        (a) up to $15,337,500 of ordinary shares issuable under the Ordinary Share Purchase Agreement, dated August 13, 2024 and effective as
        of August 15, 2024, by and between the Company and White Lion Capital, LLC (&#8220;White Lion&#8221;) (the &#8220;White Lion Purchase
        Agreement&#8221; or &#8220;ELOC Agreement&#8221;), which established an equity line of credit for the Company; (b) ordinary shares underlying
        5,940,000 outstanding warrants; and (c) ordinary shares underlying convertible promissory notes that the Company has issued to (i) Moringa&#8217;s
        sponsor, Moringa Sponsor, LP, a Cayman Islands exempted limited partnership (the &#8220;Sponsor&#8221; or &#8220;Moringa Sponsor&#8221;),
        in a principal amount of $3,433,000 (the &#8220;A&amp;R Sponsor Promissory Note&#8221;), in amendment and restatement of all promissory
        notes previously issued by Moringa to the Sponsor for funds borrowed between Moringa&#8217;s initial public offering and the completion
        of the Business Combination, and (ii) EarlyBird Capital, Inc. (&#8220;EarlyBird&#8221;), which served as the representative of the underwriters
        for Moringa&#8217;s initial public offering, in an amount of $1,250,000 (the &#8220;EarlyBird Convertible Note&#8221;), each of which
        would dilute your ownership interest and may depress the market price of our ordinary shares; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z091100cccfb84117a80ae0495e19fb34" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">those additional factors described or incorporated by reference under the heading &#8220;<span style="font-style: italic">Risk
        Factors</span>&#8221; below.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Should one or more of these risks or uncertainties
materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these
forward-looking statements. It is not possible to predict or identify all such risks. Accordingly, forward-looking statements in this
prospectus and in any document incorporated herein by reference should not be relied upon as representing our views as of any subsequent
date, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise, except as may be required under applicable securities laws.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">These forward-looking statements are based
on information available as of the date of this prospectus, and current expectations, forecasts and assumptions, and involve a number
of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as
of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances
after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable
securities laws.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">You should read this prospectus and the documents
that we reference in this prospectus and have filed as exhibits to the registration statement of which this prospectus is a part, completely
and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking
statements by these cautionary statements.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, statements that &#8220;we believe&#8221;
and similar statements reflect our beliefs and opinions on the relevant subject. Those statements are based upon information available
to us as of the date of this prospectus and while we believe such information forms a reasonable basis for such statements, such information
may be limited or incomplete, and such statements should not be read to indicate that we have conducted an exhaustive inquiry into, or
review of, all potentially available relevant information. Those statements are inherently uncertain, and investors are cautioned not
to unduly rely upon those statements.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">TABLE OF CONTENTS</div>
<span style="font-family: Times New Roman,Times,serif"><br/> </span>

<table cellspacing="0" cellpadding="0" id="zedf5660bb09a492faa82d09dbd3c1db2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 94.59%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 5.41%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Page</div> </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#PROSPECTUSSUMMARY">Prospectus Summary</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center"><span style="font-family: Times New Roman,Times,serif">1<br/>
        </span> </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#RISKFACTORS">Risk Factors</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center">7</td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#USE">Use of Proceeds</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center"><span style="font-family: Times New Roman,Times,serif">43<br/>
        </span> </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom">
        <div style="line-height: 1.25"><a href="#CAPITALIZATION"><span style="text-decoration: underline">Capitalization</span></a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman,Times,serif">44<br/> </span>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 94.59%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25"><a href="#DILUTION">Dilution</a></div> </td>
    <td rowspan="1" style="width: 5.41%; vertical-align: bottom; text-align: center; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">45<br/>
        </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#MARKETINFORMATIONFORSECUR">Market Information for Securities
        and Dividend Policy</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman,Times,serif">46<br/> </span>
        </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#UNAUDITEDPROFORMACONDENSE">Unaudited Pro Forma Condensed
        Combined Financial Information</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255)"><span style="font-family: Times New Roman,Times,serif">46<br/>
        </span> </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#MANAGEMENTSDISCUSSIONANDA">Management&#8217;s Discussion
        and Analysis of Financial Condition and Results of Operations</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman,Times,serif">61<br/> </span>
        </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#BUSINESS">Business</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255)"><span style="font-family: Times New Roman,Times,serif">77<br/>
        </span> </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#MANAGEMENT">Management</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman,Times,serif">106<br/> </span>
        </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#EXECUTIVECOMPENSATION">Executive Compensation</a></div>
        </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255)"><span style="font-family: Times New Roman,Times,serif">112<br/>
        </span> </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#CERTAINRELATIONSHIPSANDRE">Certain Relationships and
        Related Party Transactions</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman,Times,serif">123<br/> </span>
        </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#BENEFICIALOWNERSHIPOFSECU">Beneficial Ownership of
        Securities</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255)"><span style="font-family: Times New Roman,Times,serif">126<br/>
        </span> </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom">
        <div style="line-height: 1.25"><a href="#CAPITAL"><span style="text-decoration: underline">Description of Share Capital</span></a></div>
        </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman,Times,serif">129<br/> </span>
        </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25"><a href="#OFFERED">Description of Securities <span style="text-decoration: underline">Offered</span></a></div>
        </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255)"><span style="font-family: Times New Roman,Times,serif">135<br/>
        </span> </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#MATERIALU.S.FEDERALINCOME">Material U.S. Federal Income
        Tax Consequences</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman,Times,serif">138<br/> </span>
        </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#PLANOFDISTRIBUTION">Plan of Distribution</a></div>
        </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255)"><span style="font-family: Times New Roman,Times,serif">145<br/>
        </span> </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#LEGALMATTERS">Legal Matters</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman,Times,serif">148<br/> </span>
        </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#EXPERTS">Experts</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255)"><span style="font-family: Times New Roman,Times,serif">148<br/>
        </span> </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#WHEREYOUCANFINDMOREINFORM">Where You Can Find More
        Information</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman,Times,serif">149<br/> </span>
        </td> </tr>
  <tr>
    <td style="width: 94.59%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#a_001">Index to Financial Statements</a></div> </td>
    <td style="width: 5.41%; vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255)"><span style="font-family: Times New Roman,Times,serif">F-1<br/>
        </span> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"></div>

<div style="text-align: center; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>
<!--PROfilePageNumberReset%Num%1%%%-->

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span>

<div>

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div style="font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="PROSPECTUSSUMMARY"><!--Anchor--></span>PROSPECTUS
SUMMARY</div>

<div style="text-align: center; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">This summary highlights
information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your
investment decision. Before investing in our securities, you should carefully read this entire prospectus, including our consolidated
financial statements and the related notes thereto and the information set forth in the sections titled &#8220;Risk Factors&#8221; and
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Our Business</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We are a clinical-stage, oncology-focused
biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an
oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus.
Based on our research of refractory solid tumor cancers, we are actively developing a platform focused on the silencing of the KRAS oncogene
using RNA-interference therapeutics. Our lead product candidate, SIL-204B, consists of locally administered small interfering RNAs, or
siRNA, in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination
with standard-of-care chemotherapy.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The KRAS oncogene is considered to be the
most common oncogenic gene driver in human cancers, and the most notable in pancreatic, lung, and gastrointestinal (GI) (including colorectal,
esophagus, stomach, small bowel, and appendix) cancers. Considered a challenging therapeutic target due to its intrinsic characteristics,
recent advances have been made at directly inhibiting the KRAS proteins produced by the mutated gene. Our platform is designed to silence
the gene, and thus prevent the production of the harmful mutated KRAS proteins driving the growth of cancerous tumors.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We are currently focused on treatment for
pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable,
i.e., they are not able to be surgically removed. For our first indication, we are targeting the largest and least treatable form of localized
pancreatic tumors referred to as locally advanced pancreatic cancer. LAPC represents approximately 30% of the total pancreatic cancer
population. We are currently developing SIL-204B, a second-generation siRNA product candidate following a Phase 1 and Phase 2 clinical
trial with our first-generation siRNA product candidate, siG12D-LODER, which we also refer to as Loder. Results from the Phase 2 clinical
trial showed a trend for differences between treatment groups in patients with the KRAS G12D/V mutation, with the Loder arm suggesting
an overall survival advantage of 9.3 months.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">SIL-204B has been designed to optimize Loder
with the aim of improving uptake into tumor cells, enhancing stability, and improving the delivery system. We plan to conduct a Phase
2/3 prospective, randomized, controlled, multinational, two-arm, open-label trial in LAPC subjects that harbor the KRAS G12D/V mutations
to evaluate the efficacy, safety and tolerability of SIL-204B administered intratumorally in combination with standard of care (SoC) chemotherapy
versus SoC chemotherapy only. In support of our planned Phase 2/3 trial, we held a meeting with the Federal Institute for Drugs and Medical
Devices in Germany (BfArM) to discuss the planned design of the Phase 2/3 trial at which BfArM agreed, in principle, to the design. In
preparation for the study, we plan to initiate toxicology studies of SIL-204B in 2025 followed by the regulatory submission in the second
half of 2025 to initiate the Phase 2/3 trial and trial initiation in the first half of 2026 . At this time, we are focused on the further
development of the core siRNA technology underlying the Loder and SIL-204B as well as the clinical development of SIL-204B as the most
optimized version of the technology.</div> </div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Corporate Information</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">We were originally known as Biomotion Sciences, a Cayman Islands exempted company. On April 3, 2024, we
entered into an amended and restated business combination agreement (the &#8220;Business Combination Agreement&#8221;), dated April 3,
2024, by and among our company (whose name was subsequently changed to Silexion Therapeutics Corp) (&#8220;New Silexion&#8221;), August
M.S. Ltd., an Israeli company and a wholly owned subsidiary of New Silexion (&#8220;Merger Sub 1&#8221;), Moringa Acquisition Merger Sub
Corp, a Cayman Islands exempted company and a wholly owned subsidiary of Silexion (&#8220;Merger Sub 2&#8221;), Moringa Acquisition Corp
(&#8220;Moringa&#8221;) and Silexion Therapeutics Ltd., an Israeli company (&#8220;Silexion&#8221;). On August 15, 2024 (the &#8220;Closing
Date&#8221;), the transactions contemplated by the Business Combination Agreement (collectively, the &#8220;Business Combination&#8221;)
were completed (the &#8220;Closing&#8221;), following the approval of the Business Combination on August 6, 2024 by the extraordinary
general meeting of Moringa.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div> </div>
</div> </div>

<div><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">1</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div><span style="font-family: Times New Roman,Times,serif"><br/> </span>

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div style="font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 35.45pt; line-height: 1.25">Our principal executive offices are located at 12 Abba Hillel Road, Ramat Gan, Israel
5250606, Israel and our phone number is +972-8-6286005. Our corporate website address is www.silexion.com. Information contained on or
accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive
textual reference only.</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">This prospectus contains trademarks, service
marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, trademarks
and trade names referred to in this prospectus may appear without the &#174; or &#8482; symbols, but such references are not intended
to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these
trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to
imply a relationship with, or endorsement or sponsorship of us by, any other companies. <span style="font-weight: bold">&#160;</span></div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25; font-weight: bold">Proposed Reverse Share Split</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 35.45pt; line-height: 1.25">On October 22, 2024, we filed with the SEC, and soon thereafter we began to distribute
to our shareholders, a notice and proxy statement for an extraordinary general meeting of our company to be held on November 12, 2024
(the &#8220;extraordinary general meeting&#8221; or &#8220;meeting&#8221;) at which we will present to our shareholders a proposal to
effect a reverse share split of our issued and outstanding, and our remaining authorized but unissued, ordinary shares at a ratio of between
1-for-10 and 1-for-20 (the &#8220;reverse share split&#8221;). The exact ratio of the reverse share split will be finalized by our board
of directors prior to the extraordinary general meeting and will be presented at the meeting. If the reverse share split is approved at
the meeting, holders of our ordinary shares will receive one ordinary share for every 10 to 20 ordinary shares currently held by them
(depending on the final ratio), and the number of our authorized but unissued ordinary shares will be reduced at that same ratio. Furthermore,
the par value of all ordinary shares, whether issued and outstanding, or unissued, will be increased proportionately to between $0.0010
and $0.0020. As of the effective time of the reverse share split (which will occur as soon as possible following shareholder approval
of the reverse share split proposal, if approved), proportionate adjustments will be made to (i) the number of ordinary shares that are
subject to all then-outstanding equity awards and warrants, such that fewer shares would underlie such awards and warrants, (ii) the exercise
price of all then-outstanding options and warrants, such that the per share exercise price of each such option and warrant would be increased,
and (iii) the number of ordinary shares available for issuance under the our equity incentive plans, such that fewer shares will be subject
to such plans. If the reverse share split is approved and implemented, all issued and outstanding, and authorized and unissued, ordinary
share data, all ordinary share equivalent data, and all per share data, will be adjusted retroactively throughout this prospectus to reflect
the&#160;reverse share split&#160;for all periods presented.</div> <span style="font-weight: bold; font-family: Times New Roman,Times,serif">
</span></div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-weight: bold"> <span style="font-family: Times New Roman,Times,serif"><br/>
</span></div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Implications of Being
a Smaller Reporting Company and Emerging Growth Company</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We are a &#8220;smaller reporting company&#8221;
as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations,
including, among other things, providing only two years of audited financial statements and reduced disclosure obligations regarding executive
compensation. We will remain a smaller reporting company until the last day of any fiscal year for so long as either (1) the market value
of our ordinary shares held by non-affiliates does not equal or exceed $250 million as of the prior June 30th, or (2) our annual revenues
did not equal or exceed $100 million during such completed fiscal year and the market value of our ordinary shares held by non-affiliates
did not equal or exceed $700 million as of the prior June 30th. To the extent we take advantage of any reduced disclosure obligations,
it may make the comparison of our financial statements with other public companies difficult or impossible.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We are an &#8220;emerging growth company,&#8221;
as defined in the Jumpstart Our Business Startups Act of 2012 (t<span style="font-weight: normal">he &#8220;JOBS Act&#8221;). A</span>s
an emerging growth company, we are exempt from certain requirements related to executive compensation, including the requirements to hold
a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief
Executive Officer to the median of the annual total compensation of all of our employees, each as required by the Investor Protection
and Securities Reform Act of 2010, which is part of the Dodd-Frank Act.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: normal">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a registration statement under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) declared
effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial
accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the
requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have elected not to opt
out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for
public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt
the new or revised standard. This may make comparison of our financial statements with those of another public company that is neither
an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible
because of the potential differences in accounting standards used.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">We will remain an emerging growth company until the earlier of: (1) the last day of
the fiscal year (a) following the fifth anniversary of the date on which our ordinary shares were offered in exchange for ordinary shares
of each of Moringa and Silexion, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed
to be a large accelerated filer, which means the market value of our common equity that is held by non-affiliates exceeds $700 million
as of the end of the prior fiscal year&#8217;s second fiscal quarter; and (2) the date on which we have issued more than $1.00 billion
in non-convertible debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; are
to its meaning under the Securities Act, as modified by the JOBS Act.</div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div> </div>
</div> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">2</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25">

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-weight: bold">Summary of Risk Factors</div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25">Investing in our securities involves risks. You should carefully consider the risks
described in &#8220;<span style="font-style: italic">Risk Factors</span>&#8221; before making a decision to invest in our securities.
If any of these risks is actualized, our business, financial condition and results of operations would likely be materially adversely
affected. In such case, the trading price of our securities would likely decline, and you may lose all or part of your investment. In
particular, you should consider the risk factors described under &#8220;<span style="font-style: italic">Risk Factors</span>&#8221; beginning
on page 7. Such risks include, but are not limited to:</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold; font-style: italic; font-family: Times New Roman,Times,serif">Risks
Relating to our Financial Condition and Capital Requirements</span><span style="font-weight: bold; font-family: Times New Roman,Times,serif">,</span><span style="font-family: Times New Roman,Times,serif">&#160;including
that:</span></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;

<table cellspacing="0" cellpadding="0" id="z0d61e00775914ba8b6842c4e39efe34f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">We have never generated any revenue from product sales and may never be profitable.</div> </td> </tr>
  </table>

<div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze8da462e9d304bd9852082e362af6784" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">We will need to raise substantial additional funding, which may not be available on acceptable terms, or
        at all, and which will cause dilution to its shareholders.</div> </td> </tr>
  </table>

<div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </div>

<div style="line-height: 1.25"><span style="font-weight: bold; font-style: italic; font-family: Times New Roman,Times,serif">Risks Relating
to Silexion&#8217;s Business and Industry</span><span style="font-family: Times New Roman,Times,serif">, including that:</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="ze1b2300bff6e4a61aa54c5046e02fd8d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">We are a development-stage&#160;company and has a limited operating history on which to assess its business.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze26a1c79526a42a4b2cb834a86c4c10b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">The approach we are taking to discover and develop novel RNAi therapeutics is unproven for oncology and
        may never lead to marketable products.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd13bf927e55b49709e8ba1ee33582c25" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">We are heavily dependent on the success of its product candidates, which are in the early stages of preclinical
        or clinical development, and cannot give any assurance that any of our product candidates will receive regulatory approval, which is a
        lengthy, time consuming, and inherently unpredictable process.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zca0315f53cc24058a773a7b2c9e17179" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">We may find it difficult to enroll patients in our clinical studies, which could delay or prevent clinical
        studies of its product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">We are subject to a multitude of manufacturing risks, any of which could substantially increase its costs
        and limit supply of its product candidates.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="zefe169b4fde240579b916f2d9d61748b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">We rely on third parties to conduct its preclinical and clinical studies, and to manufacture the raw materials
        and products that it uses to create its product candidates and to supply it with the medical devices used to administer such products,
        which entails regulatory and trade secrets-related&#160;risks.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5374cc8bc8fd45c6b401849616c36e4c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">We do not have experience producing its product candidates at commercial levels, currently has no marketing
        and sales organization, has an uncertain market receptiveness to its product candidates, and is uncertain as to whether there will be
        insurance coverage and reimbursement for its potential products.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9f6fbf1fc711419a823c2ba01bc2ea55" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">We face competition from other companies that are working to develop novel drugs and technology platforms
        using technology similar or in the same field as ours.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z87a3fc29dd704c0fae865c4a905d613e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">If we are unable to obtain and maintain effective patent rights for its product candidates or any future
        product candidates, we may not be able to compete effectively in its markets.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8d8dc9457a9342bd80fde629052cd74f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">We may be unable to attract, develop and/or retain its key personnel or additional employees required for
        its development and future success.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </div> </div> </div>

<div><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">3</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div>

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div style="font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold; font-style: italic; font-family: Times New Roman,Times,serif">Risks
Relating to the Offering</span><span style="font-family: Times New Roman,Times,serif">, including that:</span></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="z214b15ffbf1f4f319634bb4c6e816653" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="margin-right: 25.05pt; line-height: 1.25">This offering is being made on a best efforts basis and we may sell fewer than all
        of the securities offered hereby and may receive significantly less in net proceeds from this offering, which will provide us only limited
        working capital.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="margin-right: 25.05pt; line-height: 1.25">Our management team will have immediate and broad discretion over the use of the
        net proceeds from this offering and may not use them effectively.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="margin-right: 25.05pt; line-height: 1.25">You will experience immediate dilution in the book value per share of the ordinary
        shares purchased in the offering.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="margin-right: 25.05pt; line-height: 1.25">Purchasers who purchase our securities in this offering pursuant to a securities
        purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement.</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top">&#9679;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top">
        <div style="margin-right: 25.05pt; line-height: 1.25">Ordinary shares representing a substantial percentage of our outstanding shares
        may be sold in this offering, which could cause the price of our ordinary shares to decline.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top">&#9679;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top">
        <div style="margin-right: 25.05pt; line-height: 1.25">There is no public market for the warrants being offered or pre-funded warrants
        in this offering.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top">&#9679;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top">
        <div style="margin-right: 25.05pt; line-height: 1.25">The pre-funded warrants are speculative in nature.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top">&#9679;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top">
        <div style="margin-right: 25.05pt; line-height: 1.25">The ordinary warrants may not have any value.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="margin-right: 25.05pt; line-height: 1.25">Holders of the pre-funded warrants and ordinary warrants offered hereby will have
        no rights as our ordinary shareholders with respect to the ordinary shares underlying those warrants until such holders exercise their
        warrants and acquire our ordinary shares, except as otherwise provided in the ordinary warrants.</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"> <br/> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><span style="font-weight: bold; font-style: italic">Risks Relating to Owning Our Ordinary Shares, </span>including
that:</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">The price of our ordinary shares and our warrants may be volatile.</div>
        </div> </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 88.46%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">A substantial number of our ordinary shares may be issued pursuant to the White Lion Purchase Agreement
        and/or the conversion terms of the A&amp;R Sponsor Promissory Note and the EarlyBird Convertible Note, which could cause (i) substantial
        dilution and (ii) the market price of the ordinary shares to decline.</div> </div> </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 88.46%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">We have no current plans to pay cash dividends on our ordinary
        shares for the foreseeable future.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div> </div> </div>

<div><span style="font-family: Times New Roman,Times,serif"><br/> </span> <span style="font-family: Times New Roman,Times,serif"><br/>
</span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">4</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> <span style="font-family: Times New Roman,Times,serif"><br/> </span>

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">The Offering</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="z6e2208d111ee48d5ae1400adc40f1363" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Ordinary shares</div> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 63%; vertical-align: top">
        <div style="line-height: 1.25">Up to&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ordinary shares on a best-efforts basis
        based on an assumed public offering price of $&#160; &#160; &#160; &#160; &#160; &#160; per ordinary share and accompanying ordinary warrant
        (the last reported sale price of our ordinary shares on the Nasdaq on&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; , 2024).</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 63%; vertical-align: top; font-family: Times New Roman,Times,serif"><br/> </td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Pre-funded warrants</div> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 63%; vertical-align: top">
        <div style="line-height: 1.25">We are also offering to those purchasers, if any, whose purchase of our ordinary shares in this offering
        would otherwise result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99%
        (or, at the election of the purchaser, 9.99%) of our outstanding ordinary shares immediately following the consummation of this offering,
        the opportunity, in lieu of purchasing ordinary shares, to purchase pre-funded warrants to purchase ordinary shares. Each pre-funded warrant
        will be immediately exercisable for one ordinary share at any time at the option of the holder until such pre-funded warrant is exercised
        in full, provided that the holder will be prohibited from exercising pre-funded warrants for ordinary shares if, as a result of such exercise,
        the holder, together with its affiliates and certain related parties, would own more than 4.99% (or, at the election of the purchaser,
        9.99%) of the total number of ordinary shares then issued and outstanding.&#160;The purchase price of each pre-funded warrant is $&#160;
        &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; (which is equal to the assumed public offering price per ordinary share and ordinary
        warrant to be sold in this offering minus $0.0001, the exercise price per ordinary share of each pre-funded warrant). For each pre-funded
        warrant we sell, the number of ordinary shares we are offering will be decreased on a one-for-one basis. This offering also relates to
        the ordinary shares issuable upon exercise of any pre-funded warrants sold in this offering. See &#8220;<span style="font-style: italic">Description
        of the Securities Offered</span>&#8221; for more information.</div> </td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 63%; vertical-align: top; font-family: Times New Roman,Times,serif"><br/> </td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Warrants</div> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 63%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">Each ordinary share and each pre-funded warrant will be sold together with one ordinary warrant.&#160;Each
        ordinary warrant will have an exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share (which will be no less than</div>
        <div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the assumed public offering price per ordinary share to
        be sold in this offering), will be exercisable upon issuance and will expire on&#160; &#160; &#160; &#160; &#160; , 2029. Because we will
        issue an ordinary warrant for each ordinary share and for each pre-funded warrant sold in this offering, the number of ordinary warrants
        sold in this offering will not change as a result of a change in the mix of ordinary shares and pre-funded warrants sold.&#160;This offering
        also relates to the ordinary shares issuable upon exercise of any ordinary warrants sold in this offering. See &#8220;<span style="font-style: italic">Description
        of the Securities Offered</span>&#8221; for more information.</div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 63%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Ordinary shares outstanding prior to this offering</div> </td>
    <td rowspan="1" style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 63%; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ordinary shares</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 63%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Ordinary shares outstanding after this offering</div> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 63%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">Ordinary shares (assuming no sale of any pre-funded warrants and no exercise of the ordinary warrants).</div>
        </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 63%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Use of proceeds</div> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 63%; vertical-align: top">
        <div style="line-height: 1.25">Assuming the maximum number of ordinary shares are sold in this offering at an assumed public offering
        price of $&#160; &#160; &#160; &#160; &#160; per ordinary share, which represents the closing price of our ordinary shares on Nasdaq on&#160;
        &#160; &#160; &#160; &#160; , 2024, and assuming no issuance of pre-funded warrants and no exercise of the ordinary warrants in connection
        with this offering, we estimate the net proceeds of the offering will be approximately $&#160; &#160; &#160; &#160; &#160; million, after
        deducting the placement agent fees and estimated offering expenses payable by us. However, this is a best efforts offering with no minimum
        number of securities or amount of proceeds as a condition to closing, and we may not sell all or any of these securities offered pursuant
        to this prospectus; as a result, we may receive significantly less in net proceeds.</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25">&#160;</span></div>
        <div style="line-height: 1.25">We currently intend to use the net proceeds from this offering to advance our pre-clinical clinical studies,
        and for general corporate purposes. Pending such uses, we intend to invest the net proceeds in bank deposits. We have not determined the
        amount of net proceeds to be used specifically for such purposes. As a result, our management will have broad discretion in the application
        of the net proceeds of this offering. See &#8220;<span style="font-style: italic">Use of Proceeds</span>&#8221; for additional information.</div>
        </td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 63%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Risk factors</div> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 63%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Before investing in our securities, you should carefully read and consider the information set forth in
        &#8220;Risk Factors&#8221; beginning on page 7.</div> </td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 63%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Nasdaq ticker symbols</div> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 63%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">Our ordinary shares and warrants are listed on the Nasdaq under the symbols &#8220;SLXN&#8221; and &#8220;SLXNW&#8221;,
        respectively. There is no established public trading market for the ordinary warrants being offered and the pre-funded warrants and we
        do not expect a market to develop. Without an active trading market, the liquidity of those warrants will be limited. In addition, we
        do not intend to list the pre-funded warrants or the ordinary warrants on The Nasdaq Global Market, any other national securities exchange
        or any other trading system.</div> </div>
        <div style="line-height: 1.25"> <br/> </div> </td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Best efforts offering</div> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 63%; vertical-align: top">
        <div style="line-height: 1.25">We have agreed to offer and sell the securities offered hereby to the purchasers through the Placement
        Agent. The Placement Agent is not required to buy or sell any specific number or dollar amount of the securities offered hereby, but it
        will use its reasonable best efforts to solicit offers to purchase the securities offered by this prospectus. See &#8220;<span style="font-style: italic">Plan
        of Distribution</span>&#8221; on page 145 of this prospectus.</div> </td> </tr>
  </table>

<div> <span style="font-family: Times New Roman,Times,serif"><br/> </span></div> </div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">5</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">

<div>

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div>&#160;</div>

<div>

<div style="text-indent: 36pt; line-height: 1.25">The number of the ordinary shares to be outstanding immediately after this offering
as shown above assumes that all of the ordinary shares offered hereby are sold and is based on&#160; &#160; &#160; &#160; &#160; &#160;
&#160; &#160;&#160; ordinary shares issued and outstanding as of&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; 2024. This number
excludes:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>up to 5,940,000 ordinary shares underlying an equivalent number of outstanding warrants at an exercise price of $11.50 per share;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>6,866,000 ordinary shares issuable pursuant to the A&amp;R Sponsor Promissory Note (based on the conversion of the entire $3,433,000
        principal amount of that note into ordinary shares at an assumed conversion price of $0.50 per share);</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>2,500,000 ordinary shares issuable pursuant to the EarlyBird Convertible Note (based on the conversion of the entire $1,250,000 principal
        amount of that note into ordinary shares at an assumed conversion price of $0.50 per share);</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ordinary shares issuable upon exercise of outstanding stock options
        under our equity incentive plan, at a weighted average exercise price of $&#160; &#160; &#160; &#160; &#160; ;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ordinary shares issuable upon the settlement of RSUs under our equity
        incentive plan; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">&#160; &#160; &#160; &#160; &#160;
        &#160; &#160; &#160; ordinary shares reserved for future awards under our equity incentive plan;</td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Unless otherwise indicated, all information in this prospectus
assumes or gives effect to:</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">no exercise of the options described above;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#9679;</div> </td>
    <td style="vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">no sale of pre-funded warrants in this offering;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">no exercise of the ordinary warrants and the placement agent warrants; and</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">the reverse share split effected on&#160; &#160; &#160; &#160; &#160; &#160;&#160; , 2024.</div> </td>
        </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;</div> </div> </div> </div> <span style="font-family: Times New Roman,Times,serif"><br/>
</span>

<div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">6</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="RISKFACTORS"><!--Anchor--></span>RISK
FACTORS</div>

<div style="text-align: center; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Investing in our securities
involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other
information contained in this prospectus, including our financial statements and related notes appearing at the end of this prospectus
and in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before
deciding to invest in our securities. If any of the events or developments described below were to occur, our business, prospects, operating
results and financial condition could suffer materially, the trading price of our ordinary shares could decline, and you could lose all
or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties
not presently known to us or that we currently believe to be immaterial may also adversely affect our business.</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Risks Related to Our Financial Condition and
Capital Requirements</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We are a&#160;development-stage&#160;company
and have a limited operating history on which to assess our business. We have incurred significant losses since its inception and anticipate
that we will continue to incur significant losses for the foreseeable future.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We are a development stage company with
a limited operating history focused on the discovery and development of treatments based on the emerging therapeutic modality RNA interference
(RNAi), a biological process in which ribonucleic acid (RNA) molecules inhibit gene expression. Our proposed treatment, which we refer
to as SIL-204B, consists of locally administered small interfering RNAs, or siRNA, to KRAS G12D- or KRAS G12V-mutations&#160;(G12D/V),
which is the gene driver that causes development of tumors and human cancer (oncogenic). We have incurred net losses since our inception
in November&#160;2008, including net losses of $5.1&#160;million for the year ended December&#160;31, 2023 and $2.9&#160;million for the
six months ended June&#160;30, 2024. As of June 30, 2024, we have an accumulated deficit of $29.7 million.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We have devoted substantially all of our
financial resources to design and develop our product candidates, including conducting preclinical and clinical studies and providing
general and administrative support for these operations. To date, we have financed our operations primarily through the sale of equity
securities and through royalty-bearing&#160;grants that we received from Israel&#8217;s Innovation Authority, or the IIA.&#160;The amount
of its future net losses will depend, in part, on the rate of its future expenditures and its ability to obtain funding through equity
or debt financings, strategic collaborations, or grants. Biopharmaceutical product development is a highly speculative undertaking and
involves a substantial degree of risk. We are the early stages of clinical and preclinical development for its product candidates, we
have we have not yet commenced pivotal clinical studies for any product candidate and it may be several&#160;years, if ever, before we
complete pivotal clinical studies and have a product candidate approved for commercialization. Even if we obtain regulatory approval to
market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval,
and its ability to achieve sufficient market acceptance, pricing, reimbursement from third-party&#160;payors, and adequate market share
for its product candidates in those markets.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We expect to continue to incur significant
expenses and increasing operating losses for the foreseeable future. We anticipate that its expenses will increase substantially if and
as we:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z374db9074283435c859e52b4036a5e07" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">continue and expand our research and preclinical and clinical
        development of our product candidates;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9dfbee1065d84601819f47ad8414432b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">initiate additional preclinical, toxicology, clinical, or other
        studies for our product candidates;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z331ea48290d048ab96f8b31010d42ba1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">continue to improve our quality standards and change or add
        additional manufacturers or suppliers;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z407e991d09f648b790ceb1649a6f4447" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">seek regulatory and marketing approvals for our product candidates
        that successfully complete clinical studies;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">7</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaa2c4124583f44ba80526f0c48d77277" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">establish a sales, marketing, and distribution infrastructure
        to commercialize any products for which we may obtain marketing approval;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="zd574639c2fe549b98f381afb9999fbbc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">seek to identify, assess, acquire, license, and/or develop other product candidates;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc6e9eee93f20402ba1d0f60f603f213d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">enter into license agreements;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z37078abb3a0646528db2575cf0313920" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">seek to maintain, protect, and expand our intellectual property portfolio;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5dca374fb22e440b9efe0c410eefd7c3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">seek to attract and retain skilled personnel;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z746205026bf84b6e984c93018abc18fa" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">create additional infrastructure to support its operations as a public company and our product development
        and planned future commercialization efforts; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z475580e6a38f4fe19c88ca8db35132a5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">experience any delays or encounter issues with any of the above, including but not limited to failed studies,
        complex results, safety issues, or other regulatory challenges that require longer follow-up&#160;of existing studies, additional major
        studies, or additional supportive studies in order to pursue marketing approval.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Further, the net losses we incur may fluctuate
significantly from quarter to quarter and year to year, such that a period-to-period&#160;comparison of its results of operations may
not be a good indication of our future performance.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We have never generated
any revenue from product sales and may never be profitable.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We have we have no products approved for
commercialization and has never generated any revenue. Our ability to generate revenue and achieve profitability depends on its ability,
alone or with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory and marketing approvals
necessary to commercialize, one or more of our product candidates. We do not anticipate generating revenue from product sales for the
foreseeable future. Our ability to generate future revenue from product sales depends heavily on its success in many areas, including
but not limited to:</div> </div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="ze96b3296002f439f8d28f29fd7c14f28" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">completing research and preclinical and toxicology and clinical development of our product candidates;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6fd355377df64ce8b7ae7dec93b088f0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">obtaining regulatory and marketing approvals for its product candidates, if and when we complete clinical
        studies;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb2ccb82d7ed94c1cbaaf4396183b1240" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">developing a sustainable and scalable in-house&#160;manufacturing process, meeting all regulatory standards
        for approved product candidates, and in some instances, establishing and maintaining supply and manufacturing relationships with third
        parties that can conduct the process and provide adequate (in amount and quality) products to support clinical development and the market
        demand for product candidates, if approved;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z85cf760a3d3d4467a595d70db4e7afed" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">launching and commercializing product candidates, if and when we obtain regulatory and marketing approval,
        either directly or with a collaborator or distributor;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd2215ee47c874e89b755c309ce7f9dec" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">exposing, educating and training physicians to use our products;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5a1d28a450024f7385573536b35632f7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">obtaining market acceptance of our product candidates as viable treatment options;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3d75d43ea54b428f951809543dc0dbe1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">addressing any competing technological and market developments;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z0dc69e9bc1174009ba2e8c6828bf2682" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">identifying, assessing, acquiring and/or developing new product
        candidates;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">8</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="zcd885c5e0087477f818f70337569cdc4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">negotiating favorable terms in any collaboration, licensing,
        or other arrangements into which we may enter;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8737785af37d4d1a90e4c170c07c49a8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">maintaining, protecting, and expanding its portfolio of intellectual
        property rights, including patents, trade secrets, and know-how; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zac78d5c0a16a43cdb5a46704f9f5f811" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">attracting, hiring, and retaining qualified personnel.</div>
        </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Even if one or more of the product candidates
that we develop is approved for commercial sale, it anticipates incurring significant costs associated with commercializing any approved
product candidate. Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency (EMA)
or other regulatory agencies, domestic or foreign, or ethical committees in medical centers, to change its manufacturing processes or
assays or to perform clinical, nonclinical, or other types of studies in addition to those that it currently anticipates. In cases where
we are successful in obtaining regulatory approvals to market one or more of its product candidates, its revenue will be dependent, in
part, upon the size of the markets in the territories for which it gains regulatory approval, the accepted price for the product, the
ability to get reimbursement at any price, and whether it owns the commercial rights for that territory. If the number of its addressable
disease patients is not as significant as it estimates, the indication approved by regulatory authorities is narrower than it expects,
or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate
significant revenue from sales of such products, even if approved. Additionally, there might be changes in supply or other changes in
the approved drugs of which its products will be administrated in combination, where such changes can affect its revenues. Further, if
we are not able to generate revenue from the sale of any approved products, we may be forced to cease operations.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">We expect that we will
need to raise substantial additional funding before we can expect to become profitable from product sales. This additional financing may
not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit, or
terminate our product development efforts or other operations.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We are currently advancing its SIL-204B&#160;platform
product through preclinical and clinical development. Developing its product candidates is expensive, and we expect its research and development
expenses to increase substantially in connection with its ongoing activities, particularly as it advances its product candidates through
clinical studies.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If its product candidates enter and advance
through preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing,
marketing and sales capabilities or contract with other organizations to provide those capabilities for it. We have used substantial funds
to develop its product candidates and delivery technologies and will require significant funds to conduct further research and development
and preclinical testing and clinical trials of its product candidates, to seek regulatory approvals for its product candidates and to
manufacture and market products, if any, which are approved for commercial sale.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">As of June 30, 2024, our cash and cash equivalents
were $1.75&#160;million. Based upon its then expected level of operating expenditures, Silexion had substantial doubt about its ability
to continue as a going concern as of such date. Please see the risk factor below titled &#8220;<span style="font-style: italic">our independent
registered public accounting firm&#8217;s report contains an explanatory paragraph</span>&#8230;&#8221; Beyond its activities for the
next 12&#160;months, we furthermore expect that it will require substantial additional capital to advance manufacturing capabilities for,
to obtain regulatory approval for, and to commercialize, our product candidates. In addition, our operating plans may change as a result
of many factors that may currently be unknown to it, and we may need to seek additional funds sooner than planned. Our future funding
requirements will depend on many factors, including but not limited to:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0cd57490658a4671a15708a9560a3ea6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the scope, rate of progress, results and cost of our clinical
        studies, preclinical testing, toxicology studies, and other related activities;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">9</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span>
</div>

<table cellspacing="0" cellpadding="0" id="zf158179c749e4729b0eeb153bce4de5f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the cost of manufacturing clinical supplies, and establishing
        commercial supplies of our product candidates and any future products;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z11798017303346babf879838221a37dd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the number and characteristics of product candidates that we
        pursue;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z29dae668169542319032c65d3f72dc63" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the cost, timing, and outcomes of regulatory approvals;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4ea2fe1524d041b5878357f78f4b39bd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the cost and timing of establishing sales, marketing, and distribution
        capabilities; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd7f878a6d2504c8eac4c500e88b0c901" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the terms and timing of any collaborative, licensing, and other
        arrangements that we may establish.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Any additional fundraising efforts may divert
our management from our&#160;day-to-day&#160;activities, which may adversely affect our abilities to develop and commercialize our product
candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us,
if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders, and the issuance
of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ordinary
shares to decline due to expected or actual dilution. The incurrence of indebtedness could result in increased fixed payment obligations,
and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire, sell, or license intellectual property rights, and other operating restrictions that could adversely impact
our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise
at an earlier stage than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or product
candidates or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on our business, operating results,
and prospects. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if
market conditions are favorable or if we have specific strategic considerations.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If we are unable to obtain funding on a
timely basis, it may be required to significantly curtail, delay, or discontinue one or more of our research, development or manufacturing
programs or the commercialization of any product candidates, or be unable to expand its operations or otherwise capitalize on our business
opportunities, as desired, which could materially affect our business, financial condition, and results of operations.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Our independent registered
public accounting firm&#8217;s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue
as a &#8220;going concern.&#8221;</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We have limited cash resources and will
need to obtain additional funds in order to satisfy our liquidity needs. Silexion will require significant funds to conduct further research
and development and preclinical testing and clinical trials of our product candidates, to seek regulatory approvals for our product candidates
and to manufacture and market products, if any, which are approved for commercial sale. In light of our significant working capital needs
and the absence of any committed source of financing to meet those needs, there may be substantial doubt raised about our ability to continue
as a &#8220;going concern.&#8221; Please see the explanatory paragraph under the heading &#8220;Substantial Doubt about the Company&#8217;s
Ability to Continue as a Going Concern&#8221; in our independent auditors&#8217; report on our financial statements that appear in this
prospectus. Those financial statements do not include any adjustments that might result from our inability to continue as a &#8220;going
concern.&#8221;</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">The historical financial
results of Silexion and unaudited pro forma financial information included herein may not be indicative of what our actual financial position
or results of operations would have been.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The historical financial results of Silexion
included in this prospectus do not reflect the financial condition, results of operations or cash flows it would have achieved as a public
company during the periods presented or those the Company will achieve in the future. Our financial condition and future results of operations
could be materially different from amounts reflected in certain of our historical financial statements included elsewhere in this prospectus,
and it may be difficult for investors to compare our future results to historical results or to evaluate its relative performance or trends
in our business.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">10</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Similarly, the unaudited pro forma financial
information included herein is presented for illustrative purposes only and has been prepared based on a number of assumptions. Accordingly,
such pro forma financial information is not necessarily indicative of what our actual financial position or results of operations would
have been had the Business Combination been completed on the dates indicated, and our actual financial condition and results of operations
may vary materially from such pro forma financial information, including as a result of such assumptions not being accurate. See &#8220;Unaudited
Pro Forma Condensed Combined Financial Information.&#8221;</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Risks Related to the Research and Development
of Our Product Candidates</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">The approach we are
taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We have concentrated our efforts and therapeutic
product research on RNAi technology, and RNAi drug delivery and our future success depends on the successful development of this technology
and products based on it. We have not received regulatory approval to market therapeutics utilizing RNAi based drugs, including siRNAs,
the class of molecule we are trying to develop into products. The scientific discoveries that form the basis for our efforts to discover
and develop new drugs are relatively new. The scientific evidence to support the feasibility of developing drugs and the delivery of such
drugs based on these discoveries is both preliminary and limited. Skepticism as to the feasibility of developing RNAi therapeutics for
oncology has been expressed in scientific literature. For example, there are potential challenges to achieving safe RNAi therapeutics
based on the so-called&#160;off-target&#160;effects and activation of the interferon response, and other potential challenges to achieve
safe and potent levels of RNAi drugs due to complications associated with drug delivery. In addition, decisions by other companies with
respect to their RNAi development efforts may increase skepticism in the marketplace regarding the potential for RNAi therapeutics.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Relatively few product candidates based
on these discoveries have ever been tested in animals or humans. siRNAs may not naturally possess the inherent properties typically required
of drugs, such as the ability to be stable in the body long enough to reach the tissues in which their effects are required, or the ability
to enter cells within these tissues in order to exert their effects. We are currently has only limited data, and no conclusive evidence,
to suggest that it can introduce these drug-like&#160;properties into siRNAs. We may spend large amounts of money trying to introduce
these properties, and may never succeed in doing so. In addition, these compounds may not demonstrate in patients the chemical and pharmacological
properties ascribed to them in laboratory studies, and they may interact with human biological systems in unforeseen, ineffective or harmful
ways. As a result, we may never succeed in developing a marketable product, we may not become profitable and the value of our ordinary
shares may decline.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The FDA has relatively limited experience
with RNAi and siRNA based therapeutics. Limited granted approvals to any person or entity, including us, to market and commercialize therapeutics
using RNAi based drugs including siRNA, which may increase the complexity, uncertainty and length of the regulatory approval process for
our product candidates. Further, siRNA therapies are part of a broader therapeutic category called oligonueciotides, and there are only
a few approved drugs based on this therapeutic category. We may never receive approval to market and commercialize any product candidate.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Further, our focus on RNAi technology for
developing drugs, as opposed to multiple, more proven technologies for drug development, increases the risks associated with the ownership
of our ordinary shares. If we are not successful in developing a product candidate using RNAi technology, we may be required to change
the scope and direction of our product development activities. In that case, we may not be able to identify and implement successfully
an alternative product development strategy.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We are heavily dependent
on the success of our product candidates, which are in the early stages of preclinical or clinical development. We cannot give any assurance
that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.</div> </div>
</div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">To date, we have invested a substantial
amount of our efforts and financial resources to: (i)&#160;identify and develop our product candidates, including conducting preclinical
and clinical studies and providing general and administrative support for these operations; and (ii)&#160;develop and secure our intellectual
property portfolio for our product candidates. Our future success is dependent on our ability to successfully develop, obtain regulatory
approval for, and then successfully commercialize one or more product candidates. We currently generate no revenue from sales of any drugs
or technology platforms, and we may never be able to develop or commercialize a marketable drug.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">11</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Each of our product candidates is in the
early stages of development and will require additional clinical development (and in some cases additional preclinical development), management
of nonclinical, clinical and manufacturing activities, regulatory approval, obtaining adequate manufacturing supply, building of a commercial
organization, and significant marketing efforts before we generate any revenue from product sales. We have concluded Phase&#160;II study
on first-generation&#160;Loder and moved on to SIL-204B.&#160;Silexion hopes to initiate the next clinical trial with SIL-204B&#160;during
the first half of 2026 for locally advanced pancreatic cancer. We are not permitted to market or promote any of our product candidates
before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory
approval for any of our product candidates.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We have never submitted marketing applications
to the FDA or comparable foreign regulatory authorities. We cannot be certain that any of our product candidates will be successful in
clinical studies or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are
successful in clinical studies. If it does not receive regulatory approvals for our product candidates, we may not be able to continue
our operations.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We generally plans to seek regulatory approval
to commercialize our product candidates in the United&#160;States, the EU and in additional foreign countries. To obtain regulatory approval
in other countries, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy,
chemistry, manufacturing and controls, clinical studies, commercial sales, pricing, and distribution of our product candidates. Even if
we are successful in obtaining approval in one jurisdiction, it cannot ensure that it will obtain approval in any other jurisdictions.
If we are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could
be negatively affected.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">The regulatory approval
processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately
unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The time required to develop a drug and obtain approval by the
FDA and comparable foreign authorities is unpredictable, typically takes many years following the commencement of clinical studies, and
depends upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain
approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may
cause delays in the approval or the decision not to approve an application. We have we have not obtained regulatory approval for any product
candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future
will ever obtain regulatory approval.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Applications for our product candidates could
fail to receive regulatory approval for many reasons, including but not limited to the following:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z58ac521c994b420facf8a3e6df0ba7cf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the FDA or comparable foreign regulatory authorities may disagree
        with the design or implementation of our clinical studies;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z36f4834fb66345c0963b81b7273c5f70" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">We may be unable to demonstrate to the FDA or comparable foreign
        regulatory authorities that a product candidate&#8217;s benefit to risk ratio for its proposed indication is acceptable;</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="z5b66138cffa34392aa73843737b4357e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">the population studied in the clinical program may not be sufficiently broad or representative to assure
        safety in the full population for which we seek approval;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7c91b4833c2c46899b5fb14c874c9284" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from
        preclinical studies or clinical studies;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">12</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z4766b6a235854b9fa5bd3fd299d1e5af" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">the data collected from clinical studies of our product candidates may not be sufficient to support the
        submission of a new drug application (NDA) or a biologics license application (BLA) or other submission or to obtain regulatory approval
        in the United&#160;States or elsewhere;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfe49b4e6da774bbaaa678d14a36dd32c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test
        procedures and specifications, or facilities of third-party&#160;manufacturers with which we contract for clinical and commercial supplies;
        and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc3c05ac77fe8418a8004d069ec32a709" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly
        change in a manner rendering our clinical data insufficient for approval.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">This lengthy development and approval process,
as well as the unpredictability of the results of clinical studies, may result in our failing to obtain regulatory approval to market
any of its product candidates, which would significantly harm its business, and our consolidated results of operations and prospects.</div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Clinical drug development
involves a lengthy and expensive process with an uncertain outcome, and results of preclinical activity or earlier studies may not be
predictive of future study results.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Before obtaining marketing approval from
regulatory authorities for the sale of its product candidates, we must conduct extensive clinical studies to demonstrate the safety and
efficacy of the product candidates in humans. Clinical testing is expensive and can take many&#160;years to complete, and its outcome
is inherently uncertain. Failure can occur at any time during the clinical study process. The results of preclinical studies and early
clinical studies of product candidates often are not predictive of the results of later-stage&#160;clinical studies. In general, even
product candidates that have shown promising results in preclinical activities or early-stage&#160;clinical studies may still suffer significant
setbacks in subsequent registration clinical studies. For example, the safety or efficacy results generated to date in preclinical and
clinical studies for siG12DLoder or preclinical studies with SIL-204B&#160;do not ensure that later clinical studies will demonstrate
similar results. There is a high failure rate for drugs and biologics proceeding through clinical studies, and product candidates in later
stages of clinical studies may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies
and initial clinical studies. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical
studies due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies. Moreover, preclinical
and clinical data are often susceptible to varying interpretations and analyses. We do not know whether any Phase&#160;1, Phase&#160;2,
Phase&#160;3 or other clinical studies it may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain
regulatory approval to market its drug candidates.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Events that may prevent successful or timely
completion of clinical development include but are not limited to:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z901e801e971e4cefa756e624f318d97e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">inability to generate sufficient preclinical, toxicology, or
        other&#160;<span style="font-style: italic">in vivo</span>&#160;or&#160;<span style="font-style: italic">in vitro</span>&#160;data to
        support the initiation of human clinical studies;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z023387806ce844bdaf9217d1486d257b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">delays in reaching a consensus with regulatory agencies on study
        design;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd6ffe274843c4152ab2811f3cb1dfc9a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">delays in reaching agreement on acceptable terms with prospective
        contract research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary
        significantly among different CROs and clinical study sites;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfe0d4b12a3ce4494afb2331b9bb24274" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">delays in obtaining required Institutional Review Board (IRB)
        or Ethics Committee approval at each clinical study site;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0190b3f0c39346058298bba3c61d5d50" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">imposition of a clinical hold by regulatory agencies, after review
        of an investigational new drug (IND) application, or equivalent application, or an inspection of its clinical study operations or study
        sites;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdf333797587944f0a3bb5af1be06e92a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">difficulty collaborating with patient groups and investigators;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z928e4090f1a64dfe9aafa93ea56fcc23" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">failure by its CROs, other third parties, or us to adhere to
        clinical study requirements;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze87ac1c2f67c4cd2b035a399cef248ec" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">failure to perform in accordance with the FDA&#8217;s good clinical
        practices requirements or applicable regulatory guidelines in other countries;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">13</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="z52f3081ca4f5437981126f0c403161a5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">occurrence of serious adverse events associated with the product
        candidate that are viewed to outweigh its potential benefits;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8c5b80b874334edfabd930aff2f23d0f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the cost of clinical studies of its drug candidates being greater
        than it anticipates;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaab9e340f65a45f39505e728c70c10ae" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">clinical studies of its drug candidates producing negative or
        inconclusive results, which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or abandon drug
        development programs; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9e616c8073404f93a6369af482bb1859" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">failures associated with data interpretation, data management
        and data storage of such studies.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If we ultimately is unable to successfully
complete clinical development of its product candidates, it would be forced to cease operations. Clinical study delays could also shorten
any periods during which its products have patent protection and may allow its competitors to bring products to market before we do, which
could impair its ability to obtain orphan exclusivity and to successfully commercialize its product candidates.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We may find it difficult
to enroll patients in its clinical studies. Difficulty in enrolling patients could delay or prevent clinical studies of its product candidates.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Identifying and qualifying patients to participate
in clinical studies of our product candidates is critical to its success. The timing of its clinical studies depends in part on the speed
at which it can recruit patients to participate in testing its product candidates, and we may experience delays in its clinical studies
if it encounters difficulties in enrollment.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Some of the conditions for which we plan
to evaluate its current product candidates are relatively rare diseases. For example, according to the National Cancer Institute, approximately
61,000 patients were diagnosed with pancreatic cancer in the U.S.&#160;in 2020. Accordingly, there are limited patient pools from which
to draw for clinical studies. In addition to the relative rarity of these diseases, the eligibility criteria of its clinical studies will
further limit the pool of available study participants as we will require that patients have specific characteristics that it can measure
or to assure their disease is either severe enough or not too advanced to include them in a study. We also may not be able to identify,
recruit, and enroll a sufficient number of patients to complete its clinical studies because of the perceived risks and benefits of the
product candidate under study, the availability and efficacy of competing therapies and clinical studies, the proximity and availability
of clinical study sites for prospective patients, and the patient referral practices of physicians.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In addition, even for the more prevalent
diseases which we target, such as prostate and breast cancer, enrolling patients in its clinical studies may be difficult. There may be
several ongoing clinical studies for these diseases (both RNAi based and otherwise), and we may face competition in enrolling patients.
The number of patients in such clinical studies might be significantly large. In addition, the time period required to achieve indications
of safety and efficacy in such studies may be very long. Some of these competing studies may be conducted by other biopharmaceutical companies
with more experience in clinical testing and with much greater financial, technical and human resources than we have.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If patients are unwilling to participate
in its studies for any reason, the timeline for recruiting patients, conducting studies, and obtaining regulatory approval of our potential
products will be delayed.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Our product candidates
and the administration of its product candidates may cause undesirable side effects or have other properties that could delay or prevent
their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following
marketing approval, if any.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Undesirable side effects including toxicology
caused by its product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical studies and could result
in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. For example,
there are known immune stimulation and other side effects associated with RNAi. The implantation of SIL-204B&#160;may entail the use of
endoscopic ultrasound (EUS) needles, which may cause pancreatitis, bleeding or other procedural related safety issues. The Phase&#160;2
clinical study with siG12DLoder indicated that Loder treatment was well tolerated. Safety events that were observed were primarily related
to procedure, mainly reversible abdominal pain. In addition, the presence of a foreign body such as its SIL-204B) in human tissue may
cause inflammation. Results of our studies could reveal a high and unacceptable severity and prevalence of these or other side effects.
In such an event, such studies could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order
us to cease further development of or deny or withdraw approval of its product candidates for any or all targeted indications.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">14</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The drug-related, drug-product&#160;related,
and administration related side effects could affect patient recruitment, the ability of enrolled patients to complete the study, or result
in potential product liability claims. we do not currently have product liability insurance and does not anticipate obtaining product
liability insurance until such time as we have received FDA or other comparable foreign authority approval for a product and there is
a product that is being provided to patients outside of clinical trials.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Additionally, if one or more of its product
candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of
potentially significant negative consequences could result, including but not limited to:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc465d99966744a1c978963037edf08ae" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">regulatory authorities may withdraw approvals of such product;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5dcfdd6f077948f6bbe98654fa8781ab" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">regulatory authorities may require additional warnings on the
        label;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1285205655294eee9ea3aaa692aa7081" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">We may be required to create a Risk Evaluation and Mitigation
        Strategy (REMS) plan or similar plan in other jurisdictions, which could include a medication guide outlining the risks of such side effects
        for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;</div> </div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z043a62f7dd274e20b1d31a2f80ea41fd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">We could be sued and held liable for harm caused to patients;
        and</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze83a756bedce4cfbab25c4ec6e00f0f4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Our reputation may suffer.</div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Any of these events could prevent us from
achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm its business,
results of operations, and prospects.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Even if we obtain regulatory
approval for a product candidate, its products will remain subject to regulatory scrutiny.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">If our product candidates are approved, they will be subject to ongoing regulatory requirements
for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing&#160;studies,
and submission of safety, efficacy, and other post-market&#160;information, including both federal and state requirements in the United&#160;States
and other jurisdictions, where the product might be marketed. Accordingly, us and others with whom it works must continue to expend time,
money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Any regulatory approvals that we receive
for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or
to the conditions of approval, or contain requirements for potentially costly post-marketing&#160;testing, including Phase&#160;4 clinical
trials, and surveillance to monitor the safety and efficacy of the product candidate. We will also be required to report certain adverse
reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion for its products.
Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be
consistent with the information in the product&#8217;s approved label. As such, we may not promote our products for indications or uses
for which they do not have FDA approval. The holder of an approved NDA or BLA must also submit new or supplemental applications and obtain
FDA approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct
post-marketing&#160;clinical studies to verify the safety and efficacy of its products in general or in specific patient subsets. If we
obtain original marketing approval via the accelerated approval pathway, it could be required to conduct a successful post-marketing&#160;clinical
study to confirm clinical benefit for its products. An unsuccessful post-marketing&#160;study or failure to complete such a study could
result in the withdrawal of marketing approval. Furthermore, any new legislation addressing drug safety issues could result in delays
in product development or commercialization or increased costs to assure compliance. Foreign regulatory authorities impose similar requirements.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">15</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If a regulatory agency discovers previously
unknown problems with a product, such as adverse events of unanticipated severity or frequency, or disagrees with the promotion, marketing
or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the
product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may,
among other things:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z22b5013358a6435fae0f532a6328233f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">issue warning letters;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z44f74ad5a37c4b19aa255f526131f691" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">impose civil or criminal penalties;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1ed27b85dbc94a408e87ec93c0841760" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">suspend or withdraw regulatory approval;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb895e4f8dccc4f40a4a0fb1a6f3ea9d7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif">suspend any of our ongoing clinical studies;</div>
        </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z34067454981740bd9a3ec073683db622" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">refuse to approve pending applications or
        supplements to approved applications submitted by Silexion; or</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5389eca72c05448bb80477ef151f274f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">seize or detain products, or require a product
        recall.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Any government investigation of alleged
violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure
to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue
from its products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of the Company and its operating
results will be adversely affected.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">The FDA and other regulatory
agencies actively enforce the laws and regulations prohibiting the promotion of&#160;off-label&#160;uses.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If any of its product candidates are approved
and they are found to have been improperly promoted for unapproved uses of those products, we may become subject to significant liability.
The FDA and other regulatory agencies or other governmental bodies strictly regulate the promotional claims that may be made about prescription
products, such as its product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by
the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for
a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label.
If we are found to have promoted such unapproved, or off-label, uses, they may become subject to significant liability. The U.S.&#160;federal
government has levied large civil and criminal fines against companies for alleged improper promotion of off-label&#160;use and has enjoined
several companies from engaging in off-label&#160;promotion. The FDA has also requested that companies enter into consent decrees or permanent
injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of its product
candidates, if approved, it could become subject to significant liability, which would materially adversely affect its business and financial
condition.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">We and our collaborators are subject to significant regulation with
respect to manufacturing its product candidates. The facilities we subcontract to for manufacturing may not meet regulatory requirements
and may have limited capacity.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">All entities involved in the preparation
of therapeutics for clinical studies or commercial sale are subject to extensive regulation. Components of a finished therapeutic product
approved for commercial sale or used in late-stage&#160;clinical studies must be manufactured in accordance with current GMP (cGMP) or,
in other countries, GMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation
and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control
of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of its product
candidates that may not be detectable in final product testing. Us, our collaborators, or any contract manufacturers must supply all necessary
documentation in support of an NDA, BLA, or Marketing Authorization Application (MAA) on a timely basis and must adhere to Good Laboratory
Practices (GLP) and cGMP/GMP regulations enforced by the FDA and other regulatory agencies through their facilities and data and documentation
inspection programs. We have never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite
regulatory authority approvals to do so. Our facilities and quality systems, and those of its collaborators and any third-party&#160;contractors,
must pass a pre-approval&#160;inspection for compliance with the applicable regulations as a condition of regulatory approval of its product
candidates or any of its other potential products. In addition, the regulatory authorities may, at any time, inspect a manufacturing facility
involved with the preparation of its product candidates or its other potential products or the associated quality systems for compliance
with the regulations applicable to the activities being conducted. If these facilities do not pass a preapproval plant inspection, regulatory
approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of
the regulatory authority, if ever.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">16</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The regulatory authorities also may, at
any time following approval of a product for sale, audit a manufacturing facility. If any such inspection or audit identifies a failure
to comply with applicable regulations or if a violation of its product specifications or applicable regulations occurs independent of
such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming
for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales
or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us, or third parties with whom it contracts
could materially harm its business.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If we, our collaborators, or any of our
third-party&#160;manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authorities can impose regulatory
sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, withdrawal
of an approval, or suspension of production. As a result, our business, financial condition, and results of operations may be materially
harmed.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">These factors could cause us to incur higher
costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals, or commercialization of
our product candidates.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We are subject to a
multitude of manufacturing risks, any of which could substantially increase its costs and limit supply of its product candidates.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The process of manufacturing our product
candidates is complex, highly regulated, and subject to several risks, including but not limited to:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc09517e5f1ed4e1d94f37974829c1930" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the process of manufacturing RNAi-drugs, drug substances, and
        RNAi-delivery&#160;vehicles, such as our product candidates, is extremely susceptible to product loss due to contamination, equipment
        failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing
        processes for any of its product candidates could result in reduced production yields, product defects, and other supply disruptions.
        If microbial, viral, or other contaminations are discovered in its product candidates or in the manufacturing facilities in which its
        product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy
        the contamination; and</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z887190e3e7294474b3f7659dd2015ff9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the manufacturing facilities in which its product candidates
        are made could be adversely affected by equipment failures, labor shortages, natural disasters, power failures, and numerous other factors.</div>
        </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Any adverse developments affecting manufacturing
operations for our product candidates may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls, or other
interruptions in the supply of our product candidates. We may also have to take inventory write-offs&#160;and incur other charges and
expenses for product candidates that fail to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing
alternatives.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">17</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Risks Related to Our Reliance on Third Parties</div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">We rely on third parties
to conduct its preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their
contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval
for or commercialize its product candidates, and our business could be substantially harmed</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">We have relied upon and plans to continue to rely upon third-party CROs to monitor and
manage data for its ongoing preclinical and clinical programs. We rely on these parties for execution of its preclinical and clinical
studies, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of its studies
is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and its reliance on the CROs does
not relieve us of its regulatory responsibilities. we and our CROs and other vendors are required to comply with cGMP and GLP, which are
regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area (EEA) and
comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these
regulations through periodic inspections of study sponsors, principal and other investigators, study sites, and other contractors. If
we or any of its CROs or vendors fail to comply with applicable regulations, the clinical data generated in its clinical studies may be
deemed unreliable and the FDA, EMA, or comparable foreign regulatory authorities may require us to perform additional clinical studies
before approving its marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory
authority will determine that any of its clinical studies comply with Good Clinical Practices (GCP) regulations. In addition, its clinical
studies must be conducted with product produced under cGMP/GMP regulations. Our failure to comply with these regulations may require us
to repeat clinical studies, which would delay the regulatory approval process.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If any of its relationships with these third-party&#160;CROs
terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. In addition,
its CROs are not its employees, and, except for remedies available to us under its agreements with such CROs, we cannot control whether
or not they devote sufficient time and resources to its on-going&#160;clinical, nonclinical, and preclinical programs. If CROs do not
successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality
or accuracy of the clinical data they obtain is compromised due to the failure to adhere to its clinical protocols, regulatory requirements,
or for other reasons, its clinical studies may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval
for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result, its results
of operations and the commercial prospects for its product candidates would be harmed, its costs could increase, and its ability to generate
revenue could be delayed.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Switching or adding additional CROs involves
additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work.
As a result, delays occur, which can materially impact its ability to meet its desired clinical development timelines. Though we carefully
manage its relationships with its CROs, there can be no assurance that we will not encounter similar challenges or delays in the future
or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">18</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We currently rely on
third parties to manufacture the raw materials and products that we use to create its product candidates and to supply us with the medical
devices used to administer such product. This reliance requires us to share its trade secrets with these third parties, which increases
the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Because we rely on third parties to provide
it with the materials that it uses to develop and manufacture its product candidates, we may, at times, share trade secrets with such
third parties. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material
transfer agreements, collaborative research agreements, consulting agreements, or other similar agreements with its collaborators, advisors,
employees, and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights
of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed
when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade
secrets become known by its competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation
of these agreements. Given that our proprietary position is based, in part, on its know-how&#160;and trade secrets, a competitor&#8217;s
discovery of its trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse
effect on our business.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Our reliance on third
parties to manufacture the raw materials and products that are used to create its product candidates and to supply it with the medical
devices used to administer such product might cause its business harm if manufacturers fail to provide it with sufficient quantities of
these materials and products or fail to do so at acceptable quality levels or prices.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We do not currently have the infrastructure
or capability internally to develop the raw materials and other products that we use to manufacture its product candidates, and it lacks
the resources and the capability to manufacture the medical devices which it uses to administer its products. There are a limited number
of suppliers for these raw materials, products and devices, and there may be a need to identify alternate suppliers to prevent a possible
disruption to its clinical studies, and, if approved, ultimately for commercial sale. We cannot assure you that it will be able to identify
alternate suppliers if the need arises at acceptable quality levels or prices.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Risks Related to Commercialization of Our
Product Candidates</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">If the market opportunities
for our product candidates are smaller than we believe they are, our revenue may be adversely affected, and its business may suffer. Because
some of the target patient populations of its product candidates are small, we must be able to successfully identify patients and achieve
a significant market share to maintain profitability and growth.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We focus a substantial part of its research
and product development on treatments for locally advanced pancreatic cancer with certain specific mutations. Given the small number of
patients who have this disease with these mutations, it is critical to Silexion&#8217;s ability to grow and become profitable that it
continue to successfully identify effected patients. Our projections of both the number of people who have these diseases, as well as
the subset of people with these diseases who have the potential to benefit from treatment with its product candidates, are based on its
beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics,
patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence
of these diseases. The number of patients may turn out to be lower than expected. The effort to identify patients with diseases we seek
to treat is in its early stages, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally,
the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with
its product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect
our results of operations and business.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">19</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We do not have experience
producing its product candidates at commercial levels and may not achieve the necessary regulatory approvals or produce product candidates
at the quality, quantities, locations, and timing needed to support commercialization. Additionally, we intend to rely on&#160;third-party&#160;manufacturers
to produce the raw materials and products that we use to manufacture its product candidates, but we have not entered into binding agreements
with any such manufacturers to support commercialization.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We do not currently have the experience
or ability to produce product candidates at commercial levels. We may run into technical or scientific issues related to manufacturing
or development that we may be unable to resolve in a timely manner or with available funds. We also have not completed all of the characterization
and validation activities necessary for commercialization and regulatory approvals. If we do not conduct all such necessary activities,
our commercialization efforts will be harmed.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Although we intend to rely on third-party&#160;manufacturers
for the raw materials and products to support our own manufacturing of its product candidates for commercialization, we have not yet entered
into agreements with such manufacturers. We may be unable to negotiate binding agreements with the manufacturers to support our commercialization
activities at commercially reasonable terms. Additionally, these third party manufacturers may not be able to supply us with the necessary
quantities of these raw materials and products to support its own manufacturing process, or in compliance with cGMP or other pertinent
regulatory requirements, and within our planned timeframe and cost parameters, and the development and sales of our products, if approved,
may be materially harmed.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We face intense competition
and rapid technological change and the possibility that its competitors may develop therapies that are similar, more advanced, or more
effective than ours, which may adversely affect its financial condition and its ability to successfully commercialize our product candidates.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The biotechnology and pharmaceutical industries
are intensely competitive and subject to rapid and significant technological change. We are currently aware of various existing therapies
in the market and in development that may in the future compete with its product candidates. For example, there is an increasing number
of companies commercializing treatments and/or developing programs specifically targeting KRAS mutations, including KRAS G12D and KRAS
G12V, in a variety of manners and for a variety of indications, including cancer, including Bristol-Myers&#160;Squibb Company (through
the recently acquired Mirati Therapeutics, Inc.), Revolution Medicines, Inc., AstraZeneca (in collaboration with Usynova), Boehringer
and Gilead. Smaller and other early-stage&#160;companies may also prove to be significant competitors. Treatments for cancer currently
include surgery, radiation therapy, chemotherapy, hormone therapy, immunotherapy and combined treatment modalities such as chemo-radiotherapy.
Other approaches may also emerge for the treatment of any of the disease areas in which we focuse.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We have competitors both in the United&#160;States
and internationally, including major multinational pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies.
Our competitors may succeed in developing, acquiring, or licensing on an exclusive basis, products that are more effective or less costly
than any product candidate that Silexion may develop, or achieve earlier patent protection, regulatory approval, product commercialization,
and market penetration than we do. Additionally, technologies developed by our competitors may render its potential product candidates
uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We currently have no
marketing and sales organization. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties
to market and sell our product candidates, we may be unable to generate any revenue.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">We as a company have no experience selling and marketing its product candidates, and
currently have no marketing or sales organization. To successfully commercialize any products that may result from our development programs,
we will need to develop these capabilities, either on our own or with others. If our product candidates receive regulatory approval, we
intend to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize
our product candidates in major markets, which will be expensive, difficult, and time consuming. Any failure or delay in the development
of its internal sales, marketing, and distribution capabilities would adversely impact the commercialization of our products.</div> </div>
</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">20</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">Further, given its lack of prior experience in marketing and selling biopharmaceutical
products, our initial estimate of the size of the required sales force may be materially more or less than the size of the sales force
actually required to effectively commercialize our product candidates. As such, we may be required to hire the commercialization of our
product candidates, or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect to certain
geographical markets, we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities,
but we may be unable to enter into such agreements on favorable terms, if at all. If our future collaborators do not commit sufficient
resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own,
we will be unable to generate sufficient product revenue to sustain our business. We may be competing with companies that currently have
extensive and well-funded&#160;marketing and sales operations. Without an internal team or the support of a third party to perform marketing
and sales functions, we may be unable to compete successfully against these more established companies.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">The market may not be
receptive to our product candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or
licensing of product candidates.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Even if approval is obtained for a product
candidate, we may not generate or sustain revenue from sales or licensing of the product due to factors such as whether the product can
be sold at a competitive cost and otherwise accepted in the market. The product candidates that we are developing are based on new technologies
and therapeutic approaches. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party&#160;payors,
may not adopt a treatment based on RNAi, including siRNA technology, and we may not be able to convince the medical community and third-party&#160;payors
to accept and use, or to provide favorable reimbursement for, our product candidates. Market acceptance of Silexion&#8217;s product candidates
will depend on, among other factors:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z86c6a24581af49268e6bb5ceb2400048" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the timing of our receipt of any marketing and commercialization
        approvals;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4b9c53e6d1fc479fbc58fbbe52014944" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the terms of any approvals and the countries in which approvals
        are obtained;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z291a40e9a6024b62a86327707097e3d2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the safety and efficacy of our product candidates;</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z93bd05bf18464a50a48bb43f01b093d3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the prevalence and severity of any adverse side effects associated
        with our product candidates;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z12cb65813d5e443ea1ea56c9cbf31de0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">limitations or warnings contained in any labeling approved by
        the FDA or other regulatory authorities;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zde656fd7069a4331a548af36e0d63963" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">relative convenience and ease of administration of our product
        candidates;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z355d7ffa396744758d68ab3945beb555" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the willingness of patients to accept any new methods of administration;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za08c8beabff84c0abe75d36e9ce7625a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the success of our physician education programs;</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdaef36d738dd40cca34326055ab20d91" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the availability of adequate government and third-party&#160;payor
        reimbursement;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2f77985e1d2e4997b10e345cd5df8b4c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the pricing of our products, particularly as compared to alternative
        treatments; and</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7e1b27ea77504747b3c3c087d571c53d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">availability of alternative effective treatments for the disease
        indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments.</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">With Silexion&#8217;s focus on the emerging
therapeutic modality RNAi, these risks may increase to the extent the space becomes more competitive or less favored in the commercial
marketplace. Some of Silexion&#8217;s target diseases, such as pancreatic cancer, are relatively rare. Because of the small patient population
for a rare disease, if pricing is not approved or accepted in the market at an appropriate level for an approved product, such product
may not generate enough revenue to offset costs of development, manufacturing, marketing and commercialization. Market size is also a
variable in disease indications not classified as rare. Our estimates regarding potential market size for any indication may be materially
different from what it discovers to exist at the time it commences commercialization, if any, for a product, which could result in significant
changes in our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects.</div>
</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">21</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Even if a potential product displays a favorable
efficacy and safety profile in preclinical and clinical studies, market acceptance of the product will not be fully known until after
it is launched. Ourefforts to educate the medical community and third-party&#160;payors on the benefits of the product candidates may
require significant resources and may never be successful. If our product candidates are approved but fail to achieve an adequate level
of acceptance by physicians, patients, third-party&#160;payors, and others in the medical community, we will not be able to generate sufficient
revenue for us to become or remain profitable.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">The insurance coverage
and reimbursement status of&#160;newly-approved&#160;products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement
for new or current products could limit our ability to market those products and decrease our ability to generate revenue.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Some of our target patient populations are
small, and, accordingly, the pricing, coverage, and reimbursement of our respective product candidates, if approved, must be adequate
to support our commercial infrastructure. Ourper-patient&#160;prices must be sufficient to recover our development and manufacturing costs
and potentially achieve profitability. Accordingly, the availability and adequacy of coverage and reimbursement by governmental and private
payors are essential for most patients to be able to afford expensive treatments such as our, assuming approval. Sales of our product
candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be
paid for by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government
authorities, private health insurers, and other third-party&#160;payors. If coverage and reimbursement are not available, or are available
only to limited levels, Silexion may not be able to successfully commercialize our product candidates. Even if coverage is provided, the
approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on our
investment.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">There is significant uncertainty related
to the insurance coverage and reimbursement of newly approved products. In the United&#160;States, the principal decisions about coverage
and reimbursement for new drugs are typically made by the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, an agency within
the U.S.&#160;Department of Health and Human Services, as CMS decides whether and to what extent a new drug will be covered and reimbursed
under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult
to predict what CMS will decide with respect to reimbursement for products such as our&#8217;s.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Outside the United&#160;States, international
operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing
emphasis on cost-containment&#160;initiatives in Europe, Canada, and other countries has, and will continue to, put pressure on the pricing
and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms
as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United&#160;States.
Other countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. Additional foreign
price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates.
Accordingly, in markets outside the United&#160;States, the reimbursement for our products may be reduced compared with the United&#160;States
and may be insufficient to generate commercially reasonable revenue and profits.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Moreover, increasing efforts by governmental
and third-party&#160;payors in the United&#160;States and abroad to cap or reduce healthcare costs may cause such organizations to limit
both coverage and the level of reimbursement for new products approved, and, as a result, they may not cover or provide adequate payment
for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due
to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes
like the Inflation Reduction Act. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures
and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">22</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Healthcare legislative
reform measures may have a material adverse effect on our business and results of operations.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The business and financial condition of
pharmaceutical and biotechnology companies are affected by the efforts of governmental and third-party&#160;payors to contain or reduce
the costs of health care. The U.S.&#160;Congress has enacted legislation to reform the health care system. While we anticipate that this
legislation may, over time, increase the number of patients who have insurance coverage for pharmaceutical products, it also imposes cost
containment measures that may adversely affect the amount of reimbursement for pharmaceutical products. These measures include increasing
the minimum rebates for products covered by Medicaid programs and extending such rebates to drugs dispensed to Medicaid beneficiaries
enrolled in Medicaid managed care organizations as well as expansion of the 340(B)&#160;Public Health Services drug discount program.
In addition, such legislation contains a number of provisions designed to generate the revenues necessary to fund the coverage expansion.
In foreign jurisdictions there have been, and we expect that there will continue to be, a number of legislative and regulatory proposals
aimed at changing the health care system. For example, in some countries other than the United&#160;States, pricing of prescription drugs
is subject to government control and we expect to see continued efforts to reduce healthcare costs in international markets.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Some U.S.&#160;states are also considering
legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental
rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid.
Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs.
Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may
result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint
on prices and reimbursement for drugs. It is likely that federal and state legislatures and health agencies will continue to focus on
additional health care reform in the future although we are unable to predict what additional legislation or regulation, if any, relating
to the health care industry or third-party&#160;coverage and reimbursement may be enacted in the future or what effect such legislation
or regulation would have on our business. Our ability to commercialize any product candidates that Silexion may seek to commercialize,
is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from government payors,
such as Medicare and Medicaid, private health insurers, including managed care organizations, and other third-party&#160;payors, and any
change in reimbursement levels could materially and adversely affect our business. Further, the pendency or approval of future proposals
or reforms could result in a decrease in our share price or limit our ability to raise capital or to obtain strategic partnerships or
licenses.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Our product candidates
may be approved and/or commercialized only in part, only as neoadjuvant therapy, or as an adjuvant therapy.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our product candidates may be approved by
the FDA or other regulatory agencies only as a treatment to be provided in association with other treatments, if at all. For example,
it may be possible that our SIL-204B&#160;be used as adjunct therapy with chemotherapy treatments. Limitation in commercialization of
such treatments, including limitations in supply, call-back, clinical holds, changes in medical trends, changes in cost and/or reimbursement
policy, may limit our ability to commercialize our product candidates, either directly or via third parties.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">23</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Risks Related to Competition</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">The pharmaceutical market
is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we
may be unable to commercialize successfully any drugs that it develops.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The pharmaceutical market is intensely competitive
and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public
and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to
target. Many of our competitors have:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze538b8485af241c882fc16c138b0b4a6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">much greater financial, technical and human resources than
        we have at every stage of the discovery, development, manufacture and commercialization of products;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfcab7d94f4364ce49c107db5d2fa2695" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">more extensive experience in pre-clinical&#160;testing, conducting
        clinical trials, obtaining regulatory approvals, and in manufacturing, marketing and selling pharmaceutical products;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zecf801beda7740ccba66098bca7ae657" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">product candidates that are based on previously tested or accepted
        technologies;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z36d4650b3757454891b48f99615d7779" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">products that have been approved or are in late stages of development;
        and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z13631058fdbc4f1ab48f6b504bc86da1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">collaborative arrangements in its target markets with leading
        companies and research institutions.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We will face intense competition from drugs
that have already been, or may in the future become, approved and accepted by the medical community for the treatment of the conditions
for which we may develop drugs. We also expect to face competition from new drugs that enter the market. We believe a significant number
of drugs are currently under development, and may become commercially available in the future, for the treatment of conditions for which
we may try to develop drugs and therapies. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively,
than any product we develop.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If we successfully develop our product candidates,
and obtains approval for them, we will face competition based on many different factors, including:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaf53ac951b3b47b99d2bb69baa9a06f7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the safety and effectiveness of our product;</div> </div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0c53bccfdf524b7da13154e650d08adc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the ease with which our product can be administered and the
        extent to which patients accept relatively new routes of administration;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfc08f917b8f8478eb9e5c122e923458c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the timing and scope of regulatory approvals for our product;</div>
        </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4531702db34b4eb98e8d39acb9cc5c46" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the availability and cost of manufacturing, marketing and sales
        capabilities;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0a50e7f5b9b34be2b23413725a6e0f33" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">price;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0cb0839d37d348c6885563e479ff6aca" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">reimbursement coverage; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze1344c8d0a564dd49d8765c94c69239b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">patent position.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our competitors may develop or commercialize
products with significant advantages over any products we develop based on any of the factors listed above or on other factors. Our competitors
may therefore be more successful in commercializing their products than us, which could adversely affect our competitive position and
business. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing
and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level
of expertise and the ability to execute on our business plan.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We face competition
from other companies that are working to develop novel drugs and technology platforms using technology similar or in the same field as
our&#8217;s. If these companies develop drugs more rapidly than us, or their technologies, including delivery technologies, are more effective,
our ability to successfully commercialize drugs may be adversely affected.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">In addition to the competition we face from competing drugs in general, we also face
competition from other companies working to develop novel drugs using technology that competes more directly with our own. We are aware
of multiple companies that are working in the field of RNAi therapeutics and or KRAS inhibition, including major pharmaceutical companies
such as Bristol Myers Squibb/Mirati; Amgen; AstraZeneca; E.I.&#160;Lilly; Pfizer, Novartis International AG, Takeda Pharmaceutical Company
Limited and, and biopharmaceutical/pharmaceutical companies such as Alnylam, Revolutions Medicines; Boehringer Ingelheim; Biomea Fusion
Inc; Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Silence Therapeutics plc, RXi Pharmaceuticals Corporation, Quark
Pharmaceuticals, Inc. and Marina Biotech, Inc.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">24</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">We also compete with companies working to develop antisense-based&#160;drugs. Like RNAi
therapeutics, antisense drugs target mRNAs in order to suppress the activity of specific genes. Ionis Pharmaceuticals, Inc. is currently
marketing an antisense drug and has several antisense product candidates in clinical trials, albeit none in the oncology area at this
time.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In addition to competition with respect
to RNAi and with respect to specific products, we face substantial competition to discover and develop safe and effective means to deliver
RNAi based drugs to the relevant cell and tissue types. Safe and effective means to deliver RNAi based drugs and to the relevant cell
and tissue types may be developed by our competitors, and our ability to successfully commercialize a competitive product would be adversely
affected. In addition, substantial resources are being expended by third parties in the effort to discover and develop a safe and effective
means of delivering RNAi based drugs and into the relevant cell and tissue types, both in academic laboratories and in the corporate sector.
Some of our competitors have substantially greater resources than we do, and if our competitors are able to negotiate exclusive access
to those delivery solutions developed by third parties, we may be unable to successfully commercialize our product candidates. Also, we
compete with companies working to develop non RNAi based treatments for solid tumor cancers. For example, Novartis is working on a SHP2
inhibitor, and Boehringer Ingelheim and Bayer SOS1 inhibitors; Threshold Pharmaceuticals (Threshold) is working to develop therapies that
target tumor hypoxia, a common characteristic of the tumor microenvironment. Even if we successfully develop our product candidates, and
obtain approval for them, other non RNAi treatments may be preferred, and we may not be successful in commercializing our product candidates</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Also, we compete with companies commercializing
and/or working to develop drug delivery systems, including drug delivery systems for local (or regional) release. For example, various
companies are working on nanoparticle technologies, although these products would not give the extended-release&#160;delivery of SIL-204B,
and other companies on PLGA microparticles. In addition other companies such as SurModics, Inc. is a provider of drug delivery and surface
modification technologies to the healthcare industry, including local delivery of drugs from drug eluting stents. We compete with many
companies commercializing and/or working to develop drug delivery systems for specific indications, for example for local ocular (in the
eye) release of drugs, including degradable and non-degradable&#160;products.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Risks Related to Our Intellectual Property</div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">If we are unable to
obtain and maintain effective patent rights for our product candidates or any future product candidates, we may not be able to compete
effectively in our markets.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We rely upon a combination of trade secret
protection and confidentiality agreements to protect the intellectual property related to our technologies and product candidates. We
have only issued one Israeli patent, and two U.S.&#160;patents, covering the composition of matter of our siRNAs and their use. Our success
depends in large part on our ability to obtain and maintain patent and other intellectual property protection in the United&#160;States
and in other countries with respect to our proprietary technology and products.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We have sought to protect our proprietary
position by filing patent applications in the United&#160;States and in other countries, with respect to our novel technologies and products,
which are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary
or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable
aspects of our research and development output before it is too late to obtain patent protection.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The patent position of biotechnology and
pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain
unsolved. The patent applications that we own may fail to result in issued patents with claims that cover our product candidates in the
United&#160;States or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents
and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application.
Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity,
enforceability, or scope, which may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they
are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our
product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition
from third parties, which may have an adverse impact on our business.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">25</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We have filed several patent applications
covering various aspects of our product candidates: PCT/IL2023/051276 filed on Dec.&#160;14, 2023 Priority from: US Provisional Patent
Applications; 63/387,504 filed on December&#160;15, 2022; and 63/491,776 filed on March&#160;23, 2023. We cannot offer any assurances
about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable
or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after
patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop.
Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent
protection could be reduced.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If we cannot obtain and maintain effective
patent rights for our product candidates, we may not be able to compete effectively, and our business and results of operations would
be harmed.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We may not have sufficient
patent terms to effectively protect our products and business.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In the pharmaceutical and biotechnology
industries, the majority of an innovative product&#8217;s commercial value is realized during our market exclusivity period. In the United&#160;States
and in some other countries, when market exclusivity expires and generic versions are approved and marketed or when biosimilars are introduced
(even if only for a competing product), there are usually very substantial and rapid declines in a product&#8217;s revenues.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Patents have a limited lifespan. In the United&#160;States,
the natural expiration of a patent is generally 20&#160;years after it is filed. Although various extensions may be available, the life
of a patent, and the protection it affords, is limited.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">While patent term extensions under the Hatch-Waxman&#160;Act
in the United&#160;States and under supplementary protection certificates in Europe may be available to extend the patent exclusivity
term, we cannot provide any assurances that any such patent term extension will be obtained and, if so, for how long. In addition, upon
issuance in the United&#160;States, any patent term can be adjusted based on certain delays caused by the applicant(s)&#160;or the USPTO.&#160;For
example, a patent term can be reduced based on certain delays caused by the patent applicant during patent prosecution. If we do not have
sufficient patent terms or regulatory exclusivity to protect our products, our business and results of operations will be adversely affected.
Furthermore, manufacturers of innovative products as well as generic drug manufacturers may be able to design their products around our
patents and compete with Silexion using the resulting alternative technology. Absent relevant patent protection for a product, once the
exclusivity period expires, generic or alternative versions can be approved and marketed.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Generic and biosimilar product manufacturers
as well as other groups seeking financial gain are also increasingly seeking to challenge patents before they expire, and we could face
earlier-than-expected&#160;competition for any products at any time. Patents covering our key products may be subject to validity, enforceability
and infringement challenges in patent litigations and post-grant&#160;review patent office proceedings. It may be possible for these parties
to successfully challenge our rights and launch their versions of our drugs prior to the expiration of our intellectual property rights.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, both the U.S.&#160;Congress and
the U.S.&#160;FDA have taken steps to promote the development and approval of generic drugs and biosimilar biologics, including by providing
generic and biosimilar developers a private right of action to obtain sufficient quantities of drug samples from the reference product&#8217;s
manufacturer in order to conduct testing necessary to obtain approval for generic or biosimilar products.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">26</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Further, in December&#160;2023, the Biden
Administration released a proposed framework that for the first time proposed that a drug&#8217;s price can be a factor in determining
that the drug is not accessible to the public and therefore that the government could exercise &#8220;march-in&#160;rights&#8221; and
license it to a third party to manufacture. A comment period on the proposal ran through February&#160;6, 2024, and we are not able to
predict whether a final rule will be adopted along the lines proposed and, if adopted, whether the government would seek to exercise march-in&#160;rights
for any of our products.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Patent law, policy or
rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or
defense of our issued patent.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Changes in either the patent laws or interpretation
of the patent laws in the United&#160;States and other countries may diminish the value of our patent or narrow the scope of our patent
protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United&#160;States. Publications
of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United&#160;States
and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. We therefore cannot
be certain that it or our licensors were the first to make the invention claimed in our owned and licensed patent or pending applications,
or that it or our licensor were the first to file for patent protection of such inventions. Assuming the other requirements for patentability
are met, in the United&#160;States prior to March&#160;15, 2013, the first to make the claimed invention is entitled to the patent, while
outside the United&#160;States, the first to file a patent application is entitled to the patent. After March&#160;15, 2013, under the
Leahy-Smith&#160;America Invents Act, or the Leahy-Smith&#160;Act, enacted on September&#160;16, 2011, the United&#160;States has moved
to a first to file system. The Leahy-Smith&#160;Act also includes a number of significant changes that affect the way patent applications
will be prosecuted and may also affect patent litigation. The USPTO recently developed new regulations and procedures to govern administration
of the Leahy-Smith&#160;Act, and accordingly, it is not clear what, if any, impact the Leahy-Smith&#160;Act will have on the operation
of our business. The Leahy-Smith&#160;Act and our implementation could increase the uncertainties and costs surrounding the prosecution
of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on
our business and financial condition.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In addition, patent reform legislation may
pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense
of our patents and pending patent applications. Recent U.S.&#160;Supreme Court rulings have narrowed the scope of patent protection available
in certain circumstances and weakened the rights of patent owners in certain situations. Furthermore, the U.S.&#160;Supreme Court and
the U.S.&#160;Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of
the United&#160;States are interpreted. Similarly, foreign countries have made, and will likely continue to make, changes in how the patent
laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes
to patent laws that might be enacted into law by United&#160;States and foreign legislative bodies. Those changes may materially affect
our patents or patent applications and our ability to obtain additional patent protection in the future.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The United&#160;States federal government
retains certain rights in inventions produced with our financial assistance under the Patent and Trademark Law Amendments Act, or the
Bayh-Dole&#160;Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up&#160;license&#8221; for
our own benefit. The Bayh-Dole&#160;Act also provides federal agencies with &#8220;march-in&#160;rights.&#8221; March-in&#160;rights allow
the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive,
partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to
do so, the government may grant the license itself.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">If we are unable to
maintain effective proprietary rights for our product candidates or any future product candidates, Silexion may not be able to compete
effectively in our markets.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In addition to the protection afforded by
any patents that may be granted, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how&#160;that
is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product
candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents.
However, trade secrets can be difficult to protect. we seek to protect our proprietary technology and processes, in part, by entering
into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity
and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security
of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security
measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known
or be independently discovered by competitors.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">27</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Although we expect all of our employees
and consultants to assign their inventions to it, and all of our employees, consultants, advisors, and any third parties who have access
to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that
all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed
or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information
and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a
material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may
have insufficient recourse against third parties for misappropriating the trade secret.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Intellectual property
rights of third parties could adversely affect our ability to commercialize our product candidates, and it might be required to litigate
or obtain licenses from third parties in order to develop or market our product candidate. Such litigation or licenses could be costly
or not available on commercially reasonable terms.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">Because the RNAi intellectual property landscape is still evolving, it is difficult
to conclusively assess our freedom to operate without infringing on third party rights. There are numerous companies that have pending
patent applications and issued patents broadly directed to RNAi generally and to RNAi delivery technologies.Our competitive position may
suffer if patents issued to third parties or other third party intellectual property rights cover our products or elements thereof, or
our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize products
or our product candidate unless we successfully pursue litigation to nullify or invalidate the third party intellectual property right
concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms.
we are also aware of pending patent applications, and there may be others of which we are not aware, that if they result in issued patents,
could be alleged to be infringed by its product candidates. If such an infringement claim should be brought and be successful, we may
be required to pay substantial damages, be forced to abandon our product candidates or seek a license from any patent holders. No assurances
can be given that a license will be available on commercially reasonable terms, if at all. It is also possible that we have failed to
identify relevant third party patents or applications. For example, U.S. applications filed before November 29, 2000 and certain U.S.
applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent applications
in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest
filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates or platform
technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been published
can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our product candidates or
the use of our product candidates. Third party intellectual property right holders may also actively bring infringement claims against
Us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to
successfully settle future claims on terms acceptable to it, we may be required to engage in or continue costly, unpredictable and time-consuming
litigation and may be prevented from or experience substantial delays in pursuing the development of and/or marketing of its product candidates.
If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing
our product candidates that are held to be infringing. We might, if possible, also be forced to redesign our product candidates so that
it no longer infringes the third party intellectual property rights. Any of these events, even if we were ultimately to prevail, could
require us to divert substantial financial and management resources that it would otherwise be able to devote to our business.</div> </div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">28</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Third-party&#160;claims
of intellectual property infringement may prevent or delay our development and commercialization efforts.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our commercial success depends in part on
our avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings
involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement
lawsuits, interferences, oppositions, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous
U.S.&#160;and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we
are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases
that our product candidates may be subject to claims of infringement of the patent rights of third parties.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Third parties may assert that we are employing
our proprietary technology without authorization. There may be third-party&#160;patents or patent applications with claims to materials,
formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates. Because patent
applications can take many&#160;years to issue, there may be currently pending patent applications that may later result in issued patents
that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies
infringes upon these patents. If any third-party&#160;patents were held by a court of competent jurisdiction to cover the manufacturing
process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders
of any such patents may be able to block our ability to commercialize such product candidates unless it obtains a license under the applicable
patents, or until such patents expire or are finally determined to be invalid or unenforceable.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Similarly, if any third-party&#160;patents
were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture, or methods of use, the
holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless it obtains
a license or until such patent expires or is finally determined to be invalid or unenforceable. In either case, such a license may not
be available on commercially reasonable terms or at all.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Parties making claims against us may obtain
injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our
product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial
diversion of employee resources from our business. In the event of a successful claim of infringement against it, we may have to pay substantial
damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products
or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We may not be successful
in obtaining or maintaining necessary rights to our product candidates through acquisitions and&#160;in-licenses.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Because our programs may require the use
of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license,
or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently
and the rights to these formulations may be held by others. We may be unable to acquire or in-license&#160;any compositions, methods of
use, processes, or other third-party&#160;intellectual property rights from third parties that it identifies as necessary for our product
candidates. The licensing and acquisition of third-party&#160;intellectual property rights is a competitive area, and a number of more
established companies are also pursuing strategies to license or acquire third-party&#160;intellectual property rights that we may consider
attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical
development and commercialization capabilities.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">29</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">For example, we sometimes collaborates with
U.S.&#160;and foreign academic institutions to accelerate our preclinical research or development under written agreements with these
institutions. Typically, these institutions provide we with an option to negotiate a license to any of the institution&#8217;s rights
in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified
timeframe or under terms that are acceptable to it. If we are unable to do so, the institution may offer the intellectual property rights
to other parties, potentially blocking our ability to pursue our program.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In addition, companies that perceive us
to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party&#160;intellectual
property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain
rights to required third-party&#160;intellectual property rights, we may have to abandon development of that program and our business
and financial condition could suffer.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We may be involved in
lawsuits to protect or enforce our current patent or future patents, which could be expensive, time consuming, and unsuccessful.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Competitors may infringe our current patent,
future patents or the patents of our licensors. If we or a future licensing partner were to initiate legal proceedings against a third
party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product
candidate is invalid and/or unenforceable. In patent litigation in the United&#160;States, defendant counterclaims alleging invalidity
and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory
requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation
that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during
prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Interference proceedings provoked by third
parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patent
or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to
attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license
on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have
a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs,
license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates
to market.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information
could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings,
motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could
have a material adverse effect on the price of our ordinary shares.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We may be subject to
claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third
parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We employ or engage as consultants or subcontractors
individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors
or potential competitors. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary
information or know-how&#160;of others in their work for it, we may be subject to claims that we or our employees, consultants, or independent
contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information,
of any of our employees&#8217; former employers or other third parties. Litigation may be necessary to defend against these claims. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel,
which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management and other employees.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">30</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We may be subject to
claims challenging the inventorship of our current patent or future patents and other intellectual property.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We may be subject to claims that former
employees, collaborators or other third parties have an interest in or right to compensation with respect to our current patent, future
patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting
obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against
these and other claims challenging inventorship or claiming the right to compensation. If it fails in defending any such claims, in addition
to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable
intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against
such claims, litigation could result in substantial costs and be a distraction to management and other employees. To the extent that our
employees have not effectively waived the right to compensation with respect to inventions that they helped create, they may be able to
assert claims for compensation with respect to our future revenue. As a result, we may receive less revenue from future products if such
claims are successful which in turn could impact our future profitability.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We may not be able to
protect our intellectual property rights throughout the world.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Filing, prosecuting, and defending patents
on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in
some countries outside the United&#160;States can be less extensive than those in the United&#160;States. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United&#160;States.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Competitors may use our technologies in
jurisdictions where we have not obtained patent protection to develop their own products and may also export otherwise infringing products
to territories where we have patent protection but where enforcement is not as strong as that in the United&#160;States. These products
may compete with Silexin&#8217;s products and our current patent, future patents or other intellectual property rights may not be effective
or sufficient to prevent them from competing.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Many companies have encountered significant
problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly
certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly
those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of
competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions,
whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business,
could put our current patent or future patents at risk of being invalidated or interpreted narrowly and our patent applications at risk
of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the
damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop
or license.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Risks Related to our Human Resources</div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">The loss of the services
of our key personnel would negatively affect our business.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">To successfully develop our drug candidates,
we must be able to attract and retain highly skilled personnel, including consultants and employees. The retention of their services cannot
be guaranteed. Our failure to retain or recruit such professionals might impair our performance and materially affect our technological
and product development capabilities and our product marketing ability. Our future success depends to a large extent on the continued
services of our senior management and key personnel, including in particular, Ilan Hadar, Dr.&#160;Mitchell Shirvan, Dr.&#160;Racheli
Malka and Michal Yaron. Any loss of the services of members of our senior management or key employees would adversely affect our business.
We do not currently maintain key-person&#160;insurance on the lives of any of our key personnel.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">31</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We may be unable to
attract, develop and retain additional employees required for our development and future success.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our success is largely dependent on the
performance of our management team and certain key employees and our continuing ability to attract, develop, motivate and retain highly
qualified and skilled employees. Qualified individuals are in high demand, and New Silexion may incur significant costs to attract and
retain them. The inability to attract suitably qualified persons when needed, could prevent New Silexion from executing on our business
plan and strategy, and New Silexion may be unable to find adequate replacements on a timely basis, or at all.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Risks Related to Our Operations</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Our business and operations,
or those of our CROs or third parties, may suffer in the event of computer system failures, cyberattacks or deficiencies in our cybersecurity,
which could materially affect our results.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We receive, generate and store significant
and increasing volumes of sensitive information, such as health information, insurance information and other potentially personally identifiable
information. We faces a number of risks relative to protecting the computer systems we rely on and this critical information, including
loss of access risk, inappropriate use or disclosure, inappropriate modification and the risk of being unable to adequately monitor, audit
and modify our controls over our critical information. This risk extends to the computer systems and information of any collaboration
partners, medical institutions, clinical investigators, CROs, contract laboratories, or other third parties involved in our business.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Despite the implementation of security measures,
our information technology systems, as well as those of CROs or other third parties with which we have relationships, are vulnerable to
attack and damage from computer viruses and malware (e.g., ransomware), unauthorized access, natural and manmade disasters, terrorism,
war and telecommunication and electrical failures, malfeasance by external or internal parties, and human error (e.g., social engineering,
phishing). Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity,
and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore,
because the technologies used to obtain unauthorized access to, or to sabotage or disrupt, systems change frequently and often are not
recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures.
we may also experience security breaches that may remain undetected for an extended period. We may not be able to anticipate all types
of security threats, and even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers
increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic
evidence. We may also face increased cybersecurity risks due to our reliance on internet technology and the number of our and our service
providers&#8217; employees who are (and may continue to be) working remotely, which may create additional opportunities for cybercriminals
to exploit vulnerabilities. The White House, SEC and other regulators have also increased their focus on companies&#8217; cybersecurity
vulnerabilities and risks.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Our CROs and certain of our service providers are from time to time, subject to cyberattacks
and security incidents. While we have not to our knowledge experienced any significant system failure, accident or security breach to
date, if such an event were to occur and cause interruptions in our or our critical third parties&#8217; operations, it could result in
delays and/or material disruptions of our research and development programs, our operations and ultimately, our financial results. For
example, the loss of trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product
candidates and to conduct clinical trials, and similar events relating to their computer systems could also adversely impact our business.
Further, due to the current political uncertainty involving Hamas in Gaza, Hezbollah in Lebanon, Russia and Ukraine, there is an increased
likelihood that the tensions could result in cyberattacks or cybersecurity incidents that could either directly or indirectly impact our
or our critical third parties&#8217; operations. To the extent that any disruption or security breach were to result in a loss of or damage
to data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability due
to delays in the development and commercialization of our product candidates or other business activities and/or due to reputational harm,
litigation, regulatory investigations and enforcement, fines and penalties, or increased costs of compliance and system remediation.</div>

<div style="text-indent: 36pt; line-height: 1.25"> <br/> </div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">32</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">our existing general liability and cyber
liability insurance policies may not cover, or may cover only a portion of, any potential claims related to security breaches to which
we are exposed or may not be adequate to indemnify us for all or any portion of liabilities that may be imposed. We also cannot be certain
that our existing insurance coverage will continue to be available on acceptable terms or in amounts sufficient to cover the potentially
significant losses that may result from a security incident or breach or that the insurer will not deny coverage of any future claim.
If the information technology systems of our CROs or other service providers become subject to disruptions or security breaches, we may
have insufficient recites against such third parties and we may have to expend significant resources to mitigate the impact of such an
event, and to develop and implement protections to prevent future events of this nature from occurring.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">If product liability
lawsuits are brought against it, we may incur substantial liabilities and may be required to limit commercialization of any approved products.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We face an inherent risk of product liability
as a result of the clinical testing of product candidates and will face an even greater risk if we commercialize any products. For example,
we may be sued if any product candidate we develop causes or is perceived to cause injury or is found to be otherwise unsuitable during
clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing,
defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims
could also be asserted under state consumer protection acts. If we cannot successfully defend itself against product liability claims,
it may incur substantial liabilities or be required to limit commercialization of any approved products. Even successful defense would
require significant financial and management resources.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Regardless of the merits or eventual outcome,
liability claims may result in:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2989a7a8874744d0817deb503346dd04" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">decreased demand for any approved product;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z742b8a88b828425192ff0b1878cb5734" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">injury to our reputation;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf28fd7be01fc4b73bd24ec10fe0b869e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">withdrawal of clinical trial participants;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zecb745dd88004127b899161060ad8aaa" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">initiation of investigations by regulators;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za6ec254b7881458396b76f90b8b07ad0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">costs to defend the related litigation;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfb9d1f56330348edad629e8b693060fa" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">a diversion of management&#8217;s time and our resources;</div>
        </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1a6a2c7836fa4b0688b5b267a15a0ae3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">substantial monetary awards to trial participants or patients;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdd66c46d647043f088927042d49ae433" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">product recalls, withdrawals or labeling, marketing or promotional
        restrictions;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd88575a1d34f403a9f87104491cbe5cf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">exhaustion of any available insurance and our capital resources
        and potential increase in our insurance premiums and/or retention amounts; and</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze291b82317684e3396c30720fc15cc11" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the inability to commercialize any product candidate.</div> </td>
        </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our inability to obtain sufficient product
liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization
of products we develop, alone or with collaboration partners.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">33</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Insurance coverage is increasingly expensive.
we may not be able to maintain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise, if at
all. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage.
Silexion may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are
not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements
with any current or future collaborator entitle us to indemnification against losses, such indemnification is limited and may not be available
or adequate should any claim arise.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We may not be able to
successfully identify and execute strategic alliances or other relationships with third parties or to successfully manage the impacts
of acquisitions, dispositions or relationships on our operations.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We currently have, and may expand the scope
of, and may in the future enter into, strategic alliances with third parties that it believes will complement or augment our existing
business. Ourour. Our ability to complete further such strategic alliances is dependent upon, and may be limited by, among other things,
the availability of suitable candidates and capital. In addition, strategic alliances could present unforeseen integration obstacles or
costs, may not enhance our business and may involve risks that could adversely affect us, including the investment of significant amounts
of management time that may be diverted from operations in order to pursue and complete such transactions or maintain such strategic alliances.
Future strategic alliances could result in the incurrence of debt, costs and contingent liabilities, and there can be no assurance that
future strategic alliances will achieve, or that our existing strategic alliances will continue to achieve, the expected benefits to our
business or that it will be able to consummate future strategic alliances on satisfactory terms, or at all.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Although we do not currently plan to engage
in other material strategic transactions, such as acquisitions, it may from time to time consider such transactions. Material strategic
transactions involve a number of risks, including:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4e575f0550e34320b5b69b79a360543e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the potential disruption of our ongoing business;</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc896439d38204014825a7e5f8c6ed2ad" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the distraction of management away from the ongoing oversight
        of our existing business activities;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3a4d57204b2f4e7982ad49408fdf4eb9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">incurring additional indebtedness;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfb51b75934174696bbfa6702401e037c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the anticipated benefits and cost savings of those transactions
        not being realized fully, or at all, or taking longer to realize than anticipated;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z27f6f4da245b4e298ef6c6eb3037a1c4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">an increase in the scope and complexity of our operations;
        and</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zffaf5989462b404eba93518435d1feb5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the loss or reduction of control over certain of our assets.</div>
        </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">A strategic transaction may result in a
significant change in the nature of our business, operations and strategy, and we may encounter unforeseen obstacles or costs in implementing
a strategic transaction or integrating any acquired business into our operations.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Risks Relating to our Operations in Israel&#160;and
China</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Conditions in the Middle
East and in Israel may harm our operations.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">Our executive offices and research and development facilities are located in Israel. Most of our officers
and directors are residents of Israel. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken
place between Israel and its neighboring countries, and between Israel and neighboring terrorist organizations, including Hamas (an Islamist
terrorist and political group in the Gaza Strip) and Hezbollah (an Islamist terrorist and political group in Lebanon).</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">34</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25">In particular, on October&#160;7, 2023, Hamas terrorists infiltrated Israel&#8217;s
southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive
rocket attacks on the Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas
within the State of Israel. These attacks resulted in thousands of deaths and injuries, and Hamas additionally kidnapped many Israeli
civilians and soldiers. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and commenced a military campaign
against Hamas and these terrorist organizations, in parallel to continued rocket and terror attacks against Israel by Hamas. Upon the
start of the war, the Israeli military began to call-up&#160;reservists for active duty.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">In parallel with the war against Hamas that began in October 2023, <span style="font-family: Times New Roman,Times,serif">there
have been continued hostilities along Israel&#8217;s northern border, as the Hezbollah terrorist organization based in Lebanon has conducted
rocket, drone, and, more recently, missile attacks against Israel, and there have also been rocket, drone and missile attacks against
Israel by the Houthi movement in Yemen. The hostilities with Hezbollah have escalated recently, prompting Israel to send its ground forces
into southern Lebanon to destroy terrorist positions and infrastructure used by Hezbollah for attacks on northern and central Israel,
which had caused the displacement of residents in northern Israel since early in the war.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">Iran has furthermore entered the conflict against Israel, shooting ballistic missiles
at Israel twice during the current war (on April&#160;13, 2024 and October 1, 2024). Iran is furthermore widely believed to be developing
nuclear weapons, with which it has threatened Israel. There is a risk<span style="font-family: Times New Roman,Times,serif"> that other
terrorist organizations, including Palestinian military organizations in the West Bank as well as other hostile countries will join the
hostilities against Israel. Such clashes may escalate into a greater regional conflict. </span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Armed conflicts, terrorist activities or political instability in Israel or in the broader
Middle East have been, and could continue to, in a more severe way, adversely affect business conditions in Israel, and could harm our
results of operations and make it more difficult for us to raise capital. Parties with whom we do business may decline to travel to Israel
during periods of heightened unrest or tension, forcing Silexion to make alternative arrangements when necessary in order to meet its
business partners face to face. In addition, the political and security situation in Israel may result in parties with whom we have agreements
involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force
majeure provisions in such agreements. Further, in the past, the State of Israel and Israeli companies have been subjected to economic
boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies
may have an adverse impact on our operating results, financial condition or the expansion of our business. The interruption or curtailment
of trade between Israel and its trading partners could adversely affect our operations and results of operations.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">Our commercial insurance does not cover losses that may occur as a result of events
associated with the security situation in the Middle East. Although the Israeli government currently covers the reinstatement value of
direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained.
Any losses or damages incurred by us could have a material adverse effect on our business.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">Finally, political conditions within Israel may also affect our operations. Israel held
five general elections between 2019 and 2022, and prior to October&#160;2023, the Israeli government pursued extensive changes to Israel&#8217;s
judicial system, which sparked extensive political debate and unrest. To date, these initiatives have been substantially put on hold.
Actual or perceived political instability in Israel or any negative changes in the political environment, may individually or in the aggregate
adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and growth prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">35</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">It may be difficult
to enforce a U.S.&#160;judgment against us, our officers or our directors or to assert U.S.&#160;securities law claims in Israel.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Service of process upon us and upon our
directors and officers, who reside outside the U.S., may be difficult to obtain within the U.S.&#160;In addition, because substantially
all of our assets and most of our directors and officers are located outside the U.S., any judgment obtained in the U.S.&#160;against
us or any of our directors and officers may not be collectible within the U.S.&#160;There is a doubt as to the enforceability of civil
liabilities under the Securities Act or the Exchange&#160;Act pursuant to original actions instituted in Israel. Subject to particular
time limitations and provided certain conditions are met, executory judgments of a U.S.&#160;court for monetary damages in civil matters
may be enforced by an Israeli court.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Under applicable U.S.&#160;and
Israeli law, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting
from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their inventions irrespective
of their agreements with us, which in turn could impact our future profitability.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We generally enter into non-competition&#160;agreements
with our employees and key consultants. These agreements prohibit our employees and key consultants, if they cease working for us, from
competing directly with it or working for our competitors or clients for a limited period of time. We may be unable to enforce these agreements
under the laws of the jurisdictions in which our employees work and it may be difficult for it to restrict our competitors from benefitting
from the expertise our former employees or consultants developed while working for us. For example, Israeli courts have required employers
seeking to enforce non-compete&#160;undertakings of a former employee to demonstrate that the competitive activities of the former employee
will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy
of a company&#8217;s confidential commercial information or the protection of our intellectual property. If it cannot demonstrate that
such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees
or consultants and our ability to remain competitive may be diminished.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In addition, Chapter&#160;8 of the Israeli
Patents Law,&#160;5727-1967, or the Patents Law, deals with inventions made in the course of an employee&#8217;s service and during his
or her term of employment, whether or not the invention is patentable, or service inventions. Section&#160;134 of the Patents Law, sets
forth that if there is no agreement which explicitly determines whether the employee is entitled to compensation for the service inventions
and the extent and terms of such compensation, such determination will be made by the Compensation and Rewards Committee, a statutory
committee of the Israeli Patents Office. As a result, it is unclear if, and to what extent, our research and development employees may
be able to claim compensation with respect to our future revenue. As a result, Silexion may receive less revenue from future products
if such claims are successful, which in turn could impact our future profitability.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Governmental control
of currency conversion in China may limit us our ability to utilize our cash balance&#160;effectively and affect the value of our investment.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We may be reliant on dividend payments,
equity investments, or other forms of cash infusion from PRC subsidiaries to fund any cash and financing requirements it may have. The
PRC government imposes controls on the convertibility of the Renminbi into foreign currencies and, in certain cases, the remittance of
currency out of China. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions,
interest payments and trade and service-related&#160;foreign exchange transactions, can be made in foreign currencies without prior approval
of the State Administration of Foreign Exchange (&#8220;SAFE&#8221;) (the foreign exchange management administrative body of the People&#8217;s
Bank of China) by complying with certain procedural requirements. Specifically, under the existing exchange restrictions, without prior
approval of SAFE, cash generated from the operations of PRC subsidiaries in China may be used to pay dividends to parent companies. However,
approval from or registration with appropriate government authorities is required where Renminbi is to be converted into foreign currency
and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. As a result, we would
need to obtain SAFE approval to use cash held at PRC subsidiaries to pay outside China, or to make other capital expenditure payments
outside China in a currency other than Renminbi. The PRC government may at its discretion restrict access to foreign currencies for current
account transactions in the future. If the foreign exchange control system prevents us from obtaining sufficient foreign currencies to
satisfy its foreign currency demands, it may not be able to pay dividends in foreign currencies to our shareholders.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">36</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">PRC regulations relating to dividends may
restrict the ability of our PRC subsidiaries to make payments to New Silexion, which may have an adverse effect on our ability to conduct
our business.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Under PRC laws and regulations, our PRC
subsidiaries (which are each &#8220;wholly foreign-owned&#160;enterprises&#8221; incorporated in Mainland China) are only permitted to
pay dividends out of their respective accumulated profits, as determined in accordance with PRC accounting standards and regulations.
In addition, prior to distribution of any dividends, our subsidiaries in China are each required to compensate their past losses with
after-tax&#160;profits each year, if any, and then set aside at least 10% of their after-tax&#160;profits each year to fund a statutory
reserve until such reserve reaches 50% of the subsidiary&#8217;s total registered capital. Additionally, if our PRC subsidiaries incur
debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends or make other
distributions to us.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Any limitation on the ability of our PRC
subsidiaries to pay dividends or make other distributions to us could adversely limit our ability to grow, make investments or acquisitions
that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Risks Relating to this Offering</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">The best efforts structure of this offering may have an adverse
effect on our business plan.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25">The Placement Agent has agreed to use its reasonable best efforts to solicit offers
to purchase the securities in this offering. The Placement Agent has no obligation to buy any of the securities from us or to arrange
for the purchase or sale of any specific number or dollar amount of the securities. There is no required minimum number of securities
that must be sold as a condition to completion of this offering. Because there is no minimum offering amount required as a condition to
the closing of this offering, the actual offering amount, placement agent fees and proceeds to us are not presently determinable and may
be substantially less than the maximum amounts set forth above. We may sell fewer than all of the securities offered hereby, which may
significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that
we do not sell an amount of securities sufficient to support our continued operations, including our near-term continued operations. Thus,
we may not raise the amount of capital we believe is required for our operations in the short-term and may need to raise additional funds,
which may not be available or available on terms acceptable to us. The success of this offering will impact our ability to use the proceeds
to execute our business plan. We may have insufficient capital to implement our business plan, potentially resulting in greater operating
losses unless we are able to raise the required capital from alternative sources. There is no assurance that alternative capital, if needed,
would be available on terms acceptable to us, or at all.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">This offering is being made on a best efforts basis and we may sell
fewer than all of the securities offered hereby and may receive significantly less in net proceeds from this offering, which will provide
us only limited working capital.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25">This offering is being made on a best efforts basis and we may sell fewer than all of
the securities offered hereby and may receive significantly less in net proceeds from this offering. Assuming that we receive net proceeds
of approximately $&#160; &#160; &#160; &#160; million from this offering (assuming an offering with gross proceeds of $&#160; &#160; &#160;&#160;
million), we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will meet our capital
needs for the next&#160; &#160; &#160; &#160; months under our current business plan. Assuming that we receive net proceeds of approximately
$&#160; &#160; &#160; million from this offering (assuming an offering with gross proceeds of $&#160; &#160; &#160; million), we believe
that the net proceeds from this offering, together with our existing cash and cash equivalents, will satisfy our capital needs for the
next&#160; &#160; &#160; &#160; months under our current business plan. Assuming that we receive net proceeds of approximately $&#160;
&#160; &#160;&#160; million from this offering (assuming an offering with gross proceeds of $&#160; &#160; &#160; million), we believe
that the net proceeds from this offering, together with our existing cash and cash equivalents, will satisfy our capital needs for the
next&#160; &#160; &#160; &#160; &#160; months under our current business plan. Without giving effect to the receipt of any proceeds from
this offering, we currently estimate that our existing cash and cash equivalents are sufficient to fund business operations into&#160;
&#160; &#160; &#160; &#160; &#160;&#160; 2025.</div> </div>

<div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our management team will have immediate and
broad discretion over the use of the net proceeds from this offering and may not use them effectively.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We currently intend to use the net proceeds of this offering for
continued development of our pipeline products, as well as the advancement of new programs, business development activities, and general
corporate purposes. See &#8220;Use of Proceeds.&#8221; However, our management will have broad discretion in the application of the net
proceeds. Our shareholders may not agree with the manner in which our management chooses to allocate the net proceeds from this offering.
The failure by our management to apply these funds effectively could have a material adverse effect on our business, financial condition
and results of operation. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income.
The decisions made by our management may not result in positive returns on your investment and you will not have an opportunity to evaluate
the economic, financial or other information upon which our management bases its decisions.</div> </div> <span style="font-family: Times New Roman,Times,serif"><br/>
</span>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">37</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">You will experience immediate dilution in the book value per share
of the <span style="font-family: Times New Roman,Times,serif">ordinary shares purchased in the offering.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">Since the public offering price of our ordinary shares in this offering is substantially
higher than the net tangible book value per share of our outstanding ordinary shares outstanding prior to this offering, you will suffer
dilution in the book value of the ordinary shares you purchase in this offering. The exercise of outstanding ordinary shares and <span style="font-family: Times New Roman,Times,serif">warrants,
including warrants sold in this offering, may result in further dilution of your investment. See the section titled &#8220;<span style="font-style: italic">Dilution</span>&#8221;
for a more detailed discussion of the dilution you will incur if you purchase shares in this offering.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Purchasers who purchase our securities in this offering pursuant
to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase
agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">In addition to rights and remedies available to all purchasers in this offering under
federal securities and state law, the purchasers that enter into a securities purchase agreement will also be able to bring claims of
breach of contract against us. The ability to pursue a claim for breach of contract provides those investors with the means to enforce
the covenants uniquely available to them under the securities purchase agreement including: (i) timely delivery of shares; (ii) agreement
to not enter into any financings for&#160; &#160; &#160; &#160; (&#160; &#160; &#160; ) days from closing; and (iii) indemnification for
breach of contract.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span style="font-style: italic">Ordinary shares representing a
substantial percentage of our outstanding shares may be sold in this offering, which could cause the price of our ordinary shares</span>&#160;to&#160;<span style="font-style: italic">decline</span>.</div>
</div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We may sell in this offering up to&#160;&#160; &#160; &#160; &#160;
&#160;&#160; ordinary shares, or approximately&#160;&#160; &#160; &#160;&#160; % of our outstanding ordinary shares, prior to this offering,
as of&#160;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; , 2024. This sale and any future sales of a substantial
number of ordinary shares in the public market, or the perception that such sales may occur, could materially adversely affect the price
of our ordinary shares. We cannot predict the effect, if any, that market sales of those ordinary shares or the availability of those
ordinary shares for sale will have on the market price of our ordinary shares.</div> </div> <span style="font-family: Times New Roman,Times,serif"><br/>
</span>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">There is no public market for the warrants being offered or pre-funded
warrants in this offering.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">There is no established public trading market for the warrants being offered or the
pre-funded warrants, and we do not expect a market to develop. In addition, we do not intend to apply to list the pre-funded warrants
or ordinary warrants on any national securities exchange or other nationally recognized trading system. Without an active market, the
liquidity of the pre-funded warrants and ordinary warrants will be limited.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">The pre-funded warrants are speculative in nature.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">The pre-funded warrants offered hereby do not confer any rights of ordinary share ownership
on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire ordinary shares
at a fixed price. Specifically, commencing on the date of issuance, holders of the pre-funded warrants may acquire the ordinary shares
issuable upon exercise of such warrants at an exercise price of $0.0001 per ordinary share. Moreover, following this offering, the market
value of the pre-funded warrants is uncertain and there can be no assurance that the market value of the pre-funded warrants will equal
or exceed the public offering price for the pre-funded warrants.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">The ordinary warrants may not have any value.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">Each ordinary warrant has an exercise price per ordinary share equal to $&#160; &#160;
&#160;&#160; (no less than&#160; &#160; &#160; &#160; &#160; &#160;&#160; % of the assumed public offering price of ordinary shares in
this offering) and expires on the fifth anniversary of its original issuance date. In the event the market price per our ordinary share
does not exceed the exercise price of the ordinary warrants during the period when the warrants are exercisable, the ordinary warrants
may not have any value.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Holders of the pre-funded warrants and ordinary warrants offered
hereby will have no rights as ordinary shareholders with respect to the ordinary shares underlying those warrants until such holders exercise
their warrants and acquire our ordinary shares, except as otherwise provided in the ordinary warrants.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">Until holders of the pre-funded warrants and ordinary warrants acquire our ordinary
shares upon exercise thereof, such holders will have no rights with respect to the ordinary shares underlying such warrants, except to
the extent that holders of such warrants will have certain rights to participate in distributions or dividends paid on our ordinary shares
as set forth in the warrants. Upon exercise of the pre-funded warrants and ordinary warrants, the holders will be entitled to exercise
the rights of an ordinary shareholder only as to matters for which the record date occurs after the exercise date.</div> </div> <span style="font-family: Times New Roman,Times,serif"><br/>
</span>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">38</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Risks Relating to Owning Our Ordinary Shares</div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">The price of our ordinary
shares and our warrants may be volatile, and the value of our ordinary shares and our warrants may decline.</div> </div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We cannot predict the prices at which
our ordinary shares or warrants will trade. The price of our ordinary shares and our warrants may not bear any relation to any established
criteria of the value of our business and prospects. In addition, the trading price of our ordinary shares and&#160; warrants is likely
to be volatile and could be subject to fluctuations in response to various factors, some of which are beyond our control. These fluctuations
could cause you to lose all or part of your investment in our ordinary shares and our warrants as you might be unable to sell your shares
at or above the price you paid. Factors that could cause fluctuations in the trading price of our ordinary shares and our warrants include
the following:</div> </div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">actual or anticipated fluctuations in our financial condition
        or results of operations;</div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">variance in the projected timeline for regulatory approvals of
        our product candidates from expectations of securities analysts;</div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">changes in laws or regulations applicable to our business;</div>
        </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">announcements by us or our competitors of significant business
        developments;</div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">significant data breaches, disruptions to or other incidents
        involving our company;</div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">conditions or developments affecting the biotechnology industry;</div>
        </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">future sales of New Silexion ordinary shares by us or our shareholders,
        as well as the anticipation of lock-up releases;</div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">changes in senior management or key personnel;</div> </div> </div>
        </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the trading volume of our securities;</div> </div> </div> </td>
        </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">changes in the anticipated future size and growth rate of our
        markets;</div> </div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">publication of research reports or news stories about us, our
        competitors or our industry, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</div>
        </div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">general economic and market conditions; and</div> </div> </div>
        </td> </tr>
  </table>

<div> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div> </div> </div> </div> </div> </div> </div> </div> </div>
</div> </div> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">other events or factors, including those resulting from war,
        incidents of terrorism, global pandemics or responses to those events.</div> </div> </div> </td> </tr>
  </table>

<div> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div> </div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Broad market and industry fluctuations,
as well as general economic, political, regulatory and market conditions, may also negatively impact the market price of our ordinary
shares. In the past, companies that have experienced volatility in the market price of their securities have been subject to securities
class action litigation. We may be the target of this type of litigation in the future, which could result in substantial expenses and
divert our management&#8217;s attention.</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">A substantial number of our ordinary shares may be issued pursuant
to the White Lion Purchase Agreement, as well as the conversion terms of our outstanding convertible notes (consisting of the A&amp;R
Sponsor Promissory Note and the EarlyBird Convertible Note), which could cause (i) the price of the ordinary shares to decline, and (ii)
substantial dilution to our existing shareholders.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The purchase price per ordinary share to be paid by White Lion for shares that we may
elect to issue and sell to it under the White Lion Purchase Agreement will fluctuate based on the market price of our ordinary shares
at the time we elect to sell such shares. Depending on market liquidity at the time, resales of such ordinary shares by White Lion may
cause the trading price of our ordinary shares to decrease, and any such decrease could be substantial.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">If and when we elect to issue and sell ordinary shares to White Lion, those issuances
and sales will result in dilution to the interests of existing holders of our ordinary shares, which dilution may be substantial. Additionally,
the sale of a substantial number of ordinary shares to White Lion, or the anticipation of such sales, could make it more difficult for
us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">In addition to ordinary shares that may be issued under the White Lion Purchase Agreement,
ordinary shares may also be issued upon conversion of amounts outstanding under two convertible promissory notes that we issued in connection
with the consummation of the Business Combination&#8212; consisting of the A&amp;R Sponsor Promissory Note, in an amount of $3,433,000,
that we issued to the Moringa Sponsor, due February 15, 2027, and the EarlyBird Convertible Note, due December 31, 2025, in an amount
of $1,250,000 that we issued to EarlyBird (together, the &#8220;Convertible Notes&#8221;). The conversion prices under the Convertible
Notes relate to the market price of our ordinary shares and/or the price at which we raise capital from equity financings. The issuance
of additional shares under the Convertible Notes will dilute our other equity holders, which could cause the price of our ordinary shares
to decline.</div> </div> <span style="font-family: Times New Roman,Times,serif"><br/> </span>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">39</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">The ordinary shares
(including ordinary shares underlying warrants) that are being offered by selling securityholders under another registration statement
that we currently have in effect represent a substantial percentage of our outstanding ordinary shares, and the sale of such shares, or
the perception that such sales may occur, could cause the price of our ordinary shares to be more volatile or decrease.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">On October 9, 2024, we filed, and on October 16, 2024, the SEC declared effective, a
registration statement on Form S-1 (SEC file number 333-282556), in which we registered with the SEC the sale by selling securityholders
named therein of up to 15,352,181 of our ordinary shares and up to 190,000 of our warrants (constituting our private warrants)<span style="font-weight: bold">.</span>
Depending on market liquidity, resales of ordinary shares and warrants by those selling securityholders may cause the trading price of
our ordinary shares and warrants to decrease, and any such decrease could be substantial. Additionally, the sale of a substantial number
of ordinary shares or warrants by those selling securityholders, or the perception that such sales may take place, could increase the
volatility of the market price of the ordinary shares and warrants and depress the trading price of the ordinary shares and warrants and
thereby make it more difficult for us to raise capital by selling equity or equity-related securities in the future at a time and at a
price that we might otherwise wish to effect sales.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"> <br/> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">The requirement that we
repay the EarlyBird Convertible Note could adversely affect our business plan, liquidity, financial condition, and results of operations.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If not converted, we are required to repay,
in cash, principal that is outstanding under the EarlyBird Convertible Note, as well as interest thereon, in connection with equity financings
by us, or upon the maturity of the note on December 31, 2025. That obligation could have important consequences on our business. In particular,
it could:</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0a95e0605d404bdd8a04fab6f6e1ef73" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">limit our flexibility in planning the payment of expenditures
        that arise in our clinical program and our business and operations generally;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdc3088c052ee4cb09e181c2f8c4c63f1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">increase our vulnerability to general adverse economic conditions
        that hinder our ability to obtain equity financings; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z08c440c1ab874318a61e8dc357a1c3d2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">place us at a competitive disadvantage compared to our competitors.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">No assurances can be given that we will be
successful in making the required payments under the EarlyBird Convertible Note. If we are unable to make the required cash payments,
there could be a default under the EarlyBird Convertible Note. In such event, or if a default otherwise occurs under the EarlyBird Convertible
Note:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3a9adbe702a54ee587ec0a36873cbe79" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the interest rate payable under the EarlyBird Convertible Note
        could be increased, and EarlyBird, as the holder of the EarlyBird Convertible Note, could declare all outstanding principal and interest
        to be due and payable; and/or</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z56ec2e633c6947dfa6015b31253d1cf1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">we could be forced into bankruptcy or liquidation.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Because we have no current
plans to pay cash dividends on our ordinary shares for the foreseeable future, you may not receive any return on investment unless you
sell New Silexion ordinary shares for a price greater than that which you paid for it.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We will likely retain future earnings, if
any, for future operations, expansion and debt repayment and have no current plans to pay any cash dividends for the foreseeable future.
Any decision to declare and pay dividends as a public company in the future will be made at the discretion of our board of directors and
will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions, funds
lawfully available therefor and other factors that our board of directors may deem relevant. In addition, our ability to pay dividends
may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. As a result, you may not
receive any return on an investment in our ordinary shares unless you sell our ordinary shares for a price greater than that which you
paid for it.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Our prospective reverse
share split may negatively impact the market for our ordinary shares.</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">There can be no assurance that the total
market capitalization of our ordinary shares after our prospective reverse share split will be equal to or greater than the total market
capitalization before the prospective reverse share split, or that the per share market price of our ordinary shares following the reverse
share split will increase in proportion to the reduction in the number of ordinary shares outstanding before the reverse share split.
Factors such as the results of our pre-clinical and clinical trials, progress in seeking regulatory approval for our product candidates,
our financial results, developments involving our competitors, market conditions and the market perception of our product candidates may
adversely affect the market price of our ordinary shares. As a result, a decline in the market price of our ordinary shares after the
reverse share split may result in a greater percentage decline than would occur in the absence of a reverse share split.</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman, Times, serif; font-weight: normal; font-style: normal">40</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In addition to market price, the liquidity
of our ordinary shares may also be adversely affected by the reverse share split, given the reduced number of ordinary shares that will
be outstanding following the reverse share split.</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The reverse share split may furthermore
increase the number of our shareholders who own odd lots (less than 100 shares). Any shareholder who owns fewer than 600 to 1,500 ordinary
shares, depending on the final ratio, prior to the reverse share split will own fewer than 100 ordinary shares following the reverse share
split. Shareholders who hold odd lots may experience an increase in the cost of selling their shares and may have greater difficulty in
effecting sales.</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Following, and as a
partial result of, our prospective reverse share split, our ordinary shares may experience extreme price volatility unrelated to our actual
or expected operating performance, financial condition or prospects, making it difficult for prospective investors to assess the rapidly
changing value of our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Recently, there have been instances of
extreme share price run-ups followed by rapid price declines and strong share price volatility with a number of relatively new public
companies, especially among companies with relatively smaller public floats. As a relatively small-capitalization company with relatively
small public float, we may experience greater share price volatility, extreme price run-ups, lower trading volume and less liquidity than
large-capitalization companies. The potential decrease in liquidity due to our prospective reverse share split may heighten our exposure
to those trading trends. In particular, following a reverse share split, our ordinary shares may be subject to rapid and substantial price
volatility, low volume of trades, and large spreads in bid and ask prices. Such volatility, including any stock run up, may be unrelated
to our actual or expected operating performance, financial condition or prospects, making it difficult for prospective investors to assess
the rapidly changing value of our ordinary shares.</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In addition, if the trading volumes of
our ordinary shares are low, persons buying or selling in relatively small quantities may easily influence prices of our ordinary shares.
This low volume of trades could also cause the price of our ordinary shares to fluctuate greatly, with large percentage changes in price
occurring in any trading day session. Holders of our ordinary shares may also not be able to readily liquidate their investment or may
be forced to sell at depressed prices due to low volume trading. If high spreads between the bid and ask prices of our ordinary shares
exist at the time of a purchase, the shares would have to appreciate substantially on a relative percentage basis for an investor to recoup
their investment. Broad market fluctuations and general economic and political conditions (including in Israel, where our operations are
centered) may also adversely affect the market price of our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">As a result of this volatility, investors
may experience losses on their investment in our ordinary shares. A volatile market price of our ordinary shares also could adversely
affect our ability to issue additional ordinary shares or other securities and our ability to obtain additional financing in the future,
which is a key strategic goal for us, thereby frustrating our ability to achieve one of the key purposes of our reverse share split.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Following our prospective
reverse share split, the resulting higher market price of our ordinary shares may not attract new investors, including institutional investors,
and may not satisfy the investing requirements of those investors. Consequently, the trading liquidity of our ordinary shares may not
improve.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Although we believe that a higher market
price of our ordinary shares, which is expected to result from our prospective reverse share split, may help generate greater or broader
investor interest, there can be no assurance that the reverse share split will result in a share price that will attract new investors,
including institutional investors. In addition, there can be no assurance that the market price of our ordinary shares will satisfy the
investing requirements of those investors. As a result, the trading liquidity of our ordinary shares may not necessarily improve.</div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">The Company qualifies
as an &#8220;emerging growth company&#8221; as well as a &#8220;smaller reporting company&#8221; within the meaning of the Securities
Act, and if the Company takes advantage of certain exemptions from disclosure requirements available to emerging growth companies or smaller
reporting companies, it could make our securities less attractive to investors and may make it more difficult to compare our performance
to the performance of other public companies.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The Company qualifies as an &#8220;emerging
growth company&#8221; as defined in Section&#160;2(a)(19)&#160;of the Securities Act, as modified by the JOBS Act. As such, the Company
will be eligible for and intends to take advantage of certain exemptions from various reporting requirements applicable to other public
companies that are not emerging growth companies for as long as it continues to be an emerging growth company, including (a)&#160;the
exemption from the auditor attestation requirements with respect to internal control over financial reporting under Section&#160;404(b)&#160;of
the Sarbanes-Oxley&#160;Act, (b)&#160;the exemptions from say-on-pay, say-on-frequency&#160;and say-on-golden&#160;parachute voting requirements
and (c)&#160;reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements. Wewill remain
an emerging growth company until the earliest of (i)&#160;the last&#160;day of the fiscal year in which the market value of our ordinary
shares that are held by non-affiliates&#160;is equal to or exceeds $700&#160;million as of the end of that year&#8217;s second fiscal
quarter, (ii)&#160;the last&#160;day of the fiscal year in which it has total annual gross revenue of $1.235&#160;billion or more during
such fiscal year (as indexed for inflation), (iii)&#160;the date on which it has issued more than $1&#160;billion in non-convertible&#160;debt
in the prior three-year&#160;period or (iv)&#160;the last&#160;day of the fiscal year following the fifth anniversary of the date of the
first issuance of our ordinary shares in the Business Combination. In addition, Section&#160;107 of the JOBS Act also provides that an
emerging growth company can take advantage of the exemption from complying with new or revised accounting standards provided in Section&#160;7(a)(2)(B)&#160;of
the Securities Act as long as the Company is an emerging growth company. An emerging growth company can therefore delay the adoption of
certain accounting standards until those standards would otherwise apply to private companies. We have elected not to opt out of such
extended transition period and, therefore, the Company may not be subject to the same new or revised accounting standards as other public
companies that are not emerging growth companies. Investors may find our ordinary shares less attractive because we rely on these exemptions,
which may result in a less active trading market for our ordinary shares and its price may be more volatile.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">41</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Additionally, the Company qualifies as a
&#8220;smaller reporting company&#8221; as defined in Item&#160;10(f)(1)&#160;of Regulation&#160;S-K&#160;promulgated by the SEC.&#160;Smaller
reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two&#160;years
of audited financial statements. The Company will remain a smaller reporting company until the last&#160;day of the fiscal year in which
(i)&#160;the market value of our ordinary shares held by non-affiliates&#160;is equal to or exceeds $250&#160;million as of the end of
that year&#8217;s second fiscal quarter, or (ii)&#160;our annual revenues is equal to or exceeds $100&#160;million during such completed
fiscal year and the market value of our ordinary shares held by non-affiliates&#160;is equal to or exceeds $700&#160;million as of the
end of that year&#8217;s second fiscal quarter. To the extent the Company takes advantage of such reduced disclosure obligations, it may
also make comparison of our financial statements with other public companies difficult or impossible.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Risks Related to U.S.&#160;Federal Income
Taxation</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">The PFIC status of New
Silexion could result in adverse U.S.&#160;federal income tax consequences to U.S.&#160;Holders.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In general, a non-U.S.&#160;corporation is
a PFIC for U.S.&#160;federal income tax purposes for any taxable year in which, after applying certain look-through&#160;rules, either
(i)&#160;50% or more of the average value of its assets (generally determined on the basis of a weighted quarterly average) consists of
assets that produce, or are held for the production of, passive income, or (ii)&#160;75% or more of its gross income consists of passive
income. Passive income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active
conduct of a trade or business) and gains from the disposition of passive assets. Cash and cash equivalents generally are passive assets.
The value of goodwill will generally be treated as an active or passive asset based on the nature of the income produced in the activity
to which the goodwill is attributable. For purposes of the PFIC rules, a non-U.S.&#160;corporation that owns, directly or indirectly,
at least 25% by value of the stock of another corporation is treated as if it held its proportionate share of the assets of the other
corporation and received directly its proportionate share of the income of the other corporation.</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The annual PFIC income and asset tests in
respect of Silexion will be applied based on the assets and activities of the combined business. Based on the composition of our income
and assets, it cannot be determined whether we will be classified as a PFIC for its taxable year that includes the date of the Business
Combination or in any future taxable year. Further, changes in the composition of our income or composition of our assets may cause us
to be or become a PFIC for the current or subsequent taxable&#160;years. Whether we are treated as a PFIC for U.S.&#160;federal income
tax purposes is a factual determination that must be made annually at the close of each taxable year and, thus, is subject to significant
uncertainty.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If we are treated as a PFIC for any taxable
year, or portion thereof, that is included in the holding period of a U.S.&#160;Holder, such U.S.&#160;Holder may be subject to certain
adverse U.S.&#160;federal income tax consequences and may be subject to additional reporting requirements. For a further discussion, see
&#8220;<span style="font-style: italic">Material U.S.&#160;Federal Income Tax Considerations&#160;&#8212;&#160;PFIC Rules</span>.&#8221;
U.S.&#160;Holders are strongly encouraged to consult their own advisors regarding the potential application of these rules to the ownership
of our ordinary shares and/or our public warrants.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">If a U.S.&#160;person
is treated as owning at least 10% of the shares of New Silexion, such person may be subject to adverse U.S.&#160;federal income tax consequences.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">If a U.S.&#160;Holder is treated as owning (directly, indirectly or constructively)
at least 10% of the value or voting power of the shares of Silexion, such holder may be treated as a &#8220;United&#160;States shareholder&#8221;
with respect to each of Silexion and our direct and indirect subsidiaries (the &#8220;<span style="font-weight: bold">New Silexion Group</span>&#8221;)
that is a &#8220;controlled foreign corporation,&#8221; (a &#8220;CFC&#8221;), for U.S.&#160;federal income tax purposes. A non-U.S.&#160;corporation
is considered a CFC if more than 50% of (1)&#160;the total combined voting power of all classes of stock of such corporation entitled
to vote, or (2)&#160;the total value of the stock of such corporation is owned, or is considered as owned by applying certain constructive
ownership rules, by United&#160;States shareholders on any&#160;day during the taxable year of such non-U.S.&#160;corporation. If the
New Silexion Group includes one or more non-U.S.&#160;subsidiaries, certain of our non-U.S.&#160;subsidiaries could be treated as CFCs
regardless of whether we are treated as a CFC.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If Silexion or any of our non-U.S.&#160;subsidiaries
is a CFC, 10% &#8220;United&#160;States shareholders&#8221; will be subject to adverse income inclusion and reporting requirements with
respect to such CFC.&#160;No assurance can be provided that New Silexion will assist holders in determining whether it or any of our non-U.S.&#160;subsidiaries
is treated as a CFC or whether any holder is treated as a United&#160;States shareholder with respect to any of such CFCs, or furnish
to any holder information that may be necessary to comply with reporting and tax payment obligations with respect to such CFCs.</div>
</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">42</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">General Risks</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">The Company may be subject
to securities litigation, which is expensive and could divert management attention, including securities class action and derivative lawsuits
which could result in substantial costs.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our share price may be volatile and, in
the past, companies that have experienced volatility in the market price of their stock or shares have been subject to securities litigation,
including class action litigation. The Company may be the target of this type of litigation in the future. Litigation of this type could
result in substantial costs and diversion of management&#8217;s attention and resources, which could have a material adverse effect on
our business, financial condition, and results of operations. Any adverse determination in litigation could also subject the Company to
significant liabilities.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Securities class action lawsuits and derivative
lawsuits are often brought against public companies that have entered into merger or business combination agreements. Even if the lawsuits
are without merit, defending against these claims can result in substantial costs and divert management time and resources. An adverse
judgment could result in monetary damages, which could have a negative impact on our liquidity and financial condition. We cannot predict
whether any such lawsuits will be filed.</div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold"><span id="USE"><!--Anchor--></span>USE
OF PROCEEDS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Assuming the maximum number of ordinary
shares are sold in this offering at an assumed public offering price of $&#160; &#160; &#160; &#160; &#160;&#160; per ordinary share and
accompanying ordinary warrant, which represents the closing price of our ordinary shares on Nasdaq on&#160; &#160; &#160; &#160; &#160;&#160;
, 2024, and assuming no issuance of pre-funded warrants in connection with this offering, we estimate the net proceeds of the offering
will be approximately $&#160; &#160; &#160; &#160; &#160;&#160; million, after deducting the Placement Agent&#8217;s fees and estimated
offering expenses payable by us. However, this is a best efforts offering with no minimum number of securities or amount of proceeds as
a condition to closing, and we may not sell all or any of these securities offered pursuant to this prospectus; as a result, we may receive
significantly less in net proceeds.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Each $0.10 increase (decrease) in the assumed
public offering price of $&#160; &#160; &#160; &#160;&#160; per ordinary share and accompanying ordinary warrant would increase (decrease)
the net proceeds to us from this offering, after deducting the estimated placement agent fees and estimated offering expenses payable
by us, by $&#160; &#160; &#160; million, assuming that the number of ordinary shares and accompanying ordinary warrants offered by us,
as set forth on the cover page of this prospectus, remains the same. We may also increase or decrease the number of ordinary shares and
ordinary warrants we are offering. An increase (decrease) of&#160; &#160; &#160; &#160; &#160; &#160; in the number of ordinary shares
we are offering would increase (decrease) the net proceeds to us from this offering, after deducting the estimated placement agent fees
and estimated offering expenses payable by us, by $&#160; &#160; &#160; &#160; million, assuming the assumed public offering price stays
the same.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"> <br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We currently intend to use the net proceeds
from this offering to advance our pre-clinical clinical studies, and for general corporate purposes. Accordingly, we retain broad discretion
over the use of the net proceeds from the sale of our ordinary shares and ordinary warrants (or pre-funded warrants and ordinary warrants,
if applicable), pursuant to this prospectus. The precise amount and timing of the application of such proceeds will depend upon our liquidity
needs and the availability and cost of other capital over which we have little or no control.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Pending the use of the net proceeds from
this offering as described above, we intend to invest the net proceeds in a variety of capital preservation investments, short and intermediate
term, interest-bearing, investment-grade instruments, U.S. government securities and highly rated corporate debt securities, although
our investment policy may change following the date of this prospectus supplement. It is possible that, pending their use, we may invest
the net proceeds in a way that does not yield a favorable, or any, return for us.</div>

<div style="margin-left: 69.65pt; line-height: 1.25">&#8203;</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span style="font-family: Times New Roman,Times,serif"><span id="TRANSACTIONSRELATEDTOOFFE"><!--Anchor--></span></span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">43</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="CAPITALIZATION"><!--Anchor--></span>CAPITALIZATION</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following table sets forth our capitalization&#160;as of June
30, 2024 as follows:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36.3pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>on an actual basis; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36.3pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>on an as adjusted basis to reflect assumed sale by us of all ordinary shares and accompanying ordinary warrants offered by means
        of this prospectus at an assumed public offering price of $&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; per ordinary share
        and accompanying ordinary warrant, which is based on the last reported sale price of our ordinary shares on Nasdaq on&#160; &#160; &#160;
        &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; , 2024, assuming no sale of pre-funded warrants and after deducting the
        Placement Agent&#8217;s fees and estimated offering expenses payable by us, and without giving effect to the exercise of the ordinary
        warrants issued in this offering.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span></div>

<div style="text-indent: 36pt; line-height: 1.25">The as adjusted information below is illustrative only and our capitalization following
the completion of this offering is subject to various adjustments. The as adjusted amounts shown below are unaudited and represent management&#8217;s
estimate. The information in this table should be read in conjunction with and is qualified by reference to the financial statements and
notes thereto and other financial information contained in this prospectus.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z9a5ff9aadaa14d54b921d40a6ca7ba44" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td colspan="4" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">As of June 30, 2024</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">(unaudited)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold">(U.S. dollars in thousands)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Actual</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">As Adjusted</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Cash and cash equivalents</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">1,697</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Shareholders&#8217; equity:</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Ordinary shares par value S0.0001 per share; authorized 200,000,000; issued and outstanding&#160; &#160;
        &#160; &#160; &#160; &#160; &#160; &#160; ordinary shares (actual) and&#160; &#160; &#160; &#160; &#160; &#160;&#160; ordinary shares
        (as adjusted)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Additional paid in capital</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Accumulated other comprehensive loss</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><br/> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">)<br/>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><br/> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">)<br/>
        </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Accumulated deficit</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><br/> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">)<br/>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><br/> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">)<br/>
        </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Total shareholders&#8217; equity</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Each $0.10 increase (decrease) in an assumed public offering price of $&#160; &#160;
&#160;&#160;&#160; per share and accompanying ordinary warrant would increase (decrease) the amount of cash and cash equivalents and total
shareholders&#8217; equity by $&#160; &#160; &#160; million, a by $&#160; &#160;&#160;&#160; million, assuming that the number of ordinary
shares and accompanying ordinary warrants offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting the Placement Agent&#8217;s fees and estimated offering expenses payable by us. We may also increase or decrease the number
of ordinary shares and accompanying ordinary warrants we are offering. An increase (decrease) of 100,000 in the number of ordinary shares
we are offering would increase (decrease) the amount of cash and cash equivalents and total shareholders&#8217; equity by $&#160; &#160;&#160;
million, after deducting the estimated Placement Agent&#8217;s fees and estimated offering expenses payable by us, assuming the assumed
public offering price stays the same. The information discussed above is illustrative only and will adjust based on the actual public
offering price, the actual number of shares that we offer in this offering, and other terms of this offering determined at pricing.</div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">The above table is based on&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;
shares outstanding as of June 30, 2024 and excludes as of that date:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>up to 5,940,000 ordinary shares underlying an equivalent number of outstanding warrants at an exercise price of $11.50 per share;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>6,866,000 ordinary shares issuable pursuant to the A&amp;R Sponsor Promissory Note (based on the conversion of the entire $3,433,000
        principal amount of that note into ordinary shares at an assumed conversion price of $0.50 per share);</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>2,500,000 ordinary shares issuable pursuant to the EarlyBird Convertible Note (based on the conversion of the entire $1,250,000 principal
        amount of that note into ordinary shares at an assumed conversion price of $0.50 per share);</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ordinary shares issuable upon exercise of outstanding stock options
        under our equity incentive plan, at a weighted average exercise price of $&#160; &#160; &#160; &#160; &#160; ;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; ordinary shares issuable upon the settlement of RSUs under our equity incentive
        plan; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">&#160; &#160; &#160; &#160; &#160;
        &#160; &#160; &#160; ordinary shares reserved for future awards under our equity incentive plan.</td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">44</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="DILUTION"><!--Anchor--></span>DILUTION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">If you purchase our ordinary shares and accompanying ordinary warrants in this offering,
you will experience dilution to the extent of the difference between the combined public offering price per ordinary share and ordinary
warrant you pay in this offering and the net tangible book value per share of our ordinary shares immediately after this offering.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The net tangible book value of our ordinary shares on June 30, 2024 was approximately
$&#160; &#160; &#160; &#160; &#160; million, or approximately $&#160; &#160; &#160; &#160; &#160; &#160; &#160; per share. Net tangible
book value per share is equal to the amount of our total tangible assets, less total liabilities, divided by the aggregate number of our
ordinary shares outstanding.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">After giving effect to the assumed sale by us of all ordinary shares and accompanying
ordinary warrants offered by means of this prospectus at an assumed public offering price of $&#160; &#160; &#160; &#160; &#160; &#160;
&#160; &#160; per ordinary share and accompanying ordinary warrant, which is based on the last reported sale price of our ordinary shares
on Nasdaq on&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; , 2024, assuming no sale of pre-funded
warrants and after deducting the Placement Agent&#8217;s fees and estimated offering expenses payable by us, and without giving effect
to the exercise of the ordinary warrants issued in this offering, our as adjusted net tangible book value as of June 30, 2024 would have
been approximately $&#160; &#160; &#160; &#160; &#160; &#160;&#160; million, or approximately $&#160; &#160; &#160; &#160; &#160; &#160;
per ordinary share and accompanying ordinary warrant. This represents an immediate increase in net tangible book value of approximately
$&#160; &#160; &#160; &#160; &#160; per share to existing shareholders and an immediate dilution of approximately $&#160; &#160; &#160;&#160;
per share to new investors in this offering. The following table illustrates this per share dilution:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z3a6e5de9a96d449f86fec688629e3d33" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 88%; font-family: Times New Roman,Times,serif">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25">Assumed public offering price per ordinary share and accompanying
        ordinary warrant</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">$</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 88%; font-family: Times New Roman,Times,serif">
        <div style="margin-left: 10pt; line-height: 1.25">Net tangible book value per share as of June 30, 2024</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">$</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 88%; font-family: Times New Roman,Times,serif">
        <div style="margin-left: 10pt; line-height: 1.25">Increase per share attributable to new investors in this offering</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">$</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 88%">
        <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25">As adjusted net tangible book value per share as of June 30, 2024
        after giving effect to this<span style="font-family: Times New Roman,Times,serif"> offering</span></div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">$</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 88%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Dilution in net tangible book value per share to new investors in this offering</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">$</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">Each $0.10 increase (decrease) in an assumed public offering price of $&#160; &#160;
&#160;&#160;&#160; per share and accompanying ordinary warrant would increase (decrease) our as adjusted net tangible book value after
this offering by $&#160; &#160; &#160;&#160; per share, and the dilution per share to new investors by $&#160; &#160;&#160;&#160; per
share and accompanying ordinary warrant, assuming that the number of ordinary shares and accompanying ordinary warrants offered by us,
as set forth on the cover page of this prospectus, remains the same and after deducting the Placement Agent&#8217;s fees and estimated
offering expenses payable by us. We may also increase or decrease the number of ordinary shares and accompanying ordinary warrants we
are offering. An increase (decrease) of 100,000 in the number of ordinary shares we are offering would increase (decrease) the dilution
per ordinary shares to new investors by $&#160; &#160; &#160; &#160;&#160; ,after deducting the estimated Placement Agent&#8217;s fees
and estimated offering expenses payable by us, assuming the assumed public offering price stays the same. The information discussed above
is illustrative only and will adjust based on the actual public offering price, the actual number of shares that we offer in this offering,
and other terms of this offering determined at pricing.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The number of our ordinary shares to be outstanding after this offering as shown above
is based on&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; shares outstanding as of June 30, 2024 and excludes as of that
date:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>up to 5,940,000 ordinary shares underlying an equivalent number of outstanding warrants at an exercise price of $11.50 per share;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>6,866,000 ordinary shares issuable pursuant to the A&amp;R Sponsor Promissory Note (based on the conversion of the entire $3,433,000
        principal amount of that note into ordinary shares at an assumed conversion price of $0.50 per share);</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>2,500,000 ordinary shares issuable pursuant to the EarlyBird Convertible Note (based on the conversion of the entire $1,250,000 principal
        amount of that note into ordinary shares at an assumed conversion price of $0.50 per share);</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ordinary shares issuable upon exercise of outstanding stock options
        under our equity incentive plan, at a weighted average exercise price of $&#160; &#160; &#160; &#160; &#160; ;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; ordinary shares issuable upon the settlement of RSUs under our equity incentive
        plan; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="a9364ed439ea49a4a56db6d2d277cb21" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">&#160; &#160; &#160; &#160; &#160;
        &#160; &#160; &#160; ordinary shares reserved for future awards under our equity incentive plan.</td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">To the extent that any of our options or warrants listed above are exercised, new options
are issued under our equity incentive plan and subsequently exercised or we issue additional ordinary shares in the future, there will
be further dilution to new investors participating in this offering.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">45</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span style="font-family: Times New Roman,Times,serif"><span id="MARKETANDINDUSTRYDATA"><!--Anchor--></span></span></div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="MARKETINFORMATIONFORSECUR"><!--Anchor--></span>MARKET
INFORMATION FOR SECURITIES AND DIVIDEND POLICY</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Market Information</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">Our ordinary shares and warrants are currently listed on Nasdaq under the symbols &#8220;SLXN&#8221; and
&#8220;SLXNW,&#8221; respectively. On November&#160;&#160; , 2024, there were &#160; &#160; &#160;&#160; holders of record of the ordinary
shares and three holders of record of our warrants.</div> </div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Dividend Policy</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We have never declared or paid any dividends
on ordinary shares. We anticipate that we will retain all of our future earnings, if any, for use in the operation and expansion of our
business and do not anticipate paying cash dividends in the foreseeable future. Any decision to declare and pay dividends in the future
will depend on, among other things, the consent of our lender(s), our results of operations, cash requirements, financial condition, contractual
restrictions, funds lawfully available therefor and other factors that our board of directors may deem relevant.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="UNAUDITEDPROFORMACONDENSE"><!--Anchor--></span>UNAUDITED
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Introduction</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The registrant, Silexion Therapeutics Corp
(formerly known as Biomotion Sciences), a Cayman Islands exempted company (&#8220;<span style="font-weight: bold">New Silexion</span>&#8221;)
is providing the following unaudited pro forma condensed combined financial information to aid you in your analysis of the financial aspects
of the business combination and related transactions (collectively, the &#8220;<span style="font-weight: bold">Transactions</span>&#8221;)
involving Moringa Acquisition Corp (&#8220;<span style="font-weight: bold">Moringa</span>&#8221;) and Silexion Therapeutics Ltd. (&#8220;<span style="font-weight: bold">Silexion</span>&#8221;).
The following unaudited pro forma condensed combined financial information presents the combination of the financial information of Moringa
and Silexion, as adjusted to give effect to the Transactions. Capitalized terms included in this section containing unaudited pro forma
condensed combined financial information and not otherwise defined in this section have the same meaning as is provided elsewhere in this
prospectus.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Parties to the Transaction</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Moringa is a Cayman Islands exempted company
that was originally a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share
purchase, recapitalization, reorganization or similar business combination with one or more businesses. As of June 30, 2024 and December
31, 2023, there was approximately $5.924 million and $5.698 million, respectively, held in Moringa&#8217;s trust account, which was held
for the benefit of Moringa&#8217;s public shareholders (the &#8220;<span style="font-weight: bold">Trust Account</span>&#8221;). The Trust
Account was liquidated upon the completion of the Transactions, as described below.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Silexion, an Israeli company that was known
previously as Silenseed Ltd., is a pioneering biopharma developmental-stage company dedicated to the development of innovative treatments
for pancreatic cancer.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">New Silexion is a newly formed entity that
was formed for the purpose of effecting the Transactions, and now serves as a publicly-traded holding company of its subsidiaries &#8212;
including Moringa and Silexion &#8212; after the Closing of the Transactions.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">46</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Description of the Transactions</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">On August 15, 2024, the parties completed
the previously-reported Transactions pursuant to that certain amended and restated business combination agreement, dated April 3, 3024
(the &#8220;<span style="font-weight: bold">Business Combination Agreement</span>&#8221;) by and among New Silexion (then known as Biomotion
Sciences), August M.S. Ltd., an Israeli company and a wholly owned subsidiary of New Silexion (&#8220;<span style="font-weight: bold">Merger
Sub 1</span>&#8221;), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a wholly owned subsidiary of New Silexion
(&#8220;<span style="font-weight: bold">Merger Sub 2</span>&#8221;), Moringa and Silexion.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Pursuant to the Transactions, Merger Sub 2
merged with and into Moringa, with Moringa continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion
(the &#8220;<span style="font-weight: bold">SPAC Merger</span>&#8221;), and Merger Sub 1 merged with and into Silexion, with Silexion
continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion (the &#8220;<span style="font-weight: bold">Acquisition
Merger</span>&#8221;). Upon the effectiveness of the SPAC Merger, each outstanding Moringa Class A ordinary share and the sole outstanding
Moringa Class B ordinary share converted into an ordinary share of New Silexion on a one-for-one basis. Each outstanding warrant to purchase
one Moringa Class A ordinary share converted into a warrant to purchase one New Silexion ordinary share, at the same exercise price. Upon
the effectiveness of the Acquisition Merger, each outstanding ordinary share and preferred share of Silexion converted into such number
of ordinary shares of New Silexion as is equal to the quotient obtained by dividing (x) the quotient obtained by dividing (1) $62,500,000
by (2) the number of fully diluted Silexion equity securities, by (y) $10.00 (the &#8220;<span style="font-weight: bold">Silexion Equity
Exchange Ratio</span>&#8221;). Each outstanding Silexion warrant and Silexion option to purchase one Silexion share, and Silexion restricted
share unit (RSU) that may be potentially settled for one Silexion share, became exercisable for, or became subject to settlement for (as
applicable), such number of New Silexion ordinary shares as are equal to the Silexion Equity Exchange Ratio. The exercise price per New
Silexion ordinary share of each such converted Silexion option and Silexion warrant were adjusted based on dividing the existing per share
exercise price by the Silexion Equity Exchange Ratio. The terms of vesting, exercise and/or settlement, as applicable, of such converted
options, warrants and RSUs remain the same following such conversion, except that the vesting of each Silexion option accelerated immediately
prior to the Acquisition Merger, such that the New Silexion option into which it has been converted was fully vested, and all Silexion
warrants were exercised (on a cashless basis) immediately prior to the Acquisition Merger.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Immediately prior to the Closing, seven directors
were appointed to New Silexion&#8217;s board of directors, of whom five were designated by Silexion and two were designated by Moringa&#8217;s
sponsor (Moringa Sponsor, LP, a Cayman Islands exempted limited partnership and/or its wholly-owned subsidiary, Moringa Sponsor US L.P.,
a Delaware limited partnership) (collectively, the &#8220;<span style="font-weight: bold">Moringa Sponsor</span>&#8221;).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In connection with the Closing, the ordinary
shares and warrants of New Silexion were approved for listing on the Nasdaq Global Market and began trading under the symbols &#8220;SLXN&#8221;
and &#8220;SLXNW&#8221;, respectively.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Business Combination was accounted for
as a reverse recapitalization in accordance with US GAAP. Under this method of accounting, Silexion was treated as the accounting acquirer
and Moringa was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Silexion was determined to be the accounting
acquirer based on evaluation of the following facts and circumstances:</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3a6b7979fa224072bb1d168cfd83610a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Silexion&#8217;s shareholders holding approximately 61.55% of
        the outstanding voting interests in New Silexion upon the Closing of the Transactions;</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z55f0ce87b9a04ea0a677c30fc17ce10e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Silexion&#8217;s senior management comprise the senior management
        of New Silexion;</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9956ef0cd16a4b3fba29e158340b135d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the directors nominated by Silexion constitute the majority of
        the board of directors of New Silexion (five out of seven of the initial directors); and</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">47</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="z67c4a48f0a7d468d8cf1bee18d508a16" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Silexion&#8217;s operations comprise the ongoing operations of
        New Silexion.</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the reverse recapitalization accounting
method, the Business Combination is deemed to be the equivalent of a capital transaction in which Silexion has issued shares for the net
assets of Moringa. The net assets of Moringa are stated at fair value, with no goodwill or other intangible assets recorded. Operations
prior to the Business Combination are of Silexion.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following unaudited pro forma condensed
combined balance sheet as of June 30, 2024 combines the historical condensed balance sheet of Moringa as of June 30, 2024 with the historical
balance sheet of Silexion as of June 30, 2024, with such adjustments as are necessary to properly understand New Silexion&#8217;s financial
position and results of operations upon consummation of the Business Combination and related transactions &#8212; all in accordance with
Article 11 of SEC Regulation S-X, as amended by the final rule, SEC Release No. 33-10786 &#8220;Amendments to Financial Disclosures About
Acquired and Disposed Businesses&#8221; (collectively, the &#8220;<span style="font-weight: bold">Pro Forma Adjustments</span>&#8221;)
&#8212; giving effect to the Business Combination as if it had been consummated as of June 30, 2024.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following unaudited pro forma condensed
combined statements of operations for the six-months period ended June 30, 2024 and year ended December 31, 2023 combine the historical
condensed statement of operations of Moringa for the six-months period ended June 30, 2024 and for the year ended December 31, 2023 with
the historical statements of operations of Silexion for the six-months period ended June 30, 2024 and for the year ended December 31,
2023, subject to the Pro Forma Adjustments, giving effect to the Business Combination as if it had been consummated on January 1, 2023,
the beginning of the earliest period presented.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Unaudited Condensed Combined Pro Forma Financial
Statements</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The unaudited pro forma condensed combined
financial statements have been derived from and should be read in conjunction with:</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z220f6b1956664f48835c740372ea7b3d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the accompanying notes to the unaudited pro forma condensed combined
        financial statements;</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf7787c8647b548a2937d0b60d5c7c162" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the historical unaudited financial statements of Moringa as of
        and for the six-months period ended June 30, 2024 and the related notes included elsewhere in this prospectus;</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z330aaa74b86a45aebf95de09dcc33a03" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the historical unaudited financial statements of Silexion as
        of and for the six-months period ended June 30, 2024 and the related notes included elsewhere in this prospectus;</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2fb9e50e6feb4e999804608db9bd4f93" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the historical audited financial statements of Moringa as of
        and for the year ended December 31, 2023 and the related notes included elsewhere in this prospectus;</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfb24564a26b24d2db6cc9757ff87f0be" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the historical audited financial statements of Silexion as of
        and for the year ended December 31, 2023 and the related notes included elsewhere in this prospectus;</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9d40d1803fcb4fd4af0d164dbdae8ca9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the sections entitled &#8220;Management&#8217;s Discussion and
        Analysis of Financial Condition and Results of Operations&#8221; included in Moringa&#8217;s quarterly report on Form 10-Q for the quarter
        ended June 30, 2024, filed with the SEC on August 13, 2024 (the &#8220;<span style="font-weight: bold">Moringa Q2 Form 10-Q</span>&#8221;),
        and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in this prospectus;</div>
        </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z44ae154d5bb1496ea51ab5c563f8ca0f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the other financial information relating to Moringa and Silexion
        included in this prospectus; and</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfc3711ad22b54eb8b3e28c64d88f2564" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">factors detailed under the section entitled &#8220;<span style="font-style: italic">Risk
        Factors</span>&#8221; in this prospectus.</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The unaudited pro forma condensed combined
financial information is for illustrative purposes only and is not necessarily indicative of what the actual results of operations and
financial position would have been had the Transactions included in the Pro Forma Adjustments taken place on the dates indicated, nor
are they indicative of the future results of operations or financial position of New Silexion. The Pro Forma Adjustments are based on
currently available information and certain assumptions and estimates that New Silexion believes are reasonable under the circumstances.
Management performed a comprehensive review of the accounting policies between the two entities. Management is not aware of any significant
accounting policy differences and has therefore not made any adjustments to the pro forma condensed combined financial information related
to any potential differences.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The unaudited condensed combined pro forma
financial information is qualified in its entirety by reference to, and should be read together with, Silexion&#8217;s and Moringa&#8217;s
audited financial statements and related notes included in this prospectus, as well as &#8220;Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations&#8221; included in each of this prospectus and the Moringa Q2 Form 10-Q.</div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">48</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">SILEXION THERAPEUTICS
CORP<br/> UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET<br/> AS OF JUNE 30, 2024<br/> (in thousands, except share and per share
amounts)</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="zcf51e0b505ef4546969b04b17d346d2a" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 30%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Historical</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="13" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Actual Redemptions</div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 30%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Moringa<br/> Acquisition<br/>
        Corp.</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Silexion<br/> Therapeutics<br/>
        Ltd.</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%"><span style="font-family: Times New Roman,Times,serif"><br/> </span>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Redemption<br/> Adjustments</div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-weight: bold"><span style="font-family: Times New Roman,Times,serif"><br/> </span>
        </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Business<br/> Combination<br/>
        Adjustments</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Pro Forma<br/> Balance<br/>
        Sheet</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">ASSETS</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Current Assets:</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Cash and cash equivalents</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">18</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,697</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">I
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,015</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">A
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(2,076</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,244</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">L
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">B
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(350</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">N
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(60</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Restricted cash</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">25</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">25</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Investments held in Trust Account</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">5,924</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">I
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(5,924</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Prepaid expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">25</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">527</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">552</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Other receivables</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">66</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">66</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Total Current Assets</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">5,967</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,315</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(4,909</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(486</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,887</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Restricted cash</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">25</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">25</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Long-term deposit</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">5</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">5</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Property and equipment, net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">40</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">40</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Operating lease right-of-use asset</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">140</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">140</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Total Assets</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">5,967</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,525</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(4,909</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(486</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,097</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-weight: bold; text-indent: -9pt; margin-left: 9pt; font-family: Times New Roman,Times,serif">LIABILITIES
        AND REDEEMABLE SHARES, NET OF CAPITAL DEFICIENCY</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Current Liabilities:</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Trade payables</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">281</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">281</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Current maturities of operating lease liability</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">108</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">108</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Employee related obligations</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">251</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">251</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Accrued expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">56</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,379</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">A
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(233</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,202</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Related Parties</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,346</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">F
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(3,346</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,145</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">F
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,145</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">ELOC Liability</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">M
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">337</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">337</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Warrants</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">27</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">345</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; padding-bottom: 2px"><span style="font-family: Times New Roman,Times,serif">C
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(345</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">27</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Total Current Liabilities</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,429</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,364</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(442</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">5,351</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Long-term operating lease liability</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">8</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">8</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Underwriters&#8217; Promissory note</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">B
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,197</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,197</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Total Non Current Liabilities</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">8</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,197</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,205</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Total Liabilities</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,429</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,372</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">755</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">6,556</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-weight: bold; text-indent: -9pt; margin-left: 9pt; font-family: Times New Roman,Times,serif">REDEEMABLE
        CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTERSTS:</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Convertible Preferred Shares A</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">7,307</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">H
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(7,307</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Convertible Preferred Shares A-1</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,392</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">H
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(2,392</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Convertible Preferred Shares A-2</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,264</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">H
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(2,264</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Convertible Preferred Shares A-3</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,683</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">H
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(2,683</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Convertible Preferred Shares A-4</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">411</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">H
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(411</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Non-controlling interests</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,353</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">D
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(3,353</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; text-indent: -9pt; margin-left: 9pt; font-family: Times New Roman,Times,serif">MORINGA CLASS A ORDINARY
        SHARES SUBJECT TO POSSIBLE REDEMPTION</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">5,924</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">I
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(5,924</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">SHAREHOLDERS&#8217; EQUITY (DEFICIT):</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Ordinary shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">J
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">J
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Additional paid-in capital</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">11,398</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">N
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">39,166</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">C
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">345</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">E
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">220</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">H
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">15,057</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">I
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,015</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">G
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">7,510</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">L
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">D
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,353</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">F
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">201</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">B
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(1,547</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">K
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(3,386</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Accumulated deficit</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(3,386</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(29,656</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">E
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(220</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(42,626</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">A
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(1,843</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">G
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(7,510</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">M
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(337</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">K
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,386</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; padding-bottom: 2px"><span style="font-family: Times New Roman,Times,serif">N
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(3,060</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">TOTAL EQUITY (CAPITAL DEFICIENCY)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(3,386</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(18,257</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,015</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">17,169</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(3,459</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%; padding-bottom: 4px">
        <div style="line-height: 1.25; text-indent: -9pt; margin-left: 9pt; font-family: Times New Roman,Times,serif">TOTAL CLASS A ORDINARY SHARES
        SUBJECT TO POSSIBLE REDEMPTION, REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF
        CAPITAL DEFICIENCY</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,538</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">153</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(4,909</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(1,241</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(3,459</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.2%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 30%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; text-indent: -9pt; margin-left: 9pt; font-family: Times New Roman,Times,serif">TOTAL
        LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED SHARES, NON-CONTROLLING INTEREST AND ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND
        SHAREHOLDER&#8217;S EQUITY (NET OF CAPITAL DEFICIENCY)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">5,967</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,525</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(4,909</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(486</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.2%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,097</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za4844aa2b4e64ac0a03e524ca15f3fde" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">*</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Represents an amount less than $1.</div>
        </td> </tr>
  </table>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">See accompanying notes to the unaudited pro
forma condensed combined financial information.</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">49</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">SILEXION THERAPEUTICS
CORP<br/> UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS<br/> FOR SIX-MONTHS PRIOD ENDED JUNE 30, 2024<br/> (in thousands,
except share and per share amounts)</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z3d6442210fb6424ab3d8a7c31c725343" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 44%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Historical</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Historical</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="7" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Actual Redemption</div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 44%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold"><span style="font-family: Times New Roman,Times,serif">Moringa <br/>
        </span> </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Acquisition</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"> Corp</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Silexion </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Therapeutics Ltd.</div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Business </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Combination </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Adjustments</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Pro Forma </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Statement of </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Operations</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Research and development expenses, net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,727</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">E
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(38</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,689</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">General and administrative expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">441</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">908</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">E
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(26</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,066</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">A
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(317</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">DD</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-bottom: 2px; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">60</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">OPERATING LOSS</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">441</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,635</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(321</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,755</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Financial expenses (income), net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(130</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">270</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">C
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(145</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">514</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">BB</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">420</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"> AA</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-bottom: 2px; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">99</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Loss before income tax</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">311</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,905</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">53</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,269</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Tax on Income</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">7</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%; padding-bottom: 2px">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">7</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">LOSS FOR THE PERIOD</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">311</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,912</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">53</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%; padding-bottom: 4px">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,276</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Attributable to:</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Equity holders of the Company</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,845</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">D
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">67</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,276</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Non-controlling interests</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">67</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">D
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(67</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; text-indent: -9pt; margin-left: 9pt; font-family: Times New Roman,Times,serif">PROFIT (LOSS) PER SHARE,
        BASIC AND DILUTED</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Ordinary share subject to possible redemption</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">0.32</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(0.32</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Non-redeemable ordinary shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(0.14</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(11.31</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">11.12</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(0.33</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; text-indent: -9pt; margin-left: 9pt; font-family: Times New Roman,Times,serif">WEIGHTED AVERAGE NUMBER
        OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Ordinary shares subject to possible redemption</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">87,722</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(87,722</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Non-redeemable ordinary shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,355,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">251,655</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">6,399,717</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">CC</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">10,006,372</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">See accompanying notes to the unaudited pro
forma condensed combined financial information.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">50</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">SILEXION THERAPEUTICS
CORP<br/> UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS<br/> FOR THE YEAR ENDED DECEMBER 31, 2023<br/> (in thousands,
except share and per share amounts)</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z649b3f916ad24fd68d157957f56bc56a" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Historical</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Historical</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="7" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Actual Redemption</div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Moringa </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Acquisition </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Corp</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Silexion </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Therapeutics </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Ltd.</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Business </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Combination </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Adjustments</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Pro Forma </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Statement </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">of Operations</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Research and development expenses, net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,708</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">E
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">169</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">6,753</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">G
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,876</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">General and administrative expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,122</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">973</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">E
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">115</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">12,189</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">G
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">4,639</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">DD</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">120</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">A
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,160</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; padding-bottom: 2px"><span style="font-family: Times New Roman,Times,serif">N
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,060</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%; padding-bottom: 2px">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">OPERATING LOSS</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,122</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">4,681</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">13,139</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">18,942</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Financial expenses (income), net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(1,385</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">395</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">C
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(86</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,350</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"> BB</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">725</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"> AA</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,364</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; padding-bottom: 2px"><span style="font-family: Times New Roman,Times,serif">M
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">337</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%; padding-bottom: 2px">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Loss before income tax</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(263</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">5,076</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">15,479</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">20,292</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Tax on Income</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">32</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%; padding-bottom: 2px">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">32</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">LOSS FOR THE PERIOD</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(263</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">5,108</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">15,479</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%; padding-bottom: 4px">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">20,324</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Attributable to:</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Equity holders of the Company</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">4,942</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">D
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">166</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">20,324</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Non-controlling interests</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">166</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 3%"><span style="font-family: Times New Roman,Times,serif">D
        <br/> </span> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman,Times,serif"><br/>
        </span> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(166</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: center; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; text-indent: -9pt; margin-left: 9pt; font-family: Times New Roman,Times,serif">PROFIT (LOSS) PER SHARE,
        BASIC AND DILUTED</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Ordinary share subject to possible redemption</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">0.51</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(0.51</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Non-redeemable ordinary shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(0.34</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(19.57</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">17.88</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(2.03</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; text-indent: -9pt; margin-left: 9pt; font-family: Times New Roman,Times,serif">WEIGHTED AVERAGE NUMBER
        OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Ordinary shares subject to possible redemption</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,774,850</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(2,774,850</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 44%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Non-redeemable ordinary shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,355,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">252,462</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 3%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">6,398,910</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 3%">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">CC</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">10,006,372</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">See accompanying notes to the unaudited pro
forma condensed combined financial information.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">51</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED
FINANCIAL INFORMATION</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">1. Description of the Business Combination</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">On August 15, 2024, the parties completed
the previously-reported transactions (the &#8220;<span style="font-weight: bold">Transactions</span>&#8221; or &#8220;<span style="font-weight: bold">Business
Combination</span>&#8221;) pursuant to that certain amended and restated business combination agreement, dated April 3, 3024 (the &#8220;Business
Combination Agreement&#8221;) by and among the registrant (&#8220;<span style="font-weight: bold">New Silexion</span>&#8221;, which was
then known as Biomotion Sciences), August M.S. Ltd., an Israeli company and a wholly owned subsidiary of New Silexion (&#8220;<span style="font-weight: bold">Merger
Sub 1</span>&#8221;), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a wholly owned subsidiary of New Silexion
(&#8220;<span style="font-weight: bold">Merger Sub 2</span>&#8221;), Moringa and Silexion.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Pursuant to the Transactions, Merger Sub 2
merged with and into Moringa, with Moringa continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion
(the &#8220;<span style="font-weight: bold">SPAC Merger</span>&#8221;), and Merger Sub 1 merged with and into Silexion, with Silexion
continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion (the &#8220;<span style="font-weight: bold">Acquisition
Merger</span>&#8221;). Upon the effectiveness of the SPAC Merger, each outstanding Moringa Class A ordinary share and the sole outstanding
Moringa Class B ordinary share converted into an ordinary share of New Silexion on a one-for-one basis. Each outstanding warrant to purchase
one Moringa Class A ordinary share converted into a warrant to purchase one New Silexion ordinary share, at the same exercise price. Upon
the effectiveness of the Acquisition Merger, each outstanding ordinary share and preferred share of Silexion converted into such number
of ordinary shares of New Silexion as is equal to the quotient obtained by dividing (x) the quotient obtained by dividing (1) $62,500,000
by (2) the number of fully diluted Silexion equity securities, by (y) $10.00 (the &#8220;<span style="font-weight: bold">Silexion Equity
Exchange Ratio</span>&#8221;). Each outstanding Silexion warrant and Silexion option to purchase one Silexion share, and Silexion restricted
share unit (RSU) that may be potentially settled for one Silexion share, became exercisable for, or will be subject to settlement for
(as applicable), such number of New Silexion ordinary shares as are equal to the Silexion Equity Exchange Ratio. The exercise price per
New Silexion ordinary share of each such converted Silexion option and Silexion warrant was adjusted based on dividing the existing per
share exercise price by the Silexion Equity Exchange Ratio. The terms of vesting, exercise and/or settlement, as applicable, of such converted
options, warrants and RSUs remains the same following that conversion, except that the vesting of each Silexion option accelerated immediately
prior to the Acquisition Merger, such that the New Silexion option into which it has been converted is fully vested, and all Silexion
warrants were exercised (on a cashless basis) immediately prior to the Acquisition Merger.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Immediately prior to the closing of the Business
Combination (the &#8220;<span style="font-weight: bold">Closing</span>&#8221;), seven directors were appointed to New Silexion&#8217;s
board of directors, of whom five were designated by Silexion and two were designated by Moringa&#8217;s sponsor (Moringa Sponsor, LP,
a Cayman Islands exempted limited partnership and/or its wholly-owned subsidiary, Moringa Sponsor US L.P., a Delaware limited partnership)
(collectively, the &#8220;<span style="font-weight: bold">Moringa Sponsor</span>&#8221;). Also upon Closing, New Silexion&#8217;s articles
of association were amended and restated as appears in Exhibit 3.1 to the registration statement of which this prospectus forms a part.
In connection with the Closing, the ordinary shares and warrants of New Silexion were approved for listing on the Nasdaq Global Market
and began trading under the symbols &#8220;SLXN&#8221; and &#8220;SLXNW&#8221;, respectively.</div>

<div style="text-indent: 28.35pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, at the Closing, each of the following
additional actions was taken, in accordance with the terms of the Business Combination Agreement (in certain cases, as modified by subsequent
agreements):</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"> </div>

<table cellspacing="0" cellpadding="0" id="zae5c92928d6246e4b864ddfae5cf90e5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Moringa Sponsor forfeited for retirement 1,308,000 of the Moringa founders shares held by it, while 1,567,000
        of the Moringa founders shares were transferred to non-affiliated third-party investors (including 316,750 founders shares to certain
        security holders) as Backstop Shares (as defined in the Business Combination Agreement);</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">52</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="z129fcac9cbfb43828a9c84108e2d9d1a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">New Silexion issued to the Moringa Sponsor the A&amp;R Sponsor
        Promissory Note in an amount of $3,433,000, in replacement of all promissory notes that Moringa had issued to the Moringa Sponsor for
        amounts owed by Moringa to the Moringa Sponsor prior to the Closing;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6d5eda5f8a844389920ef5458f87fdbd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">New Silexion, Moringa Sponsor, the investor in the PIPE financing
        (described below) and certain additional shareholders of New Silexion entered into an Amended and Restated Registration Rights and Lock-Up
        Agreement granting them registration rights with respect to the ordinary shares of New Silexion issued to them;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z95bda054dfcf4df581739c4a0e1e17e9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Guangzhou Sino-Israel Bio-Industry Investment Fund I (&#8220;<span style="font-weight: bold">GIBF</span>&#8221;),
        a shareholder of Silexion, transferred its noncontrolling interest in Silexion&#8217;s Chinese subsidiary, Silenseed (China) Ltd., directly
        to New Silexion, such that the subsidiary became a wholly-owned subsidiary of New Silexion, and was issued 1,835,733 ordinary shares of
        New Silexion as consideration for that transfer (the &#8220;<span style="font-weight: bold">Chinese Subsidiary Transfer</span>&#8221;)
        (in addition to the 151,349 New Silexion ordinary shares that GIBF received upon the accelerated vesting of RSUs granted to it).</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In connection with the Moringa extraordinary
general meeting at which the three proposals related to the Business Combination&#8212;the Business Combination Proposal, the Merger Proposal
and the Articles Amendment Proposal&#8212; were approved by the requisite majorities of Moringa&#8217;s shareholders, holders of an aggregate
of 427,297 Moringa public shares properly exercised their right to have their shares redeemed for a full pro rata portion of the Trust
Account holding the proceeds from Moringa&#8217;s IPO, which was approximately $11.575 per share, or $4,946,046 in the aggregate. Also
prior to the Closing, Moringa reached agreement with EarlyBird on a reduction, from $4.025 million to $1.6 million, in the aggregate,
of the fee payable to EarlyBird under the Business Combination Marketing Agreement, dated February 19, 2021 (the &#8220;<span style="font-weight: bold">Marketing
Agreement</span>&#8221;), entered into by Moringa with EarlyBird at the time of Moringa&#8217;s initial public offering. Pursuant to the
final invoice provided by EarlyBird under the Marketing Agreement at the Closing, Moringa paid $350,000 of cash to EarlyBird at the Closing,
and New Silexion issued to EarlyBird a convertible promissory note, due December 31, 2025, in an amount of $1.25 million to be paid by
New Silexion to EarlyBird in cash and/or via conversion of outstanding amounts into ordinary shares of New Silexion. After the redemption
payments, the payment to EarlyBird, and the satisfaction of amounts due to parties that arranged financing and/or capital markets advisory
services in connection with the Closing, the remaining balance of the Trust Account immediately prior to the Closing of $333,936 was used
to partially fund the Business Combination.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In connection with, and immediately prior
to the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity (PIPE) financing, whereby
Moringa sold to Greenstar, L.P. 200,000 Moringa ordinary shares at a price of $10.00 per share. Those funds, together with remaining funds
in Moringa&#8217;s Trust Account after payments to redeeming public shareholders, were used for financing support for Moringa and New
Silexion, as well as for payment to service providers to whom outstanding amounts were owed by Moringa, including parties that had provided
financial advisory services and capital markets advisory services to Moringa during the period leading up to the Closing.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Also in connection with the Closing, New Silexion
entered into an ordinary share purchase agreement for an equity line of credit with White Lion, whereby New Silexion will be able to request
to sell to White Lion, and White Lion will be required to purchase, via private placement transactions, up to $15.0 million of New Silexion
ordinary shares from time to time after the Closing, up until December 31, 2025 (unless the agreement is terminated sooner), subject to
certain limitations and conditions as described therein. The number of New Silexion ordinary shares that New Silexion may require White
Lion to purchase in any single sales notice will depend on a number of factors, including the type of purchase notice that New Silexion
delivers. Similarly, the purchase price to be paid by White Lion for any shares that New Silexion requires them to purchase will depend
on the type of sales notice that New Silexion delivers. New Silexion has also granted registration rights to White Lion pursuant to an
accompanying registration rights agreement.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">53</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In consideration for the commitments of White
Lion, New Silexion agreed to issue to White Lion an aggregate of $337,500 of New Silexion ordinary shares based on the closing price of
the New Silexion ordinary shares on the day that is the earlier of (i) the business day prior to effectiveness of the registration statement
registering the resale of the shares issuable under the White Lion Purchase Agreement and (ii) the business day prior to the 180<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>
day following the Closing Date of the Business Combination.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">Separately, the Moringa Sponsor transferred to third-party investors (in lieu of forfeiting) all 1,567,000
Moringa founders shares that had been designated to serve as Backstop Shares under the Business Combination Agreement, including 316,750
founders shares to certain security holders.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Various issuances and other actions impacted
the final number of New Silexion ordinary shares that were issued upon the Closing of the Business Combination, including the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4b7cc12a7eaf4e398a85755f4f7d3e70" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the redemption of the 427,297 Moringa public shares described
        above;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z79869c82df874d1fa7d208c10ced102c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the separation of each former Moringa unit into one Moringa Class
        A ordinary share and one-half of a Moringa warrant;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"> </div>

<table cellspacing="0" cellpadding="0" id="z0a07f6957f944bc19f3735526a9505df" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">the Sponsor Founder Shares Forfeiture (as defined in the Business Combination Agreement) of 1,308,000 founders
        shares, and transfer of the remaining 1,567,000 founders shares to third parties (including 316,750 founders shares to certain securityholders)
        as Backstop Shares, as described above;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2e910853dc304691ac76664812968288" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the issuance of 87,722 New Silexion ordinary shares in exchange
        for an equivalent number of Moringa public shares that remained outstanding immediately prior to the Closing (following the redemptions
        described above);</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z84226729164347d68c4507c375937029" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the issuance of 380,000 New Silexion ordinary shares in exchange
        for an equivalent number of Moringa private shares;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcbf8aaf50132412ea082083665a504d2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the issuance of 100,000 New Silexion ordinary shares to EarlyBird
        in exchange for an equivalent number of representative shares;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z466b2f26c3714de69adb8a01b7d76cb8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the issuance by New Silexion to the Sponsor and/or its limited
        partners to whom the Sponsor distributed such shares of the 1,382,325 Sponsor Investment Shares (as defined in the Business Combination
        Agreement);</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z37ddacb7045b4ad1bc1a5d5757b6a0c9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the issuance of 200,000 New Silexion ordinary shares to Greenstar,
        L.P. in exchange for an equivalent number of Moringa shares that were purchased in the $2.0 million PIPE financing, as described above;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2edd974f1c99416bb20e7995836cd585" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the issuance of 4,024,942 New Silexion ordinary shares as the
        Silexion Merger Consideration (as defined in the Business Combination Agreement) to security holders of Silexion;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z97d79b348a7a442dbc5ae6467b089bd7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the issuance of 1,835,733 New Silexion ordinary shares to GIBF
        in respect of the Chinese Subsidiary Transfer (in addition to 151,349 New Silexion ordinary shares issued to GIBF upon the accelerated
        vesting of RSUs granted to it), as described above; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z75a9ade9a7b3496c8c3ca39426e2512d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the issuance of 39,325 New Silexion ordinary shares to a non-employee
        director of New Silexion upon acceleration of vesting, and settlement, of an equivalent number of New Silexion RSUs granted to the director.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As a result of each of the foregoing, upon
the Closing, there were 9,768,396 New Silexion ordinary shares issued and outstanding.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">54</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Upon the Closing, the pro forma ownership
structure for New PubcCo was as set forth in the table below, based on actual number of redemptions of Moringa public shares:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze7638e67250f444ab1caf4842cc0e0e4" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Equity Holders</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Shares</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Percentage of<br/> Outstanding<br/>
        Shares</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Moringa Public Shareholders<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">87,722</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">0.88</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Silexion Shareholders<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">6,250,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">62.46</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Moringa Sponsor Shares<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,690,182</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">16.89</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Distributees of Sponsor Investment Shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">45,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">0.45</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">PIPE investor</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">200,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2.00</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Founders Shares/ Backstop Shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,567,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">15.66</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">EarlyBird<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">127,143</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1.27</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Director receiving RSU grant upon Closing</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">39,325</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">0.39</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Total</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">10,006,372</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">100</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdc2a93f8cc9c4f0b91506c0f3a2e6620" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(1)</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Excludes 5,750,000 public warrants held by Moringa&#8217;s public
        shareholders, which will be exercisable for New Silexion ordinary shares at an exercise price of $11.50 per share beginning 30 days after
        the Closing of the Business Combination.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf25fe6e8bfee4827b9dff336d138e890" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(2)</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Includes all securities issuable to security holders of Silexion
        on a fully-diluted basis, including New Silexion ordinary shares, New Silexion warrants, New Silexion options and New Silexion RSUs, and
        also includes 1,835,733 New Silexion ordinary shares issued directly to GIBF in respect of the Chinese Subsidiary Transfer, as well as
        151,349 New Silexion ordinary shares issued to GIBF upon the accelerated vesting of RSUs granted to it.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcbba5441ff784984b05fe1bb7778a3a3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(3)</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Excludes 190,000 private warrants held, in the aggregate, by
        the Moringa Sponsor and EarlyBird, which will be exercisable for New Silexion ordinary shares at an exercise price of $11.50 per share
        beginning 30 days after the Closing of the Business Combination.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2. Basis of Pro Forma Presentation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The unaudited pro forma condensed combined
financial statements were prepared in accordance with Article 11 of SEC Regulation S-X, as amended by the final rule, SEC Release No.
33-10786 &#8220;Amendments to Financial Disclosures About Acquired and Disposed Businesses&#8221;. The adjustments presented in the unaudited
pro forma condensed combined financial statements (collectively, the &#8220;<span style="font-weight: bold">Pro Forma Adjustments</span>&#8221;)
have been identified and presented to provide relevant information necessary for an understanding of New Silexion upon consummation of
the Business Combination and related transactions.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The unaudited pro forma combined balance sheet
as of June 30, 2024 has been derived from the historical unaudited balance sheet of Moringa as of June 30, 2024 and the historical unaudited
balance sheet of Silexion as of June 30, 2024, giving further effect to the Pro Forma Adjustments, as if the Business Combination had
been completed on June 30, 2024. The unaudited pro forma combined statements of operations for the six-months period ended June 30, 2024
and for the year ended December 31, 2023 combine the historical audited statements of operations of Moringa for the year ended December
31, 2023, and for the six-months period ended June 30, 2024, and the historical audited statements of operations of Silexion for the year
ended December 31, 2023, and for the six-months period ended June 30, 2024, subject to the Pro Forma Adjustments, giving effect to the
Business Combination as if it had been consummated on January 1, 2023.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The unaudited pro forma combined balance sheet
does not include a historical balance sheet of New Silexion, as it did not have any assets or liability as of the date of Closing. Similarly,
the unaudited pro forma combined statements of operations do not include historical statements of operations of New Silexion, as it had
yet to incur any income or expenses as of the date of Closing.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The historical financial information has been
adjusted to reflect the Pro Forma Adjustments giving effect to the Business Combination and related transactions as described in more
detail below.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">55</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Management has made significant estimates
and assumptions in its determination of the Pro Forma Adjustments. As the unaudited pro forma condensed combined financial information
has been prepared based on these preliminary estimates, the final amounts recorded may differ materially from the information presented.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Pro Forma Adjustments reflecting the consummation
of the Business Combination and certain other transactions as described in more detail below are based on certain currently available
information and certain assumptions and methodologies that the registrant believes are reasonable under the circumstances. The Pro Forma
Adjustments, which are described in the accompanying notes, may be revised as additional information becomes available and is evaluated.
Therefore, it is likely that the actual adjustments will differ from the pro forma adjustments, and it is possible the difference may
be material. The registrant believes that its assumptions and methodologies provide a reasonable basis for presenting all of the significant
effects of the Pro Forma Adjustments based on information available to management at this time and that the Pro Forma Adjustments give
appropriate effect to those assumptions and are properly applied in the unaudited pro forma condensed combined financial information.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The unaudited pro forma condensed combined
financial information does not give effect to any anticipated synergies, operating efficiencies, tax savings, or cost savings that may
be associated with the Business Combination and related transactions as described in more detail below. Moringa and Silexion have not
had any historical relationship prior to the Business Combination. Accordingly, no pro forma adjustments were required to eliminate activities
between the companies. However, the unaudited pro forma condensed combined financial information includes certain share-based compensation
that was granted upon the consummation of the Business Combination, as well as net exercise of all Silexion warrants outstanding for New
Silexion ordinary shares, which occurred upon the consummation of the Business Combination.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">3. Adjustments to Unaudited Pro Forma Combined
Balance Sheet as of June 30, 2024</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The unaudited pro forma balance sheet as of
June 30, 2024 has been prepared to illustrate the effect of the Pro Forma Adjustments and has been prepared for informational purposes
only.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The unaudited pro forma combined balance sheet
as of June 30, 2024 includes the Pro Forma Adjustments giving effect to the Business Combination and related transactions noted in this
filing. Moringa and Silexion did not have any historical relationship prior to the Business Combination. Accordingly, no pro forma adjustments
were required to eliminate activities between the companies.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Pro Forma Adjustments, based on preliminary
estimates that could change materially as additional information is obtained, are as follows:</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Pro forma adjustments
giving effect to the Business Combination and related transactions:</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">A) To reflect payments for Business Combination-related
costs in cash in an amount of $2,160 thousand of which an amount of $84 was paid as of June 30, 2024 and an amount of $233 thousand was
already accrued but not paid in Silexion&#8217;s financial statements for the period ended June 30, 2024. In the pro forma statement of
operations, it was assumed that the expenses were incurred in 2023 rather than 2024. Therefore, Business Combination-related expenses
of $317 recorded in Silexion&#8217;s statements of operations for the period ending June 30, 2024 were moved back to 2023 as a pro forma
adjustment.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">B) To reflect Moringa&#8217;s payment of its
obligation to EarlyBird (underwriters&#8217; deferred discount). Under the Marketing Agreement between Moringa and EarlyBird, Moringa
was committed to pay an additional fee of 3.5% of the gross proceeds of its initial public offering (or $4,025 thousand) to EarlyBird,
as an advisor in connection with Moringa&#8217;s potential business combination, upon completion of the Business Combination. Prior to
the Closing, Moringa reached agreement with EarlyBird on a reduction, from $4,025 thousand to $1,600 thousand, of that fee. Pursuant to
the final invoice provided by EarlyBird under the Marketing Agreement at the Closing, $350 thousand of that reduced fee was paid to EarlyBird
at the Closing, with New Silexion issuing a convertible promissory note in an amount of $1,250 thousand for the remainder of the reduced
fee. See also Note BB.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">56</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">C) These unaudited pro forma financial statements
reflect net exercise of all Silexion warrants outstanding and their conversion to New Silexion ordinary shares, which occurred upon the
consummation of the Business Combination. Related fair value measurement gains or losses of those warrants were eliminated from the pro
forma combined statements of operations.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">D) To reflect the transfer by GIBF of its
noncontrolling interest in Silexion&#8217;s Chinese subsidiary, Silenseed (China) Ltd., to New Silexion in exchange for 1,835,733 New
Silexion ordinary shares upon the completion of the Business Combination.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">E) Immediately prior to the Effective Time
of the Acquisition Merger, the vesting of all outstanding Silexion share-based incentive awards was accelerated and those awards became
fully vested. At the Effective Time of the Acquisition Merger, all of Silexion&#8217;s share-based incentive awards were assumed by New
Silexion and converted into options to purchase New Silexion ordinary shares, based on the Equity Exchange Ratio.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">F) To reflect the issuance by New Silexion
to the Sponsor of the A&amp;R Sponsor Promissory Note, in an amount of $3,433 thousand, which amount was determined based on amounts owed
by Moringa to the Sponsor for loans that it extended to Moringa from Moringa&#8217;s initial public offering until the Closing, subject
to a $5,500 thousand cap (the &#8220;<span style="font-weight: bold">Promissory Note Cap</span>&#8221;), which Promissory Note Cap was
reduced to $3,900 thousand due to the final $1,600 thousand paid or owed by Moringa to EarlyBird pursuant to the Marketing Agreement.
Such promissory note replaced all promissory notes that were outstanding as of June 30, 2024 and December 31, 2023 (in amounts of $3,346
thousand and $2,841 thousand, respectively), as well as additional amounts borrowed by Moringa from the Sponsor up until the completion
of the Business Combination. The maturity date of the A&amp;R Sponsor Promissory Note is the 30-month anniversary of the Closing Date,
and amounts outstanding under the note may be repaid (unless otherwise decided by New Silexion) only by way of conversion into New Silexion
ordinary shares in accordance with the terms set forth in A&amp;R Sponsor Promissory Note. The Sponsor may elect to convert amounts outstanding
under the A&amp;R Sponsor Promissory Note at the price per share at which New Silexion conducts an equity financing following the Closing,
subject to a minimum conversion amount of $100 thousand, in an amount of shares constituting up to thirty percent of the number of New
Silexion ordinary shares issued by New Silexion in such equity financing. The Sponsor may also elect to convert amounts of principal outstanding
under the A&amp;R Sponsor Promissory Note into New Silexion ordinary shares at any time following the 24-month anniversary of the Closing
Date and prior to the maturity date of the promissory note, subject to a minimum conversion of $10 thousand, at a price per share equal
to the volume weighted average price of the New Silexion ordinary shares on the principal market on which they are traded during the 20
consecutive trading days prior to the conversion date (the &#8220;<span style="font-weight: bold">VWAP Conversion Price</span>&#8221;).
Upon maturity, any outstanding principal will automatically be converted into New Silexion ordinary shares at a price per share equal
to the VWAP Conversion Price. Amounts that were loaned by the sponsor to Moringa in excess of the Promissory Note Cap were attributed
to additional paid-in capital in respect of the New Silexion ordinary shares issuable upon conversion of the total outstanding amount
under the promissory note. New Silexion has applied the fair value option to the A&amp;R Sponsor Promissory Note and is based on expected
timing of a New Silexion equity financing, discounted at a rate of 22%. See also Note BB.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">G) Reflects the issuance of 178,686 new RSUs
of Silexion, which converted into 711,688 new RSUs of New Silexion and issuance of 39,325 new RSU&#8217;s of New Silexion, in the aggregate,
at the Closing, to directors of New Silexion and employees of New Silexion and its subsidiaries (of which 200,011 RSUs were granted to
New Silexion directors) with a grant date fair value of $10 per RSU. The vesting of all of the foregoing new RSUs accelerated upon the
Closing, and the RSUs were settled for equivalent numbers of underlying New Silexion ordinary shares.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">H) Reflects the conversion of Silexion preferred
shares into New Silexion ordinary shares.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">57</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">I) Reflects the exercise by public shareholders
of their redemption rights with respect to 427,297 Moringa public shares outstanding as of June 30, 2024 of $4,909 thousand. All Moringa
public shares that were subject to possible redemption but were not actually redeemed by Moringa public shareholders were replaced by
New Silexion ordinary shares, classified as permanent equity.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">J) Pro forma adjustments made to the number
of Class A ordinary shares (par value) - consisting of those adjustments described in paragraphs C, D, E, F, G, H, I, L and N - are, in
the aggregate, less than $1 thousand.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">K) To reflect the elimination of the accumulated
deficit of Moringa.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">L) To reflect the issuance of 200,000 Moringa
ordinary shares to an investor pursuant to the PIPE financing described above, which shares converted automatically into New Silexion
ordinary shares upon the Closing. A total of 200,000 shares, at a price of $10.00 per share, or $2.0 million in the aggregate, was sold
to the PIPE investor at the Closing.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">M) Represents an obligation to issue ordinary
shares of New Silexion with a value of $337,500 (the &#8220;<span style="font-weight: bold">ELOC Commitment Shares</span>&#8221;) to White
Lion as a fee in consideration of White Lion&#8217;s commitment to purchase New Silexion ordinary shares from New Silexion under the ordinary
share purchase agreement for New Silexion's equity line of credit.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">N)&#160;Represents (1) the $60,000 fee paid
by New Silexion to J.V.B. Financial Group, LLC, acting through its Cohen &amp; Company Capital Markets division (&#8220;<span style="font-weight: bold">Cohen
&amp; Company</span>&#8221;) in respect of capital markets advisory and placement agent services provided by Cohen &amp; Company in connection
with the Business Combination; and (2) the 300,000 Moringa founders shares transferred by the Moringa Sponsor to Cohen &amp; Company,
in respect of capital markets advisory and placement agent services provided by Cohen &amp; Company in connection with the Business Combination.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">4. Adjustments to Unaudited Pro Forma Condensed
Combined Statements of Operations</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The pro forma adjustments, based on preliminary
estimates that could change materially as additional information is obtained, are as follows:</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Pro forma adjustments
giving effect to the Business Combination and related transactions:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">AA) To reflect the elimination of unrealized
interest income on investments held in the Trust Account.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">BB) To reflect the change in fair value of
the A&amp;R Sponsor Promissory Note (see Note F), and the convertible promissory note issued to EarlyBird at the closing (see Note B).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic"><span style="font-weight: bold; font-family: Times New Roman,Times,serif">Pro forma
weighted average shares outstanding</span><span style="font-family: Times New Roman,Times,serif">:</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">CC) As the Business Combination is being reflected
as if it had occurred at the beginning of the earliest period presented, the calculation of weighted average shares outstanding for basic
and diluted net loss per share assumes that the shares issuable in connection with the Pro Forma Adjustments have been outstanding for
the entirety of the periods presented. Weighted average shares outstanding - basic and diluted for the six-months period ended June 30,
2024, and for the year ended December 31, 2023 are calculated as follows based on the actual pro forma number of New Silexion ordinary
shares that were issued and outstanding upon the Closing, after taking into account actual redemptions of Moringa public shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">58</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The table below excludes a combined 5,940,000
outstanding public warrants and private placement warrants because including them would have had an anti-dilutive effect on net loss per
share.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8293e3a27e294195bf9fbaeb963e28ef" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Assuming actual redemptions</div>
        <div style="text-indent: -18pt; margin-left: 18pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Weighted
        average shares calculation &#8211; basic and diluted</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Six-Months Period Ended<br/>
        June 30, 2024 and<br/> Year Ended<br/> December 31, 2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Holders</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">% of<br/> Total</div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Moringa public shareholders</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">87,722</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">0.88</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Moringa Sponsor shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,690,182</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">16.89</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Distributees of Sponsor Investment Shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">45,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">0.45</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">PIPE investor</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">200,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2.00</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Founders Shares/ Backstop Shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,567,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">15.66</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Existing Silexion equity holders (including GIBF in respect of
        the Chinese Subsidiary Transfer)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">6,250,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">62.46</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">EarlyBird</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">127,143</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1.27</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Director receiving RSU grant upon Closing</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">39,325</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">0.39</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Total Ordinary Shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">10,006,372</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">100</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">DD) To reflect additional cash compensation
to be paid to Ilan Levin, a director of New Silexion, in an amount of $10 thousand per month, commencing on Closing and for a period of
36 months.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Comparative Share Information</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table sets forth selected historical
comparative share information for Moringa and unaudited pro forma condensed combined per share information for Moringa after giving effect
to the Business Combination.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The pro forma book value information reflects
the Business Combination as if it had occurred on June 30, 2024. The weighted average shares outstanding and net earnings per share information
reflect the Business Combination as if it had occurred on January 1, 2023.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">This information is only a summary and should
be read together with the historical financial statements of Moringa and Silexion and related notes. The unaudited pro forma condensed
combined per share information of Moringa and Silexion is derived from, and should be read in conjunction with, the unaudited pro forma
combined financial statements and related notes included above.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The unaudited pro forma combined earnings
per share information below does not purport to represent the earnings per share which would have occurred had Moringa and Silexion been
combined during the periods presented, nor the earnings per share for any future date or period. Historically, Moringa&#8217;s statement
of operations included a presentation of profit (loss) per share in a manner similar to the two-class method of income (loss) per ordinary
shares. The two-class method is not required in the pro forma income (loss) per ordinary shares as the Moringa Class A ordinary shares
are no longer subject to redemption. Moringa has included the effect of the warrants to purchase an aggregate of 5,940,000 Class A ordinary
shares, in the aggregate, sold in the IPO and the concurrent private placement in the calculation of diluted earnings per share, as they
will be exercisable commencing 30 days following the Closing. As a result, diluted earnings per ordinary share differs from basic earnings
per ordinary share for the periods presented.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">59</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z15a3f633890c4437b6c26e1eba64653e" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Moringa Acquisition Corp<br/> (Historical)</div>
        </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">For the six-months period ended June 30, 2024</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Class A<br/> subject to<br/> Possible<br/>
        Redemption</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Non-<br/> redeemable<br/> Class A and<br/>
        Class B</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Silexion<br/> Therapeutics Ltd.<br/> (Historical)</div>
        </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Pro Forma<br/> Combined<br/> (Actual<br/>
        Redemption)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 52%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Weighted average shares outstanding &#8211; basic and diluted</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">87,722</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,355,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">251,655</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">10,006,372</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Net profit (loss) per share &#8211; basic</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">0.32</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(0.14</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(11.31</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(0.33</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z51771820b6d94c3c92c329b1e9133702" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Moringa Acquisition Corp<br/> (Historical)</div>
        </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Pro Forma</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">For the year ended December 31, 2023</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Class A<br/> subject to<br/> Possible<br/>
        Redemption</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Non-<br/> redeemable<br/> Class A and<br/>
        Class B</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Silexion<br/> Therapeutics Ltd.<br/> (Historical)</div>
        </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Combined<br/> (Assuming<br/> Actual<br/>
        Redemption)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 52%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Weighted average shares outstanding &#8211; basic and diluted</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,774,850</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,355,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">252,462</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">10,006,372</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Net profit (loss) per share &#8211; basic</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">0.51</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(0.34</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(19.57</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(2.03</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  </table>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">60</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="MANAGEMENTSDISCUSSIONANDA"><!--Anchor--></span>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">OPERATIONS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Introductory Note</div>

<div style="text-indent: 18pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">The following discussion
and analysis of our financial condition and results of operations (this &#8220;<span style="font-weight: bold">MD&amp;A</span>&#8221;)
should be read in conjunction with the financial statements and the related notes included elsewhere in this prospectus. Some of the information
contained in this discussion and analysis or set forth in this prospectus, including information with respect to our plans, objectives,
expectations, projections, and strategy for our business and related financing, includes forward-looking statements that involve risks
and uncertainties. As a result of many factors, including those factors set out in the &#8220;Risk Factors&#8221; sections of this prospectus,
our actual results could differ materially from the results described in or implied by these forward-looking statements. See also the
section entitled &#8220;Special Note Regarding Forward-Looking Statements&#8221; in this prospectus.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Unless the context otherwise
requires, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; in this MD&amp;A generally
refer to Silexion Therapeutics Ltd., an Israeli company (&#8220;Silexion&#8221;), or, from and after the Business Combination, Silexion
Therapeutics Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company (also referred to herein as &#8220;New Silexion&#8221;).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">On August 15, 2024, New
Silexion, Silexion and Moringa completed the Business Combination pursuant to the Business Combination Agreement.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Overview</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Silexion is a clinical-stage, oncology-focused
biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an
oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus.
Based on its research of refractory solid tumor cancers, Silexion is actively developing a platform focused on the silencing of the KRAS
oncogene using RNA-interference therapeutics. Silexion&#8217;s lead product candidate, SIL-204B, consists of locally administered small
interfering RNAs, or siRNA, in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients,
in combination with standard-of-care chemotherapy.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">To date, Silexion has financed its operations
primarily with the net proceeds from private offerings of its ordinary shares and convertible preferred shares, grants from the Israeli
Innovation Authority (the &#8220;<span style="font-weight: bold">IIA</span>&#8221;), convertible financing agreements and Simple Agreement
for Future Equity (SAFE) financings, and through royalty-bearing grants from the IIA (which totaled $5.8 million through June 30, 2024).
Since its inception, Silexion has incurred significant operating losses. Silexion&#8217;s net losses were $5.1 million and $3.5 million
for the years ended December 31, 2023 and December 31, 2022, respectively, and $2.9 million and $2.6 million for the six-month periods
ended June 30, 2024 and 2023, respectively. As of June 30, 2024, Silexion had an accumulated deficit of $29.7 million. Silexion has not
recognized any revenue to date.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Silexion expects to continue to incur significant
expenses and operating losses for the foreseeable future. The net losses it incurs may fluctuate significantly from quarter to quarter.
Silexion&#8217;s expenses will depend on many factors, including the timing and extent of spending to further develop SIL-204 and initiate
pre-clinical and clinical trials, support research and development efforts, investments in potential additional pipe-line products, and
increased overall compensation as we continue to hire additional personnel. Silexion anticipate that its expenses will increase if and
as it:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za79210aca577483c8c90bd7bacad6de0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">applies for Orphan Drug Designation in both the U.S. and EU for
        its SIL-204B product;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5bb79032f2704e0eae0d76c2529698a7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">initiates a clinical trial powered for statistical significance
        with respect to SIL-204B;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">61</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="z3cc60231dc0b4cf8bc594b19951c0be1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">initiates toxicological studies with respect to SIL-204B;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z69c96cf0da8e442baabe9dc1b9056317" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">seeks marketing approvals for SIL-204B in various territories;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9e328cfe88ed4a88a6329f14ec6ba478" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">maintains, expands and protects its intellectual property portfolio;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd9a4b6151fb24db3969cc16a65c70dfe" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">hires additional operational, clinical, quality control and scientific
        personnel;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z04ea1b83d3aa4fabae105f788ef6e748" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">adds operational, financial and management information systems
        and personnel, including personnel to support its product development, any future commercialization efforts and its prospective transition
        to a public company; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbcda4eca8cdb440497c11d573bbab426" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">invests in research and development and regulatory approval efforts
        in order to utilize its technology as a platform focused on the silencing of the KRAS oncogene using RNA-interference therapeutics.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Recent Developments</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our prospective financial condition and results
of operations in the period following the Closing of the Business Combination will be impacted by the following transactions, all of which
were entered into at or around the time of the Closing:</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Completion of Business
Combination Transaction</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">On August 15, 2024, New Silexion, Silexion
and Moringa completed the previously-announced Business Combination pursuant to the Amended and Restated Business Combination Agreement,
dated April 3, 2024, by and among New Silexion, Merger Sub 1, Merger Sub 2, Moringa and Silexion. In connection with the Closing of the
Business Combination, New Silexion changed its name from &#8220;Biomotion Sciences&#8221; to &#8220;Silexion Therapeutics Corp&#8221;.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Pursuant to the Business Combination Agreement,
among other things, (i) Merger Sub 2 merged with and into Moringa, with Moringa continuing as the surviving company and a wholly-owned
subsidiary of New Silexion and (ii) Merger Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company and
a wholly-owned subsidiary of New Silexion.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Upon the effectiveness of the SPAC Merger,
each outstanding Moringa Class&#160;A ordinary share, that had not been redeemed and the sole outstanding Moringa Class&#160;B ordinary
share converted into a New Silexion ordinary share on a one-for-one&#160;basis. Each outstanding Moringa warrant converted into a New
Silexion warrant, exercisable at the same exercise price. Upon the effectiveness of the Acquisition Merger, each outstanding ordinary
share and preferred share of Silexion converted into such number of New Silexion ordinary shares as is equal to the quotient obtained
by dividing (x)&#160;the quotient obtained by dividing (1)&#160;$62,500,000 by (2)&#160;the number of fully diluted Silexion equity securities,
by (y)&#160;$10.00 (the &#8220;<span style="font-weight: bold">Silexion Equity Exchange Ratio</span>&#8221;). Each outstanding Silexion
warrant and Silexion option to purchase one Silexion share, and Silexion restricted share unit (RSU) that may be potentially settled for
one Silexion share, became exercisable for, or became subject to settlement for (as applicable), such number of New Silexion ordinary
shares as are equal to the Silexion Equity Exchange Ratio. The exercise price per New Silexion ordinary share of each such converted Silexion
option and Silexion warrant were adjusted based on dividing the existing per share exercise price by the Silexion Equity Exchange Ratio.
The terms of vesting, exercise and/or settlement, as applicable, of such converted options, warrants and RSUs remain the same following
such conversion, except that the vesting of each Silexion option accelerated immediately prior to the Acquisition Merger, such that the
New Silexion option into which it has been converted was fully vested, and all Silexion warrants were exercised (on a cashless basis)
immediately prior to the Acquisition Merger.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In connection with the Moringa shareholder
vote to approve the Business Combination Agreement and the Business Combination, holders of an aggregate of 427,297 Moringa ordinary shares
properly exercised their right to have their shares redeemed for a full pro rata portion of the Trust Account holding the proceeds from
Moringa&#8217;s IPO, which was approximately $11.575 per share, or $4,946,046 in the aggregate.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">62</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As a result of the redemptions of Moringa
ordinary shares, a total of 87,722 Moringa public shares remained outstanding at the Closing. After giving effect to the Business Combination
and additional changes to share capital, immediately following the Closing, there were 9,768,396 New Silexion ordinary shares issued and
outstanding.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">PIPE Financing</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">For a description of the PIPE Financing,
please see &#8220;<span style="font-style: italic">Related Party Transactions&#8212;Item 15. Recent Sales of Unregistered Securities&#8212;Issuance
of PIPE Financing Shares</span>&#8221; below in this prospectus, which description is incorporated by reference herein.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Settlement of Amounts
Due Under Marketing Agreement with EarlyBird</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">For a description of the settlement reached
by Moringa with EarlyBird in connection with the Closing as to amounts due to EarlyBird under the Marketing Agreement, please see &#8220;<span style="font-style: italic">Notes
to Unaudited Pro Forma Condensed Combined Financial Information&#8212;3. Adjustments to Unaudited Pro Forma Combined Balance Sheet as
of June 30, 2024&#8212;Pro forma adjustments giving effect to the Business Combination and related transactions</span>&#8221; above in
this prospectus, which description is incorporated by reference herein.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Amended and Restated Sponsor
Promissory Note</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">For a description of the issuance by the
Company to the Sponsor of the A&amp;R Sponsor Promissory Note in an amount of $3,433,000 in connection with the Closing, and the terms
of that convertible promissory note, please see &#8220;<span style="font-style: italic">Special Note Regarding Forward-Looking Statements</span>&#8221;
above in this prospectus.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">ELOC Financing</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Also in connection with the Closing, New
Silexion entered into the White Lion Purchase Agreement with White Lion, for an equity line of credit, whereby New Silexion will be able
to request to sell to White Lion, and White Lion will be required to purchase, via private placement transactions, up to $15.0 million
of New Silexion ordinary shares from time to time after the Closing, up until December 31, 2025 (unless the agreement is terminated sooner),
subject to certain limitations and conditions as described therein. The number of New Silexion ordinary shares that New Silexion may require
White Lion to purchase in any single sales notice will depend on a number of factors, including the type of purchase notice that New Silexion
delivers. Similarly, the purchase price to be paid by White Lion for any shares that New Silexion requires them to purchase will depend
on the type of sales notice that New Silexion delivers. New we have also granted registration rights to White Lion pursuant to an accompanying
registration rights agreement.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">In consideration for the commitments of White Lion, New Silexion
agreed to issue to White Lion an aggregate of $337,500 of New Silexion ordinary shares based on the closing price of the New Silexion
ordinary shares on the day that is the earlier of (i) the business day prior to effectiveness of the registration statement registering
the resale of the shares issuable under the White Lion Purchase Agreement and (ii) the business day prior to the 180<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>
day following the Closing Date of the Business Combination. Based on the closing price of the ordinary shares on September 16, 2024, we
issued to White Lion, on September 18, 2024, 365,418 ordinary shares in respect of White Lion&#8217;s commitments under the White Lion
Purchase Agreement.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">Through&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; , 2024, we have
issued and sold an aggregate of 4,059,418 ordinary shares (which includes the foregoing 365,418 ordinary shares issued as a commitment
fee) to White Lion under the White Lion Purchase Agreement for aggregate proceeds to us of approximately $2.3 million.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">&#160;</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">63</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#160; </span>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Prospective Reverse Share Split</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25; font-weight: bold">Proposed Reverse Share Split</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 35.45pt; line-height: 1.25">On October 22, 2024, we filed with the SEC, and soon thereafter we began to distribute
to our shareholders, a notice and proxy statement for an extraordinary general meeting of our company to be held on November 12, 2024
(the &#8220;extraordinary general meeting&#8221; or &#8220;meeting&#8221;) at which we will present to our shareholders a proposal to
effect a reverse share split of our issued and outstanding, and our remaining authorized but unissued, ordinary shares at a ratio of between
1-for-10 and 1-for-20 (the &#8220;reverse share split&#8221;). The exact ratio of the reverse share split will be finalized by our board
of directors prior to the extraordinary general meeting and will be presented at the meeting. If the reverse share split is approved at
the meeting, holders of our ordinary shares will receive one ordinary share for every 10 to 20 ordinary shares currently held by them
(depending on the final ratio), and the number of our authorized but unissued ordinary shares will be reduced at that same ratio. Furthermore,
the par value of all ordinary shares, whether issued and outstanding, or unissued, will be increased proportionately to between $0.0010
and $0.0020. As of the effective time of the reverse share split (which will occur as soon as possible following shareholder approval
of the reverse share split proposal, if approved), proportionate adjustments will be made to (i) the number of ordinary shares that are
subject to all then-outstanding equity awards and warrants, such that fewer shares would underlie such awards and warrants, (ii) the exercise
price of all then-outstanding options and warrants, such that the per share exercise price of each such option and warrant would be increased,
and (iii) the number of ordinary shares available for issuance under the our equity incentive plans, such that fewer shares will be subject
to such plans. If the reverse share split is approved and implemented, all issued and outstanding, and authorized and unissued, ordinary
share data, all ordinary share equivalent data, and all per share data, will be adjusted retroactively throughout this prospectus to reflect
the&#160;reverse share split&#160;for all periods presented.</div>

<div style="text-indent: 35.45pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span></div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Components of our Results of Operations</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Operating Expenses</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Research and Development
Expenses</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Research and development expenses include
costs directly attributable to the conduct of research and development programs, including the cost of payroll and related expenses, payroll
taxes and other employee benefits including share-based compensation related to employees, subcontractors, lab expenses, preclinical and
clinical trials cost, material costs and consulting fees.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We expect to continue to invest in research
and development to develop SIL-204, including hiring additional employees and continuing the research and development of that product
candidate. As a result, we expect that our research and development expenses will continue to increase in the future.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">General and Administrative
Expenses</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">General and administrative expenses consist
primarily of personnel costs, including share-based compensation related to directors and employees, patent application fees, office space
rental costs, and maintenance expenses, external professional service costs, including legal, accounting, audit, finance, human resource
services, travel expenses and other consulting fees.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We expect that our general and administrative
expenses will increase in the future to fund our continued research and development activities, primarily due to increased headcount to
support anticipated growth in the business and due to incremental costs associated with operating as a public company, including costs
to comply with the rules and regulations applicable to public companies such as costs related to compliance and reporting obligations
pursuant to the rules and regulations of the SEC and stock exchange listing standards, public relations, insurance and professional services.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Financial expenses (income),
net</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The finance expenses consisted primarily of
change in fair value of warrants and financial liabilities measured at fair value, interest income and exchange rate differences expenses.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">64</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Results of Operations</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Comparison of six-month
period ended June 30, 2024 and 2023</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table summarizes our results
of operations for the six-month period ended June 30, 2024 and 2023:</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3665517ea3984307a594c489e7fc8e07" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Six-month period ended<br/>
        June 30,</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"> 2024</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Operating expenses:</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Research and development, net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,727</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,916</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">General and administrative</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">908</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">306</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Total operating expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,635</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,222</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Operating loss</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,635</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,222</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Financial expenses, net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">270</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">377</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Loss before income tax</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2,905</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2,599</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Income tax</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">7</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">20</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Net loss for the six-month period</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2,912</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2,619</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Research and Development Expenses</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table summarizes our research
and development expenses for the six-month period ended June 30, 2024 and 2023:</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z176ee43171a9437199d7d005842f8fa5" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Six-month period ended<br/>
        June 30,</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"> 2024</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Payroll and related expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">514</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">569</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Subcontractors and consultants</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,128</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,208</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Materials</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">16</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Rent and maintenance</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">49</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">78</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Travel expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">13</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">27</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Other</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">20</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">18</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Total research and development expenses</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,727</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,916</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Research and development expenses decreased
by approximately $0.2 million, or 10.5% to $1.7 million for the six-month period ended June 30, 2024, compared to $1.9 million for the
six-month period ended June 30, 2023. The decrease resulted mainly from a decrease in subcontractors in the amount of $0.1 million and
from a decrease in payroll and related expenses in the amount of $0.1 million.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Research and development expenses for the
six-month period ended June 30, 2024 and June 30, 2023 included approximately $0.2 million and $0.5 million, related to the development
of Loder, respectively, and $1.5 million and $1.4 million related to the development of SIL-204B, respectively. Aggregate research and
development expenses since inception for Loder program, as of June 30, 2024 and as of June 30, 2023 were approximately $18.5 million and
$17.9 million, respectively. Aggregate research and development expenses since inception for SIL-204B program, as of June 30, 2024 and
as of June 30, 2023 were approximately $6.2 million and $2.0 million, respectively.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">65</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">General and Administrative Expenses</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table summarizes our general
and administrative expenses for the six-month periods ended June 30, 2024 and 2023:</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze374206814754172b84ff2dbc75041b2" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Six-month periods ended<br/>
        June 30,</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"> 2024</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Payroll and related expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">306</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">145</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Professional Services</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">448</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">28</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Depreciation</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">15</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">29</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Rent and maintenance</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">72</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">42</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Patent registration</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">25</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">16</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Travel expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">16</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">16</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Other</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">26</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">30</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Total general and administrative expenses</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">908</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">306</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">General and administrative expenses increased
by approximately $0.6 million, or 200.0% to $0.9 million for the six-month period ended June 30, 2024, compared to $0.3 million for the
six-month period ended June 30, 2023. The increase resulted mainly from an increase in payroll and related expenses in the amount of $0.2
million and from an increase in professional services costs in the amount of $0.4 million.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Financial expenses, net</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Financial expenses, net decreased by approximately
$0.1 million, or 25.0% to an expense of $0.3 million for the six-month period ended June 30, 2024 compared to an expense of $0.4 million
for the six months ended June 30, 2023. This decrease was mainly due to a decrease in the amount of $0.3 million in foreign exchange loss
offset by an increase in revaluation expenses of warrants in the amount of $0.15 million for the six-month period ended June 30, 2024.</div>

<div style="text-indent: 18pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Net loss</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Net loss increased by approximately $0.3 million,
or 11.5% to $2.9 million for the six-month period ended June 30, 2024, compared to $2.6 million for the six-month period ended June 30,
2023. The increase was mainly due to an increase in our general and administrative expenses partially offset by a decrease in research
and development expenses and financial expenses.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Comparison of three-month
period ended June 30, 2024 and 2023</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table summarizes our results
of operations for the three-month period ended June 30, 2024 and 2023:</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z70be10ea6cae49b1a1639d0eabe9cd84" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Three-month period ended<br/>
        June 30,</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"> 2024</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Operating expenses:</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Research and development, net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">766</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,235</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">General and administrative</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">619</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">179</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Total operating expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,385</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,414</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Operating loss</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,385</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,414</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Financial expenses, net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">102</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">452</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Loss before income tax</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">1,487</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">1,866</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Income tax</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">10</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Net loss for the three-month period</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">1,489</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">1,876</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">66</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Research and Development Expenses</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table summarizes our research
and development expenses for the three-month period ended June 30, 2024 and 2023:</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zccaf9679e30b472ca36b24353f427b2d" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Three-month period ended<br/>
        June 30,</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"> 2024</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Payroll and related expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">235</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">245</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Subcontractors and consultants</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">497</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">910</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Materials</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">6</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Rent and maintenance</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">18</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">35</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Travel expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">13</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">27</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Other</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">12</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Total research and development expenses</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">766</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,235</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Research and development expenses decreased
by approximately $0.4 million, or 33.3% to $0.8 million for the three-month period ended June 30, 2024, compared to $1.2 million for the
three-month period ended June 30, 2023. The decrease resulted mainly from a decrease in subcontractors in the amount of $0.4 million.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Research and development expenses for the
three-month period ended June 30, 2024 and June 30, 2023 included approximately $0.1 million and $0.2 million, related to the development
of Loder, respectively, and $0.7 million and $1.0 million related to the development of SIL-204B, respectively.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">General and Administrative Expenses</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table summarizes our general
and administrative expenses for the three-month periods ended June 30, 2024 and 2023:</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zca7f9fcab1e146a985006877b094c304" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Three-month periods ended<br/>
        June 30,</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"> 2024</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Payroll and related expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">164</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">97</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Professional Services</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">369</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">10</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Depreciation</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">7</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">14</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Rent and maintenance</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">46</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">21</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Patent registration</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">16</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">7</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Travel expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">7</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">16</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Other</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">10</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">14</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Total general and administrative expenses</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">619</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">179</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">General and administrative expenses increased
by approximately $0.4 million, or 200% to $0.6 million for the three-month period ended June 30, 2024, compared to $0.2 million for the
three-month period ended June 30, 2023. The increase resulted mainly from an increase in payroll and related expenses in the amount of
$0.1 million and from an increase in professional services costs in the amount of $0.36 million.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Financial expenses, net</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Financial expenses, net decreased by approximately
$0.4 million, or 80.0% to expense of $0.1 million for the three-month period ended June 30, 2024 compared to income of $0.5 million for
the three-month period ended June 30, 2023. This decrease was mainly due to a decrease in foreign exchange loss in the amount of $0.4
million.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">67</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 18pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Net loss</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Net loss decreased by approximately $0.4 million,
or 21.1% to $1.5 million for the three-month period ended June 30, 2024, compared to $1.9 million for the three-month period ended June
30, 2023. The decrease was mainly due to a decrease in our research and development expenses and financial expenses partially offset by
an increase in general and administrative expenses.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Comparison of&#160;Years
ended December&#160;31, 2023 and 2022</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table summarizes our results
of operations for the&#160;years ended December&#160;31, 2023 and 2022:</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6bb378fd93024b4f83ab8cc117a18d49" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Years ended December 31,</div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"> 2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2022</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Operating expenses:</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Research and development, net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,708</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,226</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">General and administrative</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">973</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">634</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Total operating expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">4,681</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,860</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Operating loss</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">4,681</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,860</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Financial expenses (income), net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">395</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(396</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Loss before income tax</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">5,076</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">3,464</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Income tax</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">32</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">24</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Net loss for the year</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">5,108</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">3,488</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Research and Development Expenses</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table summarizes our research
and development expenses for the&#160;years ended December&#160;31, 2023 and 2022:</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9a33427fb6244e3a84edf76449eacfa0" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Years ended December 31,</div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"> 2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2022</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Payroll and related expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">973</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,192</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Subcontractors and consultants</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,467</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,595</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Materials</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">13</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">191</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Rent and maintenance</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">160</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">175</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Travel expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">37</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">42</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Other</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">58</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">31</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Total research and development expenses</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,708</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">3,226</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Research and development expenses increased
by approximately $0.5&#160;million, or 15.6% to $3.7&#160;million for the year ended December&#160;31, 2023, compared to $3.2&#160;million
for the year ended December&#160;31, 2022. The increase resulted mainly from an increase in subcontractors in the amount of $0.9&#160;million
partially offset by a decrease in payroll and related expenses in the amount of $0.2&#160;million and a decrease in materials costs in
the amount of $0.2&#160;million.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Research and development expenses for the
year ended December&#160;31, 2023 and December&#160;31, 2022 included approximately $0.8&#160;million and $2.6&#160;million related to
the development of Loder, respectively, and $2.9&#160;million and $0.6&#160;million related to the development of SIL-204B, respectively.
Aggregate research and development expenses since inception for Loder program, as of December&#160;31, 2023 and as of December&#160;31,
2022, were approximately $18.2&#160;million and $17.4&#160;million, respectively. Aggregate research and development expenses since inception
for SIL-204B program, as of December&#160;31, 2023 and as of December&#160;31, 2022, were approximately $3.6&#160;million and $0.6&#160;million,
respectively.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">68</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">General and Administrative Expenses</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table summarizes our general
and administrative expenses for the&#160;years ended December&#160;31, 2023 and 2022:</div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="z4aad6f74db6548c1a6a00ae30c75746e" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Years ended December 31,</div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"> 2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2022</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Payroll and related expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">356</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">219</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Professional Services</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">386</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">197</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Depreciation</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">45</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">57</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Rent and maintenance</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">86</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">71</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Patent registration</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">22</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">32</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Travel expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">31</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Other</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">47</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">58</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Total general and administrative expenses</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">973</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">634</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">General and administrative expenses increased
by approximately $0.4&#160;million, or 66.7% to approximately $1.0&#160;million for year ended December&#160;31, 2023, compared to approximately
$0.6&#160;million for the year ended December&#160;31, 2022. The increase resulted mainly from an increase in payroll and related expenses
in the amount of $0.1&#160;million and from an increase of professional services costs in the amount of $0.2&#160;million.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Financial expenses, net</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Financial expenses (income), net increased
by approximately $0.8&#160;million, or 200.0% to expense of $0.4&#160;million for the year ended December&#160;31, 2023 compared to income
of $0.4&#160;million for the year ended December&#160;31, 2022. This increase was mainly due to revaluation of warrants in the amount
of $1.0&#160;million for the year ended December&#160;31, 2022 offset by a decrease of $0.2&#160;million in foreign exchange loss.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Net loss</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Net loss increased by approximately $1.6&#160;million,
or 45.7% to $5.1&#160;million for the year ended December&#160;31, 2023, compared to $3.5&#160;million for the year ended December&#160;31,
2022. The increase was mainly due to increase in our research and development expenses, general and administrative expenses and financial
expenses.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Liquidity and Capital Resources</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Overview</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our capital requirements will depend on many
factors, including the timing and extent of spending to further develop SIL-204 and initiate pre-clinical and clinical trials, support
research and development efforts, investments in potential additional pipe-line products, and increased overall compensation as we continue
to hire additional personnel. For the six-month periods ended June 30, 2024 and 2023, and for the years ended December 31, 2023 and 2022,
we had net losses of $2.9 million and $2.6 million, and $5.1 million and $3.5 million, respectively. As of June 30, 2024, our cash and
cash equivalents totaled $1.7 million.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">69</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">To date, our principal sources of liquidity
have been proceeds from private offerings of our ordinary shares and convertible preferred shares, grants from the Israeli Innovation
Authority, and issuance of convertible financing agreements (CFA) and Simple Agreement for Future Equity (SAFE).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Based on our current business plan, we believe
our current cash and cash equivalents, and anticipated cash flow from operations, will not be sufficient to meet our anticipated cash
requirements during 2024 following consummation of the Business Combination. We will need to raise additional capital to finance our operations,
expand our business and pipeline, or for other reasons.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our audited consolidated financial statements
for the year ended December 31, 2023 and our unaudited condensed financial statements for the six-month period ended June 30, 2024 included
in this prospectus note that there is substantial doubt about our ability to continue as a going concern as of such date; and in its report
accompanying our audited consolidated financial statements included herein, our independent registered public accounting firm included
an explanatory paragraph stating that our recurring losses from operations and our cash outflows from operating activities raise substantial
doubt as to our ability to continue as a going concern. This means that our management and our independent registered public accounting
firm have expressed substantial doubt about our ability to continue our operations without an additional infusion of capital from external
sources. Our audited consolidated financial statements have been prepared on a going concern basis and do not include any adjustments
that may be necessary should we be unable to continue as a going concern. If we are unable to finance our operations, our business would
be in jeopardy and we might not be able to continue operations and might have to liquidate our assets. In that case, investors might receive
less than the value at which those assets are carried on our unaudited condensed financial statements for the six-month period ended June
30, 2024 and year ended December 31, 2023, and it is likely that investors would lose all or a part of their investment.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We have lease obligations and other contractual
obligations and commitments as part of our ordinary course of business. See &#8220;<span style="font-style: italic">Note 4: Operating
Leases</span>&#8221; and &#8220;<span style="font-style: italic">Note 6: Commitments and Contingent Liabilities&#8221;</span> to our consolidated
financial statements for the year ended December 31, 2023 for information about our lease obligations.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We did not have during the periods presented,
and we do not currently have, any off-balance sheet arrangements involving commitments or obligations, including contingent obligations,
arising from arrangements with unconsolidated entities or persons that have or are reasonably likely to have a material current or future
effect on our financial condition, results of operations, liquidity, cash requirements or capital resources.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Government Grants</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our research and development efforts were
financed, in part, through royalty-bearing grants from the Israeli Innovation Authority, or the IIA. As of June 30, 2024, we received
IIA royalty-bearing grants totaling approximately $5.8 million.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We are committed to pay royalties to the IIA
at a rate of approximately 3.0% to 5.0% of the sales of all of our product candidates and other related revenues generated from such projects,
that were developed, in whole or in part, using the IIA royalty-bearing grants we received under IIA programs up to the total amount of
royalty-bearing grants received, linked to the U.S. dollar and bearing annual interest at rates prescribed by the IIA&#8217;s rules and
guidelines.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We may in the future apply to receive additional
grants from the IIA. However, we cannot predict whether we will be entitled to any future grants, or the amounts of any such grants.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Israeli Innovation Law, research
and development programs that meet specified criteria and are approved by a committee of the IIA are eligible for grants. A company that
receives a royalty-bearing grant from the IIA is typically required to pay royalties to the IIA on income generated from products incorporating
IIA-funded know-how (including income derived from services associated with such products and from IIA-funded know-how), up to 100% of
the U.S. dollar-linked royalty-bearing grant amount plus interest.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">70</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The obligation to pay royalties is contingent
on actual income generated from such products and services. In the absence of such income, no payment of royalties is required.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As of June 30, 2024, the total royalty amount
that may be payable by the Company is approximately $5.8 million ($6.4 million including interest).</div>

<div style="text-indent: 18pt; line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Cash Flows</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Cash flows for the six-month
period ended June 30, 2024 and 2023</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table summarizes our cash flows
for the six-month periods ended June 30, 2024 and 2023:</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zda42f81478a143fa9e76996c1d5ce6df" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Six-month period ended<br/>
        June 30,</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"> 2024</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Cash and cash equivalents and restricted cash
        at beginning of the period</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">4,645</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">8,309</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Net cash used in operating activities</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(2,817</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(2,587</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Net cash provided by (used in) investing activities</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(6</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">505</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Net cash provided by financing activities</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">522</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Net decrease in cash and cash equivalents
        and restricted cash</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(2,823</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(1,560</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Translation adjustments on cash and cash equivalents
        and restricted cash</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(75</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(258</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Cash and cash equivalents and restricted cash
        at end of the period</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,747</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">6,491</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaf862b9951e342bc9c7c5864b5f20a84" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">*</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Represents an amount less than $1</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Cash Flows from Operating Activities</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Net cash used in operating activities increased
by approximately $0.2 million, or 7.7%, to $2.8 million for the six-month period ended June 30, 2024, compared to $2.6 million for the
six-month period ended June 30, 2023. This increase was mainly from an increase of $0.3 million in the net loss for the six-month period
ended June 30, 2024, offset by $0.1 million change in net working capital.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Cash Flows from Investing Activities</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Net cash provided by (used in) investing activities
decreased by $0.5 million, or 100.0%, to $0 million for the six-month period ended June 30, 2024, compared to investment of $0.5 million
for the six-month period ended June 30, 2023. This decrease was mainly due to a reduction in short-term deposit in the amount of $0.5
million used for operating activities.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Cash Flows from Financing Activities</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Net cash provided by financing activities
decreased by $0.5 million, or 100.0%, to approximately $0 million for the six-month period ended June 30, 2024, compared to $0.5 million
the six-month period ended June 30, 2023. This decrease was mainly due to a decrease in proceeds from issuance of preferred shares which
was higher in the amount of $0.5 million in the six-month period ended June 30, 2023.</div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">71</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Cash flows for the three-month
period ended June 30, 2024 and 2023</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table summarizes our cash flows
for the three-month periods ended June 30, 2024 and 2023:</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc4b1e27ad0a4449eb69c5ec266bae2ab" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Three-month period ended
        June 30,</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"> 2024</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Cash and cash equivalents and restricted cash
        at beginning of the period</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,831</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">7,924</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Net cash used in operating activities</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(1,065</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(1,676</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Net cash provided by (used in) investing activities</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(2</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Net cash provided by financing activities</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">522</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Net decrease in cash and cash equivalents
        and restricted cash</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(1,065</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(1,156</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Translation adjustments on cash and cash equivalents
        and restricted cash</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(19</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(277</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Cash and cash equivalents and restricted cash
        at the end of the period</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1,747</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">6,491</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Cash Flows from Operating Activities</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Net cash used in operating activities decreased
by approximately $0.6 million, or 35.3%, to $1.1 million for the three-month period ended June 30, 2024, compared to $1.7 million for
the three-month period ended June 30, 2023. This decrease was mainly from a decrease of $0.4 million in the net loss for the three-month
period ended June 30, 2024, and $0.4 million change of net working capital, offset by a decrease in non-cash financial expenses in the
amount of $0.2 million.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Cash Flows from Financing Activities</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Net cash provided by financing activities
decreased by $0.5 million, or 100.0%, to approximately $0 million for the three-month period ended June 30, 2024, compared to $0.5 million
the three-month period ended June 30, 2023. This decrease was mainly due to a decrease in proceeds from issuance of preferred shares which
was higher in the amount of $0.5 million in the three-month period ended June 30, 2023.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Cash flows for the&#160;Years
ended December&#160;31, 2023 and 2022</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table summarizes our cash flows
for the years ended December 31, 2023 and 2022:</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z993ae18fe96d41c88c1f51903d2ed91c" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Year ended December 31,</div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"> 2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">2022</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Cash and cash equivalents and restricted cash
        at beginning of the period</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">8,309</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">10,083</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Net cash used in operating activities</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(4,529</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(3,335</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Net cash provided by (used in) investing activities</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">573</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(524</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman,Times,serif">Net cash provided by financing activities</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">522</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">2,752</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Net decrease in cash and cash equivalents
        and restricted cash</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(3,434</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(1,107</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Translation adjustments on cash and cash equivalents
        and restricted cash</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(230</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(667</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Cash and cash equivalents and restricted cash
        at the end of the period</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">4,645</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">8,309</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">72</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Cash Flows from Operating Activities</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Net cash used in operating activities increased
by approximately $1.2&#160;million, or 36.4%, to $4.5&#160;million for the year ended December&#160;31, 2023, compared to $3.3&#160;million
for the year ended December&#160;31, 2022. This increase was mainly from an increase of $1.6&#160;million in the loss for the year, offset
by a decrease of $0.6&#160;million in non-cash financial expenses.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;<span style="font-style: italic">&#160;</span></div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Cash Flows from Investing Activities</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Net cash provided by (used in) investing activities
increased by $1.1&#160;million, or 220.0%, to $0.6&#160;million for the year ended December&#160;31, 2023, compared to investment of $0.5&#160;million
for the year ended December&#160;31, 2022. This increase was mainly due to change short-term deposit in the amount of $1.0&#160;million.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Cash Flows from Financing Activities</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Net cash provided by financing activities
decreased by $2.3&#160;million, or 82.1%, to approximately $0.5&#160;million for the year ended December&#160;31, 2023, compared to $2.8&#160;million
for the year ended December&#160;31, 2022. This decrease was mainly due to a decrease in proceeds from issuance of preferred shares which
was higher in the amount of $2.2&#160;million in 2022.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Funding Requirements</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We expect to devote substantial financial
resources to our ongoing and planned activities, particularly further development of SIL-204 and as we conduct our planned pre-clinical
and clinical trials.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Identifying potential product candidates
and conducting pre-clinical testing and clinical trials is a time-consuming, expensive, and uncertain process that takes years to complete,
and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition,
our product candidates, if approved, may not achieve commercial success. For additional information please refer to the &#8220;<span style="font-style: italic">Risk
Factors</span>&#8221; section of this prospectus, including &#8220;<span style="font-style: italic">Risks Related to Our Financial Condition
and Capital Requirements</span> &#8212; <span style="font-style: italic">we have never generated any revenue from product sales and may
never be profitable&#8221; and &#8220;Risks Related to the Research and Development of our Product Candidates &#8212; Silexion is heavily
dependent on the success of its product candidates</span>&#8230;&#8221;.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We expect our expenses to increase substantially
in connection with our ongoing activities, particularly as we advance our pre-clinical studies and clinical trials. In addition, if we
obtain marketing approval for SIL-204 in any indication or for any other product candidate we are developing or may develop in the future,
we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing, and distribution. Furthermore,
upon the closing of the Business Combination, we expect to incur additional costs associated with operating as a public company. Accordingly,
we will need to obtain substantial additional funding.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our future capital requirements will depend
on many factors, including:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7bc972d6a136451d98b0e92e9180014e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Material cost.</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za47831a686e44512a67f31fd9ec39fb7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Regulatory pathway; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0f5c9191cb7448c492ee647641d35137" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif">Human clinical trial costs.</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">As of June 30, 2024, we had cash and cash
equivalents of $1.7 million. Based on our current cash balance, as well as its history of operating losses and negative cash flows from
operation, combined with its anticipated use of cash to, among other things, (i) fund the preclinical and clinical development of our
products, (ii) identify and develop new product candidates, and (iii) seek approval for SIL-204 and any other product candidates we may
develop, our management has concluded that we do not have sufficient cash to fund our operations for 12 months from the date of its unaudited
condensed financial statements for the six-month period ended June 30, 2024 included in this prospectus without additional financing,
and as a result, there is substantial doubt about our ability to continue as a going concern.</div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">73</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In making this determination, applicable accounting
standards prohibited us from considering the potential mitigating effect of plans that have not been fully implemented as of the date
of our unaudited condensed financial statements for the six-month period ended June 30, 2024, including, without limitation, plans to
consummate the Business Combination discussed below and to raise additional capital. Our financial information throughout this prospectus,
and our unaudited condensed financial statements for the six-month period ended June 30, 2024 contained herein have been prepared on a
basis that assumes that we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities
and commitments in the normal course of business. This financial information and our unaudited condensed financial statements for the
six-month period ended June 30, 2024 do not include any adjustments that may result from an unfavorable outcome of this uncertainty.</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Closing of the Business Combination was
conditioned upon the fulfillment of various conditions described in the Business Combination Agreement<span style="font-style: italic">.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We believe that following consummation of
the Business Combination, we will not have cash sufficient to sustain our operating expenses and capital expenditure requirements over
the next 12 months from the date of our unaudited condensed financial statements for the six-month period ended June 30, 2024 included
in this prospectus.</div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We have based these estimates and expectations
on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. We could
not, as of the June 30, 2024 balance sheet date of the unaudited condensed financial statements for the six-month period ended June 30,
2024, determine the exact level of funds that will be available to the Company upon consummation of the Business Combination. Our expected
use of funds represents our intentions based upon our current plans and business condition, which could change in the future as our plans
and business condition evolve and the level of funding available to the Company becomes clear. In addition, changing circumstances could
cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because
of circumstances beyond our control. As a result, we could deplete our capital resources sooner than we currently expect. In addition,
because the successful development of SIL-204 and any studies or other product candidates that we pursue is highly uncertain, at this
time we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the development
of any product candidate.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Until such time, if ever, as we can generate
substantial revenues from product sales, we expect to finance our cash needs through a combination of public and private equity offerings
and debt financings, including the private placement of ordinary shares pursuant to the White Lion Purchase Agreement, strategic alliances,
collaborations, and marketing, distribution, or licensing arrangements. However, adequate additional financing may not be available to
us on acceptable terms, or at all, and may be impacted by the economic climate and market conditions.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Critical Accounting Policies and Estimates</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">For a description of our significant accounting
policies, see Note 2 to our consolidated financial statements for the year ended December 31, 2023 and unaudited condensed consolidated
financial statements for the six-month period ended June 30, 2024 included in this prospectus.</div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The preparation of our consolidated financial
statements for the year ended December 31, 2023 and unaudited condensed consolidated financial statements for the six-month period ended
June 30, 2024 in conformity with U.S. GAAP requires management to make estimates and assumptions in certain circumstances that affect
the amounts reported in the accompanying consolidated financial statements for the year ended December 31, 2023 and unaudited condensed
consolidated financial statements for the six-month period ended June 30, 2024 and related footnotes. Actual results may differ from these
estimates. We base our judgments on our experience and on various assumptions that we believe to be reasonable under the circumstances.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">74</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Of our policies, the following are considered
critical to an understanding of our consolidated financial statements for the year ended December 31, 2023 and unaudited condensed consolidated
financial statements for the six-month period ended June 30, 2024 as they require the application of subjective and complex judgment,
involving critical accounting estimates and assumptions impacting our consolidated financial statements for the year ended December 31,
2023 and unaudited condensed consolidated financial statements for the six-month period ended June 30, 2024.</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The critical accounting estimates relate to
the following:</div>

<div style="margin-left: 36pt; line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 17.45pt; margin-left: 18pt; line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Share-Based
Compensation</div>

<div style="text-indent: 17.45pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Share-based compensation expense related to
share awards is recognized based on the fair value of the awards granted. The fair value of each option award is estimated on the grant
date using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions,
including the fair value of the underlying ordinary shares (see below), the expected term of the option, and the expected volatility of
the price of our ordinary shares. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. The
related share-based compensation expense is recognized on a straight-line basis over the requisite service period of the awards, including
awards with graded vesting and no additional conditions for vesting other than service conditions. Forfeitures are accounted for as they
occur instead of estimating the number of awards expected to be forfeited.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our use of the Black-Scholes option-pricing
model requires the input of highly subjective assumptions. If factors change and different assumptions are used, our share-based compensation
expense could be materially different in the future.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We will continue to use judgment in evaluating
the assumptions related to our share-based compensation on a prospective basis. As we continue to accumulate additional data related to
our ordinary shares, we may refine our estimation process, which could materially impact our future share-based compensation expense.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Valuations of instruments
convertible to our Ordinary and Preferred Shares</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our preferred shares are classified as temporary
equity, as they include clauses that could constitute as in-substance redemption clauses that are outside our control. Warrants and other
instruments over our Preferred Shares are classified as liabilities under ASC 480 and measured at fair value, with subsequent changes
in fair value recognized in the statements of operations in each period.</div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The fair value of our preferred shares underlying
our convertible instruments was determined by our board of directors, after considering contemporaneous third-party valuations and input
from management. In the absence of a public trading market, our board of directors, with input from management, exercised significant
judgment and considered various objective and subjective factors to determine the fair value of our equity including the following factors:</div>
</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbca26175a81d4f60ab89ee305f3d89a2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">History of transactions in our preferred
        shares;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z922f3073fa8e43a4932cb0bc8ae0fd03" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Probability of an IPO scenario (including
        de SPAC transaction);</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfe63197659f04a21b0454b34268aa860" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Probability of other liquidation events;</div>
        </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Expected time to liquidation; and</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd52cc5b3c25b4ab295ea7cc904e417f8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Expected return on equity.</div> </td> </tr>
  </table>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The resulting equity value was then allocated
to each share class based on differences in liquidation preferences of the various share classes using an Option Pricing Model (&#8220;OPM&#8221;)
through the use of a series of call options and by implementing a Monte Carlo simulation. The OPM allocates the overall company value
to the various share classes based on differences in liquidation preferences, using a series of call options. The OPM is appropriate to
use when the range of possible future outcomes is difficult to predict. Starting from 2023, for the IPO scenario (including de SPAC transaction)
we utilized a probability-weighted expected return method (&#8220;PWERM&#8221;) to allocate value among the various share classes. The
PWERM involves the estimation of the value of our company under multiple future potential outcomes and estimates the probability of each
potential outcome. After the value of each applicable class of shares was determined, a discount for lack of marketability (&#8220;DLOM&#8221;)
was applied to arrive at the fair value of the ordinary shares on a non-marketable basis. A DLOM is applied in order to reflect the lack
of a recognized market for a closely held interest and the fact that a non-controlling equity interest may not be readily transferable.
A market participant purchasing this share would recognize this illiquidity associated with the shares, which would reduce the overall
fair market value.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">75</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In some cases, we considered the amount of
time between rounds of financing to determine whether to use a mid price calculation between two dates.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Upon completion of the Business Combination,
our ordinary shares are publicly traded, and we rely on the closing price of our ordinary shares as reported on the date of the applicable
valuations.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The fair value of the warrants for the purchase
of preferred shares was calculated using the OPM as part of the allocation of the equity value to the various share classes (as described
above). The critical accounting estimates for the valuation of those warrants include (a) the fair value of the underlying preferred shares,
as mentioned above, and (b) volatility &#8212; based on peer companies&#8217; volatility.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Recent Accounting Pronouncements</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">See Note 2 on page F-64 to our financial
statements for the year ended December 31, 2023 included in this prospectus for a description of recent accounting pronouncements applicable
to our financial statements for the year ended December 31, 2023.</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Smaller Reporting Company
Status</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">We are a &#8220;smaller reporting company,&#8221; meaning that the market value of our
ordinary shares held by non-affiliates is less than $700 million and our (via its Silexion subsidiary) annual revenue was less than $100
million during the most recently completed fiscal year. We will continue to be a smaller reporting company if either (i) the market value
of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently
completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company,
we may choose to present only the two most recent fiscal years of audited financial statements and we have reduced disclosure obligations
regarding executive compensation.</div> </div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Emerging Growth Company
Status</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Section 102(b)(1) of the Jumpstart Our Business
Startups Act of 2012, or the JOBS Act, exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides
that a company can choose not to take advantage of the extended transition period and comply with the requirements that apply to non-emerging
growth companies, and any such election to not take advantage of the extended transition period is irrevocable.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We are an &#8220;emerging growth company&#8221;
as defined in Section 2(a) of the Securities Act, and has elected to take advantage of the benefits of the extended transition period
for new or revised financial accounting standards. We will remain an emerging growth company until the earliest of (i) the last day of
the fiscal year in which the market value of ordinary shares that is held by non-affiliates exceeds $700 million as of the end of that
year&#8217;s second fiscal quarter, (ii) the last day of the fiscal year in which we have total annual gross revenue of $1.235 billion
or more during such fiscal year (as indexed for inflation), (iii) the date on which we have issued more than $1.0 billion in non-convertible
debt in the prior three-year period, or (iv) December 31, 2025. We expect to continue to take advantage of the benefits of the extended
transition period, although it may decide to early adopt such new or revised accounting standards to the extent permitted by such standards.
This may make it difficult or impossible to compare our financial results with the financial results of another public company that is
either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition
period exemptions because of the potential differences in accounting standards used.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">76</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="BUSINESS"><!--Anchor--></span>BUSINESS</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Unless the context otherwise
requires, in this &#8220;Business&#8221; section, the terms &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; generally refer to
Silexion Therapeutics Ltd., an Israeli company (&#8220;Silexion&#8221;), or, from and after the Business Combination, to Silexion Therapeutics
Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company (&#8220;New Silexion&#8221;).</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Business Overview</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We are a clinical-stage, oncology-focused&#160;biotechnology
company engaged in the discovery and development of proprietary treatments for KRAS-driven&#160;cancers. The KRAS gene is an oncogene
that is&#160;involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based
on our research of refractory solid tumor cancers, we are actively developing a platform focused on the silencing of the KRAS oncogene
using RNA-interference&#160;therapeutics. Our lead product candidate, SIL-204B, consists of locally administered small interfering RNAs,
or siRNA, in an extended-release&#160;formulation, as a first-line&#160;treatment of locally advanced pancreatic cancer patients, or LAPC,
in combination with standard-of-care&#160;chemotherapy.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The KRAS oncogene is considered to be the
most common oncogenic gene driver in human cancers, and the most notable in pancreatic, lung, and gastrointestinal (GI) (including colorectal,
esophagus, stomach, small bowel, and appendix) cancers. Considered a challenging therapeutic target due to its intrinsic characteristics,
recent advances have been made at directly inhibiting the KRAS proteins produced by the mutated gene. Our platform is designed to silence
the gene, and thus prevent the production of the harmful mutated KRAS proteins driving the growth of cancerous tumors.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We are currently focused on treatment for
pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable,
i.e. they are not able to be surgically removed. For our first indication, we are targeting the largest and least treatable form of localized
pancreatic tumors referred to as locally advanced pancreatic cancer.&#160;LAPC represents approximately 30% of the total pancreatic cancer
population. We are currently developing SIL-204B, a second-generation&#160;siRNA product candidate following a Phase 1 and Phase 2 clinical
trial with our first-generation&#160;siRNA product candidate, siG12D-LODER, which we also refer to as Loder. Results from the Phase 2
clinical trial showed a trend for differences between treatment groups in patients with the KRAS G12D/V mutation, with the Loder arm suggesting
an overall survival advantage of 9.3&#160;months.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">SIL-204B has been designed to optimize Loder with the aim of improving uptake into tumor
cells, enhancing stability, and improving the delivery system. We plan to conduct a Phase 2/3 prospective, randomized, controlled, multinational,
two-arm, open-label trial in LAPC subjects that harbor the KRAS G12D/V mutations to evaluate the efficacy, safety and tolerability of
SIL-204B administered intratumorally in combination with standard of care (SoC) chemotherapy versus SoC chemotherapy only. In support
of our planned Phase 2/3 trial, we held a meeting with the Federal Institute for Drugs and Medical Devices in Germany (BfArM) to discuss
the planned design of the Phase 2/3 trial at which BfArM agreed, in principle, to the design. In preparation for the study, we plan to
initiate toxicology studies of SIL-204B in 2025 followed by the regulatory submission in the second half of 2025&#160; to initiate the
Phase 2/3 trial and trial initiation in the first half of 2026. At this time, we are focused on the further development of the core siRNA
technology underlying the Loder and SIL-204B as well as the clinical development of SIL-204B as the most optimized version of the technology.</div>
<span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">77</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Our Market Opportunity</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Activating mutations in&#160;KRAS&#160;are
among the most prevalent oncogenic driver mutations in human cancers. In a recent study of over 400,000 patients with various cancer type
malignancies, 23% of adult pan-cancer&#160;samples had KRAS alterations, 88% of which were mutations, most commonly G12D, G12V, G12C,
G13D and G12R, making the KRAS target a sought-out&#160;target in for many cancers (&#8220;Comprehensive pan-cancer&#160;genomic landscape
of KRAS altered cancers and real-world&#160;outcomes in solid tumors&#8221;, by Jessica K.&#160;Lee, etc., NPJ Precision Oncology 2022;
6:&#160;91). In addition, the study found that various cancers have an amplification of the non-mutated&#160;KRAS protein. Tumor types
with a high prevalence of KRAS mutations included pancreatic ductal adenocarcinoma (PDAC) (92%), colorectal cancer (CRC) (49%), and non-squamous&#160;non-small&#160;cell
lung cancer (NSCLC) (35%). These three cancers represent 71% of the KRAS mutant pan-tumor&#160;population studied.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following chart shows the distribution
of various alternations of the KRAS oncogene in various type of cancers:</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image1.jpg" alt="" style="width: 620px; height: 401px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">78</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Pancreatic Cancer</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">By the next decade, pancreatic cancer is expected
to become the second most deadly cancer. Every year in the U.S.&#160;approximately 50,000 people die from pancreatic cancer, while approximately
61,000 new patients are diagnosed with pancreatic cancer annually (American Cancer Society Statistics 2023).</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image2.jpg" alt="" style="width: 142px; height: 191px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image3.jpg" alt="" style="width: 611px; height: 333px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Studies have shown that pancreatic cancer
patients have short survival rates compared to other cancer types (see, for example, &#8220;Prognosis and survival analysis of patients
with pancreatic cancer: retrospective experience of a single institution&#8221;, by Qi Li and others, World Journal of Surgical Oncology,
2022; 20:11). There are four basic forms of pancreatic cancer: Resectable, those where a surgeon can remove a tumor; Borderline Resectable
(BRPC) where the tumor is not currently permissible for surgery but prior treatment with chemotherapy or radiation could in some cases
allow for surgical removal; LAPC where the tumor has surrounded more than half of a major artery or vein and is not surgically removable;
and Metastatic where the cancerous tumor has spread to other organs. Of the forms of pancreatic cancer that are localized (those which
have not yet spread), the largest and most life threatening is LAPC, which constitutes approximately 30% of pancreatic cancers (&#8220;Locally
Advanced Pancreatic Cancer: A Review of Local Ablative Therapies&#8221;, by Alette Ruarus and others, Cancers BaseI, January&#160;2018;
10(1):16).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">79</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Below is a curve of overall survival in LAPC
patients:</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image4.jpg" alt="" style="width: 622px; height: 430px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Fig. Comparison of overall survival between
different chemotherapy regimens in non-resected&#160;locally advanced pancreatic cancer patients. CHT indicates chemotherapy; FFX, FOLFIRINOX;
Gem, gemcitabine. Reference Gemenetzis, G et al. 2019. Annals of Surgery. 270 (2):340</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">KRAS mutations across their various forms
are responsible for approximately 92% of all pancreatic cancers, of which the KRAS G12D and KRAS12V mutations account for over 70% of
the cases traced to KRAS mutations (Bailey, P.&#160;<span style="font-style: italic">et al.</span>&#160;Genomic analyses identify molecular
subtypes of pancreatic cancer.&#160;<span style="font-style: italic">Nature</span>&#160;531(7592), 47&#160;&#8211;&#160;52.&#160;<span style="font-style: italic">https://doi.org/10.1038/nature16965</span>&#160;(2016)&#160;(Art.
No. 7592)). Unfortunately, those with LAPC have a short survival time, about 17&#160;months, and constitute about 30% of the total pancreatic
cancer population (&#8220;Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection&#8221;, by Georgio
Gemenetzis, MD, and others, Annals of Surgery. 270 (2):1, March&#160;2018). Among those patients with KRAS mutations, those with the mutation
type G12D and G12V show the shortest OS among the G12x mutation type.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">80</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Distribution of KRAS Mutations in Pancreatic
Cancer</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image5.jpg" alt="" style="width: 532px; height: 326px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Our Technology</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our research is focused on the development
of a platform of therapeutics that is designed to silence the KRAS oncogene using small interfering RNA, or siRNA. This function is called
interference RNA (RNAi). When the RNAi is double stranded of 19-25&#160;nucleotides (NTs), in length, it is referred to as siRNA. This
class of siRNA therapeutics exert their effect by inducing the enzymatic breakdown of the messenger (mRNA) of a targeted gene inhibiting
the process called translation, which turns the message (mRNA) into a protein. The general mechanism for the silencing the oncogene is
actually an evolutionary process developed by cells to protect against viruses.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We believe our approach also builds upon the
validation of our target KRAS mutations as a target for cancers, as seen with the two small molecule KRAS inhibitors currently on the
market for non-small&#160;cell lung cancer, and the validation of siRNA technology, as it is currently on the market for five non-oncological&#160;indications.
None of these agents is appropriate for our intended primary indication, but we believe they do support our premises regarding target
(KRAS) and basic technology (siRNA) for use in the oncological area. A key distinction between our technology and the existing inhibitors
of KRAS is that our siRNA technology prevents the production of the protein, as indicated by a decrease in the mRNA and physiological
decrease in human tumor cell line growth shown in our preclinical studies. By contrast, the existing inhibitors and to our knowledge,
those in development inhibit its activity, and clinical use of the existing inhibitors has shown that they potentially leave large unmet
needs.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The specific mechanism of this silencing activity
is depicted in the figure below. siRNAs, usually&#160;19-25&#160;NTs, enter the cell as a double-standard&#160;complex. Once in the inner
cell matrix, they bind to an RNA-induced&#160;silencing complex of enzymes (RISC), which splits the siRNA into two single RNA strands
referred to as the passenger (sense) strand and the guide (antisense) strand. It is the antisense which is the active part. The single
guide strand has complementary binding&#160;to the target mRNA and thereby acts as an inducing guide for other enzymes in the RISC complex
to bind&#160;and induce specific cleavage of the now double stranded target mRNA. As the siRNA guide strand is designed to be complementary
to the RNA message around the site of the mutation of the gene to be silenced, in our case the mutated KRAS oncogene, once the message
(mRNA) is destroyed, the oncogene is silenced. As the sense-strand&#160;of the siRNA is designed to be specific for the KRAS, there is
a specificity to the silencing of this driver of cancer.</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">81</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image6.jpg" alt="" style="width: 595px; height: 417px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our first-generation&#160;siRNA product candidate,
siG12D, is an extended-release&#160;formulation of siRNA. While originally designed to combat the KRAS G12D mutation in patients with
LAPC, siG12D was shown to have silencing activity in other KRAS mutations including G12V as well as to a lesser degree in G12C and G12R.
The product candidate is comprised of the anti-KRAS(G12D) siRNA drug substance (siG12D), formulated in a biodegradable polymeric matrix
(PLGA) as solid rods in order to obtain an extended-release&#160;profile. To overcome the difficulties of a systemic drug to enter the
pancreatic tumor environment and to obtain a sufficiently high level of siRNA in the pancreatic cell without inducing unnecessary side
effects, the siRNA is directly delivered intratumorally using a standard ultrasound guided endoscopy (EUS). Since patients should undergo
anesthesia prior to the endoscopy, the same as that required for a biopsy, the siRNA has been formulated as an extended-release&#160;formulation
to increase the time between administrations. We refer to this product formulation as siG12D-LODER&#160;or Loder. Loder has undergone
extensive pre-clinical&#160;testing as well as two open-label&#160;clinical trials.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our second-generation&#160;siRNA product candidate,
SIL-204B, is an optimized form of the first-generation&#160;Loder comprised of an anti-KRAS&#160;siRNA drug substance (SIL-204) encapsulated
into a biodegradable polymeric matrix (PLGA). While pre-clinical&#160;testing of SIL-204B&#160;has shown silencing activity of KRAS mutations
including G12D, G12V, G12C and G12R in varying degrees, it is designed to mainly combat the KRAS G12D and KRAS G12V mutations in patients
with LAPC where silencing activity is more enhanced. The second-generation&#160;siRNA drug substance aims to provide improved uptake into
tumor cells by introduction of a hydrophobic tail that enhances movement across the cell membrane. Additionally, second-generation&#160;siRNA
drug substance includes modified nucleotides in the siRNA that enhance stability and corresponding half life. Most significantly, the
delivery system has been improved in which PLGA-rods&#160;used in Loder have been replaced by PLGA-microparticles, allowing the drug substance
to be injected as a suspension, facilitating administration through smaller needles. As with Loder, the administration is by ultrasound
guided endoscopy (EUS), of the type typically used for pancreatic biopsies to diagnose pancreatic cancer and can be done by a typical
gastrointestinal endoscopist.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">82</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As discussed further below, Silexion plans
to conduct a Phase 2/3 clinical trial of SIL-204B&#160;targeting KRAS G12D and G12V mutations. The targeting of additional mutations is
expected to require additional clinical trials.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We believe the optimization of Loder allows
for more of a personalized medicine approach to the dosing, allowing the siRNA dose to be adjusted to the tumor size. The small volume
of suspension is expected to allow for treatment of smaller tumors than those treated with Loder, and to continue treatment for a longer
period of time with tumors shrinking in size. Furthermore, delivery of the extended-release&#160;PLGA formulated siRNA, SIL-204B, to be
administered using a much smaller needle is expected to allow more flexibility and decrease the risk associated with administration.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Pre-Clinical Studies</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We have conducted the evaluation of our first-generation&#160;siRNA
product candidate, Loder, in pharmacology, pharmacokinetics (PK), and toxicology studies with both the siG12D and siG12D-LODER. The results
of the extensive in vitro and in vivo nonclinical studies conducted with Loder have demonstrated its effects on the KRAS oncogene, tumor
development, and the development of new metastases. In these studies, the mechanism of action (MOA) was elucidated and the effect of Loder
on a variety of downstream processes, ultimately leading to cell apoptosis, tumor necrosis, and halting of new metastases, was investigated.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Pre-clinical&#160;data show that the siG12D
silencing is very specific and effective (peak mRNA degradation effect in vivo was found to be 98%), can down-regulate&#160;signaling
pathways, reduce pancreatic cancer cell viability, decelerate cancer cell migration, and suppress expression of genes involved in Epithelial-to-Mesenchymal&#160;Transition
(EMT). It was demonstrated in vivo that Loder protects siG12D against degradation. The product candidate induces apoptosis and necrosis
throughout the entire tumor, hinders the appearance of metastases, decelerates the development and growth of pancreatic tumors, induces
an innate immune response locally within the tumor and extends survival.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">siG12D was also found to be additive with
FOLFIRINOX, Gemcitabine, and Gemcitabine+nab-Paclitaxel. When administered into the tumor, siG12D molecules are in part spontaneously
taken up into tumor cells; the siG12D drug is distributed from the siG12D-LODER&#160;throughout the entire tumor, by diffusion and convection,
and covers the entire tumor after about a week, increasing the &#8220;void volume&#8221; in the tumor microenvironment.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">PK studies yielded validated methods for detecting
siG12D in rat and human plasma, and confirmed distribution and absorption at the local tissue level.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The toxicological study confirmed siG12D tolerability,
with minimal, not drug related, focal effect at the implantation site and No Observed Adverse Effect Level (NOAEL) 24.2 times higher than
the dose in the Loder Phase 2 trial.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Taken together, these converging effects on
multiple genetic, cellular, tumor tissue, tumor microenvironment, systemic levels and survival aspects act to produce a durable and prolonged
anti-tumor&#160;effect both in in vitro and in vivo pancreatic cancer models.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We have also conducted pre-clinical&#160;studies
of our second-generation&#160;siRNA product candidate, SIL-204B. There are three key preclinical studies which support our advancing SIL-204B&#160;into
a planned Phase 2/3 clinical trial.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The first key clinical study was a dose response
analysis of SIL-204&#160;in mouse Hepa1-6&#160;cells together with a relevant Dual Glo reporter plasmid. SIL-204&#160;in this study showed
inhibition of the drug substance across KRAS mutations G12D, G12V, G12C and G12R and the wild type to cover the KRAS amplifications. Similar
to the results found with the siRNA in the Loder (siG12D) three of the mutations (G12D, G12V, and G12R) were highly inhibited. However,
whereas G12C was mildly silenced (inhibited) with siG12D, it was significantly more inhibited with SIL-204&#160;which has implications
for potentially broadening the indications for SIL-204B&#160;to include all four of the major KRAS mutations and the wild-type. Additionally
in this model, when a prototype of SIL-204&#160;was tested for its silencing activity with and without the lipid lead we are conjugating
to the siRNA with SIL-204, the results showed that the lipid-conjugated&#160;siRNA enhanced the silencing activity of the siRNA by two-fold.
The siG12D (siRNA in the Loder) does not have the lipid conjugate.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">83</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The second key pre-clinical&#160;study examined
the stability of the guide strand of SIL-204&#160;in human serum. Whereas siG12D was completely broken down (enzymatically cleaved) in
&lt; 1 hour, SIL-204&#160;showed complete stability at 48 hours. Consistently, when SIL-204&#160;was administered to rats via subcutaneous
injection, the plasma half-life&#160;was 5 hours. In contrast when siG12D was administered systemically to mice the half life was 1 minute.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In a third key pre-clinical&#160;study, the
human pancreatic cell line CAPAN-1&#160;harboring the KRAS G12V mutation was xenografted (transplanted) to mice and the tumor growth and
necrosis (death of body tissue) in the tumor was observed following daily treatments of SIL-204&#160;compared to the controls (untreated
and vehicle treated mice). Results showed a significant growth of the tumor in the control mice while in the SIL-204-treated&#160;mice,
the tumor growth was significantly curtailed, as indicated by a significant reduction in the tumor volume and weight. In addition, when
analyzing tumor slices from the center of the tumor, the results showed a statistically significant increase in tumor necrosis in SIL-204&#160;treated
mice compared to untreated- and vehicle-treated&#160;mice.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Clinical Studies</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Phase 1 Clinical Study</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">An escalating dose, multicenter Phase 1 clinical
study of Loder was conducted in Israel from 2011 to 2015 at three sites enrolling a total of 15 patients with unresectable LAPC. The study
was designed as an open-label, single-arm, single-administration&#160;of siG12D-LODER&#160;(concomitantly with standard of care chemotherapy),
dose-escalating&#160;Phase 1 study, enrolling LAPC patients with a target tumor accessible for intra-tumor&#160;administration, with a
Karnofsky performance status equal or greater than 70% and with a life expectancy of at least three months. Single escalating doses of
LODER (0.025, 0.75, 1.5 or 3 mg) by insertion into the tumor were administered by standard EUS procedures. Following insertion, patients
received standard of care chemotherapy as first line treatment in accordance with treating physician recommendation, Gemcitabine (nine
patients) or modified FOLFIRINOX (four patients), while one patient refused to receive any chemotherapy. After study drug administration,
the patients were to be monitored for signs of systemic or local treatment- related toxicity. Active follow-up&#160;comprised scheduled
physical and clinical examinations, vital sign measurements, laboratory tests, abdominal CT and disease assessments.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The primary endpoint of the study was to assess
the safety and tolerability of siG12D-LODER, and to define the dose-limiting&#160;toxicities (DLT) of siG12D-LODER. Secondary endpoints
included the recommended Phase&#160;2 dose and defining the maximum tolerated dose (MTD). In the event of surgery, assessment of siG12D-LODER&#160;local
distribution and efficacy were to be based on histopathology measurements and RNA analysis. Progression free survival (PFS) and overall
survival (OS) were to be assessed only by long term follow-up. Due to the small size of the trial, it was not powered for statistical
significance. The study met its primary endpoints. The 15 patients reported a total of 125 adverse events (AEs). 111 of the reported AEs
(89%) were grade 1 and&#160;2, which were transient and resolved. The most common AE (grade 1-2) was diarrhea which was reported by seven
(46.7%) patients, abdominal pain and nausea were both reported by six (40%) patients, whereas fatigue was reported by five (33.3%) patients.
Thirteen severe AEs of grade 3 and one grade 4 severe were reported by 10 (66.7%) patients. The most common grade 3-4&#160;AEs were neutropenia
and cholangitis reported by three patients and two patients, respectively. Pancreatitis was reported by the investigator as possibly related
to the procedure. One adverse event (cholangitis) in one patient was considered as definitely related to the EUS intervention. At the
doses tested, no DLTs were observed and therefore if there was a DLT it was defined as being greater than 3mg, the highest dose administered.
The study also met the secondary endpoint of establishing the Phase 2 dose of up to 3mg however the MTD was not determined.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Evidence of tumor response was observed, noting
that none of the patients presented progressive disease (PD) and tumor response durability was demonstrated. The tumor marker CA19-9&#160;decreased
in 70% of relevant cases soon after siG12D-LODER&#160;administration and time to metastasis (TTM) and overall survival were comparable
to (or better than) the historical data of the disease in a similar population. However, no clear dose response was observed between the
dose of siG12D-LODER&#160;and OS or TTM probably due to several factors, including the small size of the study, the single dosing administration,
without repeat dosing, and the level of dose at the low-dose&#160;cohort, which was selected to be ~5 times higher than then the minimal
effective dose level as predicted in pre-clinical&#160;studies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">84</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Phase 2 Clinical Study</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">From 2018 to 2023, we conducted a prospective,
multi-center, Phase II, open label study to evaluate the efficacy, safety and tolerability of siG12D-LODER&#160;in two separate cohorts
across five sites in Israel and four in the U.S.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Cohort 1 was a randomized and controlled two-arm&#160;study
of 37 subjects with unresectable LAPC to assess the efficacy, safety, tolerability and pharmacokinetics of siG12D-LODER&#160;when used
in combination with standard chemotherapy treatment (gemcitabine + nab-Paclitaxel) compared to gemcitabine + nab-Paclitaxel&#160;alone
in subjects. Cohort 2 was a single arm study of 22 subjects with unresectable and borderline resectable LAPC to assess the efficacy, safety,
and tolerability of siG12D-LODER&#160;in combination with standard of care chemotherapy treatment (gemcitabine + nab-paclitaxel&#160;or
FOLFIRINOX or modified FOLFIRINOX).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">For comparative purposes, we evaluated the
randomized section of the trial for efficacy (Cohort 1) and both cohorts (Cohort 1 and Cohort 2) for safety. All patients who met the
inclusion criteria were accepted to the trial, regardless of whether they had a KRAS mutation or which specific mutation they had.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The KRAS mutation status was however determined
post-hoc&#160;in a sample of 31 patients (21 of whom were Loder treated) in the table below:</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z55885ad377654c669df621187739cd2c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: #000000 2px solid; width: 14.99%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">KRAS<br/> G12x<br/>
        Mutation</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Cohort 1<br/> Arm 2<br/>
        (Control)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Cohort 1<br/> Arm 1<br/>
        (Treatment)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Cohort 1<br/> % Arm 1<br/>
        Tx</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Cohort 2<br/> (Treatment)</div>
        </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 20%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">All<br/> Treated<br/>
        %</div> </td> </tr>
  <tr>
    <td style="width: 14.99%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">R</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">5/10</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">1/12</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">8</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">2/9</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 20%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">26 (8/31)</div> </td> </tr>
  <tr>
    <td style="width: 14.99%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">D</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">2/10</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">3/12</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">25</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">2/9</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 20%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">23 (7/31)</div> </td> </tr>
  <tr>
    <td style="width: 14.99%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">V</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">3/10</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">8/12</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">67</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">5/9</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 20%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">52 (16/31)</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">A total of up to eight Loders (2.8 mg) were
inserted into the pancreatic tumor per single administration. Insertion was done using EUS. The trial consisted of a screening period
(28 days), a treatment phase (12-week&#160;Loder treatment cycles at investigator&#8217;s discretion with concomitant chemotherapy treatment
cycles) and a follow-up&#160;phase (up to six months until end of study which is defined as death, withdrawn consent or lost to follow-up).
For efficacy, the primary endpoint in the randomized section of the trial (Cohort 1) was overall survival (OS), defined as the time that
passed from study entry (screening visit) until death from any cause. For Cohort&#160;2, the primary endpoint was the overall response
rate (ORR) by end of treatment; ORR was defined as the proportion of subjects with best overall confirmed response (BOCR) of either a
complete response (CR) or partial response (PR). Concerning the secondary endpoint of safety, the endpoints were incidence of adverse
events (AEs), and serious adverse events (SAEs) overall, by severity, by relationship to each study intervention, and those that led to
discontinuation of study interventions. Other secondary endpoints included ORR for Cohort&#160;1, progression free survival, time to metastatis,
time to response, duration of response and rate of disease control.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Overall, a total of 59 subjects with LAPC
were enrolled in the study, 38 were treated with Loder and 48 subjects overall (81.3%) completed the study. In Cohort&#160;1, 15/19 (78.9%)
completed the Loder arm and 11/18 (61.1%) completed the standard of care arm. In Cohort&#160;2, 21/22 (95.5%) completed the study.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In Cohort&#160;1, OS was comparable between
the two treatment arms. Median time to death was 691 days in the Loder-treated&#160;group, compared with 666 days in the standard of care
group. The Hazard Ratio (Loder/SoC) was 1.47 (95% CI; 0.643, 3.365) with a non-significant&#160;p-value&#160;of 0.361 for the treatment
difference. In the sub-group&#160;of subjects with D or V KRAS mutation (n=16), the median OS was 691 days for the 11 Loder treated subjects,
compared to 409 days for the five SoC subjects. The Hazard Ratio was 0.59 (95% CI; 0.179, 1.963) with a non-significant&#160;p-value&#160;of
0.393. In the subjects who were not found to have D or V KRAS mutation (n=13), the median OS in the seven Loder treated subjects was 637
days compared to 937 days in the six SoC treated subjects. The hazard ratio was 2.87 (95% CI; 0.705, 11.650) with a p-value&#160;of 0.141.
The ORR was 44.4% (8/18) in the Loder group compared to 27.3% in the SoC group (3/11). No subject had a CR in either group. The ORR in
subjects with D or V KRAS mutation was 63.6% (7/11) in the Loder group compared to 20% in the SoC group (1/5).</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">85</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In Cohort&#160;2, the ORR was 31.6% reflecting
6/19 subjects with partial responses. No subject had CR. In subjects with D or V KRAS mutation, the ORR was 57.1% (4/7), however, these
subjects also had a shorter median OS compared to subjects without these mutations (414 days vs. 671 days).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As depicted below, the survival probability
in subjects of Cohort 1 bearing a KRAS G12D/V mutation compared to the control group, showed a median survival in the Loder group (n=11)
of 22.8&#160;months compared to 13.8&#160;months in the control group (n=5).</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image7.jpg" alt="" style="width: 560px; height: 285px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Based on the above, although the primary endpoints
of all patients were not met, the results showed a trend for differences between treatment groups in patients with the KRAS G12D/V mutation,
with the Loder arm suggesting an overall survival advantage of 9.3&#160;months. With respect to the secondary efficacy endpoints, no statistically
significant differences were observed or there was insufficient data to evaluate although with respect to ORR in Cohort&#160;1, a positive
trend in the KRAS G12D/V mutation subgroup was observed. Due to the small size of the trial, it was not powered for statistical significance.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The secondary safety endpoints were met. In
Cohort&#160;1, all subjects in the Loder treatment group reported at least one moderate or severe treatment emergent adverse event (TEAE)
(18 subjects). One subject was reported with a TEAE leading to death (sepsis). This event was deemed as not related to the Loder or the
EUS procedure. Of the remaining 17 subjects, one subject was reported with a life-threatening&#160;TEAE, gastrointestinal disorders (colitis).
The majority of moderate and severe TEAEs reported in the Loder treatment group were attributed to gastrointestinal disorders (10), blood/lymphatic
disorders (14), general disorders and administration site conditions (11), metabolism and nutrition disorders (11), and investigations
(10). In the SoC treatment group, all subjects reported at least one moderate or severe TEAE (11 subjects). No subjects were reported
with a TEAE leading to death. Two subjects were reported with a life- threatening TEAE. The majority of moderate and severe TEAEs reported
in the SoC treatment group were attributed to gastrointestinal disorders (10), blood/lymphatic disorders (9), general disorders and administration
site conditions (9), metabolism and nutrition disorders (8), and investigations (9).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In Cohort&#160;2, all subjects in the Loder
treatment group reported at least one moderate or severe TEAE (20 subjects). One subject was reported with a TEAE leading to death (gastrointestinal
disorder). This event was deemed as not related to the Loder or the EUS procedure. Three subjects were reported with a life-threatening&#160;TEAE.
Of the three subjects, one subject was investigation (neutrophil count decreased) and two subjects were metabolism/nutrition (hyperglycaemia,
hyperkalaemia). The majority of moderate and severe TEAEs reported in the Loder treatment group were attributed to gastrointestinal disorders
(13), nervous system disorder (10) and investigations (11).</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">86</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Manufacturing</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We rely on and intend to continue to rely
on third-party&#160;contract manufacturing organizations for drug substance and drug products for our clinical trials. We have agreements
with contract manufacturers for the manufacturing of SIL-204B&#160;for clinical development.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Future Development Plans</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We plan to conduct a Phase 2/3 prospective,
randomized, controlled, multinational, two-arm, open-label&#160;trial in LAPC subjects that harbor the KRAS G12D/V mutations to evaluate
the efficacy, safety and tolerability of SIL-204B&#160;administered intratumorally in combination with SoC chemotherapy versus SoC chemotherapy
only. The study design, including the dose and dosing frequency, the combination with SoC chemotherapy, the proposed target population
and safety monitoring is based on the experience with the preceding Phase 1 and 2 clinical studies with the first-generation&#160;siRNA
product candidate, Loder.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The study is initially planned to enroll approximately
350 subjects and has an adaptive design with several segments; a screening period which includes a biopsy eligibility test for G12D/V
mutations, a CT scan and physiologic profiling to ensure subjects are qualified for treatment; concurrent with this, all subjects will
receive run-in&#160;SoC chemotherapy; a Phase 2 safety run-in&#160;and treatment period where initially 30 subjects will be randomized
2:1 to receive SIL-204B&#160;and SoC Chemotherapy or SoC Chemotherapy at which point a Data and Safety Monitoring Board (DSMB) will perform
a safety review and recommend whether the study is safe to proceed; a Phase 2 expansion period to continue enrollment; and when approximately
60 events have occurred, an unblinded interim analysis for sample size re-estimation&#160;and futility will be conducted, to expand the
trial from Phase 2 to Phase&#160;3, which is expected to happen approximately one year from start of enrollment. Following the interim
analysis, the study will continue into a Phase 3 treatment period to complete the enrollment of the remaining subjects for a total treatment
period of 24&#160;months. The study design is powered for statistical significance.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In support of our planned Phase 2/3 trial
of SIL-204B, we held a meeting with the Federal Institute for Drugs and Medical Devices in Germany (BfArM) to discuss the planned design
of the Phase 2/3 trial, at which BfArM agreed, in principle, to the design. In preparation for the study, we plan to initiate toxicology
studies of SIL-204B&#160;in 2025 followed by the regulatory submission in late 2025 to initiate the Phase 2/3 trial. Currently, we are
upscaling SIL-204&#160;and planning for GMP production. At this time, Silexion is focused on the further development of the core siRNA
technology underlying the Loder and SIL-204B&#160;as well as the clinical development of SIL-204B&#160;as the most optimized version of
the technology.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We expect to apply in 2024 for Orphan Drug
Designation in both the U.S. and EU.&#160;In the U.S., Orphan Drug designation by the FDA gives a company exclusive marketing rights for
a seven-year&#160;period, along with other benefits to recoup the costs of researching and developing drugs to treat rare diseases. In
the EU, a company receives data exclusivity for 10&#160;years which provides protection from similar drugs being approved. We believe
the size of the localized pancreatic cancer market fits the requirements for this designation however there can be no assurance that we
will be granted such designation and such designation neither shortens the development time or regulatory review time of a drug nor does
it increase the likelihood for any approval in the regulatory review process. Our continued development plans for SIL-204B&#160;are not
dependent on whether we are granted Orphan Drug Designation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">87</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Our Strategy</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our goal is to have a positive impact on the
health and treatment of KRAS driven cancer patients, in general and initially with pancreatic cancer through the continued development
and commercialization of our pipeline. Key elements of our strategy to advance toward this goal include the following:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3f4ebc1c561c4f2b833aa0ab0cb15634" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-weight: bold; font-style: italic; font-family: Times New Roman,Times,serif">Advancing
        the clinical development of SIL-204B&#160;for the treatment of LAPC</span><span style="font-family: Times New Roman,Times,serif">.&#160;&#160;&#160;&#160;Our
        Phase&#160;2 trial with our first-generation&#160;siRNA product, Loder in LAPC patients acts as a validation of approach and foundation
        for our continued development efforts. As further described in &#8220;Future Development Plans&#8221;, Silexion plans to initiate toxicology
        studies of SIL-204B&#160;in 2025 followed by the regulatory submission in late 2025 to initiate a Phase 2/3 trial of SIL-204B&#160;powered
        for statistical significance. At this time, Silexion is focused on the further development of the core siRNA technology underlying the
        Loder and SIL-204B&#160;as well as the clinical development of SIL-204B&#160;as the most optimized version of the technology.</span></div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7e7e46d0e37849bcb6f0706aad4919e4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-weight: bold; font-style: italic; font-family: Times New Roman,Times,serif">Leveraging
        our platform to other oncological indications&#160;</span><span style="font-family: Times New Roman,Times,serif">harboring the KRASG12D/V
        mutation.</span></div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4cfdce62b53f4a62a2bf92caf131a30a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-weight: bold; font-style: italic; font-family: Times New Roman,Times,serif">Advancing
        SIL-204B&#160;to commercialization.</span><span style="font-family: Times New Roman,Times,serif">&#160;&#160;&#160;&#160;We have assembled
        a world class clinical advisory board for better understanding the market in the U.S.&#160;and EU.</span></div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z918502e287e4422291dae40fe4606272" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-weight: bold; font-style: italic; font-family: Times New Roman,Times,serif">Forming strategic
        alliances and collaborating with partners to augment our capabilities</span><span style="font-family: Times New Roman,Times,serif">.&#160;&#160;&#160;&#160;We
        may pursue strategic alliances with other biopharmaceutical companies with well-established&#160;presences in the specialties we aim to
        target for our indications. This may include co-marketing, co-promotion, and co-development&#160;relationships, or a partnership with
        a diagnostics company to help improve availability of rapid testing. We also intend to explore options to work with partners to augment
        the study and treatment of patients and the impact of our product candidates, including medical professionals, healthcare professional
        networks, pharmacy benefit managers, insurance companies, and artificial intelligence companies.</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Our History</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Silexion was established as Silenseed Ltd
in 2008 as an Israeli company which underwent a name change to Silexion Therapeutics Ltd. in May&#160;2023. On June&#160;13, 2014, Silexion
filed a Registration Statement on Form&#160;F-1&#160;with the SEC, in contemplation of an initial public offering, and the listing of
its shares on Nasdaq. Subsequently, the public offering process was abandoned because our board of directors was not satisfied with our
valuation in the offering, and no securities were sold under the registration statement. During April&#160;2022, our management was replaced
following a health condition of the then-founder&#160;and CEO of Silexion, and the new management, after evaluating the viability of commercializing
the Loder, has decided to pivot from the first-generation&#160;siRNA product candidate to the second-generation&#160;siRNA product candidate
and develop SIL-204.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Competition</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The biotechnology and pharmaceutical industries,
and the oncology sector, are characterized by a rapid evolution of technologies, fierce competition and strong defense of intellectual
property rights. While we believe that our discovery programs and technology provide us with competitive advantages, we face competition
from major biotechnology and pharmaceutical companies, academic institutions, governmental agencies and public and private research institutions,
among others.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Any product candidates that we successfully
develop and commercialize will compete with currently approved therapies and new therapeutics that may become available in the future.
Key product features that would affect our ability to effectively compete with other therapeutics include efficacy, safety and convenience
of our products as compared to other available therapeutics.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">There are a large number of companies developing
or marketing treatments for cancer, including major biotechnology and pharmaceutical companies. These treatments consist of novel treatments
based on small molecule drug products, cell-based&#160;therapies, as well as traditional chemotherapy treatments. There are also an increasing
number of companies commercializing treatments and/or developing programs specifically targeting KRAS mutations, including KRAS G12D and
KRAS G12V, in a variety of manners and for a variety of indications, including cancer, including Amgen Inc., Bristol-Myers&#160;Squibb
Company (through the recently acquired Mirati Therapeutics, Inc.), Revolution Medicines, Inc., AstraZeneca (in collaboration with Usynova),
BioNTech, Roche, Merck/Moderna, Boehringer and Gilead. Smaller and other early-stage&#160;companies may also prove to be significant competitors.
In addition, academic research departments and public and private research institutions may be conducting research on compounds that could
prove to be competitive.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">88</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Many of the companies against which we may
compete have significantly greater financial resources and expertise in the research and development, manufacturing, preclinical testing,
conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Similar or early-stage&#160;companies
may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These
competitors also compete with us in recruiting and retaining qualified scientific and management personnel, and establishing clinical
trial sites and patient registration for clinical trials, as well as acquiring technologies complementary to, or necessary for, our programs.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our competitors have already and/or may obtain
more rapidly than we may obtain approval FDA, or other regulatory approval for commercialization of product. As a result, our competitors
could establish a strong market position before we are able to enter the market with our products. The availability of coverage and reimbursement
from government and other third-party&#160;payors for competing products at the time of commercialization of our products will also significantly
affect the pricing and competitiveness of our products.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Intellectual Property</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our business depends, in part, on our ability
to develop and maintain the proprietary aspects of our products. We currently hold one Israeli patent, and two U.S.&#160;patents.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The main patent protection for our products
is in International Patent Application No. PCT/IL2023/051276 filed on December&#160;14, 2023 (the &#8220;276 Application&#8221;), which
in turn claims priority to two U.S. Provisional Patent Applications: U.S. Provisional Patent Applications 63/387,504 filed on December&#160;15,
2022, and 63/491,776 filed on March&#160;23, 2023. Additionally, patent applications corresponding to the 276 Application were filed in
Argentina (AR 20240101502, filed on June&#160;13, 2024) and Taiwan (TW 113122679, filed on June&#160;19, 2024). Both of these patent applications
were filed prior to the publication date of the 276 Application. Silexion intends to file national phase applications of the 276 Application
in multiple worldwide jurisdictions by the standard deadlines. Silexion is the sole applicant and owner of the 276 Application and its
related applications in Argentina and Taiwan.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The 276 Application and its corresponding
applications in Argentina and Taiwan describe and claim compositions of matter, methods of treatment of,&#160;<span style="font-style: italic">inter
alia</span>, pancreatic cancer, and compositions for use in treatment of pancreatic cancer. In particular, the noted patent applications
describe and claim siRNAs that target and can inhibit expression of the KRAS oncogene mRNA in both its wildtype and mutated forms that
are associated with multiple cancers including pancreatic cancer. More particularly, the noted patent applications specifically claim
siRNAs that encompass siRNAs including, among other things, SIL-204, plus additional siRNAs which have the same or nearly the same nucleotide
sequences. These siRNAs are claimed both as isolated compositions and as part of pharmaceutical formulations for use in methods of antitumor
treatment, including extended-release&#160;formulations.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The minimum expiration date of any patent
that issues from the 276 Application is December&#160;14, 2043. However, given typical practice with respect to regulatory-related&#160;patent
term extensions, this date may be extended up to an additional five years in many countries, depending on the length of the regulatory
process, to a maximum final expiration date of December&#160;14, 2048. The minimum expiration dates for patents that issued from the noted
Argentina and Taiwan applications are 20 years from their filing dates, namely June&#160;13, 2044 and June&#160;19, 2044, respectively.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The 276 Application was published on June&#160;20,
2024 as International Patent Publication No. WO 2024/127405.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition to patent laws, we rely on copyright
and trade secret laws to protect our proprietary rights. We also attempt to protect our trade secrets and other proprietary information
through agreements with vendors, employees, and consultants.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">89</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Property and Facilities</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our principal executive officers are currently
located in Modiin, Israel, where we lease a space of 450 square meters consisting of offices, under a lease agreement that will expire
on July&#160;31, 2025.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Employees</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">As of the date of this prospectus, we have
three full time and ten part time employees. All of our employees are based in Israel. None of our employees are represented by labor
unions or covered by collective bargaining agreements. We believe that we maintain good relations with all of our employees.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Grants from the Israeli Innovation Authority</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">During 2009 to 2020, we received several
approvals from the IIA for participation in research and development activities performed by us in a total amount of $5.8&#160;million.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company is obligated to pay royalties
to the IIA amounting to 3%-5% of the sales of all of its product candidates and other related revenues generated from such projects, up
to 100% of the grants received, linked to the U.S.&#160;dollar and bearing interest at the rate of LIBOR.&#160;The obligation to pay these
royalties is contingent upon actual sales of the products and, in the absence of such sales, no payment is required. In October&#160;2023,
it was published that the interest rate of the grants will be replaced with the 12-month&#160;term SOFR published on the first&#160;trading
day of each calendar year.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As of December&#160;31, 2023, the total royalty
amount that may be payable by the Company is approximately $5.8&#160;million ($6.4&#160;million including interest).</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Legal Proceedings</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">From time to time, we may become involved
in actions, claims, suits, and other legal proceedings arising in the ordinary course of our business, including assertions by third parties
relating to intellectual property infringement, breaches of contract or warranties, or employment-related&#160;matters. We are not currently
subject to any material legal proceedings.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Regulatory Environment</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Government Regulation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Clinical trials, the drug approval process,
and the marketing of drugs are intensively regulated in the United&#160;States and in all major foreign countries. Government authorities
in the United&#160;States (including federal, state, and local authorities) and in other countries (including federal, state, and local
authorities) extensively regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging,
storage, distribution, post-approval&#160;monitoring and reporting, advertising and promotion, pricing, and export and import of pharmaceutical
products, such as those we are developing. The process of obtaining regulatory approvals and the subsequent compliance with appropriate
federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">U.S.&#160;Government Regulation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the United&#160;States, the Food and Drug
Administration, or FDA, regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and related regulations and biologics under
the FDCA and the Public Health Service Act (PHSA) and its implementing regulations. FDA approval is required before any new unapproved
drug or dosage form, including a new use of a previously approved drug, can be marketed in the United&#160;States. Drugs and biologics
are also subject to other federal, state and local statutes and regulations. Failure to comply with the applicable United&#160;States&#160;regulatory
requirements at any time during the product development process, approval process or after approval may subject an applicant to administrative
or judicial sanctions. These sanctions could include the imposition by the FDA or an Institutional Review Board, or IRB, of a clinical
hold on trials, the FDA&#8217;s refusal to approve pending applications or supplements, license suspension or revocation, withdrawal of
an approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions,
fines, civil penalties or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">90</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA and comparable regulatory agencies
in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and
marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate research and development activities
and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, distribution, record keeping, approval, advertising
and promotion of our products.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA&#8217;s policies may change and additional
government regulations may be enacted that could prevent or delay regulatory approval of our platforms and candidate products or any future
product candidates or approval of new disease indications or label changes. We cannot predict the likelihood, nature or extent of adverse
governmental regulation that might arise from future legislative or administrative action, either in the United&#160;States or abroad.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Marketing Approval</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The process required by the FDA before product
candidates may be marketed in the United&#160;States, the European Medicines Agency, or EMA, before a product can be marketed in Europe,
and Medicines&#160;&amp; Healthcare products Regulatory Agency (MHRA) for the United Kingdom. Generally involves the following:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5121d58fa6db4d72aa183b2834bccc74" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">completion of extensive preclinical laboratory tests and preclinical
        animal studies, all performed in accordance with the GLP regulations;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zedcfcf96870e411ba89ec49829908e6a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">submission to the FDA of an investigational new drug application,
        or IND, Clinical Trial Application (CTA) for Europe which must become effective or approved before human clinical studies may begin and
        must be updated on a regular basis;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcc4be9d0935a4334b83e4630da906169" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">approval by an independent institutional review board, or IRB,
        or ethics committee representing each clinical site before each clinical study may be initiated;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zba8f8c8d969f4c3488c3a3a6638b166a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">performance of adequate and well-controlled&#160;human clinical
        studies to establish the safety and efficacy of the product candidate for each proposed indication;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z25924eac06ce459a865bea5f65816338" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">preparation of and submission to the FDA of a new drug application,
        or NDA, or biologics license application, or BLA, or for Europe a Marketing Authorization Application (MAA) after completion of all pivotal
        clinical studies;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8d3dfcd36179464ab37f508f93ba46be" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">potential review of the product application by an FDA advisory
        committee, where appropriate and if applicable. In the EU, the Committee for Medicinal Products for Human Use (CHMP) issues a scientific
        opinion to the European Commission which issues the marketing authorization;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8459538af75a4c04b7eff0137c2b6a02" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">a determination by the FDA within 60&#160;days of its receipt
        of an NDA or BLA to file the application for review;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5a0ca5324b484f0d85a6192039a4f812" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">satisfactory completion of an FDA pre-approval&#160;inspection
        of the manufacturing facilities where the proposed product drug substance is produced to assess compliance with cGMP;&#160;and</div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z53f643c59e934f7c9113f73ef2f86bd3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">FDA review and approval of an NDA or BLA or marketing authorization
        in the European Union (EU) in all European Union Member States plus Norway, Iceland and Liechtenstein, prior to any commercial marketing
        or sale of the drug in the United&#160;States. Note that if the centralized procedure is used, which is mandatory for all new anticancer
        products, a marketing authorization is issued centrally by the EU commission, which is valid immediately in all member states of the EEA
        (EU plus Iceland, Norway, and Liechtenstein).</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The testing and approval process requires
substantial time and financial resources, and we cannot be certain that any approvals for our candidate products will be granted on a
timely basis, if at all.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">91</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">An IND/CTA is a request for authorization
from the FDA/national regulatory authorities in Europe to administer an investigational new drug product to humans. The central focus
of an IND/CTA submission is on the general investigational plan and the protocol(s)&#160;for human studies. The IND and CTA also include
results of animal and&#160;<span style="font-style: italic">in vitro</span>&#160;studies assessing the toxicology, pharmacokinetics, pharmacology,
and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or
literature to support the use of the investigational new drug. An IND or a CTA must become effective before human clinical trials may
begin. An IND will automatically become effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises concerns
or questions related to the proposed clinical studies. In such a case, the IND may be placed on clinical hold and the IND sponsor and
the FDA must resolve any outstanding concerns or questions before clinical studies can begin. Accordingly, submission of an IND may or
may not result in the FDA allowing clinical studies to commence. In Europe, a CTA is required to be approved by regulators, which may
take several months. Accordingly, submission of a CTA to European regulators may or may not result in permission to commence clinical
studies in Europe.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We will need to successfully complete an extensive
additional clinical trial or some clinical trials in order to be in a position to submit a new drug application to the FDA.&#160;Our planned
future clinical trials for our candidate products may not begin or be completed on schedule, if at all. Clinical trials can be delayed
for a variety of reasons, including delays in:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb13a38d9f88c484c96ce46fac039305c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">obtaining regulatory approval to commence a study;</div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z11eec5df6ca5491fbfa96315d05e83f5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">reaching agreement with third-party&#160;clinical trial sites
        and their subsequent performance in conducting accurate and reliable studies on a timely basis;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2a2acf1d05c8492183bbf25bca92a7a4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">obtaining institutional review board approval or an Ethics Committee
        approval to conduct a study at a prospective site;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfe456f69d0bc4f91addebb6f6084f2d8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">recruiting patients to participate in a study; and</div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z95ebd73c3fc44deeb814a7b8ebce48c3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">supply of the drug.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We must reach agreement with the FDA/European
national authorities on the proposed protocols for our future clinical trials in the United&#160;States and EU.&#160;A separate submission
apart from any IND or initial CTA application we submit must be made for each successive clinical trial to be conducted during product
development. Further, an independent IRB or EC for each site proposing to conduct the clinical trial must review and approve the plan
for any clinical trial before it commences at that site. Informed consent must also be obtained from each study subject. Regulatory authorities,
an IRB or EC, a data safety monitoring board or the Sponsor may suspend or terminate a clinical trial at any time on various grounds,
including a finding that the participants are being exposed to an unacceptable health risk.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Clinical Studies</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Clinical studies involve the administration
of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with current cGCP/GCP,
which include the requirement that all research subjects provide their informed consent for their participation in any clinical study.
Clinical studies are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in
monitoring safety, and the efficacy criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments
must be submitted to the FDA and/or European national authorities as part of the IND or CTA.&#160;Additionally, approval must also be
obtained from each clinical study site&#8217;s IRB or EC before the studies may be initiated, and the IRB/EC must monitor the study until
completed. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our objective is to conduct additional clinical
trials for our candidate products and, if those trials are successful, seek marketing approval from the FDA and other worldwide regulatory
bodies.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">92</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">For purposes of NDA approval, human clinical
trials are typically conducted in phases that may overlap.</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf17d0fabd1fd4aebb731e6261bee163e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Phase&#160;1.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">The
        drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution
        and excretion. In the case of some products for severe or life-threatening&#160;diseases, especially when the product may be too inherently
        toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z50c6683df50a468180dde6afb5d7bfce" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Phase&#160;2.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">This
        phase involves trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate
        the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbf894391e546432e8fe7be4cb5774b8b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Phase&#160;3.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">This
        phase involves trials undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population, often at
        geographically dispersed clinical trial sites. These trials are intended to establish the overall risk/benefit ratio of the product and
        provide an adequate basis for product labeling.</span></div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za01ce26abd774788a3280734b813ea5f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Phase&#160;4.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">In
        some cases, the FDA or the EMA may condition approval of an NDA or BLA or MAA for a product candidate on the Sponsor&#8217;s agreement
        to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct additional clinical studies after
        approval to gain more information about the drug. Such post-approval&#160;studies are typically referred to as Phase&#160;4 clinical studies.</span></div>
        </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">A pivotal study is a clinical study that adequately
meets regulatory agency requirements for the evaluation of a drug candidate&#8217;s efficacy and safety such that it can be used to justify
the approval of the product. Generally, pivotal studies are Phase&#160;3 studies, but the FDA or EMA may accept results from a Phase&#160;2
study if such study&#8217;s design provides a well-controlled&#160;and reliable assessment of clinical benefit, particularly in situations
where there is an unmet medical need and the results are sufficiently robust.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA/EMA, the IRB/EC, or the clinical study
sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects are being
exposed to an unacceptable health risk.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Additionally, some clinical studies are overseen
by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board or committee.
This group provides authorization or recommendation for whether or not a study may move forward at designated check points based on access
to certain data from the study. We may also suspend or terminate a clinical study based on evolving business objectives and/or competitive
climate. All of these trials must be conducted in accordance with cGCP requirements in order for the data to be considered reliable for
regulatory purposes.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The clinical study process can take several
(2- 12 or more) years to complete, and there can be no assurance that the data collected will support FDA or EU Commission approval or
licensure of the product. Government regulation may delay or prevent marketing of product candidates or new drugs for a considerable period
of time and impose costly procedures upon our activities. We cannot be certain that the FDA or any other regulatory agency will grant
approvals for our candidate products or any future product candidates on a timely basis, if at all. Success in early stage clinical trials
does not ensure success in later stage clinical trials. Data obtained from clinical activities is not always conclusive and may be susceptible
to varying interpretations, which could delay, limit or prevent regulatory approval.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">The NDA Approval Process</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Assuming successful completion of all required
testing in accordance with all applicable regulatory requirements, detailed investigational new drug product information is submitted
to the FDA in the form of an NDA or BLA requesting approval to market the product for one or more indications. Under federal law, the
submission of most NDAs and BLAs is subject to an application user fee. For fiscal year 2014, the application user fee exceeds $2.1&#160;million,
and the Sponsor of an approved NDA or BLA is also subject to annual product and establishment user fees, set at $104,060 per product and
$554,600 per establishment. These fees are typically increased annually. Applications for orphan drug products are exempted from the NDA
and BLA user fees and may be exempted from product and establishment user fees, unless the application includes an indication for other
than a rare disease or condition.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">93</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">An NDA or BLA must include all relevant data
available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together
with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things.
Data can come from company-sponsored&#160;clinical studies intended to test the safety and effectiveness of a use of a product, or from
a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must
be sufficient in quality and quantity to establish the safety and effectiveness of the investigational new drug product to the satisfaction
of the FDA.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA will initially review the NDA for
completeness before it accepts it for filing. The FDA has 60&#160;days from its receipt of an NDA to determine whether the application
will be accepted for filing based on the agency&#8217;s threshold determination that the application is sufficiently complete to permit
substantive review. After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether
the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP
to assure and preserve the product&#8217;s identity, strength, quality and purity. The FDA may refer applications for novel drug products
or drug products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians
and other experts, for review, evaluation and a recommendation as to whether the application should be approved and, if so, under what
conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when
making decisions.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Based on pivotal Phase&#160;3 trial results
submitted in an NDA, upon the request of an applicant, the FDA may grant a priority review designation to a product, which sets the target
date for FDA action on the application at six&#160;months, rather than the standard ten&#160;months. Priority review is given where preliminary
estimates indicate that a product, if approved, has the potential to provide a significant improvement compared to marketed products or
offers a therapy where no satisfactory alternative therapy exists. Priority review designation does not change the scientific/medical
standard for approval or the quality of evidence necessary to support approval.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">After the FDA completes its initial review
of an NDA, it will communicate to the sponsor that the drug will either be approved, or it will issue a complete response letter to communicate
that the NDA will not be approved in its current form and inform the sponsor of changes that must be made or additional clinical, nonclinical
or manufacturing data that must be received before the application can be approved, with no implication regarding the ultimate approvability
of the application.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Before approving an NDA or BLA, the FDA will
typically inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that
the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the
product within required specifications.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Additionally, before approving an NDA, the
FDA may inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines the application, manufacturing process
or manufacturing facilities are not acceptable, it typically will outline the deficiencies and often will request additional testing or
information. This may significantly delay further review of the application. If the FDA finds that a clinical site did not conduct the
clinical trial in accordance with GCP, the FDA may determine the data generated by the clinical site should be excluded from the primary
efficacy analyses provided in the NDA.&#160;Additionally, notwithstanding the submission of any requested additional information, the
FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The testing and approval process for a drug
requires substantial time, effort and financial resources, and this process may take several&#160;years to complete. Data obtained from
clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory
approval. The FDA may not grant approval on a timely basis, or at all. We may encounter difficulties or unanticipated costs in our efforts
to secure necessary governmental approvals, which could delay or preclude us from marketing our products.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">94</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA may require, or companies may pursue,
additional clinical trials after a product is approved. These so-called&#160;Phase&#160;4 studies may be made a condition to be satisfied
for continuing drug approval. The results of Phase&#160;4 studies can confirm the effectiveness of a product candidate and can provide
important safety information. In addition, the FDA now has express statutory authority to require sponsors to conduct post-market&#160;studies
to specifically address safety issues identified by the agency.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Any approvals that we may ultimately receive
could be withdrawn if required post-marketing&#160;trials or analyses do not meet the FDA requirements, which could materially harm the
commercial prospects for our candidate products.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA also has authority to require a Risk
Evaluation and Mitigation Strategy, or REMS, from manufacturers to ensure that the benefits of a drug or biological product outweigh its
risks. A sponsor may also voluntarily propose a REMS as part of the NDA submission. The need for a REMS is determined as part of the review
of the NDA.&#160;Based on statutory standards, elements of a REMS may include &#8220;dear doctor letters,&#8221; a medication guide, more
elaborate targeted educational programs, and in some cases restrictions on distribution. These elements are negotiated as part of the
NDA approval, and in some cases if consensus is not obtained until after the PDUFA review cycle, the approval date may be delayed. Once
adopted, REMS are subject to periodic assessment and modification.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Even if a product candidate receives regulatory
approval, the approval may be limited to specific disease states, patient populations and dosages, or might contain significant limitations
on use in the form of warnings, precautions or contraindications, or in the form of onerous risk management plans, restrictions on distribution,
or post-marketing&#160;study requirements. Further, even after regulatory approval is obtained, later discovery of previously unknown
problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Delay in
obtaining, or failure to obtain, regulatory approval for our candidate products, or obtaining approval but for significantly limited use,
would harm our business. In addition, we cannot predict what adverse governmental regulations may arise from future U.S.&#160;or foreign
governmental action.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Expedited Review and Accelerated Approval
Programs</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">A sponsor may seek approval of its product
candidate under programs designed to accelerate FDA&#8217;s review and approval of NDAs and BLAs. For example, Fast Track Designation
may be granted to a drug intended for treatment of a serious or life-threatening&#160;disease or condition that has potential to address
unmet medical needs for the disease or condition. The key benefits of fast track designation are the eligibility for priority review,
rolling review (submission of portions of an application before the complete marketing application is submitted), and accelerated approval,
if relevant criteria are met. Based on results of the Phase&#160;3 clinical study(ies) submitted in an NDA or BLA, upon the request of
an applicant, the FDA may grant the NDA or BLA a priority review designation, which sets the target date for FDA action on the application
at six&#160;months after the FDA accepts the application for filing. Priority review is granted where there is evidence that the proposed
product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition.
If criteria are not met for priority review, the application is subject to the standard FDA review period of ten&#160;months after FDA
accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality
of evidence necessary to support approval.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the accelerated approval program, the
FDA may approve an NDA or a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or
on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an
effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the
condition and the availability or lack of alternative treatments. Post-marketing&#160;studies or completion of ongoing studies after marketing
approval are generally required to verify the drug&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome
in relationship to the clinical benefit. In addition, the Food and Drug Administration Safety and Innovation Act (FDASIA), which was enacted
and signed into law in 2012, established the new &#8220;breakthrough therapy&#8221; designation. A sponsor may seek FDA designation of
its product candidate as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat
a serious or life-threatening&#160;disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early
in clinical development.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">95</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">FDA Post-Approval Requirements</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Drugs manufactured or distributed pursuant
to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to
recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with
the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject
to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments
at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Drug manufacturers are subject to periodic
unannounced inspections by the FDA and state agencies for compliance with cGMP requirements. Changes to the manufacturing process are
strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations
also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and
any third-party&#160;manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort
in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We rely, and expect to continue to rely, on
third parties for the production of clinical quantities of our product candidates, and expect to rely in the future on third parties for
the production of commercial quantities. Future FDA and state inspections may identify compliance issues at our facilities or at the facilities
of our contract manufacturers that may disrupt production or distribution, or require substantial resources to correct. In addition, discovery
of previously unknown problems with a product or the failure to comply with applicable requirements may result in restrictions on a product,
manufacturer or holder of an approved NDA or BLA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated&#160;or
judicial action that could delay or prohibit further marketing. Also, new government requirements, including those resulting from new
legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products
under development.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA may withdraw approval if compliance
with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery
of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing
processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information,
imposition of post-market&#160;studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other
restrictions under a REMS program. Other potential consequences include, among other things:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3983cdfedf824f858cd12b1b97fedba5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">restrictions on the marketing or manufacturing of the product,
        complete withdrawal of the product from the market or product recalls;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zae31718e0af54197a010f6b9eb951abb" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">fines, warning letters or holds on post-approval&#160;clinical
        studies;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd178b9290dd84c9eb48222df14e662ea" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">refusal of the FDA to approve pending NDAs or supplements to
        approved NDAs, or suspension or revocation of product license approvals;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5be3e2c180714d439f2f10a5dd179152" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">injunctions or the imposition of civil or criminal penalties;
        or</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z70b8f62de30d4a6ea4cef99e8888ef52" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">product seizure or detention, or refusal to permit the import
        or export of products.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA strictly regulates marketing, labeling,
advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance
with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion
of off-label&#160;uses, and a company that is found to have improperly promoted off-label&#160;uses may be subject to significant liability.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">96</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Orphan Designation and Exclusivity</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA may grant orphan drug designation
to drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United&#160;States, or, if it
affects more than 200,000 individuals in the United&#160;States, when there is no reasonable expectation that the cost of developing and
making the drug for this type of disease or condition will be recovered from sales in the United&#160;States.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Orphan drug designation entitles a party to
financial incentives such as opportunities for grant funding of clinical study costs, tax advantages, and user-fee&#160;waivers. In addition,
if a product receives FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity,
which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven&#160;years,
except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Patent Term Restoration</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Depending upon the timing, duration, and specifics
of the FDA approval of the use of our product candidates, U.S.&#160;patents that may be granted to us in the future may be eligible for
limited patent term extension under the Drug Price Competition and Patent Term Restoration Act&#160;of&#160;1984, commonly referred to
as the Hatch-Waxman&#160;Amendments. The Hatch-Waxman&#160;Amendments permit a patent restoration term of up to five&#160;years as compensation
for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend
the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period
is generally one-half&#160;the time between the effective date of an IND and the submission date of an NDA or BLA, plus the time between
the submission date and the approval of that application. Only one patent applicable to an approved product is eligible for the extension
and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA,
reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent
term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected
length of the clinical studies and other factors involved in the filing of the relevant NDA or BLA.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Biosimilars and Exclusivity</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Patient Protection and Affordable Care
Act, or Affordable Care Act, signed into law on March&#160;23, 2010, includes a subtitle called the Biologics Price Competition and Innovation
Act&#160;of&#160;2009 (BPCI Act), which created an abbreviated approval pathway for biological products shown to be similar to, or interchangeable
with, an FDA-licensed&#160;reference biological product. This amendment to the PHSA attempts to minimize duplicative testing. Biosimilarity,
which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of
safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability
requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the
same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic
may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to
exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structure of biological
products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being
worked out by the FDA.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">A reference biologic is granted twelve&#160;years
of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval
pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitting under the
abbreviated approval pathway for the lesser of (i)&#160;one year after the first commercial marketing, (ii)&#160;eighteen&#160;months
after approval if there is no legal challenge, (iii)&#160;eighteen&#160;months after the resolution in the applicant&#8217;s favor of
a lawsuit challenging the biologics&#8217; patents if an application has been submitted, or (iv)&#160;42&#160;months after the application
has been approved if a lawsuit is ongoing within the 42-month&#160;period.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">97</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Abbreviated New Drug Applications for Generic
Drugs</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In 1984, with passage of the Hatch-Waxman&#160;Act,
Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions
of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (ANDA) to the agency.
In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug
product previously approved under an NDA, known as the reference listed drug (RLD).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Specifically, in order for an ANDA to be approved,
the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration,
the dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221;
to the innovator drug. Under the statute, a generic drug is bioequivalent to an RLD if &#8220;the rate and extent of absorption of the
[generic] drug do not show a significant difference from the rate and extent of absorption of the listed drug. . . .&#8221;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Upon approval of an ANDA, the FDA indicates
that the generic product is &#8220;therapeutically equivalent&#8221; to the RLD and it assigns a therapeutic equivalence rating to the
approved generic drug in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred
to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider an &#8220;AB&#8221; therapeutic equivalence rating to mean that
a generic drug is fully substitutable for the RLD.&#160;In addition, by operation of certain state laws and numerous health insurance
programs, the FDA&#8217;s designation of an &#8220;AB&#8221; rating often results in substitution of the generic drug without the knowledge
or consent of either the prescribing physician or patient.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDCA provides a period of five&#160;years
of non-patent&#160;exclusivity for a new drug containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA
may not be filed with the FDA until the expiration of five&#160;years unless the submission is accompanied by a Paragraph&#160;IV certification,
in which case the applicant may submit its application four&#160;years following the original product approval. The FDCA also provides
for a period of three&#160;years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability
or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year&#160;exclusivity
period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or
indication.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Hatch-Waxman Patent Certification and the
30-Month Stay</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Upon approval of an NDA or a supplement thereto,
NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the
product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with
the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except
for patents covering methods of use for which the ANDA applicant is not seeking approval.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Specifically, the applicant must certify with
respect to each patent that:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2c51fb7f344d4e6a947dd4d4aad86471" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the required patent information has not been filed;</div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd15a6f0694b044d1954e4de07bf3a8e8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the listed patent has expired;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za2fc222730244435bda6b8d23fc9f38c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the listed patent has not expired, but will expire on a particular
        date and approval is sought after patent expiration; or</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb9859f28670343a49fb8c230445259bc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the listed patent is invalid, unenforceable or will not be infringed
        by the new product.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">A certification that the new product will
not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph&#160;IV
certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method
of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">98</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If the ANDA applicant has provided a Paragraph&#160;IV
certification to the FDA, the applicant must also send notice of the Paragraph&#160;IV certification to the NDA and patent holders once
the ANDA has been accepted for filing by the FDA.&#160;The NDA and patent holders may then initiate a patent infringement lawsuit in response
to the notice of the Paragraph&#160;IV certification. The filing of a patent infringement lawsuit within 45&#160;days after the receipt
of a Paragraph&#160;IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30&#160;months after
the receipt of the Paragraph&#160;IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the
ANDA applicant.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">European Union/Rest of
World Government Regulation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition to regulations in the United&#160;States,
we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and any commercial
sales and distribution of our products.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Whether or not we obtain FDA approval for
a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical
studies or marketing of the product in those countries. Certain countries outside of the United&#160;States have a similar process that
requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. In the
European Union, for example, a clinical study application, or CTA, must be submitted for each clinical protocol to each country&#8217;s
national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is accepted in accordance
with a country&#8217;s requirements, the clinical study may proceed.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The requirements and process governing the
conduct of clinical studies vary from country to country. In all cases, the clinical studies are conducted in accordance with cGCP, the
applicable regulatory requirements, and the ethical principles that have their origin in the Declaration of Helsinki.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">To obtain regulatory approval of an investigational
medicinal product under European Union regulatory systems, we must submit a marketing authorization application. The content of the NDA
or BLA filed in the United&#160;States is similar to that required in the European Union, with the exception of, among other things, country-specific&#160;document
requirements.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">For other countries outside of the European
Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing product licensing, pricing, and reimbursement
vary from country to country.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Countries that are part of the European Union,
as well as countries outside of the European Union, have their own governing bodies, requirements, and processes with respect to the approval
of pharmaceutical products. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things,
fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Authorization Procedures in the European
Union</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Medicines can be authorized in the European
Union by using either the centralized authorization procedure or national authorization procedures.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Centralized procedure</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The EMA implemented the centralized procedure
for the approval of human medicines to facilitate marketing authorizations that are valid throughout the European Economic Area, or EEA,
which is comprised of the 27 member states of the European Union plus Norway, Iceland, and Lichtenstein. This procedure results in a single
marketing authorization issued by the EMA that is valid across the EEA.&#160;The centralized procedure is compulsory for human medicines
that are: derived from biotechnology processes, such as genetic engineering, contain a new active substance indicated for the treatment
of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions,
and officially designated orphan medicines.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">99</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">For medicines that do not fall within these
categories, an applicant has the option of submitting an application for a centralized marketing authorization to the European Commission
following a favorable opinion by the EMA, as long as the medicine concerned is a significant therapeutic, scientific or technical innovation,
or if its authorization would be in the interest of public health.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">National authorization procedures</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">There are also two other possible routes to
authorize medicinal products in several European Union countries, which are available for investigational medicinal products that fall
outside the scope of the centralized procedure:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze3ea29ac7fb8496d9b3f699d5917434d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Decentralized procedure</span><span style="font-family: Times New Roman,Times,serif">.&#160;&#160;&#160;&#160;Using
        the decentralized procedure, an applicant may apply for simultaneous authorization in more than one European Union country of medicinal
        products that have not yet been authorized in any European Union country and that do not fall within the mandatory scope of the centralized
        procedure.</span></div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7f198634ab2646f1b0497ab6a3966f44" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Mutual recognition procedure.</span><span style="font-family: Times New Roman,Times,serif">&#160;&#160;&#160;&#160;In
        the mutual recognition procedure, a medicine is first authorized in one European Union Member State, in accordance with the national procedures
        of that country. Following this, further marketing authorizations can be sought from other European Union countries in a procedure whereby
        the countries concerned agree to recognize the validity of the original, national marketing authorization.</span></div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In most cases, a Pediatric Investigation Plan,
and/or a request for waiver or deferral, is required for submission prior to submitting a marketing authorization application. A PIP describes,
among other things, proposed pediatric studies and their timing relative to clinical studies in adults.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">New Chemical Entity Exclusivity</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the European Union, new chemical entities,
sometimes referred to as new active substances, qualify for eight&#160;years of data exclusivity upon marketing authorization and an additional
two&#160;years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing
the innovator&#8217;s data to assess a generic (abbreviated) application for eight&#160;years, after which generic marketing authorization
can be submitted, and the innovator&#8217;s data may be referenced, but not approved for two&#160;years. The overall ten-year&#160;period
will be extended to a maximum of eleven&#160;years if, during the first eight&#160;years of those ten&#160;years, the marketing authorization
holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization,
are held to bring a significant clinical benefit in comparison with existing therapies.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Orphan Designation and Exclusivity</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the European Union, the EMA&#8217;s Committee
for Orphan Medicinal Products, or COMP, grants orphan drug designation to promote the development of products that are intended for the
diagnosis, prevention or treatment of life-threatening&#160;or chronically debilitating conditions affecting not more than 5 in 10,000&#160;persons
in the European Union Community and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the
product would be a significant benefit to those affected). Additionally, designation is granted for products intended for the diagnosis,
prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives,
it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the
medicinal product.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the European Union, orphan drug designation
entitles a party to financial incentives such as reduction of fees or fee waivers and 10&#160;years of market exclusivity is granted following
medicinal product approval. This period may be reduced to six&#160;years if the orphan drug designation criteria are no longer met, including
where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity, and may be prolonged to
a total of 12 years, if pediatric studies in accordance with a PIP are being performed.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">100</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Orphan drug designation must be requested
before submitting an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration
of, the regulatory review and approval process.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Exceptional Circumstances/Conditional Approval</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Orphan drugs or drugs with unmet medical needs
may be eligible for EU approval under exceptional circumstances or with conditional approval. Approval under exceptional circumstances
is applicable to orphan and non-orphan&#160;products and is used when an applicant is unable to provide comprehensive data on the efficacy
and safety under normal conditions of use because the indication for which the product is intended is encountered so rarely that the applicant
cannot reasonably be expected to provide comprehensive evidence, when the present state of scientific knowledge does not allow comprehensive
information to be provided, or when it is medically unethical to collect such information. Conditional marketing authorization is applicable
to orphan medicinal products, medicinal products for seriously debilitating or life-threatening&#160;diseases, or medicinal products to
be used in emergency situations in response to recognized public threats. Conditional marketing authorization can be granted on the basis
of less complete data than is normally required in order to meet unmet medical needs and in the interest of public health, provided the
risk-benefit&#160;balance is positive, it is likely that the applicant will be able to provide the comprehensive clinical data, and unmet
medical needs will be fulfilled. Conditional marketing authorization is subject to certain specific obligations to be reviewed annually.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Accelerated Review</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Centralized Procedure in the European
Union, the maximum timeframe for the evaluation of a marketing authorization application is 210&#160;days (excluding clock stops, when
additional written or oral information is to be provided by the applicant in response to questions asked by the EMA&#8217;s Committee
for Medicinal Products for Human Use (CHMP)). Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal
product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. In this circumstance,
EMA ensures that the opinion of the CHMP is given within 150&#160;days, excluding clock stops.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Pharmaceutical Coverage,
Pricing and Reimbursement</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Significant uncertainty exists as to the coverage
and reimbursement status of any drug products for which we obtain regulatory approval. In the United&#160;States and markets in other
countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability
of coverage and reimbursement from third-party&#160;payors. Third-party&#160;payors include government authorities, managed care providers,
private health insurers and other organizations. The process for determining whether a payor will provide coverage for a drug product
may be separate from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party&#160;payors
may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved&#160;drugs
for a particular indication. Moreover, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate
reimbursement rate will be approved. Adequate third-party&#160;reimbursement may not be available to enable us to maintain price levels
sufficient to realize an appropriate return on our investment in product development.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Third-party&#160;payors are increasingly challenging
the price and examining the medical necessity and cost-effectiveness&#160;of medical products and services, in addition to their safety
and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness&#160;of our products, in addition to the
costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If
third-party&#160;payors do not consider a product to be cost-effective&#160;compared to other available therapies, they may not cover
the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company
to sell its products at a profit.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">101</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The U.S.&#160;government, state legislatures
and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid&#160;health
care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded
prescription drugs. By way of example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation
Act, collectively, the Healthcare Reform Law, contains provisions that may reduce the profitability of drug products, including, for example,
increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts
for certain Medicare Part&#160;D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health
care programs. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls
and measures, could limit payments for pharmaceuticals.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the European Community, governments influence
the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund
a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products
may only be marketed once a reimbursement price has been agreed to by the government. To obtain reimbursement or pricing approval, some
of these countries may require the completion of clinical studies that compare the cost-effectiveness&#160;of a particular product candidate
to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company
profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result,
increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border&#160;imports from
low-priced&#160;markets exert a commercial pressure on pricing within a country.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The marketability of any products for which
we receive regulatory approval for commercial sale may suffer if the government and third-party&#160;payors fail to provide adequate coverage
and reimbursement. In addition, an increasing emphasis on cost containment measures in the United&#160;States and other countries has
increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party&#160;reimbursement
rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Other Healthcare Laws
and Compliance Requirements</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If we obtain regulatory approval for any of
our product candidates, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These
laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy
regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate
include:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8633eab223104e809b98d32c44a0a8dc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the federal Anti-Kickback&#160;Statute, which prohibits, among
        other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to
        induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as
        the Medicare and Medicaid programs;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcd5d1814eed64b23895994c80beaf7c5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">federal civil and criminal false claims laws and civil monetary
        penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims
        for payment from Medicare, Medicaid, or other third-party&#160;payers that are false or fraudulent;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc76f16ad513c4a39b658aed0eff7e6b8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the federal Health Insurance Portability and Accountability Act&#160;of&#160;1996,
        or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making
        false statements relating to healthcare matters;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">102</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="zc2930a90ce2c4869b3013a7eb9b4114a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the federal transparency laws, including the federal Physician
        Payment Sunshine Act, that requires drug manufacturers to disclose payments and other transfers of value provided to physicians and teaching
        hospitals;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6ea890036f464c9d81ffc114ebddac30" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">HIPAA, as amended by HITECH and its implementing regulations,
        which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;
        and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za70b7f9691504469972c68d712a6e659" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">state law equivalents of each of the above federal laws, such
        as anti-kickback&#160;and false claims laws which may apply to items or services reimbursed by any third-party&#160;payer, including commercial
        insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from
        each other in significant ways and may not have the same effect, thus complicating compliance efforts.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Healthcare Reform Law broadened the reach
of the fraud and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback&#160;Statute and the
applicable criminal healthcare fraud statutes contained within 42&#160;U.S.C. &#167;&#160;1320a-7b, effective March&#160;23, 2010. Pursuant
to the statutory amendment, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate
it in order to have committed a violation. In addition, the Healthcare Reform Law provides that the government may assert that a claim
including items or services resulting from a violation of the federal Anti-Kickback&#160;Statute constitutes a false or fraudulent claim
for purposes of the civil False Claims Act (discussed below) or the civil monetary penalties statute. Many states have adopted laws similar
to the federal Anti-Kickback&#160;Statute, some of which apply to the referral of patients for healthcare items or services reimbursed
by any source, not only the Medicare and Medicaid programs.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We are also subject to the Foreign Corrupt
Practices Act, or FCPA, which prohibits improper payments or offers of payments to foreign governments and their officials for the purpose
of obtaining or retaining business.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Safeguards we implement to discourage improper
payments or offers of payments by our employees, consultants, and others may be ineffective, and violations of the FCPA and similar laws
may result in severe criminal or civil sanctions, or other liabilities or proceedings against us, any of which would likely harm our reputation,
business, financial condition and result of operations.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If our operations are found to be in violation
of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil
and criminal penalties, exclusion from participation in government healthcare programs, such as Medicare and Medicaid and imprisonment,
damages, fines and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our
business and our results of operations.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Labeling, Marketing and
Promotion</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA closely regulates the labeling, marketing
and promotion of drugs. While doctors are free to prescribe any drug approved by the FDA for any use, a company can only make claims relating
to safety and efficacy of a drug that are consistent with FDA approval, and the Company is allowed to actively market a drug only for
the particular use and treatment approved by the FDA.&#160;In addition, any claims we make for our products in advertising or promotion
must be appropriately balanced with important safety information and otherwise be adequately substantiated. Failure to comply with these
requirements can result in adverse publicity, warning letters, corrective advertising, injunctions and potential civil and criminal penalties.
Government regulators recently have increased their scrutiny of the promotion and marketing of drugs.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Pediatric Research Equity
Act</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Pediatric Research Equity Act (PREA) amended
the FDCA to authorize the FDA to require certain research into drugs used in pediatric patients. The intent of PREA is to compel sponsors
whose drugs have pediatric applicability to study those drugs in pediatric populations, rather than ignoring pediatric indications for
adult indications that could be more economically desirable. The Secretary of Health and Human Services may defer or waive these requirements
under specified circumstances.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">103</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Anti-Kickback and False
Claims Laws</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the United&#160;States, the research, manufacturing,
distribution, sale and promotion of drug products and medical devices are potentially subject to regulation by various federal, state
and local authorities in addition to the FDA, including the Centers for Medicare&#160;&amp; Medicaid Services, other divisions of the
U.S.&#160;Department of Health and Human Services (e.g., the Office of Inspector General), the U.S.&#160;Department of Justice, state
Attorneys General, and other state and local government agencies. For example, sales, marketing and scientific/educational grant programs
must comply with the Medicare-Medicaid&#160;Anti-Fraud&#160;and Abuse Act, as amended (the &#8220;Anti-Kickback&#160;Statute&#8221;),
the False Claims Act, as amended, the privacy regulations promulgated under the Health Insurance Portability and Accountability Act, or
HIPAA, and similar state laws. Pricing and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the Omnibus
Budget Reconciliation Act&#160;of&#160;1990, as amended, and the Veterans Health Care Act&#160;of&#160;1992, as amended. If products are
made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements
apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the United&#160;States, we are subject
to complex laws and regulations pertaining to healthcare &#8220;fraud and abuse,&#8221; including, but not limited to, the Anti-Kickback&#160;Statute,
the federal False Claims Act, and other state and federal laws and regulations. The Anti-Kickback&#160;Statute makes it illegal for any
person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer,
or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or prescription of a particular
drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The federal False Claims Act prohibits anyone
from knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items
or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically
unnecessary items or services.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">There are also an increasing number of state
laws that require manufacturers to make reports to states on pricing and marketing information. Many of these laws contain ambiguities
as to what is required to comply with the laws. In addition, as discussed below, beginning in 2013, a similar federal requirement will
require manufacturers to track and report to the federal government certain payments made to physicians and teaching hospitals made in
the previous calendar year. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and
compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions
could be subject to the penalty provisions of the pertinent state, and soon federal, authorities.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Patient Protection and
Affordable Health Care Act</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In March&#160;2010, the Patient Protection
and Affordable Health Care Act, as amended by the Health Care and Education Reconciliation Act&#160;of&#160;2010 (collectively, PPACA)
was enacted, which includes measures that have or will significantly change the way health care is financed by both governmental and private
insurers. The fees, discounts and other provisions of this law are expected to have a significant negative effect on the profitability
of pharmaceuticals.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Many of the details regarding the implementation
of PPACA are yet to be determined, and at this time, it remains unclear the full effect that PPACA would have on our business.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Other Regulations</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We are also subject to numerous federal, state
and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control,
and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations
now or in the future.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">104</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Israel</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Clinical Testing in Israel</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In order to conduct clinical testing on humans
in the State of Israel, special authorization must first be obtained from the ethics committee and general manager of the institution
in which the clinical studies are scheduled to be conducted, as required under the Guidelines for Clinical Trials in Human Subjects implemented
pursuant to the Israeli Public Health Regulations (Clinical Trials in Human Subjects)&#160;5741-1980, as amended from time to time, and
other applicable legislation. These regulations require authorization by the institutional ethics committee and general manager as well
as from the Israeli Ministry of Health, except in certain circumstances, and in the case of genetic trials, special fertility trials and
complex clinical trials, an additional authorization of the Ministry of Health&#8217;s overseeing ethics committee. The institutional
ethics committee must, among other things, evaluate the anticipated benefits that are likely to be derived from the project to determine
if it justifies the risks and inconvenience to be inflicted on the human subjects, and the committee must ensure that adequate protection
exists for the rights and safety of the participants as well as the accuracy of the information gathered in the course of the clinical
testing. Since we perform a portion of the clinical studies on certain of our therapeutic candidates in Israel, we are required to obtain
authorization from the ethics committee and general manager of each institution in which we intend to conduct our clinical trials, and
in most cases, from the Israeli Ministry of Health.</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">New Silexion Corporate
Information</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">New Silexion was formed on April 2, 2024 under
the name Biomotion Sciences as a Cayman Islands exempted limited company for the purpose of effecting a business combination with Moringa
and Silexion. On April 3, 2024, New Silexion entered into the Business Combination Agreement by and among New Silexion, Moringa, Silexion,
and New Silexion&#8217;s two wholly-owned subsidiaries&#8212; Merger Sub 1 and Merger Sub 2. On the Closing Date of August 15, 2024, following
the approval of the Business Combination (among other matters) at Moringa&#8217;s extraordinary general meeting that was held on August
6, 2024, the transactions contemplated by the Business Combination Agreement were completed. As a result, Moringa and Silexion merged
with Merger Sub 2 and Merger Sub 1 pursuant to the SPAC Merger and Acquisition Merger, respectively, and became New Silexion&#8217;s wholly-owned
subsidiaries, and their securityholders became securityholders of New Silexion at previously agreed-upon exchange ratios. In addition,
New Silexion&#8217;s ordinary shares and warrants were listed, and began trading, on the Nasdaq Global Market on August 16, 2024, and
its name was changed to Silexion Therapeutics Corp.</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">New Silexion&#8217;s principal executive offices are located at 12 Abba Hillel Road, Ramat Gan, Israel
5250606, and its phone number is +972-8-6286005. New Silexion&#8217;s corporate website address is www.silexion.com. Information contained
on or accessible through that website is not a part of this prospectus, and the inclusion of that website address in this prospectus is
an inactive textual reference only.</div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Access to Company Information</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company files or furnishes periodic reports
and amendments thereto, including its Annual Reports on Form 10-K, its Quarterly Reports on Form 10-Q and Current Reports on Form 8-K,
proxy statements and other information with the SEC. In addition, the SEC maintains a website (www.sec.gov) that contains reports, proxy
and information statements, and other information regarding issuers that file electronically. New Silexion&#8217;s internet address is
https://www.silexion.com. The Company makes available, free of charge, its Annual Report on Form 10-K, quarterly reports on Form 10-Q,
current reports on Form 8-K, and all amendments to those reports as soon as reasonably practicable after such reports have been filed
with or furnished to the SEC through its internet website.</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">105</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="MANAGEMENT"><!--Anchor--></span>MANAGEMENT</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Management and Board of Directors</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: normal">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our board of directors (sometimes referred
to as the &#8220;New Silexion Board&#8221;) is comprised of the six directors listed below.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: normal">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Each director will hold office until his
or her successor is duly elected or appointed and qualified in accordance with applicable law or until his or her death, resignation or
removal in accordance with law and our governing documents, including our Amended and Restated Memorandum and Articles of Association
(the &#8220;Articles&#8221;), which went into effect upon the Closing of the Business Combination.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following sets forth certain information
known as of the date hereof concerning the persons who currently serve as directors and executive officers of New Silexion (who have served
as such since the consummation of the Business Combination):</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z38579b82743b4bf19195dc9e7a65619a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: #000000 2px solid; width: 43.99%; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Name</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 8%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Age</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 46%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Position(s)</div> </td>
        </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Directors</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Ilan Hadar</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">55</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Chairman and Chief Executive Officer</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Dror J.&#160;Abramov</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">63</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Director</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Ruth Alon</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">72</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Director</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Ilan Levin</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">58</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Director</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Avner Lushi</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">57</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Director</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Shlomo Noy</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">71</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Director</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Executive&#160;Officers&#160;(who&#160;are&#160;not&#160;also&#160;directors)</div>
        </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Dr.&#160;Mitchell Shirvan</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">70</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Chief Scientific and Development Officer</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Mirit Horenshtein Hadar, CPA</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">40</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">EVP of Finance Affairs, Chief Financial Officer and Secretary</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Directors</div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman,Times,serif">Ilan Hadar</span><span style="font-family: Times New Roman,Times,serif">,&#160;55,<span style="font-weight: bold">&#160;</span>was
appointed as Chief Executive Officer of New Silexion, serving on a full-time&#160;basis, effective upon the Business Combination, and
has served as our (previously, Silexion&#8217;s) Chairman of the Board since May 2024. Previously, he served as Managing Director of Silexion
from April 2022 until the Business Combination. Mr. Hadar has over 20&#160;years of multinational managerial and corporate experience
with pharmaceutical and high-tech&#160;companies, as described below, over which time period he has acquired the experience and skills
to serve as a valuable member of the board of directors of a company such as Biomotion Sciences. In addition to his current role at Silexion,
Mr.&#160;Hadar has served as the Chief Executive Officer of Painreform Ltd (Nasdaq: PRFX) since November&#160;2020, a position he will
relinquish following the consummation of the Business Combination. Prior to joining Painreform and Silexion, Mr.&#160;Hadar served as
Country Manager Israel and Chief Financial Officer at Foamix Pharmaceuticals Ltd. (currently, Nasdaq: VYNE) from 2014 until August&#160;2020,
where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., and also focused on capital
markets and mergers and acquisitions. Prior to his role at Foamix, Mr.&#160;Hadar was Finance Director at Pfizer PFR Pharmaceuticals Israel
Ltd., where he oversaw all commercial, financial and operational activities of the local entity of the large pharmaceutical company. Before
his tenure at Pfizer, Mr.&#160;Hadar served as Finance Manager at HP Indigo Ltd., a world-leading&#160;company in digital printing and,
prior to that, served as Finance Director at BAE Systems, the third-largest&#160;defense company in the world, where he was responsible
for all financial activities of BAE Systems Israel. From 1998 to 2006, Mr.&#160;Hadar was Chief Financial Officer at Mango DSP, a global
leader of Intelligent Video Solutions. Mr.&#160;Hadar served on the board of directors of Kadimastem, a public Israeli biopharmaceutical
company from 2019 to 2022. He received his MBA in Finance and Business Entrepreneurship and BA from The Hebrew University in Jerusalem,
Israel. We believe Mr.&#160;Hadar is qualified to serve on our board of directors due to his extensive knowledge as Silexion&#8217;s Managing
Director, and his extensive commercial, financial and managerial experience with high-tech&#160;and pharmaceutical companies, both private
and public.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">106</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman,Times,serif">Dror J.&#160;Abramov,&#160;</span><span style="font-family: Times New Roman,Times,serif">63,
was appointed as a director of New Silexion effective upon the consummation of the Business Combination. Mr.&#160;Abramov&#8217;s experience
of over 15 years in multiple roles in changing and growing companies and markets within dynamic environments, and in particular his multi-disciplinary&#160;experience
in R&amp;D, consulting, taxes, sales, business development, finance and government, lend to his being an appropriate board member of Biomotion
Sciences. Mr.&#160;Abramov has served as Managing Director of Hewlett Packard Inc. Israel since 2015. Mr.&#160;Abramov held several other
management positions in Hewlett Packard Inc. Israel from 2006 to 2015, including finance director, general manager of imaging and printing
divisions and general manager of printing and personal systems division. From 2002 through 2006, Mr.&#160;Abramov served as Chief Financial
Officer of Applied Materials UK and Applied Materials Israel, both part of Applied Materials, Inc. (Nasdaq: AMAT), a nanomanufacturing
company that supplies equipment, services and software for the manufacture of semiconductor chips for electronics. From 2000 through 2002,
Mr.&#160;Abramov served as Vice President of business management at Avaya Communication, a cloud communications and workstream collaboration
technology company. From 1997 until 2000, Mr.&#160;Abramov held positions in Mainsoft Corporation, first as director of finance and operations
and later as general manager. From 1991 through 1997, Mr.&#160;Abramov served as consultant and manager at Maron, Sobel, Shor &amp; Co.,
an Israeli CPA firm. Mr.&#160;Abramov is a licensed CPA and holds a Bachelor of Accounting, Master of Business Administration and Bachelor
of Science in physics and computer sciences, all three degrees from Tel Aviv University. We believe Mr.&#160;Abramov is qualified to serve
on our board of directors due to his extensive financial and business management experience.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold">Ruth Alon</span>,&#160;72,<span style="font-weight: bold">&#160;</span>became
a director of New Silexion effective upon the consummation of the Business Combination. Ms. Alon&#8217;s international experience of over
30 years in the high-tech&#160;medical industry and with Israeli life sciences companies, in particular, make her a prospective valuable
member of the board of directors of Biomotion Sciences. Ms. Alon is the Founder and Chief Executive Officer of Medstrada, which was started
in 2016. From 1997 until 2016, Ms. Alon served as a General Partner in Pitango Venture Capital, where she headed the life sciences activities
and helped to facilitate the acquisition of several of the company&#8217;sportfolio companies. Currently, Ms. Alon also serves on the
board of directors of a number of private and public companies as a member or chairperson, including Vascular Biogenics Ltd. (Nasdaq:
VBLT), Brainsgate and KadimaStem. Ms. Alon previously worked on Wall Street where she held senior positions as a senior medical device
analyst with Montgomery Securities (from 1981 to 1987) and Kidder Peabody&#160;&amp; Co. (from 1987 to 1993). She also managed her own
independent consulting business in San Francisco from 1995 to 1996, providing broad-based&#160;services to early-stage&#160;companies
and venture capitalists in the medical devices industry. Ms. Alon was also instrumental in the establishment, in 2005, of Israel Life
Science Industry (ILSI), a not-for-profit&#160;organization which represented, as of 2005, the mutual goals of approximately 700 Israeli
life science companies. She is the Co-Founder&#160;of IATI, an umbrella organization established in 2012, representing Israel&#8217;s
High Tech and Life Sciences industries. Ms. Alon holds a B.A. in Economics from the Hebrew University of Jerusalem, an M.B.A. from Boston
University, and an M.Sc. from the Columbia University School of Physicians and Surgeons. We believe Ms. Alon is qualified to serve on
our board of directors given her above-described&#160;extensive experience in the high-tech&#160;medical industry and with Israeli life
sciences companies, in particular.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman,Times,serif">Ilan Levin</span><span style="font-family: Times New Roman,Times,serif">,&#160;58,<span style="font-weight: bold; font-style: italic">&#160;</span>who
was the co-founder, Chairman and Chief Executive Officer of Moringa, was appointed as a director of New Silexion after its formation in
April 2024 and has continued as a director following the consummation of the Business Combination. Mr.&#160;Levin has been involved, for
approximately 25&#160;years, as an executive and venture capital/private equity investor in high-tech, Israel-related&#160;ventures. His
experience as an executive and board member in managing growth companies that develop technology, and his knowledge of that industry in
Israel in particular, suit him well to serve as a director of Biomotion Sciences. From 2000 to 2018, Mr.&#160;Levin was a member of the
Board and Executive Committee of Objet Ltd., which as a result of a merger with Stratasys, Inc. in 2012, formed Stratasys Ltd. (Nasdaq:
SSYS), the pioneer and global leader in 3D printing. During his tenure at Objet/Stratasys, Mr.&#160;Levin held various positions including
President, Vice Chairman and from 2016 to 2018, Chief Executive Officer. From 2004 to 2009, Mr.&#160;Levin was the Chief Executive Officer
of CellGuide, a developer of software-based&#160;GPS for mobile devices. Since 1997, Mr.&#160;Levin has also served as a member of the
board of directors and as an advisor for a wide variety of Israel-based&#160;technology-related&#160;companies, including currently serving
as Chairman of Vision Sigma (TLV:&#160;VISN: IT), an Israel-based&#160;real estate and investment company. Early in his career, Mr.&#160;Levin
was a practicing attorney focusing on corporate and securities related matters. In addition to his role as our Chairman and Chief Executive
Officer, Mr.&#160;Levin also serves as the sole director and sole equity owner of an Israeli company that serves as the sole general partner
of the Sponsor. Mr.&#160;Levin earned an LL.B. from Tel Aviv University and a B.A.Sc. in Industrial Engineering from the University of
Toronto. We believe Mr.&#160;Levin is qualified to serve on our board of directors given his above-described&#160;experience in managing
growth companies that develop technology, and his knowledge of that industry in Israel in particular.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">107</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman,Times,serif">Avner Lushi</span><span style="font-family: Times New Roman,Times,serif">,&#160;57,<span style="font-weight: bold">&#160;</span>was
appointed as a director of New Silexion effective upon the consummation of the Business Combination. His experience of over 20 years and
skills acquired in his managing roles at an Israeli life sciences venture capital fund and in life sciences investment banking make him
suitable to provide similar support as a member of the board of directors of Biomotion Sciences. Mr.&#160;Lushi co-founded&#160;Guangzhou
Sino-Israel&#160;Bio-industry Investment Fund (GIBF), which currently includes two approximately $100&#160;million funds focused on introducing
Israeli and other foreign companies in the field of life sciences to the Chinese market, in which he also serves as a Managing Partner&#160;&amp;
CEO of the GP since 2016. From 2004 to 2015, Mr.&#160;Lushi served as a Partner and Managing Director of Israel Healthcare Ventures (IHCV),
a prominent Israeli life sciences venture capital fund. Before joining IHCV, Mr.&#160;Lushi was the Co-Founder&#160;&amp; CEO of Life
Sciences Transaction Support Ltd. (LTS), a PwC subsidiary dealing with life sciences investment banking. Since 2005, Mr.&#160;Lushi has
served as an independent director on the boards of nine public companies, including, currently, Brainsway Ltd. (Nasdaq: BWAY) and Ginegar
Plastic Products Ltd. In addition, he serves as a board member of several private companies as part of his role at GIBF.&#160;From 1997
to 2001, prior to turning to the private sector, he held increasingly senior roles within the Israeli Prime Minister&#8217;s Chamber and
the Israeli Supreme Court. Mr.&#160;Lushi holds an LLM in Law from the Hebrew University of Jerusalem, LLB in Law and a BA in Economics
from the Haifa University. We believe Mr.&#160;Lushi is qualified to serve on our board of directors due to his extensive executive and
board experience with life sciences companies.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman,Times,serif">Shlomo Noy</span><span style="font-family: Times New Roman,Times,serif">,
MD PhD,&#160;71,<span style="font-weight: bold">&#160;</span>was appointed as a director of New Silexion effective upon the consummation
of the Business Combination. Professor Noy&#8217;s international-level&#160;expertise in healthcare management, tech transfer, building
ecosystems and focusing hospitals on research and clinical trials will provide important knowledge to the Biomotion Sciences board of
directors in the realm of Israeli research and clinical trial activities. Professor Noy has served as Chief Medical Officer of GIBF since
January&#160;2017. Professor&#160;Noy served as the Director of&#160;the Rehabilitation Hospital at Sheba Medical Center from 1993 to
2017 and Vice President of Research and Development and Academic Affairs at Sheba Medical Center from 2000 to 2017. Prof. Noy was a Professor
at Sackler School of Medicine at Tel-Aviv&#160;University from 1993 to 2016. Prof.&#160;Noy serves as a board member of several private
companies as part of his role at GIBF. Prof. Noy&#160;possesses 25&#160;years&#8217; experience in health care management and is active
in promoting research and education at an Israeli national level as well as at an international level. Prof. Noy received his MD from
the Hebrew University, Hadassah Medical School, Jerusalem, Israel, and completed his MBA at the European School of Business Administration
(INSEAD) Fontainebleau, France, and holds a PhD degree from Tel-Aviv&#160;University, Faculty of Medicine and Management. We believe Mr.&#160;Noy
is qualified to serve on our board of directors due to his extensive medical and health care management experience.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;<span style="font-style: italic">&#160;</span></div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Executive Officers</div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman,Times,serif">Mitchell Shirvan</span><span style="font-family: Times New Roman,Times,serif">,&#160;70,
has served as the Chief Scientific and Development Officer of New Silexion since the Business Combination, and, before the Business Combination,
of Silexion, since April&#160;2022. Prior to joining Silexion, Dr.&#160;Shirvan served as the Senior Vice President of R&amp;D and&#160;V.P.&#160;Innovation
and Discovery at Foamix Pharmaceuticals Ltd. from 2014 to 2019. Dr.&#160;Shirvan has over 25&#160;years of industry experience, previously
holding positions as Chief Executive Officer at Macrocure Ltd. from 2008 to 2012. From 1992 until 2008, Dr.&#160;Shirvan held various
positions of increasing responsibility at Teva Pharmaceutical Industries, including Senior Director, Strategic Business Planning and Senior
Manager, Research&#160;&amp; Development. Prior to his tenure at Teva, he was a research fellow at the U.S.&#160;National Institutes of
Health. Dr.&#160;Shirvan holds a Ph.D. in microbiology from The Hebrew University of Jerusalem and an MBA from the University of Bradford.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman,Times,serif">Mirit Horenshtein
Hadar</span><span style="font-family: Times New Roman,Times,serif">,&#160;40, has served as the Chief Financial Officer and Secretary
of New Silexion since the Business Combination, and served as the Executive Vice President of Finance Affairs at Silexion before the Business
Combination, beginning in January&#160;2024. From August 2023 to January 2024, Ms. Horenshtein Hadar served as a part-time&#160;consultant
in a Strategy &amp; Corporate Finance Advisory capacity. Ms. Horenshtein Hadar has over 15&#160;years of corporate finance experience
in senior financial positions of public companies and privately held companies, in the pharmaceutical and high-tech&#160;industries, where
she has been instrumental in building financial infrastructures for growth, U.S. GAAP financial reporting and FP&amp;A functions, and
has led the accounting and reporting of complex M&amp;A transactions, integration processes and public offerings. Prior to joining Silexion,
from January&#160;2021 to December&#160;2022, Ms. Horenshtein Hadar served as VP of Finance and then CFO Israel of Gauzy Ltd. (currently,
Nasdaq: GAUZ), a nanotechnology company that develops and markets smart glass and vision control technologies. Since December&#160;2022,
Ms. Horenshtein Hadar continues to serve as an external advisor to the finance department at Gauzy. Prior to Gauzy, Ms. Horenshtein Hadar
served as Senior Director of Finance and Head of FP&amp;A, Accounting and Financial Reporting at Foamix Pharmaceuticals Ltd. (currently,
Nasdaq: VYNE) from July&#160;2016 until December&#160;2020. Prior to Foamix, Ms. Horenshtein Hadar was a Senior Manager at PwC Israel,
as an external auditor, from 2008 to 2016. Ms. Horenshtein Hadar became a Qualified CPA in 2011 and received a BA in Accounting, Economics
and Business Management from Tel Aviv University.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">108</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Family Relationships</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Mirit Horenshtein Hadar and Ilan Hadar are
married to one another. There are no other family relationships between the individuals who serve as directors and executive officers
of the Company.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Corporate Governance Practices</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Overall</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company does not qualify as a &#8220;foreign
private issuer&#8221; under U.S.&#160;securities laws and is therefore not currently eligible to exempt itself from any of the Nasdaq
listing rule requirements in a manner that other non-U.S.&#160;issuers often do.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Composition of the New
Silexion Board After the Business Combination</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">New Silexion&#8217;s business and affairs
are managed under the direction of the New Silexion Board. Under the terms of the Articles, the New Silexion Board may be composed of
between three and nine directors, as may be amended from time to time exclusively by ordinary resolution under Cayman Islands law, being
a resolution passed by a simple majority of the shareholders of New Silexion as, being entitled to do so, vote in person or by proxy at
a general meeting (an &#8220;<span style="font-weight: bold">Ordinary Resolution</span>&#8221;). The size of the New Silexion Board was
set by our shareholders as seven members effective upon the Closing. Ilan Hadar serves as Chairman of the New Silexion Board. Subsequent
to the Closing, Ilan Shiloah stepped down from the Board, citing competing demands on his time, thereby leaving the current size of the
Board as six members.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">Pursuant to the Articles, New Silexion&#8217;s directors are appointed by an Ordinary Resolution at an
annual general meeting. Unless the Board resolves that the election of nominees of the Board (referred to as &#8220;<span style="font-weight: bold">Nominees</span>&#8221;)
or of nominees of any shareholders entitled to present such nomination (referred to as &#8220;<span style="font-weight: bold">Alternate
Nominees</span>&#8221;) will be determined by plurality vote, the Nominees or Alternate Nominees shall be appointed by Ordinary Resolution
at the annual general meeting at which they are proposed for election.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Officers</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">New Silexion&#8217;s Chief Executive Officer
is responsible for the company&#8217;s&#160;day-to-day&#160;management. The Chief Executive Officer is appointed by, and serves at the
discretion of, the New Silexion Board, subject to his employment agreement. All other executive officers are proposed for appointment
by the Chief Executive Officer, subject to approval by the New Silexion Board, and will be subject to the terms of any applicable employment
or consulting agreements that Silexion may enter into with them.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Director Independence</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Nasdaq listing standards require that a majority
of the New Silexion Board be independent. An &#8220;independent director&#8221; is defined generally as a person who has no material relationship
with the listed company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the listed
company) that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making
these determinations, the New Silexion Board considers the current and prior relationships that each non-employee director has with the
Company and all other facts and circumstances the New Silexion Board deems relevant in determining their independence, including the beneficial
ownership of our securities by each non-employee&#160;director and the transactions described in the section titled &#8220;<span style="font-style: italic">Certain
Relationships and Related Party Transactions</span>.&#8221;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The New Silexion Board has determined that
each of Messrs. Dror J. Abramov, Ilan Levin, Avner Lushi and Shlomo Noy, and Ms. Ruth Alon, meets the definition of &#8220;independent
director&#8221; as defined in Nasdaq listing standards. For purposes of SEC rules applicable to members of the audit committee and compensation
committee, each of Mr. Abramov and Ms. Alon are deemed independent.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">109</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Board Committees</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The New Silexion Board has established an
audit committee, a compensation committee and a nominating and corporate governance committee, each of which has the composition and the
responsibilities described below. Each of these committees operates under a written charter, approved by the New Silexion Board and effective
upon the Closing, that satisfies the applicable Nasdaq rules, copies of which are available on the investor relations portion of our website.
Members will serve on these committees until their resignation or until otherwise determined by the New Silexion Board. The New Silexion
Board may establish other committees as it deems necessary or appropriate from time to time.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Audit Committee</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our audit committee consists of Dror&#160;J.
Abramov and Ruth Alon, with Mr.&#160;Abramov serving as chair. Ilan Shiloah had served as the third member of the audit committee from
the Closing until his resignation from the New Silexion Board on September 16, 2024. Rule&#160;10A-3&#160;of the Exchange&#160;Act and
the Nasdaq listing standards require that our audit committee be composed entirely of independent members. The Nasdaq listing standards
require that the audit committee be composed of at least three members. With the resignation of Mr. Siloah from the New Silexion Board
and its audit committee, we will have until the earlier of our 2025 annual general meeting or one year after Mr. Shiloah&#8217;s resignation
to restore the size of the audit committee to three members. The New Silexion Board has determined that each of Mr. Abramov and Ms. Alon
meets the definition of &#8220;independent director&#8221; for purposes of serving on the audit committee under Rule&#160;10A-3&#160;of
the Exchange&#160;Act and the Nasdaq listing standards and also meets the financial literacy requirements of the Nasdaq listing standards.
In addition, the New Silexion Board has determined that Mr.&#160;Abramov qualifies as an &#8220;audit committee financial expert&#8221;
within the meaning of the SEC regulations.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The primary purpose of the audit committee
is to discharge the responsibilities of the New Silexion Board with respect to our corporate accounting and financial reporting processes,
systems of internal control and financial statement audits and to oversee our independent registered public accounting firm. The principal
functions of the audit committee include, among other things:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9097d7be7db3435785b2ce03eaa9992a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">helping the New Silexion Board oversee our corporate accounting
        and financial reporting processes;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">110</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="z861746bb0b4d4472890438d4b872976c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">managing the selection, engagement, qualifications, independence,
        and performance of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zeb78c03ae18b44708f6987ab3efed940" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">reviewing and discussing the scope and results of the audit with
        the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end&#160;operating
        results;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze7f4b14b20ff4606aa0e37052cc6022c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">obtaining and reviewing a report by the independent registered
        public accounting firm at least annually that describes our internal quality control procedures, any material issues with such procedures
        and any steps taken to deal with such issues when required by applicable law;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbacafa00026547878185f98d86ab4c19" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">establishing procedures for employees to submit concerns anonymously
        about questionable accounting or audit matters;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z58f04559fc3a43b9bda663ed05c9bd4d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">overseeing our policies on risk assessment and risk management;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1ed43727d6174fe99a74f86f68088aa2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">overseeing compliance with our code of business conduct and ethics;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc60acbed6fce473487013bef822296e0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">reviewing related person transactions; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0b850dd1d4d3484b9572c78b9553a0a5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">approving or, as required, pre-approving&#160;audit and permissible
        non-audit&#160;services to be performed by the independent registered public accounting firm.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Compensation Committee</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our compensation committee consists of Dror
J. Abramov and Ruth Alon. The chair of the compensation committee will be chosen from among the committee&#8217;s members. The New Silexion
Board has determined that each of Mr.&#160;Abramov and Ms. Alon meets the definition of &#8220;independent director&#8221; for purposes
of serving on the compensation committee under the Nasdaq listing standards, including the heightened independence standards for members
of a compensation committee.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The primary purpose of our compensation committee
is to discharge the responsibilities of the New Silexion Board in overseeing our compensation policies, plans and programs and to review
and determine the compensation to be paid to our executive officers, directors and other senior management, as appropriate. The principal
functions of the compensation committee include, among other things:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf1b59ab9a6e1453ca90625606a3be881" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">reviewing, approving and determining, or making recommendations
        to the New Silexion Board regarding the compensation of our chief executive officer, other executive officers and senior management;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z54ebd187c94c4941b9fb81d2c7d0ecd5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">reviewing, evaluating and recommending to the New Silexion Board
        succession plans for our executive officers;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb1f63e5f8fad4c54b0c375494d7f4bc5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">reviewing and recommending to the New Silexion Board the compensation
        paid to our non-employee&#160;directors;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z17b20258efc748909326f44044ea699d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">administering our equity incentive plans and other benefit programs;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zec03f6075b44422fa4dc3de384ab88eb" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">reviewing, adopting, amending and terminating incentive compensation
        and equity plans, severance agreements, profit sharing plans, bonus plans, change-of-control&#160;protections and any other compensatory
        arrangements for our executive officers and other senior management; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaf6370aaef4a42d4a7bfd3fd1cd78396" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">reviewing and establishing general policies relating to compensation
        and benefits of our employees, including our overall compensation philosophy.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">111</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold"> <span style="font-family: Times New Roman,Times,serif"><br/> </span>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Corporate Governance and
Nominating Committee</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We have appointed a corporate governance and
nominating committee that currently consists of Dror J. Abramov, Ilan Levin and Ruth Alon. The chair of the committee will be chosen from
among the committee&#8217;s members. The New Silexion Board has determined that each of Messrs. Abramov and Levin, and Ms. Alon, meets
the definition of &#8220;independent director&#8221; under the Nasdaq listing standards.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our corporate governance and nominating committee
is responsible for, among other things:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf8302c0e876a440f80d7e0012d679246" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">identifying and evaluating candidates, including the nomination
        of incumbent directors for reelection and nominees recommended by shareholders, to serve on the New Silexion Board;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7b4496a5d1d5446cb9645f601d319454" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">considering and making recommendations to the New Silexion Board
        regarding the composition and chairmanship of the committees of the New Silexion Board;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z26fabef288724e8ca0ee376c67630eba" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">instituting plans or programs for the continuing education of
        the New Silexion Board and the orientation of new directors;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z90ae751f13554c7c824da7e7d5644f06" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">developing and making recommendations to the New Silexion Board
        regarding corporate governance guidelines and matters;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb1ed06d8d80545b28a94eee4837814bf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">overseeing our corporate governance practices;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z65062a11e51c43bbb48bdd3558309060" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">overseeing periodic evaluations of the New Silexion Board&#8217;s
        performance, including committees of the New Silexion Board; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6112659489ea42579537598450d98f39" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">contributing to succession planning.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Compensation Committee
Interlocks and Insider Participation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">None of the members of Silexion&#8217;s compensation
committee is currently, or has been at any time, one of Silexion&#8217;s, Moringa&#8217;s or Silexion&#8217;s executive officers or employees.
None of our executive officers serves as a member of the board of directors or compensation committee (or other committee performing equivalent
functions) of any entity that had one or more executive officers serving on our board of directors or compensation committee during 2023.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Code of Business Conduct
and Ethics</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Prior to the completion of the Business Combination,
we adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A
copy of the code is posted on the investor relations portion of our website. In addition, we intend to post on our website all disclosures
that are required by law or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the code.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="EXECUTIVECOMPENSATION"><!--Anchor--></span>EXECUTIVE
COMPENSATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;<span style="font-weight: bold">Silexion</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Unless the context requires
otherwise, references in this &#8220;Executive Compensation&#8221; section to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and
the &#8220;Company&#8221; generally refer to our wholly-owned subsidiary, Silexion Therapeutics Ltd., an Israeli company (&#8220;Silexion&#8221;),
and its subsidiaries.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">112</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Overview</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following tables and accompanying narrative
set forth information about the compensation, for 2023, provided to Silexion&#8217;s chief executive officer (or person serving in an
equivalent position) and the two most highly compensated executive officers of Silexion (other than its chief executive officer) who were
serving as executive officers as of December&#160;31, 2023, each of whom serves as an executive officer of New Silexion currently. These
executive officers consist of: Ilan Hadar, Silexion&#8217;s Managing Director, who now serves as New Silexion&#8217;s Chairman and Chief
Executive Officer; Mirit Horenshtein Hadar, Silexion&#8217;s EVP Finance, who now serves as New Silexion&#8217;s Chief Financial Officer;
and Dr.&#160;Mitchell Shirvan, Silexion&#8217;s (and now New Silexion&#8217;s) Chief Scientific and Development Officer. These executive
officers are referred to in this section as our &#8220;named executive officers&#8221; or &#8220;NEOs.&#8221;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">This discussion may contain forward-looking&#160;statements
that are based on our current plans, considerations, expectations and determinations regarding future compensation programs, in the period
immediately following the Business Combination. Actual compensation programs that we adopt in the future may differ materially from the
plans summarized in this discussion.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Summary Compensation Table</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table presents summary information
regarding the total compensation for services rendered in all capacities that was awarded to, earned by, or paid to Silexion&#8217;s named
executive officers for 2023.</div>

<div style="text-indent: -36pt; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z638c92b5608745e584cf047c396800e1" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Name and Principal Position</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Base Gross<br/> Salary<br/>
        ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Option<br/> Awards<br/>
        ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">All Other<br/> Compensation<br/>
        ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)(2)</sup></div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Total<br/> ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; text-indent: -9pt; margin-left: 9pt"><span style="font-family: Times New Roman,Times,serif">Ilan Hadar<br/>
        </span> <span style="font-style: italic; font-family: Times New Roman,Times,serif">Managing Director</span><span style="font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></span></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">182,976</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">0</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">70,638</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">253,614</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 45.49%">
        <div style="line-height: 1.25; text-indent: -9pt; margin-left: 9pt"><span style="font-family: Times New Roman,Times,serif">Mirit Horenshtein
        Hadar<br/> </span> <span style="font-style: italic; font-family: Times New Roman,Times,serif">EVP Finance</span><span style="font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup></span></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.21%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">26,238</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: middle; width: 1.12%; font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#1474;&#1474;</sup><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#1474;&#1473;&#1474;(5)</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.21%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">0</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.21%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.21%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">26,238</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 45.49%">
        <div style="line-height: 1.25; text-indent: -9pt; margin-left: 9pt"><span style="font-family: Times New Roman,Times,serif">Dr.&#160;Mitchell
        Shirvan<br/> </span> <span style="font-style: italic; font-family: Times New Roman,Times,serif">Chief Scientific and Development Officer</span><span style="font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(6)</sup></span></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.12%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.21%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">156,140</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.12%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.21%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">0</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.12%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.21%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">50,660</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.12%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.21%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">206,800</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.12%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8274e4415ab747faaa0e2af4b1cd92c2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(1)</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Amounts reported for the named executive officer and paid in
        New Israeli Shekels are converted from New Israeli Shekels to U.S.&#160;dollars using the 2023 average exchange rate as published by Bank
        of Israel of 3.689 New Israeli Shekels to 1 U.S.&#160;Dollar.</div> </td> </tr>
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(2)</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The amounts in this column include payments for a leased car
        or car maintenance, contributions to a pension fund, compensation fund, and continuing education fund, or payments in lieu of a continuing
        education fund.</div> </td> </tr>
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(3)</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">This was for a part-time&#160;(75%) position.</div> </td> </tr>
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(4)</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">This was for a part-time&#160;(75%) position.</div> </td> </tr>
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(5)</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">This amount reflects a salary of 4.5&#160;months during 2023,
        during which time Ms. Horenshtein Hadar served as a part-time&#160;consultant in a Strategy &amp; Corporate Finance Advisory capacity.</div>
        </td> </tr>
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(6)</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">This was for a part-time&#160;(80%) position.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Narrative Disclosure to Summary Compensation
Table</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Base Salary</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The named executive officers receive base
salaries to compensate them for services rendered to us. The base gross salary payable to each named executive officer is intended to
provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role, and responsibilities. The annual
base salaries for Ilan Hadar, Mirit Hornstein Hadar and Dr.&#160;Mitchell Shirvan, for 2023 were $253,614, $26,238, and $206,800, respectively.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">113</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Equity Compensation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: normal">From time to time, we
have granted equity awards under the Silexion Therapeutics Ltd. 2013 Equity Incentive Plan, which was replaced by the Silexion Therapeutics
Ltd. 2023 Equity Incentive Plan (the &#8220;2013 Plan&#8221; and &#8220;2023 Plan&#8221;, respectively, collectively referred to as the
&#8220;Silexion Plan&#8221;), as incentives to attract, retain and motivate our named executive officers. During 2022, we granted Ilan
Hadar and Dr.&#160;Mitchell Shirvan 32,400 options and 16,200 options, respectively.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The vesting of options granted to Ilan Hadar
and Dr.&#160;Mitchell Shirvan occurs over a period of 48&#160;months, provided that Ilan Hadar or Dr.&#160;Mitchell Shirvan, as applicable,
remain engaged by Silexion (or a Silexion affiliate) and subject to the Silexion<span style="font-weight: bold">&#160;</span>Plan. Upon
consummation of an initial public offering of Silexion&#8217;s securities or an M&amp;A Transaction (as defined in Silexion&#8217;s articles
of association), which included the Business Combination, the vesting of those options was to accelerate, such that all unvested options
immediately vest, provided that such IPO or M&amp;A Transaction was to be consummated after January&#160;1, 2023.</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Employment Agreements</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Following the Closing, Silexion has entered
or will enter into employment agreements with each of its NEOs.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Silexion 2013 Equity Incentive
Plan and Silexion 2023 Equity Incentive Plan</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Silexion has maintained the Silexion Plan
in order to provide additional incentives for employees, directors and consultants of Silexion, and to provide incentives to attract,
retain and motivate eligible persons whose present and potential contributions are important to Silexion&#8217;s success. The 2013 Plan
was adopted on July&#160;25, 2013 and was replaced by the 2023 Plan, which was adopted on April&#160;4, 2023. For a complete description
of the 2013 Plan and the 2023 Plan, please see &#8220;<span style="font-style: italic">Silexion Share Incentive Plans</span>&#8221; below.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Silexion Plan provides for grants of options
to purchase ordinary shares of Silexion, shares, restricted shares and restricted share units. As described above, during 2022, Silexion
granted option awards under the Silexion Plan to Ilan Hadar and Dr.&#160;Mitchell Shirvan.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Immediately prior to the effective time of
the Acquisition Merger, all outstanding Silexion options accelerated and became fully vested. At the effective time of the Acquisition
Merger, all Silexion options outstanding immediately prior to the Acquisition Merger automatically and without any action on the part
of any Silexion option holder or beneficiary thereof, were assumed by New Silexion, and each such Silexion option was converted into an
option to purchase New Silexion ordinary shares (based on the equity exchange ratio for Silexion under the Business Combination Agreement).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, immediately prior to the completion
of the Business Combination, New Silexion adopted the 2024 Equity Incentive Plan (described below), which provides for the grant of equity-based&#160;incentive
awards to its employees, directors, office holders, service providers and consultants in order to incentivize them to increase their efforts
on behalf of New Silexion and to promote the success of New Silexion&#8217;s business.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">114</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Outstanding Equity Awards at Fiscal Year-End</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table provides information regarding
equity awards held by Silexion&#8217;s named executive officers that were outstanding as of December&#160;31, 2023. The award listed in
this table was granted under the Silexion Plan, which is summarized above under &#8220;<span style="font-style: italic">&#8212;&#160;Narrative
Disclosure to Summary Compensation Table&#160;&#8212;&#160;Silexion 2013 Equity Incentive Plan and Silexion 2023 Equity Incentive Plan</span>.&#8221;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z033068f7ffe0458c8201af6e41f0de23" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Option Awards</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Name</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Equity<br/> Incentive<br/>
        Plan Awards:<br/> Number of<br/> Unearned<br/> Shares,<br/> Units or<br/> Other Rights<br/> That Have<br/> Not Vested<br/> (#)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Equity<br/> Incentive<br/>
        Plan Awards:<br/> Market Value of<br/> Unearned<br/> Shares.<br/> Units or<br/> Other Rights<br/> That Have<br/> Not Vested<br/>
        ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Ilan Hadar</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">32,400</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Dr.&#160;Mitchell Shirvan</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">16,200</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb3b7dde3d85b4d7a8b61e2e57b833f4b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(1)</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">See details under &#8220;<span style="font-style: italic">Equity
        Compensation&#8221; section above.</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Director Compensation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the year ended December&#160;31, 2023,
we did not pay any fees to, or make any equity or non-equity&#160;awards to, or pay any other compensation to the non-employee&#160;members
of our board of directors for their services as directors.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">New Silexion Executive Compensation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Following the Closing, we intend to develop
an executive compensation program that is designed to align compensation with New Silexion&#8217;s business objectives and the creation
of shareholder value, while enabling New Silexion to attract, retain, incentivize and reward individuals who contribute to the long-term&#160;success
of New Silexion. Decisions regarding the executive compensation program will be made by our compensation committee.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">New Silexion Equity Compensation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">It is anticipated that equity-based&#160;compensation
will continue to be an important element of executive compensation following the consummation of the Business Combination in order to
maintain a strong link between executive incentives and the creation of shareholder value. Upon the consummation of the Business Combination,
we granted 742,009 RSUs, in the aggregate, to directors of New Silexion and employees of New Silexion and its subsidiaries (of which 196,625
RSUs were granted to New Silexion directors) as a means of incentivizing them and aligning their interests with those of the shareholders
of the Company. We furthermore expect that the additional 607,241 New Silexion ordinary shares that will be available under the 2024 Equity
Incentive Plan (as referenced below) following the consummation of the Business Combination will be an important element of the new compensation
arrangements for New Silexion.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Silexion Share Incentive Plans</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">2013 Share Option Plan</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Shares Reserved
under the 2013 Share Option Plan.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">The total number
of authorized but unissued New Silexion ordinary shares available for issuance under Silexion&#8217;s 2013 Share Option Plan (the &#8220;<span style="font-weight: bold">2013
Plan</span>&#8221;) is 33,828. Any option which has expired or has been cancelled, without having been exercised in full, is available
again for issuance under the 2013 Plan. Upon the termination of the 2013 Plan, any unissued New Silexion ordinary shares available under
the 2013 Plan shall cease to be reserved for the purpose of the 2013 Plan, other than New Silexion ordinary shares underlying then-outstanding&#160;options
under the 2013 Plan.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Administration.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">Our
board of directors, or a duly authorized compensation committee of the board of directors, has the power to administer the 2013 Plan.
Subject to applicable laws and the relevant provisions of the 2013 Plan, any member of the designated committee is eligible to receive
options under the 2013 Plan. The committee has the authority, subject to applicable law and our articles of association, to interpret
the terms of the 2013 Plan and any option agreements granted thereunder, designate participants in the 2013 Plan, determine and amend
the terms of respective option agreements, including the exercise price of an option, the fair market value of the New Silexion ordinary
shares, the time and vesting schedule applicable to the option, accelerate or amend the vesting schedule applicable to an option, prescribe
the forms of option agreement for use under the 2013 Plan and take all other actions and make all other determinations necessary for the
administration of the 2013 Plan.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">115</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Eligibility.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">The
2013 Plan provides for granting options under various tax regimes, including, without limitation, in compliance with Section&#160;102
or Section&#160;3(i)&#160;of the Israeli Tax Ordinance (the &#8220;<span style="font-weight: bold">Ordinance</span>&#8221;), and for awards
granted to Silexion&#8217;s United&#160;States employees or service providers, including those who are deemed to be residents of the United&#160;States
for tax purposes, Section&#160;422 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;<span style="font-weight: bold">Code</span>&#8221;)
and Section&#160;409A of the Code.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;<span style="font-style: italic">&#160;</span></div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Options.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">All
options granted pursuant to the 2013 Plan are evidenced by an option agreement, in a form approved, from time to time, by the committee
in its sole discretion. The option agreement sets forth the terms and conditions of the number of shares to which the option relates and
the type of option granted thereunder, the purchase price per share and the vesting schedule to which such option shall become exercisable.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Unless otherwise determined by the committee
or the board of directors and as stated in the option agreement, and subject to the conditions of the 2013 Plan, options become exercisable
under the following schedule: 25% of the shares covered by the option on the first anniversary of the date on which such option was granted
and 12.5% of the shares covered by the option at the end of each subsequent six-month&#160;period during the second, third and fourth&#160;years
from the date of grant, with the committee and/or board of directors reserving the exclusive authority to accelerate the periods for exercising
an option.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Each option shall expire after ten&#160;years
from the date of the grant thereof, or five&#160;years with respect to incentive stock options unless a shorter term of expiration is
otherwise designated by the committee.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Grants.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">The
2013 Plan provides for the grant of options (including incentive stock options and nonqualified stock options).</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Options granted under the 2013 Plan to Silexion
employees who are U.S.&#160;residents may qualify as &#8220;incentive stock options&#8221; within the meaning of Section&#160;422 of the
Code, or may be non-qualified&#160;stock options. The exercise price of an option may not be less than the par value of the shares (if
the shares bear a par value) for which such option is exercisable. The exercise price of an Incentive Stock Option may not be less than
100% of the fair market value of the underlying share on the date of grant or such other amount as may be required pursuant to the Code,
and in the case of Incentive Stock Options granted to ten percent (10%) shareholders, not less than 110%.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Exercise.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">An
option under the 2013 Plan may be exercised by providing us with a written notice of exercise and full payment of the exercise price for
such shares underlying the award, if applicable, in such form and method as may be determined by the committee and the trustee and permitted
by applicable law.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Transferability.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">No
option shall be assignable, transferable or given as collateral or any right with respect to them given to any third party whatsoever,
and during the lifetime of the option-holder&#160;each and all of such option-holder&#8217;s rights to purchase New Silexion ordinary
shares thereunder shall be exercisable only by the option-holder.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Termination
of Employment.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">An option may be exercised after the
date of termination of option-holder&#8217;s service or employment with Silexion or any of its affiliates or termination of an affiliate&#8217;s
status as such only with respect to the number of options already vested and unexpired at the time of such termination according to the
vesting and expiration periods of the options set forth in the 2013 Plan, or under a different period prescribed by the committee or by
the board of directors and specified in relevant option agreement, provided however, that (i)&#160;such termination is without cause,
in which case the options shall be exercisable within not more than 90&#160;days from the effective date of such termination, or (ii)&#160;such
termination is the result of death or disability of the option-holder, in which case the options shall be exercisable within 12&#160;months,
and in the event of death, the option shall be exercisable by the option-holder&#8217;s estate, all in accordance the 2013 Plan. If termination
of employment or service is for cause, any outstanding unexercised option (whether vested or non-vested), will immediately expire and
terminate, and the option-holder&#160;shall not have any right in connection to such outstanding options.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">116</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Voting Rights.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">Option-holders&#160;shall
not have any of the rights or privileges of shareholders of New Silexion in respect of any New Silexion ordinary shares purchasable upon
the exercise of any part of an option unless and until, following exercise in accordance with the terms of the 2013 Plan and the option,
registration of the option-holder&#160;as holder of such New Silexion ordinary shares in New Silexion&#8217;s register of members, but
in case of options and New Silexion ordinary shares held by the trustee, subject to the provisions of the 2013 Plan.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;<span style="font-style: italic">&#160;</span></div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Dividends.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">With
respect to all New Silexion ordinary shares (in contrast to options not exercised for New Silexion ordinary shares) issued upon the exercise
of options purchased by an option holder, the option holder, as a shareholder of New Silexion shall be entitled to receive dividends in
accordance with the quantity of such New Silexion ordinary shares and the amended and restated memorandum and articles of association
of New Silexion, and subject to any applicable taxation on distribution of dividends.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Transactions.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">If
the outstanding shares of New Silexion shall at any time be changed or exchanged by declaration of a dividend, split, share subdivision,
combination or exchange of shares, recapitalization, or any other like event of New Silexion, then in such event only and as often as
the same shall occur, the number, class and kind of New Silexion ordinary shares (including New Silexion ordinary shares issuable pursuant
to the 2013 Plan, in respect of which options have not yet been exercised) subject to the 2013 Plan or subject to any options granted
thereunder, and the purchase prices of the options, shall be appropriately and equitably adjusted so as to maintain the proportionate
number of New Silexion ordinary shares without changing the aggregate purchase price of the options.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In the event of a merger or consolidation
of New Silexion or a sale of all, or substantially all, of our shares or assets or other transaction having a similar effect on New Silexion,
or change in the composition of the board of directors, or such other transaction or circumstances that the New Silexion Board determines
to be a relevant transaction, the merger agreement will provide for one or more of the following, without the consent of the option-holder:
(i)&#160;any outstanding option will be assumed or substituted by the successor corporation; (ii)&#160;the cancellation of such options
and a payment to the option-holder, as provided in the 2013 Plan; and (iii)&#160;the full exercisability of the option and full vesting
of the New Silexion ordinary shares subject to the option, followed by the cancellation of the option.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">2023 Equity Incentive
Plan</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The 2023 Equity Incentive (the&#160;<span style="font-weight: bold">&#8220;2023
Plan&#8221;</span>) was adopted by our board of directors in 2023. The purpose of the 2023 Plan is to provide equity-based&#160;incentive
awards in order to link the compensation and benefits of the individuals and entities providing services to Silexion or its affiliates
with the success of Silexion and long-term&#160;shareholder value. The 2023 Plan enabled Silexion to grant options to purchase ordinary
shares of Silexion (currently, following the Business Combination, New Silexion ordinary shares), restricted shares and restricted share
units, all of which are referred to as &#8220;awards&#8221;.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Shares Available for Grants.&#160;&#160;&#160;&#160;</span>The
total number of shares available for issuance under the 2023 Plan was determined from time to time by our board of directors, subject
to certain adjustments as described in the 2023 Plan. If any shares subject to awards under the 2023 Plan expires or otherwise terminates
in accordance with the terms thereunder, such shares shall become available for future grants thereunder.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Administration.&#160;&#160;&#160;&#160;</span>our board
of directors (currently, following the Business Combination, the board of directors of New Silexion), or a duly authorized committee of
its board of directors (the&#160;<span style="font-weight: bold">&#8220;Administrator&#8221;</span>), is authorized to administer the
2023 Plan. Under the 2023 Plan, the Administrator has the authority, subject to applicable law, to interpret the terms of the 2023 Plan
and any award agreements or awards granted thereunder, designate recipients of awards, determine and amend the terms of awards, including
the number of awards granted, the exercise price of an award, the time and vesting schedule applicable to an award or the method of payment
for an award, accelerate or amend the vesting schedule applicable to an award, prescribe the forms of agreement for use under the 2023
Plan and take all other actions and make all other determinations necessary for the administration of the 2023 Plan.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Administrator also has the authority to
determine the circumstances under which awards may be settled, cancelled, forfeited, exchanged, or surrendered under and in accordance
with the 2023 Plan of any or all awards or shares, and the authority to prescribe, amend and rescind rules and regulations relating to
the 2023 Plan, including the form of award agreements and rules governing the grant of awards in jurisdictions in which Silexion or any
affiliate operate, or to terminate the 2023 Plan at any time before the date of expiration of its ten-year&#160;term, provided that such
termination shall not materially affect the rights of grantees, to whom awards have already been granted.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">117</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Eligibility.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">The
2023 Plan provides for granting awards under the Israeli tax regime, including compliance with Section&#160;102 or Section&#160;3(i)&#160;of
the Ordinance.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Grants.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">All
awards granted pursuant to the 2023 Plan are evidenced by an award letter, in a form approved, from time to time, by the administrator
in its sole discretion. The award letter sets forth the terms and conditions of the award, including the type of award, number of shares
subject to such award, vesting schedule and conditions (including performance goals or measures) and the exercise price, if applicable.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Unless otherwise determined by the Administrator
and stated in the award letter, and subject to the conditions of the 2023 Plan, awards vest and become exercisable under the following
schedule: 25% of the shares covered by the award on the first anniversary of the vesting commencement date determined by the Administrator
(and in the absence of such determination, the date on which such award was granted) and the remaining 75% of the award shall vest (equally)
on a quarterly basis, over 12 quarters as of the commencement date&#8217;s first annual anniversary; provided that the grantee remains
continuously as an employee or provides services to Silexion throughout such vesting dates.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Each award will expire ten&#160;years from
the date of the grant thereof, unless a shorter term of expiration is otherwise designated by the Administrator.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Awards.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">The
2023 Plan provides for the grant of options, shares, restricted shares, RSUs, and other share-based&#160;awards.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Exercise.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">An
award under the 2023 Plan may be exercised by providing Silexion (currently, New Silexion) a written notice of exercise and full payment
of the exercise price for such shares underlying the award, if applicable, in such form and method as may be determined by the Administrator
and permitted by applicable law. The 2023 Plan allows for a net exercise of awards (as may be included in the award letter or otherwise
approved by the Administrator). An award may not be exercised for a fraction of a share.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Transferability.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">No
person other than the grantee shall have any right with respect to any award granted under the 2023 Plan. No transfer of any right to
any award or its underlying shares, by will or by the laws of descent, shall effectively bind Silexion (currently, New Silexion) unless
and until furnished with the certain signed and notarized documents, as described in the 2023 Plan.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Termination
of Engagement.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">In the event of termination of a grantee&#8217;s
employment or service with Silexion or any of its affiliates, for any reason other than death, retirement, disability or cause, any vested
and unexercised awards held by such grantee as of the date of termination may be exercised within 90-days&#160;after such date of termination,
unless otherwise determined by the Administrator, but in no event later than the date of expiration of the award as set forth in the award
letter. After such 90-days&#160;period, all such unexercised awards will terminate and the shares covered by such awards become available
for issuance under the 2023 Plan.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the event of termination of a grantee&#8217;s
employment or service with Silexion or any of its affiliates due to such grantee&#8217;s death, retirement or permanent disability, any
vested but unexercised awards shall be exercisable (a)&#160;in the case of death, by such grantee&#8217;s estate, personal representative
or beneficiary, or (b)&#160;in the case of retirement or Disability, by such grantee or his/her personal representative (as the case may
be), until the earlier of (i)&#160;180&#160;days following the date of termination for any such reason; or (ii)&#160;the date of expiration
of each such as set forth in the award letter. All such grantee&#8217;s other awards shall expire upon the date of such termination.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Notwithstanding any of the foregoing, if a
grantee&#8217;s employment or services with Silexion or any of its affiliates is terminated for &#8220;cause&#8221; (as defined in the
2023 Plan), all outstanding awards held by such grantee (whether vested or unvested) shall expire. With respect to any and all shares
owned by such grantee pursuant to the exercise of any and all awards granted under the 2023 Plan, the board of directors of Silexion may
convert such shares into deferred shares of Silexion.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">118</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Voting Rights.&#160;&#160;&#160;&#160;</span>Until
consummation of our initial public offering (or equivalent transaction, such as the Business Combination), shares underlying awards held
by grantees or the trustee, as applicable, were to be voted by an irrevocable proxy assigned to a person appointed by the board of directors.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Dividends.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">Grantees
holding shares issuable or issued upon exercise of awards granted under the 2023 Plan will, as a shareholder of New Silexion, be entitled
to receive dividends and other distributions with respect to the underlying shares.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Transactions.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">In
the event of any division or subdivision of Silexion&#8217;s (currently, New Silexion&#8217;s) issued and outstanding share capital, any
distribution of bonus shares (share split or subdivision), consolidation or combination of the share capital (reverse share split), reclassification
of the shares or any similar recapitalization event, as well as any reorganization, merger, consolidation, split-up, spin-off, combination,
repurchase, or exchange of the shares or other securities of Silexion (currently, New Silexion), or any other change in Silexion&#8217;s
(currently, New Silexion&#8217;s) corporate structure affecting the shares, the administrator may, in order to prevent diminution or enlargement
of the benefits or potential benefits intended to be made available under the 2023 Plan, adjust (A)&#160;the number and class of shares
that may be issued under the 2023 Plan; (B)&#160;the number, class, and exercise price of underlying shares for each outstanding award;
(C)&#160;any other term of the awards that in the administrator&#8217;s opinion should be adjusted (including those concerning the vesting,
exercisability and term of outstanding awards); provided, that no adjustment shall be made by reason of the distribution of subscription
rights (rights offering) on outstanding shares.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Upon any such adjustment, references herein
to shares and underlying shares shall be construed to mean those shares of Silexion (currently, New Silexion) subject to the 2023 Plan
as determined by the Administrator following such adjustment. Any fractional shares resulting from such adjustment shall be rounded down
to the nearest whole number of share and Silexion (currently, New Silexion) shall have no obligation to make any cash or other payment
with respect to such fractional shares. The adjustments shall be made by the Administrator. If the applicable awards or underlying shares
are deposited with a trustee, all of the shares formed by such adjustments shall also be deposited with the trustee on the same terms
as such awards or underlying shares.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the event of a merger, reorganization or
consolidation of Silexion (currently, New Silexion) with or into another incorporated entity, or its acquisition by another incorporated
entity by means of any transaction or series of related transactions, except any such merger, reorganization or consolidation in which
the issued shares of Silexion (currently, New Silexion) as of immediately prior to such transaction continue to represent, or are converted
into or exchanged for shares that represent, immediately following such merger, reorganization, or consolidation, at least a majority,
by voting power, of the outstanding shares of the surviving or acquiring incorporated entity; or a sale of all, or substantially all,
of our shares or assets or other transaction having a similar effect on our company, or change in the composition of the board of directors,
or liquidation or dissolution, or such other transaction or circumstances that our board of directors determines to be a relevant transaction,
then without the consent of the grantee, (i)&#160;unless otherwise determined by the Administrator, any outstanding award will be assumed
or substituted by such successor corporation or substituted by our company or by any affiliate of the successor corporation, as determined
by the Administrator, and (ii)&#160;regardless of whether or not the award is assumed or substituted, the Administrator may:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7545a129dda14c6da0959f652a9d7dc8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(a)</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">entitle a grantee to exercise an award, or to otherwise provide
        for the acceleration of such award&#8217;s vesting schedule, as to all or part of its underlying shares, including with respect to awards
        that would not otherwise be exercisable or vested, under such terms and conditions as the Administrator shall determine, including the
        cancellation of all unexercised awards upon or immediately prior to the closing of a transaction or as of such other date (the&#160;<span style="font-weight: bold">&#8220;Cut-Off&#160;Date&#8221;</span>),
        and/or the termination of all awards (whether vested but un-exercised&#160;or un-vested) as of the relevant Cut-Off&#160;Date, as of which
        they shall no longer be exercisable by the applicable grantees; and/or</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za395e52441ed4da6a979e449547526da" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(b)</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">provide for the cancellation of outstanding awards at or immediately
        prior to the closing of a transaction, and payment to the applicable grantee of a consideration determined by the Administrator to be
        fair in the circumstances (whether in shares, cash, other securities, property, or any combination thereof), taking into account the value
        of each underlying share of any such award&#8217;s vested portion as reflected by the terms of such transaction, and the exercise price
        of each such underlying share, and subject to such terms and conditions as determined by the Administrator.</div> </td> </tr>
  </table>

<div style="text-indent: 24.1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 24.1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Administrator shall have full authority
to select the method for determining the payment to the grantees, as well as to set such payment to zero, with respect to underlying shares
valued at less than their exercise price or to those of awards that would not otherwise be exercisable or vested, or to determine that
such payment be made only in excess of the exercise price.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">119</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">New Silexion Share Incentive Plans</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">2024 Equity Incentive
Plan</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Pursuant to written resolutions adopted
by our board of directors and shareholders prior to the Closing, we have approved and adopted the 2024 Equity Incentive Plan (the &#8220;<span style="font-weight: bold">2024
Plan</span>&#8221;), which became effective immediately upon the Closing.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Upon the Closing, a total of 575,572 New Silexion
ordinary shares were reserved for issuance under the terms of the 2024 Plan, which, together with New Silexion ordinary shares allocated
for issuance under the existing 2013 Plan and 2023 Plan, equaled 10% of the total number of New Silexion ordinary shares on a fully diluted
basis immediately following the Closing. A summary of the other material terms of the 2024 Incentive Plan is provided below:</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Administration</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The compensation committee of our board of
directors is the administrator of the 2024 Plan. Except as provided otherwise under the 2024 Plan, the administrator has plenary authority
to grant awards pursuant to the terms of the 2024 Plan to eligible individuals, determine the types of awards and the number of shares
covered by the awards, establish the terms and conditions for awards and take all other actions necessary or desirable to carry out the
purpose and intent of the 2024 Plan.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Eligibility and Participation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The administrator selects the individuals
who participate in the 2024 Plan. Eligibility to participate is open to officers, directors and employees of, and other individuals who
provide bona fide services to or for, us or any of our subsidiaries. Our board of directors may also select as participants prospective
officers, employees and individual service providers who have accepted an offer of employment or another service relationship from us
or one of our subsidiaries. Any awards granted to such a prospect before the individual&#8217;s start date may not become vested or exercisable,
and no shares may be issued to such individual, before the date the individual first commences performance of services with us.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Share Pool Under the 2024
Plan</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The initial number of New Silexion ordinary
shares allocated to the 2024 Plan is 575,572. The number of New Silexion ordinary shares available under the 2024 Plan (the &#8220;<span style="font-weight: bold">Share
Pool</span>&#8221;) will be subject to the following annual allocations and adjustments:</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Share Pool will be increased automatically
on January 1 of each calendar year, beginning on January 1, 2025 and for each of the subsequent nine calendar years, through (and including)
January 1, 2034, in an amount equal to the lesser of (i) 5% of the number of New Silexion ordinary shares issued and outstanding as of
that January 1 date, or (ii) an amount determined by our board of directors prior to such date.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following additional rules apply to the
number of New Silexion ordinary shares available under the Share Pool on an ongoing basis:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4e6255e6eb584a64a85fbddac5aea7a6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The Share Pool will be reduced by one share for each share made
        subject to an award granted under the 2024 Plan;</div> </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The Share Pool will be increased by the number of unissued shares
        underlying or used as a reference measure for any award or portion of an award granted under the 2024 Plan that is cancelled, forfeited,
        expired, terminated unearned or settled in cash, in any such case without the issuance of shares;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z91808c1c92b84b0d9c5e0375ba939007" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The Share Pool will be increased by the number of shares that
        are forfeited back or surrendered for no consideration to us after issuance due to a failure to meet an award contingency or condition
        with respect to any award or portion of an award granted under the 2024 Plan;</div> </td> </tr>
  </table>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">120</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z026645a89cca43b4a9c855557185fa5e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The Share Pool shall be increased, on the exercise date, by the
        number of shares withheld by or surrendered (either actually or through attestation) to the Company in payment of the exercise price of
        any award granted under the 2024 Plan; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z514abefe64364b72a07fe43449788ea0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The Share Pool shall be increased, on the relevant date, by the
        number of shares withheld by or surrendered (either actually or through attestation) to the Company in payment of any tax withholding
        obligation that arises in connection with any award granted under the 2024 Plan.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the event of a merger, consolidation, share
rights offering, statutory share exchange or similar event affecting the Company or a share dividend, share split, reverse share split,
separation, spinoff, reorganization, extraordinary dividend of cash or other property, share combination or subdivision, or recapitalization
or similar event affecting the capital structure of the Company, our board of directors will make equitable and appropriate substitutions
or proportionate adjustments to the Share Pool to reflect the transaction or event. Similar adjustments will be made to the award limitations
described below and to the terms of outstanding awards.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">ISO Award Limit</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The maximum number of New Silexion ordinary
shares that may be issued in connection with awards granted under the 2024 Plan that are intended to qualify as incentive stock options
under Section 422 of the Code is 575,572.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Types of Awards</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">General</span><span style="font-family: Times New Roman,Times,serif">.
The 2024 Plan enables the grant of share awards, performance shares, restricted share units, cash-based performance units, other share-based
awards, share options, share appreciation rights, and share unit awards, each of which may be granted separately or in tandem with other
awards. The administrator may establish sub-plans under the 2024 Plan under which awards that qualify for preferred tax treatment for
recipients in jurisdictions outside the U.S. may be granted.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We have adopted a sub-plan for Israeli participants,
which provides for granting awards in compliance with Section 102 (&#8220;<span style="font-weight: bold">Section 102</span>&#8221;) and
Section 3(i) of the Israeli Income Tax Ordinance (New Version), 5721-1961, as amended (the &#8220;<span style="font-weight: bold">ITO</span>&#8221;).
Section 102 allows employees, directors and officers who are not controlling shareholders and who are considered Israeli residents for
tax purposes to receive favorable tax treatment for compensation in the form of shares, options or certain other types of equity awards,
subject to certain terms and conditions. Our non-employee service providers and controlling shareholders who are considered Israeli residents
for tax purposes may be granted awards under Section 3(i) of the ITO, which do not provide for similar tax benefits as Section 102.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Out of the three tax tracks that are available
under Section 102 ((i) the &#8220;ordinary income track&#8221; with a trustee, (ii) the &#8220;capital gains track&#8221; with a trustee
and (iii) grants without a trustee and without a trust period), we have elected the &#8220;capital gain track&#8221; for grants to eligible
Israeli grantees as provided above, which may allow favorable tax treatment for such grantees.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Adjustments to Awards for Corporate Transactions
and Other Events</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Mandatory Adjustments</span><span style="font-family: Times New Roman,Times,serif">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the event of a merger, amalgamation, consolidation,
share rights offering, share exchange or similar event affecting the Company (a &#8220;<span style="font-weight: bold">Corporate Event</span>&#8221;)
or a share dividend, share split, reverse share split, separation, spinoff, reorganization, extraordinary dividend of cash or other property,
share combination or subdivision, or recapitalization, capital reduction distribution or similar event affecting the capital structure
of the Company, the administrator will make equitable and appropriate substitutions or proportionate adjustments to:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8154cb3c657c4612bd1abfdb34dded0a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the aggregate number and kind of shares or other securities that
        may be granted to eligible individuals under the 2024 Plan;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">121</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="z7fd55846ee9c4d5ea42cd4b6db162ff8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the maximum number of shares or other securities that may be
        issued with respect to incentive share options granted under the 2024 Plan;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze89f4849277647cf809ce9a3dce8251c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the number of shares or other securities covered by each outstanding
        award and the exercise price, base price or other price per share, if any, and other relevant terms of each outstanding award; and</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf3f721a959b142e686b64e7e54d99e95" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">all other numerical limitations relating to awards, whether contained
        in the 2024 Plan or in award agreements.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Notwithstanding the foregoing, any fractional
shares resulting from the above mandatory adjustments will be eliminated.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Discretionary Adjustments</span><span style="font-family: Times New Roman,Times,serif">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition to the adjustments specified above,
in the case of Corporate Events, the administrator may make such other adjustments to outstanding awards as it determines to be appropriate
and desirable, which adjustments may include, without limitation, (i) the cancellation of outstanding awards in exchange for payments
of cash, securities or other property or a combination thereof having an aggregate value equal to the value of such awards, (ii) the substitution
of securities or other property (including, without limitation, cash or other securities of the Company and securities of entities other
than the Company) for the shares subject to outstanding awards, and (iii) the substitution of equivalent awards, as determined in the
sole discretion of the administrator, of the surviving or successor entity or a parent thereof. The administrator may, in its discretion,
adjust the performance goals applicable to any awards to reflect any unusual or non-recurring events and other extraordinary items, impact
of charges for restructurings, discontinued operations and the cumulative effects of accounting or tax changes.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Repricing</span><span style="font-family: Times New Roman,Times,serif">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The administrator may reprice any share options
or share appreciation rights without the approval of the shareholders of the Company. For this purpose, &#8220;reprice&#8221; means (i)
any of the following or any other action that has the same effect: (A) lowering the exercise price or base price of an option or share
appreciation right after it is granted other than an adjustment made pursuant to the provisions of the 2024 Plan, (B) any other action
that is treated as a repricing under applicable accounting principles; (C) cancelling a share option or share appreciation right at a
time when its exercise price or base price exceeds the fair market value of the underlying share, in exchange for another share option,
share appreciation right, restricted share or other equity, unless the cancellation and exchange occurs in connection with a merger, acquisition,
spin-off or other similar corporate transaction; and (ii) any other action that is considered to be a repricing under formal or informal
guidance issued by the primary securities market or exchange on which the shares are listed or admitted for trading.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Treatment of Awards upon Dissolution or Liquidation
or a Change in Control</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Dissolution or Liquidation</span><span style="font-family: Times New Roman,Times,serif">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Unless the administrator determines otherwise,
all awards outstanding under the 2024 Plan will terminate upon the winding up, liquidation or dissolution of the Company.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Amendment and Termination</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our board of directors or the compensation
committee may terminate, amend or modify the 2024 Plan or any portion of it at any time; provided, that, (i) if required to comply with
Cayman Islands law and any other applicable laws or marketplace or listing rules of a securities market or securities exchange (other
than any requirement from which the Company may opt out based on any available home country exemption), the Company shall obtain shareholder
approval of any 2024 Plan amendment in such a manner and to such a degree as required, and (ii) no such termination or amendment may materially
impair the rights of a participant with respect to a previously granted award (other than as required to comply with applicable law or
the rules of any securities exchange or market on which the shares are listed or to prevent adverse tax or accounting consequences to
the Company or the participant) without such participant&#8217;s consent.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">122</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The 2024 Plan is scheduled to expire on August
14, 2034, which is ten years after the effective date of its adoption by our board of directors. After that time, no further grants may
be made under the 2024 Plan, but any then-outstanding grants will remain subject to the terms of the plan.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The foregoing description of the 2024 Incentive
Plan is qualified in its entirety by the full text of the 2024 Incentive Plan, which is attached to the registration statement of which
this prospectus forms a part as Exhibit 10.12 and incorporated herein by reference.</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Rule 10b5-1 Sales Plans</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our directors and executive officers may
adopt written plans, known as Rule 10b5-1 plans, in which they will contract with a broker to buy or sell ordinary shares on a periodic
basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or executive officer when
entering into the plan, without further direction from them. The director or executive officer may amend a Rule 10b5-1 plan in some circumstances
and may terminate a plan at any time. Our directors and executive officers also may buy or sell additional shares outside of a Rule 10b5-1
plan when they are not in possession of material nonpublic information, subject to compliance with the terms of our insider trading policy.</div>
</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Emerging Growth Company
Status</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We are an &#8220;emerging growth company,&#8221;
as defined in the JOBS Act. As an emerging growth company, it is exempt from certain requirements related to executive compensation, including
the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total
compensation of its chief executive officer to the median of the annual total compensation of all of its employees, each as required by
the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection
Act.</div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="CERTAINRELATIONSHIPSANDRE"><!--Anchor--></span>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Other than the compensation arrangements for
our directors and executive officers, which are described in the section titled &#8220;Executive Compensation&#8221;, below is a description
of transactions since our formation on April 2, 2024 to which we have been a party, in which:</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb402104a5eb8482ea5295015db74bbbe" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the amounts involved exceeded or will exceed $120,000; and</div>
        </td> </tr>
  </table>

<div style="text-indent: -18pt; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9bea474bcac542ad8ec1d804e7fccf80" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">any of our directors, executive officers or holders of more than
        5% of our share capital, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or
        will have a direct or indirect material interest.</div> </td> </tr>
  </table>

<div style="text-indent: -18pt; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Related Party Transactions</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Arrangements with Executive
Officers</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Ilan Hadar serves as our Chief Executive
Officer and Chairman of the our Board. Mr.&#160;Hadar&#8217;s employment agreement with us, as to be amended in the period following the
Closing of the Business Combination, subject to corporate approvals, will provide for him to receive an annual base salary of $357,820
(based on the average exchange rate for 2023, as published by the Bank of Israel), customary disbursements toward his providence fund,
further education fund and severance pay fund, and other fringe benefits commensurate with such position. During 2022, Silexion granted
Mr.&#160;Hadar 32,400 options to purchase New Silexion ordinary shares, vesting over a period of 48&#160;months, provided that Mr.&#160;Hadar
remains engaged by us (or a Silexion affiliate) at the end of each vesting period and subject to the Silexion<span style="font-weight: bold">&#160;</span>Plan.
Upon completion of the Business Combination, the vesting of all such options is expected to accelerate, such that all unvested options
shall become fully vested at that time.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Mirit Horenshtein Hadar, our Executive VP of Finance, Chief Financial Officer and Secretary,
is Mr.&#160;Hadar&#8217;s spouse. Ms. Horenshtein Hadar&#8217;s employment agreement with us provides for her to receive an annual base
salary of $234,210 (based on the average exchange rate for 2023, as published by the Bank of Israel), as well as customary disbursements
toward her providence fund, further education fund and severance pay fund, and other fringe benefits commensurate with such position.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span></div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">123</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Indemnification Agreements</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">On the date of, and in connection with,
the Closing of the Business Combination, the Company entered into indemnification agreements with each of its directors and executive
officers, which provide for indemnification and advancements by the Company of certain expenses and costs under certain circumstances.
The indemnification agreements provide that we will indemnify each of its directors and executive officers against any and all expenses
incurred by that director or executive officer because of his or her status as a director or officer of New Silexion, to the fullest extent
permitted under Cayman law and the Articles.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">The foregoing description of the indemnification agreements does not purport to be complete and is qualified
in its entirety by reference to the text of the form of indemnification agreement that is filed as Exhibit 10.6 to the registration statement
of which this prospectus forms a part, which is incorporated herein by reference.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Conversion Transaction
with GIBF</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Immediately following the Closing of the
Business Combination, Guangzhou Sino-Israel&#160;Bio-Industry&#160;Investment Fund&#160;I (&#8220;GIBF&#8221;) beneficially owned 20.3%
of our issued and outstanding share capital. GIBF had held the remaining 49% of the issued and outstanding share capital of our 51%-held
Chinese subsidiary, Silenseed (China) Ltd. (which 49% interest had been received by it in return for its equity investments in the Chinese
subsidiary, rather than equity investments directly in us). In connection with the consummation of the Business Combination, GIBF was
to exchange its entire holdings in the Chinese subsidiary for preferred shares of Silexion according to the terms set out in the contract
for the establishment of the Chinese subsidiary, dated August&#160;30, 2021, as amended, which preferred shares were to be automatically
converted into 1,812,525 New Silexion ordinary shares in accordance with the equity exchange ratio for our shareholders&#8217; exchange
of shares of Silexion for our shares under the Business Combination Agreement.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">However, in order to simplify the transfer
of GIBF&#8217;s 49% interest in our Chinese subsidiary to our company, in lieu of transferring that interest to Silexion, GIBF instead
transferred the interest directly to New Silexion pursuant to an Agreement on Arrangements Related to Equity Interest Conversion, dated
as of August 5, 2024 (the &#8220;GIBF Conversion Agreement&#8221;). As consideration for its transfer of that 49% interest to us, GIBF
received 1,835,733 New Silexion ordinary shares at the Closing. GIBF furthermore received an additional 70,785 of our ordinary shares
upon consummation of the Business Combination due to the conversion of our shares that were issued to it upon settlement of RSUs of Silexion
that were subject to accelerated vesting at the Closing. Those RSUs were granted to GIBF subject to GIBF&#8217;s providing certain services
to us in connection with the transfer of funds from our Chinese subsidiary to us. Avner Lushi and Shlomo Noy, both of whom serve as our
directors since the Closing, share voting and investment power over the 1,987,082 of ourordinary shares beneficially owned by GIBF after
the Closing.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: normal; font-family: Times New Roman,Times,serif">PIPE Financing</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In connection with, and immediately prior
to the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity financing (the &#8220;PIPE
Financing&#8221;), whereby Moringa sold to Greenstar, LP (the &#8220;PIPE Investor&#8221;), a Cayman Islands exempted limited partnership
and affiliate of the Moringa Sponsor, 200,000 newly issued Moringa ordinary shares (the &#8220;PIPE Shares&#8221;) at a price of $10.00
per share, pursuant to the PIPE Agreement, dated as of August 15, 2024, by and among Moringa, us and the PIPE Investor. Those 200,000
shares automatically converted upon the Closing of the Business Combination into an equivalent number of our ordinary shares, or the PIPE
Shares. The PIPE Investor is entitled to customary registration rights in respect of the PIPE Shares under the PIPE Agreement, pursuant
to which we have agreed that, within 60 days after the Closing Date, it will file with the SEC a registration statement registering the
resale of the PIPE Shares by the PIPE Investor, and use its commercially reasonable efforts to have that registration statement be declared
effective by 180 days after the Closing Date (or 90 days after the Closing Date if the SEC does not review that filing).</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">124</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The funds raised from the PIPE Financing,
together with remaining funds in Moringa&#8217;s trust account after payments to redeeming public shareholders of Moringa, were used for
financing support for Moringa and New Silexion, as well as for payment to service providers to whom outstanding amounts were owed by Moringa,
including parties that had provided financial advisory services and capital markets advisory services to Moringa during the period leading
up to the Closing.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The foregoing summary provides only a brief
description of the PIPE Agreement and does not purport to be complete. The summary is qualified in its entirety by the full text of the
PIPE Agreement, a copy of which serves as Exhibit 10.2 to the registration statement of which this prospectus forms a part, and which
is incorporated herein by reference.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Amended and Restated Sponsor
Promissory Note</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Effective as of the Closing, we issued to
the Sponsor, and Sponsor accepted, in amendment and restatement, and replacement, in their entirety, of all existing promissory notes
issued by Moringa to the Sponsor from the IPO until the Closing (and as to which the obligations of Moringa were assigned to us upon the
Closing), the A&amp;R Sponsor Promissory Note in an amount of $3,433,000, which reflected the total amount owed by Moringa to the Sponsor
through the Closing Date. The maturity date of the A&amp;R Sponsor Promissory Note is the 30-month anniversary of the Closing Date (i.e.,
February 15, 2027). Amounts outstanding under the A&amp;R Sponsor Promissory Note may be repaid (unless otherwise decided by us) only
by way of conversion into our ordinary shares (&#8220;<span style="font-weight: bold">Note Shares</span>&#8221;) in accordance with the
terms set forth in the form of A&amp;R Sponsor Promissory Note. Us and the Sponsor may also convert amounts outstanding under the A&amp;R
Sponsor Promissory Note at the price per share at which we conduct an equity financing following the Closing, subject to a minimum conversion
amount of $100,000, in an amount of Note Shares constituting up to thirty percent (30%) of the number of our ordinary shares issued and
sold by us in such equity financing. The Sponsor may also elect to convert amounts of principal outstanding under the note into our ordinary
shares at any time following the 24-month anniversary of the Closing Date, subject to a minimum conversion of $10,000, at a price per
share equal to the volume weighted average price of the our ordinary shares on the principal market on which they are traded during the
20 consecutive trading days prior to the conversion date.</div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The foregoing summary provides only a brief
description of the A&amp;R Sponsor Promissory Note and does not purport to be complete. The summary is qualified in its entirety by the
full text of the A&amp;R Sponsor Promissory Note, a copy of which serves as Exhibit 10.5 to the registration statement of which this prospectus
forms a part, and which is incorporated herein by reference.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Amended and Restated Registration
Rights and Lock-Up Agreement</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Prior to the Closing under the Business
Combination Agreement, on August 14, 2024, us, Moringa, Moringa Sponsor, the distributees of the Sponsor Investment Shares (as defined
under the Business Combination Agreement), certain of our pre-Business Combination shareholders and the PIPE Investor entered into (and
EarlyBird will be bound by) an amended and restated registration rights and lock-up&#160;agreement which became effective as of the Closing
of the Business Combination (the &#8220;A&amp;R Registration Rights and Lock-Up Agreement&#8221;). Under the agreement, we have assumed
Moringa&#8217;s existing obligations under Moringa&#8217;s prior registration rights agreement (entered into in connection with Moringa&#8217;s
initial public offering, or IPO) and has granted registration rights to the Moringa Sponsor, the distributees of Sponsor Investment Shares,
certain of our pre-Business Combination shareholders, the PIPE Investor and EarlyBird with respect to certain securities of ours.</div>
</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Under the A&amp;R Registration Rights and
Lock-Up Agreement, we have agreed to provide the holders party thereto customary demand and shelf registration rights (subject to certain
minimum size offerings) and piggy-back rights on primary and secondary offerings, subject to customary cut-back provisions.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">125</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Under the lock-up provisions of the agreement,
lock-up periods apply following the Closing to of our securities that are held by the holders who are party to the agreement, subject
to permitted transfers to certain categories of &#8220;Permitted Transferees&#8221;. Specifically, those lock-up periods apply to the
following categories of securities for the following periods of time post-Closing:</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3be9287273a14029aaf88ec260b14f72" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Sponsor Investment Shares and
        securities held by former Silexion shareholders</span>: (A) 50% of the Sponsor Investment Shares held by the Sponsor and its distributees
        and 50% of the New Silexion securities held by the former Silexion shareholders who are party to the agreement, in each case, upon the
        Closing, are subject to a lock-up period ending on the earlier of (i) six (6) months after the completion of the Business Combination,
        and (ii) the date on which New Silexion will consummate a liquidation, merger, amalgamation, share exchange, reorganization, or other
        similar transaction after the Business Combination that results in all of our shareholders having the right to exchange their ordinary
        shares for cash, securities or other property, and (B) the other 50% of the Sponsor Investment Shares held by the Sponsor and its distributees
        and 50% of the our securities held by the former Silexion shareholders party to the agreement, in each case, upon the Closing, will be
        subject to a lock-up period that will end on the earliest of (x) six (6) months after the date of the consummation of the Business Combination,
        (y) the date on which we consummate a liquidation, merger, amalgamation, share exchange, reorganization, or other similar transaction
        after the Business Combination that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities
        or other property, or (z) the date on which the last reported sale price of our ordinary shares equals or exceeds $12.00 per share (as
        adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20
        trading days within any 30-trading day period.</div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z64eeb5a6f5604a4a87ab776311fecf70" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Private Shares and Private Warrants:</span><span style="font-family: Times New Roman,Times,serif">
        The lock-up period on all New Silexion ordinary shares issued pursuant to the SPAC Merger in exchange for private placement shares and
        private placement warrants purchased by or issued to the Sponsor and EarlyBird concurrently with Moringa&#8217;s initial public offering
        will remain (as provided in the documentation for Moringa&#8217;s initial public offering) 30 days after the Closing.</span></div> </td>
        </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7110f4afe2584a048dc707ec9ce30701" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Representative Shares</span><span style="font-family: Times New Roman,Times,serif">.
        The lock-up period on all Representative Shares (as defined in the Amended and Restated Registration Rights and Lock-Up Agreement) that
        are held by EarlyBird will remain (as provided in the documentation for Moringa&#8217;s initial public offering) three months after the
        Closing.</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4e84242ac4de40618ee9c6f8189a8579" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman,Times,serif">Note Shares and PIPE Shares</span><span style="font-family: Times New Roman,Times,serif">.
        Note Shares issued to the Sponsor upon conversion of amounts due under the A&amp;R Sponsor Promissory Note and PIPE Shares issued to the
        PIPE Investor will not be subject to any lock-up periods following the Closing.</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The foregoing summary provides only a brief
description of the A&amp;R Registration Rights and Lock-Up Agreement and does not purport to be complete. The summary is qualified in
its entirety by the full text of the A&amp;R Registration Rights and Lock-Up Agreement, which serves as Exhibit 10.4 to the registration
statement of which this prospectus forms a part, and which is incorporated herein by reference.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="BENEFICIALOWNERSHIPOFSECU"><!--Anchor--></span>BENEFICIAL
OWNERSHIP OF SECURITIES</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25">The following table sets forth information known to the Company regarding the beneficial
ownership of New Silexion ordinary shares as of October&#160; &#160; &#160; &#160; &#160;&#160; , 2024 by:</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2a52c29de6ad45a095f4746665700f2e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">each person who is the beneficial owner
        of more than 5% of the outstanding New Silexion ordinary shares;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z97995235e7c0446aaf9edeff96591a8b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif">our named executive officer and directors;
        and</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z116fc5073e5c4be28023e82f3d01148e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif">all of our executive officers and directors
        as a group.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">126</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person
has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including
options and warrants that are currently exercisable or exercisable within 60 days. In computing the number of ordinary shares beneficially
owned by a person and the percentage ownership, we include, as outstanding, those ordinary shares that are subject to warrants held by
that person that are currently exercisable or exercisable within 60 days of October&#160; &#160; &#160; &#160; , 2024. We do not deem
those shares to be outstanding, however, for the purpose of computing the percentage ownership of any other person.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Unless otherwise indicated, we believe that
all persons named in the table have sole voting and investment power with respect to all New Silexion ordinary shares beneficially owned
by them.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25">The percentage ownership of New Silexion ordinary shares is based on &#160; &#160; &#160;
&#160; &#160; &#160; &#160; New Silexion ordinary shares outstanding as of October&#160; &#160; &#160; &#160; &#160;&#160; , 2024.</div>
</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z472f6fc728cd4b0dbfe0ef0e053f3a45" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 74%; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Name and Address of Beneficial Owner<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td style="width: 0.53%; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Number of Shares Beneficially
        Owned</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 0.54%; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Approximate Percentage
        of Outstanding Ordinary Shares</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Directors and Executive
        Officers of New Silexion:</div> </td>
    <td style="width: 0.53%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="2" style="vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 0.54%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td colspan="2" style="vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Ilan Hadar</div> </td>
    <td style="width: 0.53%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 9.62%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">280,438</div> </td>
    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td style="width: 0.54%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">2.0</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Dror Abramov</div> </td>
    <td style="width: 0.53%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 9.62%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">39,829</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 0.54%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 10%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">*</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Ruth Alon</div> </td>
    <td style="width: 0.53%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 9.62%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">54,325</div> </td>
    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 0.54%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">*</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Ilan Levin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>
        </td>
    <td style="width: 0.53%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 9.62%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">2,066,610</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup></div>
        </td>
    <td style="width: 0.54%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 10%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">14.8</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Avner Lushi<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(5)</sup></div>
        </td>
    <td style="width: 0.53%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 9.62%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">1,987,082</div> </td>
    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(6)</sup></div>
        </td>
    <td style="width: 0.54%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">14.4</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Shlomo Noy<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(7)</sup></div>
        </td>
    <td style="width: 0.53%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 9.62%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">1,987,082</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(6)</sup></div>
        </td>
    <td style="width: 0.54%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 10%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">14.4</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Dr. Mitchell Shirvan</div> </td>
    <td style="width: 0.53%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 9.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">196,992</div> </td>
    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(8)</sup></div>
        </td>
    <td style="width: 0.54%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">1.4</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Mirit Horenshtein Hadar, CPA</div> </td>
    <td style="width: 0.53%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 9.62%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">56,772</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 0.54%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 10%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">*</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 0.53%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 9.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 0.54%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">All executive officers
        and directors as a group (8 individuals)</div> </td>
    <td style="width: 0.53%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 9.62%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">4,682,048</div> </div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 0.54%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 10%; vertical-align: bottom; text-align: right; font-family: Times New Roman,Times,serif">33</td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Five Percent Holders:</div>
        </td>
    <td style="width: 0.53%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 9.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 0.54%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Moringa Sponsor, LP and affiliated entities <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>
        </td>
    <td style="width: 0.53%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 9.62%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">2,066,610</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup></div>
        </td>
    <td style="width: 0.54%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 10%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">14.8</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Guangzhou Sino-Israel Biotech Fund<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(9)</sup></div>
        </td>
    <td style="width: 0.53%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 9.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">1,987,082</div> </td>
    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(6)</sup></div>
        </td>
    <td style="width: 0.54%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 10%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">14.4</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  <tr>
    <td style="width: 74%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Wildcat Partner Holdings LP<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(10)</sup></div>
        </td>
    <td style="width: 0.53%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 9.62%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">1,020,852</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 0.54%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 10%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman,Times,serif">7.4</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">%</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z47aac06a0c7740ea81571da2de94107b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">*</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Less than 1%.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"> </div>

<table cellspacing="0" cellpadding="0" id="zeb9fb806fdca4194abe3c049f6254892" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(1)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Unless otherwise noted, the business address of each beneficial owner listed in the above table is c/o
        Silexion Therapeutics Corp, 12 Abba Hillel Road, Ramat Gan, Israel 5250606.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="z37468714bf2f4c64aefefac462bbb032" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(2)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Includes 129,045 New Silexion ordinary shares issuable upon exercise
        of options, at an exercise price of $6.72 per share, all of which are vested and currently exercisable.</div> </td> </tr>
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(3)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The shares reported in this row are held of record by the Sponsor,
        Moringa Sponsor, LP, and/or by the PIPE Investor, Greenstar, L.P., each a Cayman Islands exempted limited partnership, as described in
        footnote (4) below. Moringa Partners Ltd., an Israeli company that is wholly-owned by Mr. Ilan Levin, serves as the sole general partner
        of each of the Sponsor and the PIPE Investor. Mr. Levin, a director of New Silexion, is the sole director of that general partner. As
        a result of his ownership of that general partner, Mr. Levin possesses sole voting and investment authority with respect to the shares
        indirectly held by the Sponsor and the PIPE Investor. The limited partnership interests of the Sponsor and the PIPE Investor are held
        by various individuals and entities, including Mr. Levin. Mr. Levin disclaims beneficial ownership of the securities held by the Sponsor
        and the PIPE Investor other than to the extent of his direct or indirect pecuniary interest in such securities. The address of each of
        the entities beneficially owning the shares that are reported in this row is c/o Moringa Acquisition Corp, 250 Park Avenue, 7<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>
        floor, New York, NY 10177.</div> </td> </tr>
  </table>

<div><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">127</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(4)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Consists of the total of: (i) 1,337,325 New Silexion ordinary
        shares issued to the Sponsor as Sponsor Investment Shares (as defined under the Business Combination Agreement); (ii) 352,857 New Silexion
        ordinary shares issued to the Sponsor upon the Closing of the Business Combination due to the conversion, on a one-for-one basis, of the
        352,857 Moringa private shares held by it; (iii) 176,429 New Silexion ordinary shares underlying New Silexion warrants issued to the Sponsor
        upon the Closing of the Business Combination due to the conversion, on a one-for-one basis, of the 176,429 Moringa private warrants held
        by the Sponsor (which New Silexion warrants will be exercisable beginning 30 days after the Closing Date); and (iv) 200,000 New Silexion
        ordinary shares issued to Greenstar, L.P., the PIPE Investor, as PIPE Shares in respect of the PIPE Financing. The foregoing beneficial
        ownership of New Silexion ordinary shares by the Sponsor does not include any Note Shares that may be issued to the Sponsor following
        the Closing upon conversion of amounts owed by New Silexion to the Sponsor under the A&amp;R Sponsor Promissory Note, as the potential
        number of Note Shares, and the timing of issuance of Note Shares, cannot be determined in advance.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcca75589be0b48c08f65a070a5e8d568" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(5)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The shares reported in this row consist entirely of New Silexion
        ordinary shares held of record by Guangzhou Sino-Israel Biotech Fund (&#8220;<span style="font-weight: bold">GIBF</span>&#8221;), with
        respect to which Mr. Lushi possesses shared voting and investment authority as a result of his serving as a Managing Partner and CEO of
        GIBF.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1bf3cd0ce986458ab26b363b1fa2874a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(6)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Includes 1,835,733 New Silexion ordinary shares issued to GIBF
        at the Closing in respect of its transfer of its noncontrolling interest in our Chinese subsidiary, Silenseed (China) Ltd., to New Silexion
        pursuant to the Chinese Subsidiary Transfer.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5867bebbb63f4fb2b48febab262ed6ab" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(7)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The shares reported in this row consist entirely of New Silexion
        ordinary shares held of record by GIBF, with respect to which Mr. Noy possesses shared voting and investment authority as a result of
        his serving as Chief Medical Officer of GIBF.</div> </td> </tr>
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(8)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Includes 64,522 New Silexion ordinary shares issuable upon exercise
        of options, at an exercise price of $6.72 per share, all of which are vested and currently exercisable.</div> </td> </tr>
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(9)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The address of this shareholder is 34 Ha&#8217;Barzel St., Tel-Aviv
        6971052 Israel. Each of Avner Lushi and Shlomo Noy may be deemed to share voting and investment power over the securities beneficially
        owned by GIBF.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7e6d77105f034ca591e9096f55832bdd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">(10)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The address of this shareholder is 301 Commerce Street, Suite
        3150, Fort Worth, Texas 76102. Len Porter may be deemed to have sole voting and investment power over the securities beneficially owned
        by Wildcat Partner Holdings LP.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">128</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="SELLINGSECURITYHOLDERS"><!--Anchor--></span></div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-weight: bold">DESCRIPTION OF SHARE <span id="CAPITAL"><!--Anchor--></span>CAPITAL</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In connection with the consummation of the
Business Combination, New Silexion adopted the Articles. The following summary of the material terms of New Silexion&#8217;s securities
is not intended to be a complete summary of the rights and preferences of such securities. You are encouraged to read the Articles and
the agreements governing New Silexion&#8217;s warrants in their entirety, which serve as Exhibit 3.1 and Exhibits 4.1 and 4.2, respectively,
to the registration statement of which this prospectus forms a part, along with the applicable provisions of Cayman Islands law, for a
complete description of the rights and preferences of New Silexion&#8217;s securities.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Authorized and Outstanding Share Capital</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The Articles of New Silexion authorize the
issuance of 200,000,000&#160;shares, consisting of 200,000,000 ordinary shares, $0.0001 par value per share. As of October 15, 2024, there
were 13,827,814 New Silexion ordinary shares outstanding. All of such outstanding New Silexion ordinary shares were validly issued, fully
paid and non-assessable.</div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">129</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Ordinary Shares</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Voting Power</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Holders of New Silexion ordinary shares are
entitled to one vote in respect of each share held of record by such holder on all matters to be voted on by shareholders.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Dividends</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Subject to applicable law, holders of New
Silexion ordinary shares are entitled to receive dividends when, as and if declared by the New Silexion Board, payable in cash, property
or shares.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Winding Up, Liquidation
and Dissolution</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">Upon New Silexion&#8217;s winding up and liquidation and after payment in full of all amounts required
to be paid to creditors, the holders of New Silexion ordinary shares are entitled to receive a pro rata share of New Silexion&#8217;s
remaining assets available for distribution.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Preemptive or Other Rights</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Holders of New Silexion ordinary shares will
not be entitled to preemptive rights, and New Silexion ordinary shares will not be subject to conversion, redemption or sinking fund provisions.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Appointment of Directors</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">The New Silexion Board will consist of up to nine (9) directors and not less than three (3) directors,
unless increased or decreased from time to time by Ordinary Resolution in a general meeting.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Directors will generally be appointed by an
Ordinary Resolution passed at each annual general meeting.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Prior to each annual general meeting, the
New Silexion Board (or a nominating committee established by the New Silexion Board for such purpose) may select, via a resolution adopted
by a majority of the New Silexion Board or such committee, a number of persons to be proposed to the shareholders for appointment as directors
at such annual general meeting, for service until the next annual general meeting (the &#8220;Nominees&#8221;). Any shareholder entitled
under applicable law to propose one or more persons as nominees for appointment as directors at an annual general meeting (each such nominee,
an &#8220;Alternate Nominee&#8221;) may make such proposal only if a written notice of such shareholder&#8217;s intent to that effect
has been given to the Secretary of the Company (or, if there is no such Secretary, the chief executive officer) within the periods set
out in the Articles.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Unless the New Silexion Board resolves that
the appointment of Nominees or Alternate Nominees will be determined based on those Nominees or Alternate Nominees receiving the highest
number of votes of Members in favor of their appointment&#8212; even if less than a majority of all Members&#8217; votes that are cast,
the Nominees or Alternate Nominees shall be appointed by Ordinary Resolution at the annual general meeting at which they are proposed
for appointment. If the appointment of the Nominees or Alternate Nominees proposed to be appointed would cause the total number of directors
(including those then in office) to exceed the maximum number, then any directors then in office who are not named as Nominees or Alternate
Nominees will cease to hold office following the conclusion of such annual general, if any such Nominees or Alternate Nominees are appointed
in such meeting, and upon such Nominees or Alternate Nominees taking office. If (a) the appointment of the Nominees or Alternate Nominees
proposed to be appointed would not cause the total number of directors to exceed the maximum, or (b) no Nominees or Alternate Nominees
are proposed to be appointed at an annual general meeting by either the Board or Members, or (c) no Nominees or Alternate Nominees are
eventually appointed in such annual general meeting &#8212; all directors then in office shall continue to hold office until the convening
of a general meeting at which Nominees or Alternate Nominees shall be proposed and appointed, and where such appointment would cause the
total number of directors to exceed the maximum.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">130</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Each director will hold office until the next
succeeding annual general meeting and until his or her successor is appointed and qualified, or until such director&#8217;s earlier death,
resignation, disqualification or removal. The Articles will not provide for cumulative voting for the appointment of directors.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">New Silexion <span style="font-family: Times New Roman,Times,serif">Warrants</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Following the Closing of the Business Combination
and as of October 1, 2024, there were 5,940,000 New Silexion warrants to purchase New Silexion ordinary shares outstanding, consisting
of 5,750,000 New Silexion public warrants issued upon conversion of an equivalent number of Moringa public warrants and 190,000 New Silexion
private warrants issued upon conversion of an equivalent number of Moringa private warrants (of which 176,429 and 13,571 private warrants
are held by the Sponsor and EarlyBird, respectively). In connection with the Closing, each Moringa warrant was exchanged for a New Silexion
warrant on substantially similar terms, including exercise price.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">Each New Silexion public warrant entitles the registered holder to purchase one New Silexion ordinary share
at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing one month after the Closing. However,
no New Silexion public warrants will be exercisable for cash unless there is an effective and current registration statement covering
the New Silexion ordinary shares issuable upon exercise of the New Silexion public warrants and a current prospectus relating to such
New Silexion ordinary shares. Notwithstanding the foregoing, if a registration statement covering the New Silexion ordinary shares issuable
upon exercise of the New Silexion public warrants is not effective within 60&#160;business days from the closing of the Business Combination,
warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have
failed to maintain an effective registration statement, exercise New Silexion public warrants on a cashless basis pursuant to the exemption
provided by Section&#160;3(a)(9)&#160;of the Securities Act, provided that such exemption is available. If that exemption, or another
exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. In the case of a cashless exercise,
each holder would pay the exercise price by surrendering the warrants for that number of New Silexion ordinary shares equal to the quotient
obtained by dividing (x)&#160;the product of the number of New Silexion ordinary shares underlying the warrants, multiplied by the difference
between the exercise price of the warrants and the &#8220;fair market value&#8221; (defined below) by (y)&#160;the fair market value.
The &#8220;fair market value&#8221; for this purpose will mean the average reported last sale price of the ordinary shares for the five&#160;trading
days ending on the&#160;trading day prior to the date of exercise. The New Silexion public warrants will expire five&#160;years from the
Closing of the Business Combination (i.e., on August 15, 2029) at 5:00&#160;p.m., New&#160;York City time.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The New Silexion private warrants are identical
to the New Silexion public warrants, except that each New Silexion private warrant will be exercisable for cash (even if a registration
statement covering the New Silexion ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis,
at the holder&#8217;s option, and will not be redeemable by the Company, in each case so long as they are still held by the Sponsor, EarlyBird
or their respective affiliates.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">From and after the time the New Silexion warrants
become exercisable, we may call them for redemption (excluding the New Silexion private warrants), in whole and not in part, at a price
of $0.01 per warrant, upon not less than 30 days&#8217; prior written notice of redemption to each warrant holder, if and only if</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z70dd68a70a924132ae0fb17dd7f9967d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the reported last sale price of the ordinary shares equals or
        exceeds $18.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations and recapitalizations), for any
        20&#160;trading days within a 30 trading day period commencing after the warrants become exercisable and ending on the third business&#160;day
        prior to the notice of redemption to warrant holders; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd2ffc8fab902467b8f0afbc343184a4f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">a registration statement is then in effect with respect to the
        New Silexion ordinary shares underlying such warrants.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The right to exercise will be forfeited unless
the New Silexion warrants are exercised prior to the date specified in the notice of redemption. On and after the redemption date, a record
holder of a New Silexion warrant will have no further rights except to receive the redemption price for such holder&#8217;s warrant upon
surrender of such warrant.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">131</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The redemption criteria for New Silexion warrants
have been established at a price which is intended to provide warrant holders a reasonable premium to the initial exercise price and provide
a sufficient differential between the then-prevailing&#160;share price and the warrant exercise price so that if the share price declines
as a result of our redemption call, the redemption will not cause the share price to drop below the exercise price of the warrants.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If New Silexion calls the New Silexion warrants
for redemption as described above, its management will have the option to require all holders that wish to exercise warrants prior to
redemption to do so on a &#8220;cashless basis.&#8221; In such event, each holder would pay the exercise price by surrendering the warrants
for that number of New Silexion ordinary shares equal to the quotient obtained by dividing (x)&#160;the product of the number of New Silexion
ordinary shares underlying the warrants, multiplied by the difference between the exercise price of the warrants and the &#8220;fair market
value&#8221; (defined below) by (y)&#160;the fair market value. The &#8220;fair market value&#8221; shall mean the average reported last
sale price of the New Silexion ordinary shares for the 5&#160;trading days ending on the third&#160;trading day prior to the date on which
the notice of redemption is sent to the holders of warrants.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The New Silexion warrants will be issued in
registered form under a warrant agreement between Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent, and New Silexion
(as assignee of Moringa). The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder
to cure any ambiguity or correct any defective provision, but requires the approval, by written consent or vote, of the holders of at
least 50% of the then outstanding public warrants in order to make any change that adversely affects the interests of the registered holders.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The exercise price and number of New Silexion
ordinary shares issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a share capitalization
or our recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuances of New Silexion
ordinary shares at a price below their respective exercise prices.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The New Silexion warrants may be exercised
upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form
on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price,
by certified or official bank check payable to us, for the number of warrants being exercised. The warrant holders do not have the rights
or privileges of holders of New Silexion ordinary shares and any voting rights until they exercise their warrants and receive New Silexion
ordinary shares. After the issuance of New Silexion ordinary shares upon exercise of the warrants, each holder will be entitled to one
vote for each share held of record on all matters to be voted on by shareholders.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the terms of the warrant agreement,
New Silexion (as assignee of Moringa) has agreed to use its best efforts to have declared effective a registration statement relating
to the New Silexion ordinary shares issuable upon exercise of the warrants and keep such registration statement and its included prospectus
current until the expiration of the warrants. However, we cannot assure you that we will be able to do so and, if we do not maintain a
current prospectus relating to the New Silexion ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise
their warrants for cash and we will not be required to net cash settle or cash settle the warrant exercise.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Warrant holders may elect to be subject to
a restriction on the exercise of their warrants such that an electing warrant holder would not be able to exercise their warrants to the
extent that, after giving effect to such exercise, such holder would beneficially own in excess of 9.9% of the New Silexion ordinary shares
outstanding.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">No fractional shares will be issued upon exercise
of the New Silexion warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share,
we will, upon exercise, round up to the nearest whole number the number of New Silexion ordinary shares to be issued to the warrant holder.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Contractual Arrangements
with respect to the New Silexion private warrants</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">So long as the New Silexion private warrants
are still held by the Sponsor, EarlyBird or their affiliates, the Company will not redeem such warrants, and the Company will allow the
holders to exercise such warrants on a cashless basis (even if a registration statement covering the New Silexion ordinary shares issuable
upon exercise of such warrants is not effective). However, once any of the New Silexion private warrants are transferred from the Sponsor,
EarlyBird or their affiliates, these arrangements will no longer apply. Furthermore, because the New Silexion private warrants were issued
in a private transaction, the holders and their transferees will be allowed to exercise the New Silexion private warrants for cash even
if a registration statement covering the New Silexion ordinary shares issuable upon exercise of such warrants is not effective and receive
unregistered New Silexion ordinary shares.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">132</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Listing of Securities</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our ordinary shares and New Silexion warrants
are listed on the Nasdaq under the symbols &#8220;SLXN&#8221; and &#8220;SLXNW&#8221;, respectively.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Transfer Agent and Registrar</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The transfer agent and registrar for the New
Silexion ordinary shares and warrant agent for the New Silexion warrants is Continental Stock Transfer&#160;&amp; Trust Company.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">Anti-Takeover&#160;Provisions in Our Articles.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Some provisions of our Articles may discourage,
delay or prevent a change in control of our company or management that shareholders may consider favorable.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">However, under Cayman Islands law, our directors
may only exercise the rights and powers granted to them under our Articles, as amended and restated from time to time, for a proper purpose
and for what they believe in good faith to be in the best interests of our company.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Authorized but Unissued shares</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The authorized but unissued New Silexion ordinary
shares are available for future issuance without shareholder approval, subject to any limitations imposed by the listing standards of
the Nasdaq and the Articles. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee
benefit plans. The existence of authorized but unissued and unreserved New Silexion ordinary shares could make more difficult or discourage
an attempt to obtain control of New Silexion by means of a proxy contest, tender offer, merger or otherwise.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Shareholder Action; Extraordinary General
Meetings</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our Articles provide that shareholders may
take action by unanimous written resolutions or at annual or extraordinary general meetings. As a result, a holder controlling a majority
of New Silexion ordinary shares would not be able to amend the Articles or remove directors without holding a meeting of shareholders
called in accordance with the Articles or the shareholders of New Silexion passing unanimous written resolutions to approve the same.
Further, the Articles provide that only the chairperson of the Board, or the New Silexion Board pursuant to a resolution adopted by a
majority of the directors then in office&#160;&#8212;&#160;and not shareholders&#160;&#8212;&#160;may call extraordinary general meetings
of shareholders, thus prohibiting a holder of New Silexion ordinary shares from calling an extraordinary general meeting. These provisions
might delay the ability of shareholders to force consideration of a proposal or for shareholders controlling a majority of New Silexion
to take any action, including the removal of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;<span style="font-style: italic">&#160;</span></div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Advance Notice Requirements for Shareholder
Proposals and Director Nominations</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The Articles provide that shareholders seeking
to bring business before our annual general meeting, or to nominate candidates for appointment as directors at its annual general meeting,
must provide timely notice. To be timely, a shareholder&#8217;s notice will need to be delivered to the Secretary of New Silexion at its
principal executive offices not less than 90&#160;days nor more than 120&#160;calendar days prior to the one-year&#160;anniversary of
the preceding year&#8217;s annual general meeting. In the event that no annual general meeting was held during the preceding year or the
date of the annual general meeting is more than 30&#160;days before or more than 60&#160;days after such anniversary date, to be timely,
a shareholder&#8217;s notice must be so delivered no earlier than the close of business on the 120<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>&#160;day
prior to such annual general meeting and not later than the 90<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>&#160;day
prior to such annual general meeting or, if later, the 10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>&#160;day
following the&#160;day on which public disclosure of the date of such annual general meeting is first made by New Silexion. The Articles
also specify certain requirements as to the form and content of a shareholders&#8217; notice. These provisions may preclude New Silexion
shareholders from bringing matters before our annual general meeting or from making nominations for directors at our annual general meeting.</div>
</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">133</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Supermajority Requirements for the Amendment
of the Articles</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Under the Companies Act (As Revised) of
the Cayman Islands, the Articles may be amended by a special resolution of shareholders, being a resolution passed by not less than two-thirds&#160;(2/3)
of our shareholders as being entitled to do so, vote in person or by proxy at a general meeting.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Board Vacancies</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The Articles provide that any vacancy on
the New Silexion Board may be filled by the affirmative vote of a majority of the directors then in office, even if less than a quorum,
or by a sole remaining director, and not by our shareholders. Any director chosen to fill a vacancy will hold office until the next annual
general meeting and until his or her successor is duly appointed and qualified, or until his or her earlier death, resignation, disqualification
or removal. In addition, the number of directors constituting the then-authorized&#160;size of the New Silexion Board is permitted to
be set only by a resolution adopted by the Board.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Exclusive Forum Selection</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">The Articles provide that, unless New Silexion consents in writing to the selection
of an alternative forum and to the fullest extent permitted by law, the courts of the Cayman Islands have exclusive jurisdiction over
any claim or dispute arising out of or in connection with the Articles or otherwise related in any way to each shareholder&#8217;s shareholding
in the Company, including but not limited to (i)&#160;any derivative action or proceeding brought on behalf of the Company, (ii)&#160;any
action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or
our shareholders, or (iii)&#160;any action asserting a claim arising pursuant to any provision of the Companies Act (As Revised) of the
Cayman Islands or the Articles, and each shareholder shall be deemed to have irrevocably submitted to the exclusive jurisdiction of the
courts of the Cayman Islands over all such claims or disputes.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">However, such forum selection provisions will
not apply to suits brought to enforce any liability or duty created by the Securities Act or the Exchange&#160;Act. The Articles also
provide that, unless New Silexion consents in writing to the selection of an alternative forum, the federal district courts of the United&#160;States
of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act
or the Exchange Act. There is uncertainty as to whether a court would enforce that exclusivity provision. Furthermore, investors cannot
waive compliance with the U.S. federal securities laws and the rules and regulations thereunder.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Any person or entity purchasing or otherwise
acquiring any interest in New Silexion shares shall be deemed to have notice of and consented to the forum selection provisions in the
Articles.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The choice of forum provisions may limit a
shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with New Silexion or its directors,
officers, or other employees, which may discourage such lawsuits against New Silexion and its directors, officers, and other employees.
Alternatively, if a court were to find the choice of forum provisions contained in the Articles to be inapplicable or unenforceable in
an action, New Silexion may incur additional costs associated with resolving such action in other jurisdictions, which could harm its
business, results of operations, and financial condition.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">134</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Transactions with Interested Shareholders.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Cayman Islands law does not have a business
combination statute (like in Delaware) applicable to public companies prohibiting them from engaging in certain business combinations
with an &#8220;interested shareholder&#8221;. As a result, we cannot avail ourselves of the types of protections afforded by a business
combination statute. However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders,
it does provide that such transactions must be entered into bona fide in the best interests of the company and for a proper corporate
purpose and not with the effect of constituting a fraud on the minority shareholders.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Limitation on Liability and Indemnification
of Directors and Officers</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Cayman Islands law does not limit the extent
to which a company&#8217;s memorandum and articles of association may provide for indemnification of officers and directors, except to
the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification
against willful default, willful neglect, actual fraud or the consequences of committing a crime. Our Articles provide that our directors
and officers shall be indemnified out of the assets of New Silexion against any liability, action, proceeding, claim, demand, costs, damages
or expenses, including legal expenses, whatsoever which they or any of them may incur as a result of any act or failure to act in carrying
out their functions other than such liability (if any) that they may incur by reason of their own actual fraud, wilful neglect or wilful
default. No such indemnified person shall be liable to New Silexion for any loss or damage incurred by New Silexion as a result (whether
direct or indirect) of the carrying out of their functions unless that liability arises through the actual fraud, wilful neglect or wilful
default of such indemnified person. No person shall be found to have committed actual fraud, wilful neglect or wilful default under the
foregoing unless or until a court of competent jurisdiction shall have made a finding to that effect.. In addition, the Articles provide
for the advancing of certain fees and costs to such indemnified persons and the purchase by New Silexion for insurance for the benefit
of its directors and officers as further described in the Articles.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to New Silexion directors, officers and controlling persons pursuant to the foregoing
provisions, or otherwise, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act
and is, therefore, unenforceable.</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: center; line-height: 1.25; font-weight: bold">DESCRIPTION OF SECURITIES <span id="OFFERED"><!--Anchor--></span>OFFERED</div>

<div style="text-align: center; line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">We are offering up to&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;
&#160;&#160; ordinary shares, together with&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ordinary warrants to purchase up to&#160;&#160;
&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160;ordinary shares. We are also offering to those purchasers,
if any, whose purchase of our ordinary shares in this offering would otherwise result in such purchaser, together with its affiliates
and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding ordinary
shares immediately following the consummation of this offering, the opportunity, in lieu of purchasing ordinary shares, to purchase pre-funded
warrants to purchase ordinary shares. For each pre-funded warrant we sell, the number of ordinary shares we are offering will be decreased
on a one-for-one basis. The pre-funded warrants will be sold together with ordinary warrants in a fixed combination, with each pre-funded
warrant to purchase one ordinary share accompanied by one ordinary warrant to purchase one ordinary share. We are also registering the
ordinary shares issuable from time to time upon exercise of the pre-funded warrants and ordinary warrants offered hereby.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-weight: bold">Ordinary Shares</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25">The material terms and provisions of our ordinary shares are described under the caption
&#8220;Description of Share Capital&#8221; in this prospectus.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-weight: bold">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Pre-Funded Warrants</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic">The following summary of certain terms and provisions of the pre-funded
warrants offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of pre-funded warrant the
form of which will be filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should
carefully review the terms and provisions of the form of pre-funded warrant for a complete description of the terms and conditions of
the pre-funded warrants.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The term &#8220;pre-funded&#8221; refers to the fact that the purchase price of our
ordinary shares in this offering includes almost the entire exercise price that will be paid under the pre-funded warrants, except for
a nominal remaining exercise price of $0.0001. The purpose of the pre-funded warrants is to enable investors that may have restrictions
on their ability to beneficially own more than 4.99% (or, at the election of each purchaser, 9.99%) of our outstanding ordinary shares
following the consummation of this offering the opportunity to make an investment in us without triggering their ownership restrictions,
by receiving pre-funded warrants in lieu of our ordinary shares which would result in such ownership of more than 4.99% (or, at the election
of each purchaser, 9.99%), and receive the ability to exercise their option to purchase the shares underlying the pre-funded warrants
at such nominal price at a later date.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">135</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25">Each pre-funded warrant is exercisable for one ordinary share, with an exercise price
equal to $0.0001 per ordinary share, at any time that the pre-funded warrant is outstanding. There is no expiration date for the pre-funded
warrants. The holder of a pre-funded warrant will not be deemed a holder of our underlying ordinary shares until the pre-funded warrant
is exercised.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">Subject to limited exceptions, a holder of pre-funded warrants will not have the right
to exercise any portion of its pre-funded warrants if the holder (together with such holder&#8217;s affiliates, and any persons acting
as a group together with such holder or any of such holder&#8217;s affiliates) would beneficially own a number of ordinary shares in excess
of 4.99% (or, at the election of each purchaser, 9.99%) of the ordinary shares then outstanding after giving effect to such exercise.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The exercise price and the number of ordinary shares issuable upon exercise of the pre-funded
warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations,
reclassifications, reorganizations or similar events affecting our ordinary shares. The pre-funded warrant holders must pay the exercise
price in cash upon exercise of the pre-funded warrants, unless such pre-funded warrant holders are utilizing the cashless exercise provision
of the pre-funded warrants.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">Upon the holder&#8217;s exercise of a pre-funded warrant, we will issue the ordinary
shares issuable upon exercise of the pre-funded warrant within two trading days following our receipt of a notice of exercise, provided
that payment of the exercise price has been made (unless exercised to the extent permitted via the &#8220;cashless&#8221; exercise provision).
Prior to the exercise of any pre-funded warrants to purchase ordinary shares, holders of the pre-funded warrants will not have any of
the rights of holders of ordinary shares purchasable upon exercise, including the right to vote, except as set forth therein.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">As an alternative to payment in immediately available funds, the holder may elect to
exercise the pre-funded warrant through a cashless exercise, in which the holder would receive upon such exercise the net number of ordinary
shares determined according to the formula set forth in the pre-funded warrant (in which case, the pre-funded warrants may only be exercised
via a &#8220;cashless&#8221; exercise provision).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">In the event of a fundamental transaction, as described in the pre-funded warrants and
generally including any reorganization, recapitalization or reclassification of our ordinary shares, the sale, transfer or other disposition
of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more
than 50% of our outstanding ordinary shares, or any person or group becoming the beneficial owner of more than 50% of the voting power
represented by our outstanding ordinary shares, the holders of the pre-funded warrants will be entitled to receive upon exercise of the
pre-funded warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised
the pre-funded warrants immediately prior to such fundamental transaction without regard to any limitations on exercised contained in
the pre-funded warrants.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">We do not intend to apply to list the pre-funded warrants on any securities exchange
or other trading system. Without an active trading market, the liquidity of the pre-funded warrants will be limited.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-weight: bold">Ordinary Warrants</div>

<div style="line-height: 1.25; font-weight: bold">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic">The following summary of certain terms and provisions of the ordinary
warrants offered together with the ordinary shares hereby is not complete and is subject to, and qualified in its entirety by, the form
of ordinary warrant, which will be filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors
should carefully review the terms and provisions set forth in the form of ordinary warrant.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Exercisability</span>. The ordinary warrants are exercisable
at any time after their original issuance and at any time up to the date that is five years after their original issuance. The ordinary
warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and,
at any time a registration statement registering the issuance of the ordinary shares underlying the ordinary warrants under the Securities
Act of 1933, as amended, or the Securities Act, is effective and available for the issuance of such shares, by payment in full in immediately
available funds for the number of ordinary shares purchased upon such exercise. If a registration statement registering the issuance of
ordinary shares underlying the ordinary warrants under the Securities Act is not effective or available the holder may, in its sole discretion,
elect to exercise the ordinary warrant through a cashless exercise, in which case the holder would receive upon such exercise the net
number of ordinary shares determined according to the formula set forth in the ordinary warrant. No fractional shares will be issued in
connection with the exercise of an ordinary warrant. In lieu of fractional shares, we will either pay the holder an amount in cash equal
to the fractional amount multiplied by the exercise price or round up to the next whole share.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">136</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Exercise Limitation</span>. A holder will not have
the right to exercise any portion of the ordinary warrant if the holder (together with its affiliates) would beneficially own in excess
of 4.99% (or, at the election of each purchaser, 9.99%) of the number of ordinary shares outstanding immediately after giving effect to
the exercise, as such percentage ownership is determined in accordance with the terms of the ordinary warrants. However, any holder may
increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall
not be effective until 61 days following notice from the holder to us.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Exercise Price</span>. The exercise price per whole
ordinary share purchasable upon exercise of the ordinary warrants is $&#160; &#160; &#160; &#160; per share. The exercise price is subject
to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications
or similar events affecting our ordinary shares and also upon any distributions of assets, including cash, stock or other property to
our stockholders.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Transferability</span>. Subject to applicable laws,
the ordinary warrants may be offered for sale, sold, transferred or assigned without our consent.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Exchange Listing</span>. We do not intend to apply
to list the ordinary warrants on any securities exchange or nationally recognized trading system. Without an active trading market, the
liquidity of the ordinary warrants will be limited.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Fundamental Transactions.</span>&#160;In the event
of a fundamental transaction, as described in the ordinary warrants and generally including any reorganization, recapitalization or reclassification
of our ordinary shares, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation
or merger with or into another person, the acquisition of more than 50% of our outstanding ordinary shares, or any person or group becoming
the beneficial owner of more than 50% of the voting power represented by our outstanding ordinary shares, the holders of the ordinary
warrants will be entitled to receive upon exercise of the ordinary warrants the kind and amount of securities, cash or other property
that the holders would have received had they exercised the ordinary warrants immediately prior to such fundamental transaction without
regard to any limitations on exercised contained in the ordinary warrants.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Rights as a Stockholder</span>. Except as otherwise
provided in the ordinary warrants or by virtue of such holder&#8217;s ownership of our ordinary shares, the holder of a ordinary warrant
does not have the rights or privileges of a holder of our ordinary shares, including any voting rights, until the holder exercises the
ordinary warrant.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Governing Law</span>. The ordinary warrants are governed
by New York law.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25; font-weight: bold">Placement Agent Warrants</div>

<div style="line-height: 1.25; font-weight: bold">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic">The following summary of certain terms and provisions of the Placement
Agent warrants is not complete and is subject to, and qualified in its entirety by, the form of Placement Agent warrant, which will be
filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors should carefully review the
terms and provisions set forth in the form of Placement Agent warrant.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25">We have agreed to issue to the Placement Agent, or its designees, warrants to purchase
up to&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; ordinary shares (which represents 7.0% of the aggregate number of
ordinary shares issued in this offering and issuable upon the exercise of the warrants and pre-funded warrants issued in this offering)
with an exercise price of $&#160; &#160; per ordinary share (representing 125% of the public offering price per ordinary share) and exercisable
for five&#160;years from the date of the commencement of sales in this offering. The Placement Agent warrants issued in this offering
will otherwise have substantially the same terms as the ordinary warrants. The Placement Agent warrants and underlying ordinary shares
are registered on the registration statement of which this prospectus is a part.</div> </div> </div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">137</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="MATERIALU.S.FEDERALINCOME"><!--Anchor--></span>MATERIAL
U.S. FEDERAL INCOME TAX CONSEQUENCES</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following discussion is a summary of certain
material U.S. federal income tax considerations generally applicable to the ownership and disposition of our ordinary shares and the exercise,
disposition and lapse of our warrants. The ordinary shares and the warrants are referred to collectively herein as our securities. All
prospective holders of our securities should consult their tax advisors with respect to the U.S. federal, state, local and non-U.S. tax
consequences of the ownership and disposition of our securities.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">This discussion is not a complete analysis
of all potential U.S. federal income tax consequences relating to the ownership and disposition of our securities. This summary is based
upon current provisions of the Code, existing U.S. Treasury Regulations promulgated thereunder, published administrative pronouncements
and rulings of the U.S. Internal Revenue Service (the<span style="font-weight: normal"> &#8220;IRS&#8221;), </span>and judicial decisions,
all as in effect as of the date of this prospectus. These authorities are subject to change and differing interpretation, possibly with
retroactive effect. Any change or differing interpretation could alter the tax consequences to holders described in this discussion. There
can be no assurance that a court or the IRS will not challenge one or more of the tax consequences described herein, and we have not obtained,
nor do we intend to obtain, a ruling with respect to the U.S. federal income tax consequences to a holder of the ownership or disposition
of our securities.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Tax Consequences of Ownership
and Disposition of New Silexion Securities</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Distributions on New Silexion ordinary shares</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Subject to the PFIC rules discussed below, the gross amount of any distribution on New
Silexion ordinary shares that is made out of our current or accumulated earnings and profits (as determined for U.S. federal income tax
purposes) generally will be taxable to a U.S. Holder as ordinary dividend income on the date such distribution is actually or constructively
received. Any such dividends generally will not be eligible for the dividends received deduction allowed to corporations in respect of
dividends received from U.S. corporations. To the extent that the amount of the distribution exceeds our current and accumulated earnings
and profits (as determined under U.S. federal income tax principles), such excess amount will be treated first as a non-taxable return
of capital to the extent of the U.S. Holder&#8217;s tax basis in its New Silexion ordinary shares, and thereafter as capital gain recognized
on a sale or exchange. However, it is not expected that New Silexion will maintain calculations of its earnings and profits principles.
U.S. Holders should therefore assume that any distribution by New Silexion with respect to New Silexion ordinary shares will be reported
as dividend income. U.S. Holders should consult their own tax advisors with respect to the appropriate U.S. federal income tax treatment
of any distribution received from New Silexion.</div>

<div style="text-indent: 36pt; line-height: 1.25"> <br/> </div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">138</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Subject to the PFIC rules discussed below,
dividends received by non-corporate&#160;U.S.&#160;Holders (including individuals) from a &#8220;qualified foreign corporation&#8221;
may be eligible for reduced rates of taxation, provided that certain holding period requirements and other conditions are satisfied. For
these purposes, a non-U.S.&#160;corporation will be treated as a qualified foreign corporation if it is eligible for the benefits of a
comprehensive income tax treaty with the United&#160;States that meets certain requirements. A non-U.S.&#160;corporation is also treated
as a qualified foreign corporation with respect to dividends it pays on shares that are readily tradable on an established securities
market in the United&#160;States. U.S.&#160;Treasury guidance indicates that shares listed on Nasdaq (such as the New Silexion ordinary
shares) will be considered readily tradable on an established securities market in the United&#160;States. There can be no assurance that
New Silexion ordinary shares will be considered readily tradable on an established securities market in future&#160;years. Further, New
Silexion will not constitute a qualified foreign corporation for purposes of these rules if it is a PFIC for the taxable year in which
it pays a dividend or for the preceding taxable year.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Subject to certain conditions and limitations,
non-refundable&#160;withholding taxes (at a rate not in excess of any applicable income tax treaty rate), if any, on dividends paid by
New Silexion may be treated as foreign taxes eligible for credit against a U.S.&#160;Holder&#8217;s U.S.&#160;federal income tax liability
under the U.S.&#160;foreign tax credit rules. However, as a result of recent changes to the U.S.&#160;foreign tax credit rules, a withholding
tax generally may need to satisfy certain additional requirements in order to be considered a creditable tax for a U.S.&#160;Holder. New
we have not determined whether these requirements have been met with respect to any withholding tax that may apply to dividends paid by
New Silexion and, accordingly, no assurance can be given that any such withholding tax will be creditable. For purposes of calculating
the U.S.&#160;foreign tax credit, dividends paid on New Silexion ordinary shares will generally be treated as income from sources outside
the United&#160;States and will generally constitute passive category income. The rules governing the U.S.&#160;foreign tax credit are
complex. U.S.&#160;Holders should consult their tax advisors regarding the availability of the U.S.&#160;foreign tax credit under their
particular circumstances.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Sale, Taxable Exchange or Other Taxable Disposition
of New Silexion Securities</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Subject to the PFIC rules discussed below,
upon any sale, exchange or other taxable disposition of any New Silexion security, a U.S.&#160;Holder generally will recognize gain or
loss in an amount equal to the difference between (i)&#160;the sum of (x)&#160;the amount cash and (y)&#160;the fair market value of any
other property, received in such sale, taxable exchange or other taxable disposition and (ii)&#160;the U.S.&#160;Holder&#8217;s adjusted
tax basis in such New Silexion security. Any such gain or loss generally will be capital gain or loss and will be long-term&#160;capital
gain or loss if the U.S.&#160;Holder&#8217;s holding period for such New Silexion security exceeds one year. Long-term&#160;capital gain
realized by a non-corporate&#160;U.S.&#160;Holder generally will be taxable at a reduced rate. The deductibility of capital losses is
subject to limitations.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">This gain or loss generally will be treated
as U.S.&#160;source gain or loss. Accordingly, in the event that any non-U.S.&#160;tax (including withholding tax) is imposed upon such
sale, exchange or other taxable disposition, a U.S.&#160;Holder may not be able to utilize foreign tax credits in respect of such non-U.S.&#160;tax.
In addition, there may be other limitations on utilizing foreign tax credits even if a U.S.&#160;Holder has foreign source income or gain
in the same category from other sources. The rules governing foreign tax credits are complex and U.S.&#160;Holders are urged to consult
their tax advisers regarding the creditability of foreign taxes in their particular circumstances.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Exercise, Lapse or Redemption of a New Silexion
Public Warrant</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Subject to the PFIC rules discussed below,
a U.S.&#160;Holder generally will not recognize gain or loss upon the acquisition of a New Silexion ordinary share on the exercise of
a New Silexion public warrant for cash. A U.S.&#160;Holder&#8217;s tax basis in a New Silexion ordinary share received upon exercise of
the New Silexion public warrant generally will equal the sum of the U.S.&#160;Holder&#8217;s tax basis in such New Silexion public warrant
and the exercise price. It is unclear whether a U.S.&#160;Holder&#8217;s holding period for the New Silexion ordinary share received will
commence on the date of exercise of the New Silexion public warrant or the&#160;day following the date of exercise of the New Silexion
public warrant; in either case, the holding period will not include the period during which the U.S.&#160;Holder held the New Silexion
public warrant. If a New Silexion public warrant is allowed to lapse unexercised, a U.S.&#160;Holder generally will recognize a capital
loss equal to such holder&#8217;s tax basis in the New Silexion public warrant.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">139</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The tax consequences of a cashless exercise
of a warrant are not clear under current law. Subject to the PFIC rules discussed below, a cashless exercise may not be taxable, either
because the exercise is not a realization event or because the exercise is treated as a recapitalization for U.S.&#160;federal income
tax purposes. In either situation, a U.S.&#160;Holder&#8217;s tax basis in New Silexion ordinary shares received generally should equal
the U.S.&#160;Holder&#8217;s tax basis in the New Silexion public warrants exercised therefor. If the cashless exercise was not a realization
event, it is unclear whether a U.S.&#160;Holder&#8217;s holding period for the New Silexion ordinary shares received would be treated
as commencing on the date of exercise of the New Silexion public warrants or the&#160;day following the date of exercise of the New Silexion
public warrants; in either case, the holding period will not include the period during which the U.S.&#160;Holder held the New Silexion
public warrants. If the cashless exercise were treated as a recapitalization, the holding period of the New Silexion ordinary shares received
would include the holding period of the New Silexion public warrants.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">It is also possible that a cashless exercise
could be treated in part as a taxable exchange in which gain or loss would be recognized. In such event, a U.S.&#160;Holder could be deemed
to have surrendered a number of New Silexion public warrants equal to the number of New Silexion ordinary shares having a value equal
to the exercise price for the total number of New Silexion public warrants to be exercised. In such case, subject to the PFIC rules discussed
below, the U.S.&#160;Holder would recognize capital gain or loss with respect to the New Silexion public warrants deemed surrendered in
an amount equal to the difference between the fair market value of the New Silexion ordinary shares that would have been received in a
regular exercise of the New Silexion public warrants deemed surrendered and the U.S.&#160;Holder&#8217;s tax basis in the New Silexion
public warrants deemed surrendered. In this case, a U.S.&#160;Holder&#8217;s aggregate tax basis in the New Silexion ordinary shares received
would equal the sum of the U.S.&#160;Holder&#8217;s tax basis in the New Silexion public warrants deemed exercised and the aggregate exercise
price of such New Silexion public warrants. It is unclear whether a U.S.&#160;Holder&#8217;s holding period for the New Silexion ordinary
shares would commence on the date of exercise of the New Silexion public warrants or the&#160;day following the date of exercise of the
New Silexion public warrants; in either case, the holding period will not include the period during which the U.S.&#160;Holder held the
New Silexion public warrants.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Due to the absence of authority on the U.S.&#160;federal
income tax treatment of a cashless exercise, including when a U.S.&#160;Holder&#8217;s holding period would commence with respect to New
Silexion ordinary shares received, there can be no assurance regarding which, if any, of the alternative tax consequences and holding
periods described above would be adopted by the IRS or a court of law. Accordingly, U.S.&#160;Holders should consult their tax advisors
regarding the tax consequences of a cashless exercise.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">Possible Constructive Distributions</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">The terms of each New Silexion public warrant provide for an adjustment to the number
of New Silexion ordinary shares for which the New Silexion public warrant may be exercised or to the exercise price of the New Silexion
public warrant in certain events, as discussed in the section of this prospectus entitled &#8220;<span style="font-style: italic">Description
of New Silexion Securities &#8212; Warrants.</span>&#8221; An adjustment which has the effect of preventing dilution generally is not
taxable. U.S. Holders of New Silexion public warrants would, however, be treated as receiving a constructive distribution from New Silexion
if, for example, the adjustment increases such U.S. Holders&#8217; proportionate interest in our assets or earnings and profits (e.g.,
through an increase in the number of New Silexion ordinary shares that would be obtained upon exercise or through a decrease in the exercise
price of the New Silexion public warrants), which adjustment may be made as a result of a distribution of cash or other property to the
holders of New Silexion ordinary shares. Such constructive distribution to a U.S. Holder of New Silexion public warrants would be treated
as if such U.S. Holder had received a cash distribution from New Silexion generally equal to the fair market value of such increased interest
(taxed as described above under &#8220;&#8212; <span style="font-style: italic">Distributions on New Silexion ordinary shares</span>&#8221;).</div>

<div style="text-indent: 36pt; line-height: 1.25"> <br/> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">140</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">PFIC Rules</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">In General</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The treatment of U.S.&#160;Holders of New
Silexion securities could be materially different from that described above if New Silexion is treated as a PFIC for U.S.&#160;federal
income tax purposes.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In general, a non-U.S.&#160;corporation is
a PFIC for U.S.&#160;federal income tax purposes for any taxable year in which, after applying certain look-through&#160;rules, (i)&#160;50%
or more of the value of its assets (generally determined on the basis of a weighted quarterly average) consists of assets that produce,
or are held for the production of, passive income, or (ii)&#160;75% or more of its gross income consists of passive income. Passive income
generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade
or business) and gains from the disposition of passive assets. Cash and cash equivalents generally are passive assets. The value of goodwill
will generally be treated as an active or passive asset based on the nature of the income produced in the activity to which the goodwill
is attributable. For purposes of the PFIC rules, a non-U.S.&#160;corporation that owns, directly or indirectly, at least 25% by value
of the stock of another corporation is treated as if it held its proportionate share of the assets of the other corporation and directly
received its proportionate share of the income of the other corporation.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The application of the PFIC rules to warrants
is uncertain. The Code provides that, to the extent provided in Treasury Regulations, if any person has an option to acquire shares of
a PFIC, the shares will be considered as owned by that person for purposes of the PFIC rules. Under proposed Treasury Regulations that
have a retroactive effective date, an option to acquire shares of a PFIC is generally treated as ownership of those PFIC shares. The remainder
of this discussion assumes that the PFIC rules will apply to New Silexion public warrants if New Silexion was a PFIC.&#160;However, U.S.&#160;Holders
should consult their tax advisers regarding the application of the PFIC rules to New Silexion public warrants prior to the finalization
of the proposed Treasury Regulations.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If non-U.S.&#160;corporation is treated as
a PFIC during a U.S.&#160;Holder&#8217;s holding period, it will, with respect to such U.S.&#160;Holder, always be treated as a PFIC,
regardless of whether it satisfied either of the qualification tests in subsequent&#160;years, subject to certain exceptions (such as
upon making a &#8220;deemed sale&#8221; election).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The adverse impact of the PFIC rules on a
U.S.&#160;Holder that holds shares in a PFIC may generally be mitigated if the U.S.&#160;Holder makes a timely qualified electing fund
(&#8220;<span style="font-weight: bold">QEF</span>&#8221;) election or mark-to-market&#160;election for the PFIC&#8217;s first taxable
year as a PFIC in which the U.S.&#160;Holder held (or was deemed to hold) shares, or a QEF election along with an applicable purging election
(collectively, &#8220;<span style="font-weight: bold">PFIC Elections</span>&#8221;). Further detail about the PFIC Elections is provided
below under &#8220;&#8212;<span style="font-style: italic">&#160;New Silexion Securities</span>&#8221;.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">New Silexion Securities</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The annual PFIC income and asset tests in respect of New Silexion will be applied based
on the assets and activities of the combined business. Based on the projected composition of our income and assets, it cannot be determined
whether New Silexion will be classified as a PFIC for its taxable year that includes the date of the Business Combination or in any future
taxable year. Further, changes in the composition of our income or composition of our assets may cause New Silexion to be or become a
PFIC for the current or subsequent taxable years. Whether New Silexion is treated as a PFIC for U.S. federal income tax purposes is a
factual determination that must be made annually at the close of each taxable year and, thus, is subject to significant uncertainty.</div>
</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If Moringa is determined to be a PFIC with
respect to any U.S.&#160;Holder who exchanges Moringa securities for New Silexion securities in connection with the SPAC Merger, the U.S.&#160;Holder
did not make any of the PFIC Elections, and the U.S.&#160;Holder is not subject to tax on the receipt of the New Silexion securities under
Section&#160;1291(f)&#160;of the Code or otherwise, then, although not free from doubt, New Silexion may also be treated as a PFIC as
to the New Silexion ordinary shares received by such U.S.&#160;Holder in the SPAC Merger, even if New Silexion is not a PFIC in its own
right. In addition, it is possible that proposed Treasury Regulations could be finalized in a manner that would treat any New Silexion
public warrants that are received in the SPAC Merger as subject to the PFIC rules.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">141</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If New Silexion is or becomes a PFIC during
any year in which a U.S.&#160;Holder holds New Silexion securities, there are three separate taxation regimes that could apply to such
U.S.&#160;Holder under the PFIC rules: (i)&#160;the excess distribution regime (which is the default regime), (ii)&#160;the QEF regime,
or (iii)&#160;the mark-to-market&#160;regime. A U.S.&#160;Holder who holds (actually or constructively) stock in a non-U.S.&#160;corporation
during any year in which such corporation qualifies as a PFIC is subject to U.S.&#160;federal income taxation under one of these three
regimes. The effect of the PFIC rules on a U.S.&#160;Holder will depend upon which of these regimes applies to such U.S.&#160;Holder.
However, dividends paid by a PFIC are not eligible for the lower rates of taxation applicable to qualified dividend income under any of
the foregoing regimes.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="text-decoration: underline">Excess
Distribution Regime</span>.&#160;&#160;&#160;&#160;If a U.S.&#160;Holder does not make or is not eligible to make a QEF election or a
mark-to-market&#160;election, as described below, the U.S.&#160;Holder will be subject to the default &#8220;excess distribution regime&#8221;
under the PFIC rules with respect to (i)&#160;any gain realized on a sale or other disposition (including a pledge) of New Silexion securities,
and (ii)&#160;any &#8220;excess distribution&#8221; on New Silexion securities (generally, any distributions in excess of 125% of the
average of the annual distributions on New Silexion securities during the preceding three taxable&#160;years or the U.S.&#160;Holder&#8217;s
Holding period, for the New Silexion securities that preceded the taxable year of the distribution whichever is shorter). Generally, under
this excess distribution regime</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2e3efc9d06de4246a5153cc178a04aa6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the U.S.&#160;Holder&#8217;s gain or excess distribution will
        be allocated ratably over the U.S.&#160;Holder&#8217;s holding period for the New Silexion securities;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z18c3e878309b4ca7ab0c8710fdfe2726" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the amount allocated to the U.S. Holder&#8217;s taxable year
        in which the U.S. Holder recognized the gain or received the excess distribution, or to the period in the U.S. Holder&#8217;s holding
        period before the first day of our first taxable year in which New Silexion is a PFIC, will be taxed as ordinary income;</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z302bfcae47b04e05a517083bc919c2f0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">the amount allocated to other taxable&#160;years (or portions
        thereof) of the U.S.&#160;Holder and included in its holding period will be taxed at the highest tax rate in effect for that year and
        applicable to the U.S.&#160;Holder without regard to the U.S.&#160;Holder&#8217;s other items of income and loss for such year; and</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z639611203b524ed784257dd4af879fcf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">an additional amount equal to the interest charge generally applicable
        to underpayments of tax will be imposed on the U.S.&#160;Holder with respect to the tax attributable to each such other taxable year of
        the U.S.&#160;Holder.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The tax liability for amounts allocated to&#160;years
prior to the year of disposition or excess distribution will be payable generally without regard to offsets from deductions, losses and
expenses. In addition, gains (but not losses) realized on the sale of a U.S.&#160;Holder&#8217;s New Silexion securities cannot be treated
as capital gains, even if such securities are held as capital assets. Further, no portion of any distribution will be treated as qualified
dividend income.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If New Silexion is, or is treated as, a PFIC
for any taxable year during which a U.S.&#160;Holder owns New Silexion securities and any entity in which New Silexion owns equity interests
is also a PFIC (a &#8220;lower-tier&#160;PFIC&#8221;), the U.S.&#160;Holder will be deemed to own their proportionate amount (by value)
of the shares of each lower-tier&#160;PFIC and will be subject to U.S.&#160;federal income tax according to the rules described above
on (i)&#160;certain distributions by a lower-tier&#160;PFIC and (ii)&#160;dispositions of shares of lower-tier&#160;PFICs, in each case,
as if the U.S.&#160;Holder held such shares directly, even though the U.S.&#160;Holder will not receive any proceeds of those distributions
or dispositions.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="text-decoration: underline">QEF
Regime</span>.&#160;&#160;&#160;&#160;A valid QEF election is effective for the taxable year for which the election is made and all subsequent
taxable&#160;years and may not be revoked without the consent of the IRS.&#160;If a U.S.&#160;Holder makes a timely QEF election with
respect to its direct or indirect interest in a PFIC, the U.S.&#160;Holder will be required to include in income each year its allocable
portion of the ordinary earnings and net capital gains of the PFIC as QEF income inclusions, even if such portion is not distributed to
the U.S.&#160;Holder. Thus, the U.S.&#160;Holder may be required to report taxable income as a result of QEF income inclusions without
corresponding receipts of cash. U.S.&#160;Holders of New Silexion securities should not expect that they will receive cash distributions
from New Silexion sufficient to cover their respective U.S.&#160;tax liability with respect to such QEF income inclusions. In addition,
U.S.&#160;Holders of New Silexion public warrants will not be able to make a QEF election with respect to their New Silexion public warrants.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">142</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The timely QEF election also allows the electing
U.S.&#160;Holder to: (i)&#160;generally treat any gain recognized on the disposition of its shares of the PFIC as capital gain; (ii)&#160;treat
its share of the PFIC&#8217;s net capital gain, if any, as long-term&#160;capital gain instead of ordinary income; and (iii)&#160;either
avoid interest charges resulting from PFIC status, or make an annual election, subject to certain limitations, to defer payment of current
taxes on its undistributed QEF income inclusions, subject to an interest charge on the deferred tax computed by using the statutory rate
of interest applicable to an extension of time for payment of tax. In addition, net losses (if any) of a PFIC will not pass through to
its shareholders and may not be carried back or forward in computing such PFIC&#8217;s ordinary earnings and net capital gain in other
taxable&#160;years.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">A U.S.&#160;Holder&#8217;s tax basis in New
Silexion ordinary shares will be increased to reflect QEF income inclusions and will be decreased to reflect distributions of amounts
previously included in income as QEF income inclusions. No portion of the QEF income inclusions attributable to ordinary income will be
treated as qualified dividend income. Amounts included as QEF income inclusions with respect to direct and indirect PFICs generally will
not be taxed again when distributed by such PFICs.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">A U.S.&#160;Holder may make a QEF election
with respect to its New Silexion ordinary shares only if New Silexion provides U.S.&#160;Holders on an annual basis with certain information,
including a &#8220;PFIC annual information statement&#8221; as described in the Treasury Regulations. If New Silexion determines that
it is a PFIC for any taxable year, it will endeavor to provide to a U.S.&#160;Holder such information as the IRS may require, including
a PFIC annual information statement, in order to enable a U.S.&#160;Holder to make and maintain a QEF election. However, there can be
no assurance that New Silexion will have timely knowledge of its status as a PFIC in the future or that New Silexion will timely provide
U.S.&#160;Holders with the required information on an annual basis to allow U.S.&#160;Holders to make and maintain a QEF election with
respect to the New Silexion ordinary shares in the event New Silexion is treated as a PFIC for any taxable year. The failure to provide
such information on an annual basis could prevent a U.S.&#160;Holder from making a QEF election or result in the invalidation or termination
of a U.S.&#160;Holder&#8217;s prior QEF election. In addition, as mentioned above, U.S.&#160;Holders of New Silexion public warrants will
not be able to make a QEF election with respect to their warrants.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">If a U.S.&#160;Holder makes a QEF election with respect to its New Silexion ordinary
shares in a year after our first taxable year as a PFIC in which the U.S.&#160;Holder held (or was deemed to hold) New Silexion ordinary
shares, then notwithstanding such QEF election, the excess distribution regime discussed above, adjusted to take into account the QEF
income inclusions resulting from the QEF election, will continue to apply with respect to such U.S.&#160;Holder&#8217;s New Silexion ordinary
shares, unless the U.S.&#160;Holder makes a purging election under the PFIC rules. Under one type of purging election, the U.S.&#160;Holder
will be deemed to have sold such New Silexion ordinary shares at their fair market value and any gain recognized on such deemed sale will
be treated as an excess distribution, as described above. As a result of such purging election, the U.S.&#160;Holder will have additional
basis (to the extent of any gain recognized on the deemed sale) and, solely for purposes of the PFIC rules, a new holding period in the
New Silexion ordinary shares.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, as mentioned above, U.S.&#160;Holders
of New Silexion public warrants will not be able to make a QEF election with respect to their warrants. As a result, if a U.S.&#160;Holder
sells or otherwise disposes of such New Silexion public warrants (other than upon exercise of such New Silexion public warrants) and New
Silexion were a PFIC at any time during the U.S.&#160;Holder&#8217;s holding period of such New Silexion public warrants, any gain recognized
generally will be treated as an excess distribution, taxed as described above. If a U.S.&#160;Holder that exercises such New Silexion
public warrants properly makes and maintains a QEF election with respect to the newly acquired New Silexion ordinary shares (or has previously
made a QEF election with respect to New Silexion ordinary shares), the QEF election will apply to the newly acquired New Silexion ordinary
shares. Notwithstanding such QEF election, the excess distribution rules discussed above, adjusted to take into account the current income
inclusions resulting from the QEF election, will continue to apply with respect to such newly acquired New Silexion ordinary shares (which,
while not entirely clear, generally will be deemed to have a holding period for purposes of the PFIC rules that includes the period the
U.S.&#160;Holder held the New Silexion public warrants), unless the U.S.&#160;Holder makes a purging election under the PFIC rules. U.S.&#160;Holders
are urged to consult their tax advisors as to the application of the rules governing purging elections to their particular circumstances.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">143</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="text-decoration: underline">Mark-to-Market&#160;Regime</span>.&#160;&#160;&#160;&#160;Alternatively,
a U.S.&#160;Holder may make an election to mark marketable shares in a PFIC to market on an annual basis. PFIC shares generally are marketable
if they are &#8220;regularly traded&#8221; on a national securities exchange that is registered with the SEC, such as Nasdaq. New Silexion
ordinary shares are listed on Nasdaq but there can be no assurance that New Silexion ordinary shares will continue to be so listed or
will be &#8220;regularly traded&#8221; for purposes of these rules. Pursuant to such an election, a U.S.&#160;Holder of New Silexion ordinary
shares would include in each year as ordinary income the excess, if any, of the fair market value of such stock or shares over its adjusted
basis at the end of the taxable year. A U.S.&#160;Holder may treat as ordinary loss any excess of the adjusted basis of the New Silexion
ordinary shares over its fair market value at the end of the year, but only to the extent of the net amount previously included in income
as a result of the election in prior&#160;years. A U.S.&#160;Holder&#8217;s adjusted tax basis in the New Silexion ordinary shares will
be increased to reflect any amounts included in income, and decreased to reflect any amounts deducted, as a result of a mark-to-market&#160;election.
Any gain recognized on a disposition of New Silexion ordinary shares in a taxable year in which New Silexion is a PFIC will be treated
as ordinary income and any loss will be treated as ordinary loss (but only to the extent of the net amount of income previously included
as a result of a mark-to-market&#160;election, and any loss in excess of such prior inclusions generally would be treated as a capital
loss). A mark-to-market&#160;election applies for the taxable year in which the election was made, and for each subsequent taxable year,
unless the PFIC shares cease to be marketable or the IRS consents to the revocation of the election. U.S.&#160;Holders should also be
aware that the Code and the Treasury Regulations do not allow a mark-to-market&#160;election with respect to stock of lower-tier&#160;PFICs
that is non-marketable. There is also no provision in the Code, Treasury Regulations or other published authority that specifically provides
that a mark-to-market&#160;election with respect to the stock of a publicly traded holding company (such as New Silexion) effectively
exempts stock of any lower-tier&#160;PFICs from the negative tax consequences arising from the general PFIC rules. U.S.&#160;Holders are
advised to consult their own tax advisor to determine whether the mark-to-market&#160;tax election is available to them and the consequences
resulting from such election. In addition, U.S.&#160;Holders of New Silexion public warrants will not be able to make a mark-to-market&#160;election
with respect to their New Silexion public warrants.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;<span style="font-style: italic">&#160;</span></div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">PFIC Reporting Requirements</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">A U.S.&#160;Holder that owns (or is deemed
to own) shares in a PFIC during any taxable year of the U.S.&#160;Holder generally is required to file an IRS Form&#160;8621 with such
U.S.&#160;Holder&#8217;s U.S.&#160;federal income tax return and provide such other information as the IRS may require. Failure to file
IRS Form&#160;8621 for each applicable taxable year may result in substantial penalties and result in the U.S.&#160;Holder&#8217;s taxable&#160;years
being open to audit by the IRS until such forms are properly filed.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">THE RULES DEALING WITH PFICS AND PFIC ELECTIONS
ARE VERY COMPLEX AND ARE AFFECTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE. ACCORDINGLY, U.S.&#160;HOLDERS OF NEW SILEXION
SECURITIES ARE URGED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE APPLICATION OF THE PFIC RULES TO NEW SILEXION SECURITIES UNDER THEIR
PARTICULAR CIRCUMSTANCES.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Additional Reporting Requirements</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Certain U.S.&#160;Holders may be required
to file an IRS Form&#160;926 (Return by a U.S.&#160;Transferor of Property to a Foreign Corporation) to report a transfer of property
(including cash) to New Silexion. Substantial penalties may be imposed on a U.S.&#160;Holder that fails to comply with this reporting
requirement, and the period of limitations on assessment and collection of U.S.&#160;federal income taxes will be extended in the event
of a failure to comply. Furthermore, certain U.S.&#160;Holders who are individuals and certain entities will be required to report information
with respect to such U.S.&#160;Holder&#8217;s investment in &#8220;specified foreign financial assets&#8221; on IRS Form&#160;8938 (Statement
of Specified Foreign Financial Assets), subject to certain exceptions. Specified foreign financial assets generally include any financial
account maintained with a non-U.S.&#160;financial institution and should also include New Silexion ordinary shares and New Silexion public
warrants if they are not held in an account maintained with a U.S.&#160;financial institution. Persons who are required to report specified
foreign financial assets and fail to do so may be subject to substantial penalties, and the period of limitations on assessment and collection
of U.S.&#160;federal income taxes may be extended in the event of a failure to comply. U.S.&#160;Holders are urged to consult their tax
advisors regarding the foreign financial asset and other reporting obligations and their application to an investment in New Silexion
ordinary shares and New Silexion public warrants.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">144</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">Information Reporting
and Backup Withholding</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Dividend payments with respect to New Silexion
ordinary shares and proceeds from the sale, exchange or redemption of New Silexion securities may be subject to information reporting
to the IRS and possible backup withholding. Backup withholding will not apply, however, to a U.S.&#160;Holder who furnishes a correct
taxpayer identification number and makes other required certifications, or who is otherwise exempt from backup withholding and establishes
such exempt status.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Backup withholding is not an additional tax.
Amounts withheld as backup withholding may be credited against a U.S.&#160;Holder&#8217;s U.S.&#160;federal income tax liability, and
a U.S.&#160;Holder generally may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the
appropriate claim for refund with the IRS and furnishing any required information.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160; </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="PLANOFDISTRIBUTION"><!--Anchor--></span>PLAN
OF DISTRIBUTION</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">We have engaged the Placement Agent,&#160; &#160; &#160; &#160; &#160; &#160; &#160;
&#160; &#160; &#160; &#160;&#160; , to act as our exclusive placement agent to solicit offers to purchase the securities offered pursuant
to this prospectus on a reasonable best efforts basis. The engagement agreement does not give rise to any commitment by the Placement
Agent to purchase any of our securities, and the Placement Agent will have no authority to bind us by virtue of the engagement agreement.
The Placement Agent is not purchasing or selling any of the securities offered by us under this prospectus, nor is it required to arrange
for the purchase or sale of any specific number or dollar amount of securities, other than to use its &#8220;reasonable best efforts&#8221;
to arrange for the sale of such securities by us. Therefore, we may not sell all of the securities being offered. The terms of this offering
were subject to market conditions and negotiations between us, the Placement Agent and prospective investors. This is a best efforts offering
and there is no minimum offering amount required as a condition to the closing of this offering. Because there is no minimum offering
amount required as a condition to closing this offering, we may sell fewer than all of the securities offered hereby, which may significantly
reduce the amount of proceeds received by us.. The Placement Agent does not guarantee that it will be able to raise new capital in any
prospective offering. The Placement Agent may engage sub-agents or selected dealers to assist with the offering.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">Investors purchasing securities offered hereby will have the option to execute a securities
purchase agreement with us. In addition to rights and remedies available to all purchasers in this offering under federal securities and
state law, the purchasers which enter into a securities purchase agreement will also be able to bring claims of breach of contract against
us. The ability to pursue a claim for breach of contract is material to larger purchasers in this offering as a means to enforce a covenant
to not enter into any equity financings for&#160; &#160; &#160;&#160; days from closing of the offering, subject to certain exceptions.
The nature of the representations, warranties and covenants in the securities purchase agreements shall include:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb372a56fd27a461cacf6b5d48e8f1f53" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>standard issuer representations and warranties on matters such as organization, qualification, authorization, no conflict, no governmental
        filings required, current in SEC filings, no litigation, labor or other compliance issues, environmental, intellectual property and title
        matters and compliance with various laws such as the Foreign Corrupt Practices Act; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z50a612d56f9042309138a2ec101ce96e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>covenants regarding matters such as registration of warrant shares, no integration with other offerings, no stockholder rights plans,
        no material nonpublic information, use of proceeds, indemnification of purchasers, reservation and listing of shares of common stock,
        and no subsequent equity sales for&#160; &#160; &#160; &#160; days, subject to certain exceptions.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The securities will be offered at a fixed price and are expected to be issued in a single
closing. We expect this offering to be completed not later than two business days following the commencement of this offering, which will
be the date that we enter into a securities purchase agreement to sell the securities offered hereby. We expect to close the offering
on or before&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; 2024. We will deliver all securities to be issued in connection with
this offering delivery versus payment/receipt versus payment upon receipt of investor funds received by us. Accordingly, neither we nor
the Placement Agent have made any arrangements to place investor funds in an escrow account or trust account since the Placement Agent
will not receive investor funds in connection with the sale of the securities offered hereunder.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">We expect to deliver the securities being offered pursuant to this prospectus on or
about [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;], 2024.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">145</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold">Fees and Expenses</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The following table shows the per ordinary share and accompanying ordinary warrant and
per pre-funded warrant and accompanying ordinary warrant and total placement agent fees we will pay in connection with the sale of the
securities in this offering.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman,Times,serif"><br/> </span></div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="cfttable" id="zc570bab172354fc3afc207ab3dda818b" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Per Ordinary Share and<br/> Accompanying Ordinary<br/> Warrant</div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Per Pre-Funded<br/> Warrant and Accompanying</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Ordinary Warrant</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Total</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Public offering price</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 64%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Placement agent fees</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Proceeds to us, before expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; font-family: Times New Roman,Times,serif"><br/>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman,Times,serif">&#160;</td>
        </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">We have agreed to pay the Placement Agent a cash fee equal to 7.0% of the aggregate
gross proceeds raised in this offering and a management fee equal to 1.0% of the gross proceeds raised in this offering. In addition,
we have agreed to pay the Placement Agent $25,000 for its non-accountable expenses and up to $100,000 for legal fees and out-of-pocket
expenses and for its clearing expenses in the amount of up to $15,950. We estimate the total offering expenses of this offering that will
be payable by us, excluding the Placement Agent fees and expenses, will be approximately $[&#160; &#160; &#160; &#160; ].</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Placement Agent Warrants</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">In addition, we have agreed to issue to the Placement Agent, or its designees, warrants
to purchase up to&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ordinary shares (which represents 7.0% of
the aggregate number of ordinary shares issued in this offering and issuable upon the exercise of the pre-funded warrants issued in this
offering) with an exercise price of $&#160; &#160;&#160; &#160; &#160; per ordinary share (representing 125% of the public offering price
per ordinary share and accompanying common warrant) and exercisable for five&#160;years from the date of the commencement of sales in
this offering. The Placement Agent warrants and underlying ordinary shares are registered on the registration statement of which this
prospectus is a part. The form of the Placement Agent warrant will be included as an exhibit to this registration statement of which this
prospectus forms a part.</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Right of First Refusal</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have granted the Placement Agent a right of first refusal for
a period of 12 months following the closing of this offering to act as exclusive financial advisor, sole book-running manager, sole underwriter,
sole placement agent or sole agent for each and every future debt financing or refinancing and public or private equity or debt offering
or acquisition or disposition by us or any of our successors or subsidiaries.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Tail</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">We have also agreed to pay the Placement Agent a tail fee equal to the cash and warrant
compensation in this offering, if any investor, who was contacted or introduced to us by the Placement Agent during the term of its engagement,
provides us with capital in any public or private offering or other financing or capital raising transaction during the 12-month period
following expiration or termination of our engagement of the Placement Agent.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Lock-up Agreements</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">We and our subsidiaries have agreed with the Placement Agent to be subject to a lock-up
period of 60 days following the date of closing of the offering pursuant to this prospectus. Each of our officers and directors have agreed
with the Placement Agent to be subject to a lock-up period of 90 days following the date of closing of the offering pursuant to this prospectus.
This means that, during the applicable lock-up period, we and such persons may not offer for sale, contract to sell, sell, distribute,
grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly, any of our shares
of ordinary shares or any securities convertible into, or exercisable or exchangeable for, shares of ordinary shares, subject to customary
exceptions. The Placement Agent may waive the terms of these lock-up agreements in its sole discretion and without notice. In addition,
we have agreed to not issue any securities that are subject to a price reset based on the trading prices of our ordinary shares or upon
a specified or contingent event in the future, or enter into any agreement to issue securities at a future determined price for a period
of two years following the closing date of this offering, subject to an exception. The Placement Agent may waive this prohibition in its
sole discretion and without notice.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">146</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold">Regulation M</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The Placement Agent may be deemed to be an underwriter within the meaning of Section
2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the securities sold by it
while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the
Placement Agent would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation,
Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of our securities
by the Placement Agent acting as principal. Under these rules and regulations, the Placement Agent (i) may not engage in any stabilization
activity in connection with our securities and (ii) may not bid for or purchase any of our securities or attempt to induce any person
to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Indemnification</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">We have agreed to indemnify the Placement Agent against certain liabilities, including
certain liabilities arising under the Securities Act, or to contribute to payments that the Placement Agent may be required to make for
these liabilities.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25; font-weight: bold">Determination of Offering Price and Ordinary Warrants Exercise Price</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">The actual offering price of the securities we are offering has been negotiated between
us and the investors in the offering based on the trading of our ordinary shares and warrants prior to the offering, among other things.
Other factors considered in determining the public offering price of the securities we are offering include our history and our prospects,
the state of the biotechnology industry in which we operate, our recent operating results, including results of our pre-clinical studies
and clinical trials, the general condition of the securities markets at the time of this offering, and such other factors as were deemed
relevant.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25; font-weight: bold">Electronic Offer, Sale and Distribution of Securities</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">A prospectus in electronic format may be made available on the websites maintained by
the Placement Agent, if any, participating in this offering and the Placement Agent may distribute prospectuses electronically. Other
than the prospectus in electronic format, the information on these websites is not part of this prospectus or the registration statement
of which this prospectus forms a part, has not been approved or endorsed by us or the Placement Agent, and should not be relied upon by
investors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25; font-weight: bold">Other Relationships</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">From time to time, the Placement Agent or its affiliates have in the past or may in
the future provide in the future, various advisory, investment and commercial banking and other services to us in the ordinary course
of business, for which they have received and may continue to receive customary fees and commissions. However, except as disclosed in
this prospectus, we have no present arrangements with the Placement Agent for any further services.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="line-height: 1.25; font-weight: bold">Listing</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">Our ordinary shares and warrants are currently listed on the Nasdaq Global Market under
the symbols &#8220;SLXN&#8221; and &#8220;SLXNW&#8221;, respectively.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">147</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="LEGALMATTERS"><!--Anchor--></span>LEGAL
MATTERS</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The legality of the ordinary shares offered
by this prospectus and certain other Cayman Islands legal matters will be passed upon for us by Conyers Dill&#160;&amp; Pearman&#160;LLP.&#160;The
legality of the ordinary warrants, pre-funded warrants and Placement Agent warrants offered by this prospectus and certain legal matters
relating to U.S. law will be passed upon for us by Greenberg Traurig LLP. The Placement Agent is being represented&#160; &#160; &#160;
&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160; .<br/> </div> </div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="EXPERTS"><!--Anchor--></span>EXPERTS</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">The financial statements of Moringa Acquisition Corp as of December 31, 2023 and 2022,
and for the two years ended December 31, 2023, included in this prospectus, have been so included in reliance on the report (which contains
an explanatory paragraph relating to the Company&#8217;s ability to continue as a going concern as described in Note 1e to the financial
statements) of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public
accounting firm, given on the authority of said firm as experts in auditing and accounting.</div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">The financial statements of Silexion Therapeutics Ltd. as of December 31, 2023 and 2022,
and for the two years ended December 31, 2023, included in this prospectus have been so included in reliance on the report (which contains
an explanatory paragraph relating to the Company&#8217;s ability to continue as a going concern as described in Note 1e to the financial
statements) of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public
accounting firm, given on the authority of said firm as experts in auditing and accounting.</div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">148</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span id="WHEREYOUCANFINDMOREINFORM"><!--Anchor--></span>WHERE
YOU CAN FIND MORE INFORMATION</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We have filed with the SEC a registration
statement on Form S-1 under the Securities Act, with respect to the securities being offered by this prospectus. This prospectus, which
constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits.
For further information with respect to New Silexion and the securities offered by this prospectus, we refer you to the registration statement
and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not
necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration
statement. Each of these statements is qualified in all respects by this reference. You can read our SEC filings, including the registration
statement, over the internet at the SEC&#8217;s website at <span style="font-style: italic">www.sec.gov</span>.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We are subject to the information reporting
requirements of the Exchange Act, and we file reports, proxy statements and other information with the SEC. These reports, proxy statements
and other information will be available for review at the SEC&#8217;s website at www.sec.gov. We also maintain a website at https://www.completesolaria.com/,
at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or
furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman,Times,serif"> </span></p>

<div class="BRPFPageNumberArea" style="text-align: center; font-family: Times New Roman,Times,serif"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal">149</span></div>


<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman,Times,serif"> </span></p>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div> <span style="font-family: Times New Roman,Times,serif"><br/> </span> </div>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman,Times,serif"></span></p>
<!-- Field: /Include-Text -->
</div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif"><a id="a_001"></a>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>INDEX TO FINANCIAL STATEMENTS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>TABLE OF CONTENTS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;width:89%">&#160;</td>
    <td style="padding-bottom:1.5pt;white-space:nowrap;width:1%;text-align:center">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;width:10%;text-align:center"><strong>Page</strong></td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td><span style="font-size:10pt"><strong>Moringa Acquisition Corp Condensed Consolidated Financial Statements</strong></span></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">&#160;</td></tr>
  <tr style="vertical-align:bottom">
    <td><a href="#f_001_integixAnchor"><span style="font-size:10pt">Condensed Consolidated Balance Sheets</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-2</td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td><a href="#f_002_integixAnchor"><span style="font-size:10pt">Condensed Consolidated Statements of Operations</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-3</td></tr>
  <tr style="vertical-align:bottom">
    <td><a href="#f_003_integixAnchor"><span style="font-size:10pt">Condensed Consolidated Statements of Changes in Capital Deficiency</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-4</td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td><a href="#f_004_integixAnchor"><span style="font-size:10pt">Condensed Consolidated Statements of Cash Flows</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-5</td></tr>
  <tr style="vertical-align:bottom">
    <td><a href="#f_005_integixAnchor"><span style="font-size:10pt">Notes to the Condensed Consolidated Financial Statements</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-6</td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:center">&#160;</td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">&#160;</td></tr>
  <tr style="vertical-align:bottom">
    <td><span style="font-size:10pt"><strong>Moringa Acquisition Corp Audited Financial Statements</strong></span></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">&#160;</td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td><a href="#f_006_integixAnchor"><span style="font-size:10pt">Report of Independent Registered Public Accounting Firm (PCAOB ID #&#160;1309)</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-22</td></tr>
  <tr style="vertical-align:bottom">
    <td><a href="#f_007_integixAnchor"><span style="font-size:10pt">Balance Sheets</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-23</td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td><a href="#f_008_integixAnchor"><span style="font-size:10pt">Statements of Operations</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-24</td></tr>
  <tr style="vertical-align:bottom">
    <td><a href="#f_009_integixAnchor"><span style="font-size:10pt">Statements of Changes in Capital Deficiency</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-25</td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td><a href="#f_010_integixAnchor"><span style="font-size:10pt">Statements of Cash Flows</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-26</td></tr>
  <tr style="vertical-align:bottom">
    <td><a href="#f_011_integixAnchor"><span style="font-size:10pt">Notes to Financial Statements</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-27</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>SILEXION THERAPEUTICS LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>CONSOLIDATED FINANCIAL STATEMENTS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;width:89%">&#160;</td>
    <td style="padding-bottom:1.5pt;white-space:nowrap;width:1%;text-align:center">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;width:10%;text-align:center"><strong>Page</strong></td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td><span style="font-size:10pt"><strong>Silexion Therapeutics Ltd. Condensed Consolidated Financial Statements</strong></span></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">&#160;</td></tr>
  <tr style="vertical-align:bottom">
    <td><a href="#f_012_integixAnchor"><span style="font-size:10pt">Condensed Consolidated Balance Sheets (unaudited)</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-40</td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td><a href="#f_014_integixAnchor"><span style="font-size:10pt">Condensed Consolidated Statements of Operations (unaudited)</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-42</td></tr>
  <tr style="vertical-align:bottom">
    <td><a href="#f_015_integixAnchor"><span style="font-size:10pt">Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred
        Shares and Capital Deficiency (unaudited)</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-43</td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td><a href="#f_016_integixAnchor"><span style="font-size:10pt">Condensed Consolidated Statements of Cash Flows (unaudited)</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-45</td></tr>
  <tr style="vertical-align:bottom">
    <td><a href="#f_017_integixAnchor"><span style="font-size:10pt">Notes to Condensed Consolidated Financial Statements (unaudited)</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-47</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:89%"><span style="font-size:10pt"><strong>Silexion Therapeutics Ltd. Audited Financial Statements</strong></span></td>
    <td style="white-space:nowrap;width:1%;text-align:center">&#160;</td>
    <td style="width:10%;text-align:center">&#160;</td></tr>
  <tr style="vertical-align:bottom">
    <td><a href="#f_018_integixAnchor"><span style="font-size:10pt">Report of Independent Registered Public Accounting Firm</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-58</td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td><span style="font-size:10pt"><strong>CONSOLIDATED FINANCIAL STATEMENTS:</strong></span></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">&#160;</td></tr>
  <tr style="vertical-align:bottom">
    <td><a href="#f_019_integixAnchor"><span style="font-size:10pt">Consolidated Balance Sheets</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-59</td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td><a href="#f_020_integixAnchor"><span style="font-size:10pt">Consolidated Statements of Operations</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-60</td></tr>
  <tr style="vertical-align:bottom">
    <td><a href="#f_021_integixAnchor"><span style="font-size:10pt">Consolidated Statements of Changes in Redeemable Convertible Preferred Shares
        and Capital Deficiency</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-61</td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td><a href="#f_022_integixAnchor"><span style="font-size:10pt">Consolidated Statements of Cash Flows</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-62</td></tr>
  <tr style="vertical-align:bottom">
    <td><a href="#f_023_integixAnchor"><span style="font-size:10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td style="white-space:nowrap;text-align:center">&#160;</td>
    <td style="text-align:center">F-63</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-1</span></p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div><span></span></div></div>

<div style="font:10pt Times New Roman, Times, Serif">

<div>

<div>

<div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="f_001_integixAnchor"></span></span></span></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>MORINGA
ACQUISITION CORP</strong></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS</span></span></p>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June&#160;30,</span></span></td>
    <td style="font-weight:bold">&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></td>
    <td style="font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note</span></span></td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;font-weight:bold;text-align:center">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
        Dollars</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align:center">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Assets</strong></span></span></td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASSETS:</span></span></td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:64%;text-align:left;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash
        and cash equivalents</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="width:11%;text-align:center">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608827_ixv-37589" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,880</ix:nonFraction></span></span></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608827_ixv-37590" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,278</ix:nonFraction></span></span></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investments
        held in Trust Account</span></span></td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608831_ixv-37591" name="us-gaap:AssetsHeldInTrust" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,924,118</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608831_ixv-37592" name="us-gaap:AssetsHeldInTrust" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697,632</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid
        expenses</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608836_ixv-37593" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,808</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608836_ixv-37594" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,305</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        ASSETS</span></span></td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608838_ixv-37595" name="us-gaap:Assets" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,966,806</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608838_ixv-37596" name="us-gaap:Assets" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,834,215</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liabilities
        and shares subject to possible redemption net of capital deficiency</span></span></td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LIABILITIES:</span></span></td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued expenses</span></span></td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608841_ixv-37597" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,191</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608841_ixv-37598" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,560</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Related party</span></span></td>
    <td>&#160;</td>
    <td style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608843_ixv-37599" name="us-gaap:NotesPayableCurrent" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,346,000</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608843_ixv-37600" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,861,000</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Private
        warrant liability</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608846_ixv-37601" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,284</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608846_ixv-37602" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,531</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        LIABILITIES</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608849_ixv-37603" name="us-gaap:Liabilities" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,428,475</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608849_ixv-37604" name="us-gaap:Liabilities" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,985,091</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMMITMENTS
        AND CONTINGENCIES</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608854_xbrl_20241004044359123" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608854_xbrl_20241004044433500" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CLASS
        A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION: <span style="font-style:normal;font-weight:normal"><ix:nonFraction id="Fxbrl_20241004120741524" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">515,019</ix:nonFraction>
        shares at redemption value of $<ix:nonFraction id="Fxbrl_20241004120754778" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">11.50
        </ix:nonFraction>and $<ix:nonFraction id="Fxbrl_20241004120811522" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">11.06</ix:nonFraction>
        as of June 30, 2024 and December 31, 2023, respectively</span></span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608859_ixv-37609" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,924,118</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608859_ixv-37610" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697,632</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:10pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CAPITAL DEFICIENCY:</span></span></td>
    <td>&#160;</td>
    <td style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-9pt;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Class
        A Ordinary Shares, $<ix:nonFraction id="Fxbrl_20241004124428632" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124423872" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>
        par value; <ix:nonFraction id="Fxbrl_20241004124103663" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124056483" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction>
        shares authorized, <ix:nonFraction id="Fxbrl_20241004124205179" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124158838" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124147886" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124142984" name="us-gaap:CommonStockSharesIssued" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,354,999</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        issued and outstanding (excluding 515,019 shares subject to possible redemption) as of June 30, 2024 and December 31, 2023;</span></span></td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608862_ixv-37619" name="us-gaap:CommonStockValue" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608862_ixv-37620" name="us-gaap:CommonStockValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Class
        B Ordinary Shares, $<ix:nonFraction id="Fxbrl_20241004124445560" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124342863" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>
        par value; <ix:nonFraction id="Fxbrl_20241004124607686" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124602293" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></ix:nonFraction>
        shares authorized, <ix:nonFraction id="Fxbrl_20241004124709401" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124701422" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124648879" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124643246" name="us-gaap:CommonStockSharesIssued" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        issued and outstanding as of June 30, 2024 and December 31, 2023;</span></span></td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20241004054608864_hidden-fact-2">*</span></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20241004054608864_hidden-fact-3">*</span></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred
        Shares, $<ix:nonFraction id="Fxbrl_20241004124849683" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124816713" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>
        par value; <ix:nonFraction id="Fxbrl_20241004124924968" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124921281" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction>
        shares authorized, <ix:nonFraction id="Fxbrl_20241004132221375" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20241004132214715" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20241004132204312" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20241004132133690" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of June 30, 2024 and December 31, 2023.</span></span></td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608869_xbrl_20241003053051232_ixv-37619" name="us-gaap:PreferredStockValue" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608869_xbrl_20241003053051232_ixv-37620" name="us-gaap:PreferredStockValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated
        deficit</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004054608872_ixv-37633" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,386,123</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004054608872_ixv-37634" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,844</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        CAPITAL DEFICIENCY</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004054608875_ixv-37635" name="us-gaap:StockholdersEquity" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,385,787</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004054608875_ixv-37636" name="us-gaap:StockholdersEquity" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,508</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        LIABILITIES AND SHARES SUBJECT TO POSSIBLE REDEMPTION NET OF CAPITAL DEFICIENCY</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:center;padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608877_ixv-37637" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,966,806</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004054608877_ixv-37638" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,834,215</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>*</strong></span></span></td>
    <td><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less than one US dollar</span></span></td> </tr>
  </table>

<div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements</strong>.</span></span></p> </div>
</div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-2</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div><span id="f_002_integixAnchor"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Note</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Six&#160;months&#160;ended<br/>June 30,</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Three months ended<br/>June 30,</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">U.S. Dollars</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">U.S. Dollars</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Except share data</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Except share data</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:42%;text-align:left;text-indent:-9pt;padding-left:9pt">INTEREST EARNED ON INVESTMENTS HELD IN TRUST ACCOUNT</td>
    <td style="width:1%">&#160;</td>
    <td style="width:9%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37639" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">149,236</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37640" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,063,043</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37641" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">75,305</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37642" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">318,002</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-9pt;padding-left:9pt">GENERAL AND ADMINISTRATIVE</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37643" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">441,276</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37644" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">592,201</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37645" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">179,135</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37646" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">155,472</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">CHANGE IN FAIR VALUE OF WARRANT LIABILITY</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37647" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,753</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37648" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,301</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37649" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,745</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37650" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">418</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">NET PROFIT (LOSS) FOR THE PERIOD</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:center;padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37651" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">310,793</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37652" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">476,143</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37653" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">110,575</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37654" name="us-gaap:ProfitLoss" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,948</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt;font-weight:bold;text-align:left;text-indent:-9pt;padding-left:9pt">WEIGHTED AVERAGE NUMBER OF CLASS A ORDINARY
        SHARES SUBJECT TO POSSIBLE REDEMPTION</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:center">8</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37655" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">515,019</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37656" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,015,185</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37657" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">515,019</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37658" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,589,567</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">NET PROFIT PER CLASS A ORDINARY SHARE SUBJECT
        TO POSSIBLE REDEMPTION &#8211; BASIC AND DILUTED</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241003011922954" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37659" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.32</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241003011941050" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37660" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.22</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241003011957530" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37661" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.17</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241003012015225" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37662" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.19</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;font-weight:bold;text-align:left;text-indent:-9pt;padding-left:9pt">WEIGHTED AVERAGE NUMBER OF NON-REDEEMABLE
        CLASS A AND CLASS B ORDINARY SHARES</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:center">8</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37663" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37664" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37665" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37666" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">NET LOSS PER NON-REDEEMABLE CLASS A AND
        CLASS B ORDINARY SHARES &#8211; BASIC AND DILUTED</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:right;padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fxbrl_20241003012046420" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-37667" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.14</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fxbrl_20241003012101706" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-37668" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.19</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fxbrl_20241003012114195" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-37669" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.06</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fxbrl_20241003012125221" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-37670" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.10</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="text-indent:0.25in;font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>The accompanying notes are
an integral part of these unaudited condensed consolidated financial statements.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-3</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>&#160;</strong></p>

<div><span id="f_003_integixAnchor"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES
IN CAPITAL DEFICIENCY</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Class A<br/>ordinary shares</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Class B<br/>ordinary shares</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:center">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:center;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total</strong></td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid black;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt">Number&#160;of</p>
        <p style="margin-top:0pt;margin-bottom:0pt">shares</p> </td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid black;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt">Par value</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid black;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt">Number&#160;of</p>
        <p style="margin-top:0pt;margin-bottom:0pt">shares</p> </td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid black;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt">Par value</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid black;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt">Accumulated</p>
        <p style="margin-top:0pt;margin-bottom:0pt">deficit</p> </td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid black;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt">capital</p>
        <p style="margin-top:0pt;margin-bottom:0pt">deficiency</p> </td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="22">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:37%;font-weight:bold;text-indent:-9pt;padding-left:9pt">BALANCE AT December 31, 2022</td>
    <td style="width:0.5%">&#160;</td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37671" name="us-gaap:SharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">480,000</ix:nonFraction></td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:0.5%">&#160;</td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37672" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:0.5%">&#160;</td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37673" name="us-gaap:SharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction></td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:0.5%">&#160;</td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37674" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:0.5%">&#160;</td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-37675" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,203,097</ix:nonFraction></td>
    <td style="width:0.5%;text-align:left">)</td>
    <td style="width:0.5%">&#160;</td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-37676" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,202,761</ix:nonFraction></td>
    <td style="width:0.5%;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-9pt;padding-left:9pt">&#160;Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of March 31, 2023</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37677" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230101to20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">905,040</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37678" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230101to20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">905,040</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">Net profit for the period</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37679" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">313,195</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37680" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">313,195</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">BALANCE AT March 31, 2023</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37681" name="us-gaap:SharesOutstanding" contextRef="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">480,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37682" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37683" name="us-gaap:SharesOutstanding" contextRef="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37684" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37685" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,794,942</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37686" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,794,606</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-9pt;padding-left:9pt">Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of June 30, 2023</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37687" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">558,002</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37688" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">558,002</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">Net profit for the period</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37689" name="us-gaap:ProfitLoss" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,948</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37690" name="us-gaap:ProfitLoss" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,948</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">BALANCE AT June 30, 2023</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37691" name="us-gaap:SharesOutstanding" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">480,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37692" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37693" name="us-gaap:SharesOutstanding" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37694" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37695" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,189,996</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37696" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,189,660</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-indent:-9pt;padding-left:9pt">BALANCE AT December 31, 2023</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37697" name="us-gaap:SharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,354,999</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37698" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37699" name="us-gaap:SharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="-sec-ix-hidden:Fhidden-fact-70">*</span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37700" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,844</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37701" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,508</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-9pt;padding-left:9pt">Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of March 31, 2024</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37702" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20240101to20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">112,558</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37703" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20240101to20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">112,558</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">Net loss for the period</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37704" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">200,218</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37705" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">200,218</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">BALANCE AT March 31, 2024</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37706" name="us-gaap:SharesOutstanding" contextRef="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,354,999</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37707" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37708" name="us-gaap:SharesOutstanding" contextRef="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="-sec-ix-hidden:Fhidden-fact-71">*</span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37709" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,161,620</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37710" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,161,284</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-9pt;padding-left:9pt">Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of June 30, 2024</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37711" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">113,928</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37712" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">113,928</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">Net loss for the period</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37713" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">110,575</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37714" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">110,575</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">BALANCE AT June 30, 2024</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37715" name="us-gaap:SharesOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,354,999</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37716" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37717" name="us-gaap:SharesOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="-sec-ix-hidden:Fhidden-fact-72">*</span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37718" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,386,123</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37719" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,385,787</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in;text-align:left"><strong>*</strong></td>
    <td style="text-align:justify">Less than one US dollar</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-4</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>&#160;</strong></p>

<div><span id="f_004_integixAnchor"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<div>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong style="font-size:10pt">MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span></p>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six
        months ended<br/>June 30,</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH FLOWS
        FROM OPERATING ACTIVITIES:</span></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        profit (loss) for the period</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526668_ixv-37721" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">310,793</ix:nonFraction></span></span></td>
    <td style="width:1%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526668_ixv-37722" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">476,143</ix:nonFraction></span></span></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments
        to reconcile net profit (loss) to net cash provided by (used in) operating activities:</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change
        in the fair value of the private warrant liability</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526672_ixv-37723" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,753</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526672_ixv-37724" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,301</ix:nonFraction></span></span></td>
    <td style="text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in
        operating assets and liabilities:</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease
        in prepaid expenses</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526675_ixv-37725" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,497</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526675_ixv-37726" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,023</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        (decrease) in related party</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526678_ixv-37727" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></span></td>
    <td style="text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526678_ixv-37728" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">30,000</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        (decrease) in accrued expenses</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526680_ixv-37729" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">60,369</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526680_ixv-37730" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,993</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        cash provided by (used in) operating activities</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526685_ixv-37731" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">368,912</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526685_ixv-37732" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">517,858</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH FLOWS
        FROM FINANCING ACTIVITIES:</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Partial
        redemption of Class A ordinary shares subject to possible redemption</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526688_ixv-37733" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">90,750,217</ix:nonFraction></span></span></td>
    <td style="text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds
        from promissory notes &#8211; related party</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526690_ixv-37734" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">505,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526690_ixv-37735" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">920,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        cash provided by (used in) financing activities</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526692_ixv-37736" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">505,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526692_ixv-37737" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">89,830,217</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;font-weight:bold;text-align:left;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INCREASE
        (DECREASE) IN CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526695_ixv-37738" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,088</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526695_ixv-37739" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">89,312,359</ix:nonFraction></span></span></td>
    <td style="text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH,
        CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT BEGINNING OF PERIOD</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526697_ixv-37740" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,805,910</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526697_ixv-37741" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,751,752</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH,
        CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT END OF PERIOD</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526701_ixv-37742" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,941,998</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526701_ixv-37743" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,439,393</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-10pt;padding-left:10pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-weight:bold;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">RECONCILIATION
        OF CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT:</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and
        cash equivalents</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526703_ixv-37744" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,880</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526703_ixv-37745" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,530</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investments
        held in trust account</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526706_ixv-37746" name="us-gaap:AssetsHeldInTrust" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,924,118</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526706_ixv-37747" name="us-gaap:AssetsHeldInTrust" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,404,863</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:4pt;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        cash, cash equivalents and investments held in a trust account</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526708_ixv-37748" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,941,998</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526708_ixv-37749" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,439,393</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<div>&#160;</div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</strong></span></span></p> </div>
</div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-5</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div><span id="f_005_integixAnchor"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> </div> <ix:nonNumeric id="Fxbrl_20241003000117614" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Organization and General</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Moringa Acquisition Corp (hereafter &#8211; the
Company) is a blank check company, incorporated on September 24, 2020 as a Cayman Islands exempted company, formed for the purpose of
effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination (hereafter &#8211;
the Business Combination). The Company is an emerging growth company, as defined in Section&#160;2(a) of the Securities Act of 1933, as
amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;).</p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company has selected December 31 as its fiscal
year end.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Sponsor and Financing</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company&#8217;s sponsor is Moringa Sponsor,
L.P., a Cayman exempted limited partnership (which is referred to herein, together with its wholly-owned subsidiary, Moringa Sponsor (US)
LP, a Delaware limited partnership, as the &#8220;Sponsor&#8221;).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Refer to Note 7(a) for information regarding the
aggregate withdrawals of approximately $<ix:nonFraction id="Fixv-37750" name="slxn:PartialRedemptionsAmount" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">113</ix:nonFraction>
million, due to partial redemptions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>c.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>The Trust Account</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The proceeds held in the Trust Account are invested
in money market funds registered under the Investment Company Act and compliant with Rule 2a-7 thereof that maintain a stable net asset
value of $<ix:nonFraction id="Fixv-37751" name="us-gaap:NetAssetValuePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">1.00</ix:nonFraction>.</p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company complies with the provisions of ASU
2016-18, under which changes in Investments held in the Trust Account are accounted for as Changes in Cash, Cash Equivalents and Investments
Held in a Trust Account in the Company&#8217;s Statements of Cash Flows.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Refer to Note 4(a) for information regarding proceeds
received from the Sponsor under the Sixth and Eighth Promissory Notes, deposited into the Trust Account.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-6</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>d.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Initial Business Combination</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company&#8217;s management has broad discretion
with respect to the specific application of the net proceeds of the Public Offering, although substantially all of the net proceeds of
the Public Offering and the Private Placement are intended to be generally applied toward consummating an initial Business Combination.
The initial Business Combination must occur with one or more operating businesses or assets with a fair market value equal to at least
<ix:nonFraction id="Fixv-37752" name="slxn:BusinessCombinationOfNetAssetsHeldInTrustAccount" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction>%
of the net assets held in the Trust Account (excluding taxes payable on the income accrued in the Trust Account). There is no assurance
that the Company will be able to successfully consummate an initial Business Combination.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company, after signing a definitive agreement
for an Initial Business Combination, will provide its public shareholders the opportunity to redeem all or a portion of their shares upon
the completion of the initial Business Combination, either (i) in connection with a shareholder meeting called to approve the business
combination or (ii) by means of a tender offer.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">If the Company holds a shareholder vote or there
is a tender offer for shares in connection with an initial Business Combination, a public shareholder will have the right to redeem its
shares for an amount in cash equal to its pro rata share of the aggregate amount then on deposit in the Trust Account, calculated as of
two days prior to the general meeting or commencement of the Company&#8217;s tender offer, including interest but less taxes payable.
As a result, the Company&#8217;s Public Class A ordinary shares are classified as temporary equity upon the completion of the Public Offering,
in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;)
480, &#8220;Distinguishing Liabilities from Equity.&#8221;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Pursuant to the Company&#8217;s amended and restated
memorandum and articles of association, as amended, if the Company is unable to complete the initial Business Combination within 42 months
from the Closing of the Public Offering, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly
as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash,
equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable,
and less up to $<ix:nonFraction id="Fixv-37753" name="slxn:InterestToPayDissolutionExpenses" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction>
of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish
public shareholders&#8217; rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii)
as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining shareholders and
the Company&#8217;s board of directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands
law to provide for claims of creditors and the requirements of other applicable law.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Sponsor and the Company&#8217;s officers and
directors have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions
from the Trust Account with respect to any Class B ordinary share (as described in Note 7) held by them if the Company fails to complete
the initial Business Combination within 24 months of the Closing of the Public Offering or during any extended time that the Company has
to consummate an initial Business Combination beyond 24 months as a result of a shareholder vote to amend its amended and restated memorandum
and articles of association. However, if the Sponsor or any of the Company&#8217;s directors or officers acquire any Class A ordinary
shares, they will be entitled to liquidating distributions from the Trust Account with respect to such shares if the Company fails to
complete the Initial Business Combination within the prescribed time period.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:center">&#160;</p> </div>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-7</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">In the event of a liquidation, dissolution or
winding up of the Company after an initial Business Combination, the Company&#8217;s shareholders are entitled to share ratably in all
assets remaining available for distribution to them after payment of liabilities and after provision is made for each class of stock,
if any, having preference over the ordinary shares. The Company&#8217;s shareholders have no preemptive or other subscription rights.
There are no sinking fund provisions applicable to the ordinary shares, except that the Company will provide its shareholders with the
opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the Trust
Account, under the circumstances, and, subject to the limitations, described herein.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On February 9, 2023 the Company held an extraordinary
general meeting in lieu of the 2022 annual general meeting of the Company (hereafter &#8211; the First Extension Meeting). At the First
Extension Meeting, the Company&#8217;s shareholders approved the proposal to adopt, by way of special resolution, an amendment to the
Amended and Restated Articles to extend the date by which the Company has to consummate a business combination from the 24 month anniversary
of the Closing of the Public Offering &#8211; i.e., February 19, 2023 to August 19, 2023 (hereafter &#8211; the Extended Mandatory Liquidation
Date) or such earlier date as may be determined by the Board in its sole discretion.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On August 18, 2023 the Company held an extraordinary
general meeting in lieu of the 2023 annual general meeting of the Company (hereafter &#8211; the Second Extension Meeting). At the Second
Extension Meeting, the Company&#8217;s shareholders approved, among other proposals, an amendment to the Amended and Restated Memorandum
and Articles of Association to further extend the date by which the Company has to consummate a business combination from the Extended
Mandatory Liquidation Date to August 19, 2024 (hereafter &#8211; the Second Extended Mandatory Liquidation Date) or such earlier date
as may be determined by the Board in its sole discretion.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Refer to Note 7(a) for information regarding the
partial redemptions of Class A ordinary shares subject to possible redemption, following the First and Second Extensions, and for information
regarding the conversion of Class B ordinary shares into Class A ordinary shares, following the Second Extension Meeting.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>e.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Substantial Doubt about the Company&#8217;s Ability to
        Continue as a Going Concern</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">As of June 30, 2024, the Company had approximately
$<ix:nonFraction id="Fixv-37754" name="us-gaap:Cash" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction>
thousand of cash and an accumulated deficit of $<ix:nonFraction id="Fixv-37755" name="us-gaap:RetainedEarningsAppropriated" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,386</ix:nonFraction>
thousand. In connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standard
Board&#8217;s Accounting Standard Codification 205-40, &#8220;Going Concern&#8221;, the Company will need to obtain additional funds in
order to satisfy its liquidity needs in its current endeavors to consummate the Proposed Silexion Merger, as detailed in Note 1(f), or
a different Initial Business Combination, if the former does not occur.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-8</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Since its inception date and through the issuance
date of these unaudited condensed consolidated financial statements, the Company&#8217;s liquidity needs were satisfied through an initial
capital injection from the Sponsor, followed by net Private Placement proceeds, as well as several withdrawals of the Sponsor promissory
notes. Management has determined that it will need to continue to rely and is significantly dependent on both outstanding and future promissory
notes, or other forms of financial support (all of which the Sponsor is not obligated to provide). Moreover, following the Second Extension
Meeting, the Company has until August 19, 2024 to consummate an Initial Business Combination. If a business combination is not consummated
by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. There can be no assurance that the Company
will be able to consummate any business combination ahead of the Second Extended Mandatory Liquidation Date, nor will it be able to raise
sufficient funds to complete an Initial Business Combination. These matters raise substantial doubt about the Company&#8217;s ability
to continue as a going concern, for the subsequent twelve months following the issuance date of these unaudited condensed consolidated
financial statements.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">In February 2024, the Company entered into a Business
Combination Agreement with Silexion Therapeutics Ltd. (hereafter &#8211; Silexion), an Israeli company which is in its developmental stage,
dedicated to the development of innovative treatments for pancreatic cancer. Refer to Note 1(f) for further information regarding the
Proposed Silexion Merger.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">No adjustments have been made to the carrying
amounts of assets or liabilities should the company fail to obtain financial support in its pursuit to consummate an Initial Business
Combination, nor if it is required to liquidate after the Second Extended Mandatory Liquidation Date.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>f.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Proposed Business Combination</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On February 21, 2024, the Company, together with
its wholly-owned Israeli subsidiary <span>April M.G. Ltd</span>. &#8211; which was incorporated due to the original business combination
structure, entered into a business combination agreement with Silexion (hereafter &#8211; the Proposed Silexion Merger).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The&#160;Proposed Silexion Merger is expected
to close in the third quarter of 2024, subject to the satisfaction of customary closing conditions under the Business Combination Agreement,
including the approval of the business combination by Silexion&#8217;s and the Company&#8217;s shareholders, as well as Nasdaq&#8217;s
approval of the initial listing of the combined company&#8217;s securities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Proposed Silexion Merger have been unanimously
approved by the boards of directors of the Company and&#160;Silexion.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:left">On April 3, 2024, the Proposed Silexion Merger
contemplated under the original Proposed Silexion Merger agreement was restructured pursuant to the Business Combination Agreement, by
and among New Pubco (a newly formed Cayman Islands exempted company), its two newly-formed subsidiaries &#8211; Merger Sub 1 and Merger
Sub 2 &#8211; the Company and Silexion.&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:justify">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-9</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:left">As contemplated under the Business Combination
Agreement, Merger Sub 2 will merge with and into the Company, with the Company continuing as the surviving company and a wholly-owned
subsidiary of New Pubco, and Merger Sub 1 will merge with and into Silexion, with Silexion continuing as the surviving company and a wholly-owned
subsidiary of New Pubco. The shareholders and other equity holders of each of the Company and Silexion will receive corresponding securities
of New Pubco as consideration in the Prospective Business Combination at set ratios in exchange for their securities of Company and Silexion,
respectively.&#160;New Pubco will serve as the public company upon completion of the Proposed Business Combination, with its ordinary
shares and warrants listed for trading on Nasdaq.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:left">The foregoing description of the Proposed Business
Combination, as amended, does not purport to be complete. For further information and access to the full agreement and all other related
agreements, refer to the Company&#8217;s Current Report on Form 8-K filed with the SEC on April 3, 2024.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt">In connection with the Proposed Silexion Merger, on May 9,
2024, New Pubco filed with the SEC a Registration Statement on Form S-4, and has subsequently filed amendments on June 24, 2024, July
7, 2024 and July 12, 2024, that include a document that will serve as both a prospectus for the securities to be issued by New Pubco in
the Prospective Business Combination to security holders of the Company and Silexion, as well as a proxy statement of the Company for
the Company&#8217;s extraordinary general meeting at which the Prospective Business Combination and the Business Combination Agreement
(among other matters) was presented for approval (see note 9). The SEC staff declared the New Pubco Registration Statement effective on
July 16, 2024.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>g.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Impact of War in Israel</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Israel&#8217;s current war against the terrorist
organization Hamas continued to rage during the second quarter of 2024. The intensity and duration of the war has varied since it began
on October 7, 2023. Up to the balance sheet date and subsequently, the war has not had a material effect on the Company. However, the
war may cause wider macroeconomic deterioration in Israel, which may have a material adverse effect on the Company&#8217;s ability to
effectively complete the Proposed Business Combination.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-10</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003102832557" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:-0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003102923627" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, serif;width:100%;border-collapse:collapse;border:0px">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>a.</strong></span></td>
    <td><strong style="font-size:10pt">Basis of Presentation</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The condensed consolidated financial statements
herein are unaudited; however, such information reflects all adjustments (consisting of normal, recurring adjustments), which are, in
the opinion of the management, necessary for a fair statement of results for the interim period. The results of the operation for the
six and three-month periods ended June 30, 2024, are not necessarily indicative of the results to be expected for the full year. The year-end
condensed consolidated balance sheet data was derived from audited financial statements for the year ended December 31, 2023 as filed
on April 1, 2024, but does not include all disclosures required by accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;). These unaudited condensed consolidated financial statements should be read in conjunction with the audited
financial statements and related notes thereto of Moringa Acquisition Corp.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003102956859" name="slxn:EmergingGrowthCompanyPolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Emerging Growth Company</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Section 102(b)(1) of the JOBS Act exempts emerging
growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those
that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the
Exchange Act) are required to comply with the new or revised financial accounting standards.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The JOBS Act provides that a company can elect
to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such
election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a
standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth
company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">This may make comparison of the Company&#8217;s
unaudited condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging
growth company which has opted out of using the extended transition period difficult or impossible, because of the potential differences
in accounting standards used.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:center">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-11</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<div> <ix:nonNumeric id="Fxbrl_20241003103038419" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, serif;width:100%;border-collapse:collapse;border:0px">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>c.</span></strong></span></span></td>
    <td><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><strong style="font-size:10pt">Cash and cash
        equivalents</strong></strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company considers as cash equivalents all
short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the
date of purchase that are not restricted as to withdrawal or use by nature of the account and are readily convertible to known amounts
of cash.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003103058000" name="us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, serif;width:100%;border-collapse:collapse;border:0px">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>d.</strong></span></span></span></td>
    <td><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong style="font-size:10pt">Class A Ordinary Shares
        subject to possible redemption</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">As discussed in Note 1, all of the <ix:nonFraction id="Fixv-37756" name="slxn:NumberOfUnitSale" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>
shares of Class&#160;A ordinary shares sold as parts of the Units in the Public Offering contain a redemption feature. In accordance with
the Accounting Standards Codification 480-10-S99-3A &#8220;Classification and Measurement of Redeemable Securities&#8221;, redemption
provisions not solely within the control of the Company require the security to be classified outside of permanent equity. The Company
has classified all of the shares sold under the Public Units as subject to possible redemption.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Refer to Note 7(a) for information regarding the
partial redemptions of Class A ordinary shares subject to possible redemption, following the First and Second Extensions. Also, refer
to Note 9(c) regarding an additional redemption after the balance sheet date.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003103118401" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>e.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Net profit (loss) per share</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, Earnings Per Share. Net profit (loss) per share is computed by dividing net profit (loss) by the weighted
average number of shares outstanding during the period. The Company applies the two-class method in calculating net profit (loss) per
each class of shares: the non-redeemable shares, which include the Private Class A Ordinary Shares, as defined in Note 7, and the Class
B ordinary shares (hereafter and collectively &#8211; Non-Redeemable class A and B ordinary shares); and the Class A ordinary shares subject
to possible redemption.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">In order to determine the net profit (loss) attributable
to each class, the Company first considered the total profit (loss) allocable to both sets of shares. This is calculated using the total
net profit (loss) less any interest earned on investments held in trust account. Then, the accretion is fully allocated to the Class A
ordinary shares subject to redemption.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003103135474" name="us-gaap:ConcentrationRiskDisclosureTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px;text-align:justify">&#160;</td>
    <td style="width:24px;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>f.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Concentration of credit risk</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify;text-indent:1.1pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left;text-indent:1.1pt">Financial instruments that potentially
subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed
the Federal Depository Insurance Coverage of $<ix:nonFraction id="Fixv-37757" name="us-gaap:FederalDepositInsuranceCorporationPremiumExpense" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction>.
From the Company&#8217;s incorporation and through June 30, 2024, the Company has not experienced any losses on these accounts.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify;text-indent:1.1pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">As of June 30, 2024, the Company held its cash
and cash equivalents in an SVB bank account, and its investments Held in Trust Account in Goldman Sachs money market funds. Money market
funds are characterized as Level 1 investments within the fair value hierarchy under ASC 820.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify;text-indent:1.1pt">&#160;</p> </div>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-12</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<div> <ix:nonNumeric id="Fxbrl_20241003103255403" name="slxn:PublicWarrantsPolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px;text-align:justify">&#160;</td>
    <td style="width:24px;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>g.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Public Warrants</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company applied the provisions of ASC 815-40
and classified its public warrants, issued as part of the Public Units as detailed in Note 3, as equity securities.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003103316342" name="slxn:PrivateWarrantLiabilityPolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px;text-align:justify">&#160;</td>
    <td style="width:24px;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>h.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Private Warrant liability </strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company accounts for the warrants in accordance
with the guidance contained in Accounting Standards Codification 815 (&#8220;ASC 815&#8221;), &#8220;Derivatives and Hedging&#8221;, under
which the warrants do not meet the criteria for equity treatment and must be recorded as derivative liabilities. Accordingly, the Company
classifies the private warrants as liabilities at their fair value and adjusts the private warrants to fair value at each reporting period.
This liability is subject to re-measurement at each balance sheet date until the private warrants are exercised or expire, and any change
in fair value is recognized in the Company&#8217;s statements of operations. Refer to Note 6 for information regarding the model used
to estimate the fair value of the Private Warrants (as defined in Note 3).</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003103331776" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>i.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Financial instruments</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The fair value of the Company&#8217;s assets and
liabilities, which qualify as financial instruments under the FASB ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221;, approximates
the carrying amounts represented in the balance sheet, primarily due to their short-term nature.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003103546537" name="us-gaap:UseOfEstimates" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>j.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Use of estimates in the preparation of financial statements</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 45.05pt;text-indent:-0.5in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The preparation of the financial statements in
conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during
the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company&#8217;s
financial statements.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p> </div> <ix:nonNumeric id="Fxbrl_20241003103614387" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px;text-align:justify">&#160;</td>
    <td style="width:24px;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>m.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Income tax</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company accounts for income taxes in accordance
with ASC 740, &#8220;Income Taxes (hereafter &#8211; ASC&#160;740). ASC 740 prescribes the use of the liability method whereby deferred
tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and
liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more
likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative
evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU&#160;2015-17.</p> </div> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-13</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<div> <ix:nonNumeric id="Fxbrl_20241003103637026" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px;text-align:justify">&#160;</td>
    <td style="width:24px;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>n.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Recent accounting pronouncements</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 49.65pt;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Management does not believe that any recently
issued, but not yet effective, accounting pronouncements, if currently adopted would have a material effect on the Company&#8217;s financial
statements.</p> </div> </ix:nonNumeric> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241004103824622" name="slxn:PublicOfferingAndPrivatePlacementsTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 3 - PUBLIC OFFERING AND PRIVATE PLACEMENTS:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">In the Initial Public Offering, the Company issued
and sold <ix:nonFraction id="Fixv-37758" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>
units (including <ix:nonFraction id="Fixv-37759" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>
units sold at a second closing pursuant to the underwriters&#8217; exercise of their over-allotment option in full) at an offering price
of $<ix:nonFraction id="Fixv-37760" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction>
per unit (hereafter &#8211; the Units). The Sponsor and EarlyBirdCapital, Inc. (the representative of the underwriters) purchased, in
a private placement that occurred simultaneously with the two closings of the initial Public Offering (hereafter &#8211; the Private Placement),
an aggregate of <ix:nonFraction id="Fixv-37761" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">352,857</ix:nonFraction>
and <ix:nonFraction id="Fixv-37762" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">27,143</ix:nonFraction>
Units, respectively, at a price of $<ix:nonFraction id="Fixv-37763" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction>
per Unit.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Once the Public Warrants become exercisable, the
Company may redeem them in whole and not in part at a price of $<ix:nonFraction id="Fixv-37764" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>
per Warrant upon a minimum of 30 days&#8217;&#160; prior written notice of redemption, if and only if the last reported sale price of
the Company&#8217;s Class A ordinary shares equals or exceeds $<ix:nonFraction id="Fixv-37765" name="slxn:WarrantPricePerSharesExceeds" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">18.00</ix:nonFraction>
per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which
the Company sends the notice of redemption to the Public Warrant holders.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Private Warrants are identical to the Public
Warrants except that, for so long as they are held by the Sponsor, EarlyBirdCapital, Inc. or their respective affiliates: (1) will not
be redeemable by the Company; (2) may not (including the Class A ordinary shares issuable upon exercise thereof), subject to certain limited
exceptions, be transferred, assigned or sold by the holders thereof until 30 days after the completion of the Company&#8217;s Initial
Business Combination; (3) may be exercised by the holders thereof on a cashless basis; and (4) they (including the Class A ordinary shares
issuable upon exercise thereof) are entitled to registration rights.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company paid an underwriting commission of
<ix:nonFraction id="Fixv-37766" name="slxn:UnderwritingCommissionPercentage" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.0</ix:nonFraction>%
of the gross proceeds of the Public Offering and the full exercise of the underwriters&#8217; over-allotment, or $<ix:nonFraction id="Fixv-37767" name="slxn:AggregateUnderwritersAmount" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,300,000</ix:nonFraction>,
in the aggregate, to the underwriters at the two closings of the Public Offering. Refer to Notes 5(a) and 9(a) for more information regarding
an additional fee payable to the underwriters upon the consummation of an Initial Business Combination, and an amendment to the agreement.</p>
</div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-14</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<div> <ix:nonNumeric id="Fxbrl_20241003115700638" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 4 - RELATED PARTY TRANSACTIONS:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Promissory Notes</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company has issued several promissory note
agreements to its Sponsor throughout its life term, in order to fulfil its ongoing operational needs or preparations towards an Initial
Business Combination. All outstanding promissory notes bear no interest and are repayable in full upon the earlier of (a) the date of
the consummation of the Company&#8217;s Initial Business Combination, or (b) Second Extended Mandatory Liquidation Date (hereafter and
collectively &#8211; the Maturity Date).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify"><i>Second to Fifth Promissory Notes</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify"><i>&#160;</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On August 9, 2021 the Company issued its Second
Promissory Note to the Sponsor, according to which the former may withdraw up to $<ix:nonFraction id="Fixv-37768" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20210809to20210809_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSecondPromissoryNoteMember_usgaapRelatedPartyTransactionAxis_slxnSponsorMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">1</ix:nonFraction>
million &#8211; which has been withdrawn in full in several installments up until June 2022.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">In December 2022 the Company issued its Third
and Fourth Promissory Notes, according to which the Company may withdraw up to an aggregate amount of $<ix:nonFraction id="Fixv-37769" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20221231to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnThirdAndFourthPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">190</ix:nonFraction>
thousand &#8211; which were withdrawn in full on the same month.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On February 8, 2023 the Company issued its Fifth
Promissory Note to the Sponsor, in an amount of up to $<ix:nonFraction id="Fixv-37770" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230208to20230208_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnFifthPromissoryNoteMember_usgaapRelatedPartyTransactionAxis_slxnSponsorMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">310</ix:nonFraction>
thousand, which were withdrawn in full in several installments between February and June 2023.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">According to the terms of the outstanding Second,
Third, Fourth and Fifth Promissory Notes, which comprise an aggregate principal of $<ix:nonFraction id="Fixv-37771" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction>
million, the Sponsor may elect to convert any portion of the amounts outstanding into private warrants to purchase Class A ordinary shares
at a conversion price of $<ix:nonFraction id="Fixv-37772" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapClassOfWarrantOrRightAxis_slxnPrivateWarrantsMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction>
per private warrant on the Maturity Date. Such private warrants will have an exercise price of $<ix:nonFraction id="Fixv-37773" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapClassOfWarrantOrRightAxis_slxnPrivateWarrantsMember" unitRef="usdPershares" scale="0" decimals="1" format="ixt:num-dot-decimal">11.5</ix:nonFraction>
and shall be identical to the private warrants included in the private units.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><i>Sixth Promissory Note</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On February 9, 2023 the Company issued its Sixth
Promissory Note to the Sponsor, in an amount of $<ix:nonFraction id="Fixv-37774" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230209to20230209_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">480</ix:nonFraction>
thousand &#8211; under which the funds that were loaned by the Sponsor were deposited into the Company&#8217;s Trust Account, in connection
with the First Extension. The Sponsor provided six monthly injections of $<ix:nonFraction id="Fixv-37775" name="slxn:SponsorPay" contextRef="C_20230219to20230219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction>
thousand into the Company&#8217;s Trust Account under the Sixth Promissory Note, starting February 19, 2023.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><i>Seventh Promissory Note</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On June 14, 2023 the Company issued its Seventh
Promissory Note to the Sponsor in an amount of up to $<ix:nonFraction id="Fixv-37776" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230614to20230614_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSeventhPromissoryNoteMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">1</ix:nonFraction>
million, which were withdrawn in full in several installments between June 2023 and March 2024.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:1.5pt solid black">

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">F-15</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>

<p style="margin:0pt 0px 0pt 1in;text-align:justify;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:10pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><strong>MORINGA
ACQUISITION CORP</strong></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">(CONTINUED)</p>

<p style="margin:0pt 0px;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px"><strong>NOTE 4 - RELATED PARTY TRANSACTIONS </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><i>Eighth Promissory Note</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On August 18, 2023 the Company issued its Eighth
Promissory Note to the Sponsor, in an amount of approximately $<ix:nonFraction id="Fixv-37777" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230818to20230818_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnEighthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction>
thousand &#8211; under which the funds that were loaned by the Sponsor were deposited into the Company&#8217;s Trust Account, in connection
with the Second Extension. The Sponsor shall make monthly injections of approximately $<ix:nonFraction id="Fixv-37778" name="slxn:SponsorPay" contextRef="C_20230819to20230819_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnEighthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction>
thousand into the Company&#8217;s Trust Account, starting August 19, 2023 and up until the earlier of the Second Extended Mandatory Liquidation
Date (or such earlier date that the Board determines to liquidate the Company) or the date on which an Initial Business Combination is
completed. During the six months ended June 30, 2024, approximately $<ix:nonFraction id="Fixv-37779" name="slxn:InstallmentsAmount" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction>
thousand have been injected into the trust account in six monthly installments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><i>Ninth Promissory Note</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On March 27, 2024, the Company issued its Ninth
Promissory Note, according to which the Company may withdraw up to an aggregate amount of $<ix:nonFraction id="Fixv-37780" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20240327to20240327_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">180</ix:nonFraction>
thousand. As of June 30, 2024 the Ninth Promissory Note has been fully withdrawn.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><i>Tenth Promissory Note</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On June 27, 2024, the Company issued its Tenth
Promissory Note, according to which the Company may withdraw up to an aggregate amount of $<ix:nonFraction id="Fixv-37781" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20240627to20240627_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction>
thousand. The Company has made partial withdrawals in June and July 2024.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify"><i>A&amp;R Promissory Note </i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Upon the closing of the proposed business combination,
and according to the terms of the amended Silexion Business Combination agreement, all promissory notes shall be converted into one sponsor
promissory note &#8211; the A&amp;R Sponsor Promissory Note, which will be subject to a cap of (i) $<ix:nonFraction id="Fixv-37782" name="slxn:SponsorPay" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.5</ix:nonFraction>
million, minus (ii) any fee that may be paid or owed under the amended Business Marketing Agreement (See Notes 5(a) and 9(a)). Any outstanding
amount loaned by the sponsor to the Company in excess of the cap, will be attributed to the conversion shares issuable under the A&amp;R
Sponsor Promissory Note as additional paid-in capital.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px;text-align:justify">&#160;</td>
    <td style="width:24px;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Administrative Services Agreement
        </strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 53.2pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On December 16, 2020, the Company signed an agreement
with the Sponsor, under which the Company shall pay the Sponsor a fixed $<ix:nonFraction id="Fixv-37783" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20201216to20201216_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnSponsorMember_usgaapTypeOfArrangementAxis_slxnAdministrativeServicesAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction>
thousand per month for office space, utilities and other administrative expenses. The monthly payments under this administrative services
agreement commenced on the effective date of the registration statement for the initial Public Offering and will continue until the earlier
of (i) the consummation of the Company&#8217;s initial Business Combination, or (ii) the Company&#8217;s liquidation.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The composition of the Related Party balance as
of June 30, 2024 and December 31, 2023 is as follows:&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003120028982" name="us-gaap:ScheduleOfCompensatingBalancesTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">June&#160;30,<br/>2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">In U.S. dollars</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left">Promissory notes</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37785" name="us-gaap:NotesPayableCurrent" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnPromissoryNotesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">3,346,000</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37786" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnPromissoryNotesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,841,000</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt">Accrual for Administrative Services Agreement</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004161900128" name="us-gaap:NotesPayableCurrent" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapAssetManagementArrangementMember" unitRef="usd" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37787" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapAssetManagementArrangementMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37788" name="us-gaap:NotesPayableCurrent" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">3,346,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37789" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,861,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:1.5pt solid black">

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">F-16</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>

<p style="margin:0pt 0px 0pt 1in;text-align:justify;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:10pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><strong>MORINGA
ACQUISITION CORP</strong></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">(CONTINUED)</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>
</div> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-18432" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 5 - COMMITMENTS AND CONTINGENCIES:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><strong>a.</strong></td>
    <td style="text-align:justify"><strong>Underwriters&#8217; deferred discount</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify;text-indent:1.1pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left;text-indent:1.1pt">Under the Business Combination
Marketing Agreement, the Company shall pay an additional fee (hereafter &#8211; the Deferred Commission) of <ix:nonFraction id="Fixv-37790" name="slxn:DeferredCommissionPercentage" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction>%
of the gross proceeds of the Public Offering (or $<ix:nonFraction id="Fixv-37791" name="slxn:DeferredCommission" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">4,025,000</ix:nonFraction>)
payable upon the Company&#8217;s completion of the Initial Business Combination. The Deferred Commission will become payable to the underwriters
from the amounts held in the Trust Account solely in the event the Company completes an Initial Business Combination.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify;text-indent:1.1pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.75in">&#160;</td>
    <td style="width:18pt"><strong>b.</strong></td>
    <td style="text-align:justify"><strong>Advisory and Placement Agent Agreement with Cohen &amp; Company</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left;text-indent:1.1pt">Refer to Note 9(d) for information
regarding the agreement entered into after the balance sheet date.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:1.1pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>c.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Nasdaq Deficiency Notice </strong></span></td>
    <td>&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><i>Third Deficiency Notice</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On February 20, 2024, the Company received a notice
from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that unless the Company timely requests
a hearing before the Nasdaq Hearings Panel (hereafter - the Panel), trading of the Company&#8217;s securities on The Nasdaq Capital Market
would be suspended at the opening of business on February 29, 2024, due to the Company&#8217;s non-compliance with Nasdaq IM-5101-2, which
requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of
its IPO registration statement.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company timely requested a hearing before
the Panel to request sufficient time to complete its previously disclosed proposed business combination with Silexion. The hearing request
has resulted in a stay of any suspension or delisting action pending the hearing, which was held on April 23, 2024.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On April 23, 2024, the Company participated in
a hearing with Nasdaq in which the Company presented its request that Nasdaq provide the Company an additional six months to remedy the
Company&#8217;s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business
combinations within 36 months of the effectiveness of its IPO registration statement. The Company&#8217;s plan for regaining compliance
focused on the Company&#8217;s efforts to complete its previously disclosed Proposed Business Combination with Silexion. On May 10, 2024,
the Company received the results of the hearing, under which Nasdaq approved the Company&#8217;s request for a six-month extension&#8212;
until the Second Extension Date&#8212; to remain listed on Nasdaq and complete its proposed business combination.</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-17</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-18501" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 6 - FAIR VALUE MEASUREMENTS:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The fair value of a financial instrument is the
amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at
the measurement date (i.e., the exit price).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The fair value hierarchy under ASC 820 prioritizes
the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in
active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
The three levels of the fair value hierarchy are as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><strong>Basis for Fair Value Measurement</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Level 1: Unadjusted quoted prices in active markets
that are accessible at the measurement date for identical, unrestricted assets or liabilities;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Level 2: Quoted prices in markets that are not
active or financial instruments for which significant inputs to models are observable (including but not limited to quoted prices for
similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly or indirectly;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Level 3: Prices or valuations that require significant
unobservable inputs (including the Management&#8217;s assumptions in determining fair value measurement).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The following table presents information about
the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023
by level within the fair value hierarchy:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003131657032" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Level</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">June&#160;30,<br/>2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold">Assets:</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:64%;text-align:left">Money market funds held in Trust Account</td>
    <td style="width:1%">&#160;</td>
    <td style="width:11%;text-align:center">1</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37793" name="us-gaap:AssetsHeldInTrustCurrent" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,924,118</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37794" name="us-gaap:AssetsHeldInTrustCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697,632</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold">Liabilities:</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt">Private Warrant Liability</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:center;padding-bottom:4pt">3</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37795" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,284</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37796" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,531</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The estimated fair value of the Private Placement
Warrants was determined using a binomial model to extract the market&#8217;s implied probability for an Initial Business Combination,
using the Public Warrant&#8217;s market price. Once probability was extracted, a Black-Scholes-Merton model with Level 3 inputs was used
to calculate the Private Warrants&#8217; fair value. Inherent in a Black-Scholes-Merton model are assumptions related to expected life
(term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the volatility of its warrants
based on implied volatility from the Company&#8217;s traded warrants and from historical volatility of selected peer companies&#8217;
Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury
zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of
the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which
the Company anticipates remaining at zero.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The following table provides quantitative information
regarding Level 3 fair value measurements inputs:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003131709811" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">As of<br/>June&#160;30,<br/>2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">As of<br/>December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%">Share price</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37798" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputSharePriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">10.0</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37799" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputSharePriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">10.0</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Strike price</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37800" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_slxnMeasurementInputStrikevPriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">11.5</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37801" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_slxnMeasurementInputStrikevPriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">11.5</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td>Volatility</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37802" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" unitRef="pure" scale="0" decimals="0" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37803" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" unitRef="pure" scale="0" decimals="0" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Risk-free interest rate</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37804" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">4.34</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37805" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">4.78</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left">Dividend yield</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37806" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37807" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Public warrant market price</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37808" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputCommodityMarketPriceMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.08</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37809" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputCommodityMarketPriceMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.03</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p> <ix:nonNumeric id="Fixv-18660" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">In&#160;U.S&#160;dollars</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:88%;text-align:left;text-indent:-9pt;padding-left:9pt">Value of warrant liability measured with Level 3 inputs at December
        31, 2023</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37810" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,531</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">Change in fair value of private warrant liability measured
        with Level 3 inputs</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37811" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,753</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">Value of warrant liability measured with Level 3 inputs at
        June 30, 2024</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37812" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,284</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </ix:nonNumeric> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-18</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-18711" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 7 - CAPITAL DEFICIENCY:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Ordinary Shares</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><i>Class A Ordinary Shares</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-0.5in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On November 20, 2020 the Company issued <ix:nonFraction id="Fixv-37813" name="us-gaap:CommonStockSharesIssued" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">100,000</ix:nonFraction>
Class A ordinary shares of $<ix:nonFraction id="Fixv-37814" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>
par value each to designees of the Representative (hereafter &#8211; the Representative Shares) for a consideration equal to the par value
of the shares. The Representative Shares are deemed to be underwriters&#8217; compensation by FINRA pursuant to Rule 5110 of the FINRA
Manual.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company accounted for the issuance of the
Representative Shares as compensation expenses amounting to $<ix:nonFraction id="Fixv-37815" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">860</ix:nonFraction>,
with a corresponding credit to Additional Paid-In Capital, for the excess value over the consideration paid. The Company estimated the
fair value of the issuance based upon the price of Class B Ordinary Shares that were issued to the Sponsor.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Pursuant to the initial Public Offering and the
concurrent Private Placement that were each effected in two closings &#8211; on February 19, 2021 and March 3, 2021 &#8211; the Company
issued and sold an aggregate of <ix:nonFraction id="Fixv-37816" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>
and <ix:nonFraction id="Fixv-37817" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">380,000</ix:nonFraction>
Class A ordinary shares as part of the Units sold in those respective transactions. The Units (which also included Warrants) were sold
at a price of $<ix:nonFraction id="Fxbrl_20241003172049435" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37818" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>
per Unit, and for an aggregate consideration of $<ix:nonFraction id="Fixv-37820" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_slxnPublicOfferingMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">115</ix:nonFraction>
million and $<ix:nonFraction id="Fixv-37821" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction>
million in the Public Offering and Private Placement, respectively. See Note 3 above for further information regarding those share issuances.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company classified its <ix:nonFraction id="Fixv-37822" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>
Public Class A ordinary shares as temporary equity. The remaining <ix:nonFraction id="Fixv-37823" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">480,000</ix:nonFraction>
Private Class A ordinary shares were classified as permanent equity.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left"><span>In conjunction with the First and Second
Extensions, <ix:nonFraction id="Fixv-37824" name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnFirstExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">8,910,433</ix:nonFraction>
and <ix:nonFraction id="Fixv-37825" name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnSecondExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,074,548</ix:nonFraction>
Class A Ordinary Shares subject to possible redemption were redeemed, respectively, for their redemption value, including accrued interest.
As part of the partial redemptions approximately $<ix:nonFraction id="Fixv-37826" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">113</ix:nonFraction>
million has been withdrawn from the Investments held in Trust Account.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify"><i>Class B Ordinary Shares</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On November 20, 2020, the Company issued <ix:nonFraction id="Fixv-37827" name="us-gaap:CommonStockSharesIssued" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction>
Class B ordinary shares of $<ix:nonFraction id="Fixv-37828" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>
par value each for a total consideration of $<ix:nonFraction id="Fixv-37829" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20201120to20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction>
thousand to the Sponsor&#8217;s wholly-owned Delaware subsidiary.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Class B ordinary shares are convertible into non-redeemable
Class A ordinary shares, on a one-for-one basis, automatically on the day of the Business Combination or at the election of the holder
thereof at any time prior to the Business Combination. Class B ordinary shares also possess the sole right to vote for the election or
removal of directors, until the consummation of an Initial Business Combination.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Following the Second Extension Meeting, the Sponsor
converted <ix:nonFraction id="Fixv-37830" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,874,999</ix:nonFraction>
of its <ix:nonNumeric id="Fixv-37831" name="us-gaap:ConversionOfStockTypeOfStockConverted" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">Class
B ordinary shares into Class A ordinary shares on a one to one basis</ix:nonNumeric>.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px;text-align:justify">&#160;</td>
    <td style="width:24px;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Preferred shares</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company is authorized to issue up to <ix:nonFraction id="Fixv-37832" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction>
Preferred Shares of $<ix:nonFraction id="Fixv-37833" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>
par value each. As of June 30, 2024, the Company has no preferred shares issued and outstanding.</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-19</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.25in;text-indent:-10pt"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-18792" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 8 - NET PROFIT (LOSS) PER SHARE:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241004104311685" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The following table reflects the calculation
of basic and diluted net profit (loss) per share (in dollars, except share amounts):</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p>

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Six months ended<br/>June 30,</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Three months ended<br/>June 30,</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:52%;text-align:left;text-indent:-9pt;padding-left:9pt">Net profit (loss) for the period</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-37835" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">310,793</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37836" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">476,143</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-37837" name="us-gaap:NetIncomeLoss" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">110,575</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37838" name="us-gaap:NetIncomeLoss" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,948</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">Less &#8211; interest earned on Investment held in Trust
        Account</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37839" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">149,236</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37840" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,063,043</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37841" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">75,305</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37842" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">318,002</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">Net loss excluding interest</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37843" name="us-gaap:GrossProfit" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">460,029</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37844" name="us-gaap:GrossProfit" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">586,900</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37845" name="us-gaap:GrossProfit" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">185,880</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37846" name="us-gaap:GrossProfit" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">155,054</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;text-indent:-9pt;padding-left:9pt">Class A ordinary shares subject to possible redemption:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-9pt;padding-left:0.25in">Net loss excluding interest</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37847" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,220</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37848" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">351,654</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37849" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,737</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37850" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,544</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:0.25in">Accretion to Class A ordinary shares subject to possible
        redemption to redemption amount (&#8220;Accretion&#8221;)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37851" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">226,486</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37852" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,463,043</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37853" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,930</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37854" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">558,002</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37855" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">165,266</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37856" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,111,389</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37857" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">89,193</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37858" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">490,458</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;text-indent:-9pt;padding-left:0.25in">weighted average number of shares</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37859" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">515,019</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37860" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,015,185</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37861" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">515,019</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37862" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,589,567</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">Net profit per Class A ordinary share subject
        to possible redemption &#8211; basic and diluted</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37863" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.32</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37864" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.22</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37865" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.17</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37866" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.19</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;text-indent:-9pt;padding-left:9pt">Non-redeemable Class A and B ordinary shares:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-9pt;padding-left:0.25in">Net loss excluding interest</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37867" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">398,809</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37868" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,246</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37869" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,143</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37870" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,510</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt;text-indent:-9pt;padding-left:0.25in">Accretion</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37871" name="slxn:Accretion" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,250</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37872" name="slxn:Accretion" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">400,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37873" name="slxn:Accretion" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,625</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37874" name="slxn:Accretion" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37875" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">476,059</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37876" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">635,246</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37877" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">199,768</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37878" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">327,510</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt;text-indent:-9pt;padding-left:0.25in">weighted average number of shares</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37879" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37880" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37881" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37882" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">Net loss per non-redeemable Class A and
        B ordinary share &#8211; basic and diluted</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37883" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.14</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37884" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.19</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37885" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.06</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37886" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.10</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td> </tr>
  </table> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 42.55pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The potential exercise of <ix:nonFraction id="Fixv-37887" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapClassOfWarrantOrRightAxis_slxnPublicWarrantsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction>
Public Warrants and <ix:nonFraction id="Fixv-37888" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapClassOfWarrantOrRightAxis_slxnPrivateWarrantsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">190,000</ix:nonFraction>
Private Warrants sold in the Public Offering and Private Placements as detailed in Note 3 into <ix:nonFraction id="Fixv-37889" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">5,940,000</ix:nonFraction>
shares has not been included in the calculation of diluted net profit (loss) per share, since the exercise of the warrants is contingent
upon the occurrence of a future event.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 42.55pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">Additionally, the effect of the conversion
of the Second, Third, Fourth and Fifth Promissory Notes into an aggregate amount of <ix:nonFraction id="Fixv-37890" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtTitleOfIndividualAxis_slxnSecondThirdForthAndFifthPromissoryNotesMember_usgaapDerivativeInstrumentRiskAxis_slxnPrivateWarrantsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>
private warrants (exercisable into <ix:nonFraction id="Fixv-37891" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtTitleOfIndividualAxis_slxnSecondThirdForthAndFifthPromissoryNotesMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>
shares) as detailed in Note 4, has not been included in the calculation of diluted net profit (loss) per share, since the conversion of
the abovementioned promissory notes is contingent upon the occurrence of a future event.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 42.55pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">As a result, diluted net profit (loss) per
share is the same as basic net profit (loss) per share for each of the periods presented, and for each class.</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-20</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-19308" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">NOTE
9 - SUBSEQUENT EVENTS:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.75in">&#160;</td>
    <td style="width:18pt"><strong>a.</strong></td>
    <td style="text-align:justify"><strong>Additional withdrawals under the Promissory Notes</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 42.55pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Since the balance sheet date and up until the
filing date of these financial statements, an aggregate amount of $<ix:nonFraction id="Fixv-37892" name="slxn:AggregateWithdrawnAmount" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFinancialInstrumentAxis_slxnTenthPromissoryNoteMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">62</ix:nonFraction>
thousand has been withdrawn under the Tenth Promissory Note, and a final injection into the trust account of approximately $<ix:nonFraction id="Fixv-37893" name="slxn:AggregateWithdrawnAmount" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFinancialInstrumentAxis_slxnEighthPromissoryNoteMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">13</ix:nonFraction>
thousand has been withdrawn under the Eighth Promissory Note &#8211; rendering the latter fully withdrawn.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 60.55pt;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.75in">&#160;</td>
    <td style="width:18pt"><strong>b.</strong></td>
    <td style="text-align:left"><strong>Extraordinary General Meeting and redemption of Class A ordinary shares subject to possible redemption</strong></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On August 6, 2024 the Extraordinary General Meeting
has approved the proposed business combination with Silexion. In connection with the meeting, an additional <ix:nonFraction id="Fixv-37894" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_20240806_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtStatementScenarioAxis_srtScenarioForecastMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinarySharesSubjectToPossibleRedemptionMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">427,297</ix:nonFraction>
Class A ordinary shares subject to possible redemption have been redeemed. Consequently, $<ix:nonFraction id="Fixv-37895" name="slxn:AmountWithdrawnFromTrustAccount" contextRef="C_20240806_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtStatementScenarioAxis_srtScenarioForecastMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction>
million has been withdrawn from the trust account.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 60.55pt;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.75in">&#160;</td>
    <td style="width:18pt"><strong>c.</strong></td>
    <td style="text-align:justify"><strong>Advisory and Placement Agent Agreement with Cohen &amp; Company</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On July 29, 2024 the Company has entered into
agreement with Cohen &amp; Company, for providing capital markets advisory and placement agent services, in connection with both (i) the
completion of the proposed business combination with Silexion, and (ii) a private placement of equity, equity-linked, convertible and
/ or debt securities to be consummated with the business combination.</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-21</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-right:0;margin-bottom:0pt;text-align:left"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-right:0;margin-bottom:0pt;text-align:left">&#160;</p>

<div><span id="f_006_integixAnchor"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Report
of Independent Registered Public Accounting Firm</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">To
the Board of Directors and Shareholders of Moringa Acquisition Corp</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong><i>&#160;</i></strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong><i>Opinion
on the Financial Statements</i></strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">We
have audited the accompanying balance sheets of Moringa Acquisition Corp (the &#8220;Company&#8221;) as of December&#160;31, 2023 and
2022, and the related statements of operations, changes in capital deficiency and cash flows for each of the two&#160;years in the period
ended December&#160;31, 2023, including the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our
opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,
2023 and 2022, and the results of its operations and its cash flows for each of the two&#160;years in the period ended December&#160;31,
2023 in conformity with accounting principles generally accepted in the United&#160;States of America.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Substantial
Doubt about the Company&#8217;s Ability to Continue as a Going Concern</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note&#160;1(e)&#160;to
the financial statements, the Company has limited cash and has incurred losses since inception. Moreover, if the Company is unable to
complete a business combination by August&#160;19, 2024 then the Company will cease all operations except for the purpose of liquidating.
These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard
to these matters are also described in Note&#160;1(e). The financial statements do not include any adjustments that might result from
the outcome of this uncertainty.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong><i>&#160;</i></strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong><i>Basis
for Opinion</i></strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United&#160;States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">We
conducted our audits of these financial statements in accordance with the standards of the PCAOB.&#160;Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether
due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the
purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we
express no such opinion.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide
a reasonable basis for our opinion.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">/s/&#160;Kesselman&#160;&amp;
Kesselman &#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Certified
Public Accountants (Isr.)<br/>A member firm of PricewaterhouseCoopers International Limited</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Tel-Aviv,
Israel<br/>April&#160;1, 2024</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">We
have served as the Company&#8217;s auditor since 2020.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-22</span></p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<div><span id="f_007_integixAnchor"></span></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p></div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>BALANCE SHEETS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Note</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31,<br/>2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">U.S.&#160;Dollars</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:center">Assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold">ASSETS:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:64%;text-align:left;text-indent:-0.125in;padding-left:0.25in">Cash and cash equivalents</td>
    <td style="width:1%">&#160;</td>
    <td style="width:11%;text-align:center">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37896" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,278</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37897" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,714</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Investments held in Trust Account</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37898" name="us-gaap:AssetsHeldInTrust" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697,632</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37899" name="us-gaap:AssetsHeldInTrust" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,692,038</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in">Prepaid expenses</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37900" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,305</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37901" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,853</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.25in">TOTAL ASSETS</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37902" name="us-gaap:Assets" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,834,215</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37903" name="us-gaap:Assets" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,795,605</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:center;text-indent:-0.125in;padding-left:0.125in">Liabilities and shares subject to possible redemption<br/>net
        of capital deficiency</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-indent:-0.125in;padding-left:0.125in">LIABILITIES:</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Accrued expenses</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37904" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,560</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37905" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,688</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Related party</td>
    <td>&#160;</td>
    <td style="text-align:center">4</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37906" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,861,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37907" name="us-gaap:NotesPayableCurrent" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,190,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in">Private warrant liability</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37908" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,531</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37909" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,640</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in">TOTAL LIABILITIES</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37910" name="us-gaap:Liabilities" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,985,091</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37911" name="us-gaap:Liabilities" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,306,328</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">COMMITMENTS AND CONTINGENCIES</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">5</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241003060205872_ixv-37910" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241003060205872_ixv-37911" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">CLASS A ORDINARY SHARES SUBJECT
        TO POSSIBLE&#160;REDEMPTION:&#160;<ix:nonFraction id="Fixv-37912" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">515,019</ix:nonFraction>&#160;and&#160;<ix:nonFraction id="Fxbrl_20241004141149130" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>&#160;shares
        at redemption value $<ix:nonFraction id="Fixv-37914" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">11.06</ix:nonFraction>&#160;and
        $<ix:nonFraction id="Fixv-37915" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">10.15</ix:nonFraction>&#160;as
        of December&#160;31, 2023 and 2022, respectively</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37916" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697,632</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37917" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,692,038</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in">CAPITAL DEFICIENCY:</td>
    <td>&#160;</td>
    <td style="text-align:center">7</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Class&#160;A Ordinary Shares, $<ix:nonFraction id="Fxbrl_20241003170218970" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37918" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>&#160;par
        value;&#160;<ix:nonFraction id="Fxbrl_20241003170238212" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37920" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction>&#160;shares
        authorized,&#160;<ix:nonFraction id="Fxbrl_20241003170417394" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37922" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,354,999</ix:nonFraction></ix:nonFraction>&#160;and&#160;<ix:nonFraction id="Fxbrl_20241003170453400" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37924" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">480,000</ix:nonFraction></ix:nonFraction>&#160;issued
        and outstanding (excluding 515,019 and 11,500,000 shares subject to possible redemption) as of December&#160;31, 2023 and 2022, respectively;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37926" name="us-gaap:CommonStockValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37927" name="us-gaap:CommonStockValue" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Class&#160;B Ordinary Shares, $<ix:nonFraction id="Fxbrl_20241003170513312" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37928" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>&#160;par
        value;&#160;<ix:nonFraction id="Fxbrl_20241003170529994" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37930" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></ix:nonFraction>&#160;shares
        authorized,&#160;<ix:nonFraction id="Fxbrl_20241003170549074" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37932" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction>&#160;and&#160;<ix:nonFraction id="Fxbrl_20241003170625385" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37934" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction></ix:nonFraction>&#160;issued
        and outstanding as of December&#160;31, 2023 and 2022, respectively;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="-sec-ix-hidden:Fhidden-fact-12">*</span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37936" name="us-gaap:CommonStockValue" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in">Preferred Shares, $<ix:nonFraction id="Fxbrl_20241004130455363" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004130450733" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>&#160;par
        value;&#160;<ix:nonFraction id="Fxbrl_20241004130534018" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004130530146" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction>&#160;shares
        authorized, <ix:nonFraction id="Fxbrl_20241004133205153" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20241004133156405" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20241004133140765" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20241004133131102" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares
        issued and outstanding as of December&#160;31, 2023 and 2022.</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003060107337_ixv-37926" name="us-gaap:PreferredStockValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003060107337_ixv-37927" name="us-gaap:PreferredStockValue" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Additional paid-in capital</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003060110144_ixv-37926" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003060110144_ixv-37927" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in">Accumulated deficit</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37941" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,844</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37942" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,203,097</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in">TOTAL CAPITAL DEFICIENCY</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37943" name="us-gaap:StockholdersEquity" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,508</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37944" name="us-gaap:StockholdersEquity" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,202,761</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">TOTAL LIABILITIES AND SHARES SUBJECT
        TO POSSIBLE REDEMPTION NET OF CAPITAL DEFICIENCY</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37945" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,834,215</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37946" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,795,605</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 24pt;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<div style="margin-top:0pt;margin-bottom:0pt;width:25%">

<div style="font-size:1pt;border-top:Black 1.5pt solid">&#160;</div> </div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">*</span></td>
    <td style="text-align:justify">Less than&#160;one US dollar.</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>The
accompanying notes are an integral part of these financial statements</strong>.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-23</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<div><span id="f_008_integixAnchor"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>STATEMENTS OF OPERATIONS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Note</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Year ended<br/>December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Year ended<br/>December&#160;31,<br/>2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">U.S.&#160;Dollars</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Except share data</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;width:64%;text-align:left">Interest earned on investments held in trust account</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:center">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37947" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,364,444</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37948" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,685,666</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left">General and administrative</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:center">9</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37949" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,122,480</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37950" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,232,342</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Change in fair value of Private Warrant liability</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:center">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37951" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">21,109</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37952" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">130,701</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">Net profit for the year</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37953" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,073</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37954" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">584,025</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">Weighted average number of Class&#160;A Ordinary Shares
        subject to Possible Redemption</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:center">8</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37955" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,774,850</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37956" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:4pt">Basic and diluted net profit per
        Class&#160;A Ordinary Shares subject to Possible Redemption</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt;text-align:center">&#160;</td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241003013900186" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37957" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.51</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241003013918307" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37958" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.07</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">Weighted average number of non-redeemable Class&#160;A
        and Class&#160;B Ordinary shares</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37959" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37960" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:4pt;vertical-align:middle">Basic and
        diluted net loss per non-redeemable Class&#160;A and Class&#160;B Ordinary shares</td>
    <td style="padding-bottom:4pt;vertical-align:middle">&#160;</td>
    <td style="padding-bottom:4pt;text-align:left;vertical-align:middle">&#160;</td>
    <td style="padding-bottom:4pt;text-align:center;vertical-align:middle">&#160;</td>
    <td style="padding-bottom:4pt;text-align:left;vertical-align:middle">&#160;</td>
    <td style="padding-bottom:4pt;vertical-align:middle">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;vertical-align:middle">$</td>
    <td style="border-bottom:4pt double black;text-align:right;vertical-align:middle">(<ix:nonFraction id="Fxbrl_20241003014030827" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-37961" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.34</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:4px;text-align:left;vertical-align:middle">)</td>
    <td style="padding-bottom:4pt;vertical-align:middle">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;vertical-align:middle">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;vertical-align:middle">(<ix:nonFraction id="Fxbrl_20241003014051827" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-37962" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.07</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left;vertical-align:middle">)</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>The
accompanying notes are an integral part of these financial statements.</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-24</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<div><span id="f_009_integixAnchor"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Class&#160;A<br/>ordinary shares</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Class&#160;B<br/>ordinary shares</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:right">Additional</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="padding-bottom:1.5pt;font-weight:bold;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="padding-bottom:1.5pt;font-weight:bold;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Number&#160;of<br/>shares</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Par<br/>value</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Number&#160;of<br/>shares</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Par<br/>value</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">paid-in<br/>capital</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Accumulated<br/>deficit</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Total</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold">&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="26" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">U.S.&#160;Dollars (except share data)</td>
    <td style="font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:37%;font-weight:bold;text-indent:-0.125in;padding-left:0.125in">BALANCE AT December&#160;31, 2021</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:6%;text-align:right"><ix:nonFraction id="Fixv-37963" name="us-gaap:SharesOutstanding" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">480,000</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:6%;text-align:right"><ix:nonFraction id="Fixv-37964" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:6%;text-align:right"><ix:nonFraction id="Fixv-37965" name="us-gaap:SharesOutstanding" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:6%;text-align:right"><ix:nonFraction id="Fixv-37966" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:6%;text-align:right"><ix:nonFraction id="Fixv-37967" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">855,994</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:6%;text-align:right">(<ix:nonFraction id="Fixv-37968" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">951,078</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:6%;text-align:right">(<ix:nonFraction id="Fixv-37969" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">94,748</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in">Subsequent accretion of Class&#160;A Ordinary Shares subject to possible
        redemption to amount as of December&#160;31, 2022</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#8212;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004163808943" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#8212;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004163749617" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37970" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">855,994</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37971" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">836,044</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37972" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,692,038</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">Net profit for the year</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#8212;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004163904281" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#8212;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004163859376" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004163853673" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37973" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">584,025</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37974" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">584,025</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;padding-bottom:4pt;text-indent:-0.125in;padding-left:0.125in">BALANCE AT December&#160;31, 2022</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37975" name="us-gaap:SharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">480,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37976" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37977" name="us-gaap:SharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37978" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241004164156746" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37979" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,203,097</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37980" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,202,761</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in">Subsequent accretion of Class&#160;A Ordinary Shares subject to possible
        redemption to amount as of December&#160;31, 2023</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#8212;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004164115912" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#8212;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004164048712" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004164037935" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37981" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,908,820</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37982" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,908,820</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in">Conversion of Class&#160;B ordinary shares into Class&#160;A ordinary
        shares</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37983" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,874,999</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37984" name="us-gaap:ConversionOfStockAmountConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37985" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal" sign="-">2,874,999</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37986" name="us-gaap:ConversionOfStockAmountConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">288</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004164445979" name="us-gaap:ConversionOfStockAmountConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004164503938" name="us-gaap:ConversionOfStockAmountConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004164507507" name="us-gaap:ConversionOfStockAmountConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">Net profit for the year</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#8212;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004164611020" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#8212;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004164605083" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004164555833" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37987" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,073</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37988" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,073</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;padding-bottom:4pt;text-indent:-0.125in;padding-left:0.125in">BALANCE AT December&#160;31, 2023</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37989" name="us-gaap:SharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,354,999</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37990" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37991" name="us-gaap:SharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="-sec-ix-hidden:Fhidden-fact-88">*</span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241004164626074" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37992" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,844</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37993" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,508</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">)</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<div style="margin-top:0pt;margin-bottom:0pt;width:25%">

<div style="font-size:1pt;border-top:Black 1.5pt solid">&#160;</div> </div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">*</span></td>
    <td style="text-align:justify">Less than&#160;one US dollar.</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>The
accompanying notes are an integral part of these financial statements.</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-25</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div><span id="f_010_integixAnchor"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>STATEMENTS OF CASH FLOWS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year ended<br/>December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year ended<br/>December&#160;31,<br/>2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">U.S.&#160;Dollars</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left">CASH FLOWS FROM OPERATING ACTIVITIES:</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-0.125in;padding-left:0.25in">Net profit for the year</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37994" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,073</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37995" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">584,025</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Adjustments to reconcile net profit to net cash provided by operating
        activities:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in">Changes in the fair value of the private warrant liability</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37996" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">21,109</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37997" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">130,701</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Changes in operating assets and liabilities:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in">Decrease in prepaid expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37998" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15,548</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37999" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">325,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in">Increase (decrease) in related party</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38000" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">20,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38001" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.375in">Increase in accrued expenses</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38002" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,872</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38003" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,112</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in">Net cash provided by operating activities</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38004" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,384</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38005" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">816,436</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in">CASH FLOWS FROM FINANCING ACTIVITIES:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in">Partial redemption of Class&#160;A ordinary shares subject to possible
        redemption</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38006" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">112,903,226</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#8212;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.375in">Proceeds from a promissory note&#160;&#8211;&#160;related
        party</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38007" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,651,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38008" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">890,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in">Net cash provided by (used in) financing activities</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38009" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">111,252,226</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38010" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">890,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in">INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND INVESTMENTS
        HELD IN A TRUST ACCOUNT</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38011" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">110,945,842</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38012" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,706,436</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">CASH, CASH EQUIVALENTS AND INVESTMENTS
        HELD IN A TRUST&#160;ACCOUNT AT BEGINNING OF YEAR</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38013" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,751,752</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38014" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,045,316</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-0.125in;padding-left:0.125in">CASH, CASH EQUIVALENTS AND INVESTMENTS
        HELD IN A TRUST&#160;ACCOUNT AT END OF YEAR</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38015" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,805,910</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38016" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,751,752</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in">RECONCILIATION OF CASH, CASH EQUIVALENTS AND INVESTMENTS
        HELD IN A TRUST ACCOUNT:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in">Cash and cash equivalents</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38017" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,278</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38018" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,714</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.375in">Investments held in trust account</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38019" name="us-gaap:AssetsHeldInTrust" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697,632</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38020" name="us-gaap:AssetsHeldInTrust" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,692,038</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-0.125in;padding-left:0.25in">Total cash, cash equivalents and investments held
        in a trust account</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38021" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,805,910</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38022" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,751,752</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in">SUPPLEMENTARY INFORMATION REGARDING NON-CASH ACTIVITIES:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-0.125in;padding-left:0.375in">Conversion of Class&#160;B ordinary shares into Class&#160;A
        ordinary shares</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38023" name="us-gaap:StockIssued1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241004165034887" name="us-gaap:StockIssued1" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>The
accompanying notes are an integral part of these financial statements.</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-26</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<div><span id="f_011_integixAnchor"></span></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
</div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003001008037" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
1&#160;&#8212;&#160;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Organization and General</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Moringa
Acquisition Corp (hereafter&#160;&#8212;&#160;the Company) is a blank check company, incorporated on September&#160;24, 2020 as a Cayman
Islands exempted company, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination (hereafter&#160;&#8212;&#160;the Business Combination). The Company is an emerging growth company, as
defined in Section&#160;2(a)&#160;of the Securities Act&#160;of&#160;1933, as amended (the &#8220;Securities Act&#8221;), as modified
by the Jumpstart Our Business Startups Act&#160;of&#160;2012 (the &#8220;JOBS Act&#8221;).</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">All
activity for the year ended December&#160;31, 2023 relates to the Company&#8217;s search for a target company, as well as attempts to
consummate the Proposed Holisto Merger which was terminated on August&#160;8, 2023 as detailed in Note&#160;1(f).</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">In
February&#160;2024, the Company entered into a Business Combination Agreement with Silexion. Refer to Note&#160;10(b)&#160;for further
information regarding the Proposed Business Combination.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company has selected December&#160;31 as its fiscal year end.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Sponsor and Financing</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company&#8217;s sponsor is Moringa Sponsor, L.P., a Cayman exempted limited partnership (which is referred to herein, together with its
wholly-owned subsidiary, Moringa Sponsor (US) LP, a Delaware limited partnership, as the &#8220;Sponsor&#8221;).</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
registration statement relating to the Company&#8217;s Public Offering was declared effective by the United&#160;States Securities and
Exchange Commission (the &#8220;SEC&#8221;) on February&#160;16, 2021. The initial stage of the Company&#8217;s Public Offering&#160;&#8212;&#160;the
sale of&#160;<ix:nonFraction id="Fixv-38024" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction>&#160;Units&#160;&#8212;&#160;closed
on February&#160;19, 2021 (hereafter&#160;&#8212;&#160;the Closing of the Public Offering). Upon that closing and the concurrent closing
of the initial stage of the Private Placement (as defined below in Note&#160;3). $<ix:nonFraction id="Fixv-38025" name="us-gaap:AssetsHeldInTrust" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction>&#160;was
placed in a trust account (the &#8220;Trust Account&#8221;) (discussed in Note&#160;1(c)&#160;below). On March&#160;3, 2021 upon the full
exercise by the underwriters of their over-allotment option for the Public Offering, the second stage of the Public Offering&#160;&#8212;&#160;the
sale of&#160;<ix:nonFraction id="Fixv-38026" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>&#160;Units&#160;&#8212;&#160;closed.
Upon that closing and the concurrent closing of the second stage of the Private Placement, an additional $<ix:nonFraction id="Fixv-38027" name="us-gaap:AssetsHeldInTrust" contextRef="C_20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">15,000,000</ix:nonFraction>&#160;was
placed in the Trust Account. As part of the partial redemptions in conjunction with the First and Second Extensions, approximately $<ix:nonFraction id="Fixv-38028" name="slxn:AmountFromTheInvestmentsHeldInTrustAccount" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">113</ix:nonFraction>&#160;million
have been withdrawn from the Investments held in Trust Account. The Company intends to finance its Initial Business Combination with the
net proceeds from the Public Offering and the Private Placement.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>c.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>The Trust Account</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
proceeds held in the Trust Account are invested in money market funds registered under the Investment Company Act and compliant with Rule&#160;2a-7
thereof that maintain a stable net asset value of&#160;$<ix:nonFraction id="Fixv-38029" name="us-gaap:NetAssetValuePerShare" contextRef="C_20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">1.00</ix:nonFraction>.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company&#8217;s complies with the provisions of ASU&#160;2016-18, under which changes in proceeds held in the Trust Account are accounted
for as Changes in Cash, Cash Equivalents and Investments Held in a&#160;Trust Account in the Company&#8217;s Statements of Cash Flows.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Refer
to Note&#160;4(a)&#160;for information regarding proceeds loaned by the Sponsor under the Sixth and Eighth Promissory Notes, deposited
into the Trust Account.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>d.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Initial Business Combination</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Public Offering, although
substantially all of the net proceeds of the Public Offering and the Private Placement are intended to be generally applied toward consummating
an Initial Business Combination. The Initial Business Combination must occur with one or more operating businesses or assets with a fair
market value equal to at least&#160;<ix:nonFraction id="Fixv-38030" name="slxn:BusinessCombinationOfNetAssetsHeldInTrustAccount" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction>%
of the net assets held in the Trust Account (excluding taxes payable on the income accrued in the Trust Account) as of the time of entry
into the related definitive agreement for the Initial Business Combination. There is no assurance that the Company will be able to successfully
consummate an Initial Business Combination.</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-27</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
1&#160;&#8212;&#160;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:</strong> (cont.)</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company, after signing a definitive agreement for an Initial Business Combination, will provide its public shareholders the opportunity
to redeem all or a portion of their shares upon the completion of the Initial Business Combination, either (i)&#160;in connection with
a shareholder meeting called to approve the business combination or (ii)&#160;by means of a tender offer.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">If
the Company holds a shareholder vote or there is a tender offer for shares in connection with an Initial Business Combination, a public
shareholder will have the right to redeem its shares for an amount in cash equal to its pro rata share of the aggregate amount then on
deposit in the Trust Account, calculated as of two&#160;days prior to the general meeting or commencement of the Company&#8217;s tender
offer, including interest but less taxes payable. As a result, the Company&#8217;s Class&#160;A ordinary shares subject to possible redemption
are classified as temporary equity upon the completion of the Public Offering, in accordance with the Financial Accounting Standards Board
(&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, &#8220;Distinguishing Liabilities from Equity&#8221;.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Pursuant
to the Company&#8217;s amended and restated memorandum and articles of association, if the Company is unable to complete the Initial Business
Combination within 24&#160;months (as was subsequently extended, as described below) from the Closing of the Public Offering, the Company
will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than
ten&#160;business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then
on deposit in the Trust Account, including interest (which interest shall be net of taxes payable, and less up to $<ix:nonFraction id="Fixv-38031" name="slxn:InterestToPayDissolutionExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction>&#160;of
interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish
public shareholders&#8217; rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as
promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining shareholders and the
Company&#8217;s board of directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands
law to provide for claims of creditors and the requirements of other applicable law.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Sponsor and the Company&#8217;s officers and directors have entered into a letter agreement with the Company, pursuant to which they have
waived their rights to liquidating distributions from the Trust Account with respect to any Class&#160;B ordinary share, including any
Class&#160;A ordinary share issuable upon conversion of such Class&#160;B ordinary shares, and Class&#160;A ordinary share (as described
in Note&#160;7) held by them if the Company fails to complete the Initial Business Combination within 24&#160;months (as was subsequently
extended) of the Closing of the Public Offering or during any extended time that the Company has to consummate an Initial Business Combination
beyond 24&#160;months as a result of a shareholder vote to amend its amended and restated memorandum and articles of association. However,
if the Sponsor or any of the Company&#8217;s directors or officers acquire any Class&#160;A ordinary shares subject to possible redemption,
they will be entitled to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete
the Initial Business Combination within the prescribed time period.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">In
the event of a liquidation, dissolution or winding up of the Company after an Initial Business Combination, the Company&#8217;s shareholders
are entitled to share ratably in all assets remaining available for distribution to them after payment of liabilities and after provision
is made for each class of stock, if any, having preference over the ordinary shares. The Company&#8217;s shareholders have no preemptive
or other subscription rights. There are no sinking fund provisions applicable to the ordinary shares, except that the Company will provide
its shareholders with the opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then
on deposit in the Trust Account, under the circumstances, and, subject to the limitations, described herein.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-28</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
1&#160;&#8212;&#160;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:</strong> (cont.)</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
February&#160;9, 2023 the Company held an extraordinary general meeting in lieu of the 2022 annual general meeting of the Company (hereafter&#160;&#8212;&#160;the
First Extension Meeting). At the First Extension Meeting, the Company&#8217;s shareholders approved the proposal to adopt, by way of special
resolution, an amendment to the Amended and Restated Articles to extend the date by which the Company has to consummate a business combination
from the 24 month anniversary of the Closing of the Public Offering&#160;&#8212;&#160;i.e., February&#160;19, 2023 to August&#160;19,
2023 (hereafter&#160;&#8212;&#160;the Extended Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its
sole discretion.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
August&#160;18, 2023 the Company held an extraordinary general meeting in lieu of the 2023 annual general meeting of the Company (hereafter&#160;&#8212;&#160;the
Second Extension Meeting). At the Second Extension Meeting, the Company&#8217;s shareholders approved, among other proposals, an amendment
to the Amended and Restated Memorandum and Articles of Association to further extend the date by which the Company has to consummate a
business combination from the Extended Mandatory Liquidation Date to August&#160;19, 2024 (hereafter&#160;&#8212;&#160;the Second Extended
Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its sole discretion.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Refer
to Note&#160;4(a)&#160;for information regarding proceeds received by the Company from the Sponsor under the Sixth and Eighth Promissory
Notes, which were deposited into the Trust Account.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Refer
to Note&#160;7(a)&#160;for information regarding the partial redemptions of Class&#160;A ordinary shares subject to possible redemption,
following the First and Second Extension Meetings.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Refer
to Note&#160;5(b)&#160;for information regarding the conversion of Class&#160;B ordinary shares into Class&#160;A ordinary shares, following
the Second Extension Meeting.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>e.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Substantial Doubt about the
        Company&#8217;s Ability to Continue as a Going Concern</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">As
of December&#160;31, 2023 the Company had approximately $<ix:nonFraction id="Fixv-38032" name="us-gaap:Cash" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction>&#160;thousand
of cash and an accumulated deficit of approximately $<ix:nonFraction id="Fixv-38033" name="us-gaap:RetainedEarningsAppropriated" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,848</ix:nonFraction>&#160;thousand.
In connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standard Board&#8217;s
Accounting Standard Codification&#160;205-40, &#8220;Going Concern&#8221;, the Company will need to obtain additional funds in order to
satisfy its liquidity needs in its endeavors to consummate a business combination.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Since
its inception date and through the issuance date of these financial statements, the Company&#8217;s liquidity needs were satisfied through
an initial capital injection from the Sponsor, followed by net Private Placement proceeds, as well as several withdrawals of the Sponsor
promissory notes. Management has determined that it will need to continue to rely and is significantly dependent on both outstanding and
future promissory notes, or other forms of financial support (all of which the Sponsor is not obligated to provide). Moreover, following
the Second Extension Meeting, the Company has until August&#160;19, 2024 to consummate an Initial Business Combination. If a business
combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. There can
be no assurance that the Company will be able to consummate any business combination ahead of the Second Extended Mandatory Liquidation
Date, nor will it be able to raise sufficient funds to complete an Initial Business Combination. These matters raise substantial doubt
about the Company&#8217;s ability to continue as a going concern, for the subsequent twelve&#160;months following the issuance date of
these financial statements. In February&#160;2024, the Company entered into a Business Combination Agreement with Silexion Therapeutics
Ltd. (hereafter&#160;&#8212;&#160;Silexion). Refer to Note&#160;10(b)&#160;for further information regarding the Proposed Business Combination.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">No
adjustments have been made to the carrying amounts of assets or liabilities should the company fail to obtain financial support in its
pursuit to consummate an Initial Business Combination, nor if it is required to liquidate after the Second Extended Mandatory Liquidation
Date.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-29</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
1&#160;&#8212;&#160;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:</strong> (cont.)</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>f.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Proposed Business Combination</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
June&#160;9, 2022 the Company entered into a Business Combination Agreement for a proposed business combination (hereafter&#160;&#8212;&#160;the
Proposed Holisto Merger) with Holisto Ltd., a company organized under the laws of the State of Israel (hereafter&#160;&#8212;&#160;Holisto)
and Holisto MergerSub, Inc., a Cayman Islands exempted company and wholly-owned subsidiary of Holisto.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
August&#160;7, 2023 Holisto notified the Company that it was terminating the Proposed Holisto Merger agreement. The termination became
effective as of August&#160;8, 2023. Upon termination of the Proposed Holisto Merger, all rights and obligations of each party to the
agreement ceased, except for those obligations of the parties that are intended to survive such termination and which remain in effect
in accordance with their respective terms. Neither the Company nor Holisto has any remaining substantive obligation to one another following
the above-mentioned termination, as of date of these financial statements.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">In
February&#160;2024, the Company entered into a Business Combination Agreement with Silexion. Refer to Note&#160;10(b)&#160;for further
information regarding the Proposed Business Combination.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>g.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Impact of War in Israel</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
October&#160;7, 2023 Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks
on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along
Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries
and kidnapping of civilians and soldiers. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and a military
campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
intensity and duration of Israel&#8217;s current war against Hamas is difficult to predict, as are such war&#8217;s economic implications
on the business and operations on any target company with which the Company may combine, and on Israel&#8217;s economy in general. These
events may cause wider macroeconomic deterioration in Israel, which may have a material adverse effect on the Company&#8217;s ability
to effectively complete an Initial Business Combination, or on the operations of an Israel-centered target company with which the Company
may combine.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Refer
to Note&#160;10(b)&#160;for further information regarding the Proposed Business Combination.</span></p> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003104814981" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
2 &#8212;&#160;SIGNIFICANT ACCOUNTING POLICIES:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105429224" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:100%;border:0px">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>a.</strong></span></td>
    <td style="text-align:justify"><strong style="font-size:10pt">Basis of Presentation</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company&#8217;s financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States
of America (&#8220;U.S.&#160;GAAP&#8221;) and the rules and regulations of the SEC.</span></p> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003105542454" name="slxn:EmergingGrowthCompanyPolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Emerging Growth Company</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Section&#160;102(b)(1)&#160;of
the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange&#160;Act) are required to comply with the new or revised financial accounting standards.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the&#160;requirements that apply
to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended
transition period which means that&#160;</span>when a standard is issued or revised and it has different application dates for public
or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard.</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-30</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
2 &#8212;&#160;SIGNIFICANT ACCOUNTING POLICIES:</strong> (cont.)</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">This
may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible, because of the potential
differences in accounting standards used.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105605485" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>c.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Cash and cash equivalents</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original
maturities of three&#160;months or less from the date of purchase that are not restricted as to withdrawal or use by nature of the account
and are readily convertible to known amounts of cash.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105639003" name="us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>d.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Class&#160;A Ordinary Shares
        subject to possible redemption</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">As
discussed in Note&#160;1(b), all of the&#160;<ix:nonFraction id="Fxbrl_20241004144253613" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>&#160;Class&#160;A
ordinary shares sold as part of the Units&#160;in the Public Offering contained a redemption feature. In accordance with the Accounting
Standards Codification&#160;480-10-S99-3A &#8220;Classification and Measurement of Redeemable Securities&#8221;, redemption provisions
not solely within the control of the Company require the security to be classified outside of permanent equity. The Company has classified
all of the shares sold under the Public Units&#160;as subject to possible redemption.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Refer
to Note&#160;7(a)&#160;for information regarding the partial redemptions of Class&#160;A ordinary shares subject to possible redemption,
following the First Extension Meeting and the Second Extension Meeting.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105657056" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>e.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Net profit (loss) per share</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company complies with accounting and disclosure requirements of FASB ASC Topic&#160;260, Earnings Per Share. Net profit (loss) per share
is computed by dividing net profit (loss) by the weighted average number of shares outstanding during the period. The Company applies
the two-class method in calculating net profit (loss) per each class of shares: the non-redeemable shares, which include the Private Class&#160;A
Ordinary Shares, as defined in Note&#160;7(a), and the Class&#160;B ordinary shares (hereafter and collectively&#160;&#8212;&#160;Non-Redeemable
class A and B ordinary shares); and the Class&#160;A ordinary shares subject to possible redemption.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">In
order to determine the net profit (loss) attributable to each class, the Company first considered the total profit (loss) allocable to
both sets of shares. This is calculated using the total net profit (loss) less any interest earned on investments held in the Trust Account.
Then, any accretion is fully allocated to the Class&#160;A ordinary shares subject to redemption.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003105714772" name="us-gaap:ConcentrationRiskDisclosureTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>f.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Concentration of credit risk</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which, at times, may exceed the Federal Depository Insurance Coverage of $<ix:nonFraction id="Fixv-38035" name="us-gaap:FederalDepositInsuranceCorporationPremiumExpense" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction>.
From the Company&#8217;s incorporation and through December&#160;31, 2023 the Company has not experienced any losses on these accounts.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">As
of December&#160;31, 2023 the Company held its cash and cash equivalents in an SVB bank account, and its investments Held in Trust Account
in Goldman Sachs money market funds. Money market funds are characterized as Level 1 investments within the fair value hierarchy under
ASC&#160;820.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-31</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
2 &#8212;&#160;SIGNIFICANT ACCOUNTING POLICIES:</strong> (cont.)</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div> <ix:nonNumeric id="Fxbrl_20241003105739676" name="slxn:PublicWarrantsPolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>g.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Public Warrants</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company applied the provisions of ASC&#160;815-40 and classified its public warrants, issued as part of the Public Units&#160;as detailed
in Note&#160;3, as equity securities.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105757356" name="slxn:PrivateWarrantLiabilityPolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>h.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Private Warrant liability</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company accounts for the warrants in accordance with the guidance contained in Accounting Standards Codification 815 (&#8220;ASC&#160;815&#8221;),
&#8220;Derivatives and Hedging&#8221;, under which the warrants do not meet the criteria for equity treatment and must be recorded as
derivative liabilities. Accordingly, the Company classifies the warrants as liabilities at their fair value and adjusts the warrants to
fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants are exercised
or expire, and any change in fair value is recognized in the Company&#8217;s statement of operations. Refer to Note&#160;6 for information
regarding the model used to estimate the fair value of the Private Warrants (as defined in Note&#160;3).</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105809886" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>i.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Financial instruments</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the FASB ASC&#160;820, &#8220;Fair
Value Measurements and Disclosures&#8221;, approximates the carrying amounts represented in the balance sheet, primarily due to their
short-term nature.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105838625" name="us-gaap:UseOfEstimates" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:100%;border:0px">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>j.</strong></span></td>
    <td style="text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Use
        of estimates in the preparation of financial statements</strong></span></p> </td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
preparation of the financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates and such differences
may have a material impact on the Company&#8217;s financial statements.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105853286" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:100%;border:0px">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>k.</strong></span></td>
    <td style="text-align:justify">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Income
        tax</strong></span></p> </td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company accounts for income taxes in accordance with ASC&#160;740, &#8220;Income Taxes (hereafter&#160;&#8212;&#160;ASC&#160;740). ASC&#160;740
prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences
between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will
be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred
tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not
be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current
in accordance with ASU&#160;2015-17.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105910323" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>l.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Recent accounting pronouncements</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Management
does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted would have a material
effect on the Company&#8217;s financial statements.</span></p> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<div>

<div> <ix:nonNumeric id="Fxbrl_20241004103903070" name="slxn:PublicOfferingAndPrivatePlacementsTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
3 &#8212;&#160;PUBLIC OFFERING AND PRIVATE PLACEMENTS:</span></span></strong></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:37pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
the initial Public Offering, the Company issued and sold&#160;<ix:nonFraction id="Fixv-38034" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>&#160;units
(including&#160;<ix:nonFraction id="Fixv-38037" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>&#160;units
sold at a second closing pursuant to the underwriters&#8217; exercise of their over-allotment option in full) at an offering price of
$<ix:nonFraction id="Fixv-38038" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction>&#160;per
unit (hereafter&#160;&#8212;&#160;the Units). The Sponsor and EarlyBirdCapital, Inc. (the representative of the underwriters) purchased,
in a private placement that occurred simultaneously with the two closings of the initial Public Offering (hereafter&#160;&#8212;&#160;the
Private Placement), an aggregate of&#160;<ix:nonFraction id="Fixv-38039" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">352,857</ix:nonFraction>&#160;and&#160;<ix:nonFraction id="Fixv-38040" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">27,143</ix:nonFraction>&#160;Units,
respectively, at a price of $<ix:nonFraction id="Fixv-38042" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction>&#160;per
Unit.</span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:30pt">&#160;</p>

<div>

<div>

<div><ix:exclude>

<div style="border-bottom:Black 1.5pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-32</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>NOTE
3 &#8212;&#160;PUBLIC OFFERING AND PRIVATE PLACEMENTS:&#160;</span></strong><span>(cont.)</span></span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px">&#160;</p> </ix:exclude></div> </div> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Each
Unit (both those sold in the initial Public Offering and in the Private Placement) consists of one Class&#160;A ordinary share, $<ix:nonFraction id="Fixv-38043" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>&#160;par
value, and one-half of one warrant, with each whole warrant exercisable for one Class&#160;A ordinary share (hereafter&#160;&#8212;&#160;each,
a Public Warrant and a Private Warrant, and collectively, the Warrants). Each Warrant entitles the holder thereof to purchase one whole
Class&#160;A ordinary share at a price of $<ix:nonFraction id="Fixv-38044" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">11.50</ix:nonFraction>&#160;per
share, subject to adjustment. No fractional shares will be issued upon exercise of the Warrants and only whole Warrants trade. Each Warrant
will become exercisable 30&#160;days after the completion of the Company&#8217;s Initial Business Combination and will expire at 5:00&#160;p.m.,
New&#160;York City time, five years&#160;after the completion of the Initial Business Combination or earlier upon redemption (only in
the case of the Public Warrants) or liquidation.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Once
the Public Warrants become exercisable, the Company may redeem them in whole and not in part at a price of $<ix:nonFraction id="Fixv-38045" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>&#160;per
Warrant upon a minimum of 30&#160;days&#8217; prior written notice of redemption, if and only if the last reported sale price of the Company&#8217;s
Class&#160;A ordinary shares equals or exceeds $<ix:nonFraction id="Fixv-38046" name="slxn:WarrantPricePerSharesExceeds" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">18.00</ix:nonFraction>&#160;per
share (as adjusted) for any 20&#160;trading days within a 30-trading&#160;day period ending on the third&#160;trading day prior to the
date on which the Company sends the notice of redemption to the Public Warrant holders.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Private Warrants are identical to the Public Warrants except that, for so long as they are held by the Sponsor, EarlyBirdCapital, Inc.
or their respective affiliates: (1)&#160;will not be redeemable by the Company; (2)&#160;may not (including the Class&#160;A ordinary
shares issuable upon exercise thereof), subject to certain limited exceptions, be transferred, assigned or sold by the holders thereof
until 30&#160;days after the completion of the Company&#8217;s Initial Business Combination; (3)&#160;may be exercised by the holders
thereof on a cashless basis; and (4)&#160;they (including the Class&#160;A ordinary shares issuable upon exercise thereof) are entitled
to registration rights.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company paid an underwriting commission of&#160;<ix:nonFraction id="Fixv-38047" name="slxn:UnderwritingCommissionPercentage" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.0</ix:nonFraction>%
of the gross proceeds of the Public Offering and the full exercise of the underwriters&#8217; over-allotment, or $<ix:nonFraction id="Fixv-38048" name="slxn:AggregateUnderwritersAmount" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,300,000</ix:nonFraction>,
in the aggregate, to the underwriters at the two closings of the Public Offering. Refer to Note&#160;5(a)&#160;for more information regarding
an additional fee payable to the underwriters upon the consummation of an Initial Business Combination.</span></p> </div> </ix:nonNumeric>
</div> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003122251232" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
4 &#8212;&#160;RELATED PARTY TRANSACTIONS:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Promissory Notes</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company has issued several promissory note agreements to its Sponsor throughout its life term, in order to fulfil its ongoing operational
needs or preparations towards an Initial Business Combination. All outstanding promissory notes bear no interest and are repayable in
full upon the earlier of (a)&#160;the date of the consummation of the Company&#8217;s Initial Business Combination, or (b)&#160;Second
Extended Mandatory Liquidation Date (hereafter and collectively&#160;&#8212;&#160;the Maturity Date).</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>First
Promissory Note</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
First Promissory Note withdrawn was borrowed and repaid in full in early 2021 and has subsequently expired.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Second
to Fifth Promissory Notes</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
August&#160;9, 2021 the Company issued its Second Promissory Note to the Sponsor, according to which the former may withdraw up to $<ix:nonFraction id="Fixv-38049" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20210809_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSecondPromissoryNoteMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;million&#160;&#8212;&#160;which
has been withdrawn in full in several installments up until June&#160;2022.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">In
December&#160;2022 the Company issued its Third and Fourth Promissory Notes (hereafter&#160;&#8212;&#160;the Third and Fourth Promissory
Notes), according to which the Company may withdraw up to an aggregate amount of $<ix:nonFraction id="Fixv-38050" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnThirdAndFourthPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">190</ix:nonFraction>&#160;thousand&#160;&#8212;&#160;which
were withdrawn in full on the same month.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:1.5pt solid black">

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">F-33</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></div>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
4 &#8212;&#160;RELATED PARTY TRANSACTIONS:</strong> (cont.)</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
February&#160;8, 2023 the Company issued its Fifth Promissory Note to the Sponsor, in an amount of up to $<ix:nonFraction id="Fixv-38051" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20230208_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnFifthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">310</ix:nonFraction>&#160;thousand,
which were withdrawn in full in several installments between February and June&#160;2023.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">According
to the terms of the outstanding Second, Third, Fourth and Fifth Promissory Notes, which comprise an aggregate principal of $<ix:nonFraction id="Fixv-38052" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction>&#160;million,
the Sponsor may elect to convert any portion of the amounts outstanding into private warrants to purchase Class&#160;A ordinary shares
at a conversion price of $<ix:nonFraction id="Fixv-38053" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;per
private warrant on the Maturity Date. Such private warrants will have an exercise price of $<ix:nonFraction id="Fixv-38054" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFinancialInstrumentAxis_slxnPrivateWarrantsMember" unitRef="usdPershares" scale="0" decimals="1" format="ixt:num-dot-decimal">11.5</ix:nonFraction>&#160;and
shall be identical to the private warrants included in the private units.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Sixth
Promissory Note</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
February&#160;9, 2023 the Company issued its Sixth Promissory Note to the Sponsor, in an amount of $<ix:nonFraction id="Fixv-38055" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20230209_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">480</ix:nonFraction>&#160;thousand&#160;&#8212;&#160;under
which the funds that were loaned by the Sponsor were deposited into the Company&#8217;s Trust Account, in connection with the First Extension.
The Sponsor provided six monthly injections of $<ix:nonFraction id="Fixv-38056" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20230219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction>&#160;thousand
into the Company&#8217;s Trust Account under the Sixth Promissory Note, starting February&#160;19, 2023.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Seventh
Promissory Note</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
June&#160;14, 2023 the Company issued its Seventh Promissory Note to the Sponsor in an amount of up to $<ix:nonFraction id="Fixv-38057" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20230614_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSeventhPromissoryNoteMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;million,
of which $<ix:nonFraction id="Fixv-38058" name="slxn:WithdrawnAmount" contextRef="C_20230614to20230614_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSeventhPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">210</ix:nonFraction>&#160;thousand
were withdrawn at the same date; and approximately $<ix:nonFraction id="Fixv-38059" name="slxn:WithdrawnAmount" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSeventhPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">586</ix:nonFraction>&#160;thousand
were withdrawn up until December&#160;31, 2023.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Eighth
Promissory Note</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
August&#160;18, 2023 the Company issued its Eighth Promissory Note to the Sponsor, in an amount of approximately $<ix:nonFraction id="Fixv-38060" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20230818_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnEighthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction>&#160;thousand&#160;&#8212;&#160;under
which the funds that were loaned by the Sponsor were deposited into the Company&#8217;s Trust Account, in connection with the Second Extension.
The Sponsor shall make monthly injections of approximately $<ix:nonFraction id="Fixv-38061" name="slxn:SponsorPay" contextRef="C_20230819to20230819_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnEighthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction>&#160;thousand
into the Company&#8217;s Trust Account, starting August&#160;19, 2023 and up until the earlier of the Second Extended Mandatory Liquidation
Date (or such earlier date that the Board determines to liquidate the Company) or the date on which an Initial Business Combination is
completed.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Administrative Services Agreement</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
December&#160;16, 2020 the Company signed an agreement with the Sponsor, under which the Company shall pay the Sponsor a fixed $<ix:nonFraction id="Fixv-38062" name="slxn:MonthlyOfficeSpaceExpenses" contextRef="C_20201216_slxnTypeOfAgreementAxis_slxnAdministrativeServicesAgreementMember_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;thousand
per month for office space, utilities and other administrative expenses. The monthly payments under this administrative services agreement
commenced on the effective date of the registration statement for the initial Public Offering and will continue until the earlier of (i)&#160;the
consummation of the Company&#8217;s Initial Business Combination, or (ii)&#160;the Company&#8217;s liquidation.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
composition of the Related Party balance as of December 31, 2023 and 2022 is as follows:</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>
<ix:nonNumeric id="Fxbrl_20241003122446878" name="us-gaap:ScheduleOfCompensatingBalancesTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">December&#160;31,<br/>2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">U.S.&#160;dollars</td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left">Promissory notes</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38063" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnPromissoryNotesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,841,000</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38064" name="us-gaap:NotesPayableCurrent" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnPromissoryNotesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">1,190,000</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt">Accrual for Administrative Services Agreement</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38065" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapAssetManagementArrangementMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241003122518486" name="us-gaap:NotesPayableCurrent" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapAssetManagementArrangementMember" unitRef="usd" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38066" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,861,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38067" name="us-gaap:NotesPayableCurrent" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">1,190,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div> </ix:nonNumeric>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:1.5pt solid black">

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">F-34</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></div>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>
</div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-21706" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
5 &#8212;&#160;COMMITMENTS AND CONTINGENCIES:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Underwriters&#8217; Deferred
        Discount</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Under
the Business Combination Marketing Agreement, the Company shall pay an additional fee (hereafter&#160;&#8212;&#160;the Deferred Commission)
of&#160;<ix:nonFraction id="Fixv-38068" name="slxn:DeferredCommissionPercentage" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction>%
of the gross proceeds of the Public Offering (or $<ix:nonFraction id="Fixv-38069" name="slxn:AdditionalFeePayable" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">4,025,000</ix:nonFraction>)
payable upon the Company&#8217;s completion of the Initial Business Combination. The Deferred Commission will become payable to the underwriters
from the amounts held in the Trust Account solely in the event the Company completes an Initial Business Combination.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Nasdaq Deficiency Notices</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>First
Deficiency Notice</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
March&#160;28, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it is not in compliance
with Nasdaq Listing Rule&#160;5550(a)(3)&#160;(hereafter&#160;&#8212;&#160;the First Deficiency), according to which the Company must
satisfy the Minimum Public Holders Rule which requires listed companies to have at least 300 public holders. The Company has submitted
its compliance plan on May&#160;11, 2023 which was accepted by Nasdaq, which has then granted an extension of up to 180 calendar&#160;days
from the date of the notice&#160;&#8212;&#160;until September&#160;24, 2023 &#8212;&#160;to evidence compliance with the rule.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
September&#160;27, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it has regained
compliance with the First Deficiency.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Second
Deficiency Notice</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
June&#160;15, 2023 the Company received another notice from Nasdaq Listing Qualifications Department indicating that it is not in compliance
with Nasdaq Listing Rule&#160;5550(b)(2)&#160;(hereafter&#160;&#8212;&#160;the Second Deficiency), according to which the Company must
sustain a market value of listed securities of at least $<ix:nonFraction id="Fixv-38070" name="us-gaap:MarketableSecurities" contextRef="C_20230615_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">35</ix:nonFraction>&#160;million,
for continued listing on the Nasdaq Capital Market. The notice was only a notification of deficiency, not of imminent delisting, and has
no current effect on the listing or trading of the Company&#8217;s securities on the Nasdaq Capital Market.</span></p> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003132408563" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
6 &#8212;&#160;FAIR VALUE MEASUREMENTS:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Following
the Second Extension Meeting, the Sponsor converted&#160;<ix:nonFraction id="Fixv-38071" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">2,874,999</ix:nonFraction>&#160;of
its Class&#160;B ordinary shares on a one to one basis into Class&#160;A ordinary shares, in an effort to regain compliance with the Second
Deficiency.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
November&#160;24, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it has regained
compliance with the Second Deficiency.</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date (i.e., the exit price).</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
fair value hierarchy under ASC&#160;820 prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives
the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the
lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Level
1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-35</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
6 &#8212;&#160;FAIR VALUE MEASUREMENTS:</strong> (cont.)</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Level
2: Quoted prices in markets that are not active or financial instruments for which significant inputs to models are observable (including
but not limited to quoted prices for similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly
or indirectly;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Level
3: Prices or valuations that require significant unobservable inputs (including the Management&#8217;s assumptions in determining fair
value measurement).</span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Basis
for Fair Value Measurement</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis
at December&#160;31, 2023 by level within the fair value hierarchy:</span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003132225298" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Level</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31,<br/>2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-indent:-10pt;padding-left:10pt">Assets:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:64%;text-align:left;text-indent:-10pt;padding-left:10pt">Money market funds held in Trust Account</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38072" name="us-gaap:AssetsHeldInTrustCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697,632</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38073" name="us-gaap:AssetsHeldInTrustCurrent" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,692,038</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-indent:-10pt;padding-left:10pt">Liabilities:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Private warrant liability</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt;text-align:right">3</td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38074" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,531</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38075" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,640</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
estimated fair value of the Private Placement Warrants was determined using a binomial model to extract the market&#8217;s implied probability
for an Initial Business Combination, using the Public Warrant&#8217;s market price. Once probability was extracted, a Black-Scholes-Merton
model with Level 3 inputs was used to calculate the Private Warrants&#8217; fair value. Inherent in a Black-Scholes-Merton model are assumptions
related to expected life (term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the
volatility of its warrants based on implied volatility from the Company&#8217;s traded warrants and from historical volatility of selected
peer companies&#8217; Class&#160;A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate
is based on the U.S.&#160;Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of
the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is
based on the historical rate, which the Company anticipates remaining at zero.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
following table provides quantitative information regarding Level&#160;3 fair value measurements inputs:</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003132237883" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">As of<br/>December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">As of<br/>December&#160;31,<br/>2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-indent:-10pt;padding-left:10pt">Share price</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction id="Fixv-38076" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputSharePriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">10.0</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction id="Fixv-38077" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputSharePriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">10.0</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-10pt;padding-left:10pt">Strike price</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38078" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_slxnMeasurementInputStrikevPriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">11.5</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38079" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_slxnMeasurementInputStrikevPriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">11.5</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-10pt;padding-left:10pt">Volatility</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38080" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" unitRef="pure" scale="0" decimals="0" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38081" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" unitRef="pure" scale="0" decimals="0" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Risk-free interest rate</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38082" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">4.78</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38083" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">4.00</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Dividend yield</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38084" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38085" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>
<ix:nonNumeric id="Fixv-21995" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">U.S.&#160;dollars</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:88%;text-align:left">Value of warrant liability measured with Level 3 inputs at December&#160;31, 2022</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38086" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,640</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt">Change in fair value of private warrant liability measured with Level 3 inputs</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38087" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">21,109</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt">Value of warrant liability measured with Level 3 inputs at December&#160;31, 2023</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38088" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,531</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-36</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="margin-top:0;margin-bottom:0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">&#160;</strong></span></p>
</div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-22047" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
7 &#8212;&#160;CAPITAL DEFICIENCY:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Ordinary Shares</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Class&#160;A
Ordinary Shares</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
November&#160;20, 2020 the Company issued&#160;<ix:nonFraction id="Fixv-38089" name="us-gaap:CommonStockSharesIssued" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">100,000</ix:nonFraction>&#160;Class&#160;A
ordinary shares of $<ix:nonFraction id="Fixv-38090" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>&#160;par
value each to designees of the Representative (hereafter&#160;&#8212;&#160;the Representative Shares) for a consideration equal to the
par value of the shares. The Representative Shares are deemed to be underwriters&#8217; compensation by FINRA pursuant to Rule&#160;5110
of the FINRA Manual.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company accounted for the issuance of the Representative Shares as compensation expenses amounting to $<ix:nonFraction id="Fixv-38091" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">860</ix:nonFraction>,
with a corresponding credit to Additional Paid-In Capital, for the excess value over the consideration paid. The Company estimated the
fair value of the issuance based upon the price of Class&#160;B Ordinary Shares that were issued to the Sponsor.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Pursuant
to the initial Public Offering and the concurrent Private Placement that were each effected in two closings&#160;&#8212;&#160;on February&#160;19,
2021 and March&#160;3, 2021 &#8212;&#160;the Company issued and sold an aggregate of&#160;<ix:nonFraction id="Fixv-38092" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>&#160;and&#160;<ix:nonFraction id="Fixv-38093" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">380,000</ix:nonFraction>&#160;Class&#160;A
ordinary shares as part of the Units&#160;sold in those respective transactions. The Units&#160;(which also included Warrants) were sold
at a price of $<ix:nonFraction id="Fxbrl_20241003171011236" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38094" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>&#160;per
Unit, and for an aggregate consideration of $<ix:nonFraction id="Fixv-38096" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_slxnPublicOfferingMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">115</ix:nonFraction>&#160;million
and $<ix:nonFraction id="Fixv-38097" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction>&#160;million
in the Public Offering and Private Placement, respectively. See Note&#160;3 above for further information regarding those share issuances.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company classified its&#160;<ix:nonFraction id="Fixv-38098" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>&#160;Class&#160;A
ordinary shares subject to possible redemption as temporary equity. The remaining&#160;<ix:nonFraction id="Fixv-38099" name="slxn:RemainingTemporaryEquityShares" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">480,000</ix:nonFraction>&#160;Private
Class&#160;A ordinary shares were classified as permanent equity.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">In
conjunction with the First and Second Extensions,&#160;<ix:nonFraction id="Fixv-38100" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnFirstExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">8,910,433</ix:nonFraction>&#160;and&#160;<ix:nonFraction id="Fixv-38101" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnSecondExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,074,548</ix:nonFraction>&#160;Class&#160;A
Ordinary Shares subject to possible redemption were redeemed, respectively, for their redemption value, including accrued interest. As
part of the partial redemptions approximately $<ix:nonFraction id="Fixv-38102" name="slxn:PartialRedemptionWithdrawnFromInvestmentHeldInTrustAccount" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">113</ix:nonFraction>&#160;million
has been withdrawn from the Investments held in Trust Account.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Class&#160;B
Ordinary Shares</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
November&#160;20, 2020 the Company issued&#160;<ix:nonFraction id="Fixv-38103" name="us-gaap:CommonStockSharesIssued" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction>&#160;Class&#160;B
ordinary shares of $<ix:nonFraction id="Fixv-38104" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>&#160;par
value each for a total consideration of $<ix:nonFraction id="Fixv-38105" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20201120to20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction>&#160;thousand
to the Sponsor&#8217;s wholly-owned Delaware subsidiary. Out of the&#160;</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><ix:nonFraction id="Fxbrl_20241004165829305" name="us-gaap:CommonStockSharesIssued" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction>&#160;</span><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Class&#160;B
ordinary shares, up to&#160;<ix:nonFraction id="Fixv-38106" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="C_20201120to20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">375,000</ix:nonFraction>&#160;were
subject to forfeiture if the underwriters were to not exercise their over-allotment in full or in part. Because the underwriters exercised
their over-allotment option in full on March&#160;3, 2021 that potential forfeiture did not occur.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Class&#160;B
ordinary shares are convertible into non-redeemable Class&#160;A ordinary shares, on a one-for-one basis, automatically on the&#160;day
of the Business Combination or at the election of the holder thereof at any time prior to the Business Combination. Class&#160;B ordinary
shares also possess the sole right to vote for the election or removal of directors, until the consummation of an Initial Business Combination.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Refer
to Note&#160;5(b)&#160;for information regarding the conversion of Class&#160;B ordinary shares into Class&#160;A ordinary shares following
the Second Extension Meeting.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Preferred shares</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company is authorized to issue up to&#160;<ix:nonFraction id="Fixv-38107" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction>&#160;Preferred
Shares of $<ix:nonFraction id="Fixv-38108" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>&#160;par
value each. As of December&#160;31, 2023 the Company has <ix:nonFraction id="Fxbrl_20241004133939813" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20241004133925479" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>
preferred shares issued and outstanding.</span></p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-37</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-22152" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
8 &#8212;&#160;NET PROFIT (LOSS) PER SHARE:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>
<ix:nonNumeric id="Fxbrl_20241004104439701" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
following table reflects the calculation of basic and diluted net profit (loss) per share (in dollars, except share amounts):</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Year ended<br/>December&#160;31,</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;width:76%;text-align:left">Net profit for the year</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38109" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,073</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38110" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">584,025</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Less&#160;&#8211;&#160;interest earned on Investment
        held in Trust Account</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38111" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,364,444</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38112" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,685,666</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Net loss excluding interest</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38113" name="us-gaap:GrossProfit" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,101,371</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38114" name="us-gaap:GrossProfit" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,101,641</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">Class&#160;A ordinary shares subject to possible redemption:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.25in;text-align:left">Net loss excluding interest</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38115" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">498,567</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38116" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">852,835</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in;text-align:left;padding-bottom:1.5pt">Accretion to Class&#160;A ordinary shares subject
        to possible redemption to redemption amount (&#8220;Accretion&#8221;)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38117" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,908,820</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38118" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,685,666</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38119" name="slxn:TemporaryEquitySubjectToPossibleRedemption" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,410,253</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38120" name="slxn:TemporaryEquitySubjectToPossibleRedemption" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">832,831</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in;padding-bottom:1.5pt">Weighted average number of shares</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38121" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,774,850</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38122" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:4pt">Basic and diluted net profit per
        Class&#160;A ordinary share subject to possible redemption</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38123" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.51</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38124" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.07</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">Non-redeemable Class&#160;A and B ordinary shares:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in;text-align:left">Net loss excluding interest</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38125" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">602,804</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38126" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">248,806</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.25in;padding-bottom:1.5pt">Accretion</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38127" name="slxn:Accretion" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">544,376</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#8212;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(1,147,180</td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(248,806</td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in;padding-bottom:1.5pt">Weighted average number of shares</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38128" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38129" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:4pt">Basic and diluted net loss per non-redeemable
        Class&#160;A and B ordinary share</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-38130" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.34</ix:nonFraction></td>
    <td style="padding-bottom:2px;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-38131" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.07</ix:nonFraction></td>
    <td style="padding-bottom:2px;text-align:left">)</td> </tr>
  </table> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
potential exercise of&#160;<ix:nonFraction id="Fixv-38132" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDerivativeInstrumentRiskAxis_slxnPublicWarrantsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction>&#160;Public
Warrants and&#160;<ix:nonFraction id="Fixv-38133" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDerivativeInstrumentRiskAxis_slxnPrivateWarrantsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">190,000</ix:nonFraction>&#160;Private
Warrants sold in the Public Offering and Private Placements as detailed in Note&#160;3 into&#160;<ix:nonFraction id="Fixv-38134" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">5,940,000</ix:nonFraction>&#160;shares
has not been included in the calculation of diluted net profit (loss) per share, since the exercise of the warrants is contingent upon
the occurrence of a future event.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Additionally,
the effect of the conversion of the Second, Third, Forth and Fifth Promissory Notes into an aggregate amount of&#160;<ix:nonFraction id="Fixv-38135" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtTitleOfIndividualAxis_slxnSecondThirdForthAndFifthPromissoryNotesMember_usgaapDerivativeInstrumentRiskAxis_slxnPrivateWarrantsMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>&#160;private
warrants (exercisable into 1,500,000 shares) as detailed in Note&#160;4, has not been included in the calculation of diluted net profit
(loss) per share, since the conversion of the abovementioned promissory notes is contingent upon the occurrence of a future event.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">As
a result, diluted net profit (loss) per share is the same as basic net profit (loss) per share for each of the periods presented, and
for each class.</span></p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-38</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-22462" name="slxn:GeneralAndAdministrativeTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
9 &#8212;&#160;GENERAL AND ADMINISTRATIVE:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
formation and other operating expenses for the years ended December 31, 2023 and 2022 are as follows:</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>
<ix:nonNumeric id="Fxbrl_20241003025614125" name="us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">December&#160;31,<br/>2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">U.S.&#160;dollars</td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left">Legal expenses</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38136" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnLegalExpensesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">259,000</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38137" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnLegalExpensesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">398,903</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Audit, bookkeeping and accounting</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38138" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnAuditBookkeepingAndAccountingMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">146,600</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38139" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnAuditBookkeepingAndAccountingMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,101</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left">Professional services</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38140" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnProfessionalServicesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">245,538</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38141" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnProfessionalServicesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,651</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Management fees</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38142" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnManagementFeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38143" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnManagementFeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td>Insurance</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38144" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnInsuranceMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,044</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38145" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnInsuranceMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">325,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Nasdaq fees</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38146" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnNasdaqFeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38147" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnNasdaqFeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,500</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt">Other</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38148" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnOtherExpensesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">298</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38149" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnOtherExpensesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">187</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38150" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,122,480</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38151" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,232,342</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </ix:nonNumeric> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-22575" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
10 &#8212;&#160;SUBSEQUENT EVENTS:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Nasdaq Deficiency Note</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
February&#160;20, 2024, the Company received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market
LLC indicating that unless the Company timely requests a hearing before the Nasdaq Hearings Panel (hereafter&#160;&#8212;&#160;the Panel),
trading of the Company&#8217;s securities on The Nasdaq Capital Market would be suspended at the opening of business on February&#160;29,
2024, due to the Company&#8217;s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete
one or more business combinations within 36&#160;months of the effectiveness of its IPO registration statement.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company timely requested a hearing before the Panel to request sufficient time to complete its previously disclosed proposed business
combination with Silexion. The hearing request has resulted in a stay of any suspension or delisting action pending the hearing, which
is scheduled to take place on April&#160;23, 2024.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Proposed Business Combination</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
February&#160;21, 2024, the Company, together with its wholly-owned Israeli subsidiary (hereafter&#160;&#8212;&#160;the Merger Sub), entered
into a business combination agreement (hereafter&#160;&#8212;&#160;the BCA) with Silexion Therapeutics Ltd., an Israeli company (hereafter&#160;&#8212;&#160;Silexion).</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The&#160;Business
Combination is expected to close in the third quarter of 2024, subject to the satisfaction of customary closing conditions under the BCA,
including the approval of the Business Combination by Silexion&#8217;s and the Company&#8217;s shareholders, and Nasdaq approval of the
initial listing of the combined company&#8217;s securities.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Headquartered
in Israel, Silexion is a clinical-stage, oncology-focused biotechnology company that develops innovative treatments for unsatisfactorily
treated solid tumor cancers which have a mutated KRAS oncogene. The Business Combination values Silexion at a pre-transaction equity value
of $<ix:nonFraction id="Fixv-38152" name="slxn:PreTransactionEquity" contextRef="C_20240221_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.5</ix:nonFraction>&#160;million,
based on a $<ix:nonFraction id="Fixv-38153" name="slxn:PreTransactionsEquity" contextRef="C_20240221_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;price
per share.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
BCA and the Business Combination have been unanimously approved by the boards of directors of the Company and&#160;Silexion.</span></p>
</ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-39</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p>&#160;</p> </div>

<div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="f_012_integixAnchor"></span></span></span></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>SILEXION
THERAPEUTICS LTD.</strong></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS</span></span></p>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June
        30,</span></span></td>
    <td style="font-weight:bold">&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31</span></span></td>
    <td style="font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;padding-bottom:1.5pt;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
        dollars in thousands</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets</span></span></td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:right">&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:right">&#160;</td>
    <td style="font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT ASSETS:</span></span></td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:right">&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:right">&#160;</td>
    <td style="font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;width:76%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash
        and cash equivalents</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559448_ixv-38154" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,697</ix:nonFraction></span></span></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559448_ixv-38155" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,595</ix:nonFraction></span></span></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted
        cash</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559455_ixv-38156" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559455_ixv-38157" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid
        expenses</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559462_ixv-38158" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">527</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559462_ixv-38159" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">335</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-align:left;padding-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other
        current assets</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559467_ixv-38160" name="us-gaap:OtherAssetsCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559467_ixv-38161" name="us-gaap:OtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        CURRENT ASSETS</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559472_ixv-38162" name="us-gaap:AssetsCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,315</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559472_ixv-38163" name="us-gaap:AssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,979</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NON-CURRENT
        ASSETS:</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted
        cash</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559477_ixv-38164" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559477_ixv-38165" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term
        deposit</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559483_ixv-38166" name="us-gaap:DepositsAssetsNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559483_ixv-38167" name="us-gaap:DepositsAssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property
        and equipment, net</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559488_ixv-38168" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559488_ixv-38169" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-align:left;padding-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        lease right-of-use asset</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559495_ixv-38170" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559495_ixv-38171" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        NON-CURRENT ASSETS</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559500_ixv-38172" name="us-gaap:AssetsNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">210</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559500_ixv-38173" name="us-gaap:AssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">277</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        ASSETS</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559504_ixv-38174" name="us-gaap:Assets" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,525</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559504_ixv-38175" name="us-gaap:Assets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,256</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<div>&#160;</div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 15.75pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</strong></span></span></p>

<div>&#160;</div>

<div style="border-bottom:Black 1.5pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>F-40</span></span></span></p>
</div>

<div>&#160;</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">&#160;</div> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>SILEXION
THERAPEUTICS LTD.</strong></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS</span></span></p>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June
        30,</span></span></td>
    <td style="font-weight:bold">&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31</span></span></td>
    <td style="font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
        dollars in thousands</span></span></td>
    <td style="font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liabilities
        and redeemable convertible preferred shares, net of capital deficiency</span></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT LIABILITIES:</span></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-0.125in;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade
        payables</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559513_ixv-38176" name="us-gaap:AccountsPayableCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">281</ix:nonFraction></span></span></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559513_ixv-38177" name="us-gaap:AccountsPayableCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></span></span></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current
        maturities of operating lease liability</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559518_ixv-38178" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559518_ixv-38179" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        to preferred shares (including $<ix:nonFraction id="Fixv-38180" name="us-gaap:OtherNotesPayableCurrent" contextRef="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">321</ix:nonFraction>
        and $<ix:nonFraction id="Fixv-38181" name="us-gaap:OtherNotesPayableCurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction>
        due to related party, as of June 30, 2024 and December 31, 2023, respectively)</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559522_ixv-38182" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559522_ixv-38183" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee
        related obligations</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559529_ixv-38184" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">251</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559529_ixv-38185" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued
        expenses and other account payable</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559534_ixv-38186" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,379</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559534_ixv-38187" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,358</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        CURRENT LIABILITIES</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559538_ixv-38188" name="us-gaap:LiabilitiesCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,364</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559538_ixv-38189" name="us-gaap:LiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,196</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NON-CURRENT
        LIABILITIES:</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term
        operating lease liability</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559545_ixv-38190" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559545_ixv-38191" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        NON-CURRENT LIABILITIES</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559550_ixv-38192" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559550_ixv-38193" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        LIABILITIES</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559555_ixv-38194" name="us-gaap:Liabilities" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,372</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559555_ixv-38195" name="us-gaap:Liabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,255</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMMITMENTS
        AND CONTINGENT LIABILITIES</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004150241839" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20240630" unitRef="usd" xsi:nil="true"/></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004150247176" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20231231" unitRef="usd" xsi:nil="true"/></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">REDEEMABLE
        CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTERESTS:</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible
        Series A Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241004132814962" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004113904925" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction>
        par value, <ix:nonFraction id="Fxbrl_20241004132848360" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004114010036" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">510,000</ix:nonFraction></ix:nonFraction>
        shares authorized as of June 30, 2024 and December 31, 2023, <ix:nonFraction id="Fxbrl_20241004133009707" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004133003572" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004132953043" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004132947248" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $<ix:nonFraction id="Fixv-38204" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,162</ix:nonFraction>
        as of June 30, 2024;</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible
        Series A-1 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241003171931507" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38205" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_20241003171950188" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38207" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">120,000</ix:nonFraction></ix:nonFraction>
        shares authorized as of June 30, 2024 and December 31, 2023, <ix:nonFraction id="Fxbrl_20241003172033691" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241003172027107" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241003172005873" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38209" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $<ix:nonFraction id="Fixv-38213" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,443</ix:nonFraction>
        as of June 30, 2024;</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible
        Series A-2 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241003172103060" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38214" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_20241003172117677" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38216" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></ix:nonFraction>
        shares authorized as of June 30, 2024 and December 31, 2023, <ix:nonFraction id="Fxbrl_20241003172206194" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241003172159099" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241003172148909" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38218" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $<ix:nonFraction id="Fixv-38222" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction>
        as of June 30, 2024;</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible
        Series A-3 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241003172258735" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38223" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_20241003172319925" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38225" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">80,000</ix:nonFraction></ix:nonFraction>
        shares authorized as of June 30, 2024 and December 31, 2023, <ix:nonFraction id="Fxbrl_20241003172414704" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241003172358151" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241003172341503" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38227" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $<ix:nonFraction id="Fixv-38231" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,887</ix:nonFraction>
        as of June 30, 2024;</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible
        Series A-4 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241003172459110" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38232" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_20241003172514947" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38234" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">815,000</ix:nonFraction></ix:nonFraction>
        shares authorized as of June 30, 2024 and December 31, 2023, <ix:nonFraction id="Fxbrl_20241003172544747" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241003172537721" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241003172528053" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fix_0_fact" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>*
        shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $<ix:nonFraction id="Fixv-38240" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,076</ix:nonFraction>
        as of June 30, 2024;</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559561_ixv-38241" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,057</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559561_ixv-38242" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,057</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONTINGENTLY
        REDEEMABLE NON-CONTROLLING INTERESTS</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559568_ixv-38243" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,353</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559568_ixv-38244" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,420</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559575_ixv-38245" name="us-gaap:PreferredStockRedemptionAmount" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,410</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559575_ixv-38246" name="us-gaap:PreferredStockRedemptionAmount" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,477</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.25in;text-indent:-0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>CAPITAL
        DEFICIENCY:</strong></span></span></p> </td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary
        shares (NIS <ix:nonFraction id="Fxbrl_20241003172607971" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38247" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_20241003172620036" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38249" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,275,000</ix:nonFraction></ix:nonFraction>
        shares authorized as of June 30, 2024 and December 31, 2023; <ix:nonFraction id="Fxbrl_20241004121817850" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004121810921" name="us-gaap:CommonStockSharesIssued" contextRef="C_20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">250,492</ix:nonFraction></ix:nonFraction>
        and <ix:nonFraction id="Fxbrl_20241004121854270" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004121848432" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">219,354</ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively)</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559581_ixv-38255" name="us-gaap:CommonStockValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559581_ixv-38256" name="us-gaap:CommonStockValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional
        paid-in capital</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559588_ixv-38257" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,398</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559588_ixv-38258" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,334</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated
        deficit</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004052559594_ixv-38259" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">29,656</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004052559594_ixv-38260" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">26,811</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        CAPITAL DEFICIENCY</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004052559599_ixv-38261" name="us-gaap:StockholdersEquity" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,257</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004052559599_ixv-38262" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15,476</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559605_ixv-38263" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">153</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559605_ixv-38264" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,001</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTEREST NET OF CAPITAL DEFICIENCY</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559613_ixv-38265" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,525</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004052559613_ixv-38266" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,256</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>*</strong></span></span></td>
    <td><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net of 121,119 treasury shares held by the subsidiary
        as of June 30, 2024 and December 31, 2023</span></span></td> </tr>
  </table>

<div>&#160;</div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 15.75pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</strong></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 15.75pt;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:1.5pt solid black">

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">F-41</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin-top:6pt;margin-bottom:12pt">

<div style="margin-top:10pt;margin-bottom:10pt">&#160;</div> </div>

<div><span id="f_014_integixAnchor"></span></div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center"><strong>SILEXION THERAPEUTICS LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 7.65pt;text-align:center"><span style="font-weight:normal">UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 7.65pt;text-align:center"><span style="font-weight:normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;text-align:center">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Six months ended </strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>June 30</strong></p> </td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;text-align:center">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Three months ended </strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>June 30</strong></p> </td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">U.S. dollars in<br/>thousands</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">U.S. dollars in<br/>thousands</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold">OPERATING EXPENSES:</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;width:52%;text-align:left">Research and development (including $<ix:nonFraction id="Fxbrl_20241003172807441" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38268" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></ix:nonFraction>
        from related party for the six months period ended June 30, 2024 and 2023, respectively, and including $<ix:nonFraction id="Fxbrl_20241003172824835" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20230401to20230630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38270" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20240401to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></ix:nonFraction>
        from related party for the three months period ended June 30, 2024 and 2023, respectively)</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38272" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,727</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38273" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,916</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38274" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">766</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38275" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,235</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">General and administrative (including $<ix:nonFraction id="Fxbrl_20241003172846576" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38276" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></ix:nonFraction>
        from related party for the six months period ended June 30, 2024 and 2023, respectively, and including $<ix:nonFraction id="Fxbrl_20241003172901996" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20230401to20230630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38278" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20240401to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></ix:nonFraction>
        from related party for the three months period ended June 30, 2024 and 2023, respectively)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38280" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">908</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38281" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">306</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38282" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">619</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38283" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">179</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:1.5pt">TOTAL OPERATING EXPENSES</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38284" name="us-gaap:OperatingExpenses" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,635</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38285" name="us-gaap:OperatingExpenses" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,222</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38286" name="us-gaap:OperatingExpenses" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,385</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38287" name="us-gaap:OperatingExpenses" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,414</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">OPERATING LOSS</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38288" name="us-gaap:OperatingIncomeLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,635</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38289" name="us-gaap:OperatingIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,222</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38290" name="us-gaap:OperatingIncomeLoss" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,385</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38291" name="us-gaap:OperatingIncomeLoss" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,414</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">Financial expenses, net (including $<ix:nonFraction id="Fixv-38292" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction>
        and $<ix:nonFraction id="Fixv-38293" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>
        from related party for the six months period ended June 30, 2024 and 2023, respectively, and including $<ix:nonFraction id="Fixv-38294" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20240401to20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction>
        and $<ix:nonFraction id="Fixv-38295" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20230401to20230630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>
        from related party for the three months period ended June 30, 2024 and 2023, respectively)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38296" name="slxn:FinancialExpenses" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">270</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38297" name="slxn:FinancialExpenses" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">377</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38298" name="slxn:FinancialExpenses" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38299" name="slxn:FinancialExpenses" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">452</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">LOSS BEFORE INCOME TAX</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38300" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,905</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38301" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,599</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38302" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,487</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38303" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,866</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:1.5pt">INCOME TAX</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38304" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38305" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38306" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38307" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:1.5pt">NET LOSS</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38308" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,912</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38309" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,619</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38310" name="us-gaap:NetIncomeLoss" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,489</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38311" name="us-gaap:NetIncomeLoss" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,876</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left">Attributable to:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left">Equity holders of the Company</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38312" name="slxn:EquityHoldersOfTheCompany" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,845</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38313" name="slxn:EquityHoldersOfTheCompany" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,427</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38314" name="slxn:EquityHoldersOfTheCompany" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,472</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38315" name="slxn:EquityHoldersOfTheCompany" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,653</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Non-controlling interests</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38316" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">67</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38317" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">192</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38318" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">17</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38319" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">223</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38320" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,912</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38321" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,619</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38322" name="us-gaap:NetIncomeLoss" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,489</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38323" name="us-gaap:NetIncomeLoss" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,876</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">LOSS PER SHARE, BASIC AND DILUTED</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fxbrl_20241003010526903" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240101to20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-38324" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">11.31</ix:nonFraction></ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fxbrl_20241003010549199" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20230630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-38325" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">9.61</ix:nonFraction></ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fxbrl_20241003010603255" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240401to20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-38326" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240401to20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">5.87</ix:nonFraction></ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fxbrl_20241003010623640" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230401to20230630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-38327" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230401to20230630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">6.54</ix:nonFraction></ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING
        USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003010644640" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20240101to20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38328" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20240101to20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">251,655</ix:nonFraction></ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003010656609" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38329" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">252,462</ix:nonFraction></ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003010710582" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20240401to20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38330" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20240401to20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">250,847</ix:nonFraction></ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003010802301" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230401to20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38331" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230401to20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">252,462</ix:nonFraction></ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 7.65pt"><span style="font-weight:normal">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>The accompanying notes are an integral part
of the unaudited condensed consolidated financial statements.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-42</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">&#160;</p>

<div><span id="f_015_integixAnchor"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center"><strong>SILEXION THERAPEUTICS LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES
IN REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(U.S. dollars in thousands, except per share data)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:8pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="font:8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="42" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center">Redeemable Convertible
        Preferred Shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:center">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:center">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:center">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:center">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:center">Total<br/>redeemable<br/>convertible<br/>preferred<br/>shares
        and<br/>contingently<br/>redeemable</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="font:8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center">Series A<br/>preferred
        shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center">Series A-1<br/>preferred&#160;shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center">Series A-2<br/>preferred&#160;shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center">Series A-3<br/>preferred&#160;shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center">Series A-4<br/>preferred&#160;shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:center">
        <p style="font:8pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Contingently<br/>redeemable<br/>non-<br/>controlling</strong></p>
        <p style="font:8pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>interests</strong></p> </td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center">Ordinary shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:center">Additional<br/>paid-in</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:center">Accumulated</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:center">Total<br/>capital</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:center">non-<br/>controlling<br/>interests,<br/>net&#160;of<br/>capital</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="font:8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center"><strong>Shares</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center"><strong>Amount</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center"><strong>Shares</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center"><strong>Amount</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center"><strong>Shares</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center"><strong>Amount</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center"><strong>Shares</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center"><strong>Amount</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center"><strong>Shares</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center"><strong>Amount</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center"><strong>Amount</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="border-left:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center"><strong>Shares</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;text-align:center"><strong>Amount</strong></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:center"><strong>Capital</strong></td>
    <td style="font:8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:center"><strong>deficit</strong></td>
    <td style="font:8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:center"><strong>deficiency</strong></td>
    <td style="font:8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td style="font:8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:center"><strong>deficiency</strong></td>
    <td style="font:8pt Times New Roman, Times, Serif;text-align:center;padding-bottom:1.5pt"><strong>&#160;</strong></td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in;width:16.7%">BALANCE
        AT JANUARY&#160;1,<br/>2023</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38332" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38333" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38334" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38335" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38336" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38337" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38338" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38339" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fxbrl_20241004171010336" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction id="Fxbrl_20241004170910643" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38340" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,586</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38341" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">219,354</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction id="Fixv-38342" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38343" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,203</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right">(<ix:nonFraction id="Fixv-38344" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">21,869</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right">(<ix:nonFraction id="Fixv-38345" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">10,665</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38346" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,567</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="font:normal 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in"><strong>CHANGES DURING
        THE SIX MONTHS PERIOD ENDED JUNE 30, 2023</strong> (unaudited):</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left;text-indent:-0.125in;padding-left:0.125in">Issuance
        of Preferred A-4 shares, net of issuance cost</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38347" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20230101to20230630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38348" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38349" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38350" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;&#160;&#160;&#160;<ix:nonFraction id="Fixv-38351" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="font:8pt Times New Roman, Times, Serif;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in">Share-based
        compensation</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right"><ix:nonFraction id="Fixv-38352" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right"><ix:nonFraction id="Fixv-38353" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right"><ix:nonFraction id="Fixv-38354" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left;text-indent:-0.125in;padding-left:0.25in">Net loss</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38355" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">192</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38356" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,427</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38357" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,427</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38358" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,619</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-indent:-0.125in;padding-left:0.125in">BALANCE AS OF JUNE 30,<br/>2023</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38359" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38360" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38361" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38362" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38363" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38364" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38365" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38366" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38367" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38368" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38369" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,394</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38370" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">219,354</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38371" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38372" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,268</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38373" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,296</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:2.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38374" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,027</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:2.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38375" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,424</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:2.5pt;text-align:left">)</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">BALANCE AT JANUARY
        1,<br/>2024</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38376" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38377" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38378" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38379" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38380" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38381" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38382" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38383" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38384" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38385" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38386" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,420</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38387" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">219,354</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38388" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38389" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,334</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38390" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">26,811</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38391" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15,476</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38392" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,001</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font:normal 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in"><strong>CHANGES DURING
        THE SIX MONTHS PERIOD ENDED JUNE 30, 2024</strong><br/>(unaudited):</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">Exercise of options</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fix_6_fact" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">31,138</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">**</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><span style="-sec-ix-hidden:Fhidden-fact-92">*</span></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><span style="-sec-ix-hidden:Fhidden-fact-93">*</span></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><span style="-sec-ix-hidden:Fhidden-fact-94">*</span></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><span style="-sec-ix-hidden:Fhidden-fact-95">*</span></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font:8pt Times New Roman, Times, Serif;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">Share-based
        compensation</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38394" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38395" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38396" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left;text-indent:-0.125in;padding-left:0.125in">Net loss</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38397" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">67</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38398" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2845</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38399" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,845</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38400" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,912</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-indent:-0.125in;padding-left:0.125in">BALANCE AS OF JUNE 30,<br/>2024</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38401" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38402" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38403" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38404" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38405" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38406" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38407" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38408" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38409" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38410" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38411" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,353</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38412" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">250,492</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38413" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38414" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,398</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38415" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">29,656</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:2.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38416" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,257</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:2.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38417" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">153</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0in">&#160;</td>
    <td style="width:0.25in;text-align:left">*</td>
    <td style="text-align:left">Represents an amount less than $1</td> </tr>
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0in">&#160;</td>
    <td style="width:0.25in;text-align:left">**</td>
    <td style="text-align:left">Represents fully vested pre-funded&#160;options for the Company&#8217;s ordinary shares at an exercise price of
        $0.01 or 0.01 NIS per share</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>The accompanying notes are an integral part
of the unaudited condensed consolidated financial statements.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-43</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><strong>SILEXION THERAPEUTICS LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">UNAUDITED CONDENSED CONSOLIDATED
STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY</p>

<p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">(U.S. dollars in thousands, except
per share data)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:8pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font:8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="42" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Redeemable Convertible
        Preferred Shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:center">Total<br/>redeemable<br/>convertible<br/>preferred<br/>shares
        and<br/>contingently<br/>redeemable</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font:8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Series A<br/>preferred&#160;shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Series A-1<br/>preferred&#160;shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Series A-2<br/>preferred&#160;shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Series A-3<br/>preferred&#160;shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Series A-4 preferred
        shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">
        <p style="font:8pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Contingently redeemable non-controlling</strong></p>
        <p style="font:8pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>interests</strong></p> </td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Ordinary shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:center">Additional<br/>paid-in</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:center">Accumulated</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:center">Total capital</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:center">non-<br/>controlling<br/>interests,<br/>net
        of<br/>capital</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font:8pt Times New Roman, Times, Serif;text-align:center">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Amount</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Amount</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Amount</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Amount</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Amount</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Amount</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Shares</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Amount</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">Capital</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">deficit</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">deficiency</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font:bold 8pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1.5pt solid">deficiency</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;width:16.7%">BALANCE
        AT MARCH 31,<br/>2023</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38420" name="us-gaap:SharesOutstanding" contextRef="C_20230331_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38421" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38422" name="us-gaap:SharesOutstanding" contextRef="C_20230331_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38423" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38424" name="us-gaap:SharesOutstanding" contextRef="C_20230331_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38425" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38426" name="us-gaap:SharesOutstanding" contextRef="C_20230331_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38427" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fxbrl_20241004171509739" name="us-gaap:SharesOutstanding" contextRef="C_20230331_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fxbrl_20241004171405506" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38428" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,617</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38429" name="us-gaap:SharesOutstanding" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">219,354</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38430" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38431" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,235</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right">(<ix:nonFraction id="Fixv-38432" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">22,643</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right">(<ix:nonFraction id="Fixv-38433" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,407</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:0.3%;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;width:4%;text-align:right"><ix:nonFraction id="Fixv-38434" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,856</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;width:0.3%;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="font:normal 8pt Times New Roman, Times, Serif;padding-left:0.125in;text-indent:-0.125in;padding-bottom:1.5pt"><strong>CHANGES DURING
        THE THREE MONTHS PERIOD ENDED JUNE 30, 2023</strong> (unaudited):</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font:8pt Times New Roman, Times, Serif;text-align:left;padding-bottom:1.5pt">Issuance
        of Preferred A-4 shares, net of issuance cost</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38435" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20230401to20230630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38436" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230401to20230630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38437" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38438" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38439" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="font:8pt Times New Roman, Times, Serif;padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Share-based
        compensation</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38440" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38441" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38442" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;padding-left:0.25in;text-indent:-0.125in;text-align:left">Net loss</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38443" name="us-gaap:ProfitLoss" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">223</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38444" name="us-gaap:ProfitLoss" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,653</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38445" name="us-gaap:ProfitLoss" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,653</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38446" name="us-gaap:ProfitLoss" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,876</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-left:0.125in;text-indent:-0.125in;padding-bottom:4pt">BALANCE AS OF JUNE 30,
        2023</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38447" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38448" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38449" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38450" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38451" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38452" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38453" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38454" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38455" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38456" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38457" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,394</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38458" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">219,354</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38459" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38460" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,268</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38461" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,296</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:2.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38462" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,027</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:2.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38463" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,424</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:2.5pt;text-align:left">)</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">BALANCE AT MARCH 31,<br/>2024</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38464" name="us-gaap:SharesOutstanding" contextRef="C_20240331_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38465" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38466" name="us-gaap:SharesOutstanding" contextRef="C_20240331_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38467" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38468" name="us-gaap:SharesOutstanding" contextRef="C_20240331_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38469" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38470" name="us-gaap:SharesOutstanding" contextRef="C_20240331_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38471" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38472" name="us-gaap:SharesOutstanding" contextRef="C_20240331_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38473" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right">&#160;&#160;&#160;&#160;<ix:nonFraction id="Fixv-38474" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,370</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38475" name="us-gaap:SharesOutstanding" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">250,492</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38476" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38477" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,366</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38478" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">28,184</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38479" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">16,817</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="padding-bottom:1.5pt;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38480" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,610</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font:normal 8pt Times New Roman, Times, Serif;padding-left:0.125in;text-indent:-0.125in;padding-bottom:1.5pt"><strong>CHANGES DURING
        THE THREE MONTHS PERIOD ENDED JUNE 30, 2024</strong> (unaudited):</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font:8pt Times New Roman, Times, Serif;text-align:left;padding-bottom:1.5pt">Share-based
        compensation</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38481" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38482" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;font:8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38483" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;padding-left:0.125in;text-indent:-0.125in;text-align:left">Net loss</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38484" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">17</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="border-left:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38485" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,472</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38486" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,472</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font:8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38487" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,489</ix:nonFraction></td>
    <td style="font:8pt Times New Roman, Times, Serif;padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="font:8pt Times New Roman, Times, Serif;vertical-align:bottom">
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-left:0.125in;text-indent:-0.125in;padding-bottom:4pt">BALANCE AS OF JUNE 30,<br/>2024</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38488" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38489" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38490" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38491" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38492" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38493" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38494" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38495" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38496" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction id="Fixv-38497" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38498" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,353</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="border-left:Black 1.5pt solid;font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38499" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">250,492</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction id="Fixv-38500" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38501" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,398</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38502" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">29,656</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:2.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right">(<ix:nonFraction id="Fixv-38503" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,257</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:2.5pt;text-align:left">)</td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;font:bold 8pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fixv-38504" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">153</ix:nonFraction></td>
    <td style="font:bold 8pt Times New Roman, Times, Serif;padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0in">&#160;</td>
    <td style="width:0.25in;text-align:left">*</td>
    <td style="text-align:left">Represents an amount less than $1</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>The accompanying notes are an integral part
of the unaudited condensed consolidated financial statements.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-44</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">&#160;</p>

<div><span id="f_016_integixAnchor"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center"><strong>SILEXION THERAPEUTICS LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 7.65pt"><span style="font-weight:normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1.5pt solid">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Six months ended </strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>June 30</strong></p> </td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1.5pt solid">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Three months ended </strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>June 30</strong></p> </td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">U.S. dollars in<br/>thousands</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">U.S. dollars in<br/>thousands</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">CASH FLOWS FROM OPERATING ACTIVITIES:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;width:52%;text-align:left">Net loss</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-38506" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,912</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-38507" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,619</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-38508" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,489</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-38509" name="us-gaap:ProfitLoss" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,876</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">Adjustments required to reconcile loss to net cash used in operating
        activities:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.375in;text-indent:-0.125in">Depreciation</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38510" name="us-gaap:Depreciation" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38511" name="us-gaap:Depreciation" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38512" name="us-gaap:Depreciation" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38513" name="us-gaap:Depreciation" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">Share-based compensation expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38514" name="us-gaap:ShareBasedCompensation" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38515" name="us-gaap:ShareBasedCompensation" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38516" name="us-gaap:ShareBasedCompensation" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38517" name="us-gaap:ShareBasedCompensation" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">Non-cash financial expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38518" name="us-gaap:OtherNoncashExpense" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">219</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38519" name="us-gaap:OtherNoncashExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">257</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38520" name="us-gaap:OtherNoncashExpense" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38521" name="us-gaap:OtherNoncashExpense" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">278</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">Changes in operating assets and liabilities:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">Increase (decrease) in prepaid expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38522" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">192</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38523" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38524" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38525" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">decrease in other receivables</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38526" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38527" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38528" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38529" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">Increase (decrease) in trade payable</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38530" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">38</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38531" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">57</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38532" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38533" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">52</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">Net change in operating lease</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38534" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38535" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38536" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38537" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">Increase (decrease) in employee related obligations</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38538" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38539" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">62</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38540" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38541" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">20</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Increase (decrease) in accrued expenses</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38542" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38543" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">183</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38544" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">327</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38545" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">35</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Net cash used in operating activities</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38546" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,817</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38547" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,587</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38548" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,065</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38549" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,676</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">CASH FLOWS FROM INVESTING ACTIVITIES:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">Proceeds from short-term deposit</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003015310340" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38550" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">507</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003015315156" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003015319621" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Purchase of property and equipment</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38551" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38552" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241003015353105" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38553" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Net cash provided by (used in (investing activities</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38554" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38555" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">505</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241003015410161" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38556" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">CASH FLOWS FROM FINANCING ACTIVITIES:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">Proceeds from issuance of preferred shares and warrants, net of issuance
        costs</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003015457139" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38557" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003015422545" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38558" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;padding-bottom:1.5pt">Exercise of options</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:left;border-bottom:2px solid black">&#160;</td>
    <td style="text-align:right;border-bottom:2px solid black">
        <p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px;text-align:right"><span style="-sec-ix-hidden:Fxbrl_20241004172251986">*</span></p>
        </td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241003015517469_ixv-38557" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241003015517469_xbrl_20241003015422545" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241003015517469_ixv-38558" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Net cash provided by financing activities</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="-sec-ix-hidden:Fxbrl_20241004172316778">*</span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38559" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241003015434217" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38560" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED
        CASH</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38561" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,823</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38562" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,560</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38563" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,065</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38564" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,156</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS
        AND RESTRICTED CASH</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38565" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">75</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38566" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">258</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38567" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">19</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38568" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">277</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:1.5pt">BALANCE OF CASH, CASH EQUIVALENTS
        AND RESTRICTED CASH AT BEGINNING OF PERIOD</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38569" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,645</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38570" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,309</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38571" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240331" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,831</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38572" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230331" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,924</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:4pt">BALANCE OF CASH, CASH EQUIVALENTS
        AND RESTRICTED CASH AT END OF PERIOD</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38573" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,747</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38574" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,491</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38575" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,747</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38576" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,491</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.25in;text-align:left">*</td>
    <td style="text-align:left">Represents an amount less than $1</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-45</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center"><strong>SILEXION THERAPEUTICS LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 7.65pt"><span style="font-weight:normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1.5pt solid">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center;text-indent:5.1pt"><strong>Six months ended </strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center;text-indent:5.1pt"><strong>June 30</strong></p> </td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1.5pt solid">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Three months ended </strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>June 30</strong></p> </td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">U.S. dollars in thousands</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">U.S. dollars in thousands</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt">
        <p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin-top:0pt;margin-right:0;margin-bottom:0pt"><strong><span style="text-decoration:underline">Appendix
        A</span> &#8211;</strong></p> </td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;padding-bottom:1.5pt"><strong>RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED
        CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS:</strong></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;width:52%;text-align:left">Cash and cash equivalents</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38577" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,697</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38578" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,442</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38579" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,697</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38580" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,442</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Restricted cash</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38581" name="us-gaap:RestrictedCash" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38582" name="us-gaap:RestrictedCash" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38583" name="us-gaap:RestrictedCash" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38584" name="us-gaap:RestrictedCash" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:4pt">TOTAL CASH, CASH EQUIVALENTS AND<br/>RESTRICTED
        CASH SHOWN IN STATEMENT OF CASH FLOWS</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38585" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,747</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38586" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,491</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38587" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,747</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38588" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,491</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left"><span style="text-decoration:underline">Appendix B
        - SUPPLEMENTARY INFORMATION:</span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;padding-bottom:4pt">Interest received</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38589" name="us-gaap:InterestPaidNet" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38590" name="us-gaap:InterestPaidNet" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38591" name="us-gaap:InterestPaidNet" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38592" name="us-gaap:InterestPaidNet" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>The accompanying notes are an integral part
of the unaudited condensed consolidated financial statements.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-46</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<div><span id="f_017_integixAnchor"></span></div>

<p style="margin:20pt 0pt 0pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center"><strong>SILEXION LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">(U.S. dollars in thousands)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003003634825" name="us-gaap:NatureOfOperations" contextRef="C_20240101to20240630" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 1 - GENERAL:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>a.</strong></td>
    <td style="text-align:left">Silexion Therapeutics Ltd. (formerly known as Silenseed Ltd.) (hereinafter -"the Company") was incorporated in
        Israel and began its operations on November 30, 2008. Since its incorporation, the Company has been engaged in <ix:nonFraction id="Fixv-38593" name="us-gaap:NumberOfOperatingSegments" contextRef="C_20240101to20240630" unitRef="Segment" scale="0" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction>
        operating segment - the research and development of innovative treatments for pancreatic cancer based on siRNAs, aiming to stop the production
        of a specific pancreatic cancer-causing protein known as the KRAS mutation. The Company&#8217;s long-lived assets are located in Israel.</td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in;text-align:left;text-indent:0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>b.</strong></td>
    <td style="text-align:left">On April 28, 2021, the Company signed an agreement with Guangzhou Sino-Israel Biotech Investment Fund (&#8220;GIBF&#8221;)
        to establish a new company in China. On June 15, 2021 a company was established in China, named Silenseed (China) Ltd (hereinafter - the
        "Subsidiary"). The Company owns <ix:nonFraction id="Fixv-38594" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="C_20240630_srtOwnershipAxis_slxnSilexionEquityFinancingMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">51</ix:nonFraction>%
        of the shares of the Subsidiary. The Subsidiary has not yet started significant operations as of June 30, 2024. The Company and the Subsidiary,
        together - &#8220;the Group&#8221;.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-indent:-28.45pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>c.</strong></td>
    <td style="text-align:left">On February 21, 2024, the Company entered into a business combination agreement with Moringa Acquisition Corp
        (the &#8220;SPAC&#8221;), a Cayman Islands exempted company whose class A ordinary shares (as well as other instruments) are listed for
        trade on the Nasdaq Capital Market (Nasdaq: MACA), and April M.G. Ltd. (the &#8220;April Merger Sub&#8221;), an Israeli company and a
        wholly-owned subsidiary of the SPAC (the &#8220;Original BCA&#8221;). According to the Original BCA, April Merger Sub was to merge with
        and into the Company, with the Company continuing as the surviving entity and a wholly-owned subsidiary of the SPAC, and with the SPAC
        continuing as a public company following the completion of the merger and with its securities continuing to be traded on Nasdaq.</td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in;text-align:left;text-indent:0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>d.</strong></td>
    <td style="text-align:left">On April 3, 2024, the Company entered into an Amended and Restated Business Combination Agreement (hereinafter,
        &#8220;A&amp;R BCA&#8221;) with the SPAC, Biomotion Sciences, a newly-formed Cayman Islands exempted company (&#8220;Biomotion Sciences&#8221;
        or &#8220;New Pubco&#8221;), August M.S. Ltd. an Israeli company and wholly-owned subsidiary of Biomotion Sciences (&#8220;Merger Sub
        1&#8221;), and Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and wholly-owned subsidiary of Biomotion Sciences
        (&#8220;Merger Sub 2&#8221;) which replaced the Original BCA. The A&amp;R BCA, provided for a technical change in the contemplated transaction
        structure to a &#8220;double dummy&#8221; structure, as a result of which both the Company and the SPAC will become wholly-owned subsidiaries
        of Biomotion Sciences, which will be the publicly-held, Nasdaq-listed entity, rather than the Company becoming a subsidiary of the Nasdaq-listed
        SPAC, as initially contemplated under the Original BCA.</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.15pt;text-align:left;text-indent:0in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in">Pursuant to the transactions
contemplated under the A&amp;R BCA (collectively, the &#8220;Business Combination &#8221;), Merger Sub 2 was to merge with and into the
SPAC, with the SPAC continuing as the surviving company of such merger and a wholly-owned&#160;subsidiary of New Pubco (the &#8220;SPAC
Merger&#8221;), and Merger Sub 1 was to merge with and into the Company, with the Company continuing as the surviving company of such
merger and a wholly-owned&#160;subsidiary of New Pubco (the &#8220;Acquisition Merger&#8221;). Upon the effectiveness of the SPAC Merger,
each outstanding SPAC Class&#160;A ordinary share and the sole outstanding SPAC Class&#160;B ordinary share was to convert into an ordinary
share of New Pubco on a one-for-one&#160;basis. Each outstanding warrant to purchase one SPAC Class&#160;A ordinary share was to convert
into a warrant to purchase one New Pubco ordinary share, at the same exercise price. Upon the effectiveness of the Acquisition Merger,
each outstanding ordinary share and preferred share of the Company was to convert into such number of ordinary shares of New Pubco as
is equal to the quotient obtained by dividing (x)&#160;the quotient obtained by dividing (1)&#160;$<ix:nonFraction id="Fixv-38595" name="us-gaap:DebtAndEquitySecuritiesGainLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,500</ix:nonFraction>
by (2)&#160;the number of fully diluted Company equity securities, by (y)&#160;$<ix:nonFraction id="Fixv-38596" name="us-gaap:DerivativeExchangeRateCap1" contextRef="C_20240630" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>
(the &#8220;Silexion Equity Exchange Ratio&#8221;). Each outstanding Company warrant and Company option to purchase one Company share,
and Company restricted share unit (RSU) that may be potentially settled for one Company share, was to became exercisable for, or became
subject to settlement for (as applicable), such number of New Pubco ordinary shares as are equal to the Silexion Equity Exchange Ratio.
The exercise price per New Pubco ordinary share of each such converted Company option and Company warrant was to be adjusted based on
dividing the existing per share exercise price by the Silexion Equity Exchange Ratio. The terms of vesting, exercise and/or settlement,
as applicable, of such converted options, warrants and RSUs was to remain the same following such conversion, except that the vesting
of each Company option was to accelerate immediately prior to the Acquisition Merger, such that the New Pubco option into which it was
to be converted was to be fully vested, and all Company warrants were to be exercised (on a cashless basis) immediately prior to the Acquisition
Merger. Immediately prior to the closing of the Business Combination, seven directors were to be elected to New Pubco&#8217;s board of
directors, of whom five were to designated by the Company and two were to be designated by the SPAC&#8217;s sponsor (the &#8220;Sponsor&#8221;).
The A&amp;R BCA also required, as a closing condition, the transfer of the remaining outstanding shares of the Subsidiary held by GIBF
to the Company prior to the closing of the Business Combination in exchange for the issuance to GIBF of shares of the Company, which were
to convert into ordinary shares of New Pubco in accordance with the Silexion Equity Exchange Ratio upon the closing.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-47</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="text-align:center;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt 1pt;text-align:center"><strong>SILEXION LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">(U.S. dollars in thousands)</p>

<p style="text-align:center;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 1 - GENERAL (continued):</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>e.</strong></td>
    <td style="text-align:left">In connection with the closing of the Business Combination, the ordinary shares and warrants of Biomotion Sciences
        were expected to be listed on the Nasdaq Global Market and begin trading under the symbols &#8220;SLXN&#8221; and &#8220;SLXNW&#8221;,
        respectively.</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>f.</strong></td>
    <td style="text-align:left">The Business Combination was to be accounted for as a reverse recapitalization in accordance with US GAAP.&#160;Under
        this method of accounting, the Company was to be treated as the accounting acquirer and the SPAC was to be treated as the &#8220;acquired&#8221;
        company for financial reporting purposes. The Company was determined to be the accounting acquirer based on evaluation of the following
        facts and circumstances:</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-indent:-28.45pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">&#9679;</td>
    <td style="text-align:left">the Company&#8217;s shareholders were to hold approximately <ix:nonFraction id="Fixv-38597" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="C_20240630_usgaapBusinessAcquisitionAxis_slxnNewPubcoMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">61.55</ix:nonFraction>%
        of the outstanding voting interests in New Pubco upon the closing of the Business Combination;</td> </tr>
  </table>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">&#9679;</td>
    <td style="text-align:left">the Company&#8217;s senior management were to comprise the senior management of New Pubco;</td> </tr>
  </table>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">&#9679;</td>
    <td style="text-align:left">the directors nominated by the Company were to constitute a majority of the board of directors of New Pubco (five
        out of seven of the initial directors);</td> </tr>
  </table>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">&#9679;</td>
    <td style="text-align:left">the Company&#8217;s operations were to comprise the ongoing operations of New Pubco; and</td> </tr>
  </table>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">&#9679;</td>
    <td style="text-align:left">the Company&#8217;s name was to be the name used by New Pubco (in replacement of Biomotion Sciences).</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 113.4pt;text-indent:-21.25pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in">Under the reverse recapitalization
accounting method, the Business Combination was to be deemed to be the equivalent of a capital transaction in which the Company will issue
shares for the net assets of the SPAC. The net assets of the SPAC will be stated at fair value, with no goodwill or other intangible assets
recorded. Operations prior to the Business Combination will be those of the Company.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-indent:-28.45pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>g.</strong></td>
    <td style="text-align:left">On June 18, 2024 the Company entered into a waiver with the other parties to the A&amp;R BCA (the &#8220;Investments
        Waiver&#8221;). The Investments Waiver provided, in principal part, that: (i) the conditions to closing under the A&amp;R BCA requiring
        that an equity financing of the Company in an amount of at least $<ix:nonFraction id="Fixv-38598" name="us-gaap:EquityMethodInvestments" contextRef="C_20240618_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSilexionEquityFinancingMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,500</ix:nonFraction>
        (the &#8220;Silexion Equity Financing&#8221;) and an investment by the Sponsor in New Pubco of between $<ix:nonFraction id="Fixv-38599" name="us-gaap:SponsorFees" contextRef="C_20240618to20240618_srtRangeAxis_srtMinimumMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">350</ix:nonFraction>
        and $<ix:nonFraction id="Fixv-38600" name="us-gaap:SponsorFees" contextRef="C_20240618to20240618_srtRangeAxis_srtMaximumMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction>
        (the &#8220;Sponsor Investment&#8221;) shall have occurred, were waived; (ii) <ix:nonFraction id="Fixv-38601" name="us-gaap:InvestmentOwnedBalanceShares" contextRef="C_20240618" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">1,382,325</ix:nonFraction>
        of the Sponsor Investment Shares that were potentially issuable to the Sponsor by New Pubco in respect of the Sponsor Investment under
        the A&amp;R BCA were to be issued to the Sponsor upon the closing notwithstanding that the Sponsor Investment has not taken place; (iii)
        the A&amp;R Sponsor Promissory Note Cap (which sets the maximum dollar amount of Sponsor loans to the SPAC that may be converted by the
        Sponsor into New Pubco ordinary shares, subject to reduction for certain fees payable at the Closing, under an amended and restated promissory
        note to be issued by New Pubco to the Sponsor at the closing (the &#8220;A&amp;R Sponsor Promissory Note&#8221;) was increased from $<ix:nonFraction id="Fixv-38602" name="us-gaap:SponsorFees" contextRef="C_20240618to20240618_srtRangeAxis_srtMinimumMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnNewPubcoMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction>
        million to $<ix:nonFraction id="Fixv-38603" name="us-gaap:SponsorFees" contextRef="C_20240618to20240618_srtRangeAxis_srtMaximumMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnNewPubcoMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.5</ix:nonFraction>
        million, and (iv) the controlling stakeholder of the Sponsor is to be entitled to a gross monthly fee of $<ix:nonFraction id="Fixv-38604" name="us-gaap:PaymentsForFees" contextRef="C_20240618to20240618" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction>
        for a period of 36 months following closing under the A&amp;R BCA.</td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-48</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt 1pt;text-align:center"><strong>SILEXION LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">(U.S. dollars in thousands)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 1 - GENERAL: (continued):</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>h.</strong></td>
    <td style="text-align:left">On August 15, 2024, the Business Combination was completed (see Note 10).</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in;text-align:left;text-indent:0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>i.</strong></td>
    <td style="text-align:left">In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted
        a series of attacks on civilian and military targets. Following the attack, Israel&#8217;s security cabinet declared war against Hamas
        and commenced a military campaign against Hamas and other terrorist organizations.</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-indent:-28.45pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in">The Company&#8217;s headquarters
are located in Modiin, Israel. As of the issuance date of these consolidated financial statements, the conflict between Israel and Hamas
has not had a material impact on the Company&#8217;s results of operations or financial position, if at all. The Company cannot currently
predict the intensity or duration of Israel&#8217;s war against Hamas, however, as most of the Company&#8217;s trials are not executed
in Israel, the Company does not believe the recent terrorist attack and the subsequent declaration of war by the Israeli government against
the Hamas terrorist organization will have any material impact on its ongoing operations. The Company continues to monitor its ongoing
activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its
employees.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in;text-align:left;text-indent:0in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in">Any hostilities involving Israel,
or the interruption or curtailment of trade within Israel or between Israel and its trading partners could adversely affect the Company&#8217;s
operations and results of operations and could make it more difficult for the Company to raise capital.</p>

<p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>j.</strong></td>
    <td style="text-align:left"><strong>Going concern:</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in;text-align:left;text-indent:0in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in"><span>Since its inception,
the Company has devoted substantially all its efforts to research and development, clinical trials, and capital raising activities. The
Company is still in its development and clinical stage and has not yet generated revenues.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in;text-align:left;text-indent:0in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in"><span>The</span> Company has
incurred losses of $<ix:nonFraction id="Fixv-38605" name="us-gaap:InterestCostsIncurred" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,912</ix:nonFraction>
and $<ix:nonFraction id="Fixv-38606" name="us-gaap:InterestCostsIncurred" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,108</ix:nonFraction>
for the six-months period ended on June 30, 2024 and for the year ended December 31, 2023, respectively. <span>During the </span>six-month
period ended <span>on June 30, 2024, the Company had negative operating cash flows of $<ix:nonFraction id="Fixv-38607" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,817</ix:nonFraction>.
As of June 30, 2024, the Company had cash and cash equivalents of $<ix:nonFraction id="Fixv-38608" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,697</ix:nonFraction>.
On August 15, 2024, the Company completed a business combination with the SPAC (see Note 10(f)).</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in;text-align:left;text-indent:0in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in"><span>The Company expects to
continue incurring losses, and negative cash flows from operations. Management is in the process of evaluating various financing alternatives,
as the Company will need to finance future research and development activities, general and administrative expenses and working capital
through fund raising. However, there is no assurance that the Company will be successful in obtaining such funding. </span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in;text-align:left;text-indent:0in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in"><span>Under these circumstances,
in accordance with the requirements of ASC 205-40, management has concluded that there is substantial doubt about the Company&#8217;s
ability to continue as a going concern for at least 12 months from the date these financial statements are issued. The unaudited condensed
consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going
concern.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in;text-align:left;text-indent:0in">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003115431605" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0">NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<div>

<div> <ix:nonNumeric id="Fxbrl_20241003140727953" name="slxn:UnauditedCondensedFinancialStatementsPolicyTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:100%;border:0px">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>a.</span></span></strong></span></span></td>
    <td style="text-align:left">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>Unaudited
        Condensed Financial Statements</span></span></span></strong></span></span></p> </td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in"><span>The accompanying condensed
financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance
with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial statements and follow
the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial reporting. Accordingly, they do not
include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited
condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair
statement of the Company&#8217;s consolidated financial position as of June 30, 2024, and the consolidated results of operations, statements
of changes in redeemable convertible preferred shares and capital deficiency and cash flows for the six-month period ended June 30, 2024
and 2023.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-49</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt 1pt;text-align:center"><strong>SILEXION LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">(U.S. dollars in thousands)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in"><span>The consolidated results
for the six-month ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in;text-align:left;text-indent:0in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in"><span>These unaudited interim
condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company
as of and for the year ended December 31, 2023, which were included in Amendment No. 3 to the registration statement on Form S-4 filed
by Biomotion Sciences with the U.S. Securities and Exchange Commission on July 12, 2024. The significant accounting policies adopted and
used in the preparation of the financial statements are consistent with those of the previous financial year.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in">&#160;</p> </div> </div> <ix:nonNumeric id="Fxbrl_20241003115644749" name="us-gaap:UseOfEstimates" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>b.</strong></td>
    <td style="text-align:left"><strong>Use of estimates</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the
financial statements and accompanying notes. As applicable to these financial statements, the most significant estimates and assumptions
relate share-based compensation and to fair value of financial instruments. See Note 6 and Notes 4 and 7, respectively. These estimates
and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses
that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</p> </div>
</ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-align:left">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003115703865" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>c.</strong></td>
    <td style="text-align:left"><strong>Restricted cash</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in">As of June 30, 2024 and December
31, 2023, the Company pledged an amount of $<ix:nonFraction id="Fxbrl_20241003155509936" name="us-gaap:OperatingLeasePayments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241003155453831" name="us-gaap:OperatingLeasePayments" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></ix:nonFraction>
in favor of a bank as collateral for guarantees provided to secure the lease payments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in">The Company is required to
hold a minimum amount of NIS 85 in its bank account in order to maintain availability of a credit line from its credit card company.</p>
</div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-align:left">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003115737660" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>d.</strong></span></span></td>
    <td style="text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair value measurement</strong></span></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:left;text-indent:0in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in">Fair value is based on the
price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between
market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance
establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels,
which are described as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 156.5pt;text-align:left;text-indent:-63.8pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:1in">&#160;</td>
    <td style="width:0.5in;text-align:left">Level 1:</td>
    <td style="text-align:left">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.
        The fair value hierarchy gives the highest priority to Level 1 inputs.</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 134.7pt;text-align:left;text-indent:-63.8pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:1in">&#160;</td>
    <td style="width:0.5in;text-align:left">Level 2:</td>
    <td style="text-align:left">Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active
        market data of similar or identical assets or liabilities.</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:1in">&#160;</td>
    <td style="text-align:left;width:0.5in">Level 3</td>
    <td style="text-align:left">Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest
        priority to Level 3 inputs.</td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-50</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt 1pt;text-align:center"><strong>SILEXION LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">(U.S. dollars in thousands)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in">In determining fair value,
the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the
extent possible and considers counterparty credit risk in its assessment of fair value.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003115756984" name="us-gaap:ConcentrationRiskDisclosureTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>e.</strong></td>
    <td style="text-align:left"><strong>Concentration of credit risks</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-align:left;text-indent:0in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in">Financial instruments that
potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and
short-term deposits. The Company deposits cash and cash equivalents mostly with three low risk financial institution. The Company has
not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.</p>
</div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003115814299" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>f.</strong></td>
    <td style="text-align:left"><strong>Loss per share</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-indent:0in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left;text-indent:0in">The Company calculates loss
per share using the two-class&#160;method required for participating securities. This method entails allocating income available to ordinary
shareholders for the period between ordinary shares and participating securities based on their respective rights to receive dividends
as if all income for the period had been distributed. Basic loss per share is computed by dividing net loss by the weighted average number
of ordinary shares outstanding during the year, and fully vested pre-funded&#160;options for the Company&#8217;s ordinary shares at an
exercise price of $<ix:nonFraction id="Fixv-38611" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>
or <ix:nonFraction id="Fixv-38612" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20240630" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>
NIS per share. The Company considers these shares to be exercisable for little to no additional consideration. The Company also considers
its redeemable convertible preferred shares to be participating securities as the holders of the redeemable convertible preferred shares
would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata&#160;basis assuming conversion
of all redeemable convertible preferred shares into ordinary shares. However, these participating securities do not contractually require
the holders to participate in the Company&#8217;s losses. Consequently, net loss for the periods presented was not allocated to the Company&#8217;s
participating securities.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-align:left;text-indent:0in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003115833298" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>g.</strong></td>
    <td style="text-align:left"><strong>New accounting pronouncements:</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-indent:0in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:0in"><strong><i><span style="text-decoration:underline">Recently
issued accounting standards not yet adopted:</span></i></strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-indent:0in"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">1)</td>
    <td style="text-align:left">In November 2023, the FASB issued ASU No. 2023-07&#160;Segment Reporting (Topic 280): Improvements to Reportable
        Segment Disclosures. The ASU improves reportable segments disclosure requirements, primarily through enhanced disclosures about significant
        segment expenses.&#160; The ASU also require that a public entity that has a single reportable segment to provide all the disclosures
        required by the amendments and all existing segment disclosures in Topic 280.&#160;The ASU is effective for fiscal years beginning after
        December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024.&#160;The Company is currently evaluating
        this ASU to determine its impact on the Company's segment disclosures.</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 110.7pt;text-align:left;text-indent:0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">2)</td>
    <td style="text-align:left">In December, 2023, the FASB issued ASU&#160;2023-09, Improvements to Income Tax Disclosures, which requires disclosure
        of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies
        other income tax-related&#160;disclosures. The ASU will be effective for fiscal&#160;years beginning after December&#160;15, 2025, and
        allows adoption on a prospective basis, with a retrospective option. The Company is in the process of assessing the impacts and method
        of adoption.</td> </tr>
  </table> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:left">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-51</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-indent:0in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt 1pt;text-align:center"><strong>SILEXION LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">(U.S. dollars in thousands)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-indent:0in">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-27091" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" contextRef="C_20240101to20240630" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 3 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:</strong></p>

<p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.25in;text-align:left"><strong>Statement of operations:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 31.65pt;text-align:left"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:bold 10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">a.</td>
    <td style="text-align:left">Research and development expenses:</td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003043149597" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;text-align:center">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Six months ended </strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>June 30</strong></p> </td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;text-align:center">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Three months ended </strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>June 30</strong></p> </td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:52%;text-align:left">Payroll and related expenses</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38614" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">514</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38615" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">569</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38616" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">235</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38617" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">245</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Subcontractors and consultants</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38618" name="slxn:SubcontractorsAndConsultants" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,128</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38619" name="slxn:SubcontractorsAndConsultants" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,208</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38620" name="slxn:SubcontractorsAndConsultants" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">497</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38621" name="slxn:SubcontractorsAndConsultants" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">910</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td>Materials</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38622" name="slxn:MaterialsExpenses" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38623" name="slxn:MaterialsExpenses" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">-</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38624" name="slxn:MaterialsExpenses" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Rent and maintenance</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38625" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38626" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38627" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38628" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left">Travel expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38629" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38630" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38631" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38632" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt">Other</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38633" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38634" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38635" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38636" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38637" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,727</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38638" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,916</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38639" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">766</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38640" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,235</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:bold 10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">b.</td>
    <td style="text-align:left">General and administrative expenses:</td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003043201245" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:52%;text-align:left">Payroll and related expenses</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38642" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">306</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38643" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38644" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">164</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38645" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Professional services</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38646" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38647" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38648" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">369</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38649" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td>Depreciation</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38650" name="us-gaap:Depreciation" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38651" name="us-gaap:Depreciation" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38652" name="us-gaap:Depreciation" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38653" name="us-gaap:Depreciation" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Rent and maintenance</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38654" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38655" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38656" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38657" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left">Patent registration</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38658" name="slxn:PatentRegistration" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38659" name="slxn:PatentRegistration" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38660" name="slxn:PatentRegistration" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38661" name="slxn:PatentRegistration" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Travel expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38662" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38663" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38664" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38665" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt">Other</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38666" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38667" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38668" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38669" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38670" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">908</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38671" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">306</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38672" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">619</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38673" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">179</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003152044067" name="slxn:ScheduleOfFinancialExpenseNetTableTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:bold 10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">c.</td>
    <td style="text-align:left">Financial expense, net:</td> </tr>
  </table>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 51.05pt;text-align:left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;width:52%;text-align:left">Change in fair value of financial liabilities measured at
        fair value</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38675" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-38676" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38677" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-38678" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left">Issuance costs</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">-</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38679" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">-</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38680" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left">Interest income</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38681" name="us-gaap:InterestRevenueExpenseNet" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">25</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38682" name="us-gaap:InterestRevenueExpenseNet" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">78</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38683" name="us-gaap:InterestRevenueExpenseNet" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38684" name="us-gaap:InterestRevenueExpenseNet" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">39</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left">Foreign currency exchange loss (income), net</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38685" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">148</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38686" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">451</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38687" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38688" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">487</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Other</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38689" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38690" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38691" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38692" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;padding-bottom:4pt">Total financial expense (income), net</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38693" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">270</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38694" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">377</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38695" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38696" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">452</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </div> </ix:nonNumeric> </ix:nonNumeric> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-27541" name="us-gaap:PreferredStockTextBlock" contextRef="C_20240101to20240630" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 4 - WARRANTS TO PURCHASE PREFERRED SHARES:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>a.</strong></td>
    <td style="text-align:left">On January&#160;14, 2022, the Company issued warrants to acquire <ix:nonFraction id="Fixv-38697" name="slxn:WarrantsIssued" contextRef="C_20220114" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">47,495</ix:nonFraction>
        Series A-2 Preferred Shares to various investors, the warrants were issued as part of the converted Simple Agreement for Future Equity
        (SAFE).&#160;These warrants feature an exercise price of $<ix:nonFraction id="Fixv-38698" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20220114" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">60.783</ix:nonFraction>
        per share and expired during 2023. As of June 30, 2023, there are <ix:nonFraction id="Fixv-38699" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20230630" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">47,495</ix:nonFraction>
        outstanding warrants. As of June 30, 2024, all warrants are expired.</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 49.65pt;text-align:left;text-indent:0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif"><strong>b.</strong></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif">On May&#160;30, 2023, the Company issued warrants to acquire
        <ix:nonFraction id="Fixv-38700" name="slxn:WarrantsIssued" contextRef="C_20230530" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">21,717</ix:nonFraction>
        Series A-4 Preferred Shares to various investors, with an exercise price of $<ix:nonFraction id="Fixv-38701" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20230530" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">24.769</ix:nonFraction>
        per share and an expiration date of May 30, 2025. Issuance expenses amounted to $<ix:nonFraction id="Fixv-38702" name="us-gaap:OtherExpenses" contextRef="C_20230530to20230530" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span>.
        <span style="font-family:Times New Roman, Times, Serif">As of June 30, 2024, there are outstanding warrants of <ix:nonFraction id="Fixv-38703" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20240630" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">21,717</ix:nonFraction>.</span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 49.65pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The Company classified the warrants for the
purchase of shares of its convertible redeemable preferred shares as a liability in its consolidated balance sheets, as these warrants
were freestanding financial instruments which underlying shares are contingently redeemable and, therefore, may obligate the Company to
transfer assets at some point in the future. The warrant liability was initially recorded at fair value upon the date of issuance and
was subsequently remeasured at fair value at each reporting date. The Company recorded revaluation expenses (income) amounting to $<ix:nonFraction id="Fixv-38704" name="slxn:RevaluationExpensesIncome" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction>
and $(<ix:nonFraction id="Fixv-38705" name="slxn:RevaluationExpensesIncome" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction>)
for the six months periods ended June 30, 2024 and June 30, 2023 , respectively, and revaluation expenses (income) amounting to $<ix:nonFraction id="Fixv-38706" name="slxn:RevaluationExpensesIncome" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction>
and $(<ix:nonFraction id="Fixv-38707" name="slxn:RevaluationExpensesIncome" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction>)
for the three months periods ended June 30, 2024 and June 30, 2023 and accounted for such revaluation expenses as part of its financial
(income) expense, net, in the statements of operations (see Note 7).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="text-align:left;width:0.25in"><strong>c.</strong></td>
    <td style="text-align:left">For conversion of warrants after the reporting period see Note 10(e).</td> </tr>
  </table> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-52</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt 1pt;text-align:center"><strong>SILEXION LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">(U.S. dollars in thousands)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241004155034044" name="slxn:RedeemableConvertiblePreferredSharesAndShareholdersEquityTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 49.65pt;text-indent:-49.65pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
5 - REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS&#8217; EQUITY:</span></span></p>

<p style="margin:0pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241004154935857" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<div>

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:left">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>a.</strong></span></span></td>
    <td><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>As of June 30, 2024 and December 31,
        2023, the share capital is composed of <ix:nonFraction id="Fixv-38708" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>
        NIS par value shares, as follows:</strong></span></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-indent:0in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June
        30, 2024</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Authorized</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issued
        and<br/>paid</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Carrying<br/>Value</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liquidation<br/>Preference</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:52%;padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary Shares</span></span></td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;width:1%;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38710" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,275,000</ix:nonFraction></span></span></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;width:1%;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38711" name="us-gaap:CommonStockSharesIssued" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">250,492</ix:nonFraction></span></span></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;width:1%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38712" name="us-gaap:CommonStockValue" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,685</ix:nonFraction></span></span></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:9%;padding-bottom:4pt;text-align:right">&#160;</td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred A Shares</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38713" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">510,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38714" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38715" name="us-gaap:PreferredStockValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38716" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,162</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred A-1 Shares</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38717" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">120,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38718" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38719" name="us-gaap:PreferredStockValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38720" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,443</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred A-2 Shares</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38721" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38722" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38723" name="us-gaap:PreferredStockValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38724" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred A-3 Shares</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38725" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">80,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38726" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38727" name="us-gaap:PreferredStockValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38728" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,887</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred A-4 Shares</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38729" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">815,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38730" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38731" name="us-gaap:PreferredStockValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38732" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,076</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 92.7pt;text-indent:0in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December
        31, 2023</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Authorized</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issued
        and<br/>paid</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Carrying<br/>Value</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liquidation<br/>Preference</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:52%;padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary Shares</span></span></td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;width:1%;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38733" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,275,000</ix:nonFraction></span></span></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;width:1%;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38734" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">219,354</ix:nonFraction></span></span></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;width:1%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38735" name="us-gaap:CommonStockValue" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,685</ix:nonFraction></span></span></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:9%;padding-bottom:4pt;text-align:right">&#160;</td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred A Shares</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38736" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">510,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38737" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38738" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38739" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,162</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred A-1 Shares</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38740" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">120,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38741" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38742" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38743" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,443</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred A-2 Shares</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38744" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38745" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38746" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38747" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred A-3 Shares</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38748" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">80,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38749" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38750" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38751" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,887</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred A-4 Shares</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38752" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">815,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38753" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38754" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38755" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,076</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </div> </div> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003132716543" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 6 - SHARE-BASED COMPENSATION:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The Company's options expenses amounted to
a total of $<ix:nonFraction id="Fixv-38756" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction>
and $<ix:nonFraction id="Fixv-38757" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction>
in the six months periods ended June 30, 2024 and 2023, respectively. As of June 30, 2024, <ix:nonFraction id="Fixv-38758" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20240630" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">39,898</ix:nonFraction>
shares remain available for grant under the Company&#8217;s 2013 and 2023 Incentive Option Plans.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 63.8pt;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">On July 4, 2024, the Company's board of directors
approved granting <ix:nonFraction id="Fixv-38759" name="srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" contextRef="C_20240704_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">178,686</ix:nonFraction>
RSUs to the Company's employees and directors.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 63.8pt;text-align:left">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-53</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 63.8pt;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt 1pt;text-align:center"><strong>SILEXION LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">(U.S. dollars in thousands)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 63.8pt;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 6 - SHARE-BASED COMPENSATION (continued):</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left"><strong>Summary of outstanding and exercisable
options:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 63.8pt;text-align:left"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">Below is a summary of the Company's stock-based
compensation activity and related information with respect to options granted to employees and non-employees for the six months periods
ended June 30, 2024:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003132549199" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Number<br/>of options</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Weighted-<br/>average<br/>exercise price<br/>(in
        U.S.<br/>dollars)</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1.5pt solid">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Weighted-<br/>average<br/>remaining<br/>contractual<br/>term</strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>(in years)</strong></p> </td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1.5pt solid">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Aggregate</strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>intrinsic</strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>value</strong></p> </td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:52%">Outstanding at January 1, 2024</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38761" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">121,808</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38762" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20231231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">17.23</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonNumeric id="Fixv-38763" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20230101to20231231" format="ixt-sec:duryear">4.88</ix:nonNumeric></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right">-</td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003140755846" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20240101to20240630" unitRef="shares" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003140851973" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240630" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">-</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">-</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td>Exercised</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38764" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20240101to20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">31,138</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38765" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonNumeric id="Fixv-38766" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExercised" contextRef="C_20240101to20240630" format="ixt-sec:duryear">0.01</ix:nonNumeric></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38767" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">490</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38768" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20240101to20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">735</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38769" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">26.78</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonNumeric id="Fixv-38770" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermForfeited" contextRef="C_20240101to20240630" format="ixt-sec:duryear">6.02</ix:nonNumeric></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">-</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt">Expired</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38771" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_20240101to20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">30,185</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38772" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">18.08</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">-</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">-</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt">Outstanding at June 30, 2024</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38773" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">59,750</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38774" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">25.66</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonNumeric id="Fixv-38775" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20240101to20240630" format="ixt-sec:duryear">7.34</ix:nonNumeric></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241003141131357" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20240630" unitRef="usd" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt">Exercisable at June 30, 2024</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38776" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">33,554</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38777" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">24.78</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonNumeric id="Fixv-38778" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExercisable" contextRef="C_20240101to20240630" format="ixt-sec:duryear">7.00</ix:nonNumeric></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">-</td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:4pt">Vested and expected to vest at June 30, 2024</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38779" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">59,750</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38780" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">25.66</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonNumeric id="Fixv-38781" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermVestedAndExpectedToVest" contextRef="C_20240101to20240630" format="ixt-sec:duryear">7.34</ix:nonNumeric></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">-</td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 63.8pt;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">Up to June 30, 2024 and for the year ended
December 31, 2023 no options were granted.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">On June 30, 2024, there was $<ix:nonFraction id="Fixv-38782" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">220</ix:nonFraction>
of total unrecognized compensation cost related to unvested stock options granted under the Plan. That cost is expected to be recognized
over a weighted-average period of <ix:nonNumeric id="Fixv-38783" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20240101to20240630" format="ixt-sec:duryear">1.73</ix:nonNumeric>
years.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 63.8pt;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The share-based compensation expense by line
item in the accompanying consolidated statements of operations is summarized as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003132601446" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;text-align:center">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:center">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;text-align:center">
        <p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>Six months ended </strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>June 30</strong></p> </td>
    <td style="padding-bottom:1.5pt;text-align:center">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:center">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;text-align:center">
        <p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>Three months ended </strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>June 30</strong></p> </td>
    <td style="padding-bottom:1.5pt;text-align:center">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:52%;text-align:left">Research and development</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38785" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38786" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38787" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38788" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt">General and administrative</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38789" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38790" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38791" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240401to20240630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38792" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230401to20230630_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38793" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38794" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38795" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38796" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003133125365" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 7 - FAIR VALUE MEASUREMENTS:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 49.65pt;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in"><strong>Financial instruments measured at fair value on a recurring
basis</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The Company&#8217;s assets and liabilities
that are measured at fair value as of June 30, 2024, and December 31, 2023, are classified in the tables below in one of the six categories
described in &#8220;Note 2 &#8211; Fair value measurement&#8221;:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003132823137" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="text-align:center;font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">June 30, 2024</td>
    <td style="text-align:center;padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="text-align:center;font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:center;font-weight:bold;border-bottom:Black 1.5pt solid">Level 3</td>
    <td style="text-align:center;padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="text-align:center;font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Total</td>
    <td style="text-align:center;padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left">Financial Liabilities</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:center">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;padding-left:0.125in">Warrants to preferred shares</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38798" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38799" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 49.65pt;text-align:left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="text-align:center;font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">December 31, 2023</td>
    <td style="text-align:center;padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="text-align:center;font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:center;font-weight:bold;border-bottom:Black 1.5pt solid">Level 3</td>
    <td style="text-align:center;padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="text-align:center;font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Total</td>
    <td style="text-align:center;padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left">Financial Liabilities</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:center">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;padding-left:0.125in">Warrants to preferred shares</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38800" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38801" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></td>
    <td style="width:1%">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-54</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt 1pt;text-align:center"><strong>SILEXION LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">(U.S. dollars in thousands)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 7 - FAIR VALUE MEASUREMENTS (continued):</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The following is a roll forward of the fair
value of liabilities classified under Level 3:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003132834490" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Six months ended<br/>June 30,</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Three months ended<br/>June 30,</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="text-align:center;font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom:1.5pt;font-weight:bold;text-align:center">Warrants</td>
    <td style="text-align:center;padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="text-align:center;font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom:1.5pt;font-weight:bold;text-align:center">Warrants</td>
    <td style="text-align:center;padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="text-align:center;font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom:1.5pt;font-weight:bold;text-align:center">Warrants</td>
    <td style="text-align:center;padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="text-align:center;font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom:1.5pt;font-weight:bold;text-align:center">Warrants</td>
    <td style="text-align:center;padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:52%;text-align:left">Fair value at the beginning of the period</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38803" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38804" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38805" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">281</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38806" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20230331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Issuance</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004173629408" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20240101to20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38807" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20230101to20230630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004173635266" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20240401to20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38808" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20230401to20230630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt">Change in fair value</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38809" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20240101to20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38810" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20230101to20230630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38811" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20240401to20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38812" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20230401to20230630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt">Fair value at the end of the period</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38813" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38814" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20230630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38815" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38816" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20230630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The fair value of the Company&#8217;s warrant
liabilities as of June 30, 2024 and December 31, 2023 was estimated using a hybrid model in order to reflect two scenarios: (1) an IPO
event (including de-SPAC transaction) and (2) other liquidation events. For further details see Note 12 in the annual consolidated financial
statements.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The valuation under the &#8216;other liquidation
events&#8217; scenario was assessed using an option pricing model (OPM) by implementing a Monte Carlo Simulation, which treats the financial
instruments in the Company&#8217;s equity as contingent claims whose future payoff depends on the Company&#8217;s future equity value.
The Company&#8217;s entire equity value in 2023 was calculated based, among others, on the financing round closest to the valuation date.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The fair value of the Company&#8217;s warrant
liabilities as of June 30, 2023 was estimated using only the &#8216;other liquidation events&#8217; scenario.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The following table presents the main assumptions
used in the hybrid model for the periods presented:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003132846890" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="text-align:center;font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">June 30</td>
    <td style="text-align:center;padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="text-align:center;font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2024</td>
    <td style="text-align:center;padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="text-align:center;font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2023</td>
    <td style="text-align:center;padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left">Expected volatility</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38818" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20240101to20240630" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">74.82</ix:nonFraction></td>
    <td style="width:1%;text-align:left">%</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38819" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20230101to20230630" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">82.80</ix:nonFraction></td>
    <td style="width:1%;text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Assumptions regarding the price of the underlying shares:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left">Probability of an IPO scenario (including de-SPAC transaction)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38820" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20240101to20240630_usgaapMeasurementInputTypeAxis_slxnProbabilityOfAnIPOScenarioMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">67</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004173731810" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20230101to20230630_usgaapMeasurementInputTypeAxis_slxnProbabilityOfAnIPOScenarioMember" unitRef="pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Expected time to IPO (including de-SPAC transaction) (years)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonNumeric id="Fixv-38821" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20240101to20240630_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToIPOMember" format="ixt-sec:duryear">0.137</ix:nonNumeric></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="-sec-ix-hidden:Fxbrl_20241004173820946">-</span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left">Probability of other liquidation events</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38822" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20240101to20240630_usgaapMeasurementInputTypeAxis_slxnProbabilityOfOtherLiquidationEventsMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38823" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20230101to20230630_usgaapMeasurementInputTypeAxis_slxnProbabilityOfOtherLiquidationEventsMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Expected time to liquidation (years)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonNumeric id="Fixv-38824" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20240101to20240630_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToLiquidationMember" format="ixt-sec:duryear">2.25</ix:nonNumeric></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonNumeric id="Fixv-38825" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20230630_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToLiquidationMember" format="ixt-sec:duryear">3</ix:nonNumeric></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left">Expected return on Equity</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38826" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20240101to20240630_usgaapMeasurementInputTypeAxis_slxnExpectedReturnOnEquityMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003181403146" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20230101to20230630_usgaapMeasurementInputTypeAxis_slxnExpectedReturnOnEquityMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">A significant increase in the expected volatility,
or in the probability of an IPO (including de-SPAC transaction), could each increase the fair value of the related instruments. A significant
decrease in the expected term of the warrants or expected time to IPO (including de-SPAC transaction), could each decrease the fair value
of related instruments. In combination, changes in these inputs could result in a significantly higher or lower fair value measurement
if the input changes were to be compounding, or could result in a minimally higher or lower fair value measurement if the input changes
were of opposite effects and consequently offset each other.&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left"><strong>Financial instruments not measured
at fair value</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The carrying amounts of cash and cash equivalents,
restricted cash, receivables, trade payables and other liabilities approximate their fair value due to the short-term maturity of such
instruments.</p> </div> </ix:nonNumeric>

<p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-55</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt 1pt;text-align:center"><strong>SILEXION LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1pt;text-align:center">(U.S. dollars in thousands)</p>

<p style="font:bold 10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-28557" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20240101to20240630" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 8 - NET LOSS PER SHARE:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241004104525215" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The following table sets forth the computation
of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented (USD in thousands, except per
share data):</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p>

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;text-align:center">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Six months ended </strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>June 30</strong></p> </td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;text-align:center">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Three months ended </strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>June 30</strong></p> </td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold">Numerator:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;width:52%;text-align:left">Net loss</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38829" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,912</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38830" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,619</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38831" name="us-gaap:NetIncomeLoss" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,489</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38832" name="us-gaap:NetIncomeLoss" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,876</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">Net loss attributable to ordinary shareholders, basic and diluted:</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38833" name="slxn:NetLossAttributableToOrdinaryShareholdersBasics" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,845</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38834" name="slxn:NetLossAttributableToOrdinaryShareholdersBasics" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,427</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38835" name="slxn:NetLossAttributableToOrdinaryShareholdersBasics" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,472</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38836" name="slxn:NetLossAttributableToOrdinaryShareholdersBasics" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,653</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:4pt">Weighted-average shares used in computing net loss
        per share attributable to ordinary shareholders, basic and diluted</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38837" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240101to20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">251,655</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38838" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">252,462</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38839" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240401to20240630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">250,847</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38840" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230401to20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">252,462</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:4pt">Net loss per share attributable to ordinary shareholders,
        basic and diluted</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38841" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">11.31</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38842" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">9.61</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38843" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240401to20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">5.87</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38844" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230401to20230630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">6.54</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">Basic loss per share is computed on the basis
of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the period, including fully
vested pre-funded options for the Company&#8217;s ordinary shares at an exercise price of $<ix:nonFraction id="Fixv-38845" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20240630" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>
or <ix:nonFraction id="Fixv-38846" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20240630" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>
NIS per share, as the Company considers these shares to be exercised for little to no additional consideration.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">As of June 30, 2024 and June 30, 2023, the
basic loss per share calculation included a weighted average number of <ix:nonFraction id="Fixv-38847" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240101to20240630_usgaapAwardTypeAxis_slxnPreFundedOptionsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">300</ix:nonFraction>
and <ix:nonFraction id="Fixv-38848" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20230630_usgaapAwardTypeAxis_slxnPreFundedOptionsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">33,108</ix:nonFraction>,
respectively, of fully vested pre-funded options. As the inclusion of other potential ordinary shares equivalents in the calculation would
be anti-dilutive for all periods presented, diluted net loss per share is the same as basic net loss per share.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The following instruments were not included
in the computation of diluted earnings per share because of their anti-dilutive effect:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-align:left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.75in">&#160;</td>
    <td style="width:18pt">-</td>
    <td>Redeemable convertible preferred shares;</td> </tr>
  </table>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.75in">&#160;</td>
    <td style="width:18pt">-</td>
    <td>Warrants to purchase redeemable convertible preferred shares;</td> </tr>
  </table>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.75in">&#160;</td>
    <td style="width:18pt">-</td>
    <td>Share-based compensation issuable at substantial consideration.</td> </tr>
  </table> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-28730" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20240101to20240630" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 9 - TRANSACTIONS AND BALANCES WITH RELATED PARTIES</strong>:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-align:left">Transactions with related parties which are
shareholders and directors of the Company:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>a.</strong></td>
    <td style="text-align:justify"><strong>Transactions:</strong></td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003133212655" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="text-align:center;border-bottom:2px solid black">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Six months ended </strong></p>
        <p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px;text-align:center"><strong>June 30</strong></p> </td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="text-align:center;border-bottom:2px solid black">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Three months ended </strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>June 30</strong></p> </td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:2px solid black">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:2px solid black">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;width:52%;text-align:left">Share-based compensation included in research and development
        expenses</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38849" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38850" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38851" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240401to20240630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38852" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230401to20230630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left">Share-based compensation included in general and administrative expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38853" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38854" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38855" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240401to20240630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38856" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230401to20230630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;padding-bottom:4pt">Financial expenses</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38857" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20240101to20240630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241004100651570" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38858" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20240401to20240630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241004100518084" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20230401to20230630_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-align:left"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>b.</strong></td>
    <td style="text-align:justify"><strong>Balances:</strong></td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003133222896" name="us-gaap:ScheduleOfCompensatingBalancesTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="text-align:left">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">June 30,<br/>2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left">Non-Current liabilities -</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;width:76%;text-align:left;padding-bottom:4pt">Warrants to preferred shares</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="width:9%;border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38859" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">321</ix:nonFraction></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="width:9%;border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38860" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-56</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt 1pt;text-align:center"><strong>SILEXION LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">(U.S. dollars in thousands)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-28899" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20240101to20240630" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 10 - SUBSEQUENT EVENTS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-align:left">The Company&#8217;s management has performed
an evaluation of subsequent events through August 19, 2024, the date the financial statements were available to be issued.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 78pt;text-align:left;text-indent:0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">a.</td>
    <td style="text-align:left">On July 4, 2024, the Company's board of directors approved granting <ix:nonFraction id="Fixv-38861" name="slxn:RestrictedStockUnitsShares" contextRef="C_20240704_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">178,686</ix:nonFraction>
        Restricted Stock Units (RSUs) to employees, service providers, and directors. These RSUs vest immediately upon the grant date, with <ix:nonFraction id="Fixv-38862" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_20240704to20240704_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>%
        vesting at the time of grant.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.7pt;text-indent:0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">b.</td>
    <td style="text-align:left">On July 14, 2024, the Company&#8217;s shareholders approved, inter alia, the A&amp;R BCA, the Investments Waiver,
        the Business Combination and granting of new RSUs to the Company&#8217;s directors and certain related parties.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.7pt;text-indent:0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">c.</td>
    <td style="text-align:left">On July 16, 2024, the U.S. Securities and Exchange Commission (SEC) issued an order of effectiveness for the registration
        statement on Form S-4 filed by Biomotion Sciences that registered the issuance of all ordinary shares of Biomotion Sciences issuable pursuant
        to the Business Combination. On July 17, 2024, the SPAC published notice of an extraordinary general meeting at which the Business Combination
        was to be presented for approval, and on July 19, 2024, the SPAC commenced the distribution of proxy materials for that extraordinary
        general meeting. On August 6, 2024, the SPAC held that extraordinary general meeting, and all proposals related to the Business Combination
        were approved by the SPAC&#8217;s shareholders.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 56.7pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">d.</td>
    <td style="text-align:left">On August 5, 2024, a conversion agreement was signed by and among Biomotion Sciences, GIBF and the Subsidiary,
        <span>which implements the transfer of </span>GIBF&#8217;s <span><ix:nonFraction id="Fixv-38863" name="slxn:PercentageOfGIBFOfOrdinaryShares" contextRef="C_20240805to20240805_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnGuangzhouSinoIsraelBiotechInvestmentFundMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">49</ix:nonFraction>%
        </span>holdings <span>in </span>the Subsidiary directly <span>to </span>Biomotion Sciences (in lieu of to the Company) in exchange for
        the issuance to GIBF of ordinary shares of New Pubco upon the closing of the Business Combination<span>).</span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.7pt;text-align:left;text-indent:0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">e.</td>
    <td style="text-align:left">In August 2024, certain Company warrant holders exercised their warrants in a &#8216;cashless&#8217; manner for
        <ix:nonFraction id="Fixv-38864" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20240831_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">1,257</ix:nonFraction>
        A-1 Preferred Shares and <ix:nonFraction id="Fixv-38865" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20240831_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">8,320</ix:nonFraction>
        A-4 Preferred Shares of the Company.</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 74.7pt;text-align:left;text-indent:0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">f.</td>
    <td style="text-align:left">On August 15, 2024, the Business Combination was completed in accordance with the terms of the A&amp;R BCA, as
        modified by the Investments Waiver. As a result of the Business Combination, the Company has become a wholly-owned subsidiary of Biomotion
        Sciences, and its security holders have received securities of Biomotion Sciences in accordance with the Silexion Equity Exchange Ratio.
        On August 16, 2024, the ordinary shares and warrants of Biomotion Sciences begin trading on the Nasdaq Global Market under the symbols
        &#8220;SLXN&#8221; and &#8220;SLXNW&#8221;, respectively.</td> </tr>
  </table> </ix:nonNumeric>

<p style="text-align:center;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-57</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-right:0;margin-bottom:0pt;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-right:0;margin-bottom:0pt;text-align:left">&#160;</p>

<div><span id="f_018_integixAnchor"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Report of Independent Registered Public Accounting
Firm</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">To the board of directors and shareholders of Silexion
Therapeutics Ltd.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong><i>&#160;</i></strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong><i>Opinion on the Financial Statements</i></strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">We have audited the accompanying consolidated balance
sheets of Silexion Therapeutics Ltd. and its subsidiary (the &#8220;Company&#8221;) as of December&#160;31, 2023 and 2022, and the related
consolidated statements of operations, changes in redeemable convertible preferred shares and capital deficiency and cash flows for the&#160;years
then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion,
the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,
2023 and 2022, and the results of its operations and its cash flows for each of the&#160;years then ended, in conformity with accounting
principles generally accepted in the United&#160;States of America.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>&#160;</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Substantial Doubt about the Company&#8217;s Ability to Continue as
a Going Concern</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">The accompanying consolidated financial statements have
been prepared assuming that the Company will continue as a going concern. As discussed in Note&#160;1e to the consolidated financial statements,
the Company has suffered recurring losses from operations and has cash outflows from operating activities that raise substantial doubt
about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note&#160;1e.
The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong><i>&#160;</i></strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong><i>Basis for Opinion</i></strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">These consolidated financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements
based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#160;States)
(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">We conducted our audits of these consolidated financial
statements in accordance with the standards of the PCAOB.&#160;Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">Our audits included performing procedures to assess the
risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable
basis for our opinion.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:60%;padding-left:10pt;text-indent:-10pt"><span style="font-size:10pt">Tel-Aviv, Israel</span></td>
    <td style="width:40%"><span style="font-size:10pt">/s/ Kesselman&#160;&amp; Kesselman</span></td></tr>
  <tr style="vertical-align:top">
    <td style="padding-left:10pt;text-indent:-10pt"><span style="font-size:10pt">May 9, 2024</span></td>
    <td><span style="font-size:10pt">Certified Public Accountants (lsr.)<br/>A&#160;member&#160;firm&#160;of&#160;PricewaterhouseCoopers&#160;International&#160;Limited</span></td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">We have served as the Company&#8217;s auditor since 2023.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-58</span></p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:7pt">&#160;</span></p>

<div><span id="f_019_integixAnchor"></span></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p></div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>SILEXION THERAPEUTICS LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>CONSOLIDATED BALANCE SHEETS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(U.S.&#160;dollars in thousands, except share data)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:7pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:center">Assets</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold">CURRENT ASSETS:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-0.125in;padding-left:0.25in">Cash and cash equivalents</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38866" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,595</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38867" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,259</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Restricted cash</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38868" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38869" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Short term deposits</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003052800808" name="us-gaap:ShortTermInvestments" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38870" name="us-gaap:ShortTermInvestments" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">507</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Prepaid expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38871" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">335</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38872" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in">Other current assets</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38873" name="us-gaap:OtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38874" name="us-gaap:OtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">TOTAL CURRENT ASSETS</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38875" name="us-gaap:AssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,979</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38876" name="us-gaap:AssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,839</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in">NON-CURRENT ASSETS:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Restricted cash</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38877" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38878" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Long-term deposit</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38879" name="us-gaap:DepositsAssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38880" name="us-gaap:DepositsAssetsNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38881" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38882" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">159</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">Operating lease right-of-use asset</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38883" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38884" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">305</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">TOTAL NON-CURRENT ASSETS</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38885" name="us-gaap:AssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">277</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38886" name="us-gaap:AssetsNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">494</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-0.125in;padding-left:0.125in">TOTAL ASSETS</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38887" name="us-gaap:Assets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,256</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38888" name="us-gaap:Assets" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,333</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:center;text-indent:-0.125in;padding-left:0.125in">Liabilities and redeemable convertible preferred
        shares,<br/>net of capital deficiency</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in">CURRENT LIABILITIES:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Trade payables</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38889" name="us-gaap:AccountsPayableCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38890" name="us-gaap:AccountsPayableCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Current maturities of operating lease liability</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38891" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38892" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">115</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Warrants to preferred shares (including $<ix:nonFraction id="Fixv-38893" name="us-gaap:OtherNotesPayableCurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction>
        and $<ix:nonFraction id="Fixv-38894" name="us-gaap:OtherNotesPayableCurrent" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>
        due to related party, respectively)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38895" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38896" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in">Employee related obligations</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38897" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38898" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">253</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in">Accrued expenses</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38899" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,358</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38900" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">999</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">TOTAL CURRENT LIABILITIES</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38901" name="us-gaap:LiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,196</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38902" name="us-gaap:LiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,610</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in">NON-CURRENT LIABILITIES:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in">Long-term operating lease liability</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38903" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38904" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">156</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">TOTAL NON-CURRENT LIABILITIES</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38905" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38906" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">156</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in">TOTAL LIABILITIES</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38907" name="us-gaap:Liabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,255</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38908" name="us-gaap:Liabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,766</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-style:normal;font-weight:normal;text-align:left;text-indent:-0.125in;padding-left:0.125in"><strong>COMMITMENTS AND CONTINGENT
        LIABILITIES</strong> (Note&#160;6)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004150045178" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20231231" unitRef="usd" xsi:nil="true"/></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004150051329" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20221231" unitRef="usd" xsi:nil="true"/></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in">REDEEMABLE CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING
        INTERESTS:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in">Convertible Series&#160;A Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241004103603929" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004103557538" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction>
        par value, <ix:nonFraction id="Fxbrl_s_20241004103620346" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004103620346" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">510,000</ix:nonFraction></ix:nonFraction>
        shares authorized as of December&#160;31, 2023 and 2022, <ix:nonFraction id="Fxbrl_20241004104001281" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004103947431" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_s_20241004103916322" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004103916322" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of December&#160;31, 2023 and 2022); aggregate liquidation preference of $<ix:nonFraction id="Fxbrl_20241004104016075" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,162</ix:nonFraction>
        as of December&#160;31, 2023;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.25in">Convertible Series&#160;A-1 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_s_20241004104332441" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004104332441" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_s_20241004104338840" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004104338840" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">120,000</ix:nonFraction></ix:nonFraction>
        shares authorized as of December&#160;31, 2023 and 2022, <ix:nonFraction id="Fxbrl_20241004120925609" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004120916802" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004120905011" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004120852041" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of December&#160;31, 2023 and 2022); aggregate liquidation preference of $<ix:nonFraction id="Fxbrl_20241004104425728" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,443</ix:nonFraction>
        as of December&#160;31, 2023;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in">Convertible Series&#160;A-2 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_s_20241004105239998" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004105239999" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_s_20241004105253199" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004105253199" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></ix:nonFraction>
        shares authorized as of December&#160;31, 2023 and 2022, <ix:nonFraction id="Fxbrl_20241004121510627" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004121458003" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004121445832" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004121434122" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of December&#160;31, 2023 and 2022); aggregate liquidation preference of $<ix:nonFraction id="Fxbrl_20241004105354587" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction>
        as of December&#160;31, 2023;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;width:76%">Convertible Series&#160;A-3 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_s_20241004105243349" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004105243349" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_s_20241004105256279" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004105256279" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">80,000</ix:nonFraction></ix:nonFraction>
        shares authorized as of December&#160;31, 2023 and 2022, <ix:nonFraction id="Fxbrl_20241004121650066" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004121643377" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004121632527" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004121610748" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of December&#160;31, 2023 and 2022); aggregate liquidation preference of $<ix:nonFraction id="Fxbrl_20241004105358523" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,887</ix:nonFraction>
        as of December&#160;31, 2023;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in">Convertible Series&#160;A-4 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_s_20241004105246902" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004105246903" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_20241004105259703" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">815,000</ix:nonFraction>
        and <ix:nonFraction id="Fxbrl_20241004105729481" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction>
        shares authorized as of December&#160;31, 2023 and 2022, respectively, <ix:nonFraction id="Fxbrl_20241004105829007" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004105335082" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></ix:nonFraction>*
        and <ix:nonFraction id="Fxbrl_s_20241004105904225" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004105904225" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of December&#160;31, 2023 and 2022, respectively); aggregate liquidation preference of $<ix:nonFraction id="Fxbrl_20241004105405268" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,076</ix:nonFraction>
        as of December&#160;31, 2023;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:1.5pt">TOTAL REDEEMABLE CONVERTIBLE PREFERRED
        SHARES</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38954" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,057</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38955" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,646</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:1.5pt">CONTINGENTLY REDEEMABLE NON-CONTROLLING
        INTERESTS</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38956" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,420</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38957" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,586</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:1.5pt">TOTAL REDEEMABLE CONVERTIBLE PREFERRED
        SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38958" name="us-gaap:PreferredStockRedemptionAmount" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,477</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38959" name="us-gaap:PreferredStockRedemptionAmount" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,232</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">CAPITAL DEFICIENCY:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in">Ordinary shares (NIS <ix:nonFraction id="Fxbrl_20241003171236063" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20221231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38960" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_20241004101028856" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004101021924" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,275,000</ix:nonFraction></ix:nonFraction>
        shares authorized as of December&#160;31, 2023 and 2022; <ix:nonFraction id="Fxbrl_20241004101358597" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004101351481" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004101341104" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004101334096" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">219,354</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of December&#160;31, 2023 and 2022)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38968" name="us-gaap:CommonStockValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38969" name="us-gaap:CommonStockValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">Additional paid-in capital</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38970" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,334</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38971" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,203</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Accumulated deficit</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38972" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">26,811</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38973" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">21,869</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:1.5pt">TOTAL CAPITAL DEFICIENCY</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38974" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15,476</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38975" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">10,665</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:1.5pt">TOTAL REDEEMABLE CONVERTIBLE PREFERRED
        SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38976" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,001</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38977" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,567</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:4pt">TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE
        PREFERRED SHARES AND NON-CONTROLLING INTEREST NET OF CAPITAL DEFICIENCY</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38978" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,256</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38979" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,333</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 24pt;text-indent:-24pt"><strong>&#160;</strong></p>

<div style="margin-top:0pt;margin-bottom:0pt;width:25%">

<div style="font-size:1pt;border-top:Black 1.5pt solid">&#160;</div> </div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in;text-align:left"><strong>*</strong></td>
    <td style="text-align:justify">Net of 121,119 treasury shares held by a subsidiary as of December&#160;31, 2023 (see Note&#160;9(b)(2))</td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:7pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>The accompanying notes are an integral part
of these consolidated financial statements.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-59</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>&#160;</strong></p>

<div><span id="f_020_integixAnchor"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>SILEXION THERAPEUTICS LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(U.S.&#160;dollars in thousands, except share data)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year ended<br/>December&#160;31</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold">OPERATING EXPENSES:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;width:76%;text-align:left">Research and development, net (including $<ix:nonFraction id="Fixv-38981" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction>
        and $<ix:nonFraction id="Fixv-38982" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction>
        from related party, respectively)</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38983" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,708</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38984" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,226</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">General and administrative (including $<ix:nonFraction id="Fixv-38985" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction>
        and $<ix:nonFraction id="Fixv-38986" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction>
        from related party, respectively)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38987" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">973</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38988" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">634</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:1.5pt">TOTAL OPERATING EXPENSES</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38989" name="us-gaap:OperatingExpenses" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,681</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38990" name="us-gaap:OperatingExpenses" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,860</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">OPERATING LOSS</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38991" name="us-gaap:OperatingIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,681</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38992" name="us-gaap:OperatingIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,860</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Financial expenses (income), net (including $<ix:nonFraction id="Fixv-38993" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction>
        and $<ix:nonFraction id="Fixv-38994" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>
        from related party, respectively)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38995" name="slxn:FinancialExpenses" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">395</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38996" name="slxn:FinancialExpenses" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">396</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">LOSS BEFORE INCOME TAX</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38997" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,076</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38998" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,464</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:1.5pt">INCOME TAX</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38999" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39000" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:1.5pt">NET LOSS FOR THE YEAR</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39001" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,108</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39002" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,488</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left">Attributable to:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left">Equity holders of the Company</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39003" name="slxn:EquityHoldersOfTheCompany" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,942</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39004" name="slxn:EquityHoldersOfTheCompany" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,215</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Non-controlling interests</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39005" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39006" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39007" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,108</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39008" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,488</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">LOSS PER SHARE, BASIC AND DILUTED</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003011645699" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20231231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39009" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">19.57</ix:nonFraction></ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003011657107" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39010" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">12.74</ix:nonFraction></ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING
        USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003011708187" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39011" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">252,462</ix:nonFraction></ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003011734771" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39012" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">252,371</ix:nonFraction></ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 24pt;text-align:center"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 24pt;text-align:center"><strong>The accompanying notes are an integral
part of these consolidated financial statements.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 24pt;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-60</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 24pt;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 24pt;text-align:center"><strong>&#160;</strong></p>

<div><span id="f_021_integixAnchor"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>SILEXION THERAPEUTICS LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE
CONVERTIBLE PREFERRED<br/>SHARES AND CAPITAL DEFICIENCY</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(U.S.&#160;dollars in thousands, except per share data)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="38" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Re<strong>deemable
        Convertible Preferred Shares</strong></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td colspan="2" style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td colspan="2" style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td colspan="2" style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td colspan="2" style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td colspan="2" style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>&#160;</strong></span></td>
    <td colspan="2" style="text-align:center;font-weight:bold;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="text-align:center;margin-top:0pt;font:10pt Times New Roman, Times, Serif;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;font-size:8pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total<br/>redeemable<br/>convertible<br/>preferred<br/>shares
        and<br/>contingently</strong></span></p>
        <p style="text-align:center;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;font-size:8pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">redeemable</strong></span></p>
        </td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Series&#160;A
        preferred&#160;shares</span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Series&#160;A-1
        preferred&#160;shares</span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Series&#160;A-2
        preferred&#160;shares</span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Series&#160;A-3
        preferred&#160;shares</span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Series&#160;A-4
        preferred&#160;shares</span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Contingently
        redeemable non- controlling interests</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;<strong>Ordinary
        shares</strong></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Additional
        paid-in</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Accumulated</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Total capital</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="text-align:center;font-weight:bold;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;font-size:8pt;margin-top:0pt;margin-bottom:0pt">non-
        </span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;font-size:8pt;margin-top:0pt;margin-bottom:0pt">controlling
        </span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;font-size:8pt;margin-top:0pt;margin-bottom:0pt">interests,
        </span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;font-size:8pt;margin-top:0pt;margin-bottom:0pt">net
        of </span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;font-size:8pt;margin-top:0pt;margin-bottom:0pt">capital</span></p>
        </td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Shares</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>Amount</strong></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Shares</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>Amount</strong></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Shares</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>Amount</strong></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Shares</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>Amount</strong></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Shares</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><strong>Amount</strong></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Amount</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;<strong>Shares</strong></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Amount</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;<strong>Capital</strong></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">deficit</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">deficiency</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">deficiency</span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;width:4.8%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">BALANCE
        AT JANUARY 1, 2022</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39013" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39014" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39015" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39016" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:5%;text-align:right"><ix:nonFraction id="Fhidden-fact-98" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:5%;text-align:right"><ix:nonFraction id="Fhidden-fact-99" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:5%;text-align:right"><ix:nonFraction id="Fhidden-fact-100" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:5%;text-align:right"><ix:nonFraction id="Fhidden-fact-101" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:5%;text-align:right"><ix:nonFraction id="Fhidden-fact-102" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:5%;text-align:right"><ix:nonFraction id="Fhidden-fact-103" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39017" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,859</ix:nonFraction></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39018" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">219,251</ix:nonFraction></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39019" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39020" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,006</ix:nonFraction></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">(<ix:nonFraction id="Fixv-39021" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,654</ix:nonFraction></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">)</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">(<ix:nonFraction id="Fixv-39022" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,647</ix:nonFraction></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">)</span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39023" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,911</ix:nonFraction></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">CHANGES
        DURING 2022:</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Issuance
        of Preferred A-2 shares, net of issuance cost, see Note&#160;9(b)</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39024" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39025" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39026" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Conversion
        of simple agreements for future equity (SAFE) to Preferred A-3 shares, see Note&#160;7</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39027" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39028" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39029" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39030" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39031" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,752</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Exercise of options</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39032" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">103</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="-sec-ix-hidden:Fhidden-fact-104">*</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39033" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39034" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39035" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Share-based
        compensation</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39036" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39037" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39038" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Net
        loss</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">(<ix:nonFraction id="Fixv-39039" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtRestatementAxis_srtScenarioPreviouslyReportedMember_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">273</ix:nonFraction></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">)</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">(<ix:nonFraction id="Fixv-39040" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtRestatementAxis_srtScenarioPreviouslyReportedMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,215</ix:nonFraction></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">)</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">(<ix:nonFraction id="Fixv-39041" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtRestatementAxis_srtScenarioPreviouslyReportedMember_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,215</ix:nonFraction></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">)</span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">(<ix:nonFraction id="Fixv-39042" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtRestatementAxis_srtScenarioPreviouslyReportedMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,488</ix:nonFraction></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">)</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">BALANCE
        AT DECEMBER&#160;31, 2022</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39043" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39044" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39045" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39046" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39047" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39048" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39049" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39050" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:right"><ix:nonFraction id="Fhidden-fact-105" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:right"><ix:nonFraction id="Fhidden-fact-106" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39051" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,586</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39052" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">219,354</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39053" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39054" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,203</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">(<ix:nonFraction id="Fixv-39055" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">21,869</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">)</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">(<ix:nonFraction id="Fixv-39056" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">10,665</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">)</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39057" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,567</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">CHANGES
        DURING 2023:</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Issuance
        of Preferred A-4 shares, net of issuance cost, see Note&#160;9(b)</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39058" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39059" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39060" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39061" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39062" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Share-based
        compensation</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39063" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39064" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39065" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">Net
        loss</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">(<ix:nonFraction id="Fixv-39066" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">166</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">)</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">(<ix:nonFraction id="Fixv-39067" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,942</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">)</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">(<ix:nonFraction id="Fixv-39068" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,942</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">)</span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">(<ix:nonFraction id="Fixv-39069" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,108</ix:nonFraction></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">)</span></td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">BALANCE
        AT DECEMBER&#160;31, 2023</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39070" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39071" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39072" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39073" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39074" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39075" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39076" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39077" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39078" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39079" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39080" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,420</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39081" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">219,354</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39082" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39083" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,334</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">(<ix:nonFraction id="Fixv-39084" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">26,811</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">)</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">(<ix:nonFraction id="Fixv-39085" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15,476</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">)</span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">$</span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt"><ix:nonFraction id="Fixv-39086" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,001</ix:nonFraction></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:8pt">&#160;</span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:0pt;margin-bottom:0pt;width:25%">

<div style="font-size:1pt;border-top:Black 1.5pt solid">&#160;</div> </div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in;text-align:left">*</td>
    <td style="text-align:justify">Represents an amount less than $1</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>The accompanying notes are an integral part
of these consolidated financial statements.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-61</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>&#160;</strong></p>

<div><span id="f_022_integixAnchor"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>SILEXION THERAPEUTICS LTD.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(U.S.&#160;dollars in thousands)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year ended<br/>December&#160;31</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold">CASH FLOWS FROM OPERATING ACTIVITIES:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;width:76%;text-align:left">Net loss</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-39087" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,108</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-39088" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,488</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">Adjustments required to reconcile loss to net cash used in operating
        activities:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.375in;text-indent:-0.125in">Depreciation</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39089" name="us-gaap:Depreciation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39090" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">Share-based compensation expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39091" name="us-gaap:ShareBasedCompensation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39092" name="us-gaap:ShareBasedCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">Non-cash financial expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39093" name="us-gaap:OtherNoncashExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">318</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39094" name="us-gaap:OtherNoncashExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">268</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">Gain on disposal of property and equipment</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39095" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004174837231" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">Changes in operating assets and liabilities:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">Increase (decrease) in prepaid expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39096" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">329</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39097" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">415</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">Increase (decrease) in other receivables</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39098" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39099" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">Increase (decrease) in trade payable</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39100" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">79</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39101" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">38</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">Net change in operating lease</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39102" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39103" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left">Increase (decrease) in employee related obligations</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39104" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">46</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39105" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">53</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.375in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Increase (decrease) in accrued expenses</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39106" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">359</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39107" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Net cash used in operating activities</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39108" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,529</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39109" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,335</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">CASH FLOWS FROM INVESTING ACTIVITIES:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">Proceeds from long-term deposits</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004174925943" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39110" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">Investment in short-term deposit</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004175002634" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39111" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">Proceeds from short-term deposit</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39112" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">507</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004175020438" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">Purchase of property and equipment</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39113" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39114" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Proceeds from sale of property and equipment</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39115" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004175034871" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Net cash provided by (used in) investing activities</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39116" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">573</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39117" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">524</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">CASH FLOWS FROM FINANCING ACTIVITIES:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left">Proceeds from issuance of preferred shares and warrants, net of issuance
        costs</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39118" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39119" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,749</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;padding-bottom:1.5pt">Exercise of options</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004175054514" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39120" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Net cash provided by financing activities</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39121" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39122" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,752</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED
        CASH</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39123" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,434</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39124" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,107</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS
        AND RESTRICTED CASH</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39125" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">230</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39126" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">667</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:1.5pt">BALANCE OF CASH, CASH EQUIVALENTS
        AND RESTRICTED CASH AT BEGINNING OF YEAR</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39127" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,309</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39128" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,083</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:4pt">BALANCE OF CASH, CASH EQUIVALENTS
        AND RESTRICTED CASH AT END OF YEAR</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39129" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,645</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39130" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,309</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 10pt;text-indent:-10pt"><strong><span style="text-decoration:underline">Appendix
        A&#160;&#8211;</span></strong></p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 10pt;text-indent:-10pt"><strong>RECONCILIATION OF CASH, CASH EQUIVALENTS
        AND RESTRICTED CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS:</strong></p> </td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left">Cash and cash equivalents</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39131" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,595</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39132" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,259</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt">Restricted cash</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39133" name="us-gaap:RestrictedCash" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39134" name="us-gaap:RestrictedCash" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt">TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH
        FLOWS</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39135" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,645</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39136" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,309</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-decoration:underline;text-align:left">Appendix B&#160;&#8211;&#160;SUPPLEMENTARY INFORMATION:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-weight:bold;text-align:left">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING
        ACTIVITIES NOT INVOLVING CASH FLOWS:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt">Transition to ASC&#160;842&#160;&#8211;&#160;recognition of operating right of use assets
        and operating lease liabilities</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241003023320197" name="slxn:RecognitionOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39137" name="slxn:RecognitionOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">391</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt">Conversion of SAFEs to preferred shares and warrants</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241003023343093" name="slxn:ConversionOfSAFEsToPreferredSharesAndWarrants" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39138" name="slxn:ConversionOfSAFEsToPreferredSharesAndWarrants" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:4pt">Interest received</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39139" name="us-gaap:InterestPaidNet" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">153</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39140" name="us-gaap:InterestPaidNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>The accompanying notes are an integral part
of these consolidated financial statements.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-62</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>&#160;</strong></p>

<div><span id="f_023_integixAnchor"></span></div>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-32492" name="us-gaap:NatureOfOperations" contextRef="C_20230101to20231231" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 1&#160;&#8212;&#160;GENERAL:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>a.</strong></td>
    <td style="text-align:left">Silexion Therapeutics Ltd. (formerly known as Silenseed Ltd.) (hereinafter -&#8221;the Company&#8221;) was incorporated
        in Israel and began its operations on November&#160;30, 2008. Since its incorporation, the Company has been engaged in <ix:nonFraction id="Fixv-39141" name="us-gaap:NumberOfOperatingSegments" contextRef="C_20230101to20231231" unitRef="Segment" scale="0" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction>
        operating segment&#160;&#8212;&#160;the research and development of innovative treatments for pancreatic cancer based on siRNAs, aiming
        to stop the production of a specific pancreatic cancer-causing protein known as the KRAS mutation. The Company&#8217;s long-lived assets
        are located in Israel.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>b.</strong></td>
    <td style="text-align:left">On April&#160;28, 2021, the Company signed an agreement with Guangzhou Sino-Israel Biotech Investment Fund (GIBF)
        to establish a new company in China. On June&#160;15, 2021 a company was established in China, named Silenseed (China) Ltd (hereinafter&#160;&#8212;&#160;the
        &#8220;Subsidiary&#8221;). The Company owns <ix:nonFraction id="Fixv-39142" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="C_20231231_srtOwnershipAxis_slxnSilexionEquityFinancingMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">51</ix:nonFraction>%
        of the shares of the Subsidiary. The Subsidiary has not yet started significant operations as of December&#160;31, 2023. The Company and
        Silenseed (China) Ltd., together&#160;&#8212;&#160;&#8220;the Group&#8221; (see Note&#160;9d).</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>c.</strong></td>
    <td style="text-align:left">On April&#160;3, 2024, the Company entered into an Amended and Restated Business Combination Agreement (hereinafter,
        &#8220;A&amp;R BCA&#8221;) with Moringa acquisition Corp (the &#8220;SPAC&#8220;), Biomotion Sciences, August M.S.&#160;Ltd. and Moringa
        Acquisition Merger Sub Corp (hereinafter&#160;&#8212;&#160;the &#8220;Business Combination&#8221;) which replaced an earlier business
        combination agreement,&#160;for further information see Note&#160;15.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>d.</strong></td>
    <td style="text-align:left">In October&#160;2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted
        a series of attacks on civilian and military targets. Following the attack, Israel&#8217;s security cabinet declared war against Hamas
        and commenced a military campaign against Hamas and other terrorist organizations.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company&#8217;s headquarters are located
in Modiin, Israel. As of the issuance date of these consolidated financial statements, the conflict between Israel and Hamas has not had
a material impact on the Company&#8217;s results of operations or financial position, if at all. The Company cannot currently predict
the intensity or duration of Israel&#8217;s war against Hamas, however, as most of the Company&#8217;s trials are not executed in Israel,
the Company does not believe the recent terrorist attack and the subsequent declaration of war by the Israeli government against the Hamas
terrorist organization will have any material impact on its ongoing operations. The Company continues to monitor its ongoing activities
and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employees.</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Any hostilities involving Israel, or the interruption
or curtailment of trade within Israel or between Israel and its trading partners could adversely affect the Company&#8217;s operations
and results of operations and could make it more difficult for the Company to raise capital.</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>e.</strong></td>
    <td style="text-align:left"><span style="text-decoration:underline">Going concern</span>:</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Since its inception, the Company has devoted
substantially all its efforts to research and development, clinical trials, and capital raising activities. The Company is still in its
development and clinical stage and has not yet generated revenues. The Company has incurred losses of $<ix:nonFraction id="Fixv-39143" name="us-gaap:InterestCostsIncurred" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,108</ix:nonFraction>
and $<ix:nonFraction id="Fixv-39144" name="us-gaap:InterestCostsIncurred" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,488</ix:nonFraction>
for the&#160;years ended on December&#160;31, 2023 and 2022, respectively. During the&#160;years ended on December&#160;31, 2023 and 2022,
the Company had negative operating cash flows of $<ix:nonFraction id="Fixv-39145" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,529</ix:nonFraction>
and $<ix:nonFraction id="Fixv-39146" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,335</ix:nonFraction>,
respectively. As of December&#160;31, 2023, the Company had cash and cash equivalents of $<ix:nonFraction id="Fixv-39147" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction>
million. The Company expects to continue incurring losses, and negative cash flows from operations. Management is in the process of evaluating
various financing alternatives, as the Company will need to finance future research and development activities, general and administrative
expenses and working capital through fund raising. However, there is no assurance that the Company will be successful in obtaining such
funding.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Under these circumstances, in accordance with the requirements
of ASC&#160;205-40, management has concluded that it is required to disclose that there is substantial doubt about the Company&#8217;s
ability to continue as a going concern for at least 12 months from the date these financial statements are issued. The financial statements
do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-63</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>&#160;</strong></p> </div> <ix:nonNumeric id="Fxbrl_20241003121255356" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 2&#160;&#8212;&#160;SIGNIFICANT ACCOUNTING POLICIES:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003121336690" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>a.</strong></td>
    <td style="text-align:justify"><strong>Basis of presentation</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company&#8217;s consolidated financial statements have
been prepared in accordance with generally accepted accounting principles in the United&#160;States (&#8220;U.S.&#160;GAAP&#8221;).</p>
</div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003121355171" name="us-gaap:UseOfEstimates" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>b.</strong></td>
    <td style="text-align:justify"><strong>Use of estimates</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The preparation of the financial statements in conformity with
U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and
accompanying notes. Actual results could differ from those estimates. As applicable to these financial statements, the most significant
estimates and assumptions relate to fair value of financial instruments and share-based compensation see Notes 12 and 11, respectively.</p>
</div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003121416790" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>c.</strong></td>
    <td style="text-align:justify"><strong>Functional currency</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company&#8217;s operations are currently conducted in Israel
and some of the Company&#8217;s expenses are currently paid in new Israeli shekels (&#8220;NIS&#8221;); however, the markets for the Company&#8217;s
future products are located outside of Israel. Financing activities are conducted in U.S.&#160;dollar (&#8220;dollar&#8221; or &#8220;$&#8221;).
The Company&#8217;s management believes that the US dollar is the currency of the primary economic environment in which the Company operates.
Thus, the functional and reporting currency of the Company is the dollar. The functional currency of the Subsidiary is U.S.&#160;dollar,
inter alia, in light of the composition of expenses and expected volume of intercompany transactions with the Company.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Transactions and balances originally denominated in dollars
are presented at their original amounts. Balances in non-U.S.&#160;dollar currencies are translated into dollars using historical and
current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the statements
of operations (indicated below), the following exchange rates are used: (i)&#160;for transactions&#160;&#8212;&#160;exchange rates at
transaction dates or average exchange rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation
and amortization) &#8212;&#160;historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses,
as appropriate.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003121435804" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>d.</strong></td>
    <td style="text-align:justify"><strong>Principles of consolidation</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The accompanying consolidated financial statements include
the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The financial statements of the Company and
of the Subsidiary are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform accounting
policies by all companies in the Group.</p> </div> </ix:nonNumeric>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>
<ix:nonNumeric id="Fxbrl_20241003121455773" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>e.</strong></td>
    <td style="text-align:left"><strong>Cash and cash equivalents</strong></td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company considers as cash equivalents all
short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from
the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Bank balances for which use by the Company
is subject to third party contractual restrictions are included as part of cash unless the restrictions result in a bank balance no longer
meeting the definition of cash. If the contractual restrictions to use the cash extend beyond 12&#160;months after the end of the reporting
period, the related amounts are classified as non-current in Balance sheets.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003121512277" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>f.</strong></td>
    <td style="text-align:justify"><strong>Restricted cash</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">As of December&#160;31, 2023 and 2022, the Company pledged
an amount of $<ix:nonFraction id="Fxbrl_20241003122849698" name="us-gaap:OperatingLeasePayments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39148" name="us-gaap:OperatingLeasePayments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></ix:nonFraction>
in favor of a bank as collateral for guarantees provided to secure the lease payments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-64</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 2&#160;&#8212;&#160;SIGNIFICANT ACCOUNTING
POLICIES:</strong> (cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company is required to hold a minimum amount of NIS 85
in its bank account in order to maintain availability of a credit line from its credit card company.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> </div> <ix:nonNumeric id="Fxbrl_20241003121627821" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>g.</strong></td>
    <td style="text-align:justify"><strong>Property and equipment:</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Property and equipment are stated at cost, net of accumulated
depreciation.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p> </div> <ix:nonNumeric id="Fxbrl_20241004042437827" name="slxn:ScheduleOfEstimatedUsefulLivesTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets, at the following annual rates:</p> </div>

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">%</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:88%;text-align:left;text-indent:-10pt;padding-left:10pt">Computers and software</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:center"><ix:nonNumeric id="Fixv-39151" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" format="ixt-sec:duryear">33</ix:nonNumeric></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Laboratory and electronic equipment</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:center"><ix:nonNumeric id="Fixv-39152" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnLaboratoryAndElectronicEquipmentMember" format="ixt-sec:duryear">15</ix:nonNumeric></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Leasehold improvements*</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:center"><span style="font-size:10pt"><ix:nonNumeric id="Fix_7_fact" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_20231231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" format="ixt-sec:duryear">15</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric id="Fix_8_fact" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_20231231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" format="ixt-sec:duryear">40</ix:nonNumeric></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 24pt;text-indent:-24pt">&#160;</p> </div>

<div style="margin-top:0pt;margin-bottom:0pt;width:25%">

<div style="font-size:1pt;border-top:Black 1.5pt solid">&#160;</div> </div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in;text-align:left">*</td>
    <td style="text-align:justify">Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter
        than the estimated useful life of the improvements.</td> </tr>
  </table> </div> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003121713762" name="us-gaap:PostemploymentBenefitPlansPolicy" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>h.</strong></td>
    <td style="text-align:justify"><strong>Employee rights upon retirement</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company is required to make severance payments upon dismissal
of an employee or upon termination of employment in certain circumstances.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">In accordance with the current employment terms with all of
its employees located in Israel, and pursuant to Section&#160;14 of the Israeli Severance Pay Law, 1963, the Company makes and has been
continuously making, since the beginning of employment of each of its current employees, regular deposits, at a rate of <ix:nonFraction id="Fixv-39156" name="slxn:RegularDepositsByEmployee" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.33</ix:nonFraction>%
of their monthly salary, with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#8217;s
full severance pay obligation.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Under these circumstances, the Company is currently relieved
from any severance pay liability with respect to each such employee. Neither the liability in respect of these employees nor the credit
for the amounts funded are reflected on the Company&#8217;s consolidated balance sheets, as the amounts funded are not under the control
or management of the Company and the severance pay risks have been irrevocably transferred to the applicable insurance companies.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The amounts of severance payment expenses were $<ix:nonFraction id="Fixv-39157" name="us-gaap:SeveranceCosts1" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction>
and $<ix:nonFraction id="Fixv-39158" name="us-gaap:SeveranceCosts1" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction>
for the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003121737303" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>i.</strong></td>
    <td style="text-align:justify"><strong>Fair value measurement</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Fair value is based on the price that would be received from
the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement
date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that
prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:0.75in;padding-bottom:2.25pt">&#160;</td>
    <td style="width:0.75in;padding-left:10pt;text-indent:-10pt"><span style="font-size:10pt">Level&#160;1:</span></td>
    <td><span style="font-size:10pt">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.
        The fair value hierarchy gives the highest priority to Level 1 inputs.</span></td> </tr>
  <tr style="vertical-align:top">
    <td style="padding-bottom:2.25pt">&#160;</td>
    <td style="padding-left:10pt;text-indent:-10pt">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:top">
    <td style="padding-bottom:2.25pt">&#160;</td>
    <td style="padding-left:10pt;text-indent:-10pt"><span style="font-size:10pt">Level&#160;2:</span></td>
    <td><span style="font-size:10pt">Observable prices that are based on inputs not quoted on active markets, but corroborated by market data
        or active market data of similar or identical assets or liabilities.</span></td> </tr>
  <tr style="vertical-align:top">
    <td style="padding-bottom:2.25pt">&#160;</td>
    <td style="padding-left:10pt;text-indent:-10pt">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:top">
    <td style="padding-bottom:2.25pt">&#160;</td>
    <td style="padding-left:10pt;text-indent:-10pt"><span style="font-size:10pt">Level&#160;3:</span></td>
    <td><span style="font-size:10pt">Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the
        lowest priority to Level 3 inputs.</span></td> </tr>
  </table>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-65</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="margin-top:0;margin-bottom:0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 2&#160;&#8212;&#160;SIGNIFICANT ACCOUNTING
POLICIES:</strong> (cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">In determining fair value, the Company utilizes valuation techniques
that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty
credit risk in its assessment of fair value.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003121754966" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>j.</strong></td>
    <td style="text-align:justify"><strong>Financial instruments issued</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">When the Company issues preferred shares, it first considers
the provisions of ASC&#160;480, Distinguishing Liabilities from Equity (&#8220;ASC&#160;480&#8221;) in order to determine whether the
preferred share should be classified as a liability. If the instrument is not within the scope of ASC&#160;480, the Company further analyzes
the instrument&#8217;s characteristics in order to determine whether it should be classified within temporary equity (mezzanine) or within
permanent equity in accordance with the provisions of ASC&#160;480-10-S99. The Company&#8217;s redeemable convertible preferred shares
are not mandatorily or currently redeemable. However, they include clauses that could constitute as in-substance redemption clauses that
are outside of the Company&#8217;s control. As such, all shares of redeemable convertible preferred shares have been presented outside
of permanent equity.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">When the Company issues other freestanding instruments, the
Company first analyzes the provisions of ASC&#160;480 in order to determine whether the instrument should be classified as a liability,
with subsequent changes in fair value recognized in the statements of operations in each period. If the instrument is not within the scope
of ASC&#160;480, the Company further analyzes the provisions of ASC&#160;815-40 in order to determine whether the instrument should be
classified within equity or classified as an asset or liability, with subsequent changes in fair value recognized in the statements of
operations in each period.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company&#8217;s issued financial instruments convertible
to preferred shares are in the scope of ASC&#160;480. For further details see Note&#160;7 and Note&#160;8.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003121815634" name="slxn:RedeemableNoncontrollingInterestPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>k.</strong></td>
    <td style="text-align:justify"><strong>Redeemable Non-controlling Interest</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Non-controlling interests with embedded redemption features,
whose settlement is not at the Company&#8217;s discretion, are considered redeemable non-controlling interest. Redeemable non-controlling
interests are considered to be temporary equity and are therefore presented as a mezzanine section between liabilities and equity on the
Company&#8217;s consolidated balance sheets. Redeemable non-controlling interests are measured at the greater of the initial carrying
amount adjusted for the non-controlling interest&#8217;s share of comprehensive income or loss or its redemption value. Subsequent adjustment
of the amount presented in temporary equity is currently not required because the Company&#8217;s management estimates that it is not
probable that the instrument will become redeemable. Adjustments of redeemable non-controlling interest to its redemption value are recorded
through additional paid-in capital.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003121845954" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>l.</strong></td>
    <td style="text-align:justify"><strong>Research and development expenses</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Research and development costs are charged to the statements
of operations as incurred. Research and development expenses include costs directly attributable to the conduct of research and development
programs, including the cost of payroll and subcontractors, as well as share-based payments. Advance payments for goods or services that
will be used or rendered for future research and development activities are deferred. Such amounts are recognized as an expense as the
related goods are used or the services are rendered.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Grants received from the Israeli Innovation Authority (&#8220;IIA&#8221;)
for approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the
costs incurred and included as a deduction from research and development expenses, see Note&#160;5(a). The Company did not receive any
grants during 2022 and 2023.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-66</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 2&#160;&#8212;&#160;SIGNIFICANT ACCOUNTING
POLICIES:</strong> (cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div> <ix:nonNumeric id="Fxbrl_20241003121909842" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>m.</strong></td>
    <td style="text-align:justify"><strong>Share-based compensation</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company&#8217;s employees and non-employees share-based
payment awards are classified as equity awards. The Company accounts for these awards using the grant-date fair value method. The fair
value of share-based payment transactions is recognized as an expense over the requisite service period using the straight-line method.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company elected to recognize compensation costs for awards
conditioned only on continued service that have a graded vesting schedule using the straight-line method based on the multiple-option
award approach. Forfeitures are recognized as they occur.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company accounts for its non-employees&#8217; equity-classified
share-based payment in a similar manner.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003121932023" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>n.</strong></td>
    <td style="text-align:justify"><strong>Leases</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company adopted the ASC&#160;842, Leases accounting guidance.
The Company recognized new right-of-use assets and operating lease liabilities of $<ix:nonFraction id="Fixv-39159" name="us-gaap:OperatingLeaseLiability" contextRef="C_20220101" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">391</ix:nonFraction>
as of January&#160;1, 2022. The Company does not have any finance leases.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company recognizes operating lease payments in the consolidated
statements of operations on a straight-line basis over the lease term. Right-of-use (&#8220;ROU&#8221;) assets represent the right to
use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum lease payments arising from
the lease. ROU assets are initially measured at amounts representing the discounted present value of the lease payments over the lease,
plus any initial direct costs incurred. The lease liability is initially measured at lease commencement date based on the discounted present
value of minimum lease payments over the lease term. The discount rate for the lease is the rate in the lease unless that rate cannot
readily determined. As the Company&#8217;s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing
rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments. The
Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in
economic environments where the leased asset is located. The lease agreement included an option to extend or terminate the lease. The
Company exercised its option to extend the lease period up to July&#160;2025.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Payments under the Company&#8217;s lease arrangements are primarily
fixed, however, certain lease agreements contain variable payments, which are expensed as incurred and not included in the operating lease
right-of-use assets and liabilities. The Company elected the practical expedient not to separate lease and non-lease components.</p> </div>
</ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003122016949" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>o.</strong></td>
    <td style="text-align:justify"><strong>Loss per share</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company calculates loss per share using the two-class method
required for participating securities. This method entails allocating income available to ordinary shareholders for the period between
ordinary shares and participating securities based on their respective rights to receive dividends as if all income for the period had
been distributed. Basic loss per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding
during the year, and fully vested pre-funded options for the Company&#8217;s ordinary shares at an exercise price of $<ix:nonFraction id="Fixv-39160" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>
or <ix:nonFraction id="Fixv-39161" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>
NIS per share. The Company considers these shares to be exercised for little to no additional consideration. The Company also considers
its redeemable convertible preferred shares to be participating securities as the holders of the redeemable convertible preferred shares
would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis assuming conversion of
all redeemable convertible preferred shares into ordinary shares. However, these participating securities do not contractually require
the holders to participate in the Company&#8217;s losses. Consequently, net loss for the periods presented was not allocated to the Company&#8217;s
participating securities.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-67</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 2&#160;&#8212;&#160;SIGNIFICANT ACCOUNTING
POLICIES:</strong> (cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div> <ix:nonNumeric id="Fxbrl_20241003122036976" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>p.</strong></td>
    <td style="text-align:justify"><strong>Income taxes:</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">1)</td>
    <td style="text-align:justify">Deferred taxes</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">Income taxes are computed using the asset and liability method.
Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial
reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance
is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. Given
the Company&#8217;s losses, the Company has provided a full valuation allowance with respect to its deferred tax assets.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">2)</td>
    <td style="text-align:justify">Uncertainty in income tax</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">The Company follows a two-step approach in recognizing and measuring
uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates
that it is more likely than not that the tax position will be sustained upon examination, including resolution of any related appeals
or litigation processes, based on the technical merits of the position. If this threshold is met, the second step is to measure the tax
position as the largest amount that has more than a 50% likelihood of being realized upon ultimate settlement.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003122054801" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>q.</strong></td>
    <td style="text-align:justify"><strong>Concentration of credit risks</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Financial instruments that potentially subject the Company
to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term deposits. The Company
deposits cash and cash equivalents mostly with three low risk financial institution. The Company has not experienced any material credit
losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003122121074" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>r.</strong></td>
    <td style="text-align:justify"><strong>Operating segments and geographical information:</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company is managed as one R&amp;D department during its
startup phase that has yet to earn revenues. The Company&#8217;s Chief Executive Office (&#8220;CEO&#8221;) was identified as the chief
operating decision maker (&#8220;CODM&#8221;). The CODM reviews the financial information every quarter. Accordingly, the company had
determined to operate under one reportable&#160;segment.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">All of the Company long-lived assets are located in Israel.</p>
</div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003122151287" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>s.</strong></td>
    <td style="text-align:justify"><strong>New accounting pronouncements:</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company qualifies as an emerging growth company (&#8220;EGC&#8221;)
as defined under the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;). Using exemptions provided under the JOBS Act for
EGCs, the Company has elected to defer compliance with new or revised ASUs until it is required to comply with such updates, which is
generally consistent with the adoption dates of private companies.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in"><i>&#160;</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in"><i><span style="text-decoration:underline">Recently Adopted
accounting pronouncements:</span></i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">In June&#160;2016, the FASB issued ASU&#160;2016-13, &#8220;Financial
Instruments&#160;&#8212;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments&#8221;, which replaces
the existing incurred loss model with a current expected credit loss (&#8220;CECL&#8221;) model that requires consideration of a broader
range of reasonable and supportable information to inform credit loss estimates. Subsequent to the issuance of ASU&#160;2016-13, the FASB
issued several additional Accounting Standard Updates to clarify implementation guidance, provide narrow-scope improvements and provide
additional disclosure guidance. Under the ASU, the Company is required to use a forward-looking CECL model for accounts receivables and
other financial instruments. The Company adopted the ASU on January&#160;1, 2023 and it did not have a material impact on its consolidated
financial statement.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-68</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 2&#160;&#8212;&#160;SIGNIFICANT ACCOUNTING
POLICIES:</strong> (cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in"><strong><span style="text-decoration:underline">Recently issued
accounting standards not yet adopted:</span></strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">1)</td>
    <td style="text-align:left">In June&#160;2022, the FASB issued ASU&#160;2022-03 &#8220;Fair Value Measurement of Equity Securities Subject
        to Contractual Sale Restrictions&#8221;. The ASU clarifies that a contractual restriction on the sale of an equity security is not considered
        part of the unit of account of the equity security and, therefore, is not considered in measuring its fair value. The ASU also clarifies
        that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The ASU also introduces new
        disclosure requirements for equity securities subject to contractual sale restrictions. As an Emerging Growth Company, the ASU is effective
        for fiscal&#160;years beginning after December&#160;15, 2024, and interim periods within those fiscal&#160;years. Early adoption is permitted
        for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is currently
        evaluating the effect that ASU&#160;2022-03 will have on its consolidated financial statements and related disclosures.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">2)</td>
    <td style="text-align:left">In November&#160;2023, the FASB issued ASU No.&#160;2023-07&#160;Segment Reporting (Topic&#160;280): Improvements
        to Reportable Segment Disclosures. The ASU improves reportable segments disclosure requirements, primarily through enhanced disclosures
        about significant segment expenses. The ASU also require that a public entity that has a single reportable segment to provide all the
        disclosures required by the amendments and all existing segment disclosures in Topic&#160;280.&#160;The ASU is effective for fiscal&#160;years
        beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024.&#160;The
        Company is currently evaluating this ASU to determine its impact on the Company&#8217;s segment disclosures.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">3)</td>
    <td style="text-align:left">In December, 2023, the FASB issued ASU&#160;2023-09, Improvements to Income Tax Disclosures, which requires disclosure
        of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies
        other income tax-related disclosures. The ASU will be effective for fiscal&#160;years beginning after December&#160;15, 2025, and allows
        adoption on a prospective basis, with a retrospective option. The Company is in the process of assessing the impacts and method of adoption.</td>
        </tr>
  </table> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-33153" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 3&#160;&#8212;&#160;PROPERTY AND EQUIPMENT, NET:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">Composition of property and equipment, grouped by major classifications,
is as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003035115303" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_20230101to20231231" escape="true">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;font-weight:bold">Cost:</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39163" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCostMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39164" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCostMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in">Computers</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-align:left">Laboratory and electronic equipment</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004175308131" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnLaboratoryAndElectronicEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39165" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnLaboratoryAndElectronicEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">274</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-align:left">Office furniture</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39166" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39167" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-align:left">Communication equipment</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39168" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCommunicationEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39169" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCommunicationEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-align:left;padding-bottom:1.5pt">Leasehold improvements</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39170" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39171" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39172" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39173" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">398</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left">Accumulated depreciation:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in">Computers</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39174" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39175" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-align:left">Laboratory and electronic equipment</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004175326636" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnLaboratoryAndElectronicEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39176" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnLaboratoryAndElectronicEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">179</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-align:left">Office furniture</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39177" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39178" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-align:left">Communication equipment</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39179" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCommunicationEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39180" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCommunicationEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-align:left;padding-bottom:1.5pt">Leasehold improvements</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39181" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39182" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39183" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39184" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-align:left;padding-bottom:4pt">Property and equipment, net</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39185" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39186" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">159</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">Depreciation expenses were $<ix:nonFraction id="Fixv-39187" name="us-gaap:Depreciation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction>
and $<ix:nonFraction id="Fixv-39188" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction>
in the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-69</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-33352" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_20230101to20231231" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 4&#160;&#8212;&#160;LEASES:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The Company leases offices for its facilities in Israel by way
of an operating lease. The lease agreement for such offices is denominated in NIS and linked to the Israeli consumer price index (&#8220;CPI&#8221;).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The Company provided the lessor with a bank guarantee as a rental
security. The bank in turn placed a pledge over restricted cash of $<ix:nonFraction id="Fixv-39189" name="us-gaap:RestrictedCashCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction>.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The lease for the offices expires on July&#160;31, 2025. The
remaining lease term is up to <ix:nonNumeric id="Fixv-39190" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="C_20231231" format="ixt-sec:duryear">1.58</ix:nonNumeric>&#160;years
as of December&#160;31, 2023.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003040442835" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">Operating lease costs for the&#160;years ended December&#160;31,
2022 and 2023 are as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year Ended<br/>December&#160;31,</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Fixed payments and variable payments that depend on an index or rate:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-10pt;padding-left:10pt">Office and operational lease expenses</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39191" name="us-gaap:OperatingLeaseExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39192" name="us-gaap:OperatingLeaseExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Variable lease cost (included in the operating lease
        costs)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39193" name="us-gaap:VariableLeaseCost" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39194" name="us-gaap:VariableLeaseCost" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Total operating lease costs</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39195" name="us-gaap:OperatingLeaseCost" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39196" name="us-gaap:OperatingLeaseCost" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">Operating cash flows, for amounts included in the measurement
of lease liabilities, are as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year Ended<br/>December&#160;31,</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Office and operational spaces lease expenses</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="width:9%;border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39198" name="us-gaap:LeaseAndRentalExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">101</ix:nonFraction></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="width:9%;border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39199" name="us-gaap:LeaseAndRentalExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">119</ix:nonFraction></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">Supplemental information related to operating leases is as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year Ended<br/>December&#160;31,</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Operating lease right-of-use assets</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="width:9%;border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39201" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="width:9%;border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39202" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">305</ix:nonFraction></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Operating lease liabilities</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39203" name="us-gaap:OperatingLeaseLiability" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">171</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39204" name="us-gaap:OperatingLeaseLiability" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">271</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Weighted average remaining lease term (years)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonNumeric id="Fixv-39205" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_20231231" format="ixt-sec:duryear">1.58</ix:nonNumeric></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonNumeric id="Fixv-39206" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_20221231" format="ixt-sec:duryear">2.58</ix:nonNumeric></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Weighted average discount rate</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39207" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_20231231" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">12.69</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">%</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39208" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_20221231" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">12.69</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">%</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">As of December&#160;31, 2023, the Company has not entered into
lease agreements that include options to extend them that are not included in the measurement of the lease liability.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The following table outlines maturities of the Company&#8217;s
operating lease liabilities as of December&#160;31, 2023:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003040330164" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="text-align:left">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:center;font-weight:bold;border-bottom:Black 1.5pt solid">Operating lease liabilities</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:88%;text-align:left">2024</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39210" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt">2025</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39211" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left">Total undiscounted lease payments</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39212" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt">Less&#160;&#8211;&#160;imputed interest</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39213" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt">Present value of lease liabilities</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39214" name="us-gaap:OperatingLeaseLiability" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">171</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> </ix:nonNumeric>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-70</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="margin-top:0;margin-bottom:0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p> </div> <ix:nonNumeric id="Fxbrl_20241003150547389" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 5&#160;&#8212;&#160;SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.25in"><strong>Statement of operations:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>a.</strong></td>
    <td style="text-align:justify"><strong>Research and development expenses, net:</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003040809003" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font-weight:bold">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Year ended<br/>December&#160;31,</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;border-bottom:Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;border-bottom:Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-10pt;padding-left:10pt">Payroll and related expenses</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39215" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">973</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39216" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,192</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Subcontractors and consultants</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39217" name="slxn:SubcontractorsAndConsultants" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,467</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39218" name="slxn:SubcontractorsAndConsultants" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,595</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-10pt;padding-left:10pt">Materials</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39219" name="slxn:MaterialsExpenses" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39220" name="slxn:MaterialsExpenses" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">191</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Rent and maintenance</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39221" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">160</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39222" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Travel expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39223" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39224" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Other</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39225" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39226" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39227" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,708</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39228" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,226</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>b.</strong></td>
    <td style="text-align:justify"><strong>General and administrative expenses:</strong></td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003040818451" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-10pt;padding-left:10pt">Payroll and related expenses</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39229" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">356</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39230" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">219</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Professional services</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39231" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">386</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39232" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">197</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-10pt;padding-left:10pt">Depreciation</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39233" name="us-gaap:Depreciation" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39234" name="us-gaap:Depreciation" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Rent and maintenance</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39235" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39236" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">71</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Patent registration</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39237" name="slxn:PatentRegistration" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39238" name="slxn:PatentRegistration" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Travel expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39239" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004175518529" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Other</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39240" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39241" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39242" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">973</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39243" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">634</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> </div> <ix:nonNumeric id="Fxbrl_20241003152112346" name="slxn:ScheduleOfFinancialExpenseNetTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>c.</strong></td>
    <td style="text-align:justify"><strong>Financial expense, net:</strong></td> </tr>
  </table> </div>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-10pt;padding-left:10pt">Change in fair value of financial liabilities measured at fair value</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39244" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-39245" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,017</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Issuance costs</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39246" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39247" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Interest income</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39248" name="us-gaap:InterestRevenueExpenseNet" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">153</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39249" name="us-gaap:InterestRevenueExpenseNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">114</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Foreign currency exchange loss, net</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39250" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">453</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39251" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">650</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Other</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39252" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39253" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Total financial expense (income), net</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39254" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">395</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-39255" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">396</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left">)</td> </tr>
  </table> </div> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-33847" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 6&#160;&#8212;&#160;COMMITMENTS AND CONTINGENT LIABILITIES:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">During 2009 to 2020, the Company received several
approvals from the IIA for participation in research and development activities performed by the Company (&#8220;Support Grants&#8221;)
in a total amount of $<ix:nonFraction id="Fixv-39256" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapResearchAndDevelopmentArrangementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.8</ix:nonFraction>&#160;million.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The Company is obligated to pay royalties to the IIA amounting
to <ix:nonFraction id="Fixv-39257" name="slxn:PaymentsForRoyaltiesInterest" contextRef="C_20231231_srtRangeAxis_srtMinimumMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>%-<ix:nonFraction id="Fixv-39258" name="slxn:PaymentsForRoyaltiesInterest" contextRef="C_20231231_srtRangeAxis_srtMaximumMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal" sign="-">5</ix:nonFraction>%
of the sales of the core products and other related revenues generated from such projects, up to <ix:nonFraction id="Fixv-39259" name="us-gaap:InvestmentInterestRate" contextRef="C_20231231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>%
of the Support Grants received, linked to the U.S.&#160;dollar and bearing interest at the rate of LIBOR.&#160;The obligation to pay these
royalties is contingent upon actual sales of the products and, in the absence of such sales, no payment is required. In October&#160;2023,
it was published that the interest rate on the Support Grants will be replaced with the <ix:nonNumeric id="Fixv-39260" name="slxn:SupportGrantsTerms" contextRef="C_20230101to20231231" format="ixt-sec:durmonth">12</ix:nonNumeric>-month
term Secured Overnight Financing Rate (SOFR) published on the first&#160;trading day of each calendar year.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">As of December&#160;31, 2023, the total royalty amount that
may be payable by the Company is approximately $<ix:nonFraction id="Fixv-39261" name="us-gaap:PaymentsForRoyalties" contextRef="C_20230101to20231231" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.8</ix:nonFraction>&#160;million
($<ix:nonFraction id="Fixv-39262" name="us-gaap:PaymentsForRoyalties" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSupportGrantsMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.4</ix:nonFraction>&#160;million
including interest).</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-71</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10px 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241004130933045" name="slxn:SimpleAgreementForFutureEquityTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 7&#160;&#8212;&#160;SIMPLE AGREEMENT FOR FUTURE EQUITY:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On
March&#160;15, 2021, a Simple Agreement for Future Equity (&#8220;SAFE&#8221;) was signed between the Company and a group of investors,
for an aggregate amount of up to $<ix:nonFraction id="Fixv-39263" name="slxn:AgreementAggregateAmount" contextRef="C_20210315to20210315_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapInvestorMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">4,000</ix:nonFraction>,
of which $<ix:nonFraction id="Fixv-39264" name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="C_20210315to20210315_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapInvestorMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,887</ix:nonFraction>
were actually raised. The SAFE was for a period of 9&#160;months and was convertible into preferred shares with the most senior class
of rights issued by the Company at the time of conversion.</span></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
conversion rate and timing were subject to events as determined in the SAFE, the principal amount thereon was to be converted to the most
senior class of shares of the Company in accordance with the terms mentioned in the SAFE, as follows: in an event that the Company consummates
an equity investment of at least $<ix:nonFraction id="Fixv-39265" name="us-gaap:InvestmentOwnedBalancePrincipalAmount" contextRef="C_20231231" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,000</ix:nonFraction>,
the principal amount will be converted automatically to the most senior class of equity at the lower of (i)&#160;the price per share of
the most senior shares issued in such equity investment less a <ix:nonFraction id="Fixv-39266" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="C_20231231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction>%
discount, or (ii)&#160;a price per share reflecting a fully diluted pre-money Company valuation of $<ix:nonFraction id="Fixv-39267" name="slxn:PreMoneyValuationAmount" contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">70,000</ix:nonFraction>.
However, in no event was the price per share to be lower than a price per share reflecting a fully-diluted pre-money valuation of the
Company of $<ix:nonFraction id="Fixv-39268" name="slxn:PreMoneyValuationAmount" contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction>.</span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
consideration for the SAFE agreements was $<ix:nonFraction id="Fixv-39269" name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="C_20230101to20231231" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,887</ix:nonFraction>.</span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
January&#160;14, 2022, the Company converted the SAFE in the total amount of $<ix:nonFraction id="Fixv-39270" name="us-gaap:InvestmentOwnedAtFairValue" contextRef="C_20220114" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">3,204</ix:nonFraction>
(its fair value as of conversion date) into <ix:nonFraction id="Fixv-39271" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_20220114to20220114" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">63,331</ix:nonFraction>
Series&#160;A-3 Preferred Shares and <ix:nonFraction id="Fixv-39272" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20220114_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">47,495</ix:nonFraction>&#160;warrants
exercisable into Series&#160;A-2 Preferred Shares. In accordance with ASC&#160;480 the Company recorded financial expenses in amount of
$<ix:nonFraction id="Fixv-39273" name="us-gaap:CostsAndExpenses" contextRef="C_20230101to20231231" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">317</ix:nonFraction>
with respect to the discount on the SAFE conversion.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-33895" name="us-gaap:PreferredStockTextBlock" contextRef="C_20230101to20231231" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 8&#160;&#8212;&#160;WARRANTS TO PURCHASE PREFERRED SHARES:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>a.</strong></td>
    <td style="text-align:left">In connection with the Series&#160;A-2 Preferred Shares (see Note&#160;9(b)), the Company issued warrants to acquire
        <ix:nonFraction id="Fixv-39274" name="slxn:WarrantsIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">92,953</ix:nonFraction>
        Series&#160;A-2 Preferred Shares to various investors, including <ix:nonFraction id="Fixv-39275" name="slxn:WarrantsIssued" contextRef="C_20231231" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">47,495</ix:nonFraction>&#160;warrants
        issued as part of the converted SAFE (see Note&#160;9(b)). These warrants feature an exercise price of $<ix:nonFraction id="Fixv-39276" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">60.783</ix:nonFraction>
        per share and expired during 2023. As of December&#160;31, 2022, there are <ix:nonFraction id="Fixv-39277" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20221231" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">92,953</ix:nonFraction>
        outstanding warrants. As of December&#160;31, 2023, all warrants are expired.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>b.</strong></td>
    <td style="text-align:left">Concerning the Series&#160;A-4 Preferred Shares (see Note&#160;9(b)), the Company issued warrants to acquire <ix:nonFraction id="Fixv-39278" name="slxn:WarrantsIssued" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">21,717</ix:nonFraction>
        Series&#160;A-4 Preferred Shares to various investors, with an exercise price of $<ix:nonFraction id="Fixv-39279" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">24.769</ix:nonFraction>&#160;per
        share and an expiration date of May&#160;30, 2025. Issuance expenses amounted to $<ix:nonFraction id="Fixv-39280" name="us-gaap:OtherExpenses" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction>.
        As of December&#160;31, 2023, there are outstanding warrants of <ix:nonFraction id="Fixv-39281" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20231231" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">21,717</ix:nonFraction>.
        Regarding the warrants issued to the Subsidiary see Note 9(b)(2).</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company classified the warrants for the
purchase of shares of its convertible redeemable preferred shares as a liability in its consolidated balance sheets, as these warrants
were freestanding financial instruments which underlying shares are contingently redeemable and, therefore, may obligate the Company to
transfer assets at some point in the future. The warrant liability was initially recorded at fair value upon the date of issuance and
was subsequently remeasured at fair value at each reporting date. The Company recorded revaluation expenses (income) amounting to $(<ix:nonFraction id="Fixv-39282" name="slxn:RevaluationExpensesIncome" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction>)&#160;and
$<ix:nonFraction id="Fixv-39283" name="slxn:RevaluationExpensesIncome" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,017</ix:nonFraction>&#160;for
the&#160;years ended 2023 and 2022, respectively, and accounted for such revaluation expenses as part of its financial income (expense),
net, in the statements of operations.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">For further information in respect of warrants issuance to
service provider see Note&#160;11(1).</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-72</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003124342475" name="slxn:RedeemableConvertiblePreferredSharesAndShareholdersEquityTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE&#160;9&#160;&#8212;&#160;REDEEMABLE&#160;CONVERTIBLE&#160;PREFERRED&#160;SHARES&#160;AND&#160;SHAREHOLDERS&#8217;&#160;EQUITY:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003125250255" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>a.</strong></td>
    <td style="text-align:justify"><strong>As of December 31, 2023 and 2022</strong>, <strong>the share capital is composed of <ix:nonFraction id="Fixv-39284" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>
        NIS par value shares, as follows:</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="14" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31, 2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Authorized</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Issued and<br/>paid</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Carrying<br/>Value</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Liquidation<br/>Preference</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:52%;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Ordinary Shares</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="width:9%;border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39286" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,275,000</ix:nonFraction></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="width:9%;border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39287" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">219,354</ix:nonFraction></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="width:9%;border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39288" name="us-gaap:CommonStockValue" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,685</ix:nonFraction></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:9%;padding-bottom:4pt;text-align:right">&#160;</td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Preferred A Shares</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39289" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">510,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39290" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39291" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39292" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,162</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Preferred A-1&#160;Shares</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39293" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">120,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39294" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39295" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39296" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,443</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Preferred A-2&#160;Shares</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39297" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39298" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39299" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39300" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Preferred A-3&#160;Shares</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39301" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">80,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39302" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39303" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39304" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,887</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Preferred A-4&#160;Shares</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39305" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">815,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39306" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39307" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39308" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,076</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="14" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31, 2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Authorized</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Issued and<br/>paid</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Carrying<br/>Value</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Liquidation<br/>Preference</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:52%;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Ordinary Shares</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="width:9%;border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241004135423058_ixv-39286" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">4,090,000</ix:nonFraction></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="width:9%;border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241004135423058_ixv-39287" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">219,354</ix:nonFraction></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="width:9%;border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241004135423058_ixv-39288" name="us-gaap:CommonStockValue" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,685</ix:nonFraction></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:9%;padding-bottom:4pt;text-align:right">&#160;</td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Preferred A Shares</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39312" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">510,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39313" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">388,088</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39314" name="us-gaap:PreferredStockValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39315" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,162</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Preferred A-1&#160;Shares</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39316" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">120,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39317" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">91,216</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39318" name="us-gaap:PreferredStockValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39319" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,443</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Preferred A-2&#160;Shares</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39320" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39321" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39322" name="us-gaap:PreferredStockValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39323" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Preferred A-3&#160;Shares</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39324" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">80,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39325" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39326" name="us-gaap:PreferredStockValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39327" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,887</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>b.</strong></td>
    <td style="text-align:justify"><strong>Issuance of shares:</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">1)</td>
    <td style="text-align:justify">On January&#160;14, 2022, the Company signed an agreement to issue shares in consideration for an investment
        in the amount of $<ix:nonFraction id="Fixv-39328" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20220114" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction>.
        In return for this investment, the Company issued <ix:nonFraction id="Fixv-39329" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20220114_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">45,458</ix:nonFraction>
        Series&#160;A-2 Preferred Shares with a par value of NIS <ix:nonFraction id="Fixv-39330" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>.
        Issuance expenses amounted to $<ix:nonFraction id="Fixv-39331" name="us-gaap:OtherExpenses" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction>.</td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">Following this investment, the Company converted the SAFE in the
total amount of $<ix:nonFraction id="Fixv-39332" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,204</ix:nonFraction>
into <ix:nonFraction id="Fixv-39333" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,331</ix:nonFraction>
Series&#160;A-3 Preferred Shares.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">In addition, the Company issued <ix:nonFraction id="Fixv-39334" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">92,953</ix:nonFraction>&#160;warrants
for Series&#160;A-2 Preferred Shares NIS <ix:nonFraction id="Fixv-39335" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>
par value per share, including <ix:nonFraction id="Fixv-39336" name="slxn:WarrantsIssued" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">47,495</ix:nonFraction>&#160;warrants
issued as part of the converted SAFE (see Note&#160;8(a)), each exercisable at a price of $<ix:nonFraction id="Fixv-39337" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">60.78</ix:nonFraction>
per share.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">2)</td>
    <td style="text-align:justify">On May&#160;30, 2023, the Company entered into an agreement to receive an investment in a total amount of $<ix:nonFraction id="Fixv-39338" name="us-gaap:ProceedsFromSaleOfInvestmentProjects" contextRef="C_20230530to20230530" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">538</ix:nonFraction>.
        In exchange for this investment, the Company issued <ix:nonFraction id="Fixv-39339" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20230530_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">21,717</ix:nonFraction>
        Series&#160;A-4 Preferred Shares with a par value of NIS <ix:nonFraction id="Fixv-39340" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20230530_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>.
        Issuance expenses amounted to $<ix:nonFraction id="Fixv-39341" name="us-gaap:OtherExpenses" contextRef="C_20230530to20230530_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction>.</td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">Additionally, the Company issued <ix:nonFraction id="Fixv-39342" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,717</ix:nonFraction>&#160;warrants
for Series&#160;A-4 Preferred Shares, each with a par value of NIS <ix:nonFraction id="Fixv-39343" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>,
exercisable at a price of $<ix:nonFraction id="Fixv-39344" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">24.769</ix:nonFraction>
per share.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">In addition, on May&#160;30, 2023, the Subsidiary made an investment
totaling $<ix:nonFraction id="Fixv-39345" name="us-gaap:ProceedsFromSaleOfInvestmentProjects" contextRef="C_20230530to20230530_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtSubsidiariesMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">3</ix:nonFraction>&#160;million
in the Company. This investment resulted in the acquisition by the Subsidiary of <ix:nonFraction id="Fixv-39346" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="C_20230530to20230530_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtSubsidiariesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">121,119</ix:nonFraction>
Series&#160;A-4 Preferred Shares and <ix:nonFraction id="Fixv-39347" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="C_20230530to20230530_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtSubsidiariesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">121,119</ix:nonFraction>&#160;warrants
convertible into series A-4 Preferred Shares. Each warrant is exercisable into one series A-4 Preferred Share at an exercise price of
$<ix:nonFraction id="Fixv-39348" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20230530" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">24.769</ix:nonFraction>
per share. As the acquisition was eliminated in consolidation, it had no impact on the consolidated financial statement.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-73</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE&#160;9&#160;&#8212;&#160;REDEEMABLE&#160;CONVERTIBLE&#160;PREFERRED&#160;SHARES&#160;AND&#160;SHAREHOLDERS&#8217;&#160;EQUITY:</strong>
(cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>c.</strong></td>
    <td style="text-align:justify"><strong>Shareholders rights:</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">1)</td>
    <td style="text-align:left">The Ordinary shares confer upon their holders the right to participate and vote in general shareholders meetings
        of the Company and to share in the distribution of dividends, if any declared by the Company.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">The Series&#160;A Preferred Shares, Series&#160;A-1
Preferred Shares, Series&#160;A-2 Preferred Shares, Series&#160;A-3 Preferred Shares and Series&#160;A-4 Preferred Shares (collectively,
the &#8220;Preferred A Shares&#8221;) confer upon their holders all of the rights conferred upon the holders of Ordinary Shares in the
Company, as well as the following rights:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 96pt;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:1in">&#160;</td>
    <td style="width:0.25in;text-align:left">a)</td>
    <td style="text-align:justify">Distribution Preference</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 96pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in">First, the holders of Series&#160;A-4 Preferred Shares shall
be entitled to receive, prior and in preference to any holders of Series&#160;A-3 Preferred Shares, Series&#160;A-2 Preferred Shares,
Series&#160;A-1 Preferred Shares, Series&#160;A Preferred Shares, Ordinary Shares or any other equity securities of the Company, for each
outstanding Series&#160;A-4 Preferred Share held by them, an amount equal to (i)&#160;<ix:nonFraction id="Fixv-39349" name="slxn:PercentageOfOriginalIssuedPrice" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">200</ix:nonFraction>%
of the Original Issue Price per each Series&#160;A-4 Preferred Share (in cash, cash equivalents or, if applicable, securities) plus (ii)&#160;declared
and unpaid dividend in respect of such share (the &#8220;Series&#160;A-4 Preference Amount&#8221;).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 96pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in">In the event that the distributable proceeds are insufficient
for the distribution of the Series&#160;A-4 Preference Amount in full to all holders of Series&#160;A-4 Preferred Shares, then the Distributable
Proceeds shall be distributed pari passu among such holders of Series&#160;A-4 Preferred Shares in proportion to the respective full Series&#160;A-4
Preference Amount such holders would otherwise be entitled to receive.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 96pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in">Second, the holders of Series&#160;A Preferred Shares, Series&#160;A-1
Preferred Shares, Series&#160;A-2 Preferred Shares and Series&#160;A-3 Preferred Shares, shall be entitled to receive, prior and in preference
to any holders of Ordinary Shares, for each outstanding Preferred A Share held by them, an amount equal to: (a)&#160;Series&#160;A and
Series&#160;A-1&#160;Shares&#160;&#8212;&#160;the issue price paid for such share; (b)&#160;Series&#160;A-2 preferred share&#160;&#8212;&#160;US$
<ix:nonFraction id="Fixv-39350" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">60.783</ix:nonFraction>
per each Series&#160;A-2 share, and (c)&#160;Series&#160;A-3 Preferred Shares&#160;&#8212;&#160;US$<ix:nonFraction id="Fixv-39351" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">45.587</ix:nonFraction>
per each Preferred A-3 share; plus any declared and unpaid dividend in respect of such share (the &#8220;Series&#160;A, A-1, A-2 and A-3
Preference Amount&#8221;, and together with the Series&#160;A-4 Preference Amount, the &#8220;Preference Amounts&#8221;).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 96pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in">In the event that the distributable proceeds are insufficient
for the distribution of the Series&#160;A, A-1, A-2 and A-3 Preference Amount in full to all holders of Preferred A Shares, then the Distributable
Proceeds shall be distributed pari passu among such holders of Series&#160;A Preferred Shares, Series&#160;A-1 Preferred Shares, Series&#160;A-2
Preferred Shares and Series&#160;A-3 Preferred Shares in proportion to the respective full Series&#160;A, A-1, A-2 and A-3 Preference
Amount such holders would otherwise be entitled to receive.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 96pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in">Third, following the distribution of the Preference Amounts,
any remaining distributable proceeds shall be distributed pro rata among all the holders of Ordinary Shares and Preferred A Shares, based
on their respective holdings of outstanding shares of the Company, on a pari passu and as converted basis.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-74</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE&#160;9&#160;&#8212;&#160;REDEEMABLE&#160;CONVERTIBLE&#160;PREFERRED&#160;SHARES&#160;AND&#160;SHAREHOLDERS&#8217;&#160;EQUITY:</strong>
(cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:1in">&#160;</td>
    <td style="width:0.25in;text-align:left">b)</td>
    <td style="text-align:justify">Liquidation Preference:</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 96pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in">If the Company is liquidated, dissolved or wound up (including,
without limitation, upon appointment of a receiver or liquidator to all or substantially all of the Company&#8217;s assets, whether voluntary
or involuntary), then all the assets and funds of the Company available for distribution shall first be distributed in accordance with
the Preference Amounts, and thereafter among all shareholders of the Company pro rata based on the number of Ordinary Shares and Series&#160;A
Preferred Shares held by each, on an as-converted basis.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 96pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in">For the purpose of this clause, a liquidation event also includes
(a)&#160;a merger of the Company into another corporation(s)&#160;in which the holders of the Company&#8217;s shares do not, immediately
after such merger, represent a majority of the voting power of the surviving corporation (other than a merger with a company in which
the shareholders of the Company receive stock of the surviving company which is publicly traded at the time of such merger); (b)&#160;a
sale of all or substantially all of the assets of the Company to entities not controlled by the Company&#8217;s existing shareholders;
and (c)&#160;a grant of an exclusive, irrevocable licensing of all or substantially all of the Company&#8217;s intellectual property to
a third party<i>.</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 96pt;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:1in">&#160;</td>
    <td style="width:0.25in;text-align:left">c)</td>
    <td style="text-align:justify">Dividend Preference:</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 96pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in">In the event that the Company distributes a dividend in respect
of its shares, the holders of Preferred A Shares shall be entitled to receive the Preference Amounts prior to and in preference to the
distribution of dividends to all shareholders of the Company.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 96pt;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:1in">&#160;</td>
    <td style="width:0.25in;text-align:left">d)</td>
    <td style="text-align:justify">Conversion Rights:</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 96pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in">Each Preferred A Share is convertible into Ordinary Shares.
Their number is determined by multiplying such Preferred A Share by a quotient equal to (a)&#160;the applicable Original Issue Price for
such share divided by (b)&#160;the Conversion Price (as defined below) at the time in effect for such share. The Preferred A Shares are
convertible without payment of additional consideration by the holder thereof, upon each of the following events: (i)&#160;at the option
of the holder thereof, at any time and from time to time; (ii)&#160;upon the consent of, or conversion by, the holders of a majority of
the Preferred A Shares; or (iii)&#160;immediately before the consummation of an initial public offering of the Company&#8217;s securities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 96pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in">The initial conversion price per each Preferred A Share is
the applicable Original Issue Price for such share (the &#8220;Conversion Price&#8221;). The Conversion Price per each Preferred A Share
shall be adjusted in the event of a share combination or subdivision, share split, distribution of bonus shares or any other reclassification,
reorganization or recapitalization (each, a &#8220;Recapitalization Event&#8221;), so that the holder of each Preferred A Share shall
be entitled to receive, upon conversion, such number of Ordinary Shares they would have been entitled to receive following the Recapitalization
Event had each Preferred A Share been converted into Ordinary Shares prior to the Recapitalization Event.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 96pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in">Additionally, in the event that the Company issues Additional
Shares (as such term is defined in the Company&#8217;s articles of association), for a consideration per share lower than the applicable
Conversion Price for Series&#160;A-4 Preferred Shares in effect immediately prior to such issuance (the &#8220;Reduced Price&#8221;),
then the Conversion Price for Series&#160;A-4 Preferred Shares shall be reduced, for no additional consideration, concurrently with such
issuance, to the Reduced Price.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-75</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1.25in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE&#160;9&#160;&#8212;&#160;REDEEMABLE&#160;CONVERTIBLE&#160;PREFERRED&#160;SHARES&#160;AND&#160;SHAREHOLDERS&#8217;&#160;EQUITY:</strong>
(cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>d.</strong></td>
    <td style="text-align:left"><strong>Silenseed China Minority Equityholder Rights:</strong></td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The articles of association of Silenseed (China)
Ltd. (the &#8220;Subsidiary&#8217;s Articles&#8221;) provide the minority shareholder, Guangzhou Sino-Israel Bio-industry Investment Fund
(LLP) (&#8220;GIBF&#8221;) with the following minority shareholder protections:</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">a.</td>
    <td style="text-align:left"><span style="text-decoration:underline">Conversion (&#8220;Put/Call&#8221;) Option</span>:&#160;&#160;&#160;&#160;Either
        GIBF or the Company may elect that the equity rights of GIBF in the Subsidiary shall be exchanged for the most senior shares (i.e., preferred
        shares) of the Company, consequently turning the Subsidiary into a wholly-owned subsidiary of the Company. The number of shares to be
        issued to GIBF upon such exchange shall be calculated by converting the total cash amount invested by GIBF in the Subsidiary (the &#8220;Contribution
        Amount&#8221;), into the most senior class of shares of the Company as of May&#160;30, 2023, based on a pre-money valuation of the Company
        of US$<ix:nonFraction id="Fixv-39352" name="us-gaap:OptionContractIndexedToEquitySettlementShareFairValue" contextRef="C_20230530" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">20</ix:nonFraction>&#160;million
        on a fully diluted basis as of September&#160;1, 2023, or later, as shall be mutually agreed between the parties.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">b.</td>
    <td style="text-align:left">&#8220;Company Exit Event&#8221; means the consummation of: (i)&#160;an initial public offering of Company, in
        a stock exchange, directly or via a SPAC (or similar methods); (ii)&#160;the sale of all or substantially all of the securities or assets
        of the Company (or an exclusive license with respect to all or substantially all of the assets of Company); (iii)&#160;a merger or acquisition
        of the Company (following which existing shareholders as of immediately prior to such transaction hold less than <ix:nonFraction id="Fixv-39353" name="us-gaap:VariableInterestEntityOwnershipPercentage" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction>%
        of the voting power of the surviving or acquiring entity); (iv)&#160;sale of at least <ix:nonFraction id="Fixv-39354" name="slxn:PercentageOfSaleOfAssets" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction>%
        of the means of control or assets of the Company; (v)&#160;liquidation, dissolution or winding up of the Company; or (vi)&#160;at any
        time upon a party&#8217;s written notice, provided, however that the exercise of such right by the Company shall be subject to GIBF&#8217;s
        written consent, which shall not be unreasonably withheld.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">1)</td>
    <td style="text-align:left"><span style="text-decoration:underline">Anti-Dilution Protection</span>:&#160;If the Subsidiary issues any additional
        equity rights in the Subsidiary to a third-party investor in the next two equity investment rounds of the Subsidiary, reflecting a purchase
        price per equity right lower than the purchase price per equity right paid by GIBF, GIBF will be issued additional equity rights of the
        Subsidiary for no consideration, based on a broad based weighted average formula.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">2)</td>
    <td style="text-align:left"><span style="text-decoration:underline">Registration Rights</span>:&#160;GIBF shall be entitled to the same rights
        to register its equity rights in the Subsidiary as part of an IPO of the Subsidiary, as granted to Company, on a pro-rata basis.</td>
        </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">3)</td>
    <td style="text-align:left"><span style="text-decoration:underline">Liquidation Preference</span>:&#160;In the event of an IPO in which the
        Subsidiary&#8217;s valuation is at least $<ix:nonFraction id="Fixv-39355" name="us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">200</ix:nonFraction>&#160;million
        or an Exit Event (as defined in the Subsidiary&#8217;s Articles), GIBF shall be entitled to be paid out of the assets legally available
        for distribution to equity holders of the Subsidiary (the &#8220;Distributable Proceeds&#8221;), prior to any payment made to any other
        equity holder, an amount in cash equal to the Contribution Amount (the &#8220;Preference Amount&#8221;). Following payment of the Preference
        Amount, any remaining Distributable Proceeds shall be distributed among all holders of equity rights excluding GIBF, on a pro-rata basis,
        provided that GIBF shall have the right to waive its right to receive the Preference Amount, in which case all Distributable Proceeds
        shall be distributed among all equity holders of the Subsidiary on a pari passu and pro rata basis.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.75in">&#160;</td>
    <td style="width:0.25in;text-align:left">4)</td>
    <td style="text-align:left">Other rights, such as right of first refusal for GIBF to purchase the Company&#8217;s equity rights in the Subsidiary
        if the Company proposes to sell or receives an offer to sell its equity rights; a right of co-sale for GIBF to participate in a proposed
        sale of the Company&#8217;s equity rights in the Subsidiary on a pro-rata basis; a preemptive right for both investors to participate
        in the issuance of new securities by the Subsidiary until the consummation of an IPO or an Exit Event (as defined in the Subsidiary&#8217;s
        Articles).</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-76</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="margin-top:0;margin-bottom:0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p> </div> <ix:nonNumeric id="Fxbrl_20241003125143189" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 10&#160;&#8212;&#160;INCOME TAXES:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>a.</strong></td>
    <td style="text-align:justify"><strong>Corporate taxation in Israel</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company is taxed according to the regular corporate income
tax in Israel. The corporate tax rate is <ix:nonFraction id="Fxbrl_20241003125013334" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20220101to20221231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39356" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></ix:nonFraction>%
in 2023 and 2022.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>b.</strong></td>
    <td style="text-align:justify"><strong>Income taxes on non-Israeli&#160;subsidiary</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Subsidiary is taxed under the tax laws of China and the
corporate tax rate is <ix:nonFraction id="Fixv-39358" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryCN" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction>%.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>c.</strong></td>
    <td style="text-align:justify"><strong>Tax loss carryforwards</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">As of December&#160;31, 2023, the expected tax loss carryforwards
of the Company were approximately $<ix:nonFraction id="Fixv-39359" name="us-gaap:OperatingLossCarryforwards" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,151</ix:nonFraction>,
which may be carried forward and offset against taxable income in the future for an indefinite period. The Company has recognized valuation
allowance for the full amount in respect of these tax loss carryforwards since their utilization is not expected in the foreseeable future.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Israel and foreign components of loss from continuing operations,
before income taxes consisted of:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003125203061" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year ended<br/>December&#160;31</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-indent:-10pt;padding-left:10pt">Israel</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39361" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryIL" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,769</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39362" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryIL" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,929</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Subsidiary outside of Israel</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39363" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_slxnSubsidiaryOutsideOfIsraelMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">307</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39364" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_slxnSubsidiaryOutsideOfIsraelMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">535</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Total</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39365" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,076</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39366" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,464</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>d.</strong></td>
    <td style="text-align:justify"><strong>Uncertainty in income tax</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">As of December&#160;31, 2023 and 2022, no liability for unrecognized
tax benefits was recorded due to immateriality.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>e.</strong></td>
    <td style="text-align:justify"><strong>Tax rate reconciliation</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Income tax expense attributable to income from continuing operations
was $<ix:nonFraction id="Fixv-39367" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction>
and $<ix:nonFraction id="Fixv-39368" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction>
for the&#160;years ended December&#160;31, 2023 and 2022, respectively, and differed from the amounts computed by applying an Israeli
Statutory income tax rate of <ix:nonFraction id="Fixv-39369" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction>%
to pretax income from continuing operations, mainly as a result of changes in valuation allowance of $<ix:nonFraction id="Fixv-39370" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">922</ix:nonFraction>
and $<ix:nonFraction id="Fixv-39371" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction>
respectively, as well as nondeductible expenses.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The reconciliation of the theoretical tax benefit (expense)
by the Israeli statutory tax rate to the Company&#8217;s effective benefit (expense) taxes are as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003125255801" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year ended<br/>December&#160;31</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-10pt;padding-left:10pt">Loss before income taxes</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-39373" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,076</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-39374" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,464</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Statutory tax rate</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39375" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">%</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39376" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Computed &#8220;expected&#8221; tax income</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39377" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,167</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39378" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">797</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Exchange rate differences</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39379" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39380" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">588</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Non-deductible share-based compensation</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39381" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39382" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Non-deductible financial instruments valuation</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39383" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39384" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">215</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Effect of other non-deductible differences</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39385" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39386" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">162</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Change in valuation allowance</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39387" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">922</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39388" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Subsidiary tax rate differences</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39389" name="us-gaap:IncomeLossFromSubsidiariesTaxExpenseBenefit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39390" name="us-gaap:IncomeLossFromSubsidiariesTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Reported taxes on income</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39391" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39392" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </ix:nonNumeric>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-77</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<p style="text-align:center;margin-top:10pt;margin-bottom:0px"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS
IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 10&#160;&#8212;&#160;INCOME TAXES:&#160;</strong>(cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>f.</strong></td>
    <td style="text-align:justify"><strong>Deferred tax</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Deferred taxes reflect the net tax effects of temporary differences
between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
Significant components of the Company&#8217;s deferred tax assets are as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p> </div> <ix:nonNumeric id="Fxbrl_20241003125333292" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font-weight:bold">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">December&#160;31</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;border-bottom:Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;border-bottom:Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Deferred tax assets</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-10pt;padding-left:20pt">Operating loss carryforwards</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39394" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,405</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39395" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,752</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:20pt">Research and development</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39396" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">780</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39397" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">592</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:20pt">Accrued expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39398" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">304</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39399" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">219</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:20pt">Lease liability</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39400" name="slxn:DeferredTaxAssetsLeaseLiability" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39401" name="slxn:DeferredTaxAssetsLeaseLiability" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt;text-indent:-10pt;padding-left:20pt">Other</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39402" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39403" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Total deferred tax assets</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39404" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,553</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39405" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,655</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Deferred tax liabilities</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:20pt">Right of use asset</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39406" name="us-gaap:DeferredTaxLiabilitiesOtherFiniteLivedAssets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39407" name="us-gaap:DeferredTaxLiabilitiesOtherFiniteLivedAssets" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Total deferred tax liabilities</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39408" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39409" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Valuation allowance</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39410" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,507</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39411" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,585</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Deferred tax assets, net of valuation
        allowance</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241004175710019" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20231231" unitRef="usd" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241004175729646" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20221231" unitRef="usd" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>g.</strong></td>
    <td style="text-align:justify"><strong>Roll forward of valuation allowance:</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The following table presents a reconciliation of the beginning
and ending valuation allowance:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003125350553" name="us-gaap:SummaryOfValuationAllowanceTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom;background-color:#CCEEFF">
    <td style="width:86%;padding-left:10pt;text-indent:-10pt"><span style="font-size:10pt">Balance as of December&#160;31, 2021</span></td>
    <td style="white-space:nowrap;width:1%;padding-bottom:2.25pt">&#160;</td>
    <td style="white-space:nowrap;width:1%"><span style="font-size:10pt">$</span></td>
    <td style="width:11%;text-align:right"><span style="font-size:10pt">(<ix:nonFraction id="Fixv-39413" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,317</ix:nonFraction></span></td>
    <td style="white-space:nowrap;width:1%"><span style="font-size:10pt">)</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:10pt;text-indent:-10pt"><span style="font-size:10pt">Additions</span></td>
    <td style="white-space:nowrap;padding-bottom:2.25pt">&#160;</td>
    <td style="white-space:nowrap;border-bottom:Black 1pt solid;text-align:right">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right"><span style="font-size:10pt">(<ix:nonFraction id="Fixv-39414" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></td>
    <td style="white-space:nowrap"><span style="font-size:10pt">)</span></td> </tr>
  <tr style="vertical-align:bottom;background-color:#CCEEFF">
    <td style="padding-left:10pt;text-indent:-10pt"><span style="font-size:10pt">Balance as of December&#160;31, 2022</span></td>
    <td style="white-space:nowrap;padding-bottom:2.25pt">&#160;</td>
    <td style="white-space:nowrap"><span style="font-size:10pt">$</span></td>
    <td style="text-align:right"><span style="font-size:10pt">(<ix:nonFraction id="Fixv-39415" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,585</ix:nonFraction></span></td>
    <td style="white-space:nowrap"><span style="font-size:10pt">)</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:10pt;text-indent:-10pt"><span style="font-size:10pt">Additions</span></td>
    <td style="white-space:nowrap;padding-bottom:2.25pt">&#160;</td>
    <td style="white-space:nowrap;border-bottom:Black 1pt solid;text-align:right">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right"><span style="font-size:10pt">(<ix:nonFraction id="Fixv-39416" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">922</ix:nonFraction></span></td>
    <td style="white-space:nowrap"><span style="font-size:10pt">)</span></td> </tr>
  <tr style="vertical-align:bottom;background-color:#CCEEFF">
    <td style="padding-left:10pt;text-indent:-10pt"><span style="font-size:10pt">Balance as of December&#160;31, 2023</span></td>
    <td style="white-space:nowrap;padding-bottom:2.25pt">&#160;</td>
    <td style="white-space:nowrap;border-bottom:black 2.25pt double"><span style="font-size:10pt">$</span></td>
    <td style="border-bottom:black 2.25pt double;text-align:right"><span style="font-size:10pt">(<ix:nonFraction id="Fixv-39417" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,507</ix:nonFraction></span></td>
    <td style="white-space:nowrap"><span style="font-size:10pt">)</span></td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">In assessing the realization of deferred tax assets, management
considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. The ultimate realization
of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences
are deductible and net operating losses are utilized. Based on these factors, the Company recorded a full valuation allowance on December&#160;31,
2023 and 2022.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>h.</strong></td>
    <td style="text-align:justify"><strong>Income tax assessments</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company has tax assessments that are considered to be final
through tax year 2018. The subsidiary does not have final tax assessments.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-78</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003133934065" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 11&#160;&#8212;&#160;SHARE-BASED COMPENSATION:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>1)</strong></td>
    <td style="text-align:justify"><strong>Warrants to service provider</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">In conjunction with the issuance of Series&#160;A-1 Preferred
Shares, the Company issued warrants to acquire <ix:nonFraction id="Fixv-39418" name="slxn:WarrantsIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">3,837</ix:nonFraction>
Series&#160;A-1 Preferred Shares to a service provider who assisted in raising the funds, which warrants were classified as part of the
issue expenses. These warrants carry an exercise price of $<ix:nonFraction id="Fixv-39419" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">26.78</ix:nonFraction>
per share and are set to expire on January&#160;31, 2027. As of December&#160;31, 2023 and 2022, all <ix:nonFraction id="Fxbrl_20241003172646605" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39420" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">3,837</ix:nonFraction></ix:nonFraction>
of such warrants remained outstanding.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">In conjunction with the issuance of Series&#160;A-2 Preferred
Shares, the Company issued warrants to acquire <ix:nonFraction id="Fixv-39422" name="slxn:WarrantsIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">4,009</ix:nonFraction>
Series&#160;A-3 Preferred Shares to a service provider who assisted in raising the funds, which were recorded as part of issue expenses.
These warrants carry an exercise price of $<ix:nonFraction id="Fixv-39423" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">45.587</ix:nonFraction>
per share and are set to expire on January&#160;14, 2029. As of December&#160;31, 2023 and 2022, all <ix:nonFraction id="Fxbrl_20241003172656716" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39424" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">4,009</ix:nonFraction></ix:nonFraction>
of such warrants remained outstanding.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The warrants for both the Series&#160;A-1 Preferred Shares
and Series&#160;A-3 Preferred Shares were recognized as issuance costs of the SAFE round and recognized as financial expenses.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">In conjunction with the issuance of Series&#160;A-4 Preferred
Shares, the Company issued warrants to acquire <ix:nonFraction id="Fixv-39426" name="slxn:WarrantsIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">107</ix:nonFraction>
Series&#160;A-4 Preferred Shares to a service provider who assisted in raising the funds, which were recorded as part of issue expenses.
These warrants carry an exercise price as those issued to the investors in such round, and expire on May&#160;30, 2030. As of December&#160;31,
2023, all <ix:nonFraction id="Fixv-39427" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">107</ix:nonFraction>
of such warrants remained outstanding. The warrants were recognized as issuance costs and the portion attributed to the issuance of Series&#160;A-4
Preferred Shares was classified as part of the shareholders&#8217; equity. The portion attributed to the issuance of the warrants was
recognized as financial expenses.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>2)</strong></td>
    <td style="text-align:justify"><strong>Employee Stock Option Plan</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">As of December&#160;31, 2023, the&#160;Board of Directors approved
a pool of&#160;<ix:nonFraction id="Fixv-39428" name="srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" contextRef="C_20231231" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">130,889</ix:nonFraction>&#160;Ordinary
Shares for grant to Company employees, consultants, directors and other service providers.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Under the Company&#8217;s 2013 and 2023 Incentive Option Plans
(collectively &#8220;the Plan&#8221;), options to purchase Ordinary Shares may be granted to certain entities and individuals. Each option
granted under the Plan is exercisable until <ix:nonNumeric id="Fixv-39429" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20230101to20231231" format="ixt-sec:durwordsen">10
years</ix:nonNumeric> from the date of grant, or earlier upon cessation of employment or engagement of the grantee and certain other occurrences.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Grants to employees are made in accordance with the Plan and
are carried out within the provisions of Section&#160;102 of the Israel Income Tax Ordinance, under the capital gains track described
in subsection&#160;(b)(2) of Section&#160;102. In accordance with such track selected by the Company and the provisions associated with
it, the Company is not entitled to claim a tax deduction for the employee benefits.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The Company&#8217;s options expenses amounted to a total of
$<ix:nonFraction id="Fixv-39430" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction>
and $<ix:nonFraction id="Fixv-39431" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction>
in 2023 and 2022, respectively. As of December&#160;31, 2023, <ix:nonFraction id="Fixv-39432" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20231231" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">9,081</ix:nonFraction>
shares remain available for grant under the Plan.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-79</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 11&#160;&#8212;&#160;SHARE-BASED COMPENSATION:</strong>
(cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong>Summary of outstanding and exercisable options:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">Below is a summary of the Company&#8217;s stock-based compensation
activity and related information with respect to options granted to employees and non-employees for the year ended December 31, 2023 and
2022:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003133703146" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Number of<br/>options</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Weighted-<br/>average<br/>exercise price<br/>(in
        U.S.&#160;dollars)</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term<br/>(in&#160;years)</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Aggregate<br/>intrinsic<br/>value</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:52%;text-indent:-10pt;padding-left:10pt">Outstanding at December&#160;31, 2022</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39434" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">122,308</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39435" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">17.229</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonNumeric id="Fixv-39436" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231" format="ixt-sec:duryear">5.88</ix:nonNumeric></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39437" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-10pt;padding-left:10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004180038872" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230101to20231231" unitRef="shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004180346232" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="-sec-ix-hidden:Fxbrl_20241004180444170">&#8212;</span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">&#8212;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-10pt;padding-left:10pt">Exercised</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004181103978" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20230101to20231231" unitRef="shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004180400355" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="-sec-ix-hidden:Fxbrl_20241004180513328">&#8212;</span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">&#8212;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-10pt;padding-left:10pt">Forfeited</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004180121864" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20230101to20231231" unitRef="shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004180418757" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="-sec-ix-hidden:Fxbrl_20241004180602489">&#8212;</span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">&#8212;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Expired</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39438" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_20230101to20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39439" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="-sec-ix-hidden:Fxbrl_20241004180730561">&#8212;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#8212;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Outstanding at December&#160;31, 2023</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39440" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">121,808</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39441" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20231231" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">17.231</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonNumeric id="Fixv-39442" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20230101to20231231" format="ixt-sec:duryear">4.88</ix:nonNumeric></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39443" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Exercisable at December&#160;31, 2023</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39444" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">88,895</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39445" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_20231231" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">13.696</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonNumeric id="Fixv-39446" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExercisable" contextRef="C_20230101to20231231" format="ixt-sec:duryear">3.62</ix:nonNumeric></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39447" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Vested and expected to vest at December&#160;31, 2023</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39448" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">121,808</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39449" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_20231231" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">17.231</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonNumeric id="Fixv-39450" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermVestedAndExpectedToVest" contextRef="C_20230101to20231231" format="ixt-sec:duryear">4.88</ix:nonNumeric></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39451" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAggregateIntrinsicValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Number of<br/>options</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Weighted-<br/>average<br/>exercise price<br/>(in
        U.S.&#160;dollars)</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term<br/>(in&#160;years)</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Aggregate<br/>intrinsic<br/>value</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:52%;text-indent:-10pt;padding-left:10pt">Outstanding at December&#160;31, 2021</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39452" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">72,058</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39453" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20211231" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">10.568</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonNumeric id="Fixv-39454" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20210101to20211231" format="ixt-sec:duryear">4.46</ix:nonNumeric></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39455" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">493</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-10pt;padding-left:10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39456" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">54,500</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39457" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">26.780</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonNumeric id="Fixv-39458" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermGranted" contextRef="C_20220101to20221231" format="ixt-sec:duryear">9.98</ix:nonNumeric></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">&#8212;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-10pt;padding-left:10pt">Exercised</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39459" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">103</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39460" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">26.771</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonNumeric id="Fixv-39461" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExercised" contextRef="C_20220101to20221231" format="ixt-sec:duryear">8.22</ix:nonNumeric></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">&#8212;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-10pt;padding-left:10pt">Forfeited</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39462" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,548</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39463" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">26.775</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonNumeric id="Fixv-39464" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermForfeited" contextRef="C_20220101to20221231" format="ixt-sec:duryear">9.18</ix:nonNumeric></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">&#8212;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Expired</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39465" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,599</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39466" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="-sec-ix-hidden:Fxbrl_20241004180813329">&#8212;</span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#8212;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Outstanding at December&#160;31, 2022</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39467" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">122,308</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39468" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">17.229</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonNumeric id="Fixv-39469" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231" format="ixt-sec:duryear">5.88</ix:nonNumeric></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39470" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Exercisable at December&#160;31, 2022</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39471" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">69,318</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39472" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_20221231" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">9.939</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonNumeric id="Fixv-39473" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExercisable" contextRef="C_20220101to20221231" format="ixt-sec:duryear">3.29</ix:nonNumeric></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39474" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Vested and expected to vest at December&#160;31, 2022</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39475" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">122,308</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39476" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_20221231" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">17.229</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonNumeric id="Fixv-39477" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermVestedAndExpectedToVest" contextRef="C_20220101to20221231" format="ixt-sec:duryear">5.88</ix:nonNumeric></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39478" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAggregateIntrinsicValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-80</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="margin-top:0;margin-bottom:0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 11&#160;&#8212;&#160;SHARE-BASED COMPENSATION:</strong>
(cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The fair value for options granted in 2022 is
estimated at the date of grant using a Black-Scholes option pricing model based on the following assumptions:</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003133717616" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year ended<br/>December&#160;31,<br/>2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold">Employees</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Expected term (in&#160;years)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><ix:nonNumeric id="Fixv-39480" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear">6.05</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric id="Fixv-39481" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear">10.00</ix:nonNumeric></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Expected volatility</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39482" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">82.97</ix:nonFraction>%&#160;&#8211;&#160;<ix:nonFraction id="Fixv-39483" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">88.45</ix:nonFraction></span></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Risk-free interest rate</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39484" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.31</ix:nonFraction>%&#160;&#8211;&#160;<ix:nonFraction id="Fixv-39485" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.90</ix:nonFraction></span></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="width:88%;text-align:left;text-indent:-10pt;padding-left:10pt">Expected dividend yield</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39486" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
    <td style="width:1%;text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-10pt;padding-left:10pt">Exercise price</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39487" name="us-gaap:SharePrice" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">26.78</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-indent:-10pt;padding-left:10pt">Non-Employees</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Expected term (in&#160;years)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonNumeric id="Fixv-39488" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear">9.78</ix:nonNumeric></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Expected volatility</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39489" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">88.46</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Risk-free interest rate</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39490" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.31</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Expected dividend yield</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39491" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-10pt;padding-left:10pt">Exercise price</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39492" name="us-gaap:SharePrice" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">26.78</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The option-pricing model requires a number of assumptions, of
which the most significant are the expected stock price volatility and the expected option term. Since the Company is not traded, the
expected volatility was based on the average volatility rate of <ix:nonFraction id="Fixv-39493" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction>
public companies in the healthcare industry.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The expected term of options granted represents the period during
which options granted are expected to remain outstanding. The risk-free interest rate is based on the yield from U.S.&#160;treasury bonds
with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. The Company uses
the simplified method for nonexecutive employees, due to insufficient historical exercise experience&#8221;.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The fair value of options granted during 2022 was $<ix:nonFraction id="Fixv-39494" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20231231" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">529</ix:nonFraction>.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong>Options granted to employees and non-employees:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">In 2023 no options were granted, neither to employees nor to
non-employees.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">In the year ended December 31, 2022, the Company granted options
as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003133729813" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="12" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year ended December&#160;31, 2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Award<br/>amount</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Exercise<br/>price</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Vesting<br/>period</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Expiration</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:20%;text-indent:-10pt;padding-left:10pt">Employees</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:17%;text-align:right"><ix:nonFraction id="Fixv-39496" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">52,500</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:17%;text-align:right"><ix:nonFraction id="Fixv-39497" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">26.78</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:19%;text-align:center"><ix:nonNumeric id="Fixv-39498" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">up
        to 4 years</ix:nonNumeric></td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:17%;text-align:right"><span style="font-size:10pt"><ix:nonNumeric id="Fixv-39499" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear">10</ix:nonNumeric>&#160;years</span></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Non-employees</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39500" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:right"><ix:nonFraction id="Fixv-39501" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">26.78</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt"><ix:nonNumeric id="Fixv-39502" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember">Immediate</ix:nonNumeric></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:right"><span style="font-size:10pt"><ix:nonNumeric id="Fixv-39503" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear">10</ix:nonNumeric>&#160;years</span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:20pt">Total granted</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39504" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">54,500</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt;text-align:right">&#160;</td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt;text-align:right">&#160;</td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-81</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="margin-top:0;margin-bottom:0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 11&#160;&#8212;&#160;SHARE-BASED COMPENSATION:</strong>
(cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong><i>Summary of status of the Company&#8217;s nonvested
employee options:</i></strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003133814702" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The following table summarizes the number of
options outstanding for the years ended December 31, 2023 and December 31, 2022, and related information:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Number of<br/>options</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Weighted-<br/>average<br/>grant-date<br/>fair
        value<br/>price</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-indent:-10pt;padding-left:10pt">Outstanding at December&#160;31, 2022</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39506" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">52,858</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39507" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">9.59</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-10pt;padding-left:10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004181710958" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004181721280" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-10pt;padding-left:10pt">Vested</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39508" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">19,945</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39509" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">9.56</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Forfeited</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004181746879" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004181757727" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Outstanding at December&#160;31, 2023</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39510" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">32,913</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39511" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">9.61</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-10pt;padding-left:10pt">Outstanding at December&#160;31, 2021</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39512" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">4,464</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39513" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20211231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">7.67</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-10pt;padding-left:10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39514" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">52,500</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39515" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">9.63</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-10pt;padding-left:10pt">Vested</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39516" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,558</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39517" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">7.10</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Forfeited</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-39518" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,548</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39519" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">8.56</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Outstanding at December&#160;31, 2022</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39520" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">52,858</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39521" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">9.59</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong><i>&#160;</i></strong></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong><i>Summary of status of the Company&#8217;s
nonvested nonemployee options:</i></strong></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The following table summarizes the number of
options outstanding for the&#160;years ended December&#160;31, 2023 and December&#160;31, 2022, and related information:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Number of<br/>options</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Weighted-<br/>average<br/>grant-date<br/>fair
        value<br/>price</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-indent:-10pt;padding-left:10pt">Outstanding at December&#160;31, 2022</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39523" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39524" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">4.96</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-10pt;padding-left:10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004181903463" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004182010410" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20230101to20231231" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-10pt;padding-left:10pt">Vested</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39525" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39526" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">4.96</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Forfeited</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004182039944" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004182203466" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Outstanding at December&#160;31, 2023</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241004154226870" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241004154221174" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-10pt;padding-left:10pt">Outstanding at December&#160;31, 2021</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39527" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">304</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39528" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20211231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">4.91</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-10pt;padding-left:10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39529" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39530" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">11.93</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-10pt;padding-left:10pt">Vested</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39531" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,172</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39532" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">11.37</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Forfeited</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004182247732" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004182309732" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Outstanding at December&#160;31, 2022</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39533" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39534" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">4.96</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">On December&#160;31, 2023, there was $<ix:nonFraction id="Fixv-39535" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">284</ix:nonFraction>
of total unrecognized compensation cost related to unvested stock options granted under the Plan. That cost is expected to be recognized
over a weighted-average period of <ix:nonNumeric id="Fixv-39536" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_20230101to20231231" format="ixt-sec:duryear">2.22</ix:nonNumeric>&#160;years.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">On December&#160;31, 2022, there was $<ix:nonFraction id="Fixv-39537" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">414</ix:nonFraction>
of total unrecognized compensation cost related to unvested stock options granted under the Plan. That cost is expected to be recognized
over a weighted-average period of <ix:nonNumeric id="Fixv-39538" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_20220101to20221231" format="ixt-sec:duryear">3.20</ix:nonNumeric>&#160;years.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-82</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 11&#160;&#8212;&#160;SHARE-BASED COMPENSATION:</strong>
(cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The share-based compensation expense by line item in the accompanying
consolidated statements of operations is summarized as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003133829697" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year ended<br/>December&#160;31</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-10pt;padding-left:10pt">Research and development</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39540" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39541" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">General and administrative</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39542" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39543" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39544" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39545" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003134215050" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 12&#160;&#8212;&#160;FAIR VALUE MEASUREMENTS:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong>Financial instruments measured at fair value on a recurring
basis</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The Company&#8217;s assets and liabilities that are measured
at fair value as of December&#160;31, 2023, and December&#160;31, 2022, are classified in the tables below in one of the three categories
described in &#8220;Note&#160;2&#160;&#8212;&#160;Fair value measurement&#8221; above:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003134027716" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31, 2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Level 3</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Total</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold">Financial Liabilities</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;width:76%;text-align:left">Warrants to preferred shares</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39547" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39548" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31, 2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Level 3</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Total</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold">Financial Liabilities</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-10pt;padding-left:0.25in">Warrants to preferred shares</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39549" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39550" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The following is a roll forward of the fair value of liabilities
classified under Level 3:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003134051076" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="font-weight:bold;text-align:center">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Warrants</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Warrants</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">SAFE</td>
    <td style="font-weight:bold;text-align:center">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:64%;text-align:left;text-indent:-10pt;padding-left:10pt">Fair value at the beginning of the year</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39552" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fxbrl_20241003165238872" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20211231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39553" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20211231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,204</ix:nonFraction></td>
    <td style="width:9%;text-align:right">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-10pt;padding-left:10pt">Issuance</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39554" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39555" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20220101to20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,020</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003164939845" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20220101to20221231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:right">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Change in fair value</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39556" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-39557" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20220101to20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,017</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241003164951094" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20220101to20221231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:right">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">Conversion to equity</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241003165006518" name="us-gaap:InvestmentOwnedAtFairValue" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241003165002830" name="us-gaap:InvestmentOwnedAtFairValue" contextRef="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39558" name="us-gaap:InvestmentOwnedAtFairValue" contextRef="C_20221231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,204</ix:nonFraction></span></span></td>
    <td style="padding-bottom:2px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Fair value at the end of the year</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39559" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39560" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241003165050663" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:right">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The fair value of the Company&#8217;s warrant liabilities as
of December&#160;31, 2023 was estimated using a hybrid model in order to reflect two scenarios: (1)&#160;an IPO event (including de-SPAC
transaction) and (2)&#160;other liquidation events.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The IPO scenario (including de-SPAC transaction) was based on
management estimation regarding the expected value of the Company&#8217;s entire equity at the IPO event (including de-SPAC transaction).
Valuation under this scenario was assessed using the probability-weighted expected return method (PWERM).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The valuation under the &#8216;other liquidation events&#8217;
scenario was assessed using an option pricing model (OPM) by implementing a Monte Carlo Simulation, which treats the financial instruments
in the Company&#8217;s equity as contingent claims whose future payoff depends on the Company&#8217;s future equity value. The Company&#8217;s
entire equity value in 2023 was calculated based, among others, on the financing round closest to the valuation date.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The fair value of the Company&#8217;s warrant liabilities as
of December&#160;31, 2022 was estimated using only the &#8216;other liquidation events&#8217; scenario.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-83</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 12&#160;&#8212;&#160;FAIR VALUE MEASUREMENTS:</strong>
(cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">Application of these approaches and methodologies involves the
use of estimates, judgments and assumptions that are highly complex and subjective, such as those regarding discount rates, the selection
of comparable public companies, and the probability of and timing associated with possible future events.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The following table presents the main assumptions used in the
hybrid model for the periods presented:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003134106325" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-10pt;padding-left:10pt">Expected volatility</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39562" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">73.8</ix:nonFraction></td>
    <td style="width:1%;text-align:left">%</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39563" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">87.3</ix:nonFraction></td>
    <td style="width:1%;text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Assumptions regarding the price of the underlying shares:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Probability of an IPO scenario (including de-SPAC transaction)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39564" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfAnIPOScenarioMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004181405487" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfAnIPOScenarioMember" unitRef="pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Expected time to IPO (including de-SPAC transaction) (years)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonNumeric id="Fixv-39565" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToIPOMember" format="ixt-sec:duryear">0.414</ix:nonNumeric></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="-sec-ix-hidden:Fxbrl_20241004181424317">&#8212;</span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Probability of other liquidation events</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39566" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfOtherLiquidationEventsMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39567" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfOtherLiquidationEventsMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Expected time to liquidation (years)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonNumeric id="Fixv-39568" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToLiquidationMember" format="ixt-sec:duryear">2.75</ix:nonNumeric></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonNumeric id="Fixv-39569" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToLiquidationMember" format="ixt-sec:duryear">3.00</ix:nonNumeric></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Expected return on Equity</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39570" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnExpectedReturnOnEquityMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39571" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnExpectedReturnOnEquityMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">A significant increase in the expected volatility, or in the
probability of an IPO (including de-SPAC transaction) (in 2023), could each increase the fair value of the related instruments. A significant
decrease in the expected term of the warrants or expected time to IPO (including de-SPAC transaction), could each decrease the fair value
of related instruments. In combination, changes in these inputs could result in a significantly higher or lower fair value measurement
if the input changes were to be compounding, or could result in a minimally higher or lower fair value measurement if the input changes
were of opposite effects and consequently offset each other.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong>Financial instruments not measured at fair value</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The carrying amounts of cash and cash equivalents, restricted
cash, receivables, trade payables and other liabilities approximate their fair value due to the short-term maturity of such instruments.</p>
</div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003134506355" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 13&#160;&#8212;&#160;NET LOSS PER SHARE:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241004104651710" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The following table sets forth the computation of basic and
diluted net loss per share attributable to ordinary shareholders for the periods presented (USD in thousands, except per share data):</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year ended<br/>December&#160;31</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold">Numerator:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.25in;width:76%;text-align:left">Net loss for the year</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39573" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,108</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39574" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,488</ix:nonFraction></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in;text-align:left">Net loss attributable to ordinary shareholders, basic and diluted:</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39575" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,942</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39576" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,215</ix:nonFraction></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in;text-align:left;padding-bottom:4pt">Weighted-average shares used in computing net loss
        per share attributable to ordinary shareholders, basic and diluted</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39577" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">252,462</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39578" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">252,371</ix:nonFraction></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.25in;text-align:left;padding-bottom:4pt">Net loss per share attributable to ordinary shareholders,
        basic and diluted</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39579" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">19.57</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39580" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">12.74</ix:nonFraction></td>
        </tr>
  </table> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">Basic loss per share is computed on the basis of the net loss
for the period divided by the weighted average number of ordinary shares outstanding during the period, and fully vested Pre-Funded options
for the Company&#8217;s ordinary shares at an exercise price of $<ix:nonFraction id="Fixv-39581" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>
or <ix:nonFraction id="Fixv-39582" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>
NIS per share, as the Company considers these shares to be exercised for little to no additional consideration.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-84</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 13&#160;&#8212;&#160;NET LOSS PER SHARE:</strong>
(cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">As of December 31, 2023 and 2022, the basic loss per share calculation
included a weighted average number of <ix:nonFraction id="Fxbrl_20241003172727748" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_slxnPreFundedOptionsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39583" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_slxnPreFundedOptionsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">33,108</ix:nonFraction></ix:nonFraction>
of fully vested Pre-Funded options. As the inclusion of shares of ordinary shares equivalents in the calculation would be anti-dilutive
for all periods presented, diluted net loss per share is the same as basic net loss per share.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The following instruments were not included in the computation
of diluted earnings per share because of their anti-dilutive effect:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">&#9679;</td>
    <td style="text-align:justify">Redeemable convertible preferred shares (see Note&#160;9);</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">&#9679;</td>
    <td style="text-align:justify">Warrants to purchase redeemable convertible preferred shares (see Note&#160;8);</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">&#9679;</td>
    <td style="text-align:justify">Simple agreements for future equity (see Note&#160;7);</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">&#9679;</td>
    <td style="text-align:justify">Share-based compensation issuable at substantial consideration (see Note&#160;11).</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-36481" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 14&#160;&#8212;&#160;TRANSACTIONS AND BALANCES WITH RELATED
PARTIES:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">Transactions with related parties which are shareholders and
directors of the Company:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>a.</strong></td>
    <td style="text-align:justify"><strong>Transactions:</strong></td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003134535671" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year ended<br/>December&#160;31</td>
    <td style="font-weight:bold;text-align:center">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="font-weight:bold;text-align:center">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-10pt;padding-left:10pt">Share-based compensation included in research and development expenses</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39585" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39586" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
    <td style="width:9%;text-align:right">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Share-based compensation included in general and administrative expenses</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39587" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39588" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
    <td style="text-align:right">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Financial expenses</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39589" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241004095132391" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="text-align:right">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left"><strong>b.</strong></td>
    <td style="text-align:justify"><strong>Balances:</strong></td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003134544893" name="us-gaap:ScheduleOfCompensatingBalancesTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold">Non-Current liabilities&#160;&#8211;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Warrants to preferred shares</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="width:9%;border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-39590" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="width:9%;border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fxbrl_20241004095054139" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003130955369" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 15&#160;&#8212;&#160;SUBSEQUENT EVENT:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">The Company&#8217;s management has performed
an evaluation of subsequent events through May 9, 2024, the date the financial statements were available to be issued.</p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">a.</td>
    <td style="text-align:left">On February&#160;21, 2024, the Company entered into a business combination agreement with Moringa Acquisition
        Corp. (the &#8220;SPAC&#8221;), an exempted company incorporated under the Laws of the Cayman Islands whose class A ordinary shares (as
        well as other instruments) are listed for trade on the Nasdaq Global Market (NASDAQ: MACA), and April.M.G.&#160;Ltd. (the &#8220;April
        Merger Sub&#8221;), a limited liability company organized under the laws of the State of Israel and a wholly-owned subsidiary of the SPAC
        (the &#8220;Original BCA&#8221;). According to the Original BCA, April Merger Sub would merge with and into the Company, with the Company
        continuing as the surviving entity and a wholly-owned subsidiary of the SPAC, and with the SPAC continuing as a public company following
        the completion of the merger and with its securities continuing to be traded on Nasdaq.</td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-85</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="margin-top:0;margin-bottom:0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>SILEXION LTD.<br/>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS<br/>U.S.&#160;DOLLARS IN THOUSANDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 15&#160;&#8212;&#160;SUBSEQUENT EVENT</strong>
(cont.)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:0.5in">&#160;</td>
    <td style="width:0.25in;text-align:left">b.</td>
    <td style="text-align:left">On April&#160;3, 2024, the SPAC and the Company restructured the transactions contemplated under the Original
        BCA by entering into the A&amp;R BCA by and among Biomotion Sciences, a Cayman Islands exempted company (the &#8220;New Pubco&#8221;),
        August M.S.&#160;Ltd., an Israeli company and a wholly owned subsidiary of New Pubco (the &#8220;Merger Sub 1&#8221;), Moringa Acquisition
        Merger Sub Corp, a Cayman Islands exempted company and a wholly owned subsidiary of New Pubco (the &#8220;Merger Sub 2&#8221;), the SPAC
        and the Company. The A&amp;R BCA amends and restates, in its entirety, the Original BCA.</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Pursuant to the A&amp;R BCA, Merger Sub 2 will merge with and
into the SPAC, with the SPAC continuing as the surviving company of such merger and a wholly-owned subsidiary of New Pubco (the &#8220;SPAC
Merger&#8221;), and Merger Sub 1 will merge with and into the Company, with the Company continuing as the surviving company of such merger
and a wholly-owned subsidiary of New Pubco (the &#8220;Acquisition Merger&#8221;).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Upon the effectiveness of the SPAC Merger, each outstanding
SPAC Class&#160;A ordinary share and the sole outstanding SPAC Class&#160;B ordinary share will convert into an ordinary share of New
Pubco on a one-for-one basis, and each outstanding warrant to purchase <ix:nonFraction id="Fixv-39591" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSPACMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="shares" scale="0" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction>
SPAC Class&#160;A ordinary share will convert into a warrant to purchase <ix:nonFraction id="Fixv-39592" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnNewPubcoMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="shares" scale="0" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction>
New Pubco ordinary share, at the same exercise price.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">Upon the effectiveness of the Acquisition Merger, each outstanding
ordinary share and preferred share of the Company will convert into such number of ordinary shares of New Pubco as is equal to the quotient
obtained by dividing (x)&#160;the quotient obtained by dividing (1)&#160;$<ix:nonFraction id="Fixv-39593" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnNewPubcoMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,500,000</ix:nonFraction>
by (2)&#160;the number of fully diluted Company equity securities, by (y)&#160;$<ix:nonFraction id="Fixv-39594" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnNewPubcoMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction>
(the &#8220;Company Equity Exchange Ratio&#8221;). Each outstanding Company warrant and Company option to purchase one Company share,
and Company restricted share unit (RSU) that may be potentially settled for one Company share, will become exercisable for, or will be
subject to settlement for (as applicable), such number of New Pubco ordinary shares as are equal to the Company Equity Exchange Ratio.
The exercise price per New Pubco ordinary share of each such converted Company options and Company warrants will be adjusted based on
dividing the existing per share exercise price by the Company Equity Exchange Ratio. The terms of vesting, exercise and/or settlement,
as applicable, of such converted options, warrants and RSUs shall remain the same following such conversion, except that the vesting of
each Company option will accelerate immediately prior to the Acquisition Merger, such that the New Pubco option into which it has been
converted will be fully vested.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The completion of the A&amp;R BCA is subject to the satisfaction
of certain conditions, including obtaining the consent of the shareholders of each of the SPAC and the Company and the declaration of
effectiveness of a registration statement on form S-4 by the U.S.&#160;Securities and Exchange Commission in relation to issuance of New
Pubco ordinary shares to be issued or issuable to the SPAC&#8217;s and the Company&#8217;s respective security holders pursuant to the
A&amp;R BCA.&#160;To facilitate the A&amp;R BCA, the parties further entered into certain ancillary agreements.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">The A&amp;R BCA further imposes various restrictions on the
total liabilities which the SPAC may incur prior to closing, including the total indebtedness toward the sponsor of the SPAC, and the
terms on which such indebtedness will be repaid or converted, whereas such conversion, if and when it occurs, will further dilute the
holdings of all shareholders of New Pubco at that time, including the former shareholders of the Company.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-86</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:20pt">

<p style="margin:0pt">&#160;</p> </div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<div>

<div>

<div>

<div>

<div>

<div>

<div>

<div>

<div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Up
to&#160; &#160; &#160; &#160; &#160; &#160; &#160; Ordinary Shares and accompanying</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary
Warrants to Purchase up to&#160; &#160; &#160; &#160; &#160; &#160; &#160; Ordinary Shares</span></span><br/>&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Up
to&#160; &#160; &#160; &#160; &#160; &#160;&#160; Pre-funded Warrants to Purchase up to&#160; &#160; &#160; &#160; &#160; Ordinary Shares</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">and
accompanying Ordinary Warrants to Purchase up to&#160; &#160; &#160; &#160; &#160; &#160; &#160; Ordinary Shares</span></span><br/>&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Placement
Agent Warrants to Purchase up to&#160; &#160; &#160; &#160; &#160; &#160; Ordinary Shares</span></span><br/>&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Up
to&#160; &#160; &#160; &#160; &#160;&#160; Ordinary Shares Issuable Upon Exercise of the Ordinary Warrants, Pre-</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">funded
Warrants and Placement Agent Warrants</span></span></div></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;,
2024</span></span></div></div></div></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="font:10pt Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">PART
II</span></span></strong></div></div></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INFORMATION
NOT REQUIRED IN PROSPECTUS</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Item
13. Other Expenses of Issuance and Distribution.</span></span></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
following table sets forth all costs and expenses, other than underwriting discounts and commissions, payable by us in connection with
the sale of the securities being registered. All amounts shown are estimates, except for the SEC registration fee and FINRA fee.</span></span></div></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amount</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SEC registration fee</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">FINRA fee</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accountants&#8217; fees
        and expenses</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Legal fees and expenses</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Printing fees</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%;padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Miscellaneous expenses</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total expenses (other
        than Placement Agent&#8217;s fees)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  </table></div>

<div>&#160;</div></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
will pay all of the expenses related to the distribution of the securities being offered under this prospectus. Each of the above amounts
(with the exception of the SEC registration fee and FINRA fee) are estimates.</span></span></div></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Item
14. Indemnification of Directors and Officers.</span></span></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cayman
Islands law does not limit the extent to which a company&#8217;s memorandum and articles of association may provide for indemnification
of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy,
such as to provide indemnification against willful default, willful neglect, actual fraud or the consequences of committing a crime. our
amended and restated memorandum and articles of association provide for indemnification of its officers and directors to the maximum extent
permitted by law, including for any liability incurred in their capacities as such, except through their own actual fraud, willful default
or willful neglect. we have purchased a policy of directors&#8217; and officers&#8217; liability insurance that insures its officers and
directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures it against its obligations
to indemnify its officers and directors.</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
believe that these provisions and the insurance are necessary to attract and retain talented and experienced officers and directors.</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us
pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act and is therefore unenforceable.</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">we
have entered into indemnity agreements with each of its officers and directors. These agreements require New Silexion to indemnify these
individuals and entity to the fullest extent permitted under applicable Cayman Islands law and to hold harmless, exonerate and advance
expenses incurred as a result of any proceeding against them as to which they could be indemnified.</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons
pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense
of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the court of
appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and
will be governed by the final adjudication of such issue.</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
proposed form of securities purchase agreement that we may enter into with certain investors in this offering (which, if entered into,
will be filed as an exhibit to this registration statement) provides for indemnification by the underwriters of the Company and its officers
and directors, and by the Company of the Placement Agent, for certain liabilities arising under the Securities Act or otherwise in connection
with this offering.</span></span></div></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">II-1</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Item
15. Recent Sales of Unregistered Securities.</span></span></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since
our formation on April 2, 2024, we have sold securities in transactions not registered under the Securities Act as described below:</span></span></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Initial
Issuance Upon Formation</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Upon
its formation on April 2, 2024, the Company initially sold one ordinary share to its initial shareholder, Maples Corporate Services Limited,
in exchange for corporate services provided by that initial shareholder. That issuance was effected without registration under the Securities
Act in an offshore transaction pursuant to the exemption provided by Regulation S under the Securities Act.</span></span></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unregistered
Issuances Upon Closing of Business Combination</span></span></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance
of EarlyBird Convertible Note and Underlying Ordinary Shares</span></span></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-style:italic;font-weight:bold">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prior
to the Closing of the Business Combination, on August 11, 2204, Moringa reached agreement with EarlyBird on the reduction, to $1.6 million,
in the aggregate, of the fee payable to EarlyBird under the Business Combination Marketing Agreement, dated as of February 19, 2021, entered
into by Moringa with EarlyBird at the time of Moringa&#8217;s initial public offering. As part of that agreement, New Silexion issued
to EarlyBird the EarlyBird Convertible Note, in an amount of $1.25 million to be paid by New Silexion to EarlyBird in cash and/or via
conversion of outstanding amounts into ordinary shares of New Silexion, which convertible note bears interest at a rate of 6% per annum
and is due on December 31, 2025.</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">EarlyBird
may elect, at its sole discretion, at any time on or prior to the maturity date of the EarlyBird Convertible Note, to convert all or part
of the then outstanding principal and/or accrued interest under the note into New Silexion ordinary shares, at a per share conversion
price equal to 95% of the volume weighted average price of a New Silexion ordinary share for the five trading days immediately prior to
the date of our receipt of a conversion notice, provided, however, that New Silexion is not required to issue, and EarlyBird may not elect
to convert the principal and/or accrued interest into an aggregate number of New Silexion ordinary shares that would exceed the maximum
number of ordinary shares permitted by Section 5635 of the Nasdaq Listing Rules to be issued without the approval of our shareholders,
unless such approval is obtained.</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the EarlyBird Convertible Note, New Silexion agreed to promptly file a registration statement with the SEC covering the resale of the
ordinary shares that may be issued upon conversion of the note and use its best efforts to have such registration statement declared effective
as soon thereafter as possible. In the event such registration statement is not declared effective by the SEC within 180 days from the
date hereof, then an event of default shall have occurred under the note, triggering all amounts under the note to become due and payable
immediately and automatically.</span></span></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
issuance of the EarlyBird Convertible Note and the potential issuance of New Silexion ordinary shares upon conversion of amounts outstanding
under the EarlyBird Convertible Note, has been, and will be (respectively), effected in reliance upon the exemption from registration
provided under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act in a transaction not requiring registration under
the Securities Act.</span></span></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">II-2</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance
of PIPE Financing Shares</span></span></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
described under &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions&#8212;PIPE Financing</span>&#8221;
above, in connection with, and immediately prior to the Closing of, the Business Combination, Moringa raised $2.0 million via the PIPE
Financing, whereby Moringa sold to the PIPE Investor 200,000 newly issued Moringa Class A ordinary shares at a price of $10.00 per share,
pursuant to the PIPE Agreement. Upon the Closing of the Business Combination, the Company issued 200,000 New Silexion ordinary shares
to the PIPE Investor upon conversion of those 200,000 Moringa Class A ordinary shares.</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
issuance of those 200,000 PIPE Shares by the Company to the PIPE Investor (a Cayman Islands exempted limited partnership) was effected
without registration under the Securities Act in an offshore transaction pursuant to the exemption provided by Regulation S under the
Securities Act.</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuances
of Equity Line of Credit Financing Shares to White Lion</span></span></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:28.35pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
described above in this registration statement under &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations&#8212; Recent Developments&#8212;ELOC Financing</span>&#8221;, also in connection with
the Closing of the Business Combination, New Silexion entered into the White Lion Purchase Agreement, under which it will be able to request
to sell to White Lion, and White Lion will be required to purchase, under an equity line of credit, up to $15.0 million of New Silexion
ordinary shares (the &#8220;<span style="font-weight:bold">Purchase Notice Shares</span>&#8221;) from time to time after the Closing,
up until December 31, 2025 (unless the agreement is terminated sooner), subject to certain limitations and conditions as described therein.
New Silexion is furthermore required to issue to White Lion ordinary shares having a value equal to $337,500, as a commitment fee under
the White Lion Purchase Agreement (the &#8220;<span style="font-weight:bold">Commitment Shares</span>&#8221;). The issuance of all ordinary
shares to White Lion under the White Lion Purchase Agreement has been and will be effected in reliance upon the exemption from registration
provided under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act in a transaction not requiring registration under
the Securities Act.</span></span></div></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Through
October 15, 2024, we have issued and sold an aggregate of 4,059,418 ordinary shares (which includes both the Commitment Shares and some
Purchase Notice Shares) to White Lion under the White Lion Purchase Agreement for aggregate proceeds to us of approximately $2.3 million.</span></span></div></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-style:italic">&#160;</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance
of Amended and Restated Sponsor Promissory Note and Underlying Shares to Moringa Sponsor</span></span></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-style:italic;font-weight:bold">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
described above in this registration statement under &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions</span>&#8212;
<span style="font-style:italic">Amended and Restated Sponsor Promissory Note</span>&#8221;, upon the Closing of the Business Combination,
New Silexion issued to the Sponsor, in amendment and restatement, and replacement, in their entirety, of all existing promissory notes
issued by Moringa to the Sponsor from Moringa&#8217;s initial public offering until the Closing, the A&amp;R Sponsor Promissory Note in
an amount of $3,433,000, which matures on February 15, 2027. Amounts outstanding under the A&amp;R Sponsor Promissory Note may be repaid
only by way of conversion by either the Company or the Sponsor into ordinary shares, under various circumstances.</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
issuance by the Company to the Sponsor (a Cayman Islands exempted limited partnership) of the A&amp;R Sponsor Promissory Note, and the
prospective issuance by the Company to the Sponsor of underlying Note Shares, was or will be (as applicable), effected without registration
under the Securities Act in an offshore transaction pursuant to the exemption provided by Regulation S under the Securities Act.</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None
of the foregoing transactions described in this &#8220;Recent Sales of Unregistered Securities&#8221; section involved any underwriters,
underwriting discounts or commissions, or any public offering. The recipients of the securities in each of these transactions represented
their intentions to acquire the securities for investment only and not with a view to or for sale in connection with the distribution
thereof (absent registration under the Securities Act), and appropriate legends were placed on the securities certificates issued in these
transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities
were made without any general solicitation or advertising.</span></span></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">II-3</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Item&#8201;16.
Exhibits and Financial Statement Schedules</span></span></div></div>

<div>

<div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:9%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exhibit
        No.</span></span></div></td>
    <td style="width:1%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1835416/000121390024029646/ea020320401ex2-1_moringaacq.htm">2.1.1&#8224;</a></span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1835416/000121390024029646/ea020320401ex2-1_moringaacq.htm">Amended
        and Restated Business Combination Agreement, dated as of April 3, 2024, by and among Biomotion Sciences (now known as Silexion Therapeutics
        Corp), August M.S. Ltd., Moringa Acquisition Merger Sub Corp, Silexion Therapeutics Ltd. and Moringa Acquisition Corp (incorporated by
        reference to Exhibit 2.1 to Moringa Acquisition Corp&#8217;s Current Report on Form 8-K, filed with the SEC on April 3, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1835416/000121390024055254/ea020833801ex10-1_moringa.htm">2.1.2</a></span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1835416/000121390024055254/ea020833801ex10-1_moringa.htm">Waiver
        letter, dated June 18, 2024, under Amended and Restated Business Combination Agreement (incorporated by reference to Exhibit 10.1 to Moringa
        Acquisition Corp&#8217;s Current Report on Form 8-K filed with the SEC on June 24, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex2-2_silexion.htm">2.2</a></span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex2-2_silexion.htm">Plan
        of Merger for merger of Moringa Acquisition Corp and Moringa Acquisition Merger Sub Corp (incorporated by reference to Exhibit 2.2 to
        Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex3-1_silexion.htm">3.1</a></span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex3-1_silexion.htm">Amended
        and Restated Memorandum and Articles of Association of Silexion Therapeutics Corp (formerly Biomotion Sciences) (incorporated by reference
        to Exhibit 3.1 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1835416/000121390021010849/ea136177ex4-1_moringaacq.htm">4.1</a></span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1835416/000121390021010849/ea136177ex4-1_moringaacq.htm">Warrant
        Agreement, dated February&#160;19, 2021, by and between Moringa Acquisition Corp and Continental Stock Transfer&#160;&amp; Trust Company,
        as warrant agent (incorporated by reference to Exhibit&#160;4.1 to Moringa Acquisition Corp&#8217;s Current Report on Form&#160;8-K, filed
        with the SEC on February&#160;22, 2021)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex4-1_silexion.htm">4.2</a></span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex4-1_silexion.htm">Assignment,
        Assumption and Amendment Agreement, dated as of August 15, 2024, by and among Moringa Acquisition Corp, Silexion Therapeutics Corp (formerly
        known as Biomotion Sciences) and Continental Stock Transfer &amp; Trust Company (incorporated by reference to Exhibit 4.1 to Silexion
        Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr>
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.3**</span></span></div></td>
    <td rowspan="1" style="width:1%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Form of Ordinary Warrant
        to be sold in the offering</span></span></div></td></tr>
  <tr>
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.4**</span></span></div></td>
    <td rowspan="1" style="width:1%;vertical-align:top;background-color:rgb(255, 255, 255)">&#160;</td>
    <td rowspan="1" style="width:90%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Form of Pre-Funded Warrant
        to be sold in the offering</span></span></div></td></tr>
  <tr>
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.5**</span></span></div></td>
    <td rowspan="1" style="width:1%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Form of Placement Agent
        Warrant</span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.1**</span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:90%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Opinion of Conyers Dill&#160;&amp;
        Pearman LLP, Cayman legal counsel to Silexion Therapeutics Corp.</span></span></div></td></tr>
  <tr>
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.2**</span></span></td>
    <td rowspan="1" style="width:1%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Opinion of Greenberg
        Traurig, LLP, United States legal counsel to Silexion Therapeutics Corp.</span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-1i_silexion.htm">10.1.1</a></span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-1i_silexion.htm">Final
        invoice issued by EarlyBirdCapital, Inc. to Moringa Acquisition Corp under the Business Combination Marketing Agreement, dated February
        16, 2021, by and between EarlyBirdCapital, Inc. and Moringa Acquisition Corp (incorporated by reference to Exhibit 10.1.1 to Silexion
        Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-1ii_silexion.htm">10.1.2</a></span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-1ii_silexion.htm">Convertible
        Promissory Note, dated August 15, 2024, in an amount of $1,250,000, issued by Silexion Therapeutics Corp (formerly known as Biomotion
        Sciences) to EarlyBirdCapital, Inc. (incorporated by reference to Exhibit 10.1.2 to Silexion Therapeutics Corp&#8217;s Current Report
        on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-2_silexion.htm">10.2</a></span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-2_silexion.htm">Subscription
        Agreement, dated August 15, 2024, by and among Moringa Acquisition Corp, Silexion Therapeutics Corp (formerly known as Biomotion Sciences)
        and Greenstar, L.P. (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed
        with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-3i_silexion.htm">10.3.1</a></span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-3i_silexion.htm">Ordinary
        Share Purchase Agreement, dated August 13, 2024 and effective as of the closing date of the Business Combination, by and between Silexion
        Therapeutics Corp (formerly known as Biomotion Sciences) and White Lion Capital, LLC (incorporated by reference to Exhibit 10.3.1 to Silexion
        Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-3ii_silexion.htm">10.3.2</a></span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-3ii_silexion.htm">Registration
        Rights Agreement, dated August 13, 2024 and effective as of the closing date of the Business Combination, by and between Silexion Therapeutics
        Corp (formerly known as Biomotion Sciences) and White Lion Capital, LLC (incorporated by reference to Exhibit 10.3.2 to Silexion Therapeutics
        Corp&#8217;s Current Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-4_silexion.htm">10.4</a></span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-4_silexion.htm">Amended
        and Restated Registration Rights and Lock-Up Agreement, dated August 14, 2024 and effective as of the Closing Date, by and among Silexion
        Therapeutics Corp (formerly known as Biomotion Sciences), Moringa Acquisition Corp, Moringa Sponsor, L.P., the distributees of Sponsor
        Investment Shares that were issuable to Moringa Sponsor, L.P., EarlyBirdCapital, Inc., certain of Silexion Therapeutics Ltd.&#8217;s pre-Business
        Combination shareholders and Greenstar, L.P. (incorporated by reference to Exhibit 10.4 to Silexion Therapeutics Corp&#8217;s Current
        Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-5_silexion.htm">10.5</a></span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-5_silexion.htm">Amended
        and Restated Promissory Note, dated August 15, 2024, issued by Silexion Therapeutics Corp (formerly known as Biomotion Sciences) to Moringa
        Sponsor, L.P. (incorporated by reference to Exhibit 10.5 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the
        SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-6_silexion.htm">10.6</a></span></span></div></td>
    <td style="width:1%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-6_silexion.htm">Form
        of Director and Officer Indemnification Agreement, dated August 15, 2024, by and between Silexion Therapeutics Corp (formerly known as
        Biomotion Sciences) and each of its executive officers and directors (incorporated by reference to Exhibit 10.6 to Silexion Therapeutics
        Corp&#8217;s Current Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12i_bio.htm">10.11.1#</a></span></span></div></td>
    <td style="width:1%;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12i_bio.htm">Employment
        Agreement, dated April 1, 2022, by and between Silexion Therapeutics Ltd. and Ilan Hadar (incorporated by reference to Exhibit 10.12.1
        to Amendment No. 3 to the Company&#8217;s Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC on July 12, 2024)</a>.</span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12ii_bio.htm">10.11.2#</a></span></span></div></td>
    <td style="width:1%;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12ii_bio.htm">Amendment
        No. 1 to Employment Agreement, dated May 2024, by and between Silexion Therapeutics Ltd. and Ilan Hadar ((incorporated by reference to
        Exhibit 10.12.2 to Amendment No. 3 to the Company&#8217;s Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC
        on July 12, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-12_silexion.htm">10.12#</a></span></span></div></td>
    <td style="width:1%;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:90%;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-12_silexion.htm">Silexion
        Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to Silexion Therapeutics Corp&#8217;s Current
        Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024077039/ea021365401ex10-13_silexion.htm">10.13#</a></span></span></div></td>
    <td style="width:1%;vertical-align:middle;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024077039/ea021365401ex10-13_silexion.htm"><span style="text-decoration:underline">Silexion
        Therapeutics Ltd. 2023 Equity Incentive Plan</span>&#160;(incorporated by reference to Exhibit 10.13 to Silexion Therapeutics Corp&#8217;s
        Registration Statement on Form S-1 (File No. 333-282017), filed with the SEC on September 10, 2024)</a></span></span></div></div></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024077039/ea021365401ex10-14_silexion.htm">10.14#</a></span></span></div></td>
    <td style="width:1%;vertical-align:middle;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:90%;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024077039/ea021365401ex10-14_silexion.htm"><span style="text-decoration:underline">Silexion
        Therapeutics Ltd. 2013 Share Option Plan</span>&#160;(incorporated by reference to Exhibit 10.14 to Silexion Therapeutics Corp&#8217;s
        Registration Statement on Form S-1 (File No. 333-282017), filed with the SEC on September 10, 2024)</a></span></span></div></div></div></td></tr>
  <tr>
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10.15**</span></span></td>
    <td rowspan="1" style="width:1%;vertical-align:middle;background-color:rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" style="width:90%;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Form of Securities Purchase
        Agreement</span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255);white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex21-1_silexion.htm">21.1</a></span></span></div></td>
    <td style="width:1%;vertical-align:middle;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:90%;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex21-1_silexion.htm">List
        of Subsidiaries (incorporated by reference to Exhibit 21.1 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed with
        the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255);white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_23-1.htm">23.1*</a></span></span></div></td>
    <td style="width:1%;vertical-align:middle;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_23-1.htm"><span style="text-decoration:underline">Consent
        of Kesselman&#160;&amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting
        firm of Moringa Acquisition Corp</span></a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255);white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_23-2.htm">23.2*</a></span></span></div></td>
    <td style="width:1%;vertical-align:middle;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:90%;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_23-2.htm"><span style="text-decoration:underline">Consent
        of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting
        firm of Silexion Therapeutics Ltd.</span></a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255);white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23.3**</span></span></div></td>
    <td style="width:1%;vertical-align:middle;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consent of Conyers Dill
        &amp; Pearman LLP (included in Exhibit 5.1)</span></span></div></td></tr>
  <tr>
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255);font-family:'Times New Roman',Times,serif;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23.4**</span></span></div></td>
    <td rowspan="1" style="width:1%;vertical-align:middle;background-color:rgb(255, 255, 255);font-family:'Times New Roman',Times,serif">&#160;</td>
    <td rowspan="1" style="width:90%;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consent of Greenberg
        Traurig, LLP&#160; (included in Exhibit 5.2)</span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255);white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#POWER_integixAnchor">24.1*</a></span></span></div></td>
    <td style="width:1%;vertical-align:middle;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:90%;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#POWER_integixAnchor">Power
        of attorney (included on the signature page to this registration statement)</a></span></span></div></td></tr>
  <tr>
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255);white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_107.htm">107*</a></span></span></div></td>
    <td style="width:1%;vertical-align:middle;background-color:rgb(255, 255, 255);font-family:'Times New Roman',Times,serif">&#160;</td>
    <td style="width:90%;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_107.htm"><span style="text-decoration:underline">Filing
        fee table</span></a></span></span></div></td></tr>
  </table>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;
</span></span></span></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:3.85%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></div></td>
    <td style="width:96.15%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Filed
        herewith.</span></span></div></td></tr>
  <tr>
    <td rowspan="1" style="width:3.85%;vertical-align:top">&#160;</td>
    <td rowspan="1" style="width:96.15%;vertical-align:top">&#160;</td></tr>
  <tr>
    <td rowspan="1" style="width:3.85%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">**</span></span></td>
    <td rowspan="1" style="width:96.15%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To be filed by amendment</span></span></div></td></tr>
  <tr>
    <td style="width:3.85%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:96.15%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:3.85%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8224;</span></span></div></td>
    <td style="width:96.15%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Certain
        of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees
        to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.</span></span></div></td></tr>
  </table>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:3.85%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">#</span></span></div></td>
    <td style="width:96.15%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicates
        management contract or compensatory plan, contract or arrangement.</span></span></div></td></tr>
  </table>

<div style="text-align:justify;text-indent:-18pt;margin-left:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Item&#8201;17.
Undertakings</span></span></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
undersigned Registrant hereby undertakes<span style="font-style:italic">:</span>&#160;</span></span></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(a)
To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</span></span></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(i)
To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</span></span></div></div></div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">II-4</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(ii)
To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration
Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration
Fee&#8221; table in the effective registration statement; and</span></span></div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(iii)
To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or
any material change to such information in this Registration Statement.</span></span></div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(b)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment that contains
a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of
such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></span></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(c)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.</span></span></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(d)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule
424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than
prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it
is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of
the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus
that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede
or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made
in any such document immediately prior to such date of first use.</span></span></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(e)
That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications,</span></span></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
424;</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
the undersigned registrant;</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</span></span></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons
of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that
a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director,
officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by them is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.</span></span></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">II-5</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SIGNATURES</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant
to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in Ramat Gan, Israel, on October 31, 2024.</span></span></div></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td colspan="3" style="vertical-align:top">
        <div style="line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SILEXION
        THERAPEUTICS CORP</span></span></div></td>
    <td style="width:62%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:3%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td colspan="2" style="vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:62%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:3%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">By:</span></span></div></td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/
        Ilan Hadar</span></span></div></td>
    <td style="width:62%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:3%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:4%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name:&#160;</span></span></div></td>
    <td style="width:30.59%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ilan
        Hadar</span></span></div></td>
    <td style="width:62%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:3%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:4%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Title:</span></span></div></td>
    <td style="width:30.59%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chairman
        and Chief Executive Officer</span></span></div></td>
    <td style="width:62%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  </table>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="POWER_integixAnchor"></span>POWER
OF ATTORNEY</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">KNOW
ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ilan Hadar and Mirit Horenshtein
Hadar, and each of them, as his true and lawful agents, proxies and attorneys-in-fact, with full power of substitution and resubstitution,
for him or her and in his or her name, place and stead, in any and all capacities, to (i) act on, sign and file with the Securities and
Exchange Commission any and all amendments (including post-effective amendments) to this registration statement together with all schedules
and exhibits thereto and any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended,
together with all schedules and exhibits thereto, (ii) act on, sign and file such certificates, instruments, agreements and other documents
as may be necessary or appropriate in connection therewith, (iii) act on and file any supplement to any prospectus included in this registration
statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933,
as amended, and (iv) take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes
as he might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of
his substitutes may lawfully do or cause to be done by virtue thereof.</span></span></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities
and on the dates indicated.</span></span></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:30%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);white-space:nowrap">
        <div style="line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Signature</span></span></div></td>
    <td style="width:0.68%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Title</span></span></div></td>
    <td style="width:0.68%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date</span></span></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/
        Ilan Hadar</span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chairman
        and Chief Executive Officer</span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom;text-align:center">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>October 31,
        2024.</span></span></span></span></div></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Ilan
        Hadar</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-style:italic;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(Principal
        Executive Officer)</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>/s/
        Mirit Horenshtein Hadar</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chief
        Financial Officer and Secretary</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>October
        31, 2024.</span></span></span></span></div></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Mirit
        Horenshtein Hadar</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-style:italic;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(Principal
        Financial and Accounting Officer)</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>/s/
        Dror J. Abramov</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Director</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>October
        31, 2024.</span></span></span></span></div></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Dror
        J. Abramov</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>/s/
        Ruth Alon</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Director</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>October
        31<span>,</span> 2024.</span></span></span></span></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Ruth
        Alon</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>/s/
        Ilan Levin</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Director</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>October
        31<span>,</span> 2024.</span></span></span></span></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Ilan
        Levin</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>/s/
        Avner Lushi</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Director</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>October
        31<span>,</span> 2024.</span></span></span></span></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Avner
        Lushi</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>/s/
        Shlomo Noy</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Director</span></span></span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>October
        31<span>,</span> 2024.</span></span></span></span></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Shlomo
        Noy</span></span></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  </table>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">II-6</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AUTHORIZED
REPRESENTATIVE</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant
to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative of the Registrant in
the United States, has signed registration statement in Newark, Delaware, on October 31, 2024.</span></span></div></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td colspan="2" style="vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">PUGLISI&#160;&amp;
        ASSOCIATES</span></span></div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td colspan="2" style="vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:4%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">By:</span></span></div></td>
    <td style="width:46%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="text-align:justify;line-height:1.25;font-style:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>/s/
        Donald J.&#160;Puglisi</span></span></span></div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:4%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name:&#160;</span></span></div></td>
    <td style="width:46%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Donald
        J.&#160;Puglisi</span></span></div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:4%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Title:</span></span></div></td>
    <td style="width:46%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Authorized
        Representative</span></span></div></td></tr>
  </table>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>II-7</span></span></span></div></div></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><hr style="border:none;border-bottom:4px solid black;border-top:1px solid black;height:10px;color:#ffffff;background-color:#ffffff;margin-left:auto;margin-right:auto;text-align:center"/></div></div></div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div></div>

</div></div></body>
</html>
[{"type": "S-1", "sequence": "1", "filename": "zk2432189.htm", "description": "S-1", "secsgml_size_bytes": 4753501}]
{"company-data": {"conformed-name": "Silexion Therapeutics Corp", "cik": "0002022416", "assigned-sic": "2836", "organization-name": "03 Life Sciences", "irs-number": "000000000", "state-of-incorporation": "E9", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-1", "act": "33", "file-number": "333-282932", "film-number": "241416263"}, "business-address": {"street1": "12 ABBA HILLEL ROAD", "city": "RAMAT GAN", "state": "L3", "zip": "5250606", "phone": "972-8-6286005"}, "mail-address": {"street1": "12 ABBA HILLEL ROAD", "city": "RAMAT GAN", "state": "L3", "zip": "5250606"}, "former-company": {"former-conformed-name": "Biomotion Sciences", "date-changed": "20240506"}}
Silexion Therapeutics Corp - 2022416 - 2024
As filed with
the United States Securities and Exchange Commission on
October
31, 2024
.
Registration
No. 333-
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-1
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Silexion
Therapeutics Corp
(Exact name of registrant as
specified in its charter)
Cayman
        Islands
8731
N/A
(State or other jurisdiction of
incorporation or organization)
(Primary Standard Industrial
Classification
        Code Number)
(I.R.S. Employer
Identification Number)
12 Abba Hillel
Road
Ramat Gan,
Israel 5250606
+972-8-6286005
(Address, Including Zip Code,
and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)
Puglisi &
Associates
850 Library Avenue, Suite 204
Newark, DE 19711
Telephone:
(302) 738-6680
(Name,
Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)
Copies
to:
J. David
        Chertok, Adv.
Jonathan M. Nathan, Adv.
Meitar Law Offices
16 Abba Hillel Road
Ramat Gan, Israel 5251608
Tel:
        +972-3-610-3100
Mark S. Selinger, Esq.
Gary
        Emmanuel, Esq.
Greenberg
        Traurig, LLP
One Vanderbilt Avenue
New York, New York 10017-5404
Tel: (212) 801-9200
Approximate
date of commencement of proposed sale to the public:
As
soon as practicable after the effective date of this registration statement becomes effective.
If any of the
securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933, check the following box. ☒
If this Form
is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form
is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form
is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,
or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller
reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated
        filer
☒
Smaller reporting company
☒
Emerging growth company
☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☐
The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance
with Section 8(a) of the Securities Act of 1933, as amended ("Securities Act"), or until the Registration
Statement shall become effective on such date as the SEC, acting pursuant to Section 8(a), may determine.
The information in
this preliminary prospectus is not complete and may be changed. The securities described herein may not be sold until the registration
statement filed with the U.S. Securities and Exchange Commission is declared effective. This preliminary prospectus is not an offer to
sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
PRELIMINARY
PROSPECTUS
SUBJECT TO COMPLETION, DATED OCTOBER 31,
2024
Up to      
      Ordinary Shares and accompanying
Ordinary Warrants to Purchase
up to             Ordinary Shares
Up to  
          Pre-funded Warrants
to Purchase up to       
  Ordinary Shares
and accompanying Ordinary
Warrants to Purchase up to              Ordinary Shares
Placement Agent Warrants
to Purchase up to            Ordinary Shares
Up to          
Ordinary Shares Issuable Upon Exercise of the Ordinary Warrants, Pre-funded Warrants and Placement Agent Warrants
We are offering in a best-efforts offering up to           
       ordinary shares, par value $0.0001 per share of Silexion Therapeutics Corp, a Cayman Islands exempted company
("New Silexion", the "Company", "our company", "we" or "us"), together with
ordinary warrants to purchase up to                       ordinary shares
at an assumed public offering price of $      per share and ordinary warrant pursuant to this prospectus.
The ordinary shares and ordinary warrants will be sold in a fixed combination, with each ordinary share accompanied by one warrant to
purchase one ordinary share.
We are also offering to those purchasers, if any, whose purchase of our ordinary shares
in this offering would otherwise result in such purchaser, together with its affiliates and certain related parties, beneficially owning
more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding ordinary shares immediately following the consummation
of this offering, the opportunity, in lieu of purchasing ordinary shares, to purchase pre-funded warrants to purchase ordinary shares.
Each pre-funded warrant will be immediately exercisable for one ordinary share at any time at the option of the holder until such pre-funded
warrant is exercised in full, provided that the holder will be prohibited from exercising pre-funded warrants for ordinary shares if,
as a result of such exercise, the holder, together with its affiliates and certain related parties, would own more than 4.99% (or, at
the election of the purchaser, 9.99%) of the total number of ordinary shares then issued and outstanding. The purchase price of each
pre-funded warrant is $                 (which is equal to the assumed public offering price
per ordinary share and ordinary warrant to be sold in this offering minus $0.0001, the exercise price per ordinary share of each pre-funded
warrant). For each pre-funded warrant we sell, the number of ordinary shares we are offering will be decreased on a one-for-one basis.
The pre-funded warrants will be sold together with ordinary warrants in a fixed combination, with each pre-funded warrant to purchase
one ordinary share accompanied by one ordinary warrant to purchase one ordinary share.
Each ordinary warrant will have an exercise price of $      per
share (which will be no less than          % of the assumed public offering price per ordinary share to be sold
in this offering), will be exercisable upon issuance and will expire on                , 2029.
Because we will issue an ordinary warrant for each ordinary share and for each pre-funded warrant sold in this offering, the number of
ordinary warrants sold in this offering will not change as a result of a change in the mix of ordinary shares and pre-funded warrants
sold.
We are also registering the ordinary shares issuable from time to time upon the exercise
of the pre-funded warrants, ordinary warrants and placement agent warrants offered hereby.
Our ordinary shares and warrants are listed on The Nasdaq Global Market under the symbols
"SLXN" and "SLXNW," respectively. On October 30, 2024, the last reported sales price of our ordinary shares was
$0.294 per share and the last reported sales price of our warrants was $0.069 per warrant. There is no established public trading market
for the ordinary shares being offered and the  pre-funded warrants and we do not expect a market to develop. Without an active trading
market, the liquidity of those warrants will be limited. In addition, we do not intend to list the pre-funded warrants or the ordinary
warrants on The Nasdaq Global Market, any other national securities exchange or any other trading system.
The public offering price per ordinary share and any pre-funded warrant will be determined
at the time of pricing, and may be at a discount to the then current market price. The recent market price used throughout this prospectus
may not be indicative of the final offering price. The final public offering price will be a fixed price determined through negotiation
between us and investors based upon a number of factors, including our history and our prospects, the state of the biotechnology industry
in which we operate, our recent operating results, including results of our pre-clinical studies and clinical trials, and the general
condition of the securities markets at the time of this offering.
This offering will terminate on              
  , 2024, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will
have one closing for all the securities purchased in this offering. The combined public offering price per ordinary share (or pre-funded
warrant) and accompanying ordinary warrants will be fixed for the duration of this offering.
We have engaged                   
           ("Placement Agent"), to act as our exclusive placement agent in connection with this
offering. The Placement Agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this
prospectus. The Placement Agent is not purchasing or selling any of the securities we are offering and the Placement Agent is not required
to arrange the purchase or sale of any specific number of securities or dollar amount. We have agreed to pay to the Placement Agent the
placement agent fees set forth in the table, which assumes that we sell all of the securities offered by this prospectus. There is no
minimum offering requirement as a condition of closing of this offering. Because there is no minimum offering amount required as a condition
to closing this offering, we may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds
received by us. We will bear all costs associated with the offering and investors in this offering will not receive a refund in the event
that we do not sell an amount of securities sufficient to pursue our business goals described in this prospectus. In addition, because
there is no escrow account and no minimum offering amount, investors could be in a position where they have invested in our company, but
we are unable to fulfill all of our contemplated objectives due to a lack of interest in this offering. Further, any proceeds from the
sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such
funds to effectively implement our business plan. See "
Plan of Distribution
" on page
145 of this prospectus for more information regarding these arrangements.
Effective November        , 2024, we effected a 1-for-   
     reverse share split of our authorized ordinary shares, including our issued and outstanding ordinary shares. Unless
specifically provided otherwise herein, the share and per share information that follows in this prospectus, other than in the historical
financial statements and related notes included elsewhere in this prospectus, assumes the effect of the reverse share split.
We are an "emerging growth company" as defined under U.S. federal securities
laws and, as such, have elected to comply with reduced public company reporting requirements. This prospectus complies with the requirements
that apply to an issuer that is an emerging growth company.
​
Per Ordinary Share and
Accompanying Ordinary
Warrant
Per Pre-Funded
Warrant and Accompanying
Ordinary Warrant
Total
Public offering price
Placement agent fees (1)
Proceeds to us, before expenses (2) (3)
(1)
We have agreed to pay the Placement Agent cash fee equal to 7.0% of the gross proceeds raised in this offering. We have also agreed
        to reimburse the Placement Agent for certain of its offering-related expenses, including a management fee of 1.0% of the gross proceeds
        raised in this offering, to reimburse the Placement Agent for its non-accountable expenses in the amount of $25,000, for its legal fees
        and expenses and other out-of-pocket expenses in an amount up to $100,000, and for its clearing expenses in the amount of up to $15,950.
        In addition, we have agreed to issue to the Placement Agent warrants to purchase up to a number of ordinary shares equal to 7% of the
        aggregate number of our ordinary shares and pre-funded warrants being offered, at an exercise price equal to 125% of the public offering
        price of our ordinary shares. See "
Plan of Distribution
" for additional information
        and a description of the compensation payable to the Placement Agent.
(2)
We estimate the total expenses of this offering payable by us, excluding the placement agent fee, will be approximately $   
                 . Because there is no minimum number of securities or amount of proceeds required as a condition to
        closing in this offering, the actual public offering amount, Placement Agent fees, and proceeds to us, if any, are not presently determinable
        and may be substantially less than the total maximum offering amounts set forth above.
(3)
Does not include proceeds from the cash exercise of the pre-funded warrants or ordinary warrants, if any. Assumes no pre-funded warrants
        are issued.
Investing in our securities involves a high degree of risk. You should
review carefully the risks and uncertainties described in the section titled "Risk Factors" beginning on page 7 of this prospectus,
and under similar headings in any amendments or supplements to this prospectus.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus. Any representation
to the contrary is a criminal offense.
We expect to deliver the securities to the purchasers in the offering
on or about                   , 2024, subject to satisfaction of certain conditions.
Prospectus dated  
         , 2024
PRELIMINARY NOTES REGARDING
THIS
PROSPECTUS
Unless the context indicates otherwise, references
in this prospectus to "
New Silexion
", "
we
",
"
us,
" "
our
," "
the
Company
", "
our company
" and similar terms refer to Silexion Therapeutics
Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company, and its consolidated subsidiaries. References to "
Silexion
"
refer to Silexion Therapeutics Ltd., an Israeli company and wholly-owned subsidiary of the Company, and references to "
Moringa
"
refer to Moringa Acquisition Corp, a Cayman Islands exempted company and wholly-owned subsidiary of the Company. References to the "
Business
Combination
" refer collectively to the transactions completed on August 15, 2024 pursuant to that certain Amended and Restated
Business Combination Agreement, dated as of April 3, 2024 (as amended, the "
Business Combination
Agreement
"), by and among New Silexion, August M.S. Ltd., an Israeli company and a wholly-owned subsidiary of New
Silexion ("
Merger Sub 1
"), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted
company and a wholly-owned subsidiary of New Silexion ("
Merger Sub 2
"), Moringa
and Silexion. Pursuant to the Business Combination Agreement, among other things, (i) Merger Sub 2 merged with and into Moringa, with
Moringa continuing as the surviving company and a wholly-owned subsidiary of New Silexion (the "
SPAC
Merger
") and (ii) Merger Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company and a wholly-owned
subsidiary of New Silexion (the "
Acquisition Merger
"). In connection with the consummation
of the Business Combination (the "
Closing
"), New Silexion changed its name from "Biomotion
Sciences" to "Silexion Therapeutics Corp", and the ordinary shares and warrants of New Silexion commenced trading on
the Nasdaq Global Market ("
Nasdaq
") under the symbols "SLXN" and "SLXNW",
respectively, on August 16, 2024.
We and the Placement Agent have not authorized anyone to provide
any information or to make any representations other than those contained in or incorporated by reference in this prospectus or in any
free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for and can provide
no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares
offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in or incorporated
by reference in this prospectus is accurate only as of its date regardless of the time of delivery of this prospectus or of any sale of
ordinary shares.
To the extent there is a conflict between the information contained
in this prospectus, on the one hand, and the information contained in any document incorporated by reference filed with the U.S. Securities
and Exchange Commission (the "SEC") before the date of this prospectus, on the other hand, you should rely on the information
in this prospectus. If any statement in a document incorporated by reference is inconsistent with a statement in another document incorporated
by reference having a later date, the statement in the document having the later date modifies or supersedes the earlier statement.
Neither we nor the Placement Agent have done anything that would
permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other
than in the United States. Persons who come into possession of this prospectus and any free writing prospectus in jurisdictions outside
the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of
this prospectus and any free writing prospectus applicable to that jurisdiction. We will not make an offer to sell these ordinary
shares in any jurisdiction where the offer or sale is not permitted.
This prospectus contains market data and industry statistics
and forecasts that are based on independent industry publications and other publicly available information. Although we believe that these
sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this
information. Although we are not aware of any misstatements regarding the market and industry data presented or incorporated by reference
in this prospectus, these estimates involve risks and uncertainties and are subject to change based on various factors, including those
discussed under the heading "Risk Factors" and any related free writing prospectus. These and other factors could cause our
future performance to differ materially from our assumptions and estimates. See "Special Note Regarding Forward-Looking Statements."
Accordingly, investors should not place undue reliance on this information.
This prospectus contains summaries of certain
provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information.
All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have
been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a
part, and you may obtain copies of those documents as described below under "
Where You Can Find
More Information
".
SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS
The statements contained in this prospectus
that are not purely historical are forward-looking statements. Certain statements in this prospectus may constitute "forward-looking
statements" for purposes of the federal securities laws. These forward-looking statements include, but are not limited to, statements
regarding the Company's and the Company's management team's expectations, hopes, beliefs, intentions or strategies regarding
the future, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives
of management for future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future
events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intends," "may," "might,"
"plan," "possible," "potential," "predict," "project," "should,"
"will," "would" and similar expressions may identify forward-looking statements, but the absence of these words
does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements
about:
●
the ability to maintain the listing of our ordinary shares and our warrants on Nasdaq;
●
our future performance, including our projected timeline for regulatory approvals of its product candidates;
●
our market opportunity;
●
our strategy, future operations, financial position, projected costs, prospects and plans;
●
expectations regarding the time during which we will be an emerging growth company under the JOBS Act;
●
our ability to retain or recruit officers, key employees and directors;
●
the impact of the regulatory environment and complexities with compliance related to such environment;
●
expectations regarding future partnerships or other relationships with third parties; and
●
our future capital requirements and sources and uses of cash, including the our ability to obtain additional
        capital in the future.
The forward-looking statements contained
in this prospectus and in any document incorporated by reference are based on current expectations, forecasts and beliefs concerning future
developments and their potential effects on us. There can be no assurance that future developments affecting we will be those that we
have anticipated. These forward-looking statements involve a number of risks, uncertainties, some of which are beyond our control, or
other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not limited to, the following factors:
●
we are a development-stage company and have a limited operating history on which to assess its business;
●
we have never generated any revenue from product sales and
        may never be profitable;
●
we will need to raise substantial additional funding, which
        may not be available on acceptable terms, or at all, and which will cause dilution to its shareholders;
●
the approach we are taking to discover and develop novel RNAi
        therapeutics is unproven for oncology and may never lead to marketable products;
●
we do not have experience producing our product candidates at commercial levels, currently have no marketing
        and sales organization, have an uncertain market receptiveness to our product candidates, and are uncertain as to whether there will be
        insurance coverage and reimbursement for its potential products;
●
we may be unable to attract, develop and/or retain its key personnel or additional employees required for
        our development and future success;
●
we may issue additional our ordinary shares or other equity securities without your approval, including:
        (a) up to $15,337,500 of ordinary shares issuable under the Ordinary Share Purchase Agreement, dated August 13, 2024 and effective as
        of August 15, 2024, by and between the Company and White Lion Capital, LLC ("White Lion") (the "White Lion Purchase
        Agreement" or "ELOC Agreement"), which established an equity line of credit for the Company; (b) ordinary shares underlying
        5,940,000 outstanding warrants; and (c) ordinary shares underlying convertible promissory notes that the Company has issued to (i) Moringa's
        sponsor, Moringa Sponsor, LP, a Cayman Islands exempted limited partnership (the "Sponsor" or "Moringa Sponsor"),
        in a principal amount of $3,433,000 (the "A&R Sponsor Promissory Note"), in amendment and restatement of all promissory
        notes previously issued by Moringa to the Sponsor for funds borrowed between Moringa's initial public offering and the completion
        of the Business Combination, and (ii) EarlyBird Capital, Inc. ("EarlyBird"), which served as the representative of the underwriters
        for Moringa's initial public offering, in an amount of $1,250,000 (the "EarlyBird Convertible Note"), each of which
        would dilute your ownership interest and may depress the market price of our ordinary shares; and
●
those additional factors described or incorporated by reference under the heading "
Risk
        Factors
" below.
Should one or more of these risks or uncertainties
materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these
forward-looking statements. It is not possible to predict or identify all such risks. Accordingly, forward-looking statements in this
prospectus and in any document incorporated herein by reference should not be relied upon as representing our views as of any subsequent
date, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise, except as may be required under applicable securities laws.
These forward-looking statements are based
on information available as of the date of this prospectus, and current expectations, forecasts and assumptions, and involve a number
of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as
of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances
after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable
securities laws.
You should read this prospectus and the documents
that we reference in this prospectus and have filed as exhibits to the registration statement of which this prospectus is a part, completely
and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking
statements by these cautionary statements.
In addition, statements that "we believe"
and similar statements reflect our beliefs and opinions on the relevant subject. Those statements are based upon information available
to us as of the date of this prospectus and while we believe such information forms a reasonable basis for such statements, such information
may be limited or incomplete, and such statements should not be read to indicate that we have conducted an exhaustive inquiry into, or
review of, all potentially available relevant information. Those statements are inherently uncertain, and investors are cautioned not
to unduly rely upon those statements.
TABLE OF CONTENTS
Page
Prospectus Summary
1
Risk Factors
7
Use of Proceeds
43
Capitalization
44
Dilution
45
Market Information for Securities
        and Dividend Policy
46
Unaudited Pro Forma Condensed
        Combined Financial Information
46
Management's Discussion
        and Analysis of Financial Condition and Results of Operations
61
Business
77
Management
106
Executive Compensation
112
Certain Relationships and
        Related Party Transactions
123
Beneficial Ownership of
        Securities
126
Description of Share Capital
129
Description of Securities
Offered
135
Material U.S. Federal Income
        Tax Consequences
138
Plan of Distribution
145
Legal Matters
148
Experts
148
Where You Can Find More
        Information
149
Index to Financial Statements
F-1
PROSPECTUS
SUMMARY
This summary highlights
information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your
investment decision. Before investing in our securities, you should carefully read this entire prospectus, including our consolidated
financial statements and the related notes thereto and the information set forth in the sections titled "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and Results of Operations."
Our Business
We are a clinical-stage, oncology-focused
biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an
oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus.
Based on our research of refractory solid tumor cancers, we are actively developing a platform focused on the silencing of the KRAS oncogene
using RNA-interference therapeutics. Our lead product candidate, SIL-204B, consists of locally administered small interfering RNAs, or
siRNA, in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination
with standard-of-care chemotherapy.
The KRAS oncogene is considered to be the
most common oncogenic gene driver in human cancers, and the most notable in pancreatic, lung, and gastrointestinal (GI) (including colorectal,
esophagus, stomach, small bowel, and appendix) cancers. Considered a challenging therapeutic target due to its intrinsic characteristics,
recent advances have been made at directly inhibiting the KRAS proteins produced by the mutated gene. Our platform is designed to silence
the gene, and thus prevent the production of the harmful mutated KRAS proteins driving the growth of cancerous tumors.
We are currently focused on treatment for
pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable,
i.e., they are not able to be surgically removed. For our first indication, we are targeting the largest and least treatable form of localized
pancreatic tumors referred to as locally advanced pancreatic cancer. LAPC represents approximately 30% of the total pancreatic cancer
population. We are currently developing SIL-204B, a second-generation siRNA product candidate following a Phase 1 and Phase 2 clinical
trial with our first-generation siRNA product candidate, siG12D-LODER, which we also refer to as Loder. Results from the Phase 2 clinical
trial showed a trend for differences between treatment groups in patients with the KRAS G12D/V mutation, with the Loder arm suggesting
an overall survival advantage of 9.3 months.
SIL-204B has been designed to optimize Loder
with the aim of improving uptake into tumor cells, enhancing stability, and improving the delivery system. We plan to conduct a Phase
2/3 prospective, randomized, controlled, multinational, two-arm, open-label trial in LAPC subjects that harbor the KRAS G12D/V mutations
to evaluate the efficacy, safety and tolerability of SIL-204B administered intratumorally in combination with standard of care (SoC) chemotherapy
versus SoC chemotherapy only. In support of our planned Phase 2/3 trial, we held a meeting with the Federal Institute for Drugs and Medical
Devices in Germany (BfArM) to discuss the planned design of the Phase 2/3 trial at which BfArM agreed, in principle, to the design. In
preparation for the study, we plan to initiate toxicology studies of SIL-204B in 2025 followed by the regulatory submission in the second
half of 2025 to initiate the Phase 2/3 trial and trial initiation in the first half of 2026 . At this time, we are focused on the further
development of the core siRNA technology underlying the Loder and SIL-204B as well as the clinical development of SIL-204B as the most
optimized version of the technology.
Corporate Information
We were originally known as Biomotion Sciences, a Cayman Islands exempted company. On April 3, 2024, we
entered into an amended and restated business combination agreement (the "Business Combination Agreement"), dated April 3,
2024, by and among our company (whose name was subsequently changed to Silexion Therapeutics Corp) ("New Silexion"), August
M.S. Ltd., an Israeli company and a wholly owned subsidiary of New Silexion ("Merger Sub 1"), Moringa Acquisition Merger Sub
Corp, a Cayman Islands exempted company and a wholly owned subsidiary of Silexion ("Merger Sub 2"), Moringa Acquisition Corp
("Moringa") and Silexion Therapeutics Ltd., an Israeli company ("Silexion"). On August 15, 2024 (the "Closing
Date"), the transactions contemplated by the Business Combination Agreement (collectively, the "Business Combination")
were completed (the "Closing"), following the approval of the Business Combination on August 6, 2024 by the extraordinary
general meeting of Moringa.
1
Our principal executive offices are located at 12 Abba Hillel Road, Ramat Gan, Israel
5250606, Israel and our phone number is +972-8-6286005. Our corporate website address is www.silexion.com. Information contained on or
accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive
textual reference only.
This prospectus contains trademarks, service
marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, trademarks
and trade names referred to in this prospectus may appear without the ® or ™ symbols, but such references are not intended
to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these
trademarks and trade names. We do not intend our use or display of other companies' trade names, trademarks or service marks to
imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Proposed Reverse Share Split
On October 22, 2024, we filed with the SEC, and soon thereafter we began to distribute
to our shareholders, a notice and proxy statement for an extraordinary general meeting of our company to be held on November 12, 2024
(the "extraordinary general meeting" or "meeting") at which we will present to our shareholders a proposal to
effect a reverse share split of our issued and outstanding, and our remaining authorized but unissued, ordinary shares at a ratio of between
1-for-10 and 1-for-20 (the "reverse share split"). The exact ratio of the reverse share split will be finalized by our board
of directors prior to the extraordinary general meeting and will be presented at the meeting. If the reverse share split is approved at
the meeting, holders of our ordinary shares will receive one ordinary share for every 10 to 20 ordinary shares currently held by them
(depending on the final ratio), and the number of our authorized but unissued ordinary shares will be reduced at that same ratio. Furthermore,
the par value of all ordinary shares, whether issued and outstanding, or unissued, will be increased proportionately to between $0.0010
and $0.0020. As of the effective time of the reverse share split (which will occur as soon as possible following shareholder approval
of the reverse share split proposal, if approved), proportionate adjustments will be made to (i) the number of ordinary shares that are
subject to all then-outstanding equity awards and warrants, such that fewer shares would underlie such awards and warrants, (ii) the exercise
price of all then-outstanding options and warrants, such that the per share exercise price of each such option and warrant would be increased,
and (iii) the number of ordinary shares available for issuance under the our equity incentive plans, such that fewer shares will be subject
to such plans. If the reverse share split is approved and implemented, all issued and outstanding, and authorized and unissued, ordinary
share data, all ordinary share equivalent data, and all per share data, will be adjusted retroactively throughout this prospectus to reflect
the reverse share split for all periods presented.
Implications of Being
a Smaller Reporting Company and Emerging Growth Company
We are a "smaller reporting company"
as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations,
including, among other things, providing only two years of audited financial statements and reduced disclosure obligations regarding executive
compensation. We will remain a smaller reporting company until the last day of any fiscal year for so long as either (1) the market value
of our ordinary shares held by non-affiliates does not equal or exceed $250 million as of the prior June 30th, or (2) our annual revenues
did not equal or exceed $100 million during such completed fiscal year and the market value of our ordinary shares held by non-affiliates
did not equal or exceed $700 million as of the prior June 30th. To the extent we take advantage of any reduced disclosure obligations,
it may make the comparison of our financial statements with other public companies difficult or impossible.
We are an "emerging growth company,"
as defined in the Jumpstart Our Business Startups Act of 2012 (t
he "JOBS Act"). A
s
an emerging growth company, we are exempt from certain requirements related to executive compensation, including the requirements to hold
a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief
Executive Officer to the median of the annual total compensation of all of our employees, each as required by the Investor Protection
and Securities Reform Act of 2010, which is part of the Dodd-Frank Act.
Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a registration statement under the Securities Act of 1933, as amended (the "Securities Act") declared
effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial
accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the
requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have elected not to opt
out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for
public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt
the new or revised standard. This may make comparison of our financial statements with those of another public company that is neither
an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible
because of the potential differences in accounting standards used.
We will remain an emerging growth company until the earlier of: (1) the last day of
the fiscal year (a) following the fifth anniversary of the date on which our ordinary shares were offered in exchange for ordinary shares
of each of Moringa and Silexion, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed
to be a large accelerated filer, which means the market value of our common equity that is held by non-affiliates exceeds $700 million
as of the end of the prior fiscal year's second fiscal quarter; and (2) the date on which we have issued more than $1.00 billion
in non-convertible debt securities during the prior three-year period. References herein to "emerging growth company" are
to its meaning under the Securities Act, as modified by the JOBS Act.
2
Summary of Risk Factors
Investing in our securities involves risks. You should carefully consider the risks
described in "
Risk Factors
" before making a decision to invest in our securities.
If any of these risks is actualized, our business, financial condition and results of operations would likely be materially adversely
affected. In such case, the trading price of our securities would likely decline, and you may lose all or part of your investment. In
particular, you should consider the risk factors described under "
Risk Factors
" beginning
on page 7. Such risks include, but are not limited to:
Risks
Relating to our Financial Condition and Capital Requirements
,
including
that:
●
We have never generated any revenue from product sales and may never be profitable.
●
We will need to raise substantial additional funding, which may not be available on acceptable terms, or
        at all, and which will cause dilution to its shareholders.
Risks Relating
to Silexion's Business and Industry
, including that:
●
We are a development-stage company and has a limited operating history on which to assess its business.
●
The approach we are taking to discover and develop novel RNAi therapeutics is unproven for oncology and
        may never lead to marketable products.
●
We are heavily dependent on the success of its product candidates, which are in the early stages of preclinical
        or clinical development, and cannot give any assurance that any of our product candidates will receive regulatory approval, which is a
        lengthy, time consuming, and inherently unpredictable process.
●
We may find it difficult to enroll patients in our clinical studies, which could delay or prevent clinical
        studies of its product candidates.
●
We are subject to a multitude of manufacturing risks, any of which could substantially increase its costs
        and limit supply of its product candidates.
●
We rely on third parties to conduct its preclinical and clinical studies, and to manufacture the raw materials
        and products that it uses to create its product candidates and to supply it with the medical devices used to administer such products,
        which entails regulatory and trade secrets-related risks.
●
We do not have experience producing its product candidates at commercial levels, currently has no marketing
        and sales organization, has an uncertain market receptiveness to its product candidates, and is uncertain as to whether there will be
        insurance coverage and reimbursement for its potential products.
●
We face competition from other companies that are working to develop novel drugs and technology platforms
        using technology similar or in the same field as ours.
●
If we are unable to obtain and maintain effective patent rights for its product candidates or any future
        product candidates, we may not be able to compete effectively in its markets.
●
We may be unable to attract, develop and/or retain its key personnel or additional employees required for
        its development and future success.
3
Risks
Relating to the Offering
, including that:
●
This offering is being made on a best efforts basis and we may sell fewer than all
        of the securities offered hereby and may receive significantly less in net proceeds from this offering, which will provide us only limited
        working capital.
●
Our management team will have immediate and broad discretion over the use of the
        net proceeds from this offering and may not use them effectively.
●
You will experience immediate dilution in the book value per share of the ordinary
        shares purchased in the offering.
●
Purchasers who purchase our securities in this offering pursuant to a securities
        purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement.
●
Ordinary shares representing a substantial percentage of our outstanding shares
        may be sold in this offering, which could cause the price of our ordinary shares to decline.
●
There is no public market for the warrants being offered or pre-funded warrants
        in this offering.
●
The pre-funded warrants are speculative in nature.
●
The ordinary warrants may not have any value.
●
Holders of the pre-funded warrants and ordinary warrants offered hereby will have
        no rights as our ordinary shareholders with respect to the ordinary shares underlying those warrants until such holders exercise their
        warrants and acquire our ordinary shares, except as otherwise provided in the ordinary warrants.
Risks Relating to Owning Our Ordinary Shares,
including
that:
●
The price of our ordinary shares and our warrants may be volatile.
●
A substantial number of our ordinary shares may be issued pursuant to the White Lion Purchase Agreement
        and/or the conversion terms of the A&R Sponsor Promissory Note and the EarlyBird Convertible Note, which could cause (i) substantial
        dilution and (ii) the market price of the ordinary shares to decline.
●
We have no current plans to pay cash dividends on our ordinary
        shares for the foreseeable future.
4
The Offering
Ordinary shares
Up to                 ordinary shares on a best-efforts basis
        based on an assumed public offering price of $            per ordinary share and accompanying ordinary warrant
        (the last reported sale price of our ordinary shares on the Nasdaq on               , 2024).
Pre-funded warrants
We are also offering to those purchasers, if any, whose purchase of our ordinary shares in this offering
        would otherwise result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99%
        (or, at the election of the purchaser, 9.99%) of our outstanding ordinary shares immediately following the consummation of this offering,
        the opportunity, in lieu of purchasing ordinary shares, to purchase pre-funded warrants to purchase ordinary shares. Each pre-funded warrant
        will be immediately exercisable for one ordinary share at any time at the option of the holder until such pre-funded warrant is exercised
        in full, provided that the holder will be prohibited from exercising pre-funded warrants for ordinary shares if, as a result of such exercise,
        the holder, together with its affiliates and certain related parties, would own more than 4.99% (or, at the election of the purchaser,
        9.99%) of the total number of ordinary shares then issued and outstanding. The purchase price of each pre-funded warrant is $ 
                       (which is equal to the assumed public offering price per ordinary share and ordinary
        warrant to be sold in this offering minus $0.0001, the exercise price per ordinary share of each pre-funded warrant). For each pre-funded
        warrant we sell, the number of ordinary shares we are offering will be decreased on a one-for-one basis. This offering also relates to
        the ordinary shares issuable upon exercise of any pre-funded warrants sold in this offering. See "
Description
        of the Securities Offered
" for more information.
Warrants
Each ordinary share and each pre-funded warrant will be sold together with one ordinary warrant. Each
        ordinary warrant will have an exercise price of $      per share (which will be no less than
% of the assumed public offering price per ordinary share to
        be sold in this offering), will be exercisable upon issuance and will expire on          , 2029. Because we will
        issue an ordinary warrant for each ordinary share and for each pre-funded warrant sold in this offering, the number of ordinary warrants
        sold in this offering will not change as a result of a change in the mix of ordinary shares and pre-funded warrants sold. This offering
        also relates to the ordinary shares issuable upon exercise of any ordinary warrants sold in this offering. See "
Description
        of the Securities Offered
" for more information.
Ordinary shares outstanding prior to this offering
ordinary shares
Ordinary shares outstanding after this offering
Ordinary shares (assuming no sale of any pre-funded warrants and no exercise of the ordinary warrants).
Use of proceeds
Assuming the maximum number of ordinary shares are sold in this offering at an assumed public offering
        price of $          per ordinary share, which represents the closing price of our ordinary shares on Nasdaq on 
                , 2024, and assuming no issuance of pre-funded warrants and no exercise of the ordinary warrants in connection
        with this offering, we estimate the net proceeds of the offering will be approximately $          million, after
        deducting the placement agent fees and estimated offering expenses payable by us. However, this is a best efforts offering with no minimum
        number of securities or amount of proceeds as a condition to closing, and we may not sell all or any of these securities offered pursuant
        to this prospectus; as a result, we may receive significantly less in net proceeds.
We currently intend to use the net proceeds from this offering to advance our pre-clinical clinical studies,
        and for general corporate purposes. Pending such uses, we intend to invest the net proceeds in bank deposits. We have not determined the
        amount of net proceeds to be used specifically for such purposes. As a result, our management will have broad discretion in the application
        of the net proceeds of this offering. See "
Use of Proceeds
" for additional information.
Risk factors
Before investing in our securities, you should carefully read and consider the information set forth in
        "Risk Factors" beginning on page 7.
Nasdaq ticker symbols
Our ordinary shares and warrants are listed on the Nasdaq under the symbols "SLXN" and "SLXNW",
        respectively. There is no established public trading market for the ordinary warrants being offered and the pre-funded warrants and we
        do not expect a market to develop. Without an active trading market, the liquidity of those warrants will be limited. In addition, we
        do not intend to list the pre-funded warrants or the ordinary warrants on The Nasdaq Global Market, any other national securities exchange
        or any other trading system.
Best efforts offering
We have agreed to offer and sell the securities offered hereby to the purchasers through the Placement
        Agent. The Placement Agent is not required to buy or sell any specific number or dollar amount of the securities offered hereby, but it
        will use its reasonable best efforts to solicit offers to purchase the securities offered by this prospectus. See "
Plan
        of Distribution
" on page 145 of this prospectus.
5
The number of the ordinary shares to be outstanding immediately after this offering
as shown above assumes that all of the ordinary shares offered hereby are sold and is based on           
     ordinary shares issued and outstanding as of                2024. This number
excludes:
●
up to 5,940,000 ordinary shares underlying an equivalent number of outstanding warrants at an exercise price of $11.50 per share;
●
6,866,000 ordinary shares issuable pursuant to the A&R Sponsor Promissory Note (based on the conversion of the entire $3,433,000
        principal amount of that note into ordinary shares at an assumed conversion price of $0.50 per share);
●
2,500,000 ordinary shares issuable pursuant to the EarlyBird Convertible Note (based on the conversion of the entire $1,250,000 principal
        amount of that note into ordinary shares at an assumed conversion price of $0.50 per share);
●
ordinary shares issuable upon exercise of outstanding stock options
        under our equity incentive plan, at a weighted average exercise price of $          ;
●
ordinary shares issuable upon the settlement of RSUs under our equity
        incentive plan; and
●
ordinary shares reserved for future awards under our equity incentive plan;
Unless otherwise indicated, all information in this prospectus
assumes or gives effect to:
●
no exercise of the options described above;
●
no sale of pre-funded warrants in this offering;
●
no exercise of the ordinary warrants and the placement agent warrants; and
●
the reverse share split effected on             , 2024.
6
RISK
FACTORS
Investing in our securities
involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other
information contained in this prospectus, including our financial statements and related notes appearing at the end of this prospectus
and in the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations," before
deciding to invest in our securities. If any of the events or developments described below were to occur, our business, prospects, operating
results and financial condition could suffer materially, the trading price of our ordinary shares could decline, and you could lose all
or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties
not presently known to us or that we currently believe to be immaterial may also adversely affect our business.
Risks Related to Our Financial Condition and
Capital Requirements
We are a development-stage company
and have a limited operating history on which to assess our business. We have incurred significant losses since its inception and anticipate
that we will continue to incur significant losses for the foreseeable future.
We are a development stage company with
a limited operating history focused on the discovery and development of treatments based on the emerging therapeutic modality RNA interference
(RNAi), a biological process in which ribonucleic acid (RNA) molecules inhibit gene expression. Our proposed treatment, which we refer
to as SIL-204B, consists of locally administered small interfering RNAs, or siRNA, to KRAS G12D- or KRAS G12V-mutations (G12D/V),
which is the gene driver that causes development of tumors and human cancer (oncogenic). We have incurred net losses since our inception
in November 2008, including net losses of $5.1 million for the year ended December 31, 2023 and $2.9 million for the
six months ended June 30, 2024. As of June 30, 2024, we have an accumulated deficit of $29.7 million.
We have devoted substantially all of our
financial resources to design and develop our product candidates, including conducting preclinical and clinical studies and providing
general and administrative support for these operations. To date, we have financed our operations primarily through the sale of equity
securities and through royalty-bearing grants that we received from Israel's Innovation Authority, or the IIA. The amount
of its future net losses will depend, in part, on the rate of its future expenditures and its ability to obtain funding through equity
or debt financings, strategic collaborations, or grants. Biopharmaceutical product development is a highly speculative undertaking and
involves a substantial degree of risk. We are the early stages of clinical and preclinical development for its product candidates, we
have we have not yet commenced pivotal clinical studies for any product candidate and it may be several years, if ever, before we
complete pivotal clinical studies and have a product candidate approved for commercialization. Even if we obtain regulatory approval to
market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval,
and its ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors, and adequate market share
for its product candidates in those markets.
We expect to continue to incur significant
expenses and increasing operating losses for the foreseeable future. We anticipate that its expenses will increase substantially if and
as we:
●
continue and expand our research and preclinical and clinical
        development of our product candidates;
●
initiate additional preclinical, toxicology, clinical, or other
        studies for our product candidates;
●
continue to improve our quality standards and change or add
        additional manufacturers or suppliers;
●
seek regulatory and marketing approvals for our product candidates
        that successfully complete clinical studies;
7
●
establish a sales, marketing, and distribution infrastructure
        to commercialize any products for which we may obtain marketing approval;
●
seek to identify, assess, acquire, license, and/or develop other product candidates;
●
enter into license agreements;
●
seek to maintain, protect, and expand our intellectual property portfolio;
●
seek to attract and retain skilled personnel;
●
create additional infrastructure to support its operations as a public company and our product development
        and planned future commercialization efforts; and
●
experience any delays or encounter issues with any of the above, including but not limited to failed studies,
        complex results, safety issues, or other regulatory challenges that require longer follow-up of existing studies, additional major
        studies, or additional supportive studies in order to pursue marketing approval.
Further, the net losses we incur may fluctuate
significantly from quarter to quarter and year to year, such that a period-to-period comparison of its results of operations may
not be a good indication of our future performance.
We have never generated
any revenue from product sales and may never be profitable.
We have we have no products approved for
commercialization and has never generated any revenue. Our ability to generate revenue and achieve profitability depends on its ability,
alone or with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory and marketing approvals
necessary to commercialize, one or more of our product candidates. We do not anticipate generating revenue from product sales for the
foreseeable future. Our ability to generate future revenue from product sales depends heavily on its success in many areas, including
but not limited to:
●
completing research and preclinical and toxicology and clinical development of our product candidates;
●
obtaining regulatory and marketing approvals for its product candidates, if and when we complete clinical
        studies;
●
developing a sustainable and scalable in-house manufacturing process, meeting all regulatory standards
        for approved product candidates, and in some instances, establishing and maintaining supply and manufacturing relationships with third
        parties that can conduct the process and provide adequate (in amount and quality) products to support clinical development and the market
        demand for product candidates, if approved;
●
launching and commercializing product candidates, if and when we obtain regulatory and marketing approval,
        either directly or with a collaborator or distributor;
●
exposing, educating and training physicians to use our products;
●
obtaining market acceptance of our product candidates as viable treatment options;
●
addressing any competing technological and market developments;
●
identifying, assessing, acquiring and/or developing new product
        candidates;
8
●
negotiating favorable terms in any collaboration, licensing,
        or other arrangements into which we may enter;
●
maintaining, protecting, and expanding its portfolio of intellectual
        property rights, including patents, trade secrets, and know-how; and
●
attracting, hiring, and retaining qualified personnel.
Even if one or more of the product candidates
that we develop is approved for commercial sale, it anticipates incurring significant costs associated with commercializing any approved
product candidate. Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency (EMA)
or other regulatory agencies, domestic or foreign, or ethical committees in medical centers, to change its manufacturing processes or
assays or to perform clinical, nonclinical, or other types of studies in addition to those that it currently anticipates. In cases where
we are successful in obtaining regulatory approvals to market one or more of its product candidates, its revenue will be dependent, in
part, upon the size of the markets in the territories for which it gains regulatory approval, the accepted price for the product, the
ability to get reimbursement at any price, and whether it owns the commercial rights for that territory. If the number of its addressable
disease patients is not as significant as it estimates, the indication approved by regulatory authorities is narrower than it expects,
or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate
significant revenue from sales of such products, even if approved. Additionally, there might be changes in supply or other changes in
the approved drugs of which its products will be administrated in combination, where such changes can affect its revenues. Further, if
we are not able to generate revenue from the sale of any approved products, we may be forced to cease operations.
We expect that we will
need to raise substantial additional funding before we can expect to become profitable from product sales. This additional financing may
not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit, or
terminate our product development efforts or other operations.
We are currently advancing its SIL-204B platform
product through preclinical and clinical development. Developing its product candidates is expensive, and we expect its research and development
expenses to increase substantially in connection with its ongoing activities, particularly as it advances its product candidates through
clinical studies.
If its product candidates enter and advance
through preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing,
marketing and sales capabilities or contract with other organizations to provide those capabilities for it. We have used substantial funds
to develop its product candidates and delivery technologies and will require significant funds to conduct further research and development
and preclinical testing and clinical trials of its product candidates, to seek regulatory approvals for its product candidates and to
manufacture and market products, if any, which are approved for commercial sale.
As of June 30, 2024, our cash and cash equivalents
were $1.75 million. Based upon its then expected level of operating expenditures, Silexion had substantial doubt about its ability
to continue as a going concern as of such date. Please see the risk factor below titled "
our independent
registered public accounting firm's report contains an explanatory paragraph
…" Beyond its activities for the
next 12 months, we furthermore expect that it will require substantial additional capital to advance manufacturing capabilities for,
to obtain regulatory approval for, and to commercialize, our product candidates. In addition, our operating plans may change as a result
of many factors that may currently be unknown to it, and we may need to seek additional funds sooner than planned. Our future funding
requirements will depend on many factors, including but not limited to:
●
the scope, rate of progress, results and cost of our clinical
        studies, preclinical testing, toxicology studies, and other related activities;
9
●
the cost of manufacturing clinical supplies, and establishing
        commercial supplies of our product candidates and any future products;
●
the number and characteristics of product candidates that we
        pursue;
●
the cost, timing, and outcomes of regulatory approvals;
●
the cost and timing of establishing sales, marketing, and distribution
        capabilities; and
●
the terms and timing of any collaborative, licensing, and other
        arrangements that we may establish.
Any additional fundraising efforts may divert
our management from our day-to-day activities, which may adversely affect our abilities to develop and commercialize our product
candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us,
if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders, and the issuance
of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ordinary
shares to decline due to expected or actual dilution. The incurrence of indebtedness could result in increased fixed payment obligations,
and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire, sell, or license intellectual property rights, and other operating restrictions that could adversely impact
our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise
at an earlier stage than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or product
candidates or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on our business, operating results,
and prospects. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if
market conditions are favorable or if we have specific strategic considerations.
If we are unable to obtain funding on a
timely basis, it may be required to significantly curtail, delay, or discontinue one or more of our research, development or manufacturing
programs or the commercialization of any product candidates, or be unable to expand its operations or otherwise capitalize on our business
opportunities, as desired, which could materially affect our business, financial condition, and results of operations.
Our independent registered
public accounting firm's report contains an explanatory paragraph that expresses substantial doubt about our ability to continue
as a "going concern."
We have limited cash resources and will
need to obtain additional funds in order to satisfy our liquidity needs. Silexion will require significant funds to conduct further research
and development and preclinical testing and clinical trials of our product candidates, to seek regulatory approvals for our product candidates
and to manufacture and market products, if any, which are approved for commercial sale. In light of our significant working capital needs
and the absence of any committed source of financing to meet those needs, there may be substantial doubt raised about our ability to continue
as a "going concern." Please see the explanatory paragraph under the heading "Substantial Doubt about the Company's
Ability to Continue as a Going Concern" in our independent auditors' report on our financial statements that appear in this
prospectus. Those financial statements do not include any adjustments that might result from our inability to continue as a "going
concern."
The historical financial
results of Silexion and unaudited pro forma financial information included herein may not be indicative of what our actual financial position
or results of operations would have been.
The historical financial results of Silexion
included in this prospectus do not reflect the financial condition, results of operations or cash flows it would have achieved as a public
company during the periods presented or those the Company will achieve in the future. Our financial condition and future results of operations
could be materially different from amounts reflected in certain of our historical financial statements included elsewhere in this prospectus,
and it may be difficult for investors to compare our future results to historical results or to evaluate its relative performance or trends
in our business.
10
Similarly, the unaudited pro forma financial
information included herein is presented for illustrative purposes only and has been prepared based on a number of assumptions. Accordingly,
such pro forma financial information is not necessarily indicative of what our actual financial position or results of operations would
have been had the Business Combination been completed on the dates indicated, and our actual financial condition and results of operations
may vary materially from such pro forma financial information, including as a result of such assumptions not being accurate. See "Unaudited
Pro Forma Condensed Combined Financial Information."
Risks Related to the Research and Development
of Our Product Candidates
The approach we are
taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.
We have concentrated our efforts and therapeutic
product research on RNAi technology, and RNAi drug delivery and our future success depends on the successful development of this technology
and products based on it. We have not received regulatory approval to market therapeutics utilizing RNAi based drugs, including siRNAs,
the class of molecule we are trying to develop into products. The scientific discoveries that form the basis for our efforts to discover
and develop new drugs are relatively new. The scientific evidence to support the feasibility of developing drugs and the delivery of such
drugs based on these discoveries is both preliminary and limited. Skepticism as to the feasibility of developing RNAi therapeutics for
oncology has been expressed in scientific literature. For example, there are potential challenges to achieving safe RNAi therapeutics
based on the so-called off-target effects and activation of the interferon response, and other potential challenges to achieve
safe and potent levels of RNAi drugs due to complications associated with drug delivery. In addition, decisions by other companies with
respect to their RNAi development efforts may increase skepticism in the marketplace regarding the potential for RNAi therapeutics.
Relatively few product candidates based
on these discoveries have ever been tested in animals or humans. siRNAs may not naturally possess the inherent properties typically required
of drugs, such as the ability to be stable in the body long enough to reach the tissues in which their effects are required, or the ability
to enter cells within these tissues in order to exert their effects. We are currently has only limited data, and no conclusive evidence,
to suggest that it can introduce these drug-like properties into siRNAs. We may spend large amounts of money trying to introduce
these properties, and may never succeed in doing so. In addition, these compounds may not demonstrate in patients the chemical and pharmacological
properties ascribed to them in laboratory studies, and they may interact with human biological systems in unforeseen, ineffective or harmful
ways. As a result, we may never succeed in developing a marketable product, we may not become profitable and the value of our ordinary
shares may decline.
The FDA has relatively limited experience
with RNAi and siRNA based therapeutics. Limited granted approvals to any person or entity, including us, to market and commercialize therapeutics
using RNAi based drugs including siRNA, which may increase the complexity, uncertainty and length of the regulatory approval process for
our product candidates. Further, siRNA therapies are part of a broader therapeutic category called oligonueciotides, and there are only
a few approved drugs based on this therapeutic category. We may never receive approval to market and commercialize any product candidate.
Further, our focus on RNAi technology for
developing drugs, as opposed to multiple, more proven technologies for drug development, increases the risks associated with the ownership
of our ordinary shares. If we are not successful in developing a product candidate using RNAi technology, we may be required to change
the scope and direction of our product development activities. In that case, we may not be able to identify and implement successfully
an alternative product development strategy.
We are heavily dependent
on the success of our product candidates, which are in the early stages of preclinical or clinical development. We cannot give any assurance
that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.
To date, we have invested a substantial
amount of our efforts and financial resources to: (i) identify and develop our product candidates, including conducting preclinical
and clinical studies and providing general and administrative support for these operations; and (ii) develop and secure our intellectual
property portfolio for our product candidates. Our future success is dependent on our ability to successfully develop, obtain regulatory
approval for, and then successfully commercialize one or more product candidates. We currently generate no revenue from sales of any drugs
or technology platforms, and we may never be able to develop or commercialize a marketable drug.
11
Each of our product candidates is in the
early stages of development and will require additional clinical development (and in some cases additional preclinical development), management
of nonclinical, clinical and manufacturing activities, regulatory approval, obtaining adequate manufacturing supply, building of a commercial
organization, and significant marketing efforts before we generate any revenue from product sales. We have concluded Phase II study
on first-generation Loder and moved on to SIL-204B. Silexion hopes to initiate the next clinical trial with SIL-204B during
the first half of 2026 for locally advanced pancreatic cancer. We are not permitted to market or promote any of our product candidates
before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory
approval for any of our product candidates.
We have never submitted marketing applications
to the FDA or comparable foreign regulatory authorities. We cannot be certain that any of our product candidates will be successful in
clinical studies or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are
successful in clinical studies. If it does not receive regulatory approvals for our product candidates, we may not be able to continue
our operations.
We generally plans to seek regulatory approval
to commercialize our product candidates in the United States, the EU and in additional foreign countries. To obtain regulatory approval
in other countries, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy,
chemistry, manufacturing and controls, clinical studies, commercial sales, pricing, and distribution of our product candidates. Even if
we are successful in obtaining approval in one jurisdiction, it cannot ensure that it will obtain approval in any other jurisdictions.
If we are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could
be negatively affected.
The regulatory approval
processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately
unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
The time required to develop a drug and obtain approval by the
FDA and comparable foreign authorities is unpredictable, typically takes many years following the commencement of clinical studies, and
depends upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain
approval may change during the course of a product candidate's clinical development and may vary among jurisdictions, which may
cause delays in the approval or the decision not to approve an application. We have we have not obtained regulatory approval for any product
candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future
will ever obtain regulatory approval.
Applications for our product candidates could
fail to receive regulatory approval for many reasons, including but not limited to the following:
●
the FDA or comparable foreign regulatory authorities may disagree
        with the design or implementation of our clinical studies;
●
We may be unable to demonstrate to the FDA or comparable foreign
        regulatory authorities that a product candidate's benefit to risk ratio for its proposed indication is acceptable;
●
the population studied in the clinical program may not be sufficiently broad or representative to assure
        safety in the full population for which we seek approval;
●
the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from
        preclinical studies or clinical studies;
12
●
the data collected from clinical studies of our product candidates may not be sufficient to support the
        submission of a new drug application (NDA) or a biologics license application (BLA) or other submission or to obtain regulatory approval
        in the United States or elsewhere;
●
the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test
        procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;
        and
●
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly
        change in a manner rendering our clinical data insufficient for approval.
This lengthy development and approval process,
as well as the unpredictability of the results of clinical studies, may result in our failing to obtain regulatory approval to market
any of its product candidates, which would significantly harm its business, and our consolidated results of operations and prospects.
Clinical drug development
involves a lengthy and expensive process with an uncertain outcome, and results of preclinical activity or earlier studies may not be
predictive of future study results.
Before obtaining marketing approval from
regulatory authorities for the sale of its product candidates, we must conduct extensive clinical studies to demonstrate the safety and
efficacy of the product candidates in humans. Clinical testing is expensive and can take many years to complete, and its outcome
is inherently uncertain. Failure can occur at any time during the clinical study process. The results of preclinical studies and early
clinical studies of product candidates often are not predictive of the results of later-stage clinical studies. In general, even
product candidates that have shown promising results in preclinical activities or early-stage clinical studies may still suffer significant
setbacks in subsequent registration clinical studies. For example, the safety or efficacy results generated to date in preclinical and
clinical studies for siG12DLoder or preclinical studies with SIL-204B do not ensure that later clinical studies will demonstrate
similar results. There is a high failure rate for drugs and biologics proceeding through clinical studies, and product candidates in later
stages of clinical studies may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies
and initial clinical studies. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical
studies due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies. Moreover, preclinical
and clinical data are often susceptible to varying interpretations and analyses. We do not know whether any Phase 1, Phase 2,
Phase 3 or other clinical studies it may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain
regulatory approval to market its drug candidates.
Events that may prevent successful or timely
completion of clinical development include but are not limited to:
●
inability to generate sufficient preclinical, toxicology, or
        other
in vivo
or
in vitro
data to
        support the initiation of human clinical studies;
●
delays in reaching a consensus with regulatory agencies on study
        design;
●
delays in reaching agreement on acceptable terms with prospective
        contract research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary
        significantly among different CROs and clinical study sites;
●
delays in obtaining required Institutional Review Board (IRB)
        or Ethics Committee approval at each clinical study site;
●
imposition of a clinical hold by regulatory agencies, after review
        of an investigational new drug (IND) application, or equivalent application, or an inspection of its clinical study operations or study
        sites;
●
difficulty collaborating with patient groups and investigators;
●
failure by its CROs, other third parties, or us to adhere to
        clinical study requirements;
●
failure to perform in accordance with the FDA's good clinical
        practices requirements or applicable regulatory guidelines in other countries;
13
●
occurrence of serious adverse events associated with the product
        candidate that are viewed to outweigh its potential benefits;
●
the cost of clinical studies of its drug candidates being greater
        than it anticipates;
●
clinical studies of its drug candidates producing negative or
        inconclusive results, which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or abandon drug
        development programs; and
●
failures associated with data interpretation, data management
        and data storage of such studies.
If we ultimately is unable to successfully
complete clinical development of its product candidates, it would be forced to cease operations. Clinical study delays could also shorten
any periods during which its products have patent protection and may allow its competitors to bring products to market before we do, which
could impair its ability to obtain orphan exclusivity and to successfully commercialize its product candidates.
We may find it difficult
to enroll patients in its clinical studies. Difficulty in enrolling patients could delay or prevent clinical studies of its product candidates.
Identifying and qualifying patients to participate
in clinical studies of our product candidates is critical to its success. The timing of its clinical studies depends in part on the speed
at which it can recruit patients to participate in testing its product candidates, and we may experience delays in its clinical studies
if it encounters difficulties in enrollment.
Some of the conditions for which we plan
to evaluate its current product candidates are relatively rare diseases. For example, according to the National Cancer Institute, approximately
61,000 patients were diagnosed with pancreatic cancer in the U.S. in 2020. Accordingly, there are limited patient pools from which
to draw for clinical studies. In addition to the relative rarity of these diseases, the eligibility criteria of its clinical studies will
further limit the pool of available study participants as we will require that patients have specific characteristics that it can measure
or to assure their disease is either severe enough or not too advanced to include them in a study. We also may not be able to identify,
recruit, and enroll a sufficient number of patients to complete its clinical studies because of the perceived risks and benefits of the
product candidate under study, the availability and efficacy of competing therapies and clinical studies, the proximity and availability
of clinical study sites for prospective patients, and the patient referral practices of physicians.
In addition, even for the more prevalent
diseases which we target, such as prostate and breast cancer, enrolling patients in its clinical studies may be difficult. There may be
several ongoing clinical studies for these diseases (both RNAi based and otherwise), and we may face competition in enrolling patients.
The number of patients in such clinical studies might be significantly large. In addition, the time period required to achieve indications
of safety and efficacy in such studies may be very long. Some of these competing studies may be conducted by other biopharmaceutical companies
with more experience in clinical testing and with much greater financial, technical and human resources than we have.
If patients are unwilling to participate
in its studies for any reason, the timeline for recruiting patients, conducting studies, and obtaining regulatory approval of our potential
products will be delayed.
Our product candidates
and the administration of its product candidates may cause undesirable side effects or have other properties that could delay or prevent
their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following
marketing approval, if any.
Undesirable side effects including toxicology
caused by its product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical studies and could result
in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. For example,
there are known immune stimulation and other side effects associated with RNAi. The implantation of SIL-204B may entail the use of
endoscopic ultrasound (EUS) needles, which may cause pancreatitis, bleeding or other procedural related safety issues. The Phase 2
clinical study with siG12DLoder indicated that Loder treatment was well tolerated. Safety events that were observed were primarily related
to procedure, mainly reversible abdominal pain. In addition, the presence of a foreign body such as its SIL-204B) in human tissue may
cause inflammation. Results of our studies could reveal a high and unacceptable severity and prevalence of these or other side effects.
In such an event, such studies could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order
us to cease further development of or deny or withdraw approval of its product candidates for any or all targeted indications.
14
The drug-related, drug-product related,
and administration related side effects could affect patient recruitment, the ability of enrolled patients to complete the study, or result
in potential product liability claims. we do not currently have product liability insurance and does not anticipate obtaining product
liability insurance until such time as we have received FDA or other comparable foreign authority approval for a product and there is
a product that is being provided to patients outside of clinical trials.
Additionally, if one or more of its product
candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of
potentially significant negative consequences could result, including but not limited to:
●
regulatory authorities may withdraw approvals of such product;
●
regulatory authorities may require additional warnings on the
        label;
●
We may be required to create a Risk Evaluation and Mitigation
        Strategy (REMS) plan or similar plan in other jurisdictions, which could include a medication guide outlining the risks of such side effects
        for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;
●
We could be sued and held liable for harm caused to patients;
        and
●
Our reputation may suffer.
Any of these events could prevent us from
achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm its business,
results of operations, and prospects.
Even if we obtain regulatory
approval for a product candidate, its products will remain subject to regulatory scrutiny.
If our product candidates are approved, they will be subject to ongoing regulatory requirements
for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies,
and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States
and other jurisdictions, where the product might be marketed. Accordingly, us and others with whom it works must continue to expend time,
money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.
Any regulatory approvals that we receive
for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or
to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical
trials, and surveillance to monitor the safety and efficacy of the product candidate. We will also be required to report certain adverse
reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion for its products.
Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be
consistent with the information in the product's approved label. As such, we may not promote our products for indications or uses
for which they do not have FDA approval. The holder of an approved NDA or BLA must also submit new or supplemental applications and obtain
FDA approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct
post-marketing clinical studies to verify the safety and efficacy of its products in general or in specific patient subsets. If we
obtain original marketing approval via the accelerated approval pathway, it could be required to conduct a successful post-marketing clinical
study to confirm clinical benefit for its products. An unsuccessful post-marketing study or failure to complete such a study could
result in the withdrawal of marketing approval. Furthermore, any new legislation addressing drug safety issues could result in delays
in product development or commercialization or increased costs to assure compliance. Foreign regulatory authorities impose similar requirements.
15
If a regulatory agency discovers previously
unknown problems with a product, such as adverse events of unanticipated severity or frequency, or disagrees with the promotion, marketing
or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the
product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may,
among other things:
●
issue warning letters;
●
impose civil or criminal penalties;
●
suspend or withdraw regulatory approval;
●
suspend any of our ongoing clinical studies;
●
refuse to approve pending applications or
        supplements to approved applications submitted by Silexion; or
●
seize or detain products, or require a product
        recall.
Any government investigation of alleged
violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure
to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue
from its products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of the Company and its operating
results will be adversely affected.
The FDA and other regulatory
agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
If any of its product candidates are approved
and they are found to have been improperly promoted for unapproved uses of those products, we may become subject to significant liability.
The FDA and other regulatory agencies or other governmental bodies strictly regulate the promotional claims that may be made about prescription
products, such as its product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by
the FDA or such other regulatory agencies as reflected in the product's approved labeling. If we receive marketing approval for
a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label.
If we are found to have promoted such unapproved, or off-label, uses, they may become subject to significant liability. The U.S. federal
government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined
several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent
injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of its product
candidates, if approved, it could become subject to significant liability, which would materially adversely affect its business and financial
condition.
We and our collaborators are subject to significant regulation with
respect to manufacturing its product candidates. The facilities we subcontract to for manufacturing may not meet regulatory requirements
and may have limited capacity.
All entities involved in the preparation
of therapeutics for clinical studies or commercial sale are subject to extensive regulation. Components of a finished therapeutic product
approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with current GMP (cGMP) or,
in other countries, GMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation
and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control
of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of its product
candidates that may not be detectable in final product testing. Us, our collaborators, or any contract manufacturers must supply all necessary
documentation in support of an NDA, BLA, or Marketing Authorization Application (MAA) on a timely basis and must adhere to Good Laboratory
Practices (GLP) and cGMP/GMP regulations enforced by the FDA and other regulatory agencies through their facilities and data and documentation
inspection programs. We have never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite
regulatory authority approvals to do so. Our facilities and quality systems, and those of its collaborators and any third-party contractors,
must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of its product
candidates or any of its other potential products. In addition, the regulatory authorities may, at any time, inspect a manufacturing facility
involved with the preparation of its product candidates or its other potential products or the associated quality systems for compliance
with the regulations applicable to the activities being conducted. If these facilities do not pass a preapproval plant inspection, regulatory
approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of
the regulatory authority, if ever.
16
The regulatory authorities also may, at
any time following approval of a product for sale, audit a manufacturing facility. If any such inspection or audit identifies a failure
to comply with applicable regulations or if a violation of its product specifications or applicable regulations occurs independent of
such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming
for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales
or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us, or third parties with whom it contracts
could materially harm its business.
If we, our collaborators, or any of our
third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authorities can impose regulatory
sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, withdrawal
of an approval, or suspension of production. As a result, our business, financial condition, and results of operations may be materially
harmed.
These factors could cause us to incur higher
costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals, or commercialization of
our product candidates.
We are subject to a
multitude of manufacturing risks, any of which could substantially increase its costs and limit supply of its product candidates.
The process of manufacturing our product
candidates is complex, highly regulated, and subject to several risks, including but not limited to:
●
the process of manufacturing RNAi-drugs, drug substances, and
        RNAi-delivery vehicles, such as our product candidates, is extremely susceptible to product loss due to contamination, equipment
        failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing
        processes for any of its product candidates could result in reduced production yields, product defects, and other supply disruptions.
        If microbial, viral, or other contaminations are discovered in its product candidates or in the manufacturing facilities in which its
        product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy
        the contamination; and
●
the manufacturing facilities in which its product candidates
        are made could be adversely affected by equipment failures, labor shortages, natural disasters, power failures, and numerous other factors.
Any adverse developments affecting manufacturing
operations for our product candidates may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls, or other
interruptions in the supply of our product candidates. We may also have to take inventory write-offs and incur other charges and
expenses for product candidates that fail to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing
alternatives.
17
Risks Related to Our Reliance on Third Parties
We rely on third parties
to conduct its preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their
contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval
for or commercialize its product candidates, and our business could be substantially harmed
We have relied upon and plans to continue to rely upon third-party CROs to monitor and
manage data for its ongoing preclinical and clinical programs. We rely on these parties for execution of its preclinical and clinical
studies, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of its studies
is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and its reliance on the CROs does
not relieve us of its regulatory responsibilities. we and our CROs and other vendors are required to comply with cGMP and GLP, which are
regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area (EEA) and
comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these
regulations through periodic inspections of study sponsors, principal and other investigators, study sites, and other contractors. If
we or any of its CROs or vendors fail to comply with applicable regulations, the clinical data generated in its clinical studies may be
deemed unreliable and the FDA, EMA, or comparable foreign regulatory authorities may require us to perform additional clinical studies
before approving its marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory
authority will determine that any of its clinical studies comply with Good Clinical Practices (GCP) regulations. In addition, its clinical
studies must be conducted with product produced under cGMP/GMP regulations. Our failure to comply with these regulations may require us
to repeat clinical studies, which would delay the regulatory approval process.
If any of its relationships with these third-party CROs
terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. In addition,
its CROs are not its employees, and, except for remedies available to us under its agreements with such CROs, we cannot control whether
or not they devote sufficient time and resources to its on-going clinical, nonclinical, and preclinical programs. If CROs do not
successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality
or accuracy of the clinical data they obtain is compromised due to the failure to adhere to its clinical protocols, regulatory requirements,
or for other reasons, its clinical studies may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval
for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result, its results
of operations and the commercial prospects for its product candidates would be harmed, its costs could increase, and its ability to generate
revenue could be delayed.
Switching or adding additional CROs involves
additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work.
As a result, delays occur, which can materially impact its ability to meet its desired clinical development timelines. Though we carefully
manage its relationships with its CROs, there can be no assurance that we will not encounter similar challenges or delays in the future
or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects.
18
We currently rely on
third parties to manufacture the raw materials and products that we use to create its product candidates and to supply us with the medical
devices used to administer such product. This reliance requires us to share its trade secrets with these third parties, which increases
the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
Because we rely on third parties to provide
it with the materials that it uses to develop and manufacture its product candidates, we may, at times, share trade secrets with such
third parties. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material
transfer agreements, collaborative research agreements, consulting agreements, or other similar agreements with its collaborators, advisors,
employees, and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights
of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed
when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade
secrets become known by its competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation
of these agreements. Given that our proprietary position is based, in part, on its know-how and trade secrets, a competitor's
discovery of its trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse
effect on our business.
Our reliance on third
parties to manufacture the raw materials and products that are used to create its product candidates and to supply it with the medical
devices used to administer such product might cause its business harm if manufacturers fail to provide it with sufficient quantities of
these materials and products or fail to do so at acceptable quality levels or prices.
We do not currently have the infrastructure
or capability internally to develop the raw materials and other products that we use to manufacture its product candidates, and it lacks
the resources and the capability to manufacture the medical devices which it uses to administer its products. There are a limited number
of suppliers for these raw materials, products and devices, and there may be a need to identify alternate suppliers to prevent a possible
disruption to its clinical studies, and, if approved, ultimately for commercial sale. We cannot assure you that it will be able to identify
alternate suppliers if the need arises at acceptable quality levels or prices.
Risks Related to Commercialization of Our
Product Candidates
If the market opportunities
for our product candidates are smaller than we believe they are, our revenue may be adversely affected, and its business may suffer. Because
some of the target patient populations of its product candidates are small, we must be able to successfully identify patients and achieve
a significant market share to maintain profitability and growth.
We focus a substantial part of its research
and product development on treatments for locally advanced pancreatic cancer with certain specific mutations. Given the small number of
patients who have this disease with these mutations, it is critical to Silexion's ability to grow and become profitable that it
continue to successfully identify effected patients. Our projections of both the number of people who have these diseases, as well as
the subset of people with these diseases who have the potential to benefit from treatment with its product candidates, are based on its
beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics,
patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence
of these diseases. The number of patients may turn out to be lower than expected. The effort to identify patients with diseases we seek
to treat is in its early stages, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally,
the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with
its product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect
our results of operations and business.
19
We do not have experience
producing its product candidates at commercial levels and may not achieve the necessary regulatory approvals or produce product candidates
at the quality, quantities, locations, and timing needed to support commercialization. Additionally, we intend to rely on third-party manufacturers
to produce the raw materials and products that we use to manufacture its product candidates, but we have not entered into binding agreements
with any such manufacturers to support commercialization.
We do not currently have the experience
or ability to produce product candidates at commercial levels. We may run into technical or scientific issues related to manufacturing
or development that we may be unable to resolve in a timely manner or with available funds. We also have not completed all of the characterization
and validation activities necessary for commercialization and regulatory approvals. If we do not conduct all such necessary activities,
our commercialization efforts will be harmed.
Although we intend to rely on third-party manufacturers
for the raw materials and products to support our own manufacturing of its product candidates for commercialization, we have not yet entered
into agreements with such manufacturers. We may be unable to negotiate binding agreements with the manufacturers to support our commercialization
activities at commercially reasonable terms. Additionally, these third party manufacturers may not be able to supply us with the necessary
quantities of these raw materials and products to support its own manufacturing process, or in compliance with cGMP or other pertinent
regulatory requirements, and within our planned timeframe and cost parameters, and the development and sales of our products, if approved,
may be materially harmed.
We face intense competition
and rapid technological change and the possibility that its competitors may develop therapies that are similar, more advanced, or more
effective than ours, which may adversely affect its financial condition and its ability to successfully commercialize our product candidates.
The biotechnology and pharmaceutical industries
are intensely competitive and subject to rapid and significant technological change. We are currently aware of various existing therapies
in the market and in development that may in the future compete with its product candidates. For example, there is an increasing number
of companies commercializing treatments and/or developing programs specifically targeting KRAS mutations, including KRAS G12D and KRAS
G12V, in a variety of manners and for a variety of indications, including cancer, including Bristol-Myers Squibb Company (through
the recently acquired Mirati Therapeutics, Inc.), Revolution Medicines, Inc., AstraZeneca (in collaboration with Usynova), Boehringer
and Gilead. Smaller and other early-stage companies may also prove to be significant competitors. Treatments for cancer currently
include surgery, radiation therapy, chemotherapy, hormone therapy, immunotherapy and combined treatment modalities such as chemo-radiotherapy.
Other approaches may also emerge for the treatment of any of the disease areas in which we focuse.
We have competitors both in the United States
and internationally, including major multinational pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies.
Our competitors may succeed in developing, acquiring, or licensing on an exclusive basis, products that are more effective or less costly
than any product candidate that Silexion may develop, or achieve earlier patent protection, regulatory approval, product commercialization,
and market penetration than we do. Additionally, technologies developed by our competitors may render its potential product candidates
uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.
We currently have no
marketing and sales organization. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties
to market and sell our product candidates, we may be unable to generate any revenue.
We as a company have no experience selling and marketing its product candidates, and
currently have no marketing or sales organization. To successfully commercialize any products that may result from our development programs,
we will need to develop these capabilities, either on our own or with others. If our product candidates receive regulatory approval, we
intend to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize
our product candidates in major markets, which will be expensive, difficult, and time consuming. Any failure or delay in the development
of its internal sales, marketing, and distribution capabilities would adversely impact the commercialization of our products.
20
Further, given its lack of prior experience in marketing and selling biopharmaceutical
products, our initial estimate of the size of the required sales force may be materially more or less than the size of the sales force
actually required to effectively commercialize our product candidates. As such, we may be required to hire the commercialization of our
product candidates, or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect to certain
geographical markets, we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities,
but we may be unable to enter into such agreements on favorable terms, if at all. If our future collaborators do not commit sufficient
resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own,
we will be unable to generate sufficient product revenue to sustain our business. We may be competing with companies that currently have
extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing
and sales functions, we may be unable to compete successfully against these more established companies.
The market may not be
receptive to our product candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or
licensing of product candidates.
Even if approval is obtained for a product
candidate, we may not generate or sustain revenue from sales or licensing of the product due to factors such as whether the product can
be sold at a competitive cost and otherwise accepted in the market. The product candidates that we are developing are based on new technologies
and therapeutic approaches. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors,
may not adopt a treatment based on RNAi, including siRNA technology, and we may not be able to convince the medical community and third-party payors
to accept and use, or to provide favorable reimbursement for, our product candidates. Market acceptance of Silexion's product candidates
will depend on, among other factors:
●
the timing of our receipt of any marketing and commercialization
        approvals;
●
the terms of any approvals and the countries in which approvals
        are obtained;
●
the safety and efficacy of our product candidates;
●
the prevalence and severity of any adverse side effects associated
        with our product candidates;
●
limitations or warnings contained in any labeling approved by
        the FDA or other regulatory authorities;
●
relative convenience and ease of administration of our product
        candidates;
●
the willingness of patients to accept any new methods of administration;
●
the success of our physician education programs;
●
the availability of adequate government and third-party payor
        reimbursement;
●
the pricing of our products, particularly as compared to alternative
        treatments; and
●
availability of alternative effective treatments for the disease
        indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments.
With Silexion's focus on the emerging
therapeutic modality RNAi, these risks may increase to the extent the space becomes more competitive or less favored in the commercial
marketplace. Some of Silexion's target diseases, such as pancreatic cancer, are relatively rare. Because of the small patient population
for a rare disease, if pricing is not approved or accepted in the market at an appropriate level for an approved product, such product
may not generate enough revenue to offset costs of development, manufacturing, marketing and commercialization. Market size is also a
variable in disease indications not classified as rare. Our estimates regarding potential market size for any indication may be materially
different from what it discovers to exist at the time it commences commercialization, if any, for a product, which could result in significant
changes in our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects.
21
Even if a potential product displays a favorable
efficacy and safety profile in preclinical and clinical studies, market acceptance of the product will not be fully known until after
it is launched. Ourefforts to educate the medical community and third-party payors on the benefits of the product candidates may
require significant resources and may never be successful. If our product candidates are approved but fail to achieve an adequate level
of acceptance by physicians, patients, third-party payors, and others in the medical community, we will not be able to generate sufficient
revenue for us to become or remain profitable.
The insurance coverage
and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement
for new or current products could limit our ability to market those products and decrease our ability to generate revenue.
Some of our target patient populations are
small, and, accordingly, the pricing, coverage, and reimbursement of our respective product candidates, if approved, must be adequate
to support our commercial infrastructure. Ourper-patient prices must be sufficient to recover our development and manufacturing costs
and potentially achieve profitability. Accordingly, the availability and adequacy of coverage and reimbursement by governmental and private
payors are essential for most patients to be able to afford expensive treatments such as our, assuming approval. Sales of our product
candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be
paid for by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government
authorities, private health insurers, and other third-party payors. If coverage and reimbursement are not available, or are available
only to limited levels, Silexion may not be able to successfully commercialize our product candidates. Even if coverage is provided, the
approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on our
investment.
There is significant uncertainty related
to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about coverage
and reimbursement for new drugs are typically made by the Centers for Medicare & Medicaid Services, or CMS, an agency within
the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new drug will be covered and reimbursed
under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult
to predict what CMS will decide with respect to reimbursement for products such as our's.
Outside the United States, international
operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing
emphasis on cost-containment initiatives in Europe, Canada, and other countries has, and will continue to, put pressure on the pricing
and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms
as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States.
Other countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. Additional foreign
price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates.
Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States
and may be insufficient to generate commercially reasonable revenue and profits.
Moreover, increasing efforts by governmental
and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit
both coverage and the level of reimbursement for new products approved, and, as a result, they may not cover or provide adequate payment
for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due
to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes
like the Inflation Reduction Act. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures
and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.
22
Healthcare legislative
reform measures may have a material adverse effect on our business and results of operations.
The business and financial condition of
pharmaceutical and biotechnology companies are affected by the efforts of governmental and third-party payors to contain or reduce
the costs of health care. The U.S. Congress has enacted legislation to reform the health care system. While we anticipate that this
legislation may, over time, increase the number of patients who have insurance coverage for pharmaceutical products, it also imposes cost
containment measures that may adversely affect the amount of reimbursement for pharmaceutical products. These measures include increasing
the minimum rebates for products covered by Medicaid programs and extending such rebates to drugs dispensed to Medicaid beneficiaries
enrolled in Medicaid managed care organizations as well as expansion of the 340(B) Public Health Services drug discount program.
In addition, such legislation contains a number of provisions designed to generate the revenues necessary to fund the coverage expansion.
In foreign jurisdictions there have been, and we expect that there will continue to be, a number of legislative and regulatory proposals
aimed at changing the health care system. For example, in some countries other than the United States, pricing of prescription drugs
is subject to government control and we expect to see continued efforts to reduce healthcare costs in international markets.
Some U.S. states are also considering
legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental
rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid.
Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs.
Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may
result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint
on prices and reimbursement for drugs. It is likely that federal and state legislatures and health agencies will continue to focus on
additional health care reform in the future although we are unable to predict what additional legislation or regulation, if any, relating
to the health care industry or third-party coverage and reimbursement may be enacted in the future or what effect such legislation
or regulation would have on our business. Our ability to commercialize any product candidates that Silexion may seek to commercialize,
is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from government payors,
such as Medicare and Medicaid, private health insurers, including managed care organizations, and other third-party payors, and any
change in reimbursement levels could materially and adversely affect our business. Further, the pendency or approval of future proposals
or reforms could result in a decrease in our share price or limit our ability to raise capital or to obtain strategic partnerships or
licenses.
Our product candidates
may be approved and/or commercialized only in part, only as neoadjuvant therapy, or as an adjuvant therapy.
Our product candidates may be approved by
the FDA or other regulatory agencies only as a treatment to be provided in association with other treatments, if at all. For example,
it may be possible that our SIL-204B be used as adjunct therapy with chemotherapy treatments. Limitation in commercialization of
such treatments, including limitations in supply, call-back, clinical holds, changes in medical trends, changes in cost and/or reimbursement
policy, may limit our ability to commercialize our product candidates, either directly or via third parties.
23
Risks Related to Competition
The pharmaceutical market
is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we
may be unable to commercialize successfully any drugs that it develops.
The pharmaceutical market is intensely competitive
and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public
and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to
target. Many of our competitors have:
●
much greater financial, technical and human resources than
        we have at every stage of the discovery, development, manufacture and commercialization of products;
●
more extensive experience in pre-clinical testing, conducting
        clinical trials, obtaining regulatory approvals, and in manufacturing, marketing and selling pharmaceutical products;
●
product candidates that are based on previously tested or accepted
        technologies;
●
products that have been approved or are in late stages of development;
        and
●
collaborative arrangements in its target markets with leading
        companies and research institutions.
We will face intense competition from drugs
that have already been, or may in the future become, approved and accepted by the medical community for the treatment of the conditions
for which we may develop drugs. We also expect to face competition from new drugs that enter the market. We believe a significant number
of drugs are currently under development, and may become commercially available in the future, for the treatment of conditions for which
we may try to develop drugs and therapies. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively,
than any product we develop.
If we successfully develop our product candidates,
and obtains approval for them, we will face competition based on many different factors, including:
●
the safety and effectiveness of our product;
●
the ease with which our product can be administered and the
        extent to which patients accept relatively new routes of administration;
●
the timing and scope of regulatory approvals for our product;
●
the availability and cost of manufacturing, marketing and sales
        capabilities;
●
price;
●
reimbursement coverage; and
●
patent position.
Our competitors may develop or commercialize
products with significant advantages over any products we develop based on any of the factors listed above or on other factors. Our competitors
may therefore be more successful in commercializing their products than us, which could adversely affect our competitive position and
business. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing
and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level
of expertise and the ability to execute on our business plan.
We face competition
from other companies that are working to develop novel drugs and technology platforms using technology similar or in the same field as
our's. If these companies develop drugs more rapidly than us, or their technologies, including delivery technologies, are more effective,
our ability to successfully commercialize drugs may be adversely affected.
In addition to the competition we face from competing drugs in general, we also face
competition from other companies working to develop novel drugs using technology that competes more directly with our own. We are aware
of multiple companies that are working in the field of RNAi therapeutics and or KRAS inhibition, including major pharmaceutical companies
such as Bristol Myers Squibb/Mirati; Amgen; AstraZeneca; E.I. Lilly; Pfizer, Novartis International AG, Takeda Pharmaceutical Company
Limited and, and biopharmaceutical/pharmaceutical companies such as Alnylam, Revolutions Medicines; Boehringer Ingelheim; Biomea Fusion
Inc; Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Silence Therapeutics plc, RXi Pharmaceuticals Corporation, Quark
Pharmaceuticals, Inc. and Marina Biotech, Inc.
24
We also compete with companies working to develop antisense-based drugs. Like RNAi
therapeutics, antisense drugs target mRNAs in order to suppress the activity of specific genes. Ionis Pharmaceuticals, Inc. is currently
marketing an antisense drug and has several antisense product candidates in clinical trials, albeit none in the oncology area at this
time.
In addition to competition with respect
to RNAi and with respect to specific products, we face substantial competition to discover and develop safe and effective means to deliver
RNAi based drugs to the relevant cell and tissue types. Safe and effective means to deliver RNAi based drugs and to the relevant cell
and tissue types may be developed by our competitors, and our ability to successfully commercialize a competitive product would be adversely
affected. In addition, substantial resources are being expended by third parties in the effort to discover and develop a safe and effective
means of delivering RNAi based drugs and into the relevant cell and tissue types, both in academic laboratories and in the corporate sector.
Some of our competitors have substantially greater resources than we do, and if our competitors are able to negotiate exclusive access
to those delivery solutions developed by third parties, we may be unable to successfully commercialize our product candidates. Also, we
compete with companies working to develop non RNAi based treatments for solid tumor cancers. For example, Novartis is working on a SHP2
inhibitor, and Boehringer Ingelheim and Bayer SOS1 inhibitors; Threshold Pharmaceuticals (Threshold) is working to develop therapies that
target tumor hypoxia, a common characteristic of the tumor microenvironment. Even if we successfully develop our product candidates, and
obtain approval for them, other non RNAi treatments may be preferred, and we may not be successful in commercializing our product candidates
Also, we compete with companies commercializing
and/or working to develop drug delivery systems, including drug delivery systems for local (or regional) release. For example, various
companies are working on nanoparticle technologies, although these products would not give the extended-release delivery of SIL-204B,
and other companies on PLGA microparticles. In addition other companies such as SurModics, Inc. is a provider of drug delivery and surface
modification technologies to the healthcare industry, including local delivery of drugs from drug eluting stents. We compete with many
companies commercializing and/or working to develop drug delivery systems for specific indications, for example for local ocular (in the
eye) release of drugs, including degradable and non-degradable products.
Risks Related to Our Intellectual Property
If we are unable to
obtain and maintain effective patent rights for our product candidates or any future product candidates, we may not be able to compete
effectively in our markets.
We rely upon a combination of trade secret
protection and confidentiality agreements to protect the intellectual property related to our technologies and product candidates. We
have only issued one Israeli patent, and two U.S. patents, covering the composition of matter of our siRNAs and their use. Our success
depends in large part on our ability to obtain and maintain patent and other intellectual property protection in the United States
and in other countries with respect to our proprietary technology and products.
We have sought to protect our proprietary
position by filing patent applications in the United States and in other countries, with respect to our novel technologies and products,
which are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary
or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable
aspects of our research and development output before it is too late to obtain patent protection.
The patent position of biotechnology and
pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain
unsolved. The patent applications that we own may fail to result in issued patents with claims that cover our product candidates in the
United States or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents
and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application.
Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity,
enforceability, or scope, which may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they
are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our
product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition
from third parties, which may have an adverse impact on our business.
25
We have filed several patent applications
covering various aspects of our product candidates: PCT/IL2023/051276 filed on Dec. 14, 2023 Priority from: US Provisional Patent
Applications; 63/387,504 filed on December 15, 2022; and 63/491,776 filed on March 23, 2023. We cannot offer any assurances
about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable
or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after
patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop.
Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent
protection could be reduced.
If we cannot obtain and maintain effective
patent rights for our product candidates, we may not be able to compete effectively, and our business and results of operations would
be harmed.
We may not have sufficient
patent terms to effectively protect our products and business.
In the pharmaceutical and biotechnology
industries, the majority of an innovative product's commercial value is realized during our market exclusivity period. In the United States
and in some other countries, when market exclusivity expires and generic versions are approved and marketed or when biosimilars are introduced
(even if only for a competing product), there are usually very substantial and rapid declines in a product's revenues.
Patents have a limited lifespan. In the United States,
the natural expiration of a patent is generally 20 years after it is filed. Although various extensions may be available, the life
of a patent, and the protection it affords, is limited.
While patent term extensions under the Hatch-Waxman Act
in the United States and under supplementary protection certificates in Europe may be available to extend the patent exclusivity
term, we cannot provide any assurances that any such patent term extension will be obtained and, if so, for how long. In addition, upon
issuance in the United States, any patent term can be adjusted based on certain delays caused by the applicant(s) or the USPTO. For
example, a patent term can be reduced based on certain delays caused by the patent applicant during patent prosecution. If we do not have
sufficient patent terms or regulatory exclusivity to protect our products, our business and results of operations will be adversely affected.
Furthermore, manufacturers of innovative products as well as generic drug manufacturers may be able to design their products around our
patents and compete with Silexion using the resulting alternative technology. Absent relevant patent protection for a product, once the
exclusivity period expires, generic or alternative versions can be approved and marketed.
Generic and biosimilar product manufacturers
as well as other groups seeking financial gain are also increasingly seeking to challenge patents before they expire, and we could face
earlier-than-expected competition for any products at any time. Patents covering our key products may be subject to validity, enforceability
and infringement challenges in patent litigations and post-grant review patent office proceedings. It may be possible for these parties
to successfully challenge our rights and launch their versions of our drugs prior to the expiration of our intellectual property rights.
In addition, both the U.S. Congress and
the U.S. FDA have taken steps to promote the development and approval of generic drugs and biosimilar biologics, including by providing
generic and biosimilar developers a private right of action to obtain sufficient quantities of drug samples from the reference product's
manufacturer in order to conduct testing necessary to obtain approval for generic or biosimilar products.
26
Further, in December 2023, the Biden
Administration released a proposed framework that for the first time proposed that a drug's price can be a factor in determining
that the drug is not accessible to the public and therefore that the government could exercise "march-in rights" and
license it to a third party to manufacture. A comment period on the proposal ran through February 6, 2024, and we are not able to
predict whether a final rule will be adopted along the lines proposed and, if adopted, whether the government would seek to exercise march-in rights
for any of our products.
Patent law, policy or
rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or
defense of our issued patent.
Changes in either the patent laws or interpretation
of the patent laws in the United States and other countries may diminish the value of our patent or narrow the scope of our patent
protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications
of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States
and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. We therefore cannot
be certain that it or our licensors were the first to make the invention claimed in our owned and licensed patent or pending applications,
or that it or our licensor were the first to file for patent protection of such inventions. Assuming the other requirements for patentability
are met, in the United States prior to March 15, 2013, the first to make the claimed invention is entitled to the patent, while
outside the United States, the first to file a patent application is entitled to the patent. After March 15, 2013, under the
Leahy-Smith America Invents Act, or the Leahy-Smith Act, enacted on September 16, 2011, the United States has moved
to a first to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications
will be prosecuted and may also affect patent litigation. The USPTO recently developed new regulations and procedures to govern administration
of the Leahy-Smith Act, and accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation
of our business. The Leahy-Smith Act and our implementation could increase the uncertainties and costs surrounding the prosecution
of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on
our business and financial condition.
In addition, patent reform legislation may
pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense
of our patents and pending patent applications. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available
in certain circumstances and weakened the rights of patent owners in certain situations. Furthermore, the U.S. Supreme Court and
the U.S. Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of
the United States are interpreted. Similarly, foreign countries have made, and will likely continue to make, changes in how the patent
laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes
to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may materially affect
our patents or patent applications and our ability to obtain additional patent protection in the future.
The United States federal government
retains certain rights in inventions produced with our financial assistance under the Patent and Trademark Law Amendments Act, or the
Bayh-Dole Act. The federal government retains a "nonexclusive, nontransferable, irrevocable, paid-up license" for
our own benefit. The Bayh-Dole Act also provides federal agencies with "march-in rights." March-in rights allow
the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a "nonexclusive,
partially exclusive, or exclusive license" to a "responsible applicant or applicants." If the patent owner refuses to
do so, the government may grant the license itself.
If we are unable to
maintain effective proprietary rights for our product candidates or any future product candidates, Silexion may not be able to compete
effectively in our markets.
In addition to the protection afforded by
any patents that may be granted, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that
is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product
candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents.
However, trade secrets can be difficult to protect. we seek to protect our proprietary technology and processes, in part, by entering
into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity
and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security
of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security
measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known
or be independently discovered by competitors.
27
Although we expect all of our employees
and consultants to assign their inventions to it, and all of our employees, consultants, advisors, and any third parties who have access
to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that
all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed
or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information
and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a
material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may
have insufficient recourse against third parties for misappropriating the trade secret.
Intellectual property
rights of third parties could adversely affect our ability to commercialize our product candidates, and it might be required to litigate
or obtain licenses from third parties in order to develop or market our product candidate. Such litigation or licenses could be costly
or not available on commercially reasonable terms.
Because the RNAi intellectual property landscape is still evolving, it is difficult
to conclusively assess our freedom to operate without infringing on third party rights. There are numerous companies that have pending
patent applications and issued patents broadly directed to RNAi generally and to RNAi delivery technologies.Our competitive position may
suffer if patents issued to third parties or other third party intellectual property rights cover our products or elements thereof, or
our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize products
or our product candidate unless we successfully pursue litigation to nullify or invalidate the third party intellectual property right
concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms.
we are also aware of pending patent applications, and there may be others of which we are not aware, that if they result in issued patents,
could be alleged to be infringed by its product candidates. If such an infringement claim should be brought and be successful, we may
be required to pay substantial damages, be forced to abandon our product candidates or seek a license from any patent holders. No assurances
can be given that a license will be available on commercially reasonable terms, if at all. It is also possible that we have failed to
identify relevant third party patents or applications. For example, U.S. applications filed before November 29, 2000 and certain U.S.
applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent applications
in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest
filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates or platform
technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been published
can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our product candidates or
the use of our product candidates. Third party intellectual property right holders may also actively bring infringement claims against
Us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to
successfully settle future claims on terms acceptable to it, we may be required to engage in or continue costly, unpredictable and time-consuming
litigation and may be prevented from or experience substantial delays in pursuing the development of and/or marketing of its product candidates.
If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing
our product candidates that are held to be infringing. We might, if possible, also be forced to redesign our product candidates so that
it no longer infringes the third party intellectual property rights. Any of these events, even if we were ultimately to prevail, could
require us to divert substantial financial and management resources that it would otherwise be able to devote to our business.
28
Third-party claims
of intellectual property infringement may prevent or delay our development and commercialization efforts.
Our commercial success depends in part on
our avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings
involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement
lawsuits, interferences, oppositions, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous
U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we
are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases
that our product candidates may be subject to claims of infringement of the patent rights of third parties.
Third parties may assert that we are employing
our proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials,
formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates. Because patent
applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents
that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies
infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing
process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders
of any such patents may be able to block our ability to commercialize such product candidates unless it obtains a license under the applicable
patents, or until such patents expire or are finally determined to be invalid or unenforceable.
Similarly, if any third-party patents
were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture, or methods of use, the
holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless it obtains
a license or until such patent expires or is finally determined to be invalid or unenforceable. In either case, such a license may not
be available on commercially reasonable terms or at all.
Parties making claims against us may obtain
injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our
product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial
diversion of employee resources from our business. In the event of a successful claim of infringement against it, we may have to pay substantial
damages, including treble damages and attorneys' fees for willful infringement, pay royalties, redesign our infringing products
or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.
We may not be successful
in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.
Because our programs may require the use
of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license,
or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently
and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of
use, processes, or other third-party intellectual property rights from third parties that it identifies as necessary for our product
candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more
established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider
attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical
development and commercialization capabilities.
29
For example, we sometimes collaborates with
U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these
institutions. Typically, these institutions provide we with an option to negotiate a license to any of the institution's rights
in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified
timeframe or under terms that are acceptable to it. If we are unable to do so, the institution may offer the intellectual property rights
to other parties, potentially blocking our ability to pursue our program.
In addition, companies that perceive us
to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual
property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain
rights to required third-party intellectual property rights, we may have to abandon development of that program and our business
and financial condition could suffer.
We may be involved in
lawsuits to protect or enforce our current patent or future patents, which could be expensive, time consuming, and unsuccessful.
Competitors may infringe our current patent,
future patents or the patents of our licensors. If we or a future licensing partner were to initiate legal proceedings against a third
party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product
candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity
and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory
requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation
that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during
prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.
Interference proceedings provoked by third
parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patent
or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to
attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license
on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have
a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs,
license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates
to market.
Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information
could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings,
motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could
have a material adverse effect on the price of our ordinary shares.
We may be subject to
claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third
parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
We employ or engage as consultants or subcontractors
individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors
or potential competitors. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary
information or know-how of others in their work for it, we may be subject to claims that we or our employees, consultants, or independent
contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information,
of any of our employees' former employers or other third parties. Litigation may be necessary to defend against these claims. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel,
which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management and other employees.
30
We may be subject to
claims challenging the inventorship of our current patent or future patents and other intellectual property.
We may be subject to claims that former
employees, collaborators or other third parties have an interest in or right to compensation with respect to our current patent, future
patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting
obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against
these and other claims challenging inventorship or claiming the right to compensation. If it fails in defending any such claims, in addition
to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable
intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against
such claims, litigation could result in substantial costs and be a distraction to management and other employees. To the extent that our
employees have not effectively waived the right to compensation with respect to inventions that they helped create, they may be able to
assert claims for compensation with respect to our future revenue. As a result, we may receive less revenue from future products if such
claims are successful which in turn could impact our future profitability.
We may not be able to
protect our intellectual property rights throughout the world.
Filing, prosecuting, and defending patents
on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in
some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.
Competitors may use our technologies in
jurisdictions where we have not obtained patent protection to develop their own products and may also export otherwise infringing products
to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products
may compete with Silexin's products and our current patent, future patents or other intellectual property rights may not be effective
or sufficient to prevent them from competing.
Many companies have encountered significant
problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly
certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly
those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of
competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions,
whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business,
could put our current patent or future patents at risk of being invalidated or interpreted narrowly and our patent applications at risk
of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the
damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop
or license.
Risks Related to our Human Resources
The loss of the services
of our key personnel would negatively affect our business.
To successfully develop our drug candidates,
we must be able to attract and retain highly skilled personnel, including consultants and employees. The retention of their services cannot
be guaranteed. Our failure to retain or recruit such professionals might impair our performance and materially affect our technological
and product development capabilities and our product marketing ability. Our future success depends to a large extent on the continued
services of our senior management and key personnel, including in particular, Ilan Hadar, Dr. Mitchell Shirvan, Dr. Racheli
Malka and Michal Yaron. Any loss of the services of members of our senior management or key employees would adversely affect our business.
We do not currently maintain key-person insurance on the lives of any of our key personnel.
31
We may be unable to
attract, develop and retain additional employees required for our development and future success.
Our success is largely dependent on the
performance of our management team and certain key employees and our continuing ability to attract, develop, motivate and retain highly
qualified and skilled employees. Qualified individuals are in high demand, and New Silexion may incur significant costs to attract and
retain them. The inability to attract suitably qualified persons when needed, could prevent New Silexion from executing on our business
plan and strategy, and New Silexion may be unable to find adequate replacements on a timely basis, or at all.
Risks Related to Our Operations
Our business and operations,
or those of our CROs or third parties, may suffer in the event of computer system failures, cyberattacks or deficiencies in our cybersecurity,
which could materially affect our results.
We receive, generate and store significant
and increasing volumes of sensitive information, such as health information, insurance information and other potentially personally identifiable
information. We faces a number of risks relative to protecting the computer systems we rely on and this critical information, including
loss of access risk, inappropriate use or disclosure, inappropriate modification and the risk of being unable to adequately monitor, audit
and modify our controls over our critical information. This risk extends to the computer systems and information of any collaboration
partners, medical institutions, clinical investigators, CROs, contract laboratories, or other third parties involved in our business.
Despite the implementation of security measures,
our information technology systems, as well as those of CROs or other third parties with which we have relationships, are vulnerable to
attack and damage from computer viruses and malware (e.g., ransomware), unauthorized access, natural and manmade disasters, terrorism,
war and telecommunication and electrical failures, malfeasance by external or internal parties, and human error (e.g., social engineering,
phishing). Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity,
and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore,
because the technologies used to obtain unauthorized access to, or to sabotage or disrupt, systems change frequently and often are not
recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures.
we may also experience security breaches that may remain undetected for an extended period. We may not be able to anticipate all types
of security threats, and even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers
increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic
evidence. We may also face increased cybersecurity risks due to our reliance on internet technology and the number of our and our service
providers' employees who are (and may continue to be) working remotely, which may create additional opportunities for cybercriminals
to exploit vulnerabilities. The White House, SEC and other regulators have also increased their focus on companies' cybersecurity
vulnerabilities and risks.
Our CROs and certain of our service providers are from time to time, subject to cyberattacks
and security incidents. While we have not to our knowledge experienced any significant system failure, accident or security breach to
date, if such an event were to occur and cause interruptions in our or our critical third parties' operations, it could result in
delays and/or material disruptions of our research and development programs, our operations and ultimately, our financial results. For
example, the loss of trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product
candidates and to conduct clinical trials, and similar events relating to their computer systems could also adversely impact our business.
Further, due to the current political uncertainty involving Hamas in Gaza, Hezbollah in Lebanon, Russia and Ukraine, there is an increased
likelihood that the tensions could result in cyberattacks or cybersecurity incidents that could either directly or indirectly impact our
or our critical third parties' operations. To the extent that any disruption or security breach were to result in a loss of or damage
to data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability due
to delays in the development and commercialization of our product candidates or other business activities and/or due to reputational harm,
litigation, regulatory investigations and enforcement, fines and penalties, or increased costs of compliance and system remediation.
32
our existing general liability and cyber
liability insurance policies may not cover, or may cover only a portion of, any potential claims related to security breaches to which
we are exposed or may not be adequate to indemnify us for all or any portion of liabilities that may be imposed. We also cannot be certain
that our existing insurance coverage will continue to be available on acceptable terms or in amounts sufficient to cover the potentially
significant losses that may result from a security incident or breach or that the insurer will not deny coverage of any future claim.
If the information technology systems of our CROs or other service providers become subject to disruptions or security breaches, we may
have insufficient recites against such third parties and we may have to expend significant resources to mitigate the impact of such an
event, and to develop and implement protections to prevent future events of this nature from occurring.
If product liability
lawsuits are brought against it, we may incur substantial liabilities and may be required to limit commercialization of any approved products.
We face an inherent risk of product liability
as a result of the clinical testing of product candidates and will face an even greater risk if we commercialize any products. For example,
we may be sued if any product candidate we develop causes or is perceived to cause injury or is found to be otherwise unsuitable during
clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing,
defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims
could also be asserted under state consumer protection acts. If we cannot successfully defend itself against product liability claims,
it may incur substantial liabilities or be required to limit commercialization of any approved products. Even successful defense would
require significant financial and management resources.
Regardless of the merits or eventual outcome,
liability claims may result in:
●
decreased demand for any approved product;
●
injury to our reputation;
●
withdrawal of clinical trial participants;
●
initiation of investigations by regulators;
●
costs to defend the related litigation;
●
a diversion of management's time and our resources;
●
substantial monetary awards to trial participants or patients;
●
product recalls, withdrawals or labeling, marketing or promotional
        restrictions;
●
exhaustion of any available insurance and our capital resources
        and potential increase in our insurance premiums and/or retention amounts; and
●
the inability to commercialize any product candidate.
Our inability to obtain sufficient product
liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization
of products we develop, alone or with collaboration partners.
33
Insurance coverage is increasingly expensive.
we may not be able to maintain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise, if at
all. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage.
Silexion may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are
not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements
with any current or future collaborator entitle us to indemnification against losses, such indemnification is limited and may not be available
or adequate should any claim arise.
We may not be able to
successfully identify and execute strategic alliances or other relationships with third parties or to successfully manage the impacts
of acquisitions, dispositions or relationships on our operations.
We currently have, and may expand the scope
of, and may in the future enter into, strategic alliances with third parties that it believes will complement or augment our existing
business. Ourour. Our ability to complete further such strategic alliances is dependent upon, and may be limited by, among other things,
the availability of suitable candidates and capital. In addition, strategic alliances could present unforeseen integration obstacles or
costs, may not enhance our business and may involve risks that could adversely affect us, including the investment of significant amounts
of management time that may be diverted from operations in order to pursue and complete such transactions or maintain such strategic alliances.
Future strategic alliances could result in the incurrence of debt, costs and contingent liabilities, and there can be no assurance that
future strategic alliances will achieve, or that our existing strategic alliances will continue to achieve, the expected benefits to our
business or that it will be able to consummate future strategic alliances on satisfactory terms, or at all.
Although we do not currently plan to engage
in other material strategic transactions, such as acquisitions, it may from time to time consider such transactions. Material strategic
transactions involve a number of risks, including:
●
the potential disruption of our ongoing business;
●
the distraction of management away from the ongoing oversight
        of our existing business activities;
●
incurring additional indebtedness;
●
the anticipated benefits and cost savings of those transactions
        not being realized fully, or at all, or taking longer to realize than anticipated;
●
an increase in the scope and complexity of our operations;
        and
●
the loss or reduction of control over certain of our assets.
A strategic transaction may result in a
significant change in the nature of our business, operations and strategy, and we may encounter unforeseen obstacles or costs in implementing
a strategic transaction or integrating any acquired business into our operations.
Risks Relating to our Operations in Israel and
China
Conditions in the Middle
East and in Israel may harm our operations.
Our executive offices and research and development facilities are located in Israel. Most of our officers
and directors are residents of Israel. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken
place between Israel and its neighboring countries, and between Israel and neighboring terrorist organizations, including Hamas (an Islamist
terrorist and political group in the Gaza Strip) and Hezbollah (an Islamist terrorist and political group in Lebanon).
34
In particular, on October 7, 2023, Hamas terrorists infiltrated Israel's
southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive
rocket attacks on the Israeli population and industrial centers located along Israel's border with the Gaza Strip and in other areas
within the State of Israel. These attacks resulted in thousands of deaths and injuries, and Hamas additionally kidnapped many Israeli
civilians and soldiers. Following the attack, Israel's security cabinet declared war against Hamas and commenced a military campaign
against Hamas and these terrorist organizations, in parallel to continued rocket and terror attacks against Israel by Hamas. Upon the
start of the war, the Israeli military began to call-up reservists for active duty.
In parallel with the war against Hamas that began in October 2023,
there
have been continued hostilities along Israel's northern border, as the Hezbollah terrorist organization based in Lebanon has conducted
rocket, drone, and, more recently, missile attacks against Israel, and there have also been rocket, drone and missile attacks against
Israel by the Houthi movement in Yemen. The hostilities with Hezbollah have escalated recently, prompting Israel to send its ground forces
into southern Lebanon to destroy terrorist positions and infrastructure used by Hezbollah for attacks on northern and central Israel,
which had caused the displacement of residents in northern Israel since early in the war.
Iran has furthermore entered the conflict against Israel, shooting ballistic missiles
at Israel twice during the current war (on April 13, 2024 and October 1, 2024). Iran is furthermore widely believed to be developing
nuclear weapons, with which it has threatened Israel. There is a risk
that other
terrorist organizations, including Palestinian military organizations in the West Bank as well as other hostile countries will join the
hostilities against Israel. Such clashes may escalate into a greater regional conflict.
Armed conflicts, terrorist activities or political instability in Israel or in the broader
Middle East have been, and could continue to, in a more severe way, adversely affect business conditions in Israel, and could harm our
results of operations and make it more difficult for us to raise capital. Parties with whom we do business may decline to travel to Israel
during periods of heightened unrest or tension, forcing Silexion to make alternative arrangements when necessary in order to meet its
business partners face to face. In addition, the political and security situation in Israel may result in parties with whom we have agreements
involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force
majeure provisions in such agreements. Further, in the past, the State of Israel and Israeli companies have been subjected to economic
boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies
may have an adverse impact on our operating results, financial condition or the expansion of our business. The interruption or curtailment
of trade between Israel and its trading partners could adversely affect our operations and results of operations.
Our commercial insurance does not cover losses that may occur as a result of events
associated with the security situation in the Middle East. Although the Israeli government currently covers the reinstatement value of
direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained.
Any losses or damages incurred by us could have a material adverse effect on our business.
Finally, political conditions within Israel may also affect our operations. Israel held
five general elections between 2019 and 2022, and prior to October 2023, the Israeli government pursued extensive changes to Israel's
judicial system, which sparked extensive political debate and unrest. To date, these initiatives have been substantially put on hold.
Actual or perceived political instability in Israel or any negative changes in the political environment, may individually or in the aggregate
adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and growth prospects.
35
It may be difficult
to enforce a U.S. judgment against us, our officers or our directors or to assert U.S. securities law claims in Israel.
Service of process upon us and upon our
directors and officers, who reside outside the U.S., may be difficult to obtain within the U.S. In addition, because substantially
all of our assets and most of our directors and officers are located outside the U.S., any judgment obtained in the U.S. against
us or any of our directors and officers may not be collectible within the U.S. There is a doubt as to the enforceability of civil
liabilities under the Securities Act or the Exchange Act pursuant to original actions instituted in Israel. Subject to particular
time limitations and provided certain conditions are met, executory judgments of a U.S. court for monetary damages in civil matters
may be enforced by an Israeli court.
Under applicable U.S. and
Israeli law, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting
from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their inventions irrespective
of their agreements with us, which in turn could impact our future profitability.
We generally enter into non-competition agreements
with our employees and key consultants. These agreements prohibit our employees and key consultants, if they cease working for us, from
competing directly with it or working for our competitors or clients for a limited period of time. We may be unable to enforce these agreements
under the laws of the jurisdictions in which our employees work and it may be difficult for it to restrict our competitors from benefitting
from the expertise our former employees or consultants developed while working for us. For example, Israeli courts have required employers
seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee
will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy
of a company's confidential commercial information or the protection of our intellectual property. If it cannot demonstrate that
such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees
or consultants and our ability to remain competitive may be diminished.
In addition, Chapter 8 of the Israeli
Patents Law, 5727-1967, or the Patents Law, deals with inventions made in the course of an employee's service and during his
or her term of employment, whether or not the invention is patentable, or service inventions. Section 134 of the Patents Law, sets
forth that if there is no agreement which explicitly determines whether the employee is entitled to compensation for the service inventions
and the extent and terms of such compensation, such determination will be made by the Compensation and Rewards Committee, a statutory
committee of the Israeli Patents Office. As a result, it is unclear if, and to what extent, our research and development employees may
be able to claim compensation with respect to our future revenue. As a result, Silexion may receive less revenue from future products
if such claims are successful, which in turn could impact our future profitability.
Governmental control
of currency conversion in China may limit us our ability to utilize our cash balance effectively and affect the value of our investment.
We may be reliant on dividend payments,
equity investments, or other forms of cash infusion from PRC subsidiaries to fund any cash and financing requirements it may have. The
PRC government imposes controls on the convertibility of the Renminbi into foreign currencies and, in certain cases, the remittance of
currency out of China. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions,
interest payments and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior approval
of the State Administration of Foreign Exchange ("SAFE") (the foreign exchange management administrative body of the People's
Bank of China) by complying with certain procedural requirements. Specifically, under the existing exchange restrictions, without prior
approval of SAFE, cash generated from the operations of PRC subsidiaries in China may be used to pay dividends to parent companies. However,
approval from or registration with appropriate government authorities is required where Renminbi is to be converted into foreign currency
and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. As a result, we would
need to obtain SAFE approval to use cash held at PRC subsidiaries to pay outside China, or to make other capital expenditure payments
outside China in a currency other than Renminbi. The PRC government may at its discretion restrict access to foreign currencies for current
account transactions in the future. If the foreign exchange control system prevents us from obtaining sufficient foreign currencies to
satisfy its foreign currency demands, it may not be able to pay dividends in foreign currencies to our shareholders.
36
PRC regulations relating to dividends may
restrict the ability of our PRC subsidiaries to make payments to New Silexion, which may have an adverse effect on our ability to conduct
our business.
Under PRC laws and regulations, our PRC
subsidiaries (which are each "wholly foreign-owned enterprises" incorporated in Mainland China) are only permitted to
pay dividends out of their respective accumulated profits, as determined in accordance with PRC accounting standards and regulations.
In addition, prior to distribution of any dividends, our subsidiaries in China are each required to compensate their past losses with
after-tax profits each year, if any, and then set aside at least 10% of their after-tax profits each year to fund a statutory
reserve until such reserve reaches 50% of the subsidiary's total registered capital. Additionally, if our PRC subsidiaries incur
debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends or make other
distributions to us.
Any limitation on the ability of our PRC
subsidiaries to pay dividends or make other distributions to us could adversely limit our ability to grow, make investments or acquisitions
that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business.
Risks Relating to this Offering
The best efforts structure of this offering may have an adverse
effect on our business plan.
The Placement Agent has agreed to use its reasonable best efforts to solicit offers
to purchase the securities in this offering. The Placement Agent has no obligation to buy any of the securities from us or to arrange
for the purchase or sale of any specific number or dollar amount of the securities. There is no required minimum number of securities
that must be sold as a condition to completion of this offering. Because there is no minimum offering amount required as a condition to
the closing of this offering, the actual offering amount, placement agent fees and proceeds to us are not presently determinable and may
be substantially less than the maximum amounts set forth above. We may sell fewer than all of the securities offered hereby, which may
significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that
we do not sell an amount of securities sufficient to support our continued operations, including our near-term continued operations. Thus,
we may not raise the amount of capital we believe is required for our operations in the short-term and may need to raise additional funds,
which may not be available or available on terms acceptable to us. The success of this offering will impact our ability to use the proceeds
to execute our business plan. We may have insufficient capital to implement our business plan, potentially resulting in greater operating
losses unless we are able to raise the required capital from alternative sources. There is no assurance that alternative capital, if needed,
would be available on terms acceptable to us, or at all.
This offering is being made on a best efforts basis and we may sell
fewer than all of the securities offered hereby and may receive significantly less in net proceeds from this offering, which will provide
us only limited working capital.
This offering is being made on a best efforts basis and we may sell fewer than all of
the securities offered hereby and may receive significantly less in net proceeds from this offering. Assuming that we receive net proceeds
of approximately $        million from this offering (assuming an offering with gross proceeds of $      
million), we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will meet our capital
needs for the next        months under our current business plan. Assuming that we receive net proceeds of approximately
$      million from this offering (assuming an offering with gross proceeds of $      million), we believe
that the net proceeds from this offering, together with our existing cash and cash equivalents, will satisfy our capital needs for the
next        months under our current business plan. Assuming that we receive net proceeds of approximately $ 
     million from this offering (assuming an offering with gross proceeds of $      million), we believe
that the net proceeds from this offering, together with our existing cash and cash equivalents, will satisfy our capital needs for the
next          months under our current business plan. Without giving effect to the receipt of any proceeds from
this offering, we currently estimate that our existing cash and cash equivalents are sufficient to fund business operations into 
           2025.
Our management team will have immediate and
broad discretion over the use of the net proceeds from this offering and may not use them effectively.
We currently intend to use the net proceeds of this offering for
continued development of our pipeline products, as well as the advancement of new programs, business development activities, and general
corporate purposes. See "Use of Proceeds." However, our management will have broad discretion in the application of the net
proceeds. Our shareholders may not agree with the manner in which our management chooses to allocate the net proceeds from this offering.
The failure by our management to apply these funds effectively could have a material adverse effect on our business, financial condition
and results of operation. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income.
The decisions made by our management may not result in positive returns on your investment and you will not have an opportunity to evaluate
the economic, financial or other information upon which our management bases its decisions.
37
You will experience immediate dilution in the book value per share
of the
ordinary shares purchased in the offering.
Since the public offering price of our ordinary shares in this offering is substantially
higher than the net tangible book value per share of our outstanding ordinary shares outstanding prior to this offering, you will suffer
dilution in the book value of the ordinary shares you purchase in this offering. The exercise of outstanding ordinary shares and
warrants,
including warrants sold in this offering, may result in further dilution of your investment. See the section titled "
Dilution
"
for a more detailed discussion of the dilution you will incur if you purchase shares in this offering.
Purchasers who purchase our securities in this offering pursuant
to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase
agreement.
In addition to rights and remedies available to all purchasers in this offering under
federal securities and state law, the purchasers that enter into a securities purchase agreement will also be able to bring claims of
breach of contract against us. The ability to pursue a claim for breach of contract provides those investors with the means to enforce
the covenants uniquely available to them under the securities purchase agreement including: (i) timely delivery of shares; (ii) agreement
to not enter into any financings for        (      ) days from closing; and (iii) indemnification for
breach of contract.
Ordinary shares representing a
substantial percentage of our outstanding shares may be sold in this offering, which could cause the price of our ordinary shares
to
decline
.
We may sell in this offering up to        
   ordinary shares, or approximately        % of our outstanding ordinary shares, prior to this offering,
as of                     , 2024. This sale and any future sales of a substantial
number of ordinary shares in the public market, or the perception that such sales may occur, could materially adversely affect the price
of our ordinary shares. We cannot predict the effect, if any, that market sales of those ordinary shares or the availability of those
ordinary shares for sale will have on the market price of our ordinary shares.
There is no public market for the warrants being offered or pre-funded
warrants in this offering.
There is no established public trading market for the warrants being offered or the
pre-funded warrants, and we do not expect a market to develop. In addition, we do not intend to apply to list the pre-funded warrants
or ordinary warrants on any national securities exchange or other nationally recognized trading system. Without an active market, the
liquidity of the pre-funded warrants and ordinary warrants will be limited.
The pre-funded warrants are speculative in nature.
The pre-funded warrants offered hereby do not confer any rights of ordinary share ownership
on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire ordinary shares
at a fixed price. Specifically, commencing on the date of issuance, holders of the pre-funded warrants may acquire the ordinary shares
issuable upon exercise of such warrants at an exercise price of $0.0001 per ordinary share. Moreover, following this offering, the market
value of the pre-funded warrants is uncertain and there can be no assurance that the market value of the pre-funded warrants will equal
or exceed the public offering price for the pre-funded warrants.
The ordinary warrants may not have any value.
Each ordinary warrant has an exercise price per ordinary share equal to $   
   (no less than             % of the assumed public offering price of ordinary shares in
this offering) and expires on the fifth anniversary of its original issuance date. In the event the market price per our ordinary share
does not exceed the exercise price of the ordinary warrants during the period when the warrants are exercisable, the ordinary warrants
may not have any value.
Holders of the pre-funded warrants and ordinary warrants offered
hereby will have no rights as ordinary shareholders with respect to the ordinary shares underlying those warrants until such holders exercise
their warrants and acquire our ordinary shares, except as otherwise provided in the ordinary warrants.
Until holders of the pre-funded warrants and ordinary warrants acquire our ordinary
shares upon exercise thereof, such holders will have no rights with respect to the ordinary shares underlying such warrants, except to
the extent that holders of such warrants will have certain rights to participate in distributions or dividends paid on our ordinary shares
as set forth in the warrants. Upon exercise of the pre-funded warrants and ordinary warrants, the holders will be entitled to exercise
the rights of an ordinary shareholder only as to matters for which the record date occurs after the exercise date.
38
Risks Relating to Owning Our Ordinary Shares
The price of our ordinary
shares and our warrants may be volatile, and the value of our ordinary shares and our warrants may decline.
We cannot predict the prices at which
our ordinary shares or warrants will trade. The price of our ordinary shares and our warrants may not bear any relation to any established
criteria of the value of our business and prospects. In addition, the trading price of our ordinary shares and  warrants is likely
to be volatile and could be subject to fluctuations in response to various factors, some of which are beyond our control. These fluctuations
could cause you to lose all or part of your investment in our ordinary shares and our warrants as you might be unable to sell your shares
at or above the price you paid. Factors that could cause fluctuations in the trading price of our ordinary shares and our warrants include
the following:
●
actual or anticipated fluctuations in our financial condition
        or results of operations;
●
variance in the projected timeline for regulatory approvals of
        our product candidates from expectations of securities analysts;
●
changes in laws or regulations applicable to our business;
●
announcements by us or our competitors of significant business
        developments;
●
significant data breaches, disruptions to or other incidents
        involving our company;
●
conditions or developments affecting the biotechnology industry;
●
future sales of New Silexion ordinary shares by us or our shareholders,
        as well as the anticipation of lock-up releases;
●
changes in senior management or key personnel;
●
the trading volume of our securities;
●
changes in the anticipated future size and growth rate of our
        markets;
●
publication of research reports or news stories about us, our
        competitors or our industry, or positive or negative recommendations or withdrawal of research coverage by securities analysts;
●
general economic and market conditions; and
●
other events or factors, including those resulting from war,
        incidents of terrorism, global pandemics or responses to those events.
Broad market and industry fluctuations,
as well as general economic, political, regulatory and market conditions, may also negatively impact the market price of our ordinary
shares. In the past, companies that have experienced volatility in the market price of their securities have been subject to securities
class action litigation. We may be the target of this type of litigation in the future, which could result in substantial expenses and
divert our management's attention.
A substantial number of our ordinary shares may be issued pursuant
to the White Lion Purchase Agreement, as well as the conversion terms of our outstanding convertible notes (consisting of the A&R
Sponsor Promissory Note and the EarlyBird Convertible Note), which could cause (i) the price of the ordinary shares to decline, and (ii)
substantial dilution to our existing shareholders.
The purchase price per ordinary share to be paid by White Lion for shares that we may
elect to issue and sell to it under the White Lion Purchase Agreement will fluctuate based on the market price of our ordinary shares
at the time we elect to sell such shares. Depending on market liquidity at the time, resales of such ordinary shares by White Lion may
cause the trading price of our ordinary shares to decrease, and any such decrease could be substantial.
If and when we elect to issue and sell ordinary shares to White Lion, those issuances
and sales will result in dilution to the interests of existing holders of our ordinary shares, which dilution may be substantial. Additionally,
the sale of a substantial number of ordinary shares to White Lion, or the anticipation of such sales, could make it more difficult for
us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.
In addition to ordinary shares that may be issued under the White Lion Purchase Agreement,
ordinary shares may also be issued upon conversion of amounts outstanding under two convertible promissory notes that we issued in connection
with the consummation of the Business Combination— consisting of the A&R Sponsor Promissory Note, in an amount of $3,433,000,
that we issued to the Moringa Sponsor, due February 15, 2027, and the EarlyBird Convertible Note, due December 31, 2025, in an amount
of $1,250,000 that we issued to EarlyBird (together, the "Convertible Notes"). The conversion prices under the Convertible
Notes relate to the market price of our ordinary shares and/or the price at which we raise capital from equity financings. The issuance
of additional shares under the Convertible Notes will dilute our other equity holders, which could cause the price of our ordinary shares
to decline.
39
The ordinary shares
(including ordinary shares underlying warrants) that are being offered by selling securityholders under another registration statement
that we currently have in effect represent a substantial percentage of our outstanding ordinary shares, and the sale of such shares, or
the perception that such sales may occur, could cause the price of our ordinary shares to be more volatile or decrease.
On October 9, 2024, we filed, and on October 16, 2024, the SEC declared effective, a
registration statement on Form S-1 (SEC file number 333-282556), in which we registered with the SEC the sale by selling securityholders
named therein of up to 15,352,181 of our ordinary shares and up to 190,000 of our warrants (constituting our private warrants)
.
Depending on market liquidity, resales of ordinary shares and warrants by those selling securityholders may cause the trading price of
our ordinary shares and warrants to decrease, and any such decrease could be substantial. Additionally, the sale of a substantial number
of ordinary shares or warrants by those selling securityholders, or the perception that such sales may take place, could increase the
volatility of the market price of the ordinary shares and warrants and depress the trading price of the ordinary shares and warrants and
thereby make it more difficult for us to raise capital by selling equity or equity-related securities in the future at a time and at a
price that we might otherwise wish to effect sales.
The requirement that we
repay the EarlyBird Convertible Note could adversely affect our business plan, liquidity, financial condition, and results of operations.
If not converted, we are required to repay,
in cash, principal that is outstanding under the EarlyBird Convertible Note, as well as interest thereon, in connection with equity financings
by us, or upon the maturity of the note on December 31, 2025. That obligation could have important consequences on our business. In particular,
it could:
●
limit our flexibility in planning the payment of expenditures
        that arise in our clinical program and our business and operations generally;
●
increase our vulnerability to general adverse economic conditions
        that hinder our ability to obtain equity financings; and
●
place us at a competitive disadvantage compared to our competitors.
No assurances can be given that we will be
successful in making the required payments under the EarlyBird Convertible Note. If we are unable to make the required cash payments,
there could be a default under the EarlyBird Convertible Note. In such event, or if a default otherwise occurs under the EarlyBird Convertible
Note:
●
the interest rate payable under the EarlyBird Convertible Note
        could be increased, and EarlyBird, as the holder of the EarlyBird Convertible Note, could declare all outstanding principal and interest
        to be due and payable; and/or
●
we could be forced into bankruptcy or liquidation.
Because we have no current
plans to pay cash dividends on our ordinary shares for the foreseeable future, you may not receive any return on investment unless you
sell New Silexion ordinary shares for a price greater than that which you paid for it.
We will likely retain future earnings, if
any, for future operations, expansion and debt repayment and have no current plans to pay any cash dividends for the foreseeable future.
Any decision to declare and pay dividends as a public company in the future will be made at the discretion of our board of directors and
will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions, funds
lawfully available therefor and other factors that our board of directors may deem relevant. In addition, our ability to pay dividends
may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. As a result, you may not
receive any return on an investment in our ordinary shares unless you sell our ordinary shares for a price greater than that which you
paid for it.
Our prospective reverse
share split may negatively impact the market for our ordinary shares.
There can be no assurance that the total
market capitalization of our ordinary shares after our prospective reverse share split will be equal to or greater than the total market
capitalization before the prospective reverse share split, or that the per share market price of our ordinary shares following the reverse
share split will increase in proportion to the reduction in the number of ordinary shares outstanding before the reverse share split.
Factors such as the results of our pre-clinical and clinical trials, progress in seeking regulatory approval for our product candidates,
our financial results, developments involving our competitors, market conditions and the market perception of our product candidates may
adversely affect the market price of our ordinary shares. As a result, a decline in the market price of our ordinary shares after the
reverse share split may result in a greater percentage decline than would occur in the absence of a reverse share split.
40
In addition to market price, the liquidity
of our ordinary shares may also be adversely affected by the reverse share split, given the reduced number of ordinary shares that will
be outstanding following the reverse share split.
The reverse share split may furthermore
increase the number of our shareholders who own odd lots (less than 100 shares). Any shareholder who owns fewer than 600 to 1,500 ordinary
shares, depending on the final ratio, prior to the reverse share split will own fewer than 100 ordinary shares following the reverse share
split. Shareholders who hold odd lots may experience an increase in the cost of selling their shares and may have greater difficulty in
effecting sales.
Following, and as a
partial result of, our prospective reverse share split, our ordinary shares may experience extreme price volatility unrelated to our actual
or expected operating performance, financial condition or prospects, making it difficult for prospective investors to assess the rapidly
changing value of our ordinary shares.
Recently, there have been instances of
extreme share price run-ups followed by rapid price declines and strong share price volatility with a number of relatively new public
companies, especially among companies with relatively smaller public floats. As a relatively small-capitalization company with relatively
small public float, we may experience greater share price volatility, extreme price run-ups, lower trading volume and less liquidity than
large-capitalization companies. The potential decrease in liquidity due to our prospective reverse share split may heighten our exposure
to those trading trends. In particular, following a reverse share split, our ordinary shares may be subject to rapid and substantial price
volatility, low volume of trades, and large spreads in bid and ask prices. Such volatility, including any stock run up, may be unrelated
to our actual or expected operating performance, financial condition or prospects, making it difficult for prospective investors to assess
the rapidly changing value of our ordinary shares.
In addition, if the trading volumes of
our ordinary shares are low, persons buying or selling in relatively small quantities may easily influence prices of our ordinary shares.
This low volume of trades could also cause the price of our ordinary shares to fluctuate greatly, with large percentage changes in price
occurring in any trading day session. Holders of our ordinary shares may also not be able to readily liquidate their investment or may
be forced to sell at depressed prices due to low volume trading. If high spreads between the bid and ask prices of our ordinary shares
exist at the time of a purchase, the shares would have to appreciate substantially on a relative percentage basis for an investor to recoup
their investment. Broad market fluctuations and general economic and political conditions (including in Israel, where our operations are
centered) may also adversely affect the market price of our ordinary shares.
As a result of this volatility, investors
may experience losses on their investment in our ordinary shares. A volatile market price of our ordinary shares also could adversely
affect our ability to issue additional ordinary shares or other securities and our ability to obtain additional financing in the future,
which is a key strategic goal for us, thereby frustrating our ability to achieve one of the key purposes of our reverse share split.
Following our prospective
reverse share split, the resulting higher market price of our ordinary shares may not attract new investors, including institutional investors,
and may not satisfy the investing requirements of those investors. Consequently, the trading liquidity of our ordinary shares may not
improve.
Although we believe that a higher market
price of our ordinary shares, which is expected to result from our prospective reverse share split, may help generate greater or broader
investor interest, there can be no assurance that the reverse share split will result in a share price that will attract new investors,
including institutional investors. In addition, there can be no assurance that the market price of our ordinary shares will satisfy the
investing requirements of those investors. As a result, the trading liquidity of our ordinary shares may not necessarily improve.
The Company qualifies
as an "emerging growth company" as well as a "smaller reporting company" within the meaning of the Securities
Act, and if the Company takes advantage of certain exemptions from disclosure requirements available to emerging growth companies or smaller
reporting companies, it could make our securities less attractive to investors and may make it more difficult to compare our performance
to the performance of other public companies.
The Company qualifies as an "emerging
growth company" as defined in Section 2(a)(19) of the Securities Act, as modified by the JOBS Act. As such, the Company
will be eligible for and intends to take advantage of certain exemptions from various reporting requirements applicable to other public
companies that are not emerging growth companies for as long as it continues to be an emerging growth company, including (a) the
exemption from the auditor attestation requirements with respect to internal control over financial reporting under Section 404(b) of
the Sarbanes-Oxley Act, (b) the exemptions from say-on-pay, say-on-frequency and say-on-golden parachute voting requirements
and (c) reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements. Wewill remain
an emerging growth company until the earliest of (i) the last day of the fiscal year in which the market value of our ordinary
shares that are held by non-affiliates is equal to or exceeds $700 million as of the end of that year's second fiscal
quarter, (ii) the last day of the fiscal year in which it has total annual gross revenue of $1.235 billion or more during
such fiscal year (as indexed for inflation), (iii) the date on which it has issued more than $1 billion in non-convertible debt
in the prior three-year period or (iv) the last day of the fiscal year following the fifth anniversary of the date of the
first issuance of our ordinary shares in the Business Combination. In addition, Section 107 of the JOBS Act also provides that an
emerging growth company can take advantage of the exemption from complying with new or revised accounting standards provided in Section 7(a)(2)(B) of
the Securities Act as long as the Company is an emerging growth company. An emerging growth company can therefore delay the adoption of
certain accounting standards until those standards would otherwise apply to private companies. We have elected not to opt out of such
extended transition period and, therefore, the Company may not be subject to the same new or revised accounting standards as other public
companies that are not emerging growth companies. Investors may find our ordinary shares less attractive because we rely on these exemptions,
which may result in a less active trading market for our ordinary shares and its price may be more volatile.
41
Additionally, the Company qualifies as a
"smaller reporting company" as defined in Item 10(f)(1) of Regulation S-K promulgated by the SEC. Smaller
reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years
of audited financial statements. The Company will remain a smaller reporting company until the last day of the fiscal year in which
(i) the market value of our ordinary shares held by non-affiliates is equal to or exceeds $250 million as of the end of
that year's second fiscal quarter, or (ii) our annual revenues is equal to or exceeds $100 million during such completed
fiscal year and the market value of our ordinary shares held by non-affiliates is equal to or exceeds $700 million as of the
end of that year's second fiscal quarter. To the extent the Company takes advantage of such reduced disclosure obligations, it may
also make comparison of our financial statements with other public companies difficult or impossible.
Risks Related to U.S. Federal Income
Taxation
The PFIC status of New
Silexion could result in adverse U.S. federal income tax consequences to U.S. Holders.
In general, a non-U.S. corporation is
a PFIC for U.S. federal income tax purposes for any taxable year in which, after applying certain look-through rules, either
(i) 50% or more of the average value of its assets (generally determined on the basis of a weighted quarterly average) consists of
assets that produce, or are held for the production of, passive income, or (ii) 75% or more of its gross income consists of passive
income. Passive income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active
conduct of a trade or business) and gains from the disposition of passive assets. Cash and cash equivalents generally are passive assets.
The value of goodwill will generally be treated as an active or passive asset based on the nature of the income produced in the activity
to which the goodwill is attributable. For purposes of the PFIC rules, a non-U.S. corporation that owns, directly or indirectly,
at least 25% by value of the stock of another corporation is treated as if it held its proportionate share of the assets of the other
corporation and received directly its proportionate share of the income of the other corporation.
The annual PFIC income and asset tests in
respect of Silexion will be applied based on the assets and activities of the combined business. Based on the composition of our income
and assets, it cannot be determined whether we will be classified as a PFIC for its taxable year that includes the date of the Business
Combination or in any future taxable year. Further, changes in the composition of our income or composition of our assets may cause us
to be or become a PFIC for the current or subsequent taxable years. Whether we are treated as a PFIC for U.S. federal income
tax purposes is a factual determination that must be made annually at the close of each taxable year and, thus, is subject to significant
uncertainty.
If we are treated as a PFIC for any taxable
year, or portion thereof, that is included in the holding period of a U.S. Holder, such U.S. Holder may be subject to certain
adverse U.S. federal income tax consequences and may be subject to additional reporting requirements. For a further discussion, see
"
Material U.S. Federal Income Tax Considerations — PFIC Rules
."
U.S. Holders are strongly encouraged to consult their own advisors regarding the potential application of these rules to the ownership
of our ordinary shares and/or our public warrants.
If a U.S. person
is treated as owning at least 10% of the shares of New Silexion, such person may be subject to adverse U.S. federal income tax consequences.
If a U.S. Holder is treated as owning (directly, indirectly or constructively)
at least 10% of the value or voting power of the shares of Silexion, such holder may be treated as a "United States shareholder"
with respect to each of Silexion and our direct and indirect subsidiaries (the "
New Silexion Group
")
that is a "controlled foreign corporation," (a "CFC"), for U.S. federal income tax purposes. A non-U.S. corporation
is considered a CFC if more than 50% of (1) the total combined voting power of all classes of stock of such corporation entitled
to vote, or (2) the total value of the stock of such corporation is owned, or is considered as owned by applying certain constructive
ownership rules, by United States shareholders on any day during the taxable year of such non-U.S. corporation. If the
New Silexion Group includes one or more non-U.S. subsidiaries, certain of our non-U.S. subsidiaries could be treated as CFCs
regardless of whether we are treated as a CFC.
If Silexion or any of our non-U.S. subsidiaries
is a CFC, 10% "United States shareholders" will be subject to adverse income inclusion and reporting requirements with
respect to such CFC. No assurance can be provided that New Silexion will assist holders in determining whether it or any of our non-U.S. subsidiaries
is treated as a CFC or whether any holder is treated as a United States shareholder with respect to any of such CFCs, or furnish
to any holder information that may be necessary to comply with reporting and tax payment obligations with respect to such CFCs.
42
General Risks
The Company may be subject
to securities litigation, which is expensive and could divert management attention, including securities class action and derivative lawsuits
which could result in substantial costs.
Our share price may be volatile and, in
the past, companies that have experienced volatility in the market price of their stock or shares have been subject to securities litigation,
including class action litigation. The Company may be the target of this type of litigation in the future. Litigation of this type could
result in substantial costs and diversion of management's attention and resources, which could have a material adverse effect on
our business, financial condition, and results of operations. Any adverse determination in litigation could also subject the Company to
significant liabilities.
Securities class action lawsuits and derivative
lawsuits are often brought against public companies that have entered into merger or business combination agreements. Even if the lawsuits
are without merit, defending against these claims can result in substantial costs and divert management time and resources. An adverse
judgment could result in monetary damages, which could have a negative impact on our liquidity and financial condition. We cannot predict
whether any such lawsuits will be filed.
USE
OF PROCEEDS
Assuming the maximum number of ordinary
shares are sold in this offering at an assumed public offering price of $           per ordinary share and
accompanying ordinary warrant, which represents the closing price of our ordinary shares on Nasdaq on          
, 2024, and assuming no issuance of pre-funded warrants in connection with this offering, we estimate the net proceeds of the offering
will be approximately $           million, after deducting the Placement Agent's fees and estimated
offering expenses payable by us. However, this is a best efforts offering with no minimum number of securities or amount of proceeds as
a condition to closing, and we may not sell all or any of these securities offered pursuant to this prospectus; as a result, we may receive
significantly less in net proceeds.
Each $0.10 increase (decrease) in the assumed
public offering price of $         per ordinary share and accompanying ordinary warrant would increase (decrease)
the net proceeds to us from this offering, after deducting the estimated placement agent fees and estimated offering expenses payable
by us, by $      million, assuming that the number of ordinary shares and accompanying ordinary warrants offered by us,
as set forth on the cover page of this prospectus, remains the same. We may also increase or decrease the number of ordinary shares and
ordinary warrants we are offering. An increase (decrease) of            in the number of ordinary shares
we are offering would increase (decrease) the net proceeds to us from this offering, after deducting the estimated placement agent fees
and estimated offering expenses payable by us, by $        million, assuming the assumed public offering price stays
the same.
We currently intend to use the net proceeds
from this offering to advance our pre-clinical clinical studies, and for general corporate purposes. Accordingly, we retain broad discretion
over the use of the net proceeds from the sale of our ordinary shares and ordinary warrants (or pre-funded warrants and ordinary warrants,
if applicable), pursuant to this prospectus. The precise amount and timing of the application of such proceeds will depend upon our liquidity
needs and the availability and cost of other capital over which we have little or no control.
Pending the use of the net proceeds from
this offering as described above, we intend to invest the net proceeds in a variety of capital preservation investments, short and intermediate
term, interest-bearing, investment-grade instruments, U.S. government securities and highly rated corporate debt securities, although
our investment policy may change following the date of this prospectus supplement. It is possible that, pending their use, we may invest
the net proceeds in a way that does not yield a favorable, or any, return for us.
​
43
CAPITALIZATION
The following table sets forth our capitalization as of June
30, 2024 as follows:
•
on an actual basis; and
•
on an as adjusted basis to reflect assumed sale by us of all ordinary shares and accompanying ordinary warrants offered by means
        of this prospectus at an assumed public offering price of $                per ordinary share
        and accompanying ordinary warrant, which is based on the last reported sale price of our ordinary shares on Nasdaq on     
                          , 2024, assuming no sale of pre-funded warrants and after deducting the
        Placement Agent's fees and estimated offering expenses payable by us, and without giving effect to the exercise of the ordinary
        warrants issued in this offering.
The as adjusted information below is illustrative only and our capitalization following
the completion of this offering is subject to various adjustments. The as adjusted amounts shown below are unaudited and represent management's
estimate. The information in this table should be read in conjunction with and is qualified by reference to the financial statements and
notes thereto and other financial information contained in this prospectus.
As of June 30, 2024
(unaudited)
(U.S. dollars in thousands)
Actual
As Adjusted
Cash and cash equivalents
$
1,697
$
Shareholders' equity:
Ordinary shares par value S0.0001 per share; authorized 200,000,000; issued and outstanding   
                    ordinary shares (actual) and             ordinary shares
        (as adjusted)
Additional paid in capital
Accumulated other comprehensive loss
)
)
Accumulated deficit
)
)
Total shareholders' equity
Each $0.10 increase (decrease) in an assumed public offering price of $   
    per share and accompanying ordinary warrant would increase (decrease) the amount of cash and cash equivalents and total
shareholders' equity by $      million, a by $      million, assuming that the number of ordinary
shares and accompanying ordinary warrants offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting the Placement Agent's fees and estimated offering expenses payable by us. We may also increase or decrease the number
of ordinary shares and accompanying ordinary warrants we are offering. An increase (decrease) of 100,000 in the number of ordinary shares
we are offering would increase (decrease) the amount of cash and cash equivalents and total shareholders' equity by $    
million, after deducting the estimated Placement Agent's fees and estimated offering expenses payable by us, assuming the assumed
public offering price stays the same. The information discussed above is illustrative only and will adjust based on the actual public
offering price, the actual number of shares that we offer in this offering, and other terms of this offering determined at pricing.
The above table is based on                 
shares outstanding as of June 30, 2024 and excludes as of that date:
●
up to 5,940,000 ordinary shares underlying an equivalent number of outstanding warrants at an exercise price of $11.50 per share;
●
6,866,000 ordinary shares issuable pursuant to the A&R Sponsor Promissory Note (based on the conversion of the entire $3,433,000
        principal amount of that note into ordinary shares at an assumed conversion price of $0.50 per share);
●
2,500,000 ordinary shares issuable pursuant to the EarlyBird Convertible Note (based on the conversion of the entire $1,250,000 principal
        amount of that note into ordinary shares at an assumed conversion price of $0.50 per share);
●
ordinary shares issuable upon exercise of outstanding stock options
        under our equity incentive plan, at a weighted average exercise price of $          ;
●
ordinary shares issuable upon the settlement of RSUs under our equity incentive
        plan; and
●
ordinary shares reserved for future awards under our equity incentive plan.
44
DILUTION
If you purchase our ordinary shares and accompanying ordinary warrants in this offering,
you will experience dilution to the extent of the difference between the combined public offering price per ordinary share and ordinary
warrant you pay in this offering and the net tangible book value per share of our ordinary shares immediately after this offering.
The net tangible book value of our ordinary shares on June 30, 2024 was approximately
$          million, or approximately $              per share. Net tangible
book value per share is equal to the amount of our total tangible assets, less total liabilities, divided by the aggregate number of our
ordinary shares outstanding.
After giving effect to the assumed sale by us of all ordinary shares and accompanying
ordinary warrants offered by means of this prospectus at an assumed public offering price of $           
    per ordinary share and accompanying ordinary warrant, which is based on the last reported sale price of our ordinary shares
on Nasdaq on                        , 2024, assuming no sale of pre-funded
warrants and after deducting the Placement Agent's fees and estimated offering expenses payable by us, and without giving effect
to the exercise of the ordinary warrants issued in this offering, our as adjusted net tangible book value as of June 30, 2024 would have
been approximately $             million, or approximately $           
per ordinary share and accompanying ordinary warrant. This represents an immediate increase in net tangible book value of approximately
$          per share to existing shareholders and an immediate dilution of approximately $      
per share to new investors in this offering. The following table illustrates this per share dilution:
Assumed public offering price per ordinary share and accompanying
        ordinary warrant
$
Net tangible book value per share as of June 30, 2024
$
Increase per share attributable to new investors in this offering
$
As adjusted net tangible book value per share as of June 30, 2024
        after giving effect to this
offering
$
Dilution in net tangible book value per share to new investors in this offering
$
Each $0.10 increase (decrease) in an assumed public offering price of $   
    per share and accompanying ordinary warrant would increase (decrease) our as adjusted net tangible book value after
this offering by $       per share, and the dilution per share to new investors by $      per
share and accompanying ordinary warrant, assuming that the number of ordinary shares and accompanying ordinary warrants offered by us,
as set forth on the cover page of this prospectus, remains the same and after deducting the Placement Agent's fees and estimated
offering expenses payable by us. We may also increase or decrease the number of ordinary shares and accompanying ordinary warrants we
are offering. An increase (decrease) of 100,000 in the number of ordinary shares we are offering would increase (decrease) the dilution
per ordinary shares to new investors by $         ,after deducting the estimated Placement Agent's fees
and estimated offering expenses payable by us, assuming the assumed public offering price stays the same. The information discussed above
is illustrative only and will adjust based on the actual public offering price, the actual number of shares that we offer in this offering,
and other terms of this offering determined at pricing.
The number of our ordinary shares to be outstanding after this offering as shown above
is based on                  shares outstanding as of June 30, 2024 and excludes as of that
date:
●
up to 5,940,000 ordinary shares underlying an equivalent number of outstanding warrants at an exercise price of $11.50 per share;
●
6,866,000 ordinary shares issuable pursuant to the A&R Sponsor Promissory Note (based on the conversion of the entire $3,433,000
        principal amount of that note into ordinary shares at an assumed conversion price of $0.50 per share);
●
2,500,000 ordinary shares issuable pursuant to the EarlyBird Convertible Note (based on the conversion of the entire $1,250,000 principal
        amount of that note into ordinary shares at an assumed conversion price of $0.50 per share);
●
ordinary shares issuable upon exercise of outstanding stock options
        under our equity incentive plan, at a weighted average exercise price of $          ;
●
ordinary shares issuable upon the settlement of RSUs under our equity incentive
        plan; and
●
ordinary shares reserved for future awards under our equity incentive plan.
To the extent that any of our options or warrants listed above are exercised, new options
are issued under our equity incentive plan and subsequently exercised or we issue additional ordinary shares in the future, there will
be further dilution to new investors participating in this offering.
45
MARKET
INFORMATION FOR SECURITIES AND DIVIDEND POLICY
Market Information
Our ordinary shares and warrants are currently listed on Nasdaq under the symbols "SLXN" and
"SLXNW," respectively. On November   , 2024, there were        holders of record of the ordinary
shares and three holders of record of our warrants.
Dividend Policy
We have never declared or paid any dividends
on ordinary shares. We anticipate that we will retain all of our future earnings, if any, for use in the operation and expansion of our
business and do not anticipate paying cash dividends in the foreseeable future. Any decision to declare and pay dividends in the future
will depend on, among other things, the consent of our lender(s), our results of operations, cash requirements, financial condition, contractual
restrictions, funds lawfully available therefor and other factors that our board of directors may deem relevant.
UNAUDITED
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Introduction
The registrant, Silexion Therapeutics Corp
(formerly known as Biomotion Sciences), a Cayman Islands exempted company ("
New Silexion
")
is providing the following unaudited pro forma condensed combined financial information to aid you in your analysis of the financial aspects
of the business combination and related transactions (collectively, the "
Transactions
")
involving Moringa Acquisition Corp ("
Moringa
") and Silexion Therapeutics Ltd. ("
Silexion
").
The following unaudited pro forma condensed combined financial information presents the combination of the financial information of Moringa
and Silexion, as adjusted to give effect to the Transactions. Capitalized terms included in this section containing unaudited pro forma
condensed combined financial information and not otherwise defined in this section have the same meaning as is provided elsewhere in this
prospectus.
Parties to the Transaction
Moringa is a Cayman Islands exempted company
that was originally a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share
purchase, recapitalization, reorganization or similar business combination with one or more businesses. As of June 30, 2024 and December
31, 2023, there was approximately $5.924 million and $5.698 million, respectively, held in Moringa's trust account, which was held
for the benefit of Moringa's public shareholders (the "
Trust Account
"). The Trust
Account was liquidated upon the completion of the Transactions, as described below.
Silexion, an Israeli company that was known
previously as Silenseed Ltd., is a pioneering biopharma developmental-stage company dedicated to the development of innovative treatments
for pancreatic cancer.
New Silexion is a newly formed entity that
was formed for the purpose of effecting the Transactions, and now serves as a publicly-traded holding company of its subsidiaries —
including Moringa and Silexion — after the Closing of the Transactions.
46
Description of the Transactions
On August 15, 2024, the parties completed
the previously-reported Transactions pursuant to that certain amended and restated business combination agreement, dated April 3, 3024
(the "
Business Combination Agreement
") by and among New Silexion (then known as Biomotion
Sciences), August M.S. Ltd., an Israeli company and a wholly owned subsidiary of New Silexion ("
Merger
Sub 1
"), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a wholly owned subsidiary of New Silexion
("
Merger Sub 2
"), Moringa and Silexion.
Pursuant to the Transactions, Merger Sub 2
merged with and into Moringa, with Moringa continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion
(the "
SPAC Merger
"), and Merger Sub 1 merged with and into Silexion, with Silexion
continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion (the "
Acquisition
Merger
"). Upon the effectiveness of the SPAC Merger, each outstanding Moringa Class A ordinary share and the sole outstanding
Moringa Class B ordinary share converted into an ordinary share of New Silexion on a one-for-one basis. Each outstanding warrant to purchase
one Moringa Class A ordinary share converted into a warrant to purchase one New Silexion ordinary share, at the same exercise price. Upon
the effectiveness of the Acquisition Merger, each outstanding ordinary share and preferred share of Silexion converted into such number
of ordinary shares of New Silexion as is equal to the quotient obtained by dividing (x) the quotient obtained by dividing (1) $62,500,000
by (2) the number of fully diluted Silexion equity securities, by (y) $10.00 (the "
Silexion Equity
Exchange Ratio
"). Each outstanding Silexion warrant and Silexion option to purchase one Silexion share, and Silexion restricted
share unit (RSU) that may be potentially settled for one Silexion share, became exercisable for, or became subject to settlement for (as
applicable), such number of New Silexion ordinary shares as are equal to the Silexion Equity Exchange Ratio. The exercise price per New
Silexion ordinary share of each such converted Silexion option and Silexion warrant were adjusted based on dividing the existing per share
exercise price by the Silexion Equity Exchange Ratio. The terms of vesting, exercise and/or settlement, as applicable, of such converted
options, warrants and RSUs remain the same following such conversion, except that the vesting of each Silexion option accelerated immediately
prior to the Acquisition Merger, such that the New Silexion option into which it has been converted was fully vested, and all Silexion
warrants were exercised (on a cashless basis) immediately prior to the Acquisition Merger.
Immediately prior to the Closing, seven directors
were appointed to New Silexion's board of directors, of whom five were designated by Silexion and two were designated by Moringa's
sponsor (Moringa Sponsor, LP, a Cayman Islands exempted limited partnership and/or its wholly-owned subsidiary, Moringa Sponsor US L.P.,
a Delaware limited partnership) (collectively, the "
Moringa Sponsor
").
In connection with the Closing, the ordinary
shares and warrants of New Silexion were approved for listing on the Nasdaq Global Market and began trading under the symbols "SLXN"
and "SLXNW", respectively.
The Business Combination was accounted for
as a reverse recapitalization in accordance with US GAAP. Under this method of accounting, Silexion was treated as the accounting acquirer
and Moringa was treated as the "acquired" company for financial reporting purposes. Silexion was determined to be the accounting
acquirer based on evaluation of the following facts and circumstances:
●
Silexion's shareholders holding approximately 61.55% of
        the outstanding voting interests in New Silexion upon the Closing of the Transactions;
●
Silexion's senior management comprise the senior management
        of New Silexion;
●
the directors nominated by Silexion constitute the majority of
        the board of directors of New Silexion (five out of seven of the initial directors); and
47
●
Silexion's operations comprise the ongoing operations of
        New Silexion.
Under the reverse recapitalization accounting
method, the Business Combination is deemed to be the equivalent of a capital transaction in which Silexion has issued shares for the net
assets of Moringa. The net assets of Moringa are stated at fair value, with no goodwill or other intangible assets recorded. Operations
prior to the Business Combination are of Silexion.
The following unaudited pro forma condensed
combined balance sheet as of June 30, 2024 combines the historical condensed balance sheet of Moringa as of June 30, 2024 with the historical
balance sheet of Silexion as of June 30, 2024, with such adjustments as are necessary to properly understand New Silexion's financial
position and results of operations upon consummation of the Business Combination and related transactions — all in accordance with
Article 11 of SEC Regulation S-X, as amended by the final rule, SEC Release No. 33-10786 "Amendments to Financial Disclosures About
Acquired and Disposed Businesses" (collectively, the "
Pro Forma Adjustments
")
— giving effect to the Business Combination as if it had been consummated as of June 30, 2024.
The following unaudited pro forma condensed
combined statements of operations for the six-months period ended June 30, 2024 and year ended December 31, 2023 combine the historical
condensed statement of operations of Moringa for the six-months period ended June 30, 2024 and for the year ended December 31, 2023 with
the historical statements of operations of Silexion for the six-months period ended June 30, 2024 and for the year ended December 31,
2023, subject to the Pro Forma Adjustments, giving effect to the Business Combination as if it had been consummated on January 1, 2023,
the beginning of the earliest period presented.
Unaudited Condensed Combined Pro Forma Financial
Statements
The unaudited pro forma condensed combined
financial statements have been derived from and should be read in conjunction with:
●
the accompanying notes to the unaudited pro forma condensed combined
        financial statements;
●
the historical unaudited financial statements of Moringa as of
        and for the six-months period ended June 30, 2024 and the related notes included elsewhere in this prospectus;
●
the historical unaudited financial statements of Silexion as
        of and for the six-months period ended June 30, 2024 and the related notes included elsewhere in this prospectus;
●
the historical audited financial statements of Moringa as of
        and for the year ended December 31, 2023 and the related notes included elsewhere in this prospectus;
●
the historical audited financial statements of Silexion as of
        and for the year ended December 31, 2023 and the related notes included elsewhere in this prospectus;
●
the sections entitled "Management's Discussion and
        Analysis of Financial Condition and Results of Operations" included in Moringa's quarterly report on Form 10-Q for the quarter
        ended June 30, 2024, filed with the SEC on August 13, 2024 (the "
Moringa Q2 Form 10-Q
"),
        and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in this prospectus;
●
the other financial information relating to Moringa and Silexion
        included in this prospectus; and
●
factors detailed under the section entitled "
Risk
        Factors
" in this prospectus.
The unaudited pro forma condensed combined
financial information is for illustrative purposes only and is not necessarily indicative of what the actual results of operations and
financial position would have been had the Transactions included in the Pro Forma Adjustments taken place on the dates indicated, nor
are they indicative of the future results of operations or financial position of New Silexion. The Pro Forma Adjustments are based on
currently available information and certain assumptions and estimates that New Silexion believes are reasonable under the circumstances.
Management performed a comprehensive review of the accounting policies between the two entities. Management is not aware of any significant
accounting policy differences and has therefore not made any adjustments to the pro forma condensed combined financial information related
to any potential differences.
The unaudited condensed combined pro forma
financial information is qualified in its entirety by reference to, and should be read together with, Silexion's and Moringa's
audited financial statements and related notes included in this prospectus, as well as "Management's Discussion and Analysis
of Financial Condition and Results of Operations" included in each of this prospectus and the Moringa Q2 Form 10-Q.
48
SILEXION THERAPEUTICS
CORP
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET
AS OF JUNE 30, 2024
(in thousands, except share and per share
amounts)
Historical
Actual Redemptions
Moringa
Acquisition
Corp.
Silexion
Therapeutics
Ltd.
Redemption
Adjustments
Business
Combination
Adjustments
Pro Forma
Balance
Sheet
ASSETS
Current Assets:
Cash and cash equivalents
$
18
$
1,697
I
$
1,015
A
$
(2,076
)
$
2,244
—
—
—
L
2,000
—
—
—
B
(350
)
—
—
—
N
(60
)
Restricted cash
—
25
—
—
25
Investments held in Trust Account
5,924
—
I
(5,924
)
—
—
Prepaid expenses
25
527
—
—
552
Other receivables
—
66
—
—
66
Total Current Assets
5,967
2,315
(4,909
)
(486
)
2,887
Restricted cash
—
25
—
—
25
Long-term deposit
—
5
—
—
5
Property and equipment, net
—
40
—
—
40
Operating lease right-of-use asset
—
140
—
—
140
Total Assets
$
5,967
$
2,525
$
(4,909
)
$
(486
)
$
3,097
LIABILITIES
        AND REDEEMABLE SHARES, NET OF CAPITAL DEFICIENCY
Current Liabilities:
Trade payables
$
—
$
281
$
—
$
—
$
281
Current maturities of operating lease liability
—
108
—
—
108
Employee related obligations
—
251
—
—
251
Accrued expenses
56
1,379
—
A
(233
)
1,202
Related Parties
3,346
—
—
F
(3,346
)
3,145
—
—
—
F
3,145
ELOC Liability
—
—
—
M
337
337
Warrants
27
345
—
C
(345
)
27
Total Current Liabilities
3,429
2,364
—
(442
)
5,351
Long-term operating lease liability
—
8
—
—
8
Underwriters' Promissory note
—
—
—
B
1,197
1,197
Total Non Current Liabilities
—
8
—
1,197
1,205
Total Liabilities
$
3,429
$
2,372
$
—
$
755
$
6,556
REDEEMABLE
        CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTERSTS:
Convertible Preferred Shares A
$
—
$
7,307
$
—
H
$
(7,307
)
$
—
Convertible Preferred Shares A-1
—
2,392
—
H
(2,392
)
—
Convertible Preferred Shares A-2
—
2,264
—
H
(2,264
)
—
Convertible Preferred Shares A-3
—
2,683
—
H
(2,683
)
—
Convertible Preferred Shares A-4
—
411
—
H
(411
)
—
Non-controlling interests
—
3,353
—
D
(3,353
)
—
MORINGA CLASS A ORDINARY
        SHARES SUBJECT TO POSSIBLE REDEMPTION
$
5,924
$
—
I
$
(5,924
)
$
—
$
—
SHAREHOLDERS' EQUITY (DEFICIT):
Ordinary shares
*
1
J
*
J
*
1
Additional paid-in capital
—
11,398
—
N
3,000
39,166
—
—
—
C
345
—
—
—
E
220
—
—
—
H
15,057
—
—
I
1,015
G
7,510
—
—
—
L
2,000
—
—
—
D
3,353
—
—
—
F
201
—
—
—
B
(1,547
)
—
—
—
K
(3,386
)
Accumulated deficit
(3,386
)
(29,656
)
—
E
(220
)
(42,626
)
—
—
—
A
(1,843
)
—
—
—
G
(7,510
)
—
—
—
M
(337
)
—
—
—
K
3,386
—
—
—
N
(3,060
)
TOTAL EQUITY (CAPITAL DEFICIENCY)
(3,386
)
(18,257
)
1,015
17,169
(3,459
)
TOTAL CLASS A ORDINARY SHARES
        SUBJECT TO POSSIBLE REDEMPTION, REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF
        CAPITAL DEFICIENCY
2,538
153
(4,909
)
(1,241
)
(3,459
)
TOTAL
        LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED SHARES, NON-CONTROLLING INTEREST AND ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND
        SHAREHOLDER'S EQUITY (NET OF CAPITAL DEFICIENCY)
$
5,967
$
2,525
$
(4,909
)
$
(486
)
$
3,097
*
Represents an amount less than $1.
See accompanying notes to the unaudited pro
forma condensed combined financial information.
49
SILEXION THERAPEUTICS
CORP
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
FOR SIX-MONTHS PRIOD ENDED JUNE 30, 2024
(in thousands,
except share and per share amounts)
Historical
Historical
Actual Redemption
Moringa
Acquisition
Corp
Silexion
Therapeutics Ltd.
Business
Combination
Adjustments
Pro Forma
Statement of
Operations
Research and development expenses, net
$
—
$
1,727
E
$
(38
)
$
1,689
General and administrative expenses
441
908
E
(26
)
1,066
—
—
A
(317
)
—
—
DD
60
OPERATING LOSS
441
2,635
(321
)
2,755
Financial expenses (income), net
(130
)
270
C
(145
)
514
—
—
BB
420
AA
99
Loss before income tax
311
2,905
53
3,269
Tax on Income
—
7
—
7
LOSS FOR THE PERIOD
$
311
$
2,912
$
53
$
3,276
Attributable to:
Equity holders of the Company
—
2,845
D
67
3,276
Non-controlling interests
—
67
D
(67
)
—
PROFIT (LOSS) PER SHARE,
        BASIC AND DILUTED
Ordinary share subject to possible redemption
$
0.32
$
—
$
(0.32
)
$
—
Non-redeemable ordinary shares
$
(0.14
)
$
(11.31
)
$
11.12
$
(0.33
)
WEIGHTED AVERAGE NUMBER
        OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
Ordinary shares subject to possible redemption
87,722
—
(87,722
)
—
Non-redeemable ordinary shares
3,355,000
251,655
6,399,717
CC
10,006,372
See accompanying notes to the unaudited pro
forma condensed combined financial information.
50
SILEXION THERAPEUTICS
CORP
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 31, 2023
(in thousands,
except share and per share amounts)
Historical
Historical
Actual Redemption
Moringa
Acquisition
Corp
Silexion
Therapeutics
Ltd.
Business
Combination
Adjustments
Pro Forma
Statement
of Operations
Research and development expenses, net
$
—
$
3,708
E
$
169
$
6,753
—
—
G
2,876
General and administrative expenses
1,122
973
E
115
12,189
—
—
G
4,639
—
—
DD
120
—
—
A
2,160
—
—
N
3,060
OPERATING LOSS
1,122
4,681
13,139
18,942
Financial expenses (income), net
(1,385
)
395
C
(86
)
1,350
BB
725
AA
1,364
M
337
Loss before income tax
(263
)
5,076
15,479
20,292
Tax on Income
—
32
—
32
LOSS FOR THE PERIOD
$
(263
)
$
5,108
$
15,479
$
20,324
Attributable to:
Equity holders of the Company
—
4,942
D
166
20,324
Non-controlling interests
—
166
D
(166
)
—
PROFIT (LOSS) PER SHARE,
        BASIC AND DILUTED
Ordinary share subject to possible redemption
$
0.51
$
—
$
(0.51
)
$
—
Non-redeemable ordinary shares
$
(0.34
)
$
(19.57
)
$
17.88
$
(2.03
)
WEIGHTED AVERAGE NUMBER
        OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
Ordinary shares subject to possible redemption
2,774,850
—
(2,774,850
)
—
Non-redeemable ordinary shares
3,355,000
252,462
6,398,910
CC
10,006,372
See accompanying notes to the unaudited pro
forma condensed combined financial information.
51
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED
FINANCIAL INFORMATION
1. Description of the Business Combination
On August 15, 2024, the parties completed
the previously-reported transactions (the "
Transactions
" or "
Business
Combination
") pursuant to that certain amended and restated business combination agreement, dated April 3, 3024 (the "Business
Combination Agreement") by and among the registrant ("
New Silexion
", which was
then known as Biomotion Sciences), August M.S. Ltd., an Israeli company and a wholly owned subsidiary of New Silexion ("
Merger
Sub 1
"), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a wholly owned subsidiary of New Silexion
("
Merger Sub 2
"), Moringa and Silexion.
Pursuant to the Transactions, Merger Sub 2
merged with and into Moringa, with Moringa continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion
(the "
SPAC Merger
"), and Merger Sub 1 merged with and into Silexion, with Silexion
continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion (the "
Acquisition
Merger
"). Upon the effectiveness of the SPAC Merger, each outstanding Moringa Class A ordinary share and the sole outstanding
Moringa Class B ordinary share converted into an ordinary share of New Silexion on a one-for-one basis. Each outstanding warrant to purchase
one Moringa Class A ordinary share converted into a warrant to purchase one New Silexion ordinary share, at the same exercise price. Upon
the effectiveness of the Acquisition Merger, each outstanding ordinary share and preferred share of Silexion converted into such number
of ordinary shares of New Silexion as is equal to the quotient obtained by dividing (x) the quotient obtained by dividing (1) $62,500,000
by (2) the number of fully diluted Silexion equity securities, by (y) $10.00 (the "
Silexion Equity
Exchange Ratio
"). Each outstanding Silexion warrant and Silexion option to purchase one Silexion share, and Silexion restricted
share unit (RSU) that may be potentially settled for one Silexion share, became exercisable for, or will be subject to settlement for
(as applicable), such number of New Silexion ordinary shares as are equal to the Silexion Equity Exchange Ratio. The exercise price per
New Silexion ordinary share of each such converted Silexion option and Silexion warrant was adjusted based on dividing the existing per
share exercise price by the Silexion Equity Exchange Ratio. The terms of vesting, exercise and/or settlement, as applicable, of such converted
options, warrants and RSUs remains the same following that conversion, except that the vesting of each Silexion option accelerated immediately
prior to the Acquisition Merger, such that the New Silexion option into which it has been converted is fully vested, and all Silexion
warrants were exercised (on a cashless basis) immediately prior to the Acquisition Merger.
Immediately prior to the closing of the Business
Combination (the "
Closing
"), seven directors were appointed to New Silexion's
board of directors, of whom five were designated by Silexion and two were designated by Moringa's sponsor (Moringa Sponsor, LP,
a Cayman Islands exempted limited partnership and/or its wholly-owned subsidiary, Moringa Sponsor US L.P., a Delaware limited partnership)
(collectively, the "
Moringa Sponsor
"). Also upon Closing, New Silexion's articles
of association were amended and restated as appears in Exhibit 3.1 to the registration statement of which this prospectus forms a part.
In connection with the Closing, the ordinary shares and warrants of New Silexion were approved for listing on the Nasdaq Global Market
and began trading under the symbols "SLXN" and "SLXNW", respectively.
In addition, at the Closing, each of the following
additional actions was taken, in accordance with the terms of the Business Combination Agreement (in certain cases, as modified by subsequent
agreements):
●
Moringa Sponsor forfeited for retirement 1,308,000 of the Moringa founders shares held by it, while 1,567,000
        of the Moringa founders shares were transferred to non-affiliated third-party investors (including 316,750 founders shares to certain
        security holders) as Backstop Shares (as defined in the Business Combination Agreement);
52
●
New Silexion issued to the Moringa Sponsor the A&R Sponsor
        Promissory Note in an amount of $3,433,000, in replacement of all promissory notes that Moringa had issued to the Moringa Sponsor for
        amounts owed by Moringa to the Moringa Sponsor prior to the Closing;
●
New Silexion, Moringa Sponsor, the investor in the PIPE financing
        (described below) and certain additional shareholders of New Silexion entered into an Amended and Restated Registration Rights and Lock-Up
        Agreement granting them registration rights with respect to the ordinary shares of New Silexion issued to them;
●
Guangzhou Sino-Israel Bio-Industry Investment Fund I ("
GIBF
"),
        a shareholder of Silexion, transferred its noncontrolling interest in Silexion's Chinese subsidiary, Silenseed (China) Ltd., directly
        to New Silexion, such that the subsidiary became a wholly-owned subsidiary of New Silexion, and was issued 1,835,733 ordinary shares of
        New Silexion as consideration for that transfer (the "
Chinese Subsidiary Transfer
")
        (in addition to the 151,349 New Silexion ordinary shares that GIBF received upon the accelerated vesting of RSUs granted to it).
In connection with the Moringa extraordinary
general meeting at which the three proposals related to the Business Combination—the Business Combination Proposal, the Merger Proposal
and the Articles Amendment Proposal— were approved by the requisite majorities of Moringa's shareholders, holders of an aggregate
of 427,297 Moringa public shares properly exercised their right to have their shares redeemed for a full pro rata portion of the Trust
Account holding the proceeds from Moringa's IPO, which was approximately $11.575 per share, or $4,946,046 in the aggregate. Also
prior to the Closing, Moringa reached agreement with EarlyBird on a reduction, from $4.025 million to $1.6 million, in the aggregate,
of the fee payable to EarlyBird under the Business Combination Marketing Agreement, dated February 19, 2021 (the "
Marketing
Agreement
"), entered into by Moringa with EarlyBird at the time of Moringa's initial public offering. Pursuant to the
final invoice provided by EarlyBird under the Marketing Agreement at the Closing, Moringa paid $350,000 of cash to EarlyBird at the Closing,
and New Silexion issued to EarlyBird a convertible promissory note, due December 31, 2025, in an amount of $1.25 million to be paid by
New Silexion to EarlyBird in cash and/or via conversion of outstanding amounts into ordinary shares of New Silexion. After the redemption
payments, the payment to EarlyBird, and the satisfaction of amounts due to parties that arranged financing and/or capital markets advisory
services in connection with the Closing, the remaining balance of the Trust Account immediately prior to the Closing of $333,936 was used
to partially fund the Business Combination.
In connection with, and immediately prior
to the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity (PIPE) financing, whereby
Moringa sold to Greenstar, L.P. 200,000 Moringa ordinary shares at a price of $10.00 per share. Those funds, together with remaining funds
in Moringa's Trust Account after payments to redeeming public shareholders, were used for financing support for Moringa and New
Silexion, as well as for payment to service providers to whom outstanding amounts were owed by Moringa, including parties that had provided
financial advisory services and capital markets advisory services to Moringa during the period leading up to the Closing.
Also in connection with the Closing, New Silexion
entered into an ordinary share purchase agreement for an equity line of credit with White Lion, whereby New Silexion will be able to request
to sell to White Lion, and White Lion will be required to purchase, via private placement transactions, up to $15.0 million of New Silexion
ordinary shares from time to time after the Closing, up until December 31, 2025 (unless the agreement is terminated sooner), subject to
certain limitations and conditions as described therein. The number of New Silexion ordinary shares that New Silexion may require White
Lion to purchase in any single sales notice will depend on a number of factors, including the type of purchase notice that New Silexion
delivers. Similarly, the purchase price to be paid by White Lion for any shares that New Silexion requires them to purchase will depend
on the type of sales notice that New Silexion delivers. New Silexion has also granted registration rights to White Lion pursuant to an
accompanying registration rights agreement.
53
In consideration for the commitments of White
Lion, New Silexion agreed to issue to White Lion an aggregate of $337,500 of New Silexion ordinary shares based on the closing price of
the New Silexion ordinary shares on the day that is the earlier of (i) the business day prior to effectiveness of the registration statement
registering the resale of the shares issuable under the White Lion Purchase Agreement and (ii) the business day prior to the 180
th
day following the Closing Date of the Business Combination.
Separately, the Moringa Sponsor transferred to third-party investors (in lieu of forfeiting) all 1,567,000
Moringa founders shares that had been designated to serve as Backstop Shares under the Business Combination Agreement, including 316,750
founders shares to certain security holders.
Various issuances and other actions impacted
the final number of New Silexion ordinary shares that were issued upon the Closing of the Business Combination, including the following:
●
the redemption of the 427,297 Moringa public shares described
        above;
●
the separation of each former Moringa unit into one Moringa Class
        A ordinary share and one-half of a Moringa warrant;
●
the Sponsor Founder Shares Forfeiture (as defined in the Business Combination Agreement) of 1,308,000 founders
        shares, and transfer of the remaining 1,567,000 founders shares to third parties (including 316,750 founders shares to certain securityholders)
        as Backstop Shares, as described above;
●
the issuance of 87,722 New Silexion ordinary shares in exchange
        for an equivalent number of Moringa public shares that remained outstanding immediately prior to the Closing (following the redemptions
        described above);
●
the issuance of 380,000 New Silexion ordinary shares in exchange
        for an equivalent number of Moringa private shares;
●
the issuance of 100,000 New Silexion ordinary shares to EarlyBird
        in exchange for an equivalent number of representative shares;
●
the issuance by New Silexion to the Sponsor and/or its limited
        partners to whom the Sponsor distributed such shares of the 1,382,325 Sponsor Investment Shares (as defined in the Business Combination
        Agreement);
●
the issuance of 200,000 New Silexion ordinary shares to Greenstar,
        L.P. in exchange for an equivalent number of Moringa shares that were purchased in the $2.0 million PIPE financing, as described above;
●
the issuance of 4,024,942 New Silexion ordinary shares as the
        Silexion Merger Consideration (as defined in the Business Combination Agreement) to security holders of Silexion;
●
the issuance of 1,835,733 New Silexion ordinary shares to GIBF
        in respect of the Chinese Subsidiary Transfer (in addition to 151,349 New Silexion ordinary shares issued to GIBF upon the accelerated
        vesting of RSUs granted to it), as described above; and
●
the issuance of 39,325 New Silexion ordinary shares to a non-employee
        director of New Silexion upon acceleration of vesting, and settlement, of an equivalent number of New Silexion RSUs granted to the director.
As a result of each of the foregoing, upon
the Closing, there were 9,768,396 New Silexion ordinary shares issued and outstanding.
54
Upon the Closing, the pro forma ownership
structure for New PubcCo was as set forth in the table below, based on actual number of redemptions of Moringa public shares:
Equity Holders
Shares
Percentage of
Outstanding
Shares
Moringa Public Shareholders
(1)
87,722
0.88
%
Silexion Shareholders
(2)
6,250,000
62.46
%
Moringa Sponsor Shares
(3)
1,690,182
16.89
%
Distributees of Sponsor Investment Shares
45,000
0.45
%
PIPE investor
200,000
2.00
%
Founders Shares/ Backstop Shares
1,567,000
15.66
%
EarlyBird
(3)
127,143
1.27
%
Director receiving RSU grant upon Closing
39,325
0.39
%
Total
10,006,372
100
%
(1)
Excludes 5,750,000 public warrants held by Moringa's public
        shareholders, which will be exercisable for New Silexion ordinary shares at an exercise price of $11.50 per share beginning 30 days after
        the Closing of the Business Combination.
(2)
Includes all securities issuable to security holders of Silexion
        on a fully-diluted basis, including New Silexion ordinary shares, New Silexion warrants, New Silexion options and New Silexion RSUs, and
        also includes 1,835,733 New Silexion ordinary shares issued directly to GIBF in respect of the Chinese Subsidiary Transfer, as well as
        151,349 New Silexion ordinary shares issued to GIBF upon the accelerated vesting of RSUs granted to it.
(3)
Excludes 190,000 private warrants held, in the aggregate, by
        the Moringa Sponsor and EarlyBird, which will be exercisable for New Silexion ordinary shares at an exercise price of $11.50 per share
        beginning 30 days after the Closing of the Business Combination.
2. Basis of Pro Forma Presentation
The unaudited pro forma condensed combined
financial statements were prepared in accordance with Article 11 of SEC Regulation S-X, as amended by the final rule, SEC Release No.
33-10786 "Amendments to Financial Disclosures About Acquired and Disposed Businesses". The adjustments presented in the unaudited
pro forma condensed combined financial statements (collectively, the "
Pro Forma Adjustments
")
have been identified and presented to provide relevant information necessary for an understanding of New Silexion upon consummation of
the Business Combination and related transactions.
The unaudited pro forma combined balance sheet
as of June 30, 2024 has been derived from the historical unaudited balance sheet of Moringa as of June 30, 2024 and the historical unaudited
balance sheet of Silexion as of June 30, 2024, giving further effect to the Pro Forma Adjustments, as if the Business Combination had
been completed on June 30, 2024. The unaudited pro forma combined statements of operations for the six-months period ended June 30, 2024
and for the year ended December 31, 2023 combine the historical audited statements of operations of Moringa for the year ended December
31, 2023, and for the six-months period ended June 30, 2024, and the historical audited statements of operations of Silexion for the year
ended December 31, 2023, and for the six-months period ended June 30, 2024, subject to the Pro Forma Adjustments, giving effect to the
Business Combination as if it had been consummated on January 1, 2023.
The unaudited pro forma combined balance sheet
does not include a historical balance sheet of New Silexion, as it did not have any assets or liability as of the date of Closing. Similarly,
the unaudited pro forma combined statements of operations do not include historical statements of operations of New Silexion, as it had
yet to incur any income or expenses as of the date of Closing.
The historical financial information has been
adjusted to reflect the Pro Forma Adjustments giving effect to the Business Combination and related transactions as described in more
detail below.
55
Management has made significant estimates
and assumptions in its determination of the Pro Forma Adjustments. As the unaudited pro forma condensed combined financial information
has been prepared based on these preliminary estimates, the final amounts recorded may differ materially from the information presented.
The Pro Forma Adjustments reflecting the consummation
of the Business Combination and certain other transactions as described in more detail below are based on certain currently available
information and certain assumptions and methodologies that the registrant believes are reasonable under the circumstances. The Pro Forma
Adjustments, which are described in the accompanying notes, may be revised as additional information becomes available and is evaluated.
Therefore, it is likely that the actual adjustments will differ from the pro forma adjustments, and it is possible the difference may
be material. The registrant believes that its assumptions and methodologies provide a reasonable basis for presenting all of the significant
effects of the Pro Forma Adjustments based on information available to management at this time and that the Pro Forma Adjustments give
appropriate effect to those assumptions and are properly applied in the unaudited pro forma condensed combined financial information.
The unaudited pro forma condensed combined
financial information does not give effect to any anticipated synergies, operating efficiencies, tax savings, or cost savings that may
be associated with the Business Combination and related transactions as described in more detail below. Moringa and Silexion have not
had any historical relationship prior to the Business Combination. Accordingly, no pro forma adjustments were required to eliminate activities
between the companies. However, the unaudited pro forma condensed combined financial information includes certain share-based compensation
that was granted upon the consummation of the Business Combination, as well as net exercise of all Silexion warrants outstanding for New
Silexion ordinary shares, which occurred upon the consummation of the Business Combination.
3. Adjustments to Unaudited Pro Forma Combined
Balance Sheet as of June 30, 2024
The unaudited pro forma balance sheet as of
June 30, 2024 has been prepared to illustrate the effect of the Pro Forma Adjustments and has been prepared for informational purposes
only.
The unaudited pro forma combined balance sheet
as of June 30, 2024 includes the Pro Forma Adjustments giving effect to the Business Combination and related transactions noted in this
filing. Moringa and Silexion did not have any historical relationship prior to the Business Combination. Accordingly, no pro forma adjustments
were required to eliminate activities between the companies.
The Pro Forma Adjustments, based on preliminary
estimates that could change materially as additional information is obtained, are as follows:
Pro forma adjustments
giving effect to the Business Combination and related transactions:
A) To reflect payments for Business Combination-related
costs in cash in an amount of $2,160 thousand of which an amount of $84 was paid as of June 30, 2024 and an amount of $233 thousand was
already accrued but not paid in Silexion's financial statements for the period ended June 30, 2024. In the pro forma statement of
operations, it was assumed that the expenses were incurred in 2023 rather than 2024. Therefore, Business Combination-related expenses
of $317 recorded in Silexion's statements of operations for the period ending June 30, 2024 were moved back to 2023 as a pro forma
adjustment.
B) To reflect Moringa's payment of its
obligation to EarlyBird (underwriters' deferred discount). Under the Marketing Agreement between Moringa and EarlyBird, Moringa
was committed to pay an additional fee of 3.5% of the gross proceeds of its initial public offering (or $4,025 thousand) to EarlyBird,
as an advisor in connection with Moringa's potential business combination, upon completion of the Business Combination. Prior to
the Closing, Moringa reached agreement with EarlyBird on a reduction, from $4,025 thousand to $1,600 thousand, of that fee. Pursuant to
the final invoice provided by EarlyBird under the Marketing Agreement at the Closing, $350 thousand of that reduced fee was paid to EarlyBird
at the Closing, with New Silexion issuing a convertible promissory note in an amount of $1,250 thousand for the remainder of the reduced
fee. See also Note BB.
56
C) These unaudited pro forma financial statements
reflect net exercise of all Silexion warrants outstanding and their conversion to New Silexion ordinary shares, which occurred upon the
consummation of the Business Combination. Related fair value measurement gains or losses of those warrants were eliminated from the pro
forma combined statements of operations.
D) To reflect the transfer by GIBF of its
noncontrolling interest in Silexion's Chinese subsidiary, Silenseed (China) Ltd., to New Silexion in exchange for 1,835,733 New
Silexion ordinary shares upon the completion of the Business Combination.
E) Immediately prior to the Effective Time
of the Acquisition Merger, the vesting of all outstanding Silexion share-based incentive awards was accelerated and those awards became
fully vested. At the Effective Time of the Acquisition Merger, all of Silexion's share-based incentive awards were assumed by New
Silexion and converted into options to purchase New Silexion ordinary shares, based on the Equity Exchange Ratio.
F) To reflect the issuance by New Silexion
to the Sponsor of the A&R Sponsor Promissory Note, in an amount of $3,433 thousand, which amount was determined based on amounts owed
by Moringa to the Sponsor for loans that it extended to Moringa from Moringa's initial public offering until the Closing, subject
to a $5,500 thousand cap (the "
Promissory Note Cap
"), which Promissory Note Cap was
reduced to $3,900 thousand due to the final $1,600 thousand paid or owed by Moringa to EarlyBird pursuant to the Marketing Agreement.
Such promissory note replaced all promissory notes that were outstanding as of June 30, 2024 and December 31, 2023 (in amounts of $3,346
thousand and $2,841 thousand, respectively), as well as additional amounts borrowed by Moringa from the Sponsor up until the completion
of the Business Combination. The maturity date of the A&R Sponsor Promissory Note is the 30-month anniversary of the Closing Date,
and amounts outstanding under the note may be repaid (unless otherwise decided by New Silexion) only by way of conversion into New Silexion
ordinary shares in accordance with the terms set forth in A&R Sponsor Promissory Note. The Sponsor may elect to convert amounts outstanding
under the A&R Sponsor Promissory Note at the price per share at which New Silexion conducts an equity financing following the Closing,
subject to a minimum conversion amount of $100 thousand, in an amount of shares constituting up to thirty percent of the number of New
Silexion ordinary shares issued by New Silexion in such equity financing. The Sponsor may also elect to convert amounts of principal outstanding
under the A&R Sponsor Promissory Note into New Silexion ordinary shares at any time following the 24-month anniversary of the Closing
Date and prior to the maturity date of the promissory note, subject to a minimum conversion of $10 thousand, at a price per share equal
to the volume weighted average price of the New Silexion ordinary shares on the principal market on which they are traded during the 20
consecutive trading days prior to the conversion date (the "
VWAP Conversion Price
").
Upon maturity, any outstanding principal will automatically be converted into New Silexion ordinary shares at a price per share equal
to the VWAP Conversion Price. Amounts that were loaned by the sponsor to Moringa in excess of the Promissory Note Cap were attributed
to additional paid-in capital in respect of the New Silexion ordinary shares issuable upon conversion of the total outstanding amount
under the promissory note. New Silexion has applied the fair value option to the A&R Sponsor Promissory Note and is based on expected
timing of a New Silexion equity financing, discounted at a rate of 22%. See also Note BB.
G) Reflects the issuance of 178,686 new RSUs
of Silexion, which converted into 711,688 new RSUs of New Silexion and issuance of 39,325 new RSU's of New Silexion, in the aggregate,
at the Closing, to directors of New Silexion and employees of New Silexion and its subsidiaries (of which 200,011 RSUs were granted to
New Silexion directors) with a grant date fair value of $10 per RSU. The vesting of all of the foregoing new RSUs accelerated upon the
Closing, and the RSUs were settled for equivalent numbers of underlying New Silexion ordinary shares.
H) Reflects the conversion of Silexion preferred
shares into New Silexion ordinary shares.
57
I) Reflects the exercise by public shareholders
of their redemption rights with respect to 427,297 Moringa public shares outstanding as of June 30, 2024 of $4,909 thousand. All Moringa
public shares that were subject to possible redemption but were not actually redeemed by Moringa public shareholders were replaced by
New Silexion ordinary shares, classified as permanent equity.
J) Pro forma adjustments made to the number
of Class A ordinary shares (par value) - consisting of those adjustments described in paragraphs C, D, E, F, G, H, I, L and N - are, in
the aggregate, less than $1 thousand.
K) To reflect the elimination of the accumulated
deficit of Moringa.
L) To reflect the issuance of 200,000 Moringa
ordinary shares to an investor pursuant to the PIPE financing described above, which shares converted automatically into New Silexion
ordinary shares upon the Closing. A total of 200,000 shares, at a price of $10.00 per share, or $2.0 million in the aggregate, was sold
to the PIPE investor at the Closing.
M) Represents an obligation to issue ordinary
shares of New Silexion with a value of $337,500 (the "
ELOC Commitment Shares
") to White
Lion as a fee in consideration of White Lion's commitment to purchase New Silexion ordinary shares from New Silexion under the ordinary
share purchase agreement for New Silexion's equity line of credit.
N) Represents (1) the $60,000 fee paid
by New Silexion to J.V.B. Financial Group, LLC, acting through its Cohen & Company Capital Markets division ("
Cohen
& Company
") in respect of capital markets advisory and placement agent services provided by Cohen & Company in connection
with the Business Combination; and (2) the 300,000 Moringa founders shares transferred by the Moringa Sponsor to Cohen & Company,
in respect of capital markets advisory and placement agent services provided by Cohen & Company in connection with the Business Combination.
4. Adjustments to Unaudited Pro Forma Condensed
Combined Statements of Operations
The pro forma adjustments, based on preliminary
estimates that could change materially as additional information is obtained, are as follows:
Pro forma adjustments
giving effect to the Business Combination and related transactions:
AA) To reflect the elimination of unrealized
interest income on investments held in the Trust Account.
BB) To reflect the change in fair value of
the A&R Sponsor Promissory Note (see Note F), and the convertible promissory note issued to EarlyBird at the closing (see Note B).
Pro forma
weighted average shares outstanding
:
CC) As the Business Combination is being reflected
as if it had occurred at the beginning of the earliest period presented, the calculation of weighted average shares outstanding for basic
and diluted net loss per share assumes that the shares issuable in connection with the Pro Forma Adjustments have been outstanding for
the entirety of the periods presented. Weighted average shares outstanding - basic and diluted for the six-months period ended June 30,
2024, and for the year ended December 31, 2023 are calculated as follows based on the actual pro forma number of New Silexion ordinary
shares that were issued and outstanding upon the Closing, after taking into account actual redemptions of Moringa public shares.
58
The table below excludes a combined 5,940,000
outstanding public warrants and private placement warrants because including them would have had an anti-dilutive effect on net loss per
share.
Assuming actual redemptions
Weighted
        average shares calculation – basic and diluted
Six-Months Period Ended
June 30, 2024 and
Year Ended
December 31, 2023
Holders
% of
Total
Moringa public shareholders
87,722
0.88
%
Moringa Sponsor shares
1,690,182
16.89
%
Distributees of Sponsor Investment Shares
45,000
0.45
%
PIPE investor
200,000
2.00
%
Founders Shares/ Backstop Shares
1,567,000
15.66
%
Existing Silexion equity holders (including GIBF in respect of
        the Chinese Subsidiary Transfer)
6,250,000
62.46
%
EarlyBird
127,143
1.27
%
Director receiving RSU grant upon Closing
39,325
0.39
%
Total Ordinary Shares
10,006,372
100
%
DD) To reflect additional cash compensation
to be paid to Ilan Levin, a director of New Silexion, in an amount of $10 thousand per month, commencing on Closing and for a period of
36 months.
Comparative Share Information
The following table sets forth selected historical
comparative share information for Moringa and unaudited pro forma condensed combined per share information for Moringa after giving effect
to the Business Combination.
The pro forma book value information reflects
the Business Combination as if it had occurred on June 30, 2024. The weighted average shares outstanding and net earnings per share information
reflect the Business Combination as if it had occurred on January 1, 2023.
This information is only a summary and should
be read together with the historical financial statements of Moringa and Silexion and related notes. The unaudited pro forma condensed
combined per share information of Moringa and Silexion is derived from, and should be read in conjunction with, the unaudited pro forma
combined financial statements and related notes included above.
The unaudited pro forma combined earnings
per share information below does not purport to represent the earnings per share which would have occurred had Moringa and Silexion been
combined during the periods presented, nor the earnings per share for any future date or period. Historically, Moringa's statement
of operations included a presentation of profit (loss) per share in a manner similar to the two-class method of income (loss) per ordinary
shares. The two-class method is not required in the pro forma income (loss) per ordinary shares as the Moringa Class A ordinary shares
are no longer subject to redemption. Moringa has included the effect of the warrants to purchase an aggregate of 5,940,000 Class A ordinary
shares, in the aggregate, sold in the IPO and the concurrent private placement in the calculation of diluted earnings per share, as they
will be exercisable commencing 30 days following the Closing. As a result, diluted earnings per ordinary share differs from basic earnings
per ordinary share for the periods presented.
59
Moringa Acquisition Corp
(Historical)
For the six-months period ended June 30, 2024
Class A
subject to
Possible
Redemption
Non-
redeemable
Class A and
Class B
Silexion
Therapeutics Ltd.
(Historical)
Pro Forma
Combined
(Actual
Redemption)
Weighted average shares outstanding – basic and diluted
87,722
3,355,000
251,655
10,006,372
Net profit (loss) per share – basic
$
0.32
$
(0.14
)
$
(11.31
)
$
(0.33
)
Moringa Acquisition Corp
(Historical)
Pro Forma
For the year ended December 31, 2023
Class A
subject to
Possible
Redemption
Non-
redeemable
Class A and
Class B
Silexion
Therapeutics Ltd.
(Historical)
Combined
(Assuming
Actual
Redemption)
Weighted average shares outstanding – basic and diluted
2,774,850
3,355,000
252,462
10,006,372
Net profit (loss) per share – basic
$
0.51
$
(0.34
)
$
(19.57
)
$
(2.03
)
60
MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Introductory Note
The following discussion
and analysis of our financial condition and results of operations (this "
MD&A
")
should be read in conjunction with the financial statements and the related notes included elsewhere in this prospectus. Some of the information
contained in this discussion and analysis or set forth in this prospectus, including information with respect to our plans, objectives,
expectations, projections, and strategy for our business and related financing, includes forward-looking statements that involve risks
and uncertainties. As a result of many factors, including those factors set out in the "Risk Factors" sections of this prospectus,
our actual results could differ materially from the results described in or implied by these forward-looking statements. See also the
section entitled "Special Note Regarding Forward-Looking Statements" in this prospectus.
Unless the context otherwise
requires, references to the "Company," "we," "us" and "our" in this MD&A generally
refer to Silexion Therapeutics Ltd., an Israeli company ("Silexion"), or, from and after the Business Combination, Silexion
Therapeutics Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company (also referred to herein as "New Silexion").
On August 15, 2024, New
Silexion, Silexion and Moringa completed the Business Combination pursuant to the Business Combination Agreement.
Overview
Silexion is a clinical-stage, oncology-focused
biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an
oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus.
Based on its research of refractory solid tumor cancers, Silexion is actively developing a platform focused on the silencing of the KRAS
oncogene using RNA-interference therapeutics. Silexion's lead product candidate, SIL-204B, consists of locally administered small
interfering RNAs, or siRNA, in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients,
in combination with standard-of-care chemotherapy.
To date, Silexion has financed its operations
primarily with the net proceeds from private offerings of its ordinary shares and convertible preferred shares, grants from the Israeli
Innovation Authority (the "
IIA
"), convertible financing agreements and Simple Agreement
for Future Equity (SAFE) financings, and through royalty-bearing grants from the IIA (which totaled $5.8 million through June 30, 2024).
Since its inception, Silexion has incurred significant operating losses. Silexion's net losses were $5.1 million and $3.5 million
for the years ended December 31, 2023 and December 31, 2022, respectively, and $2.9 million and $2.6 million for the six-month periods
ended June 30, 2024 and 2023, respectively. As of June 30, 2024, Silexion had an accumulated deficit of $29.7 million. Silexion has not
recognized any revenue to date.
Silexion expects to continue to incur significant
expenses and operating losses for the foreseeable future. The net losses it incurs may fluctuate significantly from quarter to quarter.
Silexion's expenses will depend on many factors, including the timing and extent of spending to further develop SIL-204 and initiate
pre-clinical and clinical trials, support research and development efforts, investments in potential additional pipe-line products, and
increased overall compensation as we continue to hire additional personnel. Silexion anticipate that its expenses will increase if and
as it:
●
applies for Orphan Drug Designation in both the U.S. and EU for
        its SIL-204B product;
●
initiates a clinical trial powered for statistical significance
        with respect to SIL-204B;
61
●
initiates toxicological studies with respect to SIL-204B;
●
seeks marketing approvals for SIL-204B in various territories;
●
maintains, expands and protects its intellectual property portfolio;
●
hires additional operational, clinical, quality control and scientific
        personnel;
●
adds operational, financial and management information systems
        and personnel, including personnel to support its product development, any future commercialization efforts and its prospective transition
        to a public company; and
●
invests in research and development and regulatory approval efforts
        in order to utilize its technology as a platform focused on the silencing of the KRAS oncogene using RNA-interference therapeutics.
Recent Developments
Our prospective financial condition and results
of operations in the period following the Closing of the Business Combination will be impacted by the following transactions, all of which
were entered into at or around the time of the Closing:
Completion of Business
Combination Transaction
On August 15, 2024, New Silexion, Silexion
and Moringa completed the previously-announced Business Combination pursuant to the Amended and Restated Business Combination Agreement,
dated April 3, 2024, by and among New Silexion, Merger Sub 1, Merger Sub 2, Moringa and Silexion. In connection with the Closing of the
Business Combination, New Silexion changed its name from "Biomotion Sciences" to "Silexion Therapeutics Corp".
Pursuant to the Business Combination Agreement,
among other things, (i) Merger Sub 2 merged with and into Moringa, with Moringa continuing as the surviving company and a wholly-owned
subsidiary of New Silexion and (ii) Merger Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company and
a wholly-owned subsidiary of New Silexion.
Upon the effectiveness of the SPAC Merger,
each outstanding Moringa Class A ordinary share, that had not been redeemed and the sole outstanding Moringa Class B ordinary
share converted into a New Silexion ordinary share on a one-for-one basis. Each outstanding Moringa warrant converted into a New
Silexion warrant, exercisable at the same exercise price. Upon the effectiveness of the Acquisition Merger, each outstanding ordinary
share and preferred share of Silexion converted into such number of New Silexion ordinary shares as is equal to the quotient obtained
by dividing (x) the quotient obtained by dividing (1) $62,500,000 by (2) the number of fully diluted Silexion equity securities,
by (y) $10.00 (the "
Silexion Equity Exchange Ratio
"). Each outstanding Silexion
warrant and Silexion option to purchase one Silexion share, and Silexion restricted share unit (RSU) that may be potentially settled for
one Silexion share, became exercisable for, or became subject to settlement for (as applicable), such number of New Silexion ordinary
shares as are equal to the Silexion Equity Exchange Ratio. The exercise price per New Silexion ordinary share of each such converted Silexion
option and Silexion warrant were adjusted based on dividing the existing per share exercise price by the Silexion Equity Exchange Ratio.
The terms of vesting, exercise and/or settlement, as applicable, of such converted options, warrants and RSUs remain the same following
such conversion, except that the vesting of each Silexion option accelerated immediately prior to the Acquisition Merger, such that the
New Silexion option into which it has been converted was fully vested, and all Silexion warrants were exercised (on a cashless basis)
immediately prior to the Acquisition Merger.
In connection with the Moringa shareholder
vote to approve the Business Combination Agreement and the Business Combination, holders of an aggregate of 427,297 Moringa ordinary shares
properly exercised their right to have their shares redeemed for a full pro rata portion of the Trust Account holding the proceeds from
Moringa's IPO, which was approximately $11.575 per share, or $4,946,046 in the aggregate.
62
As a result of the redemptions of Moringa
ordinary shares, a total of 87,722 Moringa public shares remained outstanding at the Closing. After giving effect to the Business Combination
and additional changes to share capital, immediately following the Closing, there were 9,768,396 New Silexion ordinary shares issued and
outstanding.
PIPE Financing
For a description of the PIPE Financing,
please see "
Related Party Transactions—Item 15. Recent Sales of Unregistered Securities—Issuance
of PIPE Financing Shares
" below in this prospectus, which description is incorporated by reference herein.
Settlement of Amounts
Due Under Marketing Agreement with EarlyBird
For a description of the settlement reached
by Moringa with EarlyBird in connection with the Closing as to amounts due to EarlyBird under the Marketing Agreement, please see "
Notes
to Unaudited Pro Forma Condensed Combined Financial Information—3. Adjustments to Unaudited Pro Forma Combined Balance Sheet as
of June 30, 2024—Pro forma adjustments giving effect to the Business Combination and related transactions
" above in
this prospectus, which description is incorporated by reference herein.
Amended and Restated Sponsor
Promissory Note
For a description of the issuance by the
Company to the Sponsor of the A&R Sponsor Promissory Note in an amount of $3,433,000 in connection with the Closing, and the terms
of that convertible promissory note, please see "
Special Note Regarding Forward-Looking Statements
"
above in this prospectus.
ELOC Financing
Also in connection with the Closing, New
Silexion entered into the White Lion Purchase Agreement with White Lion, for an equity line of credit, whereby New Silexion will be able
to request to sell to White Lion, and White Lion will be required to purchase, via private placement transactions, up to $15.0 million
of New Silexion ordinary shares from time to time after the Closing, up until December 31, 2025 (unless the agreement is terminated sooner),
subject to certain limitations and conditions as described therein. The number of New Silexion ordinary shares that New Silexion may require
White Lion to purchase in any single sales notice will depend on a number of factors, including the type of purchase notice that New Silexion
delivers. Similarly, the purchase price to be paid by White Lion for any shares that New Silexion requires them to purchase will depend
on the type of sales notice that New Silexion delivers. New we have also granted registration rights to White Lion pursuant to an accompanying
registration rights agreement.
In consideration for the commitments of White Lion, New Silexion
agreed to issue to White Lion an aggregate of $337,500 of New Silexion ordinary shares based on the closing price of the New Silexion
ordinary shares on the day that is the earlier of (i) the business day prior to effectiveness of the registration statement registering
the resale of the shares issuable under the White Lion Purchase Agreement and (ii) the business day prior to the 180
th
day following the Closing Date of the Business Combination. Based on the closing price of the ordinary shares on September 16, 2024, we
issued to White Lion, on September 18, 2024, 365,418 ordinary shares in respect of White Lion's commitments under the White Lion
Purchase Agreement.
Through                  , 2024, we have
issued and sold an aggregate of 4,059,418 ordinary shares (which includes the foregoing 365,418 ordinary shares issued as a commitment
fee) to White Lion under the White Lion Purchase Agreement for aggregate proceeds to us of approximately $2.3 million.
63
Prospective Reverse Share Split
Proposed Reverse Share Split
On October 22, 2024, we filed with the SEC, and soon thereafter we began to distribute
to our shareholders, a notice and proxy statement for an extraordinary general meeting of our company to be held on November 12, 2024
(the "extraordinary general meeting" or "meeting") at which we will present to our shareholders a proposal to
effect a reverse share split of our issued and outstanding, and our remaining authorized but unissued, ordinary shares at a ratio of between
1-for-10 and 1-for-20 (the "reverse share split"). The exact ratio of the reverse share split will be finalized by our board
of directors prior to the extraordinary general meeting and will be presented at the meeting. If the reverse share split is approved at
the meeting, holders of our ordinary shares will receive one ordinary share for every 10 to 20 ordinary shares currently held by them
(depending on the final ratio), and the number of our authorized but unissued ordinary shares will be reduced at that same ratio. Furthermore,
the par value of all ordinary shares, whether issued and outstanding, or unissued, will be increased proportionately to between $0.0010
and $0.0020. As of the effective time of the reverse share split (which will occur as soon as possible following shareholder approval
of the reverse share split proposal, if approved), proportionate adjustments will be made to (i) the number of ordinary shares that are
subject to all then-outstanding equity awards and warrants, such that fewer shares would underlie such awards and warrants, (ii) the exercise
price of all then-outstanding options and warrants, such that the per share exercise price of each such option and warrant would be increased,
and (iii) the number of ordinary shares available for issuance under the our equity incentive plans, such that fewer shares will be subject
to such plans. If the reverse share split is approved and implemented, all issued and outstanding, and authorized and unissued, ordinary
share data, all ordinary share equivalent data, and all per share data, will be adjusted retroactively throughout this prospectus to reflect
the reverse share split for all periods presented.
Components of our Results of Operations
Operating Expenses
Research and Development
Expenses
Research and development expenses include
costs directly attributable to the conduct of research and development programs, including the cost of payroll and related expenses, payroll
taxes and other employee benefits including share-based compensation related to employees, subcontractors, lab expenses, preclinical and
clinical trials cost, material costs and consulting fees.
We expect to continue to invest in research
and development to develop SIL-204, including hiring additional employees and continuing the research and development of that product
candidate. As a result, we expect that our research and development expenses will continue to increase in the future.
General and Administrative
Expenses
General and administrative expenses consist
primarily of personnel costs, including share-based compensation related to directors and employees, patent application fees, office space
rental costs, and maintenance expenses, external professional service costs, including legal, accounting, audit, finance, human resource
services, travel expenses and other consulting fees.
We expect that our general and administrative
expenses will increase in the future to fund our continued research and development activities, primarily due to increased headcount to
support anticipated growth in the business and due to incremental costs associated with operating as a public company, including costs
to comply with the rules and regulations applicable to public companies such as costs related to compliance and reporting obligations
pursuant to the rules and regulations of the SEC and stock exchange listing standards, public relations, insurance and professional services.
Financial expenses (income),
net
The finance expenses consisted primarily of
change in fair value of warrants and financial liabilities measured at fair value, interest income and exchange rate differences expenses.
64
Results of Operations
Comparison of six-month
period ended June 30, 2024 and 2023
The following table summarizes our results
of operations for the six-month period ended June 30, 2024 and 2023:
Six-month period ended
June 30,
2024
2023
Operating expenses:
Research and development, net
$
1,727
$
1,916
General and administrative
908
306
Total operating expenses
2,635
2,222
Operating loss
2,635
2,222
Financial expenses, net
270
377
Loss before income tax
2,905
2,599
Income tax
7
20
Net loss for the six-month period
$
2,912
$
2,619
Research and Development Expenses
The following table summarizes our research
and development expenses for the six-month period ended June 30, 2024 and 2023:
Six-month period ended
June 30,
2024
2023
Payroll and related expenses
$
514
$
569
Subcontractors and consultants
1,128
1,208
Materials
3
16
Rent and maintenance
49
78
Travel expenses
13
27
Other
20
18
Total research and development expenses
$
1,727
$
1,916
Research and development expenses decreased
by approximately $0.2 million, or 10.5% to $1.7 million for the six-month period ended June 30, 2024, compared to $1.9 million for the
six-month period ended June 30, 2023. The decrease resulted mainly from a decrease in subcontractors in the amount of $0.1 million and
from a decrease in payroll and related expenses in the amount of $0.1 million.
Research and development expenses for the
six-month period ended June 30, 2024 and June 30, 2023 included approximately $0.2 million and $0.5 million, related to the development
of Loder, respectively, and $1.5 million and $1.4 million related to the development of SIL-204B, respectively. Aggregate research and
development expenses since inception for Loder program, as of June 30, 2024 and as of June 30, 2023 were approximately $18.5 million and
$17.9 million, respectively. Aggregate research and development expenses since inception for SIL-204B program, as of June 30, 2024 and
as of June 30, 2023 were approximately $6.2 million and $2.0 million, respectively.
65
General and Administrative Expenses
The following table summarizes our general
and administrative expenses for the six-month periods ended June 30, 2024 and 2023:
Six-month periods ended
June 30,
2024
2023
Payroll and related expenses
$
306
$
145
Professional Services
448
28
Depreciation
15
29
Rent and maintenance
72
42
Patent registration
25
16
Travel expenses
16
16
Other
26
30
Total general and administrative expenses
$
908
$
306
General and administrative expenses increased
by approximately $0.6 million, or 200.0% to $0.9 million for the six-month period ended June 30, 2024, compared to $0.3 million for the
six-month period ended June 30, 2023. The increase resulted mainly from an increase in payroll and related expenses in the amount of $0.2
million and from an increase in professional services costs in the amount of $0.4 million.
Financial expenses, net
Financial expenses, net decreased by approximately
$0.1 million, or 25.0% to an expense of $0.3 million for the six-month period ended June 30, 2024 compared to an expense of $0.4 million
for the six months ended June 30, 2023. This decrease was mainly due to a decrease in the amount of $0.3 million in foreign exchange loss
offset by an increase in revaluation expenses of warrants in the amount of $0.15 million for the six-month period ended June 30, 2024.
Net loss
Net loss increased by approximately $0.3 million,
or 11.5% to $2.9 million for the six-month period ended June 30, 2024, compared to $2.6 million for the six-month period ended June 30,
2023. The increase was mainly due to an increase in our general and administrative expenses partially offset by a decrease in research
and development expenses and financial expenses.
Comparison of three-month
period ended June 30, 2024 and 2023
The following table summarizes our results
of operations for the three-month period ended June 30, 2024 and 2023:
Three-month period ended
June 30,
2024
2023
Operating expenses:
Research and development, net
$
766
$
1,235
General and administrative
619
179
Total operating expenses
1,385
1,414
Operating loss
1,385
1,414
Financial expenses, net
102
452
Loss before income tax
1,487
1,866
Income tax
2
10
Net loss for the three-month period
$
1,489
$
1,876
66
Research and Development Expenses
The following table summarizes our research
and development expenses for the three-month period ended June 30, 2024 and 2023:
Three-month period ended
June 30,
2024
2023
Payroll and related expenses
$
235
$
245
Subcontractors and consultants
497
910
Materials
-
6
Rent and maintenance
18
35
Travel expenses
13
27
Other
3
12
Total research and development expenses
$
766
$
1,235
Research and development expenses decreased
by approximately $0.4 million, or 33.3% to $0.8 million for the three-month period ended June 30, 2024, compared to $1.2 million for the
three-month period ended June 30, 2023. The decrease resulted mainly from a decrease in subcontractors in the amount of $0.4 million.
Research and development expenses for the
three-month period ended June 30, 2024 and June 30, 2023 included approximately $0.1 million and $0.2 million, related to the development
of Loder, respectively, and $0.7 million and $1.0 million related to the development of SIL-204B, respectively.
General and Administrative Expenses
The following table summarizes our general
and administrative expenses for the three-month periods ended June 30, 2024 and 2023:
Three-month periods ended
June 30,
2024
2023
Payroll and related expenses
$
164
$
97
Professional Services
369
10
Depreciation
7
14
Rent and maintenance
46
21
Patent registration
16
7
Travel expenses
7
16
Other
10
14
Total general and administrative expenses
$
619
$
179
General and administrative expenses increased
by approximately $0.4 million, or 200% to $0.6 million for the three-month period ended June 30, 2024, compared to $0.2 million for the
three-month period ended June 30, 2023. The increase resulted mainly from an increase in payroll and related expenses in the amount of
$0.1 million and from an increase in professional services costs in the amount of $0.36 million.
Financial expenses, net
Financial expenses, net decreased by approximately
$0.4 million, or 80.0% to expense of $0.1 million for the three-month period ended June 30, 2024 compared to income of $0.5 million for
the three-month period ended June 30, 2023. This decrease was mainly due to a decrease in foreign exchange loss in the amount of $0.4
million.
67
Net loss
Net loss decreased by approximately $0.4 million,
or 21.1% to $1.5 million for the three-month period ended June 30, 2024, compared to $1.9 million for the three-month period ended June
30, 2023. The decrease was mainly due to a decrease in our research and development expenses and financial expenses partially offset by
an increase in general and administrative expenses.
Comparison of Years
ended December 31, 2023 and 2022
The following table summarizes our results
of operations for the years ended December 31, 2023 and 2022:
Years ended December 31,
2023
2022
Operating expenses:
Research and development, net
$
3,708
$
3,226
General and administrative
973
634
Total operating expenses
4,681
3,860
Operating loss
4,681
3,860
Financial expenses (income), net
395
(396
)
Loss before income tax
5,076
3,464
Income tax
32
24
Net loss for the year
$
5,108
$
3,488
Research and Development Expenses
The following table summarizes our research
and development expenses for the years ended December 31, 2023 and 2022:
Years ended December 31,
2023
2022
Payroll and related expenses
$
973
$
1,192
Subcontractors and consultants
2,467
1,595
Materials
13
191
Rent and maintenance
160
175
Travel expenses
37
42
Other
58
31
Total research and development expenses
$
3,708
$
3,226
Research and development expenses increased
by approximately $0.5 million, or 15.6% to $3.7 million for the year ended December 31, 2023, compared to $3.2 million
for the year ended December 31, 2022. The increase resulted mainly from an increase in subcontractors in the amount of $0.9 million
partially offset by a decrease in payroll and related expenses in the amount of $0.2 million and a decrease in materials costs in
the amount of $0.2 million.
Research and development expenses for the
year ended December 31, 2023 and December 31, 2022 included approximately $0.8 million and $2.6 million related to
the development of Loder, respectively, and $2.9 million and $0.6 million related to the development of SIL-204B, respectively.
Aggregate research and development expenses since inception for Loder program, as of December 31, 2023 and as of December 31,
2022, were approximately $18.2 million and $17.4 million, respectively. Aggregate research and development expenses since inception
for SIL-204B program, as of December 31, 2023 and as of December 31, 2022, were approximately $3.6 million and $0.6 million,
respectively.
68
General and Administrative Expenses
The following table summarizes our general
and administrative expenses for the years ended December 31, 2023 and 2022:
Years ended December 31,
2023
2022
Payroll and related expenses
$
356
$
219
Professional Services
386
197
Depreciation
45
57
Rent and maintenance
86
71
Patent registration
22
32
Travel expenses
31
—
Other
47
58
Total general and administrative expenses
$
973
$
634
General and administrative expenses increased
by approximately $0.4 million, or 66.7% to approximately $1.0 million for year ended December 31, 2023, compared to approximately
$0.6 million for the year ended December 31, 2022. The increase resulted mainly from an increase in payroll and related expenses
in the amount of $0.1 million and from an increase of professional services costs in the amount of $0.2 million.
Financial expenses, net
Financial expenses (income), net increased
by approximately $0.8 million, or 200.0% to expense of $0.4 million for the year ended December 31, 2023 compared to income
of $0.4 million for the year ended December 31, 2022. This increase was mainly due to revaluation of warrants in the amount
of $1.0 million for the year ended December 31, 2022 offset by a decrease of $0.2 million in foreign exchange loss.
Net loss
Net loss increased by approximately $1.6 million,
or 45.7% to $5.1 million for the year ended December 31, 2023, compared to $3.5 million for the year ended December 31,
2022. The increase was mainly due to increase in our research and development expenses, general and administrative expenses and financial
expenses.
Liquidity and Capital Resources
Overview
Our capital requirements will depend on many
factors, including the timing and extent of spending to further develop SIL-204 and initiate pre-clinical and clinical trials, support
research and development efforts, investments in potential additional pipe-line products, and increased overall compensation as we continue
to hire additional personnel. For the six-month periods ended June 30, 2024 and 2023, and for the years ended December 31, 2023 and 2022,
we had net losses of $2.9 million and $2.6 million, and $5.1 million and $3.5 million, respectively. As of June 30, 2024, our cash and
cash equivalents totaled $1.7 million.
69
To date, our principal sources of liquidity
have been proceeds from private offerings of our ordinary shares and convertible preferred shares, grants from the Israeli Innovation
Authority, and issuance of convertible financing agreements (CFA) and Simple Agreement for Future Equity (SAFE).
Based on our current business plan, we believe
our current cash and cash equivalents, and anticipated cash flow from operations, will not be sufficient to meet our anticipated cash
requirements during 2024 following consummation of the Business Combination. We will need to raise additional capital to finance our operations,
expand our business and pipeline, or for other reasons.
Our audited consolidated financial statements
for the year ended December 31, 2023 and our unaudited condensed financial statements for the six-month period ended June 30, 2024 included
in this prospectus note that there is substantial doubt about our ability to continue as a going concern as of such date; and in its report
accompanying our audited consolidated financial statements included herein, our independent registered public accounting firm included
an explanatory paragraph stating that our recurring losses from operations and our cash outflows from operating activities raise substantial
doubt as to our ability to continue as a going concern. This means that our management and our independent registered public accounting
firm have expressed substantial doubt about our ability to continue our operations without an additional infusion of capital from external
sources. Our audited consolidated financial statements have been prepared on a going concern basis and do not include any adjustments
that may be necessary should we be unable to continue as a going concern. If we are unable to finance our operations, our business would
be in jeopardy and we might not be able to continue operations and might have to liquidate our assets. In that case, investors might receive
less than the value at which those assets are carried on our unaudited condensed financial statements for the six-month period ended June
30, 2024 and year ended December 31, 2023, and it is likely that investors would lose all or a part of their investment.
We have lease obligations and other contractual
obligations and commitments as part of our ordinary course of business. See "
Note 4: Operating
Leases
" and "
Note 6: Commitments and Contingent Liabilities"
to our consolidated
financial statements for the year ended December 31, 2023 for information about our lease obligations.
We did not have during the periods presented,
and we do not currently have, any off-balance sheet arrangements involving commitments or obligations, including contingent obligations,
arising from arrangements with unconsolidated entities or persons that have or are reasonably likely to have a material current or future
effect on our financial condition, results of operations, liquidity, cash requirements or capital resources.
Government Grants
Our research and development efforts were
financed, in part, through royalty-bearing grants from the Israeli Innovation Authority, or the IIA. As of June 30, 2024, we received
IIA royalty-bearing grants totaling approximately $5.8 million.
We are committed to pay royalties to the IIA
at a rate of approximately 3.0% to 5.0% of the sales of all of our product candidates and other related revenues generated from such projects,
that were developed, in whole or in part, using the IIA royalty-bearing grants we received under IIA programs up to the total amount of
royalty-bearing grants received, linked to the U.S. dollar and bearing annual interest at rates prescribed by the IIA's rules and
guidelines.
We may in the future apply to receive additional
grants from the IIA. However, we cannot predict whether we will be entitled to any future grants, or the amounts of any such grants.
Under the Israeli Innovation Law, research
and development programs that meet specified criteria and are approved by a committee of the IIA are eligible for grants. A company that
receives a royalty-bearing grant from the IIA is typically required to pay royalties to the IIA on income generated from products incorporating
IIA-funded know-how (including income derived from services associated with such products and from IIA-funded know-how), up to 100% of
the U.S. dollar-linked royalty-bearing grant amount plus interest.
70
The obligation to pay royalties is contingent
on actual income generated from such products and services. In the absence of such income, no payment of royalties is required.
As of June 30, 2024, the total royalty amount
that may be payable by the Company is approximately $5.8 million ($6.4 million including interest).
Cash Flows
Cash flows for the six-month
period ended June 30, 2024 and 2023
The following table summarizes our cash flows
for the six-month periods ended June 30, 2024 and 2023:
Six-month period ended
June 30,
2024
2023
Cash and cash equivalents and restricted cash
        at beginning of the period
$
4,645
$
8,309
Net cash used in operating activities
(2,817
)
(2,587
)
Net cash provided by (used in) investing activities
(6
)
505
Net cash provided by financing activities
*
522
Net decrease in cash and cash equivalents
        and restricted cash
$
(2,823
)
$
(1,560
)
Translation adjustments on cash and cash equivalents
        and restricted cash
(75
)
(258
)
Cash and cash equivalents and restricted cash
        at end of the period
$
1,747
$
6,491
*
Represents an amount less than $1
Cash Flows from Operating Activities
Net cash used in operating activities increased
by approximately $0.2 million, or 7.7%, to $2.8 million for the six-month period ended June 30, 2024, compared to $2.6 million for the
six-month period ended June 30, 2023. This increase was mainly from an increase of $0.3 million in the net loss for the six-month period
ended June 30, 2024, offset by $0.1 million change in net working capital.
Cash Flows from Investing Activities
Net cash provided by (used in) investing activities
decreased by $0.5 million, or 100.0%, to $0 million for the six-month period ended June 30, 2024, compared to investment of $0.5 million
for the six-month period ended June 30, 2023. This decrease was mainly due to a reduction in short-term deposit in the amount of $0.5
million used for operating activities.
Cash Flows from Financing Activities
Net cash provided by financing activities
decreased by $0.5 million, or 100.0%, to approximately $0 million for the six-month period ended June 30, 2024, compared to $0.5 million
the six-month period ended June 30, 2023. This decrease was mainly due to a decrease in proceeds from issuance of preferred shares which
was higher in the amount of $0.5 million in the six-month period ended June 30, 2023.
71
Cash flows for the three-month
period ended June 30, 2024 and 2023
The following table summarizes our cash flows
for the three-month periods ended June 30, 2024 and 2023:
Three-month period ended
        June 30,
2024
2023
Cash and cash equivalents and restricted cash
        at beginning of the period
$
2,831
$
7,924
Net cash used in operating activities
(1,065
)
(1,676
)
Net cash provided by (used in) investing activities
-
(2
)
Net cash provided by financing activities
-
522
Net decrease in cash and cash equivalents
        and restricted cash
$
(1,065
)
$
(1,156
)
Translation adjustments on cash and cash equivalents
        and restricted cash
(19
)
(277
)
Cash and cash equivalents and restricted cash
        at the end of the period
$
1,747
$
6,491
Cash Flows from Operating Activities
Net cash used in operating activities decreased
by approximately $0.6 million, or 35.3%, to $1.1 million for the three-month period ended June 30, 2024, compared to $1.7 million for
the three-month period ended June 30, 2023. This decrease was mainly from a decrease of $0.4 million in the net loss for the three-month
period ended June 30, 2024, and $0.4 million change of net working capital, offset by a decrease in non-cash financial expenses in the
amount of $0.2 million.
Cash Flows from Financing Activities
Net cash provided by financing activities
decreased by $0.5 million, or 100.0%, to approximately $0 million for the three-month period ended June 30, 2024, compared to $0.5 million
the three-month period ended June 30, 2023. This decrease was mainly due to a decrease in proceeds from issuance of preferred shares which
was higher in the amount of $0.5 million in the three-month period ended June 30, 2023.
Cash flows for the Years
ended December 31, 2023 and 2022
The following table summarizes our cash flows
for the years ended December 31, 2023 and 2022:
Year ended December 31,
2023
2022
Cash and cash equivalents and restricted cash
        at beginning of the period
$
8,309
$
10,083
Net cash used in operating activities
(4,529
)
(3,335
)
Net cash provided by (used in) investing activities
573
(524
)
Net cash provided by financing activities
522
2,752
Net decrease in cash and cash equivalents
        and restricted cash
$
(3,434
)
$
(1,107
)
Translation adjustments on cash and cash equivalents
        and restricted cash
(230
)
(667
)
Cash and cash equivalents and restricted cash
        at the end of the period
$
4,645
$
8,309
72
Cash Flows from Operating Activities
Net cash used in operating activities increased
by approximately $1.2 million, or 36.4%, to $4.5 million for the year ended December 31, 2023, compared to $3.3 million
for the year ended December 31, 2022. This increase was mainly from an increase of $1.6 million in the loss for the year, offset
by a decrease of $0.6 million in non-cash financial expenses.
Cash Flows from Investing Activities
Net cash provided by (used in) investing activities
increased by $1.1 million, or 220.0%, to $0.6 million for the year ended December 31, 2023, compared to investment of $0.5 million
for the year ended December 31, 2022. This increase was mainly due to change short-term deposit in the amount of $1.0 million.
Cash Flows from Financing Activities
Net cash provided by financing activities
decreased by $2.3 million, or 82.1%, to approximately $0.5 million for the year ended December 31, 2023, compared to $2.8 million
for the year ended December 31, 2022. This decrease was mainly due to a decrease in proceeds from issuance of preferred shares which
was higher in the amount of $2.2 million in 2022.
Funding Requirements
We expect to devote substantial financial
resources to our ongoing and planned activities, particularly further development of SIL-204 and as we conduct our planned pre-clinical
and clinical trials.
Identifying potential product candidates
and conducting pre-clinical testing and clinical trials is a time-consuming, expensive, and uncertain process that takes years to complete,
and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition,
our product candidates, if approved, may not achieve commercial success. For additional information please refer to the "
Risk
Factors
" section of this prospectus, including "
Risks Related to Our Financial Condition
and Capital Requirements
—
we have never generated any revenue from product sales and may
never be profitable" and "Risks Related to the Research and Development of our Product Candidates — Silexion is heavily
dependent on the success of its product candidates
…".
We expect our expenses to increase substantially
in connection with our ongoing activities, particularly as we advance our pre-clinical studies and clinical trials. In addition, if we
obtain marketing approval for SIL-204 in any indication or for any other product candidate we are developing or may develop in the future,
we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing, and distribution. Furthermore,
upon the closing of the Business Combination, we expect to incur additional costs associated with operating as a public company. Accordingly,
we will need to obtain substantial additional funding.
Our future capital requirements will depend
on many factors, including:
●
Material cost.
●
Regulatory pathway; and
●
Human clinical trial costs.
As of June 30, 2024, we had cash and cash
equivalents of $1.7 million. Based on our current cash balance, as well as its history of operating losses and negative cash flows from
operation, combined with its anticipated use of cash to, among other things, (i) fund the preclinical and clinical development of our
products, (ii) identify and develop new product candidates, and (iii) seek approval for SIL-204 and any other product candidates we may
develop, our management has concluded that we do not have sufficient cash to fund our operations for 12 months from the date of its unaudited
condensed financial statements for the six-month period ended June 30, 2024 included in this prospectus without additional financing,
and as a result, there is substantial doubt about our ability to continue as a going concern.
73
In making this determination, applicable accounting
standards prohibited us from considering the potential mitigating effect of plans that have not been fully implemented as of the date
of our unaudited condensed financial statements for the six-month period ended June 30, 2024, including, without limitation, plans to
consummate the Business Combination discussed below and to raise additional capital. Our financial information throughout this prospectus,
and our unaudited condensed financial statements for the six-month period ended June 30, 2024 contained herein have been prepared on a
basis that assumes that we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities
and commitments in the normal course of business. This financial information and our unaudited condensed financial statements for the
six-month period ended June 30, 2024 do not include any adjustments that may result from an unfavorable outcome of this uncertainty.
The Closing of the Business Combination was
conditioned upon the fulfillment of various conditions described in the Business Combination Agreement
.
We believe that following consummation of
the Business Combination, we will not have cash sufficient to sustain our operating expenses and capital expenditure requirements over
the next 12 months from the date of our unaudited condensed financial statements for the six-month period ended June 30, 2024 included
in this prospectus.
We have based these estimates and expectations
on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. We could
not, as of the June 30, 2024 balance sheet date of the unaudited condensed financial statements for the six-month period ended June 30,
2024, determine the exact level of funds that will be available to the Company upon consummation of the Business Combination. Our expected
use of funds represents our intentions based upon our current plans and business condition, which could change in the future as our plans
and business condition evolve and the level of funding available to the Company becomes clear. In addition, changing circumstances could
cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because
of circumstances beyond our control. As a result, we could deplete our capital resources sooner than we currently expect. In addition,
because the successful development of SIL-204 and any studies or other product candidates that we pursue is highly uncertain, at this
time we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the development
of any product candidate.
Until such time, if ever, as we can generate
substantial revenues from product sales, we expect to finance our cash needs through a combination of public and private equity offerings
and debt financings, including the private placement of ordinary shares pursuant to the White Lion Purchase Agreement, strategic alliances,
collaborations, and marketing, distribution, or licensing arrangements. However, adequate additional financing may not be available to
us on acceptable terms, or at all, and may be impacted by the economic climate and market conditions.
Critical Accounting Policies and Estimates
For a description of our significant accounting
policies, see Note 2 to our consolidated financial statements for the year ended December 31, 2023 and unaudited condensed consolidated
financial statements for the six-month period ended June 30, 2024 included in this prospectus.
The preparation of our consolidated financial
statements for the year ended December 31, 2023 and unaudited condensed consolidated financial statements for the six-month period ended
June 30, 2024 in conformity with U.S. GAAP requires management to make estimates and assumptions in certain circumstances that affect
the amounts reported in the accompanying consolidated financial statements for the year ended December 31, 2023 and unaudited condensed
consolidated financial statements for the six-month period ended June 30, 2024 and related footnotes. Actual results may differ from these
estimates. We base our judgments on our experience and on various assumptions that we believe to be reasonable under the circumstances.
74
Of our policies, the following are considered
critical to an understanding of our consolidated financial statements for the year ended December 31, 2023 and unaudited condensed consolidated
financial statements for the six-month period ended June 30, 2024 as they require the application of subjective and complex judgment,
involving critical accounting estimates and assumptions impacting our consolidated financial statements for the year ended December 31,
2023 and unaudited condensed consolidated financial statements for the six-month period ended June 30, 2024.
The critical accounting estimates relate to
the following:
Share-Based
Compensation
Share-based compensation expense related to
share awards is recognized based on the fair value of the awards granted. The fair value of each option award is estimated on the grant
date using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions,
including the fair value of the underlying ordinary shares (see below), the expected term of the option, and the expected volatility of
the price of our ordinary shares. These estimates involve inherent uncertainties and the application of management's judgment. The
related share-based compensation expense is recognized on a straight-line basis over the requisite service period of the awards, including
awards with graded vesting and no additional conditions for vesting other than service conditions. Forfeitures are accounted for as they
occur instead of estimating the number of awards expected to be forfeited.
Our use of the Black-Scholes option-pricing
model requires the input of highly subjective assumptions. If factors change and different assumptions are used, our share-based compensation
expense could be materially different in the future.
We will continue to use judgment in evaluating
the assumptions related to our share-based compensation on a prospective basis. As we continue to accumulate additional data related to
our ordinary shares, we may refine our estimation process, which could materially impact our future share-based compensation expense.
Valuations of instruments
convertible to our Ordinary and Preferred Shares
Our preferred shares are classified as temporary
equity, as they include clauses that could constitute as in-substance redemption clauses that are outside our control. Warrants and other
instruments over our Preferred Shares are classified as liabilities under ASC 480 and measured at fair value, with subsequent changes
in fair value recognized in the statements of operations in each period.
The fair value of our preferred shares underlying
our convertible instruments was determined by our board of directors, after considering contemporaneous third-party valuations and input
from management. In the absence of a public trading market, our board of directors, with input from management, exercised significant
judgment and considered various objective and subjective factors to determine the fair value of our equity including the following factors:
●
History of transactions in our preferred
        shares;
●
Probability of an IPO scenario (including
        de SPAC transaction);
●
Probability of other liquidation events;
●
Expected time to liquidation; and
●
Expected return on equity.
The resulting equity value was then allocated
to each share class based on differences in liquidation preferences of the various share classes using an Option Pricing Model ("OPM")
through the use of a series of call options and by implementing a Monte Carlo simulation. The OPM allocates the overall company value
to the various share classes based on differences in liquidation preferences, using a series of call options. The OPM is appropriate to
use when the range of possible future outcomes is difficult to predict. Starting from 2023, for the IPO scenario (including de SPAC transaction)
we utilized a probability-weighted expected return method ("PWERM") to allocate value among the various share classes. The
PWERM involves the estimation of the value of our company under multiple future potential outcomes and estimates the probability of each
potential outcome. After the value of each applicable class of shares was determined, a discount for lack of marketability ("DLOM")
was applied to arrive at the fair value of the ordinary shares on a non-marketable basis. A DLOM is applied in order to reflect the lack
of a recognized market for a closely held interest and the fact that a non-controlling equity interest may not be readily transferable.
A market participant purchasing this share would recognize this illiquidity associated with the shares, which would reduce the overall
fair market value.
75
In some cases, we considered the amount of
time between rounds of financing to determine whether to use a mid price calculation between two dates.
Upon completion of the Business Combination,
our ordinary shares are publicly traded, and we rely on the closing price of our ordinary shares as reported on the date of the applicable
valuations.
The fair value of the warrants for the purchase
of preferred shares was calculated using the OPM as part of the allocation of the equity value to the various share classes (as described
above). The critical accounting estimates for the valuation of those warrants include (a) the fair value of the underlying preferred shares,
as mentioned above, and (b) volatility — based on peer companies' volatility.
Recent Accounting Pronouncements
See Note 2 on page F-64 to our financial
statements for the year ended December 31, 2023 included in this prospectus for a description of recent accounting pronouncements applicable
to our financial statements for the year ended December 31, 2023.
Smaller Reporting Company
Status
We are a "smaller reporting company," meaning that the market value of our
ordinary shares held by non-affiliates is less than $700 million and our (via its Silexion subsidiary) annual revenue was less than $100
million during the most recently completed fiscal year. We will continue to be a smaller reporting company if either (i) the market value
of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently
completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company,
we may choose to present only the two most recent fiscal years of audited financial statements and we have reduced disclosure obligations
regarding executive compensation.
Emerging Growth Company
Status
Section 102(b)(1) of the Jumpstart Our Business
Startups Act of 2012, or the JOBS Act, exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides
that a company can choose not to take advantage of the extended transition period and comply with the requirements that apply to non-emerging
growth companies, and any such election to not take advantage of the extended transition period is irrevocable.
We are an "emerging growth company"
as defined in Section 2(a) of the Securities Act, and has elected to take advantage of the benefits of the extended transition period
for new or revised financial accounting standards. We will remain an emerging growth company until the earliest of (i) the last day of
the fiscal year in which the market value of ordinary shares that is held by non-affiliates exceeds $700 million as of the end of that
year's second fiscal quarter, (ii) the last day of the fiscal year in which we have total annual gross revenue of $1.235 billion
or more during such fiscal year (as indexed for inflation), (iii) the date on which we have issued more than $1.0 billion in non-convertible
debt in the prior three-year period, or (iv) December 31, 2025. We expect to continue to take advantage of the benefits of the extended
transition period, although it may decide to early adopt such new or revised accounting standards to the extent permitted by such standards.
This may make it difficult or impossible to compare our financial results with the financial results of another public company that is
either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition
period exemptions because of the potential differences in accounting standards used.
76
BUSINESS
Unless the context otherwise
requires, in this "Business" section, the terms "we," "us" and "our" generally refer to
Silexion Therapeutics Ltd., an Israeli company ("Silexion"), or, from and after the Business Combination, to Silexion Therapeutics
Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company ("New Silexion").
Business Overview
We are a clinical-stage, oncology-focused biotechnology
company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene
that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based
on our research of refractory solid tumor cancers, we are actively developing a platform focused on the silencing of the KRAS oncogene
using RNA-interference therapeutics. Our lead product candidate, SIL-204B, consists of locally administered small interfering RNAs,
or siRNA, in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC,
in combination with standard-of-care chemotherapy.
The KRAS oncogene is considered to be the
most common oncogenic gene driver in human cancers, and the most notable in pancreatic, lung, and gastrointestinal (GI) (including colorectal,
esophagus, stomach, small bowel, and appendix) cancers. Considered a challenging therapeutic target due to its intrinsic characteristics,
recent advances have been made at directly inhibiting the KRAS proteins produced by the mutated gene. Our platform is designed to silence
the gene, and thus prevent the production of the harmful mutated KRAS proteins driving the growth of cancerous tumors.
We are currently focused on treatment for
pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable,
i.e. they are not able to be surgically removed. For our first indication, we are targeting the largest and least treatable form of localized
pancreatic tumors referred to as locally advanced pancreatic cancer. LAPC represents approximately 30% of the total pancreatic cancer
population. We are currently developing SIL-204B, a second-generation siRNA product candidate following a Phase 1 and Phase 2 clinical
trial with our first-generation siRNA product candidate, siG12D-LODER, which we also refer to as Loder. Results from the Phase 2
clinical trial showed a trend for differences between treatment groups in patients with the KRAS G12D/V mutation, with the Loder arm suggesting
an overall survival advantage of 9.3 months.
SIL-204B has been designed to optimize Loder with the aim of improving uptake into tumor
cells, enhancing stability, and improving the delivery system. We plan to conduct a Phase 2/3 prospective, randomized, controlled, multinational,
two-arm, open-label trial in LAPC subjects that harbor the KRAS G12D/V mutations to evaluate the efficacy, safety and tolerability of
SIL-204B administered intratumorally in combination with standard of care (SoC) chemotherapy versus SoC chemotherapy only. In support
of our planned Phase 2/3 trial, we held a meeting with the Federal Institute for Drugs and Medical Devices in Germany (BfArM) to discuss
the planned design of the Phase 2/3 trial at which BfArM agreed, in principle, to the design. In preparation for the study, we plan to
initiate toxicology studies of SIL-204B in 2025 followed by the regulatory submission in the second half of 2025  to initiate the
Phase 2/3 trial and trial initiation in the first half of 2026. At this time, we are focused on the further development of the core siRNA
technology underlying the Loder and SIL-204B as well as the clinical development of SIL-204B as the most optimized version of the technology.
77
Our Market Opportunity
Activating mutations in KRAS are
among the most prevalent oncogenic driver mutations in human cancers. In a recent study of over 400,000 patients with various cancer type
malignancies, 23% of adult pan-cancer samples had KRAS alterations, 88% of which were mutations, most commonly G12D, G12V, G12C,
G13D and G12R, making the KRAS target a sought-out target in for many cancers ("Comprehensive pan-cancer genomic landscape
of KRAS altered cancers and real-world outcomes in solid tumors", by Jessica K. Lee, etc., NPJ Precision Oncology 2022;
6: 91). In addition, the study found that various cancers have an amplification of the non-mutated KRAS protein. Tumor types
with a high prevalence of KRAS mutations included pancreatic ductal adenocarcinoma (PDAC) (92%), colorectal cancer (CRC) (49%), and non-squamous non-small cell
lung cancer (NSCLC) (35%). These three cancers represent 71% of the KRAS mutant pan-tumor population studied.
The following chart shows the distribution
of various alternations of the KRAS oncogene in various type of cancers:
78
Pancreatic Cancer
By the next decade, pancreatic cancer is expected
to become the second most deadly cancer. Every year in the U.S. approximately 50,000 people die from pancreatic cancer, while approximately
61,000 new patients are diagnosed with pancreatic cancer annually (American Cancer Society Statistics 2023).
Studies have shown that pancreatic cancer
patients have short survival rates compared to other cancer types (see, for example, "Prognosis and survival analysis of patients
with pancreatic cancer: retrospective experience of a single institution", by Qi Li and others, World Journal of Surgical Oncology,
2022; 20:11). There are four basic forms of pancreatic cancer: Resectable, those where a surgeon can remove a tumor; Borderline Resectable
(BRPC) where the tumor is not currently permissible for surgery but prior treatment with chemotherapy or radiation could in some cases
allow for surgical removal; LAPC where the tumor has surrounded more than half of a major artery or vein and is not surgically removable;
and Metastatic where the cancerous tumor has spread to other organs. Of the forms of pancreatic cancer that are localized (those which
have not yet spread), the largest and most life threatening is LAPC, which constitutes approximately 30% of pancreatic cancers ("Locally
Advanced Pancreatic Cancer: A Review of Local Ablative Therapies", by Alette Ruarus and others, Cancers BaseI, January 2018;
10(1):16).
79
Below is a curve of overall survival in LAPC
patients:
Fig. Comparison of overall survival between
different chemotherapy regimens in non-resected locally advanced pancreatic cancer patients. CHT indicates chemotherapy; FFX, FOLFIRINOX;
Gem, gemcitabine. Reference Gemenetzis, G et al. 2019. Annals of Surgery. 270 (2):340
KRAS mutations across their various forms
are responsible for approximately 92% of all pancreatic cancers, of which the KRAS G12D and KRAS12V mutations account for over 70% of
the cases traced to KRAS mutations (Bailey, P.
et al.
Genomic analyses identify molecular
subtypes of pancreatic cancer.
Nature
531(7592), 47 – 52.
https://doi.org/10.1038/nature16965
(2016) (Art.
No. 7592)). Unfortunately, those with LAPC have a short survival time, about 17 months, and constitute about 30% of the total pancreatic
cancer population ("Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection", by Georgio
Gemenetzis, MD, and others, Annals of Surgery. 270 (2):1, March 2018). Among those patients with KRAS mutations, those with the mutation
type G12D and G12V show the shortest OS among the G12x mutation type.
80
Distribution of KRAS Mutations in Pancreatic
Cancer
Our Technology
Our research is focused on the development
of a platform of therapeutics that is designed to silence the KRAS oncogene using small interfering RNA, or siRNA. This function is called
interference RNA (RNAi). When the RNAi is double stranded of 19-25 nucleotides (NTs), in length, it is referred to as siRNA. This
class of siRNA therapeutics exert their effect by inducing the enzymatic breakdown of the messenger (mRNA) of a targeted gene inhibiting
the process called translation, which turns the message (mRNA) into a protein. The general mechanism for the silencing the oncogene is
actually an evolutionary process developed by cells to protect against viruses.
We believe our approach also builds upon the
validation of our target KRAS mutations as a target for cancers, as seen with the two small molecule KRAS inhibitors currently on the
market for non-small cell lung cancer, and the validation of siRNA technology, as it is currently on the market for five non-oncological indications.
None of these agents is appropriate for our intended primary indication, but we believe they do support our premises regarding target
(KRAS) and basic technology (siRNA) for use in the oncological area. A key distinction between our technology and the existing inhibitors
of KRAS is that our siRNA technology prevents the production of the protein, as indicated by a decrease in the mRNA and physiological
decrease in human tumor cell line growth shown in our preclinical studies. By contrast, the existing inhibitors and to our knowledge,
those in development inhibit its activity, and clinical use of the existing inhibitors has shown that they potentially leave large unmet
needs.
The specific mechanism of this silencing activity
is depicted in the figure below. siRNAs, usually 19-25 NTs, enter the cell as a double-standard complex. Once in the inner
cell matrix, they bind to an RNA-induced silencing complex of enzymes (RISC), which splits the siRNA into two single RNA strands
referred to as the passenger (sense) strand and the guide (antisense) strand. It is the antisense which is the active part. The single
guide strand has complementary binding to the target mRNA and thereby acts as an inducing guide for other enzymes in the RISC complex
to bind and induce specific cleavage of the now double stranded target mRNA. As the siRNA guide strand is designed to be complementary
to the RNA message around the site of the mutation of the gene to be silenced, in our case the mutated KRAS oncogene, once the message
(mRNA) is destroyed, the oncogene is silenced. As the sense-strand of the siRNA is designed to be specific for the KRAS, there is
a specificity to the silencing of this driver of cancer.
81
Our first-generation siRNA product candidate,
siG12D, is an extended-release formulation of siRNA. While originally designed to combat the KRAS G12D mutation in patients with
LAPC, siG12D was shown to have silencing activity in other KRAS mutations including G12V as well as to a lesser degree in G12C and G12R.
The product candidate is comprised of the anti-KRAS(G12D) siRNA drug substance (siG12D), formulated in a biodegradable polymeric matrix
(PLGA) as solid rods in order to obtain an extended-release profile. To overcome the difficulties of a systemic drug to enter the
pancreatic tumor environment and to obtain a sufficiently high level of siRNA in the pancreatic cell without inducing unnecessary side
effects, the siRNA is directly delivered intratumorally using a standard ultrasound guided endoscopy (EUS). Since patients should undergo
anesthesia prior to the endoscopy, the same as that required for a biopsy, the siRNA has been formulated as an extended-release formulation
to increase the time between administrations. We refer to this product formulation as siG12D-LODER or Loder. Loder has undergone
extensive pre-clinical testing as well as two open-label clinical trials.
Our second-generation siRNA product candidate,
SIL-204B, is an optimized form of the first-generation Loder comprised of an anti-KRAS siRNA drug substance (SIL-204) encapsulated
into a biodegradable polymeric matrix (PLGA). While pre-clinical testing of SIL-204B has shown silencing activity of KRAS mutations
including G12D, G12V, G12C and G12R in varying degrees, it is designed to mainly combat the KRAS G12D and KRAS G12V mutations in patients
with LAPC where silencing activity is more enhanced. The second-generation siRNA drug substance aims to provide improved uptake into
tumor cells by introduction of a hydrophobic tail that enhances movement across the cell membrane. Additionally, second-generation siRNA
drug substance includes modified nucleotides in the siRNA that enhance stability and corresponding half life. Most significantly, the
delivery system has been improved in which PLGA-rods used in Loder have been replaced by PLGA-microparticles, allowing the drug substance
to be injected as a suspension, facilitating administration through smaller needles. As with Loder, the administration is by ultrasound
guided endoscopy (EUS), of the type typically used for pancreatic biopsies to diagnose pancreatic cancer and can be done by a typical
gastrointestinal endoscopist.
82
As discussed further below, Silexion plans
to conduct a Phase 2/3 clinical trial of SIL-204B targeting KRAS G12D and G12V mutations. The targeting of additional mutations is
expected to require additional clinical trials.
We believe the optimization of Loder allows
for more of a personalized medicine approach to the dosing, allowing the siRNA dose to be adjusted to the tumor size. The small volume
of suspension is expected to allow for treatment of smaller tumors than those treated with Loder, and to continue treatment for a longer
period of time with tumors shrinking in size. Furthermore, delivery of the extended-release PLGA formulated siRNA, SIL-204B, to be
administered using a much smaller needle is expected to allow more flexibility and decrease the risk associated with administration.
Pre-Clinical Studies
We have conducted the evaluation of our first-generation siRNA
product candidate, Loder, in pharmacology, pharmacokinetics (PK), and toxicology studies with both the siG12D and siG12D-LODER. The results
of the extensive in vitro and in vivo nonclinical studies conducted with Loder have demonstrated its effects on the KRAS oncogene, tumor
development, and the development of new metastases. In these studies, the mechanism of action (MOA) was elucidated and the effect of Loder
on a variety of downstream processes, ultimately leading to cell apoptosis, tumor necrosis, and halting of new metastases, was investigated.
Pre-clinical data show that the siG12D
silencing is very specific and effective (peak mRNA degradation effect in vivo was found to be 98%), can down-regulate signaling
pathways, reduce pancreatic cancer cell viability, decelerate cancer cell migration, and suppress expression of genes involved in Epithelial-to-Mesenchymal Transition
(EMT). It was demonstrated in vivo that Loder protects siG12D against degradation. The product candidate induces apoptosis and necrosis
throughout the entire tumor, hinders the appearance of metastases, decelerates the development and growth of pancreatic tumors, induces
an innate immune response locally within the tumor and extends survival.
siG12D was also found to be additive with
FOLFIRINOX, Gemcitabine, and Gemcitabine+nab-Paclitaxel. When administered into the tumor, siG12D molecules are in part spontaneously
taken up into tumor cells; the siG12D drug is distributed from the siG12D-LODER throughout the entire tumor, by diffusion and convection,
and covers the entire tumor after about a week, increasing the "void volume" in the tumor microenvironment.
PK studies yielded validated methods for detecting
siG12D in rat and human plasma, and confirmed distribution and absorption at the local tissue level.
The toxicological study confirmed siG12D tolerability,
with minimal, not drug related, focal effect at the implantation site and No Observed Adverse Effect Level (NOAEL) 24.2 times higher than
the dose in the Loder Phase 2 trial.
Taken together, these converging effects on
multiple genetic, cellular, tumor tissue, tumor microenvironment, systemic levels and survival aspects act to produce a durable and prolonged
anti-tumor effect both in in vitro and in vivo pancreatic cancer models.
We have also conducted pre-clinical studies
of our second-generation siRNA product candidate, SIL-204B. There are three key preclinical studies which support our advancing SIL-204B into
a planned Phase 2/3 clinical trial.
The first key clinical study was a dose response
analysis of SIL-204 in mouse Hepa1-6 cells together with a relevant Dual Glo reporter plasmid. SIL-204 in this study showed
inhibition of the drug substance across KRAS mutations G12D, G12V, G12C and G12R and the wild type to cover the KRAS amplifications. Similar
to the results found with the siRNA in the Loder (siG12D) three of the mutations (G12D, G12V, and G12R) were highly inhibited. However,
whereas G12C was mildly silenced (inhibited) with siG12D, it was significantly more inhibited with SIL-204 which has implications
for potentially broadening the indications for SIL-204B to include all four of the major KRAS mutations and the wild-type. Additionally
in this model, when a prototype of SIL-204 was tested for its silencing activity with and without the lipid lead we are conjugating
to the siRNA with SIL-204, the results showed that the lipid-conjugated siRNA enhanced the silencing activity of the siRNA by two-fold.
The siG12D (siRNA in the Loder) does not have the lipid conjugate.
83
The second key pre-clinical study examined
the stability of the guide strand of SIL-204 in human serum. Whereas siG12D was completely broken down (enzymatically cleaved) in
< 1 hour, SIL-204 showed complete stability at 48 hours. Consistently, when SIL-204 was administered to rats via subcutaneous
injection, the plasma half-life was 5 hours. In contrast when siG12D was administered systemically to mice the half life was 1 minute.
In a third key pre-clinical study, the
human pancreatic cell line CAPAN-1 harboring the KRAS G12V mutation was xenografted (transplanted) to mice and the tumor growth and
necrosis (death of body tissue) in the tumor was observed following daily treatments of SIL-204 compared to the controls (untreated
and vehicle treated mice). Results showed a significant growth of the tumor in the control mice while in the SIL-204-treated mice,
the tumor growth was significantly curtailed, as indicated by a significant reduction in the tumor volume and weight. In addition, when
analyzing tumor slices from the center of the tumor, the results showed a statistically significant increase in tumor necrosis in SIL-204 treated
mice compared to untreated- and vehicle-treated mice.
Clinical Studies
Phase 1 Clinical Study
An escalating dose, multicenter Phase 1 clinical
study of Loder was conducted in Israel from 2011 to 2015 at three sites enrolling a total of 15 patients with unresectable LAPC. The study
was designed as an open-label, single-arm, single-administration of siG12D-LODER (concomitantly with standard of care chemotherapy),
dose-escalating Phase 1 study, enrolling LAPC patients with a target tumor accessible for intra-tumor administration, with a
Karnofsky performance status equal or greater than 70% and with a life expectancy of at least three months. Single escalating doses of
LODER (0.025, 0.75, 1.5 or 3 mg) by insertion into the tumor were administered by standard EUS procedures. Following insertion, patients
received standard of care chemotherapy as first line treatment in accordance with treating physician recommendation, Gemcitabine (nine
patients) or modified FOLFIRINOX (four patients), while one patient refused to receive any chemotherapy. After study drug administration,
the patients were to be monitored for signs of systemic or local treatment- related toxicity. Active follow-up comprised scheduled
physical and clinical examinations, vital sign measurements, laboratory tests, abdominal CT and disease assessments.
The primary endpoint of the study was to assess
the safety and tolerability of siG12D-LODER, and to define the dose-limiting toxicities (DLT) of siG12D-LODER. Secondary endpoints
included the recommended Phase 2 dose and defining the maximum tolerated dose (MTD). In the event of surgery, assessment of siG12D-LODER local
distribution and efficacy were to be based on histopathology measurements and RNA analysis. Progression free survival (PFS) and overall
survival (OS) were to be assessed only by long term follow-up. Due to the small size of the trial, it was not powered for statistical
significance. The study met its primary endpoints. The 15 patients reported a total of 125 adverse events (AEs). 111 of the reported AEs
(89%) were grade 1 and 2, which were transient and resolved. The most common AE (grade 1-2) was diarrhea which was reported by seven
(46.7%) patients, abdominal pain and nausea were both reported by six (40%) patients, whereas fatigue was reported by five (33.3%) patients.
Thirteen severe AEs of grade 3 and one grade 4 severe were reported by 10 (66.7%) patients. The most common grade 3-4 AEs were neutropenia
and cholangitis reported by three patients and two patients, respectively. Pancreatitis was reported by the investigator as possibly related
to the procedure. One adverse event (cholangitis) in one patient was considered as definitely related to the EUS intervention. At the
doses tested, no DLTs were observed and therefore if there was a DLT it was defined as being greater than 3mg, the highest dose administered.
The study also met the secondary endpoint of establishing the Phase 2 dose of up to 3mg however the MTD was not determined.
Evidence of tumor response was observed, noting
that none of the patients presented progressive disease (PD) and tumor response durability was demonstrated. The tumor marker CA19-9 decreased
in 70% of relevant cases soon after siG12D-LODER administration and time to metastasis (TTM) and overall survival were comparable
to (or better than) the historical data of the disease in a similar population. However, no clear dose response was observed between the
dose of siG12D-LODER and OS or TTM probably due to several factors, including the small size of the study, the single dosing administration,
without repeat dosing, and the level of dose at the low-dose cohort, which was selected to be ~5 times higher than then the minimal
effective dose level as predicted in pre-clinical studies.
84
Phase 2 Clinical Study
From 2018 to 2023, we conducted a prospective,
multi-center, Phase II, open label study to evaluate the efficacy, safety and tolerability of siG12D-LODER in two separate cohorts
across five sites in Israel and four in the U.S.
Cohort 1 was a randomized and controlled two-arm study
of 37 subjects with unresectable LAPC to assess the efficacy, safety, tolerability and pharmacokinetics of siG12D-LODER when used
in combination with standard chemotherapy treatment (gemcitabine + nab-Paclitaxel) compared to gemcitabine + nab-Paclitaxel alone
in subjects. Cohort 2 was a single arm study of 22 subjects with unresectable and borderline resectable LAPC to assess the efficacy, safety,
and tolerability of siG12D-LODER in combination with standard of care chemotherapy treatment (gemcitabine + nab-paclitaxel or
FOLFIRINOX or modified FOLFIRINOX).
For comparative purposes, we evaluated the
randomized section of the trial for efficacy (Cohort 1) and both cohorts (Cohort 1 and Cohort 2) for safety. All patients who met the
inclusion criteria were accepted to the trial, regardless of whether they had a KRAS mutation or which specific mutation they had.
The KRAS mutation status was however determined
post-hoc in a sample of 31 patients (21 of whom were Loder treated) in the table below:
KRAS
G12x
Mutation
Cohort 1
Arm 2
(Control)
Cohort 1
Arm 1
(Treatment)
Cohort 1
% Arm 1
Tx
Cohort 2
(Treatment)
All
Treated
%
R
5/10
1/12
8
2/9
26 (8/31)
D
2/10
3/12
25
2/9
23 (7/31)
V
3/10
8/12
67
5/9
52 (16/31)
A total of up to eight Loders (2.8 mg) were
inserted into the pancreatic tumor per single administration. Insertion was done using EUS. The trial consisted of a screening period
(28 days), a treatment phase (12-week Loder treatment cycles at investigator's discretion with concomitant chemotherapy treatment
cycles) and a follow-up phase (up to six months until end of study which is defined as death, withdrawn consent or lost to follow-up).
For efficacy, the primary endpoint in the randomized section of the trial (Cohort 1) was overall survival (OS), defined as the time that
passed from study entry (screening visit) until death from any cause. For Cohort 2, the primary endpoint was the overall response
rate (ORR) by end of treatment; ORR was defined as the proportion of subjects with best overall confirmed response (BOCR) of either a
complete response (CR) or partial response (PR). Concerning the secondary endpoint of safety, the endpoints were incidence of adverse
events (AEs), and serious adverse events (SAEs) overall, by severity, by relationship to each study intervention, and those that led to
discontinuation of study interventions. Other secondary endpoints included ORR for Cohort 1, progression free survival, time to metastatis,
time to response, duration of response and rate of disease control.
Overall, a total of 59 subjects with LAPC
were enrolled in the study, 38 were treated with Loder and 48 subjects overall (81.3%) completed the study. In Cohort 1, 15/19 (78.9%)
completed the Loder arm and 11/18 (61.1%) completed the standard of care arm. In Cohort 2, 21/22 (95.5%) completed the study.
In Cohort 1, OS was comparable between
the two treatment arms. Median time to death was 691 days in the Loder-treated group, compared with 666 days in the standard of care
group. The Hazard Ratio (Loder/SoC) was 1.47 (95% CI; 0.643, 3.365) with a non-significant p-value of 0.361 for the treatment
difference. In the sub-group of subjects with D or V KRAS mutation (n=16), the median OS was 691 days for the 11 Loder treated subjects,
compared to 409 days for the five SoC subjects. The Hazard Ratio was 0.59 (95% CI; 0.179, 1.963) with a non-significant p-value of
0.393. In the subjects who were not found to have D or V KRAS mutation (n=13), the median OS in the seven Loder treated subjects was 637
days compared to 937 days in the six SoC treated subjects. The hazard ratio was 2.87 (95% CI; 0.705, 11.650) with a p-value of 0.141.
The ORR was 44.4% (8/18) in the Loder group compared to 27.3% in the SoC group (3/11). No subject had a CR in either group. The ORR in
subjects with D or V KRAS mutation was 63.6% (7/11) in the Loder group compared to 20% in the SoC group (1/5).
85
In Cohort 2, the ORR was 31.6% reflecting
6/19 subjects with partial responses. No subject had CR. In subjects with D or V KRAS mutation, the ORR was 57.1% (4/7), however, these
subjects also had a shorter median OS compared to subjects without these mutations (414 days vs. 671 days).
As depicted below, the survival probability
in subjects of Cohort 1 bearing a KRAS G12D/V mutation compared to the control group, showed a median survival in the Loder group (n=11)
of 22.8 months compared to 13.8 months in the control group (n=5).
Based on the above, although the primary endpoints
of all patients were not met, the results showed a trend for differences between treatment groups in patients with the KRAS G12D/V mutation,
with the Loder arm suggesting an overall survival advantage of 9.3 months. With respect to the secondary efficacy endpoints, no statistically
significant differences were observed or there was insufficient data to evaluate although with respect to ORR in Cohort 1, a positive
trend in the KRAS G12D/V mutation subgroup was observed. Due to the small size of the trial, it was not powered for statistical significance.
The secondary safety endpoints were met. In
Cohort 1, all subjects in the Loder treatment group reported at least one moderate or severe treatment emergent adverse event (TEAE)
(18 subjects). One subject was reported with a TEAE leading to death (sepsis). This event was deemed as not related to the Loder or the
EUS procedure. Of the remaining 17 subjects, one subject was reported with a life-threatening TEAE, gastrointestinal disorders (colitis).
The majority of moderate and severe TEAEs reported in the Loder treatment group were attributed to gastrointestinal disorders (10), blood/lymphatic
disorders (14), general disorders and administration site conditions (11), metabolism and nutrition disorders (11), and investigations
(10). In the SoC treatment group, all subjects reported at least one moderate or severe TEAE (11 subjects). No subjects were reported
with a TEAE leading to death. Two subjects were reported with a life- threatening TEAE. The majority of moderate and severe TEAEs reported
in the SoC treatment group were attributed to gastrointestinal disorders (10), blood/lymphatic disorders (9), general disorders and administration
site conditions (9), metabolism and nutrition disorders (8), and investigations (9).
In Cohort 2, all subjects in the Loder
treatment group reported at least one moderate or severe TEAE (20 subjects). One subject was reported with a TEAE leading to death (gastrointestinal
disorder). This event was deemed as not related to the Loder or the EUS procedure. Three subjects were reported with a life-threatening TEAE.
Of the three subjects, one subject was investigation (neutrophil count decreased) and two subjects were metabolism/nutrition (hyperglycaemia,
hyperkalaemia). The majority of moderate and severe TEAEs reported in the Loder treatment group were attributed to gastrointestinal disorders
(13), nervous system disorder (10) and investigations (11).
86
Manufacturing
We rely on and intend to continue to rely
on third-party contract manufacturing organizations for drug substance and drug products for our clinical trials. We have agreements
with contract manufacturers for the manufacturing of SIL-204B for clinical development.
Future Development Plans
We plan to conduct a Phase 2/3 prospective,
randomized, controlled, multinational, two-arm, open-label trial in LAPC subjects that harbor the KRAS G12D/V mutations to evaluate
the efficacy, safety and tolerability of SIL-204B administered intratumorally in combination with SoC chemotherapy versus SoC chemotherapy
only. The study design, including the dose and dosing frequency, the combination with SoC chemotherapy, the proposed target population
and safety monitoring is based on the experience with the preceding Phase 1 and 2 clinical studies with the first-generation siRNA
product candidate, Loder.
The study is initially planned to enroll approximately
350 subjects and has an adaptive design with several segments; a screening period which includes a biopsy eligibility test for G12D/V
mutations, a CT scan and physiologic profiling to ensure subjects are qualified for treatment; concurrent with this, all subjects will
receive run-in SoC chemotherapy; a Phase 2 safety run-in and treatment period where initially 30 subjects will be randomized
2:1 to receive SIL-204B and SoC Chemotherapy or SoC Chemotherapy at which point a Data and Safety Monitoring Board (DSMB) will perform
a safety review and recommend whether the study is safe to proceed; a Phase 2 expansion period to continue enrollment; and when approximately
60 events have occurred, an unblinded interim analysis for sample size re-estimation and futility will be conducted, to expand the
trial from Phase 2 to Phase 3, which is expected to happen approximately one year from start of enrollment. Following the interim
analysis, the study will continue into a Phase 3 treatment period to complete the enrollment of the remaining subjects for a total treatment
period of 24 months. The study design is powered for statistical significance.
In support of our planned Phase 2/3 trial
of SIL-204B, we held a meeting with the Federal Institute for Drugs and Medical Devices in Germany (BfArM) to discuss the planned design
of the Phase 2/3 trial, at which BfArM agreed, in principle, to the design. In preparation for the study, we plan to initiate toxicology
studies of SIL-204B in 2025 followed by the regulatory submission in late 2025 to initiate the Phase 2/3 trial. Currently, we are
upscaling SIL-204 and planning for GMP production. At this time, Silexion is focused on the further development of the core siRNA
technology underlying the Loder and SIL-204B as well as the clinical development of SIL-204B as the most optimized version of
the technology.
We expect to apply in 2024 for Orphan Drug
Designation in both the U.S. and EU. In the U.S., Orphan Drug designation by the FDA gives a company exclusive marketing rights for
a seven-year period, along with other benefits to recoup the costs of researching and developing drugs to treat rare diseases. In
the EU, a company receives data exclusivity for 10 years which provides protection from similar drugs being approved. We believe
the size of the localized pancreatic cancer market fits the requirements for this designation however there can be no assurance that we
will be granted such designation and such designation neither shortens the development time or regulatory review time of a drug nor does
it increase the likelihood for any approval in the regulatory review process. Our continued development plans for SIL-204B are not
dependent on whether we are granted Orphan Drug Designation.
87
Our Strategy
Our goal is to have a positive impact on the
health and treatment of KRAS driven cancer patients, in general and initially with pancreatic cancer through the continued development
and commercialization of our pipeline. Key elements of our strategy to advance toward this goal include the following:
●
Advancing
        the clinical development of SIL-204B for the treatment of LAPC
.    Our
        Phase 2 trial with our first-generation siRNA product, Loder in LAPC patients acts as a validation of approach and foundation
        for our continued development efforts. As further described in "Future Development Plans", Silexion plans to initiate toxicology
        studies of SIL-204B in 2025 followed by the regulatory submission in late 2025 to initiate a Phase 2/3 trial of SIL-204B powered
        for statistical significance. At this time, Silexion is focused on the further development of the core siRNA technology underlying the
        Loder and SIL-204B as well as the clinical development of SIL-204B as the most optimized version of the technology.
●
Leveraging
        our platform to other oncological indications
harboring the KRASG12D/V
        mutation.
●
Advancing
        SIL-204B to commercialization.
We have assembled
        a world class clinical advisory board for better understanding the market in the U.S. and EU.
●
Forming strategic
        alliances and collaborating with partners to augment our capabilities
.    We
        may pursue strategic alliances with other biopharmaceutical companies with well-established presences in the specialties we aim to
        target for our indications. This may include co-marketing, co-promotion, and co-development relationships, or a partnership with
        a diagnostics company to help improve availability of rapid testing. We also intend to explore options to work with partners to augment
        the study and treatment of patients and the impact of our product candidates, including medical professionals, healthcare professional
        networks, pharmacy benefit managers, insurance companies, and artificial intelligence companies.
Our History
Silexion was established as Silenseed Ltd
in 2008 as an Israeli company which underwent a name change to Silexion Therapeutics Ltd. in May 2023. On June 13, 2014, Silexion
filed a Registration Statement on Form F-1 with the SEC, in contemplation of an initial public offering, and the listing of
its shares on Nasdaq. Subsequently, the public offering process was abandoned because our board of directors was not satisfied with our
valuation in the offering, and no securities were sold under the registration statement. During April 2022, our management was replaced
following a health condition of the then-founder and CEO of Silexion, and the new management, after evaluating the viability of commercializing
the Loder, has decided to pivot from the first-generation siRNA product candidate to the second-generation siRNA product candidate
and develop SIL-204.
Competition
The biotechnology and pharmaceutical industries,
and the oncology sector, are characterized by a rapid evolution of technologies, fierce competition and strong defense of intellectual
property rights. While we believe that our discovery programs and technology provide us with competitive advantages, we face competition
from major biotechnology and pharmaceutical companies, academic institutions, governmental agencies and public and private research institutions,
among others.
Any product candidates that we successfully
develop and commercialize will compete with currently approved therapies and new therapeutics that may become available in the future.
Key product features that would affect our ability to effectively compete with other therapeutics include efficacy, safety and convenience
of our products as compared to other available therapeutics.
There are a large number of companies developing
or marketing treatments for cancer, including major biotechnology and pharmaceutical companies. These treatments consist of novel treatments
based on small molecule drug products, cell-based therapies, as well as traditional chemotherapy treatments. There are also an increasing
number of companies commercializing treatments and/or developing programs specifically targeting KRAS mutations, including KRAS G12D and
KRAS G12V, in a variety of manners and for a variety of indications, including cancer, including Amgen Inc., Bristol-Myers Squibb
Company (through the recently acquired Mirati Therapeutics, Inc.), Revolution Medicines, Inc., AstraZeneca (in collaboration with Usynova),
BioNTech, Roche, Merck/Moderna, Boehringer and Gilead. Smaller and other early-stage companies may also prove to be significant competitors.
In addition, academic research departments and public and private research institutions may be conducting research on compounds that could
prove to be competitive.
88
Many of the companies against which we may
compete have significantly greater financial resources and expertise in the research and development, manufacturing, preclinical testing,
conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Similar or early-stage companies
may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These
competitors also compete with us in recruiting and retaining qualified scientific and management personnel, and establishing clinical
trial sites and patient registration for clinical trials, as well as acquiring technologies complementary to, or necessary for, our programs.
Our competitors have already and/or may obtain
more rapidly than we may obtain approval FDA, or other regulatory approval for commercialization of product. As a result, our competitors
could establish a strong market position before we are able to enter the market with our products. The availability of coverage and reimbursement
from government and other third-party payors for competing products at the time of commercialization of our products will also significantly
affect the pricing and competitiveness of our products.
Intellectual Property
Our business depends, in part, on our ability
to develop and maintain the proprietary aspects of our products. We currently hold one Israeli patent, and two U.S. patents.
The main patent protection for our products
is in International Patent Application No. PCT/IL2023/051276 filed on December 14, 2023 (the "276 Application"), which
in turn claims priority to two U.S. Provisional Patent Applications: U.S. Provisional Patent Applications 63/387,504 filed on December 15,
2022, and 63/491,776 filed on March 23, 2023. Additionally, patent applications corresponding to the 276 Application were filed in
Argentina (AR 20240101502, filed on June 13, 2024) and Taiwan (TW 113122679, filed on June 19, 2024). Both of these patent applications
were filed prior to the publication date of the 276 Application. Silexion intends to file national phase applications of the 276 Application
in multiple worldwide jurisdictions by the standard deadlines. Silexion is the sole applicant and owner of the 276 Application and its
related applications in Argentina and Taiwan.
The 276 Application and its corresponding
applications in Argentina and Taiwan describe and claim compositions of matter, methods of treatment of,
inter
alia
, pancreatic cancer, and compositions for use in treatment of pancreatic cancer. In particular, the noted patent applications
describe and claim siRNAs that target and can inhibit expression of the KRAS oncogene mRNA in both its wildtype and mutated forms that
are associated with multiple cancers including pancreatic cancer. More particularly, the noted patent applications specifically claim
siRNAs that encompass siRNAs including, among other things, SIL-204, plus additional siRNAs which have the same or nearly the same nucleotide
sequences. These siRNAs are claimed both as isolated compositions and as part of pharmaceutical formulations for use in methods of antitumor
treatment, including extended-release formulations.
The minimum expiration date of any patent
that issues from the 276 Application is December 14, 2043. However, given typical practice with respect to regulatory-related patent
term extensions, this date may be extended up to an additional five years in many countries, depending on the length of the regulatory
process, to a maximum final expiration date of December 14, 2048. The minimum expiration dates for patents that issued from the noted
Argentina and Taiwan applications are 20 years from their filing dates, namely June 13, 2044 and June 19, 2044, respectively.
The 276 Application was published on June 20,
2024 as International Patent Publication No. WO 2024/127405.
In addition to patent laws, we rely on copyright
and trade secret laws to protect our proprietary rights. We also attempt to protect our trade secrets and other proprietary information
through agreements with vendors, employees, and consultants.
89
Property and Facilities
Our principal executive officers are currently
located in Modiin, Israel, where we lease a space of 450 square meters consisting of offices, under a lease agreement that will expire
on July 31, 2025.
Employees
As of the date of this prospectus, we have
three full time and ten part time employees. All of our employees are based in Israel. None of our employees are represented by labor
unions or covered by collective bargaining agreements. We believe that we maintain good relations with all of our employees.
Grants from the Israeli Innovation Authority
During 2009 to 2020, we received several
approvals from the IIA for participation in research and development activities performed by us in a total amount of $5.8 million.
The Company is obligated to pay royalties
to the IIA amounting to 3%-5% of the sales of all of its product candidates and other related revenues generated from such projects, up
to 100% of the grants received, linked to the U.S. dollar and bearing interest at the rate of LIBOR. The obligation to pay these
royalties is contingent upon actual sales of the products and, in the absence of such sales, no payment is required. In October 2023,
it was published that the interest rate of the grants will be replaced with the 12-month term SOFR published on the first trading
day of each calendar year.
As of December 31, 2023, the total royalty
amount that may be payable by the Company is approximately $5.8 million ($6.4 million including interest).
Legal Proceedings
From time to time, we may become involved
in actions, claims, suits, and other legal proceedings arising in the ordinary course of our business, including assertions by third parties
relating to intellectual property infringement, breaches of contract or warranties, or employment-related matters. We are not currently
subject to any material legal proceedings.
Regulatory Environment
Government Regulation
Clinical trials, the drug approval process,
and the marketing of drugs are intensively regulated in the United States and in all major foreign countries. Government authorities
in the United States (including federal, state, and local authorities) and in other countries (including federal, state, and local
authorities) extensively regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging,
storage, distribution, post-approval monitoring and reporting, advertising and promotion, pricing, and export and import of pharmaceutical
products, such as those we are developing. The process of obtaining regulatory approvals and the subsequent compliance with appropriate
federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources.
U.S. Government Regulation
In the United States, the Food and Drug
Administration, or FDA, regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and related regulations and biologics under
the FDCA and the Public Health Service Act (PHSA) and its implementing regulations. FDA approval is required before any new unapproved
drug or dosage form, including a new use of a previously approved drug, can be marketed in the United States. Drugs and biologics
are also subject to other federal, state and local statutes and regulations. Failure to comply with the applicable United States regulatory
requirements at any time during the product development process, approval process or after approval may subject an applicant to administrative
or judicial sanctions. These sanctions could include the imposition by the FDA or an Institutional Review Board, or IRB, of a clinical
hold on trials, the FDA's refusal to approve pending applications or supplements, license suspension or revocation, withdrawal of
an approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions,
fines, civil penalties or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.
90
The FDA and comparable regulatory agencies
in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and
marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate research and development activities
and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, distribution, record keeping, approval, advertising
and promotion of our products.
The FDA's policies may change and additional
government regulations may be enacted that could prevent or delay regulatory approval of our platforms and candidate products or any future
product candidates or approval of new disease indications or label changes. We cannot predict the likelihood, nature or extent of adverse
governmental regulation that might arise from future legislative or administrative action, either in the United States or abroad.
Marketing Approval
The process required by the FDA before product
candidates may be marketed in the United States, the European Medicines Agency, or EMA, before a product can be marketed in Europe,
and Medicines & Healthcare products Regulatory Agency (MHRA) for the United Kingdom. Generally involves the following:
●
completion of extensive preclinical laboratory tests and preclinical
        animal studies, all performed in accordance with the GLP regulations;
●
submission to the FDA of an investigational new drug application,
        or IND, Clinical Trial Application (CTA) for Europe which must become effective or approved before human clinical studies may begin and
        must be updated on a regular basis;
●
approval by an independent institutional review board, or IRB,
        or ethics committee representing each clinical site before each clinical study may be initiated;
●
performance of adequate and well-controlled human clinical
        studies to establish the safety and efficacy of the product candidate for each proposed indication;
●
preparation of and submission to the FDA of a new drug application,
        or NDA, or biologics license application, or BLA, or for Europe a Marketing Authorization Application (MAA) after completion of all pivotal
        clinical studies;
●
potential review of the product application by an FDA advisory
        committee, where appropriate and if applicable. In the EU, the Committee for Medicinal Products for Human Use (CHMP) issues a scientific
        opinion to the European Commission which issues the marketing authorization;
●
a determination by the FDA within 60 days of its receipt
        of an NDA or BLA to file the application for review;
●
satisfactory completion of an FDA pre-approval inspection
        of the manufacturing facilities where the proposed product drug substance is produced to assess compliance with cGMP; and
●
FDA review and approval of an NDA or BLA or marketing authorization
        in the European Union (EU) in all European Union Member States plus Norway, Iceland and Liechtenstein, prior to any commercial marketing
        or sale of the drug in the United States. Note that if the centralized procedure is used, which is mandatory for all new anticancer
        products, a marketing authorization is issued centrally by the EU commission, which is valid immediately in all member states of the EEA
        (EU plus Iceland, Norway, and Liechtenstein).
The testing and approval process requires
substantial time and financial resources, and we cannot be certain that any approvals for our candidate products will be granted on a
timely basis, if at all.
91
An IND/CTA is a request for authorization
from the FDA/national regulatory authorities in Europe to administer an investigational new drug product to humans. The central focus
of an IND/CTA submission is on the general investigational plan and the protocol(s) for human studies. The IND and CTA also include
results of animal and
in vitro
studies assessing the toxicology, pharmacokinetics, pharmacology,
and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or
literature to support the use of the investigational new drug. An IND or a CTA must become effective before human clinical trials may
begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns
or questions related to the proposed clinical studies. In such a case, the IND may be placed on clinical hold and the IND sponsor and
the FDA must resolve any outstanding concerns or questions before clinical studies can begin. Accordingly, submission of an IND may or
may not result in the FDA allowing clinical studies to commence. In Europe, a CTA is required to be approved by regulators, which may
take several months. Accordingly, submission of a CTA to European regulators may or may not result in permission to commence clinical
studies in Europe.
We will need to successfully complete an extensive
additional clinical trial or some clinical trials in order to be in a position to submit a new drug application to the FDA. Our planned
future clinical trials for our candidate products may not begin or be completed on schedule, if at all. Clinical trials can be delayed
for a variety of reasons, including delays in:
●
obtaining regulatory approval to commence a study;
●
reaching agreement with third-party clinical trial sites
        and their subsequent performance in conducting accurate and reliable studies on a timely basis;
●
obtaining institutional review board approval or an Ethics Committee
        approval to conduct a study at a prospective site;
●
recruiting patients to participate in a study; and
●
supply of the drug.
We must reach agreement with the FDA/European
national authorities on the proposed protocols for our future clinical trials in the United States and EU. A separate submission
apart from any IND or initial CTA application we submit must be made for each successive clinical trial to be conducted during product
development. Further, an independent IRB or EC for each site proposing to conduct the clinical trial must review and approve the plan
for any clinical trial before it commences at that site. Informed consent must also be obtained from each study subject. Regulatory authorities,
an IRB or EC, a data safety monitoring board or the Sponsor may suspend or terminate a clinical trial at any time on various grounds,
including a finding that the participants are being exposed to an unacceptable health risk.
Clinical Studies
Clinical studies involve the administration
of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with current cGCP/GCP,
which include the requirement that all research subjects provide their informed consent for their participation in any clinical study.
Clinical studies are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in
monitoring safety, and the efficacy criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments
must be submitted to the FDA and/or European national authorities as part of the IND or CTA. Additionally, approval must also be
obtained from each clinical study site's IRB or EC before the studies may be initiated, and the IRB/EC must monitor the study until
completed. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.
Our objective is to conduct additional clinical
trials for our candidate products and, if those trials are successful, seek marketing approval from the FDA and other worldwide regulatory
bodies.
92
For purposes of NDA approval, human clinical
trials are typically conducted in phases that may overlap.
●
Phase 1.
The
        drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution
        and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently
        toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.
●
Phase 2.
This
        phase involves trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate
        the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.
●
Phase 3.
This
        phase involves trials undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population, often at
        geographically dispersed clinical trial sites. These trials are intended to establish the overall risk/benefit ratio of the product and
        provide an adequate basis for product labeling.
●
Phase 4.
In
        some cases, the FDA or the EMA may condition approval of an NDA or BLA or MAA for a product candidate on the Sponsor's agreement
        to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct additional clinical studies after
        approval to gain more information about the drug. Such post-approval studies are typically referred to as Phase 4 clinical studies.
A pivotal study is a clinical study that adequately
meets regulatory agency requirements for the evaluation of a drug candidate's efficacy and safety such that it can be used to justify
the approval of the product. Generally, pivotal studies are Phase 3 studies, but the FDA or EMA may accept results from a Phase 2
study if such study's design provides a well-controlled and reliable assessment of clinical benefit, particularly in situations
where there is an unmet medical need and the results are sufficiently robust.
The FDA/EMA, the IRB/EC, or the clinical study
sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects are being
exposed to an unacceptable health risk.
Additionally, some clinical studies are overseen
by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board or committee.
This group provides authorization or recommendation for whether or not a study may move forward at designated check points based on access
to certain data from the study. We may also suspend or terminate a clinical study based on evolving business objectives and/or competitive
climate. All of these trials must be conducted in accordance with cGCP requirements in order for the data to be considered reliable for
regulatory purposes.
The clinical study process can take several
(2- 12 or more) years to complete, and there can be no assurance that the data collected will support FDA or EU Commission approval or
licensure of the product. Government regulation may delay or prevent marketing of product candidates or new drugs for a considerable period
of time and impose costly procedures upon our activities. We cannot be certain that the FDA or any other regulatory agency will grant
approvals for our candidate products or any future product candidates on a timely basis, if at all. Success in early stage clinical trials
does not ensure success in later stage clinical trials. Data obtained from clinical activities is not always conclusive and may be susceptible
to varying interpretations, which could delay, limit or prevent regulatory approval.
The NDA Approval Process
Assuming successful completion of all required
testing in accordance with all applicable regulatory requirements, detailed investigational new drug product information is submitted
to the FDA in the form of an NDA or BLA requesting approval to market the product for one or more indications. Under federal law, the
submission of most NDAs and BLAs is subject to an application user fee. For fiscal year 2014, the application user fee exceeds $2.1 million,
and the Sponsor of an approved NDA or BLA is also subject to annual product and establishment user fees, set at $104,060 per product and
$554,600 per establishment. These fees are typically increased annually. Applications for orphan drug products are exempted from the NDA
and BLA user fees and may be exempted from product and establishment user fees, unless the application includes an indication for other
than a rare disease or condition.
93
An NDA or BLA must include all relevant data
available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together
with detailed information relating to the product's chemistry, manufacturing, controls, and proposed labeling, among other things.
Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of a product, or from
a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must
be sufficient in quality and quantity to establish the safety and effectiveness of the investigational new drug product to the satisfaction
of the FDA.
The FDA will initially review the NDA for
completeness before it accepts it for filing. The FDA has 60 days from its receipt of an NDA to determine whether the application
will be accepted for filing based on the agency's threshold determination that the application is sufficiently complete to permit
substantive review. After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether
the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP
to assure and preserve the product's identity, strength, quality and purity. The FDA may refer applications for novel drug products
or drug products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians
and other experts, for review, evaluation and a recommendation as to whether the application should be approved and, if so, under what
conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when
making decisions.
Based on pivotal Phase 3 trial results
submitted in an NDA, upon the request of an applicant, the FDA may grant a priority review designation to a product, which sets the target
date for FDA action on the application at six months, rather than the standard ten months. Priority review is given where preliminary
estimates indicate that a product, if approved, has the potential to provide a significant improvement compared to marketed products or
offers a therapy where no satisfactory alternative therapy exists. Priority review designation does not change the scientific/medical
standard for approval or the quality of evidence necessary to support approval.
After the FDA completes its initial review
of an NDA, it will communicate to the sponsor that the drug will either be approved, or it will issue a complete response letter to communicate
that the NDA will not be approved in its current form and inform the sponsor of changes that must be made or additional clinical, nonclinical
or manufacturing data that must be received before the application can be approved, with no implication regarding the ultimate approvability
of the application.
Before approving an NDA or BLA, the FDA will
typically inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that
the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the
product within required specifications.
Additionally, before approving an NDA, the
FDA may inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines the application, manufacturing process
or manufacturing facilities are not acceptable, it typically will outline the deficiencies and often will request additional testing or
information. This may significantly delay further review of the application. If the FDA finds that a clinical site did not conduct the
clinical trial in accordance with GCP, the FDA may determine the data generated by the clinical site should be excluded from the primary
efficacy analyses provided in the NDA. Additionally, notwithstanding the submission of any requested additional information, the
FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.
The testing and approval process for a drug
requires substantial time, effort and financial resources, and this process may take several years to complete. Data obtained from
clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory
approval. The FDA may not grant approval on a timely basis, or at all. We may encounter difficulties or unanticipated costs in our efforts
to secure necessary governmental approvals, which could delay or preclude us from marketing our products.
94
The FDA may require, or companies may pursue,
additional clinical trials after a product is approved. These so-called Phase 4 studies may be made a condition to be satisfied
for continuing drug approval. The results of Phase 4 studies can confirm the effectiveness of a product candidate and can provide
important safety information. In addition, the FDA now has express statutory authority to require sponsors to conduct post-market studies
to specifically address safety issues identified by the agency.
Any approvals that we may ultimately receive
could be withdrawn if required post-marketing trials or analyses do not meet the FDA requirements, which could materially harm the
commercial prospects for our candidate products.
The FDA also has authority to require a Risk
Evaluation and Mitigation Strategy, or REMS, from manufacturers to ensure that the benefits of a drug or biological product outweigh its
risks. A sponsor may also voluntarily propose a REMS as part of the NDA submission. The need for a REMS is determined as part of the review
of the NDA. Based on statutory standards, elements of a REMS may include "dear doctor letters," a medication guide, more
elaborate targeted educational programs, and in some cases restrictions on distribution. These elements are negotiated as part of the
NDA approval, and in some cases if consensus is not obtained until after the PDUFA review cycle, the approval date may be delayed. Once
adopted, REMS are subject to periodic assessment and modification.
Even if a product candidate receives regulatory
approval, the approval may be limited to specific disease states, patient populations and dosages, or might contain significant limitations
on use in the form of warnings, precautions or contraindications, or in the form of onerous risk management plans, restrictions on distribution,
or post-marketing study requirements. Further, even after regulatory approval is obtained, later discovery of previously unknown
problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Delay in
obtaining, or failure to obtain, regulatory approval for our candidate products, or obtaining approval but for significantly limited use,
would harm our business. In addition, we cannot predict what adverse governmental regulations may arise from future U.S. or foreign
governmental action.
Expedited Review and Accelerated Approval
Programs
A sponsor may seek approval of its product
candidate under programs designed to accelerate FDA's review and approval of NDAs and BLAs. For example, Fast Track Designation
may be granted to a drug intended for treatment of a serious or life-threatening disease or condition that has potential to address
unmet medical needs for the disease or condition. The key benefits of fast track designation are the eligibility for priority review,
rolling review (submission of portions of an application before the complete marketing application is submitted), and accelerated approval,
if relevant criteria are met. Based on results of the Phase 3 clinical study(ies) submitted in an NDA or BLA, upon the request of
an applicant, the FDA may grant the NDA or BLA a priority review designation, which sets the target date for FDA action on the application
at six months after the FDA accepts the application for filing. Priority review is granted where there is evidence that the proposed
product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition.
If criteria are not met for priority review, the application is subject to the standard FDA review period of ten months after FDA
accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality
of evidence necessary to support approval.
Under the accelerated approval program, the
FDA may approve an NDA or a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or
on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an
effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the
condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing
approval are generally required to verify the drug's clinical benefit in relationship to the surrogate endpoint or ultimate outcome
in relationship to the clinical benefit. In addition, the Food and Drug Administration Safety and Innovation Act (FDASIA), which was enacted
and signed into law in 2012, established the new "breakthrough therapy" designation. A sponsor may seek FDA designation of
its product candidate as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat
a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early
in clinical development.
95
FDA Post-Approval Requirements
Drugs manufactured or distributed pursuant
to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to
recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with
the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject
to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments
at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.
Drug manufacturers are subject to periodic
unannounced inspections by the FDA and state agencies for compliance with cGMP requirements. Changes to the manufacturing process are
strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations
also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and
any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort
in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.
We rely, and expect to continue to rely, on
third parties for the production of clinical quantities of our product candidates, and expect to rely in the future on third parties for
the production of commercial quantities. Future FDA and state inspections may identify compliance issues at our facilities or at the facilities
of our contract manufacturers that may disrupt production or distribution, or require substantial resources to correct. In addition, discovery
of previously unknown problems with a product or the failure to comply with applicable requirements may result in restrictions on a product,
manufacturer or holder of an approved NDA or BLA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or
judicial action that could delay or prohibit further marketing. Also, new government requirements, including those resulting from new
legislation, may be established, or the FDA's policies may change, which could delay or prevent regulatory approval of our products
under development.
The FDA may withdraw approval if compliance
with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery
of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing
processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information,
imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other
restrictions under a REMS program. Other potential consequences include, among other things:
●
restrictions on the marketing or manufacturing of the product,
        complete withdrawal of the product from the market or product recalls;
●
fines, warning letters or holds on post-approval clinical
        studies;
●
refusal of the FDA to approve pending NDAs or supplements to
        approved NDAs, or suspension or revocation of product license approvals;
●
injunctions or the imposition of civil or criminal penalties;
        or
●
product seizure or detention, or refusal to permit the import
        or export of products.
The FDA strictly regulates marketing, labeling,
advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance
with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion
of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.
96
Orphan Designation and Exclusivity
The FDA may grant orphan drug designation
to drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or, if it
affects more than 200,000 individuals in the United States, when there is no reasonable expectation that the cost of developing and
making the drug for this type of disease or condition will be recovered from sales in the United States.
Orphan drug designation entitles a party to
financial incentives such as opportunities for grant funding of clinical study costs, tax advantages, and user-fee waivers. In addition,
if a product receives FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity,
which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years,
except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity.
Patent Term Restoration
Depending upon the timing, duration, and specifics
of the FDA approval of the use of our product candidates, U.S. patents that may be granted to us in the future may be eligible for
limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to
as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation
for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend
the remaining term of a patent beyond a total of 14 years from the product's approval date. The patent term restoration period
is generally one-half the time between the effective date of an IND and the submission date of an NDA or BLA, plus the time between
the submission date and the approval of that application. Only one patent applicable to an approved product is eligible for the extension
and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA,
reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent
term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected
length of the clinical studies and other factors involved in the filing of the relevant NDA or BLA.
Biosimilars and Exclusivity
The Patient Protection and Affordable Care
Act, or Affordable Care Act, signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition and Innovation
Act of 2009 (BPCI Act), which created an abbreviated approval pathway for biological products shown to be similar to, or interchangeable
with, an FDA-licensed reference biological product. This amendment to the PHSA attempts to minimize duplicative testing. Biosimilarity,
which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of
safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability
requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the
same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic
may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to
exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structure of biological
products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being
worked out by the FDA.
A reference biologic is granted twelve years
of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval
pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitting under the
abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing, (ii) eighteen months
after approval if there is no legal challenge, (iii) eighteen months after the resolution in the applicant's favor of
a lawsuit challenging the biologics' patents if an application has been submitted, or (iv) 42 months after the application
has been approved if a lawsuit is ongoing within the 42-month period.
97
Abbreviated New Drug Applications for Generic
Drugs
In 1984, with passage of the Hatch-Waxman Act,
Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions
of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (ANDA) to the agency.
In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug
product previously approved under an NDA, known as the reference listed drug (RLD).
Specifically, in order for an ANDA to be approved,
the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration,
the dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is "bioequivalent"
to the innovator drug. Under the statute, a generic drug is bioequivalent to an RLD if "the rate and extent of absorption of the
[generic] drug do not show a significant difference from the rate and extent of absorption of the listed drug. . . ."
Upon approval of an ANDA, the FDA indicates
that the generic product is "therapeutically equivalent" to the RLD and it assigns a therapeutic equivalence rating to the
approved generic drug in its publication "Approved Drug Products with Therapeutic Equivalence Evaluations," also referred
to as the "Orange Book." Physicians and pharmacists consider an "AB" therapeutic equivalence rating to mean that
a generic drug is fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance
programs, the FDA's designation of an "AB" rating often results in substitution of the generic drug without the knowledge
or consent of either the prescribing physician or patient.
The FDCA provides a period of five years
of non-patent exclusivity for a new drug containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA
may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification,
in which case the applicant may submit its application four years following the original product approval. The FDCA also provides
for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability
or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity
period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or
indication.
Hatch-Waxman Patent Certification and the
30-Month Stay
Upon approval of an NDA or a supplement thereto,
NDA sponsors are required to list with the FDA each patent with claims that cover the applicant's product or a method of using the
product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with
the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except
for patents covering methods of use for which the ANDA applicant is not seeking approval.
Specifically, the applicant must certify with
respect to each patent that:
●
the required patent information has not been filed;
●
the listed patent has expired;
●
the listed patent has not expired, but will expire on a particular
        date and approval is sought after patent expiration; or
●
the listed patent is invalid, unenforceable or will not be infringed
        by the new product.
A certification that the new product will
not infringe the already approved product's listed patents or that such patents are invalid or unenforceable is called a Paragraph IV
certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method
of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.
98
If the ANDA applicant has provided a Paragraph IV
certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once
the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response
to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt
of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months after
the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the
ANDA applicant.
European Union/Rest of
World Government Regulation
In addition to regulations in the United States,
we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and any commercial
sales and distribution of our products.
Whether or not we obtain FDA approval for
a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical
studies or marketing of the product in those countries. Certain countries outside of the United States have a similar process that
requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. In the
European Union, for example, a clinical study application, or CTA, must be submitted for each clinical protocol to each country's
national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is accepted in accordance
with a country's requirements, the clinical study may proceed.
The requirements and process governing the
conduct of clinical studies vary from country to country. In all cases, the clinical studies are conducted in accordance with cGCP, the
applicable regulatory requirements, and the ethical principles that have their origin in the Declaration of Helsinki.
To obtain regulatory approval of an investigational
medicinal product under European Union regulatory systems, we must submit a marketing authorization application. The content of the NDA
or BLA filed in the United States is similar to that required in the European Union, with the exception of, among other things, country-specific document
requirements.
For other countries outside of the European
Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing product licensing, pricing, and reimbursement
vary from country to country.
Countries that are part of the European Union,
as well as countries outside of the European Union, have their own governing bodies, requirements, and processes with respect to the approval
of pharmaceutical products. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things,
fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.
Authorization Procedures in the European
Union
Medicines can be authorized in the European
Union by using either the centralized authorization procedure or national authorization procedures.
Centralized procedure
The EMA implemented the centralized procedure
for the approval of human medicines to facilitate marketing authorizations that are valid throughout the European Economic Area, or EEA,
which is comprised of the 27 member states of the European Union plus Norway, Iceland, and Lichtenstein. This procedure results in a single
marketing authorization issued by the EMA that is valid across the EEA. The centralized procedure is compulsory for human medicines
that are: derived from biotechnology processes, such as genetic engineering, contain a new active substance indicated for the treatment
of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions,
and officially designated orphan medicines.
99
For medicines that do not fall within these
categories, an applicant has the option of submitting an application for a centralized marketing authorization to the European Commission
following a favorable opinion by the EMA, as long as the medicine concerned is a significant therapeutic, scientific or technical innovation,
or if its authorization would be in the interest of public health.
National authorization procedures
There are also two other possible routes to
authorize medicinal products in several European Union countries, which are available for investigational medicinal products that fall
outside the scope of the centralized procedure:
●
Decentralized procedure
.    Using
        the decentralized procedure, an applicant may apply for simultaneous authorization in more than one European Union country of medicinal
        products that have not yet been authorized in any European Union country and that do not fall within the mandatory scope of the centralized
        procedure.
●
Mutual recognition procedure.
In
        the mutual recognition procedure, a medicine is first authorized in one European Union Member State, in accordance with the national procedures
        of that country. Following this, further marketing authorizations can be sought from other European Union countries in a procedure whereby
        the countries concerned agree to recognize the validity of the original, national marketing authorization.
In most cases, a Pediatric Investigation Plan,
and/or a request for waiver or deferral, is required for submission prior to submitting a marketing authorization application. A PIP describes,
among other things, proposed pediatric studies and their timing relative to clinical studies in adults.
New Chemical Entity Exclusivity
In the European Union, new chemical entities,
sometimes referred to as new active substances, qualify for eight years of data exclusivity upon marketing authorization and an additional
two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing
the innovator's data to assess a generic (abbreviated) application for eight years, after which generic marketing authorization
can be submitted, and the innovator's data may be referenced, but not approved for two years. The overall ten-year period
will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization
holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization,
are held to bring a significant clinical benefit in comparison with existing therapies.
Orphan Designation and Exclusivity
In the European Union, the EMA's Committee
for Orphan Medicinal Products, or COMP, grants orphan drug designation to promote the development of products that are intended for the
diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons
in the European Union Community and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the
product would be a significant benefit to those affected). Additionally, designation is granted for products intended for the diagnosis,
prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives,
it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the
medicinal product.
In the European Union, orphan drug designation
entitles a party to financial incentives such as reduction of fees or fee waivers and 10 years of market exclusivity is granted following
medicinal product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including
where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity, and may be prolonged to
a total of 12 years, if pediatric studies in accordance with a PIP are being performed.
100
Orphan drug designation must be requested
before submitting an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration
of, the regulatory review and approval process.
Exceptional Circumstances/Conditional Approval
Orphan drugs or drugs with unmet medical needs
may be eligible for EU approval under exceptional circumstances or with conditional approval. Approval under exceptional circumstances
is applicable to orphan and non-orphan products and is used when an applicant is unable to provide comprehensive data on the efficacy
and safety under normal conditions of use because the indication for which the product is intended is encountered so rarely that the applicant
cannot reasonably be expected to provide comprehensive evidence, when the present state of scientific knowledge does not allow comprehensive
information to be provided, or when it is medically unethical to collect such information. Conditional marketing authorization is applicable
to orphan medicinal products, medicinal products for seriously debilitating or life-threatening diseases, or medicinal products to
be used in emergency situations in response to recognized public threats. Conditional marketing authorization can be granted on the basis
of less complete data than is normally required in order to meet unmet medical needs and in the interest of public health, provided the
risk-benefit balance is positive, it is likely that the applicant will be able to provide the comprehensive clinical data, and unmet
medical needs will be fulfilled. Conditional marketing authorization is subject to certain specific obligations to be reviewed annually.
Accelerated Review
Under the Centralized Procedure in the European
Union, the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding clock stops, when
additional written or oral information is to be provided by the applicant in response to questions asked by the EMA's Committee
for Medicinal Products for Human Use (CHMP)). Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal
product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. In this circumstance,
EMA ensures that the opinion of the CHMP is given within 150 days, excluding clock stops.
Pharmaceutical Coverage,
Pricing and Reimbursement
Significant uncertainty exists as to the coverage
and reimbursement status of any drug products for which we obtain regulatory approval. In the United States and markets in other
countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability
of coverage and reimbursement from third-party payors. Third-party payors include government authorities, managed care providers,
private health insurers and other organizations. The process for determining whether a payor will provide coverage for a drug product
may be separate from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party payors
may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs
for a particular indication. Moreover, a payor's decision to provide coverage for a drug product does not imply that an adequate
reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels
sufficient to realize an appropriate return on our investment in product development.
Third-party payors are increasingly challenging
the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety
and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the
costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If
third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover
the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company
to sell its products at a profit.
101
The U.S. government, state legislatures
and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health
care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded
prescription drugs. By way of example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation
Act, collectively, the Healthcare Reform Law, contains provisions that may reduce the profitability of drug products, including, for example,
increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts
for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies' share of sales to federal health
care programs. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls
and measures, could limit payments for pharmaceuticals.
In the European Community, governments influence
the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund
a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products
may only be marketed once a reimbursement price has been agreed to by the government. To obtain reimbursement or pricing approval, some
of these countries may require the completion of clinical studies that compare the cost-effectiveness of a particular product candidate
to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company
profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result,
increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from
low-priced markets exert a commercial pressure on pricing within a country.
The marketability of any products for which
we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage
and reimbursement. In addition, an increasing emphasis on cost containment measures in the United States and other countries has
increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement
rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
Other Healthcare Laws
and Compliance Requirements
If we obtain regulatory approval for any of
our product candidates, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These
laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy
regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate
include:
●
the federal Anti-Kickback Statute, which prohibits, among
        other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to
        induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as
        the Medicare and Medicaid programs;
●
federal civil and criminal false claims laws and civil monetary
        penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims
        for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent;
●
the federal Health Insurance Portability and Accountability Act of 1996,
        or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making
        false statements relating to healthcare matters;
102
●
the federal transparency laws, including the federal Physician
        Payment Sunshine Act, that requires drug manufacturers to disclose payments and other transfers of value provided to physicians and teaching
        hospitals;
●
HIPAA, as amended by HITECH and its implementing regulations,
        which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;
        and
●
state law equivalents of each of the above federal laws, such
        as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial
        insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from
        each other in significant ways and may not have the same effect, thus complicating compliance efforts.
The Healthcare Reform Law broadened the reach
of the fraud and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback Statute and the
applicable criminal healthcare fraud statutes contained within 42 U.S.C. § 1320a-7b, effective March 23, 2010. Pursuant
to the statutory amendment, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate
it in order to have committed a violation. In addition, the Healthcare Reform Law provides that the government may assert that a claim
including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim
for purposes of the civil False Claims Act (discussed below) or the civil monetary penalties statute. Many states have adopted laws similar
to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed
by any source, not only the Medicare and Medicaid programs.
We are also subject to the Foreign Corrupt
Practices Act, or FCPA, which prohibits improper payments or offers of payments to foreign governments and their officials for the purpose
of obtaining or retaining business.
Safeguards we implement to discourage improper
payments or offers of payments by our employees, consultants, and others may be ineffective, and violations of the FCPA and similar laws
may result in severe criminal or civil sanctions, or other liabilities or proceedings against us, any of which would likely harm our reputation,
business, financial condition and result of operations.
If our operations are found to be in violation
of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil
and criminal penalties, exclusion from participation in government healthcare programs, such as Medicare and Medicaid and imprisonment,
damages, fines and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our
business and our results of operations.
Labeling, Marketing and
Promotion
The FDA closely regulates the labeling, marketing
and promotion of drugs. While doctors are free to prescribe any drug approved by the FDA for any use, a company can only make claims relating
to safety and efficacy of a drug that are consistent with FDA approval, and the Company is allowed to actively market a drug only for
the particular use and treatment approved by the FDA. In addition, any claims we make for our products in advertising or promotion
must be appropriately balanced with important safety information and otherwise be adequately substantiated. Failure to comply with these
requirements can result in adverse publicity, warning letters, corrective advertising, injunctions and potential civil and criminal penalties.
Government regulators recently have increased their scrutiny of the promotion and marketing of drugs.
Pediatric Research Equity
Act
The Pediatric Research Equity Act (PREA) amended
the FDCA to authorize the FDA to require certain research into drugs used in pediatric patients. The intent of PREA is to compel sponsors
whose drugs have pediatric applicability to study those drugs in pediatric populations, rather than ignoring pediatric indications for
adult indications that could be more economically desirable. The Secretary of Health and Human Services may defer or waive these requirements
under specified circumstances.
103
Anti-Kickback and False
Claims Laws
In the United States, the research, manufacturing,
distribution, sale and promotion of drug products and medical devices are potentially subject to regulation by various federal, state
and local authorities in addition to the FDA, including the Centers for Medicare & Medicaid Services, other divisions of the
U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice, state
Attorneys General, and other state and local government agencies. For example, sales, marketing and scientific/educational grant programs
must comply with the Medicare-Medicaid Anti-Fraud and Abuse Act, as amended (the "Anti-Kickback Statute"),
the False Claims Act, as amended, the privacy regulations promulgated under the Health Insurance Portability and Accountability Act, or
HIPAA, and similar state laws. Pricing and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the Omnibus
Budget Reconciliation Act of 1990, as amended, and the Veterans Health Care Act of 1992, as amended. If products are
made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements
apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws.
In the United States, we are subject
to complex laws and regulations pertaining to healthcare "fraud and abuse," including, but not limited to, the Anti-Kickback Statute,
the federal False Claims Act, and other state and federal laws and regulations. The Anti-Kickback Statute makes it illegal for any
person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer,
or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or prescription of a particular
drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.
The federal False Claims Act prohibits anyone
from knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items
or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically
unnecessary items or services.
There are also an increasing number of state
laws that require manufacturers to make reports to states on pricing and marketing information. Many of these laws contain ambiguities
as to what is required to comply with the laws. In addition, as discussed below, beginning in 2013, a similar federal requirement will
require manufacturers to track and report to the federal government certain payments made to physicians and teaching hospitals made in
the previous calendar year. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and
compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions
could be subject to the penalty provisions of the pertinent state, and soon federal, authorities.
Patient Protection and
Affordable Health Care Act
In March 2010, the Patient Protection
and Affordable Health Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, PPACA)
was enacted, which includes measures that have or will significantly change the way health care is financed by both governmental and private
insurers. The fees, discounts and other provisions of this law are expected to have a significant negative effect on the profitability
of pharmaceuticals.
Many of the details regarding the implementation
of PPACA are yet to be determined, and at this time, it remains unclear the full effect that PPACA would have on our business.
Other Regulations
We are also subject to numerous federal, state
and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control,
and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations
now or in the future.
104
Israel
Clinical Testing in Israel
In order to conduct clinical testing on humans
in the State of Israel, special authorization must first be obtained from the ethics committee and general manager of the institution
in which the clinical studies are scheduled to be conducted, as required under the Guidelines for Clinical Trials in Human Subjects implemented
pursuant to the Israeli Public Health Regulations (Clinical Trials in Human Subjects) 5741-1980, as amended from time to time, and
other applicable legislation. These regulations require authorization by the institutional ethics committee and general manager as well
as from the Israeli Ministry of Health, except in certain circumstances, and in the case of genetic trials, special fertility trials and
complex clinical trials, an additional authorization of the Ministry of Health's overseeing ethics committee. The institutional
ethics committee must, among other things, evaluate the anticipated benefits that are likely to be derived from the project to determine
if it justifies the risks and inconvenience to be inflicted on the human subjects, and the committee must ensure that adequate protection
exists for the rights and safety of the participants as well as the accuracy of the information gathered in the course of the clinical
testing. Since we perform a portion of the clinical studies on certain of our therapeutic candidates in Israel, we are required to obtain
authorization from the ethics committee and general manager of each institution in which we intend to conduct our clinical trials, and
in most cases, from the Israeli Ministry of Health.
New Silexion Corporate
Information
New Silexion was formed on April 2, 2024 under
the name Biomotion Sciences as a Cayman Islands exempted limited company for the purpose of effecting a business combination with Moringa
and Silexion. On April 3, 2024, New Silexion entered into the Business Combination Agreement by and among New Silexion, Moringa, Silexion,
and New Silexion's two wholly-owned subsidiaries— Merger Sub 1 and Merger Sub 2. On the Closing Date of August 15, 2024, following
the approval of the Business Combination (among other matters) at Moringa's extraordinary general meeting that was held on August
6, 2024, the transactions contemplated by the Business Combination Agreement were completed. As a result, Moringa and Silexion merged
with Merger Sub 2 and Merger Sub 1 pursuant to the SPAC Merger and Acquisition Merger, respectively, and became New Silexion's wholly-owned
subsidiaries, and their securityholders became securityholders of New Silexion at previously agreed-upon exchange ratios. In addition,
New Silexion's ordinary shares and warrants were listed, and began trading, on the Nasdaq Global Market on August 16, 2024, and
its name was changed to Silexion Therapeutics Corp.
New Silexion's principal executive offices are located at 12 Abba Hillel Road, Ramat Gan, Israel
5250606, and its phone number is +972-8-6286005. New Silexion's corporate website address is www.silexion.com. Information contained
on or accessible through that website is not a part of this prospectus, and the inclusion of that website address in this prospectus is
an inactive textual reference only.
Access to Company Information
The Company files or furnishes periodic reports
and amendments thereto, including its Annual Reports on Form 10-K, its Quarterly Reports on Form 10-Q and Current Reports on Form 8-K,
proxy statements and other information with the SEC. In addition, the SEC maintains a website (www.sec.gov) that contains reports, proxy
and information statements, and other information regarding issuers that file electronically. New Silexion's internet address is
https://www.silexion.com. The Company makes available, free of charge, its Annual Report on Form 10-K, quarterly reports on Form 10-Q,
current reports on Form 8-K, and all amendments to those reports as soon as reasonably practicable after such reports have been filed
with or furnished to the SEC through its internet website.
105
MANAGEMENT
Management and Board of Directors
Our board of directors (sometimes referred
to as the "New Silexion Board") is comprised of the six directors listed below.
Each director will hold office until his
or her successor is duly elected or appointed and qualified in accordance with applicable law or until his or her death, resignation or
removal in accordance with law and our governing documents, including our Amended and Restated Memorandum and Articles of Association
(the "Articles"), which went into effect upon the Closing of the Business Combination.
The following sets forth certain information
known as of the date hereof concerning the persons who currently serve as directors and executive officers of New Silexion (who have served
as such since the consummation of the Business Combination):
Name
Age
Position(s)
Directors
Ilan Hadar
55
Chairman and Chief Executive Officer
Dror J. Abramov
63
Director
Ruth Alon
72
Director
Ilan Levin
58
Director
Avner Lushi
57
Director
Shlomo Noy
71
Director
Executive Officers (who are not also directors)
Dr. Mitchell Shirvan
70
Chief Scientific and Development Officer
Mirit Horenshtein Hadar, CPA
40
EVP of Finance Affairs, Chief Financial Officer and Secretary
Directors
Ilan Hadar
, 55,
was
appointed as Chief Executive Officer of New Silexion, serving on a full-time basis, effective upon the Business Combination, and
has served as our (previously, Silexion's) Chairman of the Board since May 2024. Previously, he served as Managing Director of Silexion
from April 2022 until the Business Combination. Mr. Hadar has over 20 years of multinational managerial and corporate experience
with pharmaceutical and high-tech companies, as described below, over which time period he has acquired the experience and skills
to serve as a valuable member of the board of directors of a company such as Biomotion Sciences. In addition to his current role at Silexion,
Mr. Hadar has served as the Chief Executive Officer of Painreform Ltd (Nasdaq: PRFX) since November 2020, a position he will
relinquish following the consummation of the Business Combination. Prior to joining Painreform and Silexion, Mr. Hadar served as
Country Manager Israel and Chief Financial Officer at Foamix Pharmaceuticals Ltd. (currently, Nasdaq: VYNE) from 2014 until August 2020,
where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., and also focused on capital
markets and mergers and acquisitions. Prior to his role at Foamix, Mr. Hadar was Finance Director at Pfizer PFR Pharmaceuticals Israel
Ltd., where he oversaw all commercial, financial and operational activities of the local entity of the large pharmaceutical company. Before
his tenure at Pfizer, Mr. Hadar served as Finance Manager at HP Indigo Ltd., a world-leading company in digital printing and,
prior to that, served as Finance Director at BAE Systems, the third-largest defense company in the world, where he was responsible
for all financial activities of BAE Systems Israel. From 1998 to 2006, Mr. Hadar was Chief Financial Officer at Mango DSP, a global
leader of Intelligent Video Solutions. Mr. Hadar served on the board of directors of Kadimastem, a public Israeli biopharmaceutical
company from 2019 to 2022. He received his MBA in Finance and Business Entrepreneurship and BA from The Hebrew University in Jerusalem,
Israel. We believe Mr. Hadar is qualified to serve on our board of directors due to his extensive knowledge as Silexion's Managing
Director, and his extensive commercial, financial and managerial experience with high-tech and pharmaceutical companies, both private
and public.
106
Dror J. Abramov,
63,
was appointed as a director of New Silexion effective upon the consummation of the Business Combination. Mr. Abramov's experience
of over 15 years in multiple roles in changing and growing companies and markets within dynamic environments, and in particular his multi-disciplinary experience
in R&D, consulting, taxes, sales, business development, finance and government, lend to his being an appropriate board member of Biomotion
Sciences. Mr. Abramov has served as Managing Director of Hewlett Packard Inc. Israel since 2015. Mr. Abramov held several other
management positions in Hewlett Packard Inc. Israel from 2006 to 2015, including finance director, general manager of imaging and printing
divisions and general manager of printing and personal systems division. From 2002 through 2006, Mr. Abramov served as Chief Financial
Officer of Applied Materials UK and Applied Materials Israel, both part of Applied Materials, Inc. (Nasdaq: AMAT), a nanomanufacturing
company that supplies equipment, services and software for the manufacture of semiconductor chips for electronics. From 2000 through 2002,
Mr. Abramov served as Vice President of business management at Avaya Communication, a cloud communications and workstream collaboration
technology company. From 1997 until 2000, Mr. Abramov held positions in Mainsoft Corporation, first as director of finance and operations
and later as general manager. From 1991 through 1997, Mr. Abramov served as consultant and manager at Maron, Sobel, Shor & Co.,
an Israeli CPA firm. Mr. Abramov is a licensed CPA and holds a Bachelor of Accounting, Master of Business Administration and Bachelor
of Science in physics and computer sciences, all three degrees from Tel Aviv University. We believe Mr. Abramov is qualified to serve
on our board of directors due to his extensive financial and business management experience.
Ruth Alon
, 72,
became
a director of New Silexion effective upon the consummation of the Business Combination. Ms. Alon's international experience of over
30 years in the high-tech medical industry and with Israeli life sciences companies, in particular, make her a prospective valuable
member of the board of directors of Biomotion Sciences. Ms. Alon is the Founder and Chief Executive Officer of Medstrada, which was started
in 2016. From 1997 until 2016, Ms. Alon served as a General Partner in Pitango Venture Capital, where she headed the life sciences activities
and helped to facilitate the acquisition of several of the company'sportfolio companies. Currently, Ms. Alon also serves on the
board of directors of a number of private and public companies as a member or chairperson, including Vascular Biogenics Ltd. (Nasdaq:
VBLT), Brainsgate and KadimaStem. Ms. Alon previously worked on Wall Street where she held senior positions as a senior medical device
analyst with Montgomery Securities (from 1981 to 1987) and Kidder Peabody & Co. (from 1987 to 1993). She also managed her own
independent consulting business in San Francisco from 1995 to 1996, providing broad-based services to early-stage companies
and venture capitalists in the medical devices industry. Ms. Alon was also instrumental in the establishment, in 2005, of Israel Life
Science Industry (ILSI), a not-for-profit organization which represented, as of 2005, the mutual goals of approximately 700 Israeli
life science companies. She is the Co-Founder of IATI, an umbrella organization established in 2012, representing Israel's
High Tech and Life Sciences industries. Ms. Alon holds a B.A. in Economics from the Hebrew University of Jerusalem, an M.B.A. from Boston
University, and an M.Sc. from the Columbia University School of Physicians and Surgeons. We believe Ms. Alon is qualified to serve on
our board of directors given her above-described extensive experience in the high-tech medical industry and with Israeli life
sciences companies, in particular.
Ilan Levin
, 58,
who
was the co-founder, Chairman and Chief Executive Officer of Moringa, was appointed as a director of New Silexion after its formation in
April 2024 and has continued as a director following the consummation of the Business Combination. Mr. Levin has been involved, for
approximately 25 years, as an executive and venture capital/private equity investor in high-tech, Israel-related ventures. His
experience as an executive and board member in managing growth companies that develop technology, and his knowledge of that industry in
Israel in particular, suit him well to serve as a director of Biomotion Sciences. From 2000 to 2018, Mr. Levin was a member of the
Board and Executive Committee of Objet Ltd., which as a result of a merger with Stratasys, Inc. in 2012, formed Stratasys Ltd. (Nasdaq:
SSYS), the pioneer and global leader in 3D printing. During his tenure at Objet/Stratasys, Mr. Levin held various positions including
President, Vice Chairman and from 2016 to 2018, Chief Executive Officer. From 2004 to 2009, Mr. Levin was the Chief Executive Officer
of CellGuide, a developer of software-based GPS for mobile devices. Since 1997, Mr. Levin has also served as a member of the
board of directors and as an advisor for a wide variety of Israel-based technology-related companies, including currently serving
as Chairman of Vision Sigma (TLV: VISN: IT), an Israel-based real estate and investment company. Early in his career, Mr. Levin
was a practicing attorney focusing on corporate and securities related matters. In addition to his role as our Chairman and Chief Executive
Officer, Mr. Levin also serves as the sole director and sole equity owner of an Israeli company that serves as the sole general partner
of the Sponsor. Mr. Levin earned an LL.B. from Tel Aviv University and a B.A.Sc. in Industrial Engineering from the University of
Toronto. We believe Mr. Levin is qualified to serve on our board of directors given his above-described experience in managing
growth companies that develop technology, and his knowledge of that industry in Israel in particular.
107
Avner Lushi
, 57,
was
appointed as a director of New Silexion effective upon the consummation of the Business Combination. His experience of over 20 years and
skills acquired in his managing roles at an Israeli life sciences venture capital fund and in life sciences investment banking make him
suitable to provide similar support as a member of the board of directors of Biomotion Sciences. Mr. Lushi co-founded Guangzhou
Sino-Israel Bio-industry Investment Fund (GIBF), which currently includes two approximately $100 million funds focused on introducing
Israeli and other foreign companies in the field of life sciences to the Chinese market, in which he also serves as a Managing Partner &
CEO of the GP since 2016. From 2004 to 2015, Mr. Lushi served as a Partner and Managing Director of Israel Healthcare Ventures (IHCV),
a prominent Israeli life sciences venture capital fund. Before joining IHCV, Mr. Lushi was the Co-Founder & CEO of Life
Sciences Transaction Support Ltd. (LTS), a PwC subsidiary dealing with life sciences investment banking. Since 2005, Mr. Lushi has
served as an independent director on the boards of nine public companies, including, currently, Brainsway Ltd. (Nasdaq: BWAY) and Ginegar
Plastic Products Ltd. In addition, he serves as a board member of several private companies as part of his role at GIBF. From 1997
to 2001, prior to turning to the private sector, he held increasingly senior roles within the Israeli Prime Minister's Chamber and
the Israeli Supreme Court. Mr. Lushi holds an LLM in Law from the Hebrew University of Jerusalem, LLB in Law and a BA in Economics
from the Haifa University. We believe Mr. Lushi is qualified to serve on our board of directors due to his extensive executive and
board experience with life sciences companies.
Shlomo Noy
,
MD PhD, 71,
was appointed as a director of New Silexion effective upon the consummation
of the Business Combination. Professor Noy's international-level expertise in healthcare management, tech transfer, building
ecosystems and focusing hospitals on research and clinical trials will provide important knowledge to the Biomotion Sciences board of
directors in the realm of Israeli research and clinical trial activities. Professor Noy has served as Chief Medical Officer of GIBF since
January 2017. Professor Noy served as the Director of the Rehabilitation Hospital at Sheba Medical Center from 1993 to
2017 and Vice President of Research and Development and Academic Affairs at Sheba Medical Center from 2000 to 2017. Prof. Noy was a Professor
at Sackler School of Medicine at Tel-Aviv University from 1993 to 2016. Prof. Noy serves as a board member of several private
companies as part of his role at GIBF. Prof. Noy possesses 25 years' experience in health care management and is active
in promoting research and education at an Israeli national level as well as at an international level. Prof. Noy received his MD from
the Hebrew University, Hadassah Medical School, Jerusalem, Israel, and completed his MBA at the European School of Business Administration
(INSEAD) Fontainebleau, France, and holds a PhD degree from Tel-Aviv University, Faculty of Medicine and Management. We believe Mr. Noy
is qualified to serve on our board of directors due to his extensive medical and health care management experience.
Executive Officers
Mitchell Shirvan
, 70,
has served as the Chief Scientific and Development Officer of New Silexion since the Business Combination, and, before the Business Combination,
of Silexion, since April 2022. Prior to joining Silexion, Dr. Shirvan served as the Senior Vice President of R&D and V.P. Innovation
and Discovery at Foamix Pharmaceuticals Ltd. from 2014 to 2019. Dr. Shirvan has over 25 years of industry experience, previously
holding positions as Chief Executive Officer at Macrocure Ltd. from 2008 to 2012. From 1992 until 2008, Dr. Shirvan held various
positions of increasing responsibility at Teva Pharmaceutical Industries, including Senior Director, Strategic Business Planning and Senior
Manager, Research & Development. Prior to his tenure at Teva, he was a research fellow at the U.S. National Institutes of
Health. Dr. Shirvan holds a Ph.D. in microbiology from The Hebrew University of Jerusalem and an MBA from the University of Bradford.
Mirit Horenshtein
Hadar
, 40, has served as the Chief Financial Officer and Secretary
of New Silexion since the Business Combination, and served as the Executive Vice President of Finance Affairs at Silexion before the Business
Combination, beginning in January 2024. From August 2023 to January 2024, Ms. Horenshtein Hadar served as a part-time consultant
in a Strategy & Corporate Finance Advisory capacity. Ms. Horenshtein Hadar has over 15 years of corporate finance experience
in senior financial positions of public companies and privately held companies, in the pharmaceutical and high-tech industries, where
she has been instrumental in building financial infrastructures for growth, U.S. GAAP financial reporting and FP&A functions, and
has led the accounting and reporting of complex M&A transactions, integration processes and public offerings. Prior to joining Silexion,
from January 2021 to December 2022, Ms. Horenshtein Hadar served as VP of Finance and then CFO Israel of Gauzy Ltd. (currently,
Nasdaq: GAUZ), a nanotechnology company that develops and markets smart glass and vision control technologies. Since December 2022,
Ms. Horenshtein Hadar continues to serve as an external advisor to the finance department at Gauzy. Prior to Gauzy, Ms. Horenshtein Hadar
served as Senior Director of Finance and Head of FP&A, Accounting and Financial Reporting at Foamix Pharmaceuticals Ltd. (currently,
Nasdaq: VYNE) from July 2016 until December 2020. Prior to Foamix, Ms. Horenshtein Hadar was a Senior Manager at PwC Israel,
as an external auditor, from 2008 to 2016. Ms. Horenshtein Hadar became a Qualified CPA in 2011 and received a BA in Accounting, Economics
and Business Management from Tel Aviv University.
108
Family Relationships
Mirit Horenshtein Hadar and Ilan Hadar are
married to one another. There are no other family relationships between the individuals who serve as directors and executive officers
of the Company.
Corporate Governance Practices
Overall
The Company does not qualify as a "foreign
private issuer" under U.S. securities laws and is therefore not currently eligible to exempt itself from any of the Nasdaq
listing rule requirements in a manner that other non-U.S. issuers often do.
Composition of the New
Silexion Board After the Business Combination
New Silexion's business and affairs
are managed under the direction of the New Silexion Board. Under the terms of the Articles, the New Silexion Board may be composed of
between three and nine directors, as may be amended from time to time exclusively by ordinary resolution under Cayman Islands law, being
a resolution passed by a simple majority of the shareholders of New Silexion as, being entitled to do so, vote in person or by proxy at
a general meeting (an "
Ordinary Resolution
"). The size of the New Silexion Board was
set by our shareholders as seven members effective upon the Closing. Ilan Hadar serves as Chairman of the New Silexion Board. Subsequent
to the Closing, Ilan Shiloah stepped down from the Board, citing competing demands on his time, thereby leaving the current size of the
Board as six members.
Pursuant to the Articles, New Silexion's directors are appointed by an Ordinary Resolution at an
annual general meeting. Unless the Board resolves that the election of nominees of the Board (referred to as "
Nominees
")
or of nominees of any shareholders entitled to present such nomination (referred to as "
Alternate
Nominees
") will be determined by plurality vote, the Nominees or Alternate Nominees shall be appointed by Ordinary Resolution
at the annual general meeting at which they are proposed for election.
Officers
New Silexion's Chief Executive Officer
is responsible for the company's day-to-day management. The Chief Executive Officer is appointed by, and serves at the
discretion of, the New Silexion Board, subject to his employment agreement. All other executive officers are proposed for appointment
by the Chief Executive Officer, subject to approval by the New Silexion Board, and will be subject to the terms of any applicable employment
or consulting agreements that Silexion may enter into with them.
Director Independence
Nasdaq listing standards require that a majority
of the New Silexion Board be independent. An "independent director" is defined generally as a person who has no material relationship
with the listed company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the listed
company) that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making
these determinations, the New Silexion Board considers the current and prior relationships that each non-employee director has with the
Company and all other facts and circumstances the New Silexion Board deems relevant in determining their independence, including the beneficial
ownership of our securities by each non-employee director and the transactions described in the section titled "
Certain
Relationships and Related Party Transactions
."
The New Silexion Board has determined that
each of Messrs. Dror J. Abramov, Ilan Levin, Avner Lushi and Shlomo Noy, and Ms. Ruth Alon, meets the definition of "independent
director" as defined in Nasdaq listing standards. For purposes of SEC rules applicable to members of the audit committee and compensation
committee, each of Mr. Abramov and Ms. Alon are deemed independent.
109
Board Committees
The New Silexion Board has established an
audit committee, a compensation committee and a nominating and corporate governance committee, each of which has the composition and the
responsibilities described below. Each of these committees operates under a written charter, approved by the New Silexion Board and effective
upon the Closing, that satisfies the applicable Nasdaq rules, copies of which are available on the investor relations portion of our website.
Members will serve on these committees until their resignation or until otherwise determined by the New Silexion Board. The New Silexion
Board may establish other committees as it deems necessary or appropriate from time to time.
Audit Committee
Our audit committee consists of Dror J.
Abramov and Ruth Alon, with Mr. Abramov serving as chair. Ilan Shiloah had served as the third member of the audit committee from
the Closing until his resignation from the New Silexion Board on September 16, 2024. Rule 10A-3 of the Exchange Act and
the Nasdaq listing standards require that our audit committee be composed entirely of independent members. The Nasdaq listing standards
require that the audit committee be composed of at least three members. With the resignation of Mr. Siloah from the New Silexion Board
and its audit committee, we will have until the earlier of our 2025 annual general meeting or one year after Mr. Shiloah's resignation
to restore the size of the audit committee to three members. The New Silexion Board has determined that each of Mr. Abramov and Ms. Alon
meets the definition of "independent director" for purposes of serving on the audit committee under Rule 10A-3 of
the Exchange Act and the Nasdaq listing standards and also meets the financial literacy requirements of the Nasdaq listing standards.
In addition, the New Silexion Board has determined that Mr. Abramov qualifies as an "audit committee financial expert"
within the meaning of the SEC regulations.
The primary purpose of the audit committee
is to discharge the responsibilities of the New Silexion Board with respect to our corporate accounting and financial reporting processes,
systems of internal control and financial statement audits and to oversee our independent registered public accounting firm. The principal
functions of the audit committee include, among other things:
●
helping the New Silexion Board oversee our corporate accounting
        and financial reporting processes;
110
●
managing the selection, engagement, qualifications, independence,
        and performance of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;
●
reviewing and discussing the scope and results of the audit with
        the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating
        results;
●
obtaining and reviewing a report by the independent registered
        public accounting firm at least annually that describes our internal quality control procedures, any material issues with such procedures
        and any steps taken to deal with such issues when required by applicable law;
●
establishing procedures for employees to submit concerns anonymously
        about questionable accounting or audit matters;
●
overseeing our policies on risk assessment and risk management;
●
overseeing compliance with our code of business conduct and ethics;
●
reviewing related person transactions; and
●
approving or, as required, pre-approving audit and permissible
        non-audit services to be performed by the independent registered public accounting firm.
Compensation Committee
Our compensation committee consists of Dror
J. Abramov and Ruth Alon. The chair of the compensation committee will be chosen from among the committee's members. The New Silexion
Board has determined that each of Mr. Abramov and Ms. Alon meets the definition of "independent director" for purposes
of serving on the compensation committee under the Nasdaq listing standards, including the heightened independence standards for members
of a compensation committee.
The primary purpose of our compensation committee
is to discharge the responsibilities of the New Silexion Board in overseeing our compensation policies, plans and programs and to review
and determine the compensation to be paid to our executive officers, directors and other senior management, as appropriate. The principal
functions of the compensation committee include, among other things:
●
reviewing, approving and determining, or making recommendations
        to the New Silexion Board regarding the compensation of our chief executive officer, other executive officers and senior management;
●
reviewing, evaluating and recommending to the New Silexion Board
        succession plans for our executive officers;
●
reviewing and recommending to the New Silexion Board the compensation
        paid to our non-employee directors;
●
administering our equity incentive plans and other benefit programs;
●
reviewing, adopting, amending and terminating incentive compensation
        and equity plans, severance agreements, profit sharing plans, bonus plans, change-of-control protections and any other compensatory
        arrangements for our executive officers and other senior management; and
●
reviewing and establishing general policies relating to compensation
        and benefits of our employees, including our overall compensation philosophy.
111
Corporate Governance and
Nominating Committee
We have appointed a corporate governance and
nominating committee that currently consists of Dror J. Abramov, Ilan Levin and Ruth Alon. The chair of the committee will be chosen from
among the committee's members. The New Silexion Board has determined that each of Messrs. Abramov and Levin, and Ms. Alon, meets
the definition of "independent director" under the Nasdaq listing standards.
Our corporate governance and nominating committee
is responsible for, among other things:
●
identifying and evaluating candidates, including the nomination
        of incumbent directors for reelection and nominees recommended by shareholders, to serve on the New Silexion Board;
●
considering and making recommendations to the New Silexion Board
        regarding the composition and chairmanship of the committees of the New Silexion Board;
●
instituting plans or programs for the continuing education of
        the New Silexion Board and the orientation of new directors;
●
developing and making recommendations to the New Silexion Board
        regarding corporate governance guidelines and matters;
●
overseeing our corporate governance practices;
●
overseeing periodic evaluations of the New Silexion Board's
        performance, including committees of the New Silexion Board; and
●
contributing to succession planning.
Compensation Committee
Interlocks and Insider Participation
None of the members of Silexion's compensation
committee is currently, or has been at any time, one of Silexion's, Moringa's or Silexion's executive officers or employees.
None of our executive officers serves as a member of the board of directors or compensation committee (or other committee performing equivalent
functions) of any entity that had one or more executive officers serving on our board of directors or compensation committee during 2023.
Code of Business Conduct
and Ethics
Prior to the completion of the Business Combination,
we adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A
copy of the code is posted on the investor relations portion of our website. In addition, we intend to post on our website all disclosures
that are required by law or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the code.
EXECUTIVE
COMPENSATION
Silexion
Unless the context requires
otherwise, references in this "Executive Compensation" section to "we," "our," "us" and
the "Company" generally refer to our wholly-owned subsidiary, Silexion Therapeutics Ltd., an Israeli company ("Silexion"),
and its subsidiaries.
112
Overview
The following tables and accompanying narrative
set forth information about the compensation, for 2023, provided to Silexion's chief executive officer (or person serving in an
equivalent position) and the two most highly compensated executive officers of Silexion (other than its chief executive officer) who were
serving as executive officers as of December 31, 2023, each of whom serves as an executive officer of New Silexion currently. These
executive officers consist of: Ilan Hadar, Silexion's Managing Director, who now serves as New Silexion's Chairman and Chief
Executive Officer; Mirit Horenshtein Hadar, Silexion's EVP Finance, who now serves as New Silexion's Chief Financial Officer;
and Dr. Mitchell Shirvan, Silexion's (and now New Silexion's) Chief Scientific and Development Officer. These executive
officers are referred to in this section as our "named executive officers" or "NEOs."
This discussion may contain forward-looking statements
that are based on our current plans, considerations, expectations and determinations regarding future compensation programs, in the period
immediately following the Business Combination. Actual compensation programs that we adopt in the future may differ materially from the
plans summarized in this discussion.
Summary Compensation Table
The following table presents summary information
regarding the total compensation for services rendered in all capacities that was awarded to, earned by, or paid to Silexion's named
executive officers for 2023.
Name and Principal Position
Base Gross
Salary
($)
(1)
Option
Awards
($)
All Other
Compensation
($)
(1)(2)
Total
($)
(1)
Ilan Hadar
Managing Director
(3)
182,976
0
70,638
253,614
Mirit Horenshtein
        Hadar
EVP Finance
(4)
26,238
ׂׂ
ׁׂׂ(5)
0
—
26,238
Dr. Mitchell
        Shirvan
Chief Scientific and Development Officer
(6)
156,140
0
50,660
206,800
(1)
Amounts reported for the named executive officer and paid in
        New Israeli Shekels are converted from New Israeli Shekels to U.S. dollars using the 2023 average exchange rate as published by Bank
        of Israel of 3.689 New Israeli Shekels to 1 U.S. Dollar.
(2)
The amounts in this column include payments for a leased car
        or car maintenance, contributions to a pension fund, compensation fund, and continuing education fund, or payments in lieu of a continuing
        education fund.
(3)
This was for a part-time (75%) position.
(4)
This was for a part-time (75%) position.
(5)
This amount reflects a salary of 4.5 months during 2023,
        during which time Ms. Horenshtein Hadar served as a part-time consultant in a Strategy & Corporate Finance Advisory capacity.
(6)
This was for a part-time (80%) position.
Narrative Disclosure to Summary Compensation
Table
Base Salary
The named executive officers receive base
salaries to compensate them for services rendered to us. The base gross salary payable to each named executive officer is intended to
provide a fixed component of compensation reflecting the executive's skill set, experience, role, and responsibilities. The annual
base salaries for Ilan Hadar, Mirit Hornstein Hadar and Dr. Mitchell Shirvan, for 2023 were $253,614, $26,238, and $206,800, respectively.
113
Equity Compensation
From time to time, we
have granted equity awards under the Silexion Therapeutics Ltd. 2013 Equity Incentive Plan, which was replaced by the Silexion Therapeutics
Ltd. 2023 Equity Incentive Plan (the "2013 Plan" and "2023 Plan", respectively, collectively referred to as the
"Silexion Plan"), as incentives to attract, retain and motivate our named executive officers. During 2022, we granted Ilan
Hadar and Dr. Mitchell Shirvan 32,400 options and 16,200 options, respectively.
The vesting of options granted to Ilan Hadar
and Dr. Mitchell Shirvan occurs over a period of 48 months, provided that Ilan Hadar or Dr. Mitchell Shirvan, as applicable,
remain engaged by Silexion (or a Silexion affiliate) and subject to the Silexion
Plan. Upon
consummation of an initial public offering of Silexion's securities or an M&A Transaction (as defined in Silexion's articles
of association), which included the Business Combination, the vesting of those options was to accelerate, such that all unvested options
immediately vest, provided that such IPO or M&A Transaction was to be consummated after January 1, 2023.
Employment Agreements
Following the Closing, Silexion has entered
or will enter into employment agreements with each of its NEOs.
Silexion 2013 Equity Incentive
Plan and Silexion 2023 Equity Incentive Plan
Silexion has maintained the Silexion Plan
in order to provide additional incentives for employees, directors and consultants of Silexion, and to provide incentives to attract,
retain and motivate eligible persons whose present and potential contributions are important to Silexion's success. The 2013 Plan
was adopted on July 25, 2013 and was replaced by the 2023 Plan, which was adopted on April 4, 2023. For a complete description
of the 2013 Plan and the 2023 Plan, please see "
Silexion Share Incentive Plans
" below.
The Silexion Plan provides for grants of options
to purchase ordinary shares of Silexion, shares, restricted shares and restricted share units. As described above, during 2022, Silexion
granted option awards under the Silexion Plan to Ilan Hadar and Dr. Mitchell Shirvan.
Immediately prior to the effective time of
the Acquisition Merger, all outstanding Silexion options accelerated and became fully vested. At the effective time of the Acquisition
Merger, all Silexion options outstanding immediately prior to the Acquisition Merger automatically and without any action on the part
of any Silexion option holder or beneficiary thereof, were assumed by New Silexion, and each such Silexion option was converted into an
option to purchase New Silexion ordinary shares (based on the equity exchange ratio for Silexion under the Business Combination Agreement).
In addition, immediately prior to the completion
of the Business Combination, New Silexion adopted the 2024 Equity Incentive Plan (described below), which provides for the grant of equity-based incentive
awards to its employees, directors, office holders, service providers and consultants in order to incentivize them to increase their efforts
on behalf of New Silexion and to promote the success of New Silexion's business.
114
Outstanding Equity Awards at Fiscal Year-End
The following table provides information regarding
equity awards held by Silexion's named executive officers that were outstanding as of December 31, 2023. The award listed in
this table was granted under the Silexion Plan, which is summarized above under "
— Narrative
Disclosure to Summary Compensation Table — Silexion 2013 Equity Incentive Plan and Silexion 2023 Equity Incentive Plan
."
Option Awards
Name
Equity
Incentive
Plan Awards:
Number of
Unearned
Shares,
Units or
Other Rights
That Have
Not Vested
(#)
(1)
Equity
Incentive
Plan Awards:
Market Value of
Unearned
Shares.
Units or
Other Rights
That Have
Not Vested
($)
Ilan Hadar
32,400
—
Dr. Mitchell Shirvan
16,200
—
(1)
See details under "
Equity
        Compensation" section above.
Director Compensation
In the year ended December 31, 2023,
we did not pay any fees to, or make any equity or non-equity awards to, or pay any other compensation to the non-employee members
of our board of directors for their services as directors.
New Silexion Executive Compensation
Following the Closing, we intend to develop
an executive compensation program that is designed to align compensation with New Silexion's business objectives and the creation
of shareholder value, while enabling New Silexion to attract, retain, incentivize and reward individuals who contribute to the long-term success
of New Silexion. Decisions regarding the executive compensation program will be made by our compensation committee.
New Silexion Equity Compensation
It is anticipated that equity-based compensation
will continue to be an important element of executive compensation following the consummation of the Business Combination in order to
maintain a strong link between executive incentives and the creation of shareholder value. Upon the consummation of the Business Combination,
we granted 742,009 RSUs, in the aggregate, to directors of New Silexion and employees of New Silexion and its subsidiaries (of which 196,625
RSUs were granted to New Silexion directors) as a means of incentivizing them and aligning their interests with those of the shareholders
of the Company. We furthermore expect that the additional 607,241 New Silexion ordinary shares that will be available under the 2024 Equity
Incentive Plan (as referenced below) following the consummation of the Business Combination will be an important element of the new compensation
arrangements for New Silexion.
Silexion Share Incentive Plans
2013 Share Option Plan
Shares Reserved
under the 2013 Share Option Plan.
The total number
of authorized but unissued New Silexion ordinary shares available for issuance under Silexion's 2013 Share Option Plan (the "
2013
Plan
") is 33,828. Any option which has expired or has been cancelled, without having been exercised in full, is available
again for issuance under the 2013 Plan. Upon the termination of the 2013 Plan, any unissued New Silexion ordinary shares available under
the 2013 Plan shall cease to be reserved for the purpose of the 2013 Plan, other than New Silexion ordinary shares underlying then-outstanding options
under the 2013 Plan.
Administration.
Our
board of directors, or a duly authorized compensation committee of the board of directors, has the power to administer the 2013 Plan.
Subject to applicable laws and the relevant provisions of the 2013 Plan, any member of the designated committee is eligible to receive
options under the 2013 Plan. The committee has the authority, subject to applicable law and our articles of association, to interpret
the terms of the 2013 Plan and any option agreements granted thereunder, designate participants in the 2013 Plan, determine and amend
the terms of respective option agreements, including the exercise price of an option, the fair market value of the New Silexion ordinary
shares, the time and vesting schedule applicable to the option, accelerate or amend the vesting schedule applicable to an option, prescribe
the forms of option agreement for use under the 2013 Plan and take all other actions and make all other determinations necessary for the
administration of the 2013 Plan.
115
Eligibility.
The
2013 Plan provides for granting options under various tax regimes, including, without limitation, in compliance with Section 102
or Section 3(i) of the Israeli Tax Ordinance (the "
Ordinance
"), and for awards
granted to Silexion's United States employees or service providers, including those who are deemed to be residents of the United States
for tax purposes, Section 422 of the U.S. Internal Revenue Code of 1986, as amended (the "
Code
")
and Section 409A of the Code.
Options.
All
options granted pursuant to the 2013 Plan are evidenced by an option agreement, in a form approved, from time to time, by the committee
in its sole discretion. The option agreement sets forth the terms and conditions of the number of shares to which the option relates and
the type of option granted thereunder, the purchase price per share and the vesting schedule to which such option shall become exercisable.
Unless otherwise determined by the committee
or the board of directors and as stated in the option agreement, and subject to the conditions of the 2013 Plan, options become exercisable
under the following schedule: 25% of the shares covered by the option on the first anniversary of the date on which such option was granted
and 12.5% of the shares covered by the option at the end of each subsequent six-month period during the second, third and fourth years
from the date of grant, with the committee and/or board of directors reserving the exclusive authority to accelerate the periods for exercising
an option.
Each option shall expire after ten years
from the date of the grant thereof, or five years with respect to incentive stock options unless a shorter term of expiration is
otherwise designated by the committee.
Grants.
The
2013 Plan provides for the grant of options (including incentive stock options and nonqualified stock options).
Options granted under the 2013 Plan to Silexion
employees who are U.S. residents may qualify as "incentive stock options" within the meaning of Section 422 of the
Code, or may be non-qualified stock options. The exercise price of an option may not be less than the par value of the shares (if
the shares bear a par value) for which such option is exercisable. The exercise price of an Incentive Stock Option may not be less than
100% of the fair market value of the underlying share on the date of grant or such other amount as may be required pursuant to the Code,
and in the case of Incentive Stock Options granted to ten percent (10%) shareholders, not less than 110%.
Exercise.
An
option under the 2013 Plan may be exercised by providing us with a written notice of exercise and full payment of the exercise price for
such shares underlying the award, if applicable, in such form and method as may be determined by the committee and the trustee and permitted
by applicable law.
Transferability.
No
option shall be assignable, transferable or given as collateral or any right with respect to them given to any third party whatsoever,
and during the lifetime of the option-holder each and all of such option-holder's rights to purchase New Silexion ordinary
shares thereunder shall be exercisable only by the option-holder.
Termination
of Employment.
An option may be exercised after the
date of termination of option-holder's service or employment with Silexion or any of its affiliates or termination of an affiliate's
status as such only with respect to the number of options already vested and unexpired at the time of such termination according to the
vesting and expiration periods of the options set forth in the 2013 Plan, or under a different period prescribed by the committee or by
the board of directors and specified in relevant option agreement, provided however, that (i) such termination is without cause,
in which case the options shall be exercisable within not more than 90 days from the effective date of such termination, or (ii) such
termination is the result of death or disability of the option-holder, in which case the options shall be exercisable within 12 months,
and in the event of death, the option shall be exercisable by the option-holder's estate, all in accordance the 2013 Plan. If termination
of employment or service is for cause, any outstanding unexercised option (whether vested or non-vested), will immediately expire and
terminate, and the option-holder shall not have any right in connection to such outstanding options.
116
Voting Rights.
Option-holders shall
not have any of the rights or privileges of shareholders of New Silexion in respect of any New Silexion ordinary shares purchasable upon
the exercise of any part of an option unless and until, following exercise in accordance with the terms of the 2013 Plan and the option,
registration of the option-holder as holder of such New Silexion ordinary shares in New Silexion's register of members, but
in case of options and New Silexion ordinary shares held by the trustee, subject to the provisions of the 2013 Plan.
Dividends.
With
respect to all New Silexion ordinary shares (in contrast to options not exercised for New Silexion ordinary shares) issued upon the exercise
of options purchased by an option holder, the option holder, as a shareholder of New Silexion shall be entitled to receive dividends in
accordance with the quantity of such New Silexion ordinary shares and the amended and restated memorandum and articles of association
of New Silexion, and subject to any applicable taxation on distribution of dividends.
Transactions.
If
the outstanding shares of New Silexion shall at any time be changed or exchanged by declaration of a dividend, split, share subdivision,
combination or exchange of shares, recapitalization, or any other like event of New Silexion, then in such event only and as often as
the same shall occur, the number, class and kind of New Silexion ordinary shares (including New Silexion ordinary shares issuable pursuant
to the 2013 Plan, in respect of which options have not yet been exercised) subject to the 2013 Plan or subject to any options granted
thereunder, and the purchase prices of the options, shall be appropriately and equitably adjusted so as to maintain the proportionate
number of New Silexion ordinary shares without changing the aggregate purchase price of the options.
In the event of a merger or consolidation
of New Silexion or a sale of all, or substantially all, of our shares or assets or other transaction having a similar effect on New Silexion,
or change in the composition of the board of directors, or such other transaction or circumstances that the New Silexion Board determines
to be a relevant transaction, the merger agreement will provide for one or more of the following, without the consent of the option-holder:
(i) any outstanding option will be assumed or substituted by the successor corporation; (ii) the cancellation of such options
and a payment to the option-holder, as provided in the 2013 Plan; and (iii) the full exercisability of the option and full vesting
of the New Silexion ordinary shares subject to the option, followed by the cancellation of the option.
2023 Equity Incentive
Plan
The 2023 Equity Incentive (the
"2023
Plan"
) was adopted by our board of directors in 2023. The purpose of the 2023 Plan is to provide equity-based incentive
awards in order to link the compensation and benefits of the individuals and entities providing services to Silexion or its affiliates
with the success of Silexion and long-term shareholder value. The 2023 Plan enabled Silexion to grant options to purchase ordinary
shares of Silexion (currently, following the Business Combination, New Silexion ordinary shares), restricted shares and restricted share
units, all of which are referred to as "awards".
Shares Available for Grants.
The
total number of shares available for issuance under the 2023 Plan was determined from time to time by our board of directors, subject
to certain adjustments as described in the 2023 Plan. If any shares subject to awards under the 2023 Plan expires or otherwise terminates
in accordance with the terms thereunder, such shares shall become available for future grants thereunder.
Administration.
our board
of directors (currently, following the Business Combination, the board of directors of New Silexion), or a duly authorized committee of
its board of directors (the
"Administrator"
), is authorized to administer the
2023 Plan. Under the 2023 Plan, the Administrator has the authority, subject to applicable law, to interpret the terms of the 2023 Plan
and any award agreements or awards granted thereunder, designate recipients of awards, determine and amend the terms of awards, including
the number of awards granted, the exercise price of an award, the time and vesting schedule applicable to an award or the method of payment
for an award, accelerate or amend the vesting schedule applicable to an award, prescribe the forms of agreement for use under the 2023
Plan and take all other actions and make all other determinations necessary for the administration of the 2023 Plan.
The Administrator also has the authority to
determine the circumstances under which awards may be settled, cancelled, forfeited, exchanged, or surrendered under and in accordance
with the 2023 Plan of any or all awards or shares, and the authority to prescribe, amend and rescind rules and regulations relating to
the 2023 Plan, including the form of award agreements and rules governing the grant of awards in jurisdictions in which Silexion or any
affiliate operate, or to terminate the 2023 Plan at any time before the date of expiration of its ten-year term, provided that such
termination shall not materially affect the rights of grantees, to whom awards have already been granted.
117
Eligibility.
The
2023 Plan provides for granting awards under the Israeli tax regime, including compliance with Section 102 or Section 3(i) of
the Ordinance.
Grants.
All
awards granted pursuant to the 2023 Plan are evidenced by an award letter, in a form approved, from time to time, by the administrator
in its sole discretion. The award letter sets forth the terms and conditions of the award, including the type of award, number of shares
subject to such award, vesting schedule and conditions (including performance goals or measures) and the exercise price, if applicable.
Unless otherwise determined by the Administrator
and stated in the award letter, and subject to the conditions of the 2023 Plan, awards vest and become exercisable under the following
schedule: 25% of the shares covered by the award on the first anniversary of the vesting commencement date determined by the Administrator
(and in the absence of such determination, the date on which such award was granted) and the remaining 75% of the award shall vest (equally)
on a quarterly basis, over 12 quarters as of the commencement date's first annual anniversary; provided that the grantee remains
continuously as an employee or provides services to Silexion throughout such vesting dates.
Each award will expire ten years from
the date of the grant thereof, unless a shorter term of expiration is otherwise designated by the Administrator.
Awards.
The
2023 Plan provides for the grant of options, shares, restricted shares, RSUs, and other share-based awards.
Exercise.
An
award under the 2023 Plan may be exercised by providing Silexion (currently, New Silexion) a written notice of exercise and full payment
of the exercise price for such shares underlying the award, if applicable, in such form and method as may be determined by the Administrator
and permitted by applicable law. The 2023 Plan allows for a net exercise of awards (as may be included in the award letter or otherwise
approved by the Administrator). An award may not be exercised for a fraction of a share.
Transferability.
No
person other than the grantee shall have any right with respect to any award granted under the 2023 Plan. No transfer of any right to
any award or its underlying shares, by will or by the laws of descent, shall effectively bind Silexion (currently, New Silexion) unless
and until furnished with the certain signed and notarized documents, as described in the 2023 Plan.
Termination
of Engagement.
In the event of termination of a grantee's
employment or service with Silexion or any of its affiliates, for any reason other than death, retirement, disability or cause, any vested
and unexercised awards held by such grantee as of the date of termination may be exercised within 90-days after such date of termination,
unless otherwise determined by the Administrator, but in no event later than the date of expiration of the award as set forth in the award
letter. After such 90-days period, all such unexercised awards will terminate and the shares covered by such awards become available
for issuance under the 2023 Plan.
In the event of termination of a grantee's
employment or service with Silexion or any of its affiliates due to such grantee's death, retirement or permanent disability, any
vested but unexercised awards shall be exercisable (a) in the case of death, by such grantee's estate, personal representative
or beneficiary, or (b) in the case of retirement or Disability, by such grantee or his/her personal representative (as the case may
be), until the earlier of (i) 180 days following the date of termination for any such reason; or (ii) the date of expiration
of each such as set forth in the award letter. All such grantee's other awards shall expire upon the date of such termination.
Notwithstanding any of the foregoing, if a
grantee's employment or services with Silexion or any of its affiliates is terminated for "cause" (as defined in the
2023 Plan), all outstanding awards held by such grantee (whether vested or unvested) shall expire. With respect to any and all shares
owned by such grantee pursuant to the exercise of any and all awards granted under the 2023 Plan, the board of directors of Silexion may
convert such shares into deferred shares of Silexion.
118
Voting Rights.
Until
consummation of our initial public offering (or equivalent transaction, such as the Business Combination), shares underlying awards held
by grantees or the trustee, as applicable, were to be voted by an irrevocable proxy assigned to a person appointed by the board of directors.
Dividends.
Grantees
holding shares issuable or issued upon exercise of awards granted under the 2023 Plan will, as a shareholder of New Silexion, be entitled
to receive dividends and other distributions with respect to the underlying shares.
Transactions.
In
the event of any division or subdivision of Silexion's (currently, New Silexion's) issued and outstanding share capital, any
distribution of bonus shares (share split or subdivision), consolidation or combination of the share capital (reverse share split), reclassification
of the shares or any similar recapitalization event, as well as any reorganization, merger, consolidation, split-up, spin-off, combination,
repurchase, or exchange of the shares or other securities of Silexion (currently, New Silexion), or any other change in Silexion's
(currently, New Silexion's) corporate structure affecting the shares, the administrator may, in order to prevent diminution or enlargement
of the benefits or potential benefits intended to be made available under the 2023 Plan, adjust (A) the number and class of shares
that may be issued under the 2023 Plan; (B) the number, class, and exercise price of underlying shares for each outstanding award;
(C) any other term of the awards that in the administrator's opinion should be adjusted (including those concerning the vesting,
exercisability and term of outstanding awards); provided, that no adjustment shall be made by reason of the distribution of subscription
rights (rights offering) on outstanding shares.
Upon any such adjustment, references herein
to shares and underlying shares shall be construed to mean those shares of Silexion (currently, New Silexion) subject to the 2023 Plan
as determined by the Administrator following such adjustment. Any fractional shares resulting from such adjustment shall be rounded down
to the nearest whole number of share and Silexion (currently, New Silexion) shall have no obligation to make any cash or other payment
with respect to such fractional shares. The adjustments shall be made by the Administrator. If the applicable awards or underlying shares
are deposited with a trustee, all of the shares formed by such adjustments shall also be deposited with the trustee on the same terms
as such awards or underlying shares.
In the event of a merger, reorganization or
consolidation of Silexion (currently, New Silexion) with or into another incorporated entity, or its acquisition by another incorporated
entity by means of any transaction or series of related transactions, except any such merger, reorganization or consolidation in which
the issued shares of Silexion (currently, New Silexion) as of immediately prior to such transaction continue to represent, or are converted
into or exchanged for shares that represent, immediately following such merger, reorganization, or consolidation, at least a majority,
by voting power, of the outstanding shares of the surviving or acquiring incorporated entity; or a sale of all, or substantially all,
of our shares or assets or other transaction having a similar effect on our company, or change in the composition of the board of directors,
or liquidation or dissolution, or such other transaction or circumstances that our board of directors determines to be a relevant transaction,
then without the consent of the grantee, (i) unless otherwise determined by the Administrator, any outstanding award will be assumed
or substituted by such successor corporation or substituted by our company or by any affiliate of the successor corporation, as determined
by the Administrator, and (ii) regardless of whether or not the award is assumed or substituted, the Administrator may:
(a)
entitle a grantee to exercise an award, or to otherwise provide
        for the acceleration of such award's vesting schedule, as to all or part of its underlying shares, including with respect to awards
        that would not otherwise be exercisable or vested, under such terms and conditions as the Administrator shall determine, including the
        cancellation of all unexercised awards upon or immediately prior to the closing of a transaction or as of such other date (the
"Cut-Off Date"
),
        and/or the termination of all awards (whether vested but un-exercised or un-vested) as of the relevant Cut-Off Date, as of which
        they shall no longer be exercisable by the applicable grantees; and/or
(b)
provide for the cancellation of outstanding awards at or immediately
        prior to the closing of a transaction, and payment to the applicable grantee of a consideration determined by the Administrator to be
        fair in the circumstances (whether in shares, cash, other securities, property, or any combination thereof), taking into account the value
        of each underlying share of any such award's vested portion as reflected by the terms of such transaction, and the exercise price
        of each such underlying share, and subject to such terms and conditions as determined by the Administrator.
The Administrator shall have full authority
to select the method for determining the payment to the grantees, as well as to set such payment to zero, with respect to underlying shares
valued at less than their exercise price or to those of awards that would not otherwise be exercisable or vested, or to determine that
such payment be made only in excess of the exercise price.
119
New Silexion Share Incentive Plans
2024 Equity Incentive
Plan
Pursuant to written resolutions adopted
by our board of directors and shareholders prior to the Closing, we have approved and adopted the 2024 Equity Incentive Plan (the "
2024
Plan
"), which became effective immediately upon the Closing.
Upon the Closing, a total of 575,572 New Silexion
ordinary shares were reserved for issuance under the terms of the 2024 Plan, which, together with New Silexion ordinary shares allocated
for issuance under the existing 2013 Plan and 2023 Plan, equaled 10% of the total number of New Silexion ordinary shares on a fully diluted
basis immediately following the Closing. A summary of the other material terms of the 2024 Incentive Plan is provided below:
Administration
The compensation committee of our board of
directors is the administrator of the 2024 Plan. Except as provided otherwise under the 2024 Plan, the administrator has plenary authority
to grant awards pursuant to the terms of the 2024 Plan to eligible individuals, determine the types of awards and the number of shares
covered by the awards, establish the terms and conditions for awards and take all other actions necessary or desirable to carry out the
purpose and intent of the 2024 Plan.
Eligibility and Participation
The administrator selects the individuals
who participate in the 2024 Plan. Eligibility to participate is open to officers, directors and employees of, and other individuals who
provide bona fide services to or for, us or any of our subsidiaries. Our board of directors may also select as participants prospective
officers, employees and individual service providers who have accepted an offer of employment or another service relationship from us
or one of our subsidiaries. Any awards granted to such a prospect before the individual's start date may not become vested or exercisable,
and no shares may be issued to such individual, before the date the individual first commences performance of services with us.
Share Pool Under the 2024
Plan
The initial number of New Silexion ordinary
shares allocated to the 2024 Plan is 575,572. The number of New Silexion ordinary shares available under the 2024 Plan (the "
Share
Pool
") will be subject to the following annual allocations and adjustments:
The Share Pool will be increased automatically
on January 1 of each calendar year, beginning on January 1, 2025 and for each of the subsequent nine calendar years, through (and including)
January 1, 2034, in an amount equal to the lesser of (i) 5% of the number of New Silexion ordinary shares issued and outstanding as of
that January 1 date, or (ii) an amount determined by our board of directors prior to such date.
The following additional rules apply to the
number of New Silexion ordinary shares available under the Share Pool on an ongoing basis:
●
The Share Pool will be reduced by one share for each share made
        subject to an award granted under the 2024 Plan;
●
The Share Pool will be increased by the number of unissued shares
        underlying or used as a reference measure for any award or portion of an award granted under the 2024 Plan that is cancelled, forfeited,
        expired, terminated unearned or settled in cash, in any such case without the issuance of shares;
●
The Share Pool will be increased by the number of shares that
        are forfeited back or surrendered for no consideration to us after issuance due to a failure to meet an award contingency or condition
        with respect to any award or portion of an award granted under the 2024 Plan;
120
●
The Share Pool shall be increased, on the exercise date, by the
        number of shares withheld by or surrendered (either actually or through attestation) to the Company in payment of the exercise price of
        any award granted under the 2024 Plan; and
●
The Share Pool shall be increased, on the relevant date, by the
        number of shares withheld by or surrendered (either actually or through attestation) to the Company in payment of any tax withholding
        obligation that arises in connection with any award granted under the 2024 Plan.
In the event of a merger, consolidation, share
rights offering, statutory share exchange or similar event affecting the Company or a share dividend, share split, reverse share split,
separation, spinoff, reorganization, extraordinary dividend of cash or other property, share combination or subdivision, or recapitalization
or similar event affecting the capital structure of the Company, our board of directors will make equitable and appropriate substitutions
or proportionate adjustments to the Share Pool to reflect the transaction or event. Similar adjustments will be made to the award limitations
described below and to the terms of outstanding awards.
ISO Award Limit
The maximum number of New Silexion ordinary
shares that may be issued in connection with awards granted under the 2024 Plan that are intended to qualify as incentive stock options
under Section 422 of the Code is 575,572.
Types of Awards
General
.
The 2024 Plan enables the grant of share awards, performance shares, restricted share units, cash-based performance units, other share-based
awards, share options, share appreciation rights, and share unit awards, each of which may be granted separately or in tandem with other
awards. The administrator may establish sub-plans under the 2024 Plan under which awards that qualify for preferred tax treatment for
recipients in jurisdictions outside the U.S. may be granted.
We have adopted a sub-plan for Israeli participants,
which provides for granting awards in compliance with Section 102 ("
Section 102
") and
Section 3(i) of the Israeli Income Tax Ordinance (New Version), 5721-1961, as amended (the "
ITO
").
Section 102 allows employees, directors and officers who are not controlling shareholders and who are considered Israeli residents for
tax purposes to receive favorable tax treatment for compensation in the form of shares, options or certain other types of equity awards,
subject to certain terms and conditions. Our non-employee service providers and controlling shareholders who are considered Israeli residents
for tax purposes may be granted awards under Section 3(i) of the ITO, which do not provide for similar tax benefits as Section 102.
Out of the three tax tracks that are available
under Section 102 ((i) the "ordinary income track" with a trustee, (ii) the "capital gains track" with a trustee
and (iii) grants without a trustee and without a trust period), we have elected the "capital gain track" for grants to eligible
Israeli grantees as provided above, which may allow favorable tax treatment for such grantees.
Adjustments to Awards for Corporate Transactions
and Other Events
Mandatory Adjustments
.
In the event of a merger, amalgamation, consolidation,
share rights offering, share exchange or similar event affecting the Company (a "
Corporate Event
")
or a share dividend, share split, reverse share split, separation, spinoff, reorganization, extraordinary dividend of cash or other property,
share combination or subdivision, or recapitalization, capital reduction distribution or similar event affecting the capital structure
of the Company, the administrator will make equitable and appropriate substitutions or proportionate adjustments to:
●
the aggregate number and kind of shares or other securities that
        may be granted to eligible individuals under the 2024 Plan;
121
●
the maximum number of shares or other securities that may be
        issued with respect to incentive share options granted under the 2024 Plan;
●
the number of shares or other securities covered by each outstanding
        award and the exercise price, base price or other price per share, if any, and other relevant terms of each outstanding award; and
●
all other numerical limitations relating to awards, whether contained
        in the 2024 Plan or in award agreements.
Notwithstanding the foregoing, any fractional
shares resulting from the above mandatory adjustments will be eliminated.
Discretionary Adjustments
.
In addition to the adjustments specified above,
in the case of Corporate Events, the administrator may make such other adjustments to outstanding awards as it determines to be appropriate
and desirable, which adjustments may include, without limitation, (i) the cancellation of outstanding awards in exchange for payments
of cash, securities or other property or a combination thereof having an aggregate value equal to the value of such awards, (ii) the substitution
of securities or other property (including, without limitation, cash or other securities of the Company and securities of entities other
than the Company) for the shares subject to outstanding awards, and (iii) the substitution of equivalent awards, as determined in the
sole discretion of the administrator, of the surviving or successor entity or a parent thereof. The administrator may, in its discretion,
adjust the performance goals applicable to any awards to reflect any unusual or non-recurring events and other extraordinary items, impact
of charges for restructurings, discontinued operations and the cumulative effects of accounting or tax changes.
Repricing
.
The administrator may reprice any share options
or share appreciation rights without the approval of the shareholders of the Company. For this purpose, "reprice" means (i)
any of the following or any other action that has the same effect: (A) lowering the exercise price or base price of an option or share
appreciation right after it is granted other than an adjustment made pursuant to the provisions of the 2024 Plan, (B) any other action
that is treated as a repricing under applicable accounting principles; (C) cancelling a share option or share appreciation right at a
time when its exercise price or base price exceeds the fair market value of the underlying share, in exchange for another share option,
share appreciation right, restricted share or other equity, unless the cancellation and exchange occurs in connection with a merger, acquisition,
spin-off or other similar corporate transaction; and (ii) any other action that is considered to be a repricing under formal or informal
guidance issued by the primary securities market or exchange on which the shares are listed or admitted for trading.
Treatment of Awards upon Dissolution or Liquidation
or a Change in Control
Dissolution or Liquidation
.
Unless the administrator determines otherwise,
all awards outstanding under the 2024 Plan will terminate upon the winding up, liquidation or dissolution of the Company.
Amendment and Termination
Our board of directors or the compensation
committee may terminate, amend or modify the 2024 Plan or any portion of it at any time; provided, that, (i) if required to comply with
Cayman Islands law and any other applicable laws or marketplace or listing rules of a securities market or securities exchange (other
than any requirement from which the Company may opt out based on any available home country exemption), the Company shall obtain shareholder
approval of any 2024 Plan amendment in such a manner and to such a degree as required, and (ii) no such termination or amendment may materially
impair the rights of a participant with respect to a previously granted award (other than as required to comply with applicable law or
the rules of any securities exchange or market on which the shares are listed or to prevent adverse tax or accounting consequences to
the Company or the participant) without such participant's consent.
122
The 2024 Plan is scheduled to expire on August
14, 2034, which is ten years after the effective date of its adoption by our board of directors. After that time, no further grants may
be made under the 2024 Plan, but any then-outstanding grants will remain subject to the terms of the plan.
The foregoing description of the 2024 Incentive
Plan is qualified in its entirety by the full text of the 2024 Incentive Plan, which is attached to the registration statement of which
this prospectus forms a part as Exhibit 10.12 and incorporated herein by reference.
Rule 10b5-1 Sales Plans
Our directors and executive officers may
adopt written plans, known as Rule 10b5-1 plans, in which they will contract with a broker to buy or sell ordinary shares on a periodic
basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or executive officer when
entering into the plan, without further direction from them. The director or executive officer may amend a Rule 10b5-1 plan in some circumstances
and may terminate a plan at any time. Our directors and executive officers also may buy or sell additional shares outside of a Rule 10b5-1
plan when they are not in possession of material nonpublic information, subject to compliance with the terms of our insider trading policy.
Emerging Growth Company
Status
We are an "emerging growth company,"
as defined in the JOBS Act. As an emerging growth company, it is exempt from certain requirements related to executive compensation, including
the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total
compensation of its chief executive officer to the median of the annual total compensation of all of its employees, each as required by
the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection
Act.
CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Other than the compensation arrangements for
our directors and executive officers, which are described in the section titled "Executive Compensation", below is a description
of transactions since our formation on April 2, 2024 to which we have been a party, in which:
●
the amounts involved exceeded or will exceed $120,000; and
●
any of our directors, executive officers or holders of more than
        5% of our share capital, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or
        will have a direct or indirect material interest.
Related Party Transactions
Arrangements with Executive
Officers
Ilan Hadar serves as our Chief Executive
Officer and Chairman of the our Board. Mr. Hadar's employment agreement with us, as to be amended in the period following the
Closing of the Business Combination, subject to corporate approvals, will provide for him to receive an annual base salary of $357,820
(based on the average exchange rate for 2023, as published by the Bank of Israel), customary disbursements toward his providence fund,
further education fund and severance pay fund, and other fringe benefits commensurate with such position. During 2022, Silexion granted
Mr. Hadar 32,400 options to purchase New Silexion ordinary shares, vesting over a period of 48 months, provided that Mr. Hadar
remains engaged by us (or a Silexion affiliate) at the end of each vesting period and subject to the Silexion
Plan.
Upon completion of the Business Combination, the vesting of all such options is expected to accelerate, such that all unvested options
shall become fully vested at that time.
Mirit Horenshtein Hadar, our Executive VP of Finance, Chief Financial Officer and Secretary,
is Mr. Hadar's spouse. Ms. Horenshtein Hadar's employment agreement with us provides for her to receive an annual base
salary of $234,210 (based on the average exchange rate for 2023, as published by the Bank of Israel), as well as customary disbursements
toward her providence fund, further education fund and severance pay fund, and other fringe benefits commensurate with such position.
123
Indemnification Agreements
On the date of, and in connection with,
the Closing of the Business Combination, the Company entered into indemnification agreements with each of its directors and executive
officers, which provide for indemnification and advancements by the Company of certain expenses and costs under certain circumstances.
The indemnification agreements provide that we will indemnify each of its directors and executive officers against any and all expenses
incurred by that director or executive officer because of his or her status as a director or officer of New Silexion, to the fullest extent
permitted under Cayman law and the Articles.
The foregoing description of the indemnification agreements does not purport to be complete and is qualified
in its entirety by reference to the text of the form of indemnification agreement that is filed as Exhibit 10.6 to the registration statement
of which this prospectus forms a part, which is incorporated herein by reference.
Conversion Transaction
with GIBF
Immediately following the Closing of the
Business Combination, Guangzhou Sino-Israel Bio-Industry Investment Fund I ("GIBF") beneficially owned 20.3%
of our issued and outstanding share capital. GIBF had held the remaining 49% of the issued and outstanding share capital of our 51%-held
Chinese subsidiary, Silenseed (China) Ltd. (which 49% interest had been received by it in return for its equity investments in the Chinese
subsidiary, rather than equity investments directly in us). In connection with the consummation of the Business Combination, GIBF was
to exchange its entire holdings in the Chinese subsidiary for preferred shares of Silexion according to the terms set out in the contract
for the establishment of the Chinese subsidiary, dated August 30, 2021, as amended, which preferred shares were to be automatically
converted into 1,812,525 New Silexion ordinary shares in accordance with the equity exchange ratio for our shareholders' exchange
of shares of Silexion for our shares under the Business Combination Agreement.
However, in order to simplify the transfer
of GIBF's 49% interest in our Chinese subsidiary to our company, in lieu of transferring that interest to Silexion, GIBF instead
transferred the interest directly to New Silexion pursuant to an Agreement on Arrangements Related to Equity Interest Conversion, dated
as of August 5, 2024 (the "GIBF Conversion Agreement"). As consideration for its transfer of that 49% interest to us, GIBF
received 1,835,733 New Silexion ordinary shares at the Closing. GIBF furthermore received an additional 70,785 of our ordinary shares
upon consummation of the Business Combination due to the conversion of our shares that were issued to it upon settlement of RSUs of Silexion
that were subject to accelerated vesting at the Closing. Those RSUs were granted to GIBF subject to GIBF's providing certain services
to us in connection with the transfer of funds from our Chinese subsidiary to us. Avner Lushi and Shlomo Noy, both of whom serve as our
directors since the Closing, share voting and investment power over the 1,987,082 of ourordinary shares beneficially owned by GIBF after
the Closing.
PIPE Financing
In connection with, and immediately prior
to the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity financing (the "PIPE
Financing"), whereby Moringa sold to Greenstar, LP (the "PIPE Investor"), a Cayman Islands exempted limited partnership
and affiliate of the Moringa Sponsor, 200,000 newly issued Moringa ordinary shares (the "PIPE Shares") at a price of $10.00
per share, pursuant to the PIPE Agreement, dated as of August 15, 2024, by and among Moringa, us and the PIPE Investor. Those 200,000
shares automatically converted upon the Closing of the Business Combination into an equivalent number of our ordinary shares, or the PIPE
Shares. The PIPE Investor is entitled to customary registration rights in respect of the PIPE Shares under the PIPE Agreement, pursuant
to which we have agreed that, within 60 days after the Closing Date, it will file with the SEC a registration statement registering the
resale of the PIPE Shares by the PIPE Investor, and use its commercially reasonable efforts to have that registration statement be declared
effective by 180 days after the Closing Date (or 90 days after the Closing Date if the SEC does not review that filing).
124
The funds raised from the PIPE Financing,
together with remaining funds in Moringa's trust account after payments to redeeming public shareholders of Moringa, were used for
financing support for Moringa and New Silexion, as well as for payment to service providers to whom outstanding amounts were owed by Moringa,
including parties that had provided financial advisory services and capital markets advisory services to Moringa during the period leading
up to the Closing.
The foregoing summary provides only a brief
description of the PIPE Agreement and does not purport to be complete. The summary is qualified in its entirety by the full text of the
PIPE Agreement, a copy of which serves as Exhibit 10.2 to the registration statement of which this prospectus forms a part, and which
is incorporated herein by reference.
Amended and Restated Sponsor
Promissory Note
Effective as of the Closing, we issued to
the Sponsor, and Sponsor accepted, in amendment and restatement, and replacement, in their entirety, of all existing promissory notes
issued by Moringa to the Sponsor from the IPO until the Closing (and as to which the obligations of Moringa were assigned to us upon the
Closing), the A&R Sponsor Promissory Note in an amount of $3,433,000, which reflected the total amount owed by Moringa to the Sponsor
through the Closing Date. The maturity date of the A&R Sponsor Promissory Note is the 30-month anniversary of the Closing Date (i.e.,
February 15, 2027). Amounts outstanding under the A&R Sponsor Promissory Note may be repaid (unless otherwise decided by us) only
by way of conversion into our ordinary shares ("
Note Shares
") in accordance with the
terms set forth in the form of A&R Sponsor Promissory Note. Us and the Sponsor may also convert amounts outstanding under the A&R
Sponsor Promissory Note at the price per share at which we conduct an equity financing following the Closing, subject to a minimum conversion
amount of $100,000, in an amount of Note Shares constituting up to thirty percent (30%) of the number of our ordinary shares issued and
sold by us in such equity financing. The Sponsor may also elect to convert amounts of principal outstanding under the note into our ordinary
shares at any time following the 24-month anniversary of the Closing Date, subject to a minimum conversion of $10,000, at a price per
share equal to the volume weighted average price of the our ordinary shares on the principal market on which they are traded during the
20 consecutive trading days prior to the conversion date.
The foregoing summary provides only a brief
description of the A&R Sponsor Promissory Note and does not purport to be complete. The summary is qualified in its entirety by the
full text of the A&R Sponsor Promissory Note, a copy of which serves as Exhibit 10.5 to the registration statement of which this prospectus
forms a part, and which is incorporated herein by reference.
Amended and Restated Registration
Rights and Lock-Up Agreement
Prior to the Closing under the Business
Combination Agreement, on August 14, 2024, us, Moringa, Moringa Sponsor, the distributees of the Sponsor Investment Shares (as defined
under the Business Combination Agreement), certain of our pre-Business Combination shareholders and the PIPE Investor entered into (and
EarlyBird will be bound by) an amended and restated registration rights and lock-up agreement which became effective as of the Closing
of the Business Combination (the "A&R Registration Rights and Lock-Up Agreement"). Under the agreement, we have assumed
Moringa's existing obligations under Moringa's prior registration rights agreement (entered into in connection with Moringa's
initial public offering, or IPO) and has granted registration rights to the Moringa Sponsor, the distributees of Sponsor Investment Shares,
certain of our pre-Business Combination shareholders, the PIPE Investor and EarlyBird with respect to certain securities of ours.
Under the A&R Registration Rights and
Lock-Up Agreement, we have agreed to provide the holders party thereto customary demand and shelf registration rights (subject to certain
minimum size offerings) and piggy-back rights on primary and secondary offerings, subject to customary cut-back provisions.
125
Under the lock-up provisions of the agreement,
lock-up periods apply following the Closing to of our securities that are held by the holders who are party to the agreement, subject
to permitted transfers to certain categories of "Permitted Transferees". Specifically, those lock-up periods apply to the
following categories of securities for the following periods of time post-Closing:
●
Sponsor Investment Shares and
        securities held by former Silexion shareholders
: (A) 50% of the Sponsor Investment Shares held by the Sponsor and its distributees
        and 50% of the New Silexion securities held by the former Silexion shareholders who are party to the agreement, in each case, upon the
        Closing, are subject to a lock-up period ending on the earlier of (i) six (6) months after the completion of the Business Combination,
        and (ii) the date on which New Silexion will consummate a liquidation, merger, amalgamation, share exchange, reorganization, or other
        similar transaction after the Business Combination that results in all of our shareholders having the right to exchange their ordinary
        shares for cash, securities or other property, and (B) the other 50% of the Sponsor Investment Shares held by the Sponsor and its distributees
        and 50% of the our securities held by the former Silexion shareholders party to the agreement, in each case, upon the Closing, will be
        subject to a lock-up period that will end on the earliest of (x) six (6) months after the date of the consummation of the Business Combination,
        (y) the date on which we consummate a liquidation, merger, amalgamation, share exchange, reorganization, or other similar transaction
        after the Business Combination that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities
        or other property, or (z) the date on which the last reported sale price of our ordinary shares equals or exceeds $12.00 per share (as
        adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20
        trading days within any 30-trading day period.
●
Private Shares and Private Warrants:
The lock-up period on all New Silexion ordinary shares issued pursuant to the SPAC Merger in exchange for private placement shares and
        private placement warrants purchased by or issued to the Sponsor and EarlyBird concurrently with Moringa's initial public offering
        will remain (as provided in the documentation for Moringa's initial public offering) 30 days after the Closing.
●
Representative Shares
.
        The lock-up period on all Representative Shares (as defined in the Amended and Restated Registration Rights and Lock-Up Agreement) that
        are held by EarlyBird will remain (as provided in the documentation for Moringa's initial public offering) three months after the
        Closing.
●
Note Shares and PIPE Shares
.
        Note Shares issued to the Sponsor upon conversion of amounts due under the A&R Sponsor Promissory Note and PIPE Shares issued to the
        PIPE Investor will not be subject to any lock-up periods following the Closing.
The foregoing summary provides only a brief
description of the A&R Registration Rights and Lock-Up Agreement and does not purport to be complete. The summary is qualified in
its entirety by the full text of the A&R Registration Rights and Lock-Up Agreement, which serves as Exhibit 10.4 to the registration
statement of which this prospectus forms a part, and which is incorporated herein by reference.
BENEFICIAL
OWNERSHIP OF SECURITIES
The following table sets forth information known to the Company regarding the beneficial
ownership of New Silexion ordinary shares as of October           , 2024 by:
●
each person who is the beneficial owner
        of more than 5% of the outstanding New Silexion ordinary shares;
●
our named executive officer and directors;
        and
●
all of our executive officers and directors
        as a group.
126
Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person
has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including
options and warrants that are currently exercisable or exercisable within 60 days. In computing the number of ordinary shares beneficially
owned by a person and the percentage ownership, we include, as outstanding, those ordinary shares that are subject to warrants held by
that person that are currently exercisable or exercisable within 60 days of October        , 2024. We do not deem
those shares to be outstanding, however, for the purpose of computing the percentage ownership of any other person.
Unless otherwise indicated, we believe that
all persons named in the table have sole voting and investment power with respect to all New Silexion ordinary shares beneficially owned
by them.
The percentage ownership of New Silexion ordinary shares is based on      
        New Silexion ordinary shares outstanding as of October           , 2024.
Name and Address of Beneficial Owner
(1)
Number of Shares Beneficially
        Owned
Approximate Percentage
        of Outstanding Ordinary Shares
Directors and Executive
        Officers of New Silexion:
Ilan Hadar
280,438
(2)
2.0
%
Dror Abramov
39,829
*
Ruth Alon
54,325
*
Ilan Levin
(3)
2,066,610
(4)
14.8
%
Avner Lushi
(5)
1,987,082
(6)
14.4
%
Shlomo Noy
(7)
1,987,082
(6)
14.4
%
Dr. Mitchell Shirvan
196,992
(8)
1.4
%
Mirit Horenshtein Hadar, CPA
56,772
*
All executive officers
        and directors as a group (8 individuals)
4,682,048
33
%
Five Percent Holders:
Moringa Sponsor, LP and affiliated entities
(3)
2,066,610
(4)
14.8
%
Guangzhou Sino-Israel Biotech Fund
(9)
1,987,082
(6)
14.4
%
Wildcat Partner Holdings LP
(10)
1,020,852
7.4
%
*
Less than 1%.
(1)
Unless otherwise noted, the business address of each beneficial owner listed in the above table is c/o
        Silexion Therapeutics Corp, 12 Abba Hillel Road, Ramat Gan, Israel 5250606.
(2)
Includes 129,045 New Silexion ordinary shares issuable upon exercise
        of options, at an exercise price of $6.72 per share, all of which are vested and currently exercisable.
(3)
The shares reported in this row are held of record by the Sponsor,
        Moringa Sponsor, LP, and/or by the PIPE Investor, Greenstar, L.P., each a Cayman Islands exempted limited partnership, as described in
        footnote (4) below. Moringa Partners Ltd., an Israeli company that is wholly-owned by Mr. Ilan Levin, serves as the sole general partner
        of each of the Sponsor and the PIPE Investor. Mr. Levin, a director of New Silexion, is the sole director of that general partner. As
        a result of his ownership of that general partner, Mr. Levin possesses sole voting and investment authority with respect to the shares
        indirectly held by the Sponsor and the PIPE Investor. The limited partnership interests of the Sponsor and the PIPE Investor are held
        by various individuals and entities, including Mr. Levin. Mr. Levin disclaims beneficial ownership of the securities held by the Sponsor
        and the PIPE Investor other than to the extent of his direct or indirect pecuniary interest in such securities. The address of each of
        the entities beneficially owning the shares that are reported in this row is c/o Moringa Acquisition Corp, 250 Park Avenue, 7
th
floor, New York, NY 10177.
127
(4)
Consists of the total of: (i) 1,337,325 New Silexion ordinary
        shares issued to the Sponsor as Sponsor Investment Shares (as defined under the Business Combination Agreement); (ii) 352,857 New Silexion
        ordinary shares issued to the Sponsor upon the Closing of the Business Combination due to the conversion, on a one-for-one basis, of the
        352,857 Moringa private shares held by it; (iii) 176,429 New Silexion ordinary shares underlying New Silexion warrants issued to the Sponsor
        upon the Closing of the Business Combination due to the conversion, on a one-for-one basis, of the 176,429 Moringa private warrants held
        by the Sponsor (which New Silexion warrants will be exercisable beginning 30 days after the Closing Date); and (iv) 200,000 New Silexion
        ordinary shares issued to Greenstar, L.P., the PIPE Investor, as PIPE Shares in respect of the PIPE Financing. The foregoing beneficial
        ownership of New Silexion ordinary shares by the Sponsor does not include any Note Shares that may be issued to the Sponsor following
        the Closing upon conversion of amounts owed by New Silexion to the Sponsor under the A&R Sponsor Promissory Note, as the potential
        number of Note Shares, and the timing of issuance of Note Shares, cannot be determined in advance.
(5)
The shares reported in this row consist entirely of New Silexion
        ordinary shares held of record by Guangzhou Sino-Israel Biotech Fund ("
GIBF
"), with
        respect to which Mr. Lushi possesses shared voting and investment authority as a result of his serving as a Managing Partner and CEO of
        GIBF.
(6)
Includes 1,835,733 New Silexion ordinary shares issued to GIBF
        at the Closing in respect of its transfer of its noncontrolling interest in our Chinese subsidiary, Silenseed (China) Ltd., to New Silexion
        pursuant to the Chinese Subsidiary Transfer.
(7)
The shares reported in this row consist entirely of New Silexion
        ordinary shares held of record by GIBF, with respect to which Mr. Noy possesses shared voting and investment authority as a result of
        his serving as Chief Medical Officer of GIBF.
(8)
Includes 64,522 New Silexion ordinary shares issuable upon exercise
        of options, at an exercise price of $6.72 per share, all of which are vested and currently exercisable.
(9)
The address of this shareholder is 34 Ha'Barzel St., Tel-Aviv
        6971052 Israel. Each of Avner Lushi and Shlomo Noy may be deemed to share voting and investment power over the securities beneficially
        owned by GIBF.
(10)
The address of this shareholder is 301 Commerce Street, Suite
        3150, Fort Worth, Texas 76102. Len Porter may be deemed to have sole voting and investment power over the securities beneficially owned
        by Wildcat Partner Holdings LP.
128
DESCRIPTION OF SHARE
CAPITAL
In connection with the consummation of the
Business Combination, New Silexion adopted the Articles. The following summary of the material terms of New Silexion's securities
is not intended to be a complete summary of the rights and preferences of such securities. You are encouraged to read the Articles and
the agreements governing New Silexion's warrants in their entirety, which serve as Exhibit 3.1 and Exhibits 4.1 and 4.2, respectively,
to the registration statement of which this prospectus forms a part, along with the applicable provisions of Cayman Islands law, for a
complete description of the rights and preferences of New Silexion's securities.
Authorized and Outstanding Share Capital
The Articles of New Silexion authorize the
issuance of 200,000,000 shares, consisting of 200,000,000 ordinary shares, $0.0001 par value per share. As of October 15, 2024, there
were 13,827,814 New Silexion ordinary shares outstanding. All of such outstanding New Silexion ordinary shares were validly issued, fully
paid and non-assessable.
129
Ordinary Shares
Voting Power
Holders of New Silexion ordinary shares are
entitled to one vote in respect of each share held of record by such holder on all matters to be voted on by shareholders.
Dividends
Subject to applicable law, holders of New
Silexion ordinary shares are entitled to receive dividends when, as and if declared by the New Silexion Board, payable in cash, property
or shares.
Winding Up, Liquidation
and Dissolution
Upon New Silexion's winding up and liquidation and after payment in full of all amounts required
to be paid to creditors, the holders of New Silexion ordinary shares are entitled to receive a pro rata share of New Silexion's
remaining assets available for distribution.
Preemptive or Other Rights
Holders of New Silexion ordinary shares will
not be entitled to preemptive rights, and New Silexion ordinary shares will not be subject to conversion, redemption or sinking fund provisions.
Appointment of Directors
The New Silexion Board will consist of up to nine (9) directors and not less than three (3) directors,
unless increased or decreased from time to time by Ordinary Resolution in a general meeting.
Directors will generally be appointed by an
Ordinary Resolution passed at each annual general meeting.
Prior to each annual general meeting, the
New Silexion Board (or a nominating committee established by the New Silexion Board for such purpose) may select, via a resolution adopted
by a majority of the New Silexion Board or such committee, a number of persons to be proposed to the shareholders for appointment as directors
at such annual general meeting, for service until the next annual general meeting (the "Nominees"). Any shareholder entitled
under applicable law to propose one or more persons as nominees for appointment as directors at an annual general meeting (each such nominee,
an "Alternate Nominee") may make such proposal only if a written notice of such shareholder's intent to that effect
has been given to the Secretary of the Company (or, if there is no such Secretary, the chief executive officer) within the periods set
out in the Articles.
Unless the New Silexion Board resolves that
the appointment of Nominees or Alternate Nominees will be determined based on those Nominees or Alternate Nominees receiving the highest
number of votes of Members in favor of their appointment— even if less than a majority of all Members' votes that are cast,
the Nominees or Alternate Nominees shall be appointed by Ordinary Resolution at the annual general meeting at which they are proposed
for appointment. If the appointment of the Nominees or Alternate Nominees proposed to be appointed would cause the total number of directors
(including those then in office) to exceed the maximum number, then any directors then in office who are not named as Nominees or Alternate
Nominees will cease to hold office following the conclusion of such annual general, if any such Nominees or Alternate Nominees are appointed
in such meeting, and upon such Nominees or Alternate Nominees taking office. If (a) the appointment of the Nominees or Alternate Nominees
proposed to be appointed would not cause the total number of directors to exceed the maximum, or (b) no Nominees or Alternate Nominees
are proposed to be appointed at an annual general meeting by either the Board or Members, or (c) no Nominees or Alternate Nominees are
eventually appointed in such annual general meeting — all directors then in office shall continue to hold office until the convening
of a general meeting at which Nominees or Alternate Nominees shall be proposed and appointed, and where such appointment would cause the
total number of directors to exceed the maximum.
130
Each director will hold office until the next
succeeding annual general meeting and until his or her successor is appointed and qualified, or until such director's earlier death,
resignation, disqualification or removal. The Articles will not provide for cumulative voting for the appointment of directors.
New Silexion
Warrants
Following the Closing of the Business Combination
and as of October 1, 2024, there were 5,940,000 New Silexion warrants to purchase New Silexion ordinary shares outstanding, consisting
of 5,750,000 New Silexion public warrants issued upon conversion of an equivalent number of Moringa public warrants and 190,000 New Silexion
private warrants issued upon conversion of an equivalent number of Moringa private warrants (of which 176,429 and 13,571 private warrants
are held by the Sponsor and EarlyBird, respectively). In connection with the Closing, each Moringa warrant was exchanged for a New Silexion
warrant on substantially similar terms, including exercise price.
Each New Silexion public warrant entitles the registered holder to purchase one New Silexion ordinary share
at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing one month after the Closing. However,
no New Silexion public warrants will be exercisable for cash unless there is an effective and current registration statement covering
the New Silexion ordinary shares issuable upon exercise of the New Silexion public warrants and a current prospectus relating to such
New Silexion ordinary shares. Notwithstanding the foregoing, if a registration statement covering the New Silexion ordinary shares issuable
upon exercise of the New Silexion public warrants is not effective within 60 business days from the closing of the Business Combination,
warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have
failed to maintain an effective registration statement, exercise New Silexion public warrants on a cashless basis pursuant to the exemption
provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or another
exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. In the case of a cashless exercise,
each holder would pay the exercise price by surrendering the warrants for that number of New Silexion ordinary shares equal to the quotient
obtained by dividing (x) the product of the number of New Silexion ordinary shares underlying the warrants, multiplied by the difference
between the exercise price of the warrants and the "fair market value" (defined below) by (y) the fair market value.
The "fair market value" for this purpose will mean the average reported last sale price of the ordinary shares for the five trading
days ending on the trading day prior to the date of exercise. The New Silexion public warrants will expire five years from the
Closing of the Business Combination (i.e., on August 15, 2029) at 5:00 p.m., New York City time.
The New Silexion private warrants are identical
to the New Silexion public warrants, except that each New Silexion private warrant will be exercisable for cash (even if a registration
statement covering the New Silexion ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis,
at the holder's option, and will not be redeemable by the Company, in each case so long as they are still held by the Sponsor, EarlyBird
or their respective affiliates.
From and after the time the New Silexion warrants
become exercisable, we may call them for redemption (excluding the New Silexion private warrants), in whole and not in part, at a price
of $0.01 per warrant, upon not less than 30 days' prior written notice of redemption to each warrant holder, if and only if
●
the reported last sale price of the ordinary shares equals or
        exceeds $18.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations and recapitalizations), for any
        20 trading days within a 30 trading day period commencing after the warrants become exercisable and ending on the third business day
        prior to the notice of redemption to warrant holders; and
●
a registration statement is then in effect with respect to the
        New Silexion ordinary shares underlying such warrants.
The right to exercise will be forfeited unless
the New Silexion warrants are exercised prior to the date specified in the notice of redemption. On and after the redemption date, a record
holder of a New Silexion warrant will have no further rights except to receive the redemption price for such holder's warrant upon
surrender of such warrant.
131
The redemption criteria for New Silexion warrants
have been established at a price which is intended to provide warrant holders a reasonable premium to the initial exercise price and provide
a sufficient differential between the then-prevailing share price and the warrant exercise price so that if the share price declines
as a result of our redemption call, the redemption will not cause the share price to drop below the exercise price of the warrants.
If New Silexion calls the New Silexion warrants
for redemption as described above, its management will have the option to require all holders that wish to exercise warrants prior to
redemption to do so on a "cashless basis." In such event, each holder would pay the exercise price by surrendering the warrants
for that number of New Silexion ordinary shares equal to the quotient obtained by dividing (x) the product of the number of New Silexion
ordinary shares underlying the warrants, multiplied by the difference between the exercise price of the warrants and the "fair market
value" (defined below) by (y) the fair market value. The "fair market value" shall mean the average reported last
sale price of the New Silexion ordinary shares for the 5 trading days ending on the third trading day prior to the date on which
the notice of redemption is sent to the holders of warrants.
The New Silexion warrants will be issued in
registered form under a warrant agreement between Continental Stock Transfer & Trust Company, as warrant agent, and New Silexion
(as assignee of Moringa). The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder
to cure any ambiguity or correct any defective provision, but requires the approval, by written consent or vote, of the holders of at
least 50% of the then outstanding public warrants in order to make any change that adversely affects the interests of the registered holders.
The exercise price and number of New Silexion
ordinary shares issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a share capitalization
or our recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuances of New Silexion
ordinary shares at a price below their respective exercise prices.
The New Silexion warrants may be exercised
upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form
on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price,
by certified or official bank check payable to us, for the number of warrants being exercised. The warrant holders do not have the rights
or privileges of holders of New Silexion ordinary shares and any voting rights until they exercise their warrants and receive New Silexion
ordinary shares. After the issuance of New Silexion ordinary shares upon exercise of the warrants, each holder will be entitled to one
vote for each share held of record on all matters to be voted on by shareholders.
Under the terms of the warrant agreement,
New Silexion (as assignee of Moringa) has agreed to use its best efforts to have declared effective a registration statement relating
to the New Silexion ordinary shares issuable upon exercise of the warrants and keep such registration statement and its included prospectus
current until the expiration of the warrants. However, we cannot assure you that we will be able to do so and, if we do not maintain a
current prospectus relating to the New Silexion ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise
their warrants for cash and we will not be required to net cash settle or cash settle the warrant exercise.
Warrant holders may elect to be subject to
a restriction on the exercise of their warrants such that an electing warrant holder would not be able to exercise their warrants to the
extent that, after giving effect to such exercise, such holder would beneficially own in excess of 9.9% of the New Silexion ordinary shares
outstanding.
No fractional shares will be issued upon exercise
of the New Silexion warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share,
we will, upon exercise, round up to the nearest whole number the number of New Silexion ordinary shares to be issued to the warrant holder.
Contractual Arrangements
with respect to the New Silexion private warrants
So long as the New Silexion private warrants
are still held by the Sponsor, EarlyBird or their affiliates, the Company will not redeem such warrants, and the Company will allow the
holders to exercise such warrants on a cashless basis (even if a registration statement covering the New Silexion ordinary shares issuable
upon exercise of such warrants is not effective). However, once any of the New Silexion private warrants are transferred from the Sponsor,
EarlyBird or their affiliates, these arrangements will no longer apply. Furthermore, because the New Silexion private warrants were issued
in a private transaction, the holders and their transferees will be allowed to exercise the New Silexion private warrants for cash even
if a registration statement covering the New Silexion ordinary shares issuable upon exercise of such warrants is not effective and receive
unregistered New Silexion ordinary shares.
132
Listing of Securities
Our ordinary shares and New Silexion warrants
are listed on the Nasdaq under the symbols "SLXN" and "SLXNW", respectively.
Transfer Agent and Registrar
The transfer agent and registrar for the New
Silexion ordinary shares and warrant agent for the New Silexion warrants is Continental Stock Transfer & Trust Company.
Anti-Takeover Provisions in Our Articles.
Some provisions of our Articles may discourage,
delay or prevent a change in control of our company or management that shareholders may consider favorable.
However, under Cayman Islands law, our directors
may only exercise the rights and powers granted to them under our Articles, as amended and restated from time to time, for a proper purpose
and for what they believe in good faith to be in the best interests of our company.
Authorized but Unissued shares
The authorized but unissued New Silexion ordinary
shares are available for future issuance without shareholder approval, subject to any limitations imposed by the listing standards of
the Nasdaq and the Articles. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee
benefit plans. The existence of authorized but unissued and unreserved New Silexion ordinary shares could make more difficult or discourage
an attempt to obtain control of New Silexion by means of a proxy contest, tender offer, merger or otherwise.
Shareholder Action; Extraordinary General
Meetings
Our Articles provide that shareholders may
take action by unanimous written resolutions or at annual or extraordinary general meetings. As a result, a holder controlling a majority
of New Silexion ordinary shares would not be able to amend the Articles or remove directors without holding a meeting of shareholders
called in accordance with the Articles or the shareholders of New Silexion passing unanimous written resolutions to approve the same.
Further, the Articles provide that only the chairperson of the Board, or the New Silexion Board pursuant to a resolution adopted by a
majority of the directors then in office — and not shareholders — may call extraordinary general meetings
of shareholders, thus prohibiting a holder of New Silexion ordinary shares from calling an extraordinary general meeting. These provisions
might delay the ability of shareholders to force consideration of a proposal or for shareholders controlling a majority of New Silexion
to take any action, including the removal of directors.
Advance Notice Requirements for Shareholder
Proposals and Director Nominations
The Articles provide that shareholders seeking
to bring business before our annual general meeting, or to nominate candidates for appointment as directors at its annual general meeting,
must provide timely notice. To be timely, a shareholder's notice will need to be delivered to the Secretary of New Silexion at its
principal executive offices not less than 90 days nor more than 120 calendar days prior to the one-year anniversary of
the preceding year's annual general meeting. In the event that no annual general meeting was held during the preceding year or the
date of the annual general meeting is more than 30 days before or more than 60 days after such anniversary date, to be timely,
a shareholder's notice must be so delivered no earlier than the close of business on the 120
th
day
prior to such annual general meeting and not later than the 90
th
day
prior to such annual general meeting or, if later, the 10
th
day
following the day on which public disclosure of the date of such annual general meeting is first made by New Silexion. The Articles
also specify certain requirements as to the form and content of a shareholders' notice. These provisions may preclude New Silexion
shareholders from bringing matters before our annual general meeting or from making nominations for directors at our annual general meeting.
133
Supermajority Requirements for the Amendment
of the Articles
Under the Companies Act (As Revised) of
the Cayman Islands, the Articles may be amended by a special resolution of shareholders, being a resolution passed by not less than two-thirds (2/3)
of our shareholders as being entitled to do so, vote in person or by proxy at a general meeting.
Board Vacancies
The Articles provide that any vacancy on
the New Silexion Board may be filled by the affirmative vote of a majority of the directors then in office, even if less than a quorum,
or by a sole remaining director, and not by our shareholders. Any director chosen to fill a vacancy will hold office until the next annual
general meeting and until his or her successor is duly appointed and qualified, or until his or her earlier death, resignation, disqualification
or removal. In addition, the number of directors constituting the then-authorized size of the New Silexion Board is permitted to
be set only by a resolution adopted by the Board.
Exclusive Forum Selection
The Articles provide that, unless New Silexion consents in writing to the selection
of an alternative forum and to the fullest extent permitted by law, the courts of the Cayman Islands have exclusive jurisdiction over
any claim or dispute arising out of or in connection with the Articles or otherwise related in any way to each shareholder's shareholding
in the Company, including but not limited to (i) any derivative action or proceeding brought on behalf of the Company, (ii) any
action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or
our shareholders, or (iii) any action asserting a claim arising pursuant to any provision of the Companies Act (As Revised) of the
Cayman Islands or the Articles, and each shareholder shall be deemed to have irrevocably submitted to the exclusive jurisdiction of the
courts of the Cayman Islands over all such claims or disputes.
However, such forum selection provisions will
not apply to suits brought to enforce any liability or duty created by the Securities Act or the Exchange Act. The Articles also
provide that, unless New Silexion consents in writing to the selection of an alternative forum, the federal district courts of the United States
of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act
or the Exchange Act. There is uncertainty as to whether a court would enforce that exclusivity provision. Furthermore, investors cannot
waive compliance with the U.S. federal securities laws and the rules and regulations thereunder.
Any person or entity purchasing or otherwise
acquiring any interest in New Silexion shares shall be deemed to have notice of and consented to the forum selection provisions in the
Articles.
The choice of forum provisions may limit a
shareholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with New Silexion or its directors,
officers, or other employees, which may discourage such lawsuits against New Silexion and its directors, officers, and other employees.
Alternatively, if a court were to find the choice of forum provisions contained in the Articles to be inapplicable or unenforceable in
an action, New Silexion may incur additional costs associated with resolving such action in other jurisdictions, which could harm its
business, results of operations, and financial condition.
134
Transactions with Interested Shareholders.
Cayman Islands law does not have a business
combination statute (like in Delaware) applicable to public companies prohibiting them from engaging in certain business combinations
with an "interested shareholder". As a result, we cannot avail ourselves of the types of protections afforded by a business
combination statute. However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders,
it does provide that such transactions must be entered into bona fide in the best interests of the company and for a proper corporate
purpose and not with the effect of constituting a fraud on the minority shareholders.
Limitation on Liability and Indemnification
of Directors and Officers
Cayman Islands law does not limit the extent
to which a company's memorandum and articles of association may provide for indemnification of officers and directors, except to
the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification
against willful default, willful neglect, actual fraud or the consequences of committing a crime. Our Articles provide that our directors
and officers shall be indemnified out of the assets of New Silexion against any liability, action, proceeding, claim, demand, costs, damages
or expenses, including legal expenses, whatsoever which they or any of them may incur as a result of any act or failure to act in carrying
out their functions other than such liability (if any) that they may incur by reason of their own actual fraud, wilful neglect or wilful
default. No such indemnified person shall be liable to New Silexion for any loss or damage incurred by New Silexion as a result (whether
direct or indirect) of the carrying out of their functions unless that liability arises through the actual fraud, wilful neglect or wilful
default of such indemnified person. No person shall be found to have committed actual fraud, wilful neglect or wilful default under the
foregoing unless or until a court of competent jurisdiction shall have made a finding to that effect.. In addition, the Articles provide
for the advancing of certain fees and costs to such indemnified persons and the purchase by New Silexion for insurance for the benefit
of its directors and officers as further described in the Articles.
Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to New Silexion directors, officers and controlling persons pursuant to the foregoing
provisions, or otherwise, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act
and is, therefore, unenforceable.
DESCRIPTION OF SECURITIES
OFFERED
We are offering up to                 
   ordinary shares, together with               ordinary warrants to purchase up to  
                    ordinary shares. We are also offering to those purchasers,
if any, whose purchase of our ordinary shares in this offering would otherwise result in such purchaser, together with its affiliates
and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding ordinary
shares immediately following the consummation of this offering, the opportunity, in lieu of purchasing ordinary shares, to purchase pre-funded
warrants to purchase ordinary shares. For each pre-funded warrant we sell, the number of ordinary shares we are offering will be decreased
on a one-for-one basis. The pre-funded warrants will be sold together with ordinary warrants in a fixed combination, with each pre-funded
warrant to purchase one ordinary share accompanied by one ordinary warrant to purchase one ordinary share. We are also registering the
ordinary shares issuable from time to time upon exercise of the pre-funded warrants and ordinary warrants offered hereby.
Ordinary Shares
The material terms and provisions of our ordinary shares are described under the caption
"Description of Share Capital" in this prospectus.
Pre-Funded Warrants
The following summary of certain terms and provisions of the pre-funded
warrants offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of pre-funded warrant the
form of which will be filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should
carefully review the terms and provisions of the form of pre-funded warrant for a complete description of the terms and conditions of
the pre-funded warrants.
The term "pre-funded" refers to the fact that the purchase price of our
ordinary shares in this offering includes almost the entire exercise price that will be paid under the pre-funded warrants, except for
a nominal remaining exercise price of $0.0001. The purpose of the pre-funded warrants is to enable investors that may have restrictions
on their ability to beneficially own more than 4.99% (or, at the election of each purchaser, 9.99%) of our outstanding ordinary shares
following the consummation of this offering the opportunity to make an investment in us without triggering their ownership restrictions,
by receiving pre-funded warrants in lieu of our ordinary shares which would result in such ownership of more than 4.99% (or, at the election
of each purchaser, 9.99%), and receive the ability to exercise their option to purchase the shares underlying the pre-funded warrants
at such nominal price at a later date.
135
Each pre-funded warrant is exercisable for one ordinary share, with an exercise price
equal to $0.0001 per ordinary share, at any time that the pre-funded warrant is outstanding. There is no expiration date for the pre-funded
warrants. The holder of a pre-funded warrant will not be deemed a holder of our underlying ordinary shares until the pre-funded warrant
is exercised.
Subject to limited exceptions, a holder of pre-funded warrants will not have the right
to exercise any portion of its pre-funded warrants if the holder (together with such holder's affiliates, and any persons acting
as a group together with such holder or any of such holder's affiliates) would beneficially own a number of ordinary shares in excess
of 4.99% (or, at the election of each purchaser, 9.99%) of the ordinary shares then outstanding after giving effect to such exercise.
The exercise price and the number of ordinary shares issuable upon exercise of the pre-funded
warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations,
reclassifications, reorganizations or similar events affecting our ordinary shares. The pre-funded warrant holders must pay the exercise
price in cash upon exercise of the pre-funded warrants, unless such pre-funded warrant holders are utilizing the cashless exercise provision
of the pre-funded warrants.
Upon the holder's exercise of a pre-funded warrant, we will issue the ordinary
shares issuable upon exercise of the pre-funded warrant within two trading days following our receipt of a notice of exercise, provided
that payment of the exercise price has been made (unless exercised to the extent permitted via the "cashless" exercise provision).
Prior to the exercise of any pre-funded warrants to purchase ordinary shares, holders of the pre-funded warrants will not have any of
the rights of holders of ordinary shares purchasable upon exercise, including the right to vote, except as set forth therein.
As an alternative to payment in immediately available funds, the holder may elect to
exercise the pre-funded warrant through a cashless exercise, in which the holder would receive upon such exercise the net number of ordinary
shares determined according to the formula set forth in the pre-funded warrant (in which case, the pre-funded warrants may only be exercised
via a "cashless" exercise provision).
In the event of a fundamental transaction, as described in the pre-funded warrants and
generally including any reorganization, recapitalization or reclassification of our ordinary shares, the sale, transfer or other disposition
of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more
than 50% of our outstanding ordinary shares, or any person or group becoming the beneficial owner of more than 50% of the voting power
represented by our outstanding ordinary shares, the holders of the pre-funded warrants will be entitled to receive upon exercise of the
pre-funded warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised
the pre-funded warrants immediately prior to such fundamental transaction without regard to any limitations on exercised contained in
the pre-funded warrants.
We do not intend to apply to list the pre-funded warrants on any securities exchange
or other trading system. Without an active trading market, the liquidity of the pre-funded warrants will be limited.
Ordinary Warrants
The following summary of certain terms and provisions of the ordinary
warrants offered together with the ordinary shares hereby is not complete and is subject to, and qualified in its entirety by, the form
of ordinary warrant, which will be filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors
should carefully review the terms and provisions set forth in the form of ordinary warrant.
Exercisability
. The ordinary warrants are exercisable
at any time after their original issuance and at any time up to the date that is five years after their original issuance. The ordinary
warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and,
at any time a registration statement registering the issuance of the ordinary shares underlying the ordinary warrants under the Securities
Act of 1933, as amended, or the Securities Act, is effective and available for the issuance of such shares, by payment in full in immediately
available funds for the number of ordinary shares purchased upon such exercise. If a registration statement registering the issuance of
ordinary shares underlying the ordinary warrants under the Securities Act is not effective or available the holder may, in its sole discretion,
elect to exercise the ordinary warrant through a cashless exercise, in which case the holder would receive upon such exercise the net
number of ordinary shares determined according to the formula set forth in the ordinary warrant. No fractional shares will be issued in
connection with the exercise of an ordinary warrant. In lieu of fractional shares, we will either pay the holder an amount in cash equal
to the fractional amount multiplied by the exercise price or round up to the next whole share.
136
Exercise Limitation
. A holder will not have
the right to exercise any portion of the ordinary warrant if the holder (together with its affiliates) would beneficially own in excess
of 4.99% (or, at the election of each purchaser, 9.99%) of the number of ordinary shares outstanding immediately after giving effect to
the exercise, as such percentage ownership is determined in accordance with the terms of the ordinary warrants. However, any holder may
increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall
not be effective until 61 days following notice from the holder to us.
Exercise Price
. The exercise price per whole
ordinary share purchasable upon exercise of the ordinary warrants is $        per share. The exercise price is subject
to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications
or similar events affecting our ordinary shares and also upon any distributions of assets, including cash, stock or other property to
our stockholders.
Transferability
. Subject to applicable laws,
the ordinary warrants may be offered for sale, sold, transferred or assigned without our consent.
Exchange Listing
. We do not intend to apply
to list the ordinary warrants on any securities exchange or nationally recognized trading system. Without an active trading market, the
liquidity of the ordinary warrants will be limited.
Fundamental Transactions.
In the event
of a fundamental transaction, as described in the ordinary warrants and generally including any reorganization, recapitalization or reclassification
of our ordinary shares, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation
or merger with or into another person, the acquisition of more than 50% of our outstanding ordinary shares, or any person or group becoming
the beneficial owner of more than 50% of the voting power represented by our outstanding ordinary shares, the holders of the ordinary
warrants will be entitled to receive upon exercise of the ordinary warrants the kind and amount of securities, cash or other property
that the holders would have received had they exercised the ordinary warrants immediately prior to such fundamental transaction without
regard to any limitations on exercised contained in the ordinary warrants.
Rights as a Stockholder
. Except as otherwise
provided in the ordinary warrants or by virtue of such holder's ownership of our ordinary shares, the holder of a ordinary warrant
does not have the rights or privileges of a holder of our ordinary shares, including any voting rights, until the holder exercises the
ordinary warrant.
Governing Law
. The ordinary warrants are governed
by New York law.
Placement Agent Warrants
The following summary of certain terms and provisions of the Placement
Agent warrants is not complete and is subject to, and qualified in its entirety by, the form of Placement Agent warrant, which will be
filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors should carefully review the
terms and provisions set forth in the form of Placement Agent warrant.
We have agreed to issue to the Placement Agent, or its designees, warrants to purchase
up to                  ordinary shares (which represents 7.0% of the aggregate number of
ordinary shares issued in this offering and issuable upon the exercise of the warrants and pre-funded warrants issued in this offering)
with an exercise price of $    per ordinary share (representing 125% of the public offering price per ordinary share) and exercisable
for five years from the date of the commencement of sales in this offering. The Placement Agent warrants issued in this offering
will otherwise have substantially the same terms as the ordinary warrants. The Placement Agent warrants and underlying ordinary shares
are registered on the registration statement of which this prospectus is a part.
137
MATERIAL
U.S. FEDERAL INCOME TAX CONSEQUENCES
The following discussion is a summary of certain
material U.S. federal income tax considerations generally applicable to the ownership and disposition of our ordinary shares and the exercise,
disposition and lapse of our warrants. The ordinary shares and the warrants are referred to collectively herein as our securities. All
prospective holders of our securities should consult their tax advisors with respect to the U.S. federal, state, local and non-U.S. tax
consequences of the ownership and disposition of our securities.
This discussion is not a complete analysis
of all potential U.S. federal income tax consequences relating to the ownership and disposition of our securities. This summary is based
upon current provisions of the Code, existing U.S. Treasury Regulations promulgated thereunder, published administrative pronouncements
and rulings of the U.S. Internal Revenue Service (the
"IRS"),
and judicial decisions,
all as in effect as of the date of this prospectus. These authorities are subject to change and differing interpretation, possibly with
retroactive effect. Any change or differing interpretation could alter the tax consequences to holders described in this discussion. There
can be no assurance that a court or the IRS will not challenge one or more of the tax consequences described herein, and we have not obtained,
nor do we intend to obtain, a ruling with respect to the U.S. federal income tax consequences to a holder of the ownership or disposition
of our securities.
Tax Consequences of Ownership
and Disposition of New Silexion Securities
Distributions on New Silexion ordinary shares
Subject to the PFIC rules discussed below, the gross amount of any distribution on New
Silexion ordinary shares that is made out of our current or accumulated earnings and profits (as determined for U.S. federal income tax
purposes) generally will be taxable to a U.S. Holder as ordinary dividend income on the date such distribution is actually or constructively
received. Any such dividends generally will not be eligible for the dividends received deduction allowed to corporations in respect of
dividends received from U.S. corporations. To the extent that the amount of the distribution exceeds our current and accumulated earnings
and profits (as determined under U.S. federal income tax principles), such excess amount will be treated first as a non-taxable return
of capital to the extent of the U.S. Holder's tax basis in its New Silexion ordinary shares, and thereafter as capital gain recognized
on a sale or exchange. However, it is not expected that New Silexion will maintain calculations of its earnings and profits principles.
U.S. Holders should therefore assume that any distribution by New Silexion with respect to New Silexion ordinary shares will be reported
as dividend income. U.S. Holders should consult their own tax advisors with respect to the appropriate U.S. federal income tax treatment
of any distribution received from New Silexion.
138
Subject to the PFIC rules discussed below,
dividends received by non-corporate U.S. Holders (including individuals) from a "qualified foreign corporation"
may be eligible for reduced rates of taxation, provided that certain holding period requirements and other conditions are satisfied. For
these purposes, a non-U.S. corporation will be treated as a qualified foreign corporation if it is eligible for the benefits of a
comprehensive income tax treaty with the United States that meets certain requirements. A non-U.S. corporation is also treated
as a qualified foreign corporation with respect to dividends it pays on shares that are readily tradable on an established securities
market in the United States. U.S. Treasury guidance indicates that shares listed on Nasdaq (such as the New Silexion ordinary
shares) will be considered readily tradable on an established securities market in the United States. There can be no assurance that
New Silexion ordinary shares will be considered readily tradable on an established securities market in future years. Further, New
Silexion will not constitute a qualified foreign corporation for purposes of these rules if it is a PFIC for the taxable year in which
it pays a dividend or for the preceding taxable year.
Subject to certain conditions and limitations,
non-refundable withholding taxes (at a rate not in excess of any applicable income tax treaty rate), if any, on dividends paid by
New Silexion may be treated as foreign taxes eligible for credit against a U.S. Holder's U.S. federal income tax liability
under the U.S. foreign tax credit rules. However, as a result of recent changes to the U.S. foreign tax credit rules, a withholding
tax generally may need to satisfy certain additional requirements in order to be considered a creditable tax for a U.S. Holder. New
we have not determined whether these requirements have been met with respect to any withholding tax that may apply to dividends paid by
New Silexion and, accordingly, no assurance can be given that any such withholding tax will be creditable. For purposes of calculating
the U.S. foreign tax credit, dividends paid on New Silexion ordinary shares will generally be treated as income from sources outside
the United States and will generally constitute passive category income. The rules governing the U.S. foreign tax credit are
complex. U.S. Holders should consult their tax advisors regarding the availability of the U.S. foreign tax credit under their
particular circumstances.
Sale, Taxable Exchange or Other Taxable Disposition
of New Silexion Securities
Subject to the PFIC rules discussed below,
upon any sale, exchange or other taxable disposition of any New Silexion security, a U.S. Holder generally will recognize gain or
loss in an amount equal to the difference between (i) the sum of (x) the amount cash and (y) the fair market value of any
other property, received in such sale, taxable exchange or other taxable disposition and (ii) the U.S. Holder's adjusted
tax basis in such New Silexion security. Any such gain or loss generally will be capital gain or loss and will be long-term capital
gain or loss if the U.S. Holder's holding period for such New Silexion security exceeds one year. Long-term capital gain
realized by a non-corporate U.S. Holder generally will be taxable at a reduced rate. The deductibility of capital losses is
subject to limitations.
This gain or loss generally will be treated
as U.S. source gain or loss. Accordingly, in the event that any non-U.S. tax (including withholding tax) is imposed upon such
sale, exchange or other taxable disposition, a U.S. Holder may not be able to utilize foreign tax credits in respect of such non-U.S. tax.
In addition, there may be other limitations on utilizing foreign tax credits even if a U.S. Holder has foreign source income or gain
in the same category from other sources. The rules governing foreign tax credits are complex and U.S. Holders are urged to consult
their tax advisers regarding the creditability of foreign taxes in their particular circumstances.
Exercise, Lapse or Redemption of a New Silexion
Public Warrant
Subject to the PFIC rules discussed below,
a U.S. Holder generally will not recognize gain or loss upon the acquisition of a New Silexion ordinary share on the exercise of
a New Silexion public warrant for cash. A U.S. Holder's tax basis in a New Silexion ordinary share received upon exercise of
the New Silexion public warrant generally will equal the sum of the U.S. Holder's tax basis in such New Silexion public warrant
and the exercise price. It is unclear whether a U.S. Holder's holding period for the New Silexion ordinary share received will
commence on the date of exercise of the New Silexion public warrant or the day following the date of exercise of the New Silexion
public warrant; in either case, the holding period will not include the period during which the U.S. Holder held the New Silexion
public warrant. If a New Silexion public warrant is allowed to lapse unexercised, a U.S. Holder generally will recognize a capital
loss equal to such holder's tax basis in the New Silexion public warrant.
139
The tax consequences of a cashless exercise
of a warrant are not clear under current law. Subject to the PFIC rules discussed below, a cashless exercise may not be taxable, either
because the exercise is not a realization event or because the exercise is treated as a recapitalization for U.S. federal income
tax purposes. In either situation, a U.S. Holder's tax basis in New Silexion ordinary shares received generally should equal
the U.S. Holder's tax basis in the New Silexion public warrants exercised therefor. If the cashless exercise was not a realization
event, it is unclear whether a U.S. Holder's holding period for the New Silexion ordinary shares received would be treated
as commencing on the date of exercise of the New Silexion public warrants or the day following the date of exercise of the New Silexion
public warrants; in either case, the holding period will not include the period during which the U.S. Holder held the New Silexion
public warrants. If the cashless exercise were treated as a recapitalization, the holding period of the New Silexion ordinary shares received
would include the holding period of the New Silexion public warrants.
It is also possible that a cashless exercise
could be treated in part as a taxable exchange in which gain or loss would be recognized. In such event, a U.S. Holder could be deemed
to have surrendered a number of New Silexion public warrants equal to the number of New Silexion ordinary shares having a value equal
to the exercise price for the total number of New Silexion public warrants to be exercised. In such case, subject to the PFIC rules discussed
below, the U.S. Holder would recognize capital gain or loss with respect to the New Silexion public warrants deemed surrendered in
an amount equal to the difference between the fair market value of the New Silexion ordinary shares that would have been received in a
regular exercise of the New Silexion public warrants deemed surrendered and the U.S. Holder's tax basis in the New Silexion
public warrants deemed surrendered. In this case, a U.S. Holder's aggregate tax basis in the New Silexion ordinary shares received
would equal the sum of the U.S. Holder's tax basis in the New Silexion public warrants deemed exercised and the aggregate exercise
price of such New Silexion public warrants. It is unclear whether a U.S. Holder's holding period for the New Silexion ordinary
shares would commence on the date of exercise of the New Silexion public warrants or the day following the date of exercise of the
New Silexion public warrants; in either case, the holding period will not include the period during which the U.S. Holder held the
New Silexion public warrants.
Due to the absence of authority on the U.S. federal
income tax treatment of a cashless exercise, including when a U.S. Holder's holding period would commence with respect to New
Silexion ordinary shares received, there can be no assurance regarding which, if any, of the alternative tax consequences and holding
periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult their tax advisors
regarding the tax consequences of a cashless exercise.
Possible Constructive Distributions
The terms of each New Silexion public warrant provide for an adjustment to the number
of New Silexion ordinary shares for which the New Silexion public warrant may be exercised or to the exercise price of the New Silexion
public warrant in certain events, as discussed in the section of this prospectus entitled "
Description
of New Silexion Securities — Warrants.
" An adjustment which has the effect of preventing dilution generally is not
taxable. U.S. Holders of New Silexion public warrants would, however, be treated as receiving a constructive distribution from New Silexion
if, for example, the adjustment increases such U.S. Holders' proportionate interest in our assets or earnings and profits (e.g.,
through an increase in the number of New Silexion ordinary shares that would be obtained upon exercise or through a decrease in the exercise
price of the New Silexion public warrants), which adjustment may be made as a result of a distribution of cash or other property to the
holders of New Silexion ordinary shares. Such constructive distribution to a U.S. Holder of New Silexion public warrants would be treated
as if such U.S. Holder had received a cash distribution from New Silexion generally equal to the fair market value of such increased interest
(taxed as described above under "—
Distributions on New Silexion ordinary shares
").
140
PFIC Rules
In General
The treatment of U.S. Holders of New
Silexion securities could be materially different from that described above if New Silexion is treated as a PFIC for U.S. federal
income tax purposes.
In general, a non-U.S. corporation is
a PFIC for U.S. federal income tax purposes for any taxable year in which, after applying certain look-through rules, (i) 50%
or more of the value of its assets (generally determined on the basis of a weighted quarterly average) consists of assets that produce,
or are held for the production of, passive income, or (ii) 75% or more of its gross income consists of passive income. Passive income
generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade
or business) and gains from the disposition of passive assets. Cash and cash equivalents generally are passive assets. The value of goodwill
will generally be treated as an active or passive asset based on the nature of the income produced in the activity to which the goodwill
is attributable. For purposes of the PFIC rules, a non-U.S. corporation that owns, directly or indirectly, at least 25% by value
of the stock of another corporation is treated as if it held its proportionate share of the assets of the other corporation and directly
received its proportionate share of the income of the other corporation.
The application of the PFIC rules to warrants
is uncertain. The Code provides that, to the extent provided in Treasury Regulations, if any person has an option to acquire shares of
a PFIC, the shares will be considered as owned by that person for purposes of the PFIC rules. Under proposed Treasury Regulations that
have a retroactive effective date, an option to acquire shares of a PFIC is generally treated as ownership of those PFIC shares. The remainder
of this discussion assumes that the PFIC rules will apply to New Silexion public warrants if New Silexion was a PFIC. However, U.S. Holders
should consult their tax advisers regarding the application of the PFIC rules to New Silexion public warrants prior to the finalization
of the proposed Treasury Regulations.
If non-U.S. corporation is treated as
a PFIC during a U.S. Holder's holding period, it will, with respect to such U.S. Holder, always be treated as a PFIC,
regardless of whether it satisfied either of the qualification tests in subsequent years, subject to certain exceptions (such as
upon making a "deemed sale" election).
The adverse impact of the PFIC rules on a
U.S. Holder that holds shares in a PFIC may generally be mitigated if the U.S. Holder makes a timely qualified electing fund
("
QEF
") election or mark-to-market election for the PFIC's first taxable
year as a PFIC in which the U.S. Holder held (or was deemed to hold) shares, or a QEF election along with an applicable purging election
(collectively, "
PFIC Elections
"). Further detail about the PFIC Elections is provided
below under "—
New Silexion Securities
".
New Silexion Securities
The annual PFIC income and asset tests in respect of New Silexion will be applied based
on the assets and activities of the combined business. Based on the projected composition of our income and assets, it cannot be determined
whether New Silexion will be classified as a PFIC for its taxable year that includes the date of the Business Combination or in any future
taxable year. Further, changes in the composition of our income or composition of our assets may cause New Silexion to be or become a
PFIC for the current or subsequent taxable years. Whether New Silexion is treated as a PFIC for U.S. federal income tax purposes is a
factual determination that must be made annually at the close of each taxable year and, thus, is subject to significant uncertainty.
If Moringa is determined to be a PFIC with
respect to any U.S. Holder who exchanges Moringa securities for New Silexion securities in connection with the SPAC Merger, the U.S. Holder
did not make any of the PFIC Elections, and the U.S. Holder is not subject to tax on the receipt of the New Silexion securities under
Section 1291(f) of the Code or otherwise, then, although not free from doubt, New Silexion may also be treated as a PFIC as
to the New Silexion ordinary shares received by such U.S. Holder in the SPAC Merger, even if New Silexion is not a PFIC in its own
right. In addition, it is possible that proposed Treasury Regulations could be finalized in a manner that would treat any New Silexion
public warrants that are received in the SPAC Merger as subject to the PFIC rules.
141
If New Silexion is or becomes a PFIC during
any year in which a U.S. Holder holds New Silexion securities, there are three separate taxation regimes that could apply to such
U.S. Holder under the PFIC rules: (i) the excess distribution regime (which is the default regime), (ii) the QEF regime,
or (iii) the mark-to-market regime. A U.S. Holder who holds (actually or constructively) stock in a non-U.S. corporation
during any year in which such corporation qualifies as a PFIC is subject to U.S. federal income taxation under one of these three
regimes. The effect of the PFIC rules on a U.S. Holder will depend upon which of these regimes applies to such U.S. Holder.
However, dividends paid by a PFIC are not eligible for the lower rates of taxation applicable to qualified dividend income under any of
the foregoing regimes.
Excess
Distribution Regime
.    If a U.S. Holder does not make or is not eligible to make a QEF election or a
mark-to-market election, as described below, the U.S. Holder will be subject to the default "excess distribution regime"
under the PFIC rules with respect to (i) any gain realized on a sale or other disposition (including a pledge) of New Silexion securities,
and (ii) any "excess distribution" on New Silexion securities (generally, any distributions in excess of 125% of the
average of the annual distributions on New Silexion securities during the preceding three taxable years or the U.S. Holder's
Holding period, for the New Silexion securities that preceded the taxable year of the distribution whichever is shorter). Generally, under
this excess distribution regime
●
the U.S. Holder's gain or excess distribution will
        be allocated ratably over the U.S. Holder's holding period for the New Silexion securities;
●
the amount allocated to the U.S. Holder's taxable year
        in which the U.S. Holder recognized the gain or received the excess distribution, or to the period in the U.S. Holder's holding
        period before the first day of our first taxable year in which New Silexion is a PFIC, will be taxed as ordinary income;
●
the amount allocated to other taxable years (or portions
        thereof) of the U.S. Holder and included in its holding period will be taxed at the highest tax rate in effect for that year and
        applicable to the U.S. Holder without regard to the U.S. Holder's other items of income and loss for such year; and
●
an additional amount equal to the interest charge generally applicable
        to underpayments of tax will be imposed on the U.S. Holder with respect to the tax attributable to each such other taxable year of
        the U.S. Holder.
The tax liability for amounts allocated to years
prior to the year of disposition or excess distribution will be payable generally without regard to offsets from deductions, losses and
expenses. In addition, gains (but not losses) realized on the sale of a U.S. Holder's New Silexion securities cannot be treated
as capital gains, even if such securities are held as capital assets. Further, no portion of any distribution will be treated as qualified
dividend income.
If New Silexion is, or is treated as, a PFIC
for any taxable year during which a U.S. Holder owns New Silexion securities and any entity in which New Silexion owns equity interests
is also a PFIC (a "lower-tier PFIC"), the U.S. Holder will be deemed to own their proportionate amount (by value)
of the shares of each lower-tier PFIC and will be subject to U.S. federal income tax according to the rules described above
on (i) certain distributions by a lower-tier PFIC and (ii) dispositions of shares of lower-tier PFICs, in each case,
as if the U.S. Holder held such shares directly, even though the U.S. Holder will not receive any proceeds of those distributions
or dispositions.
QEF
Regime
.    A valid QEF election is effective for the taxable year for which the election is made and all subsequent
taxable years and may not be revoked without the consent of the IRS. If a U.S. Holder makes a timely QEF election with
respect to its direct or indirect interest in a PFIC, the U.S. Holder will be required to include in income each year its allocable
portion of the ordinary earnings and net capital gains of the PFIC as QEF income inclusions, even if such portion is not distributed to
the U.S. Holder. Thus, the U.S. Holder may be required to report taxable income as a result of QEF income inclusions without
corresponding receipts of cash. U.S. Holders of New Silexion securities should not expect that they will receive cash distributions
from New Silexion sufficient to cover their respective U.S. tax liability with respect to such QEF income inclusions. In addition,
U.S. Holders of New Silexion public warrants will not be able to make a QEF election with respect to their New Silexion public warrants.
142
The timely QEF election also allows the electing
U.S. Holder to: (i) generally treat any gain recognized on the disposition of its shares of the PFIC as capital gain; (ii) treat
its share of the PFIC's net capital gain, if any, as long-term capital gain instead of ordinary income; and (iii) either
avoid interest charges resulting from PFIC status, or make an annual election, subject to certain limitations, to defer payment of current
taxes on its undistributed QEF income inclusions, subject to an interest charge on the deferred tax computed by using the statutory rate
of interest applicable to an extension of time for payment of tax. In addition, net losses (if any) of a PFIC will not pass through to
its shareholders and may not be carried back or forward in computing such PFIC's ordinary earnings and net capital gain in other
taxable years.
A U.S. Holder's tax basis in New
Silexion ordinary shares will be increased to reflect QEF income inclusions and will be decreased to reflect distributions of amounts
previously included in income as QEF income inclusions. No portion of the QEF income inclusions attributable to ordinary income will be
treated as qualified dividend income. Amounts included as QEF income inclusions with respect to direct and indirect PFICs generally will
not be taxed again when distributed by such PFICs.
A U.S. Holder may make a QEF election
with respect to its New Silexion ordinary shares only if New Silexion provides U.S. Holders on an annual basis with certain information,
including a "PFIC annual information statement" as described in the Treasury Regulations. If New Silexion determines that
it is a PFIC for any taxable year, it will endeavor to provide to a U.S. Holder such information as the IRS may require, including
a PFIC annual information statement, in order to enable a U.S. Holder to make and maintain a QEF election. However, there can be
no assurance that New Silexion will have timely knowledge of its status as a PFIC in the future or that New Silexion will timely provide
U.S. Holders with the required information on an annual basis to allow U.S. Holders to make and maintain a QEF election with
respect to the New Silexion ordinary shares in the event New Silexion is treated as a PFIC for any taxable year. The failure to provide
such information on an annual basis could prevent a U.S. Holder from making a QEF election or result in the invalidation or termination
of a U.S. Holder's prior QEF election. In addition, as mentioned above, U.S. Holders of New Silexion public warrants will
not be able to make a QEF election with respect to their warrants.
If a U.S. Holder makes a QEF election with respect to its New Silexion ordinary
shares in a year after our first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) New Silexion ordinary
shares, then notwithstanding such QEF election, the excess distribution regime discussed above, adjusted to take into account the QEF
income inclusions resulting from the QEF election, will continue to apply with respect to such U.S. Holder's New Silexion ordinary
shares, unless the U.S. Holder makes a purging election under the PFIC rules. Under one type of purging election, the U.S. Holder
will be deemed to have sold such New Silexion ordinary shares at their fair market value and any gain recognized on such deemed sale will
be treated as an excess distribution, as described above. As a result of such purging election, the U.S. Holder will have additional
basis (to the extent of any gain recognized on the deemed sale) and, solely for purposes of the PFIC rules, a new holding period in the
New Silexion ordinary shares.
In addition, as mentioned above, U.S. Holders
of New Silexion public warrants will not be able to make a QEF election with respect to their warrants. As a result, if a U.S. Holder
sells or otherwise disposes of such New Silexion public warrants (other than upon exercise of such New Silexion public warrants) and New
Silexion were a PFIC at any time during the U.S. Holder's holding period of such New Silexion public warrants, any gain recognized
generally will be treated as an excess distribution, taxed as described above. If a U.S. Holder that exercises such New Silexion
public warrants properly makes and maintains a QEF election with respect to the newly acquired New Silexion ordinary shares (or has previously
made a QEF election with respect to New Silexion ordinary shares), the QEF election will apply to the newly acquired New Silexion ordinary
shares. Notwithstanding such QEF election, the excess distribution rules discussed above, adjusted to take into account the current income
inclusions resulting from the QEF election, will continue to apply with respect to such newly acquired New Silexion ordinary shares (which,
while not entirely clear, generally will be deemed to have a holding period for purposes of the PFIC rules that includes the period the
U.S. Holder held the New Silexion public warrants), unless the U.S. Holder makes a purging election under the PFIC rules. U.S. Holders
are urged to consult their tax advisors as to the application of the rules governing purging elections to their particular circumstances.
143
Mark-to-Market Regime
.    Alternatively,
a U.S. Holder may make an election to mark marketable shares in a PFIC to market on an annual basis. PFIC shares generally are marketable
if they are "regularly traded" on a national securities exchange that is registered with the SEC, such as Nasdaq. New Silexion
ordinary shares are listed on Nasdaq but there can be no assurance that New Silexion ordinary shares will continue to be so listed or
will be "regularly traded" for purposes of these rules. Pursuant to such an election, a U.S. Holder of New Silexion ordinary
shares would include in each year as ordinary income the excess, if any, of the fair market value of such stock or shares over its adjusted
basis at the end of the taxable year. A U.S. Holder may treat as ordinary loss any excess of the adjusted basis of the New Silexion
ordinary shares over its fair market value at the end of the year, but only to the extent of the net amount previously included in income
as a result of the election in prior years. A U.S. Holder's adjusted tax basis in the New Silexion ordinary shares will
be increased to reflect any amounts included in income, and decreased to reflect any amounts deducted, as a result of a mark-to-market election.
Any gain recognized on a disposition of New Silexion ordinary shares in a taxable year in which New Silexion is a PFIC will be treated
as ordinary income and any loss will be treated as ordinary loss (but only to the extent of the net amount of income previously included
as a result of a mark-to-market election, and any loss in excess of such prior inclusions generally would be treated as a capital
loss). A mark-to-market election applies for the taxable year in which the election was made, and for each subsequent taxable year,
unless the PFIC shares cease to be marketable or the IRS consents to the revocation of the election. U.S. Holders should also be
aware that the Code and the Treasury Regulations do not allow a mark-to-market election with respect to stock of lower-tier PFICs
that is non-marketable. There is also no provision in the Code, Treasury Regulations or other published authority that specifically provides
that a mark-to-market election with respect to the stock of a publicly traded holding company (such as New Silexion) effectively
exempts stock of any lower-tier PFICs from the negative tax consequences arising from the general PFIC rules. U.S. Holders are
advised to consult their own tax advisor to determine whether the mark-to-market tax election is available to them and the consequences
resulting from such election. In addition, U.S. Holders of New Silexion public warrants will not be able to make a mark-to-market election
with respect to their New Silexion public warrants.
PFIC Reporting Requirements
A U.S. Holder that owns (or is deemed
to own) shares in a PFIC during any taxable year of the U.S. Holder generally is required to file an IRS Form 8621 with such
U.S. Holder's U.S. federal income tax return and provide such other information as the IRS may require. Failure to file
IRS Form 8621 for each applicable taxable year may result in substantial penalties and result in the U.S. Holder's taxable years
being open to audit by the IRS until such forms are properly filed.
THE RULES DEALING WITH PFICS AND PFIC ELECTIONS
ARE VERY COMPLEX AND ARE AFFECTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE. ACCORDINGLY, U.S. HOLDERS OF NEW SILEXION
SECURITIES ARE URGED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE APPLICATION OF THE PFIC RULES TO NEW SILEXION SECURITIES UNDER THEIR
PARTICULAR CIRCUMSTANCES.
Additional Reporting Requirements
Certain U.S. Holders may be required
to file an IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) to report a transfer of property
(including cash) to New Silexion. Substantial penalties may be imposed on a U.S. Holder that fails to comply with this reporting
requirement, and the period of limitations on assessment and collection of U.S. federal income taxes will be extended in the event
of a failure to comply. Furthermore, certain U.S. Holders who are individuals and certain entities will be required to report information
with respect to such U.S. Holder's investment in "specified foreign financial assets" on IRS Form 8938 (Statement
of Specified Foreign Financial Assets), subject to certain exceptions. Specified foreign financial assets generally include any financial
account maintained with a non-U.S. financial institution and should also include New Silexion ordinary shares and New Silexion public
warrants if they are not held in an account maintained with a U.S. financial institution. Persons who are required to report specified
foreign financial assets and fail to do so may be subject to substantial penalties, and the period of limitations on assessment and collection
of U.S. federal income taxes may be extended in the event of a failure to comply. U.S. Holders are urged to consult their tax
advisors regarding the foreign financial asset and other reporting obligations and their application to an investment in New Silexion
ordinary shares and New Silexion public warrants.
144
Information Reporting
and Backup Withholding
Dividend payments with respect to New Silexion
ordinary shares and proceeds from the sale, exchange or redemption of New Silexion securities may be subject to information reporting
to the IRS and possible backup withholding. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct
taxpayer identification number and makes other required certifications, or who is otherwise exempt from backup withholding and establishes
such exempt status.
Backup withholding is not an additional tax.
Amounts withheld as backup withholding may be credited against a U.S. Holder's U.S. federal income tax liability, and
a U.S. Holder generally may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the
appropriate claim for refund with the IRS and furnishing any required information.
PLAN
OF DISTRIBUTION
We have engaged the Placement Agent,             
         , to act as our exclusive placement agent to solicit offers to purchase the securities offered pursuant
to this prospectus on a reasonable best efforts basis. The engagement agreement does not give rise to any commitment by the Placement
Agent to purchase any of our securities, and the Placement Agent will have no authority to bind us by virtue of the engagement agreement.
The Placement Agent is not purchasing or selling any of the securities offered by us under this prospectus, nor is it required to arrange
for the purchase or sale of any specific number or dollar amount of securities, other than to use its "reasonable best efforts"
to arrange for the sale of such securities by us. Therefore, we may not sell all of the securities being offered. The terms of this offering
were subject to market conditions and negotiations between us, the Placement Agent and prospective investors. This is a best efforts offering
and there is no minimum offering amount required as a condition to the closing of this offering. Because there is no minimum offering
amount required as a condition to closing this offering, we may sell fewer than all of the securities offered hereby, which may significantly
reduce the amount of proceeds received by us.. The Placement Agent does not guarantee that it will be able to raise new capital in any
prospective offering. The Placement Agent may engage sub-agents or selected dealers to assist with the offering.
Investors purchasing securities offered hereby will have the option to execute a securities
purchase agreement with us. In addition to rights and remedies available to all purchasers in this offering under federal securities and
state law, the purchasers which enter into a securities purchase agreement will also be able to bring claims of breach of contract against
us. The ability to pursue a claim for breach of contract is material to larger purchasers in this offering as a means to enforce a covenant
to not enter into any equity financings for       days from closing of the offering, subject to certain exceptions.
The nature of the representations, warranties and covenants in the securities purchase agreements shall include:
•
standard issuer representations and warranties on matters such as organization, qualification, authorization, no conflict, no governmental
        filings required, current in SEC filings, no litigation, labor or other compliance issues, environmental, intellectual property and title
        matters and compliance with various laws such as the Foreign Corrupt Practices Act; and
•
covenants regarding matters such as registration of warrant shares, no integration with other offerings, no stockholder rights plans,
        no material nonpublic information, use of proceeds, indemnification of purchasers, reservation and listing of shares of common stock,
        and no subsequent equity sales for        days, subject to certain exceptions.
The securities will be offered at a fixed price and are expected to be issued in a single
closing. We expect this offering to be completed not later than two business days following the commencement of this offering, which will
be the date that we enter into a securities purchase agreement to sell the securities offered hereby. We expect to close the offering
on or before                2024. We will deliver all securities to be issued in connection with
this offering delivery versus payment/receipt versus payment upon receipt of investor funds received by us. Accordingly, neither we nor
the Placement Agent have made any arrangements to place investor funds in an escrow account or trust account since the Placement Agent
will not receive investor funds in connection with the sale of the securities offered hereunder.
We expect to deliver the securities being offered pursuant to this prospectus on or
about [           ], 2024.
145
Fees and Expenses
The following table shows the per ordinary share and accompanying ordinary warrant and
per pre-funded warrant and accompanying ordinary warrant and total placement agent fees we will pay in connection with the sale of the
securities in this offering.
​
Per Ordinary Share and
Accompanying Ordinary
Warrant
Per Pre-Funded
Warrant and Accompanying
Ordinary Warrant
Total
Public offering price
Placement agent fees
Proceeds to us, before expenses
We have agreed to pay the Placement Agent a cash fee equal to 7.0% of the aggregate
gross proceeds raised in this offering and a management fee equal to 1.0% of the gross proceeds raised in this offering. In addition,
we have agreed to pay the Placement Agent $25,000 for its non-accountable expenses and up to $100,000 for legal fees and out-of-pocket
expenses and for its clearing expenses in the amount of up to $15,950. We estimate the total offering expenses of this offering that will
be payable by us, excluding the Placement Agent fees and expenses, will be approximately $[        ].
Placement Agent Warrants
In addition, we have agreed to issue to the Placement Agent, or its designees, warrants
to purchase up to                     ordinary shares (which represents 7.0% of
the aggregate number of ordinary shares issued in this offering and issuable upon the exercise of the pre-funded warrants issued in this
offering) with an exercise price of $         per ordinary share (representing 125% of the public offering price
per ordinary share and accompanying common warrant) and exercisable for five years from the date of the commencement of sales in
this offering. The Placement Agent warrants and underlying ordinary shares are registered on the registration statement of which this
prospectus is a part. The form of the Placement Agent warrant will be included as an exhibit to this registration statement of which this
prospectus forms a part.
Right of First Refusal
We have granted the Placement Agent a right of first refusal for
a period of 12 months following the closing of this offering to act as exclusive financial advisor, sole book-running manager, sole underwriter,
sole placement agent or sole agent for each and every future debt financing or refinancing and public or private equity or debt offering
or acquisition or disposition by us or any of our successors or subsidiaries.
Tail
We have also agreed to pay the Placement Agent a tail fee equal to the cash and warrant
compensation in this offering, if any investor, who was contacted or introduced to us by the Placement Agent during the term of its engagement,
provides us with capital in any public or private offering or other financing or capital raising transaction during the 12-month period
following expiration or termination of our engagement of the Placement Agent.
Lock-up Agreements
We and our subsidiaries have agreed with the Placement Agent to be subject to a lock-up
period of 60 days following the date of closing of the offering pursuant to this prospectus. Each of our officers and directors have agreed
with the Placement Agent to be subject to a lock-up period of 90 days following the date of closing of the offering pursuant to this prospectus.
This means that, during the applicable lock-up period, we and such persons may not offer for sale, contract to sell, sell, distribute,
grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly, any of our shares
of ordinary shares or any securities convertible into, or exercisable or exchangeable for, shares of ordinary shares, subject to customary
exceptions. The Placement Agent may waive the terms of these lock-up agreements in its sole discretion and without notice. In addition,
we have agreed to not issue any securities that are subject to a price reset based on the trading prices of our ordinary shares or upon
a specified or contingent event in the future, or enter into any agreement to issue securities at a future determined price for a period
of two years following the closing date of this offering, subject to an exception. The Placement Agent may waive this prohibition in its
sole discretion and without notice.
146
Regulation M
The Placement Agent may be deemed to be an underwriter within the meaning of Section
2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the securities sold by it
while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the
Placement Agent would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation,
Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of our securities
by the Placement Agent acting as principal. Under these rules and regulations, the Placement Agent (i) may not engage in any stabilization
activity in connection with our securities and (ii) may not bid for or purchase any of our securities or attempt to induce any person
to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.
Indemnification
We have agreed to indemnify the Placement Agent against certain liabilities, including
certain liabilities arising under the Securities Act, or to contribute to payments that the Placement Agent may be required to make for
these liabilities.
Determination of Offering Price and Ordinary Warrants Exercise Price
The actual offering price of the securities we are offering has been negotiated between
us and the investors in the offering based on the trading of our ordinary shares and warrants prior to the offering, among other things.
Other factors considered in determining the public offering price of the securities we are offering include our history and our prospects,
the state of the biotechnology industry in which we operate, our recent operating results, including results of our pre-clinical studies
and clinical trials, the general condition of the securities markets at the time of this offering, and such other factors as were deemed
relevant.
Electronic Offer, Sale and Distribution of Securities
A prospectus in electronic format may be made available on the websites maintained by
the Placement Agent, if any, participating in this offering and the Placement Agent may distribute prospectuses electronically. Other
than the prospectus in electronic format, the information on these websites is not part of this prospectus or the registration statement
of which this prospectus forms a part, has not been approved or endorsed by us or the Placement Agent, and should not be relied upon by
investors.
Other Relationships
From time to time, the Placement Agent or its affiliates have in the past or may in
the future provide in the future, various advisory, investment and commercial banking and other services to us in the ordinary course
of business, for which they have received and may continue to receive customary fees and commissions. However, except as disclosed in
this prospectus, we have no present arrangements with the Placement Agent for any further services.
Listing
Our ordinary shares and warrants are currently listed on the Nasdaq Global Market under
the symbols "SLXN" and "SLXNW", respectively.
147
LEGAL
MATTERS
The legality of the ordinary shares offered
by this prospectus and certain other Cayman Islands legal matters will be passed upon for us by Conyers Dill & Pearman LLP. The
legality of the ordinary warrants, pre-funded warrants and Placement Agent warrants offered by this prospectus and certain legal matters
relating to U.S. law will be passed upon for us by Greenberg Traurig LLP. The Placement Agent is being represented     
          .
EXPERTS
The financial statements of Moringa Acquisition Corp as of December 31, 2023 and 2022,
and for the two years ended December 31, 2023, included in this prospectus, have been so included in reliance on the report (which contains
an explanatory paragraph relating to the Company's ability to continue as a going concern as described in Note 1e to the financial
statements) of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public
accounting firm, given on the authority of said firm as experts in auditing and accounting.
The financial statements of Silexion Therapeutics Ltd. as of December 31, 2023 and 2022,
and for the two years ended December 31, 2023, included in this prospectus have been so included in reliance on the report (which contains
an explanatory paragraph relating to the Company's ability to continue as a going concern as described in Note 1e to the financial
statements) of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public
accounting firm, given on the authority of said firm as experts in auditing and accounting.
148
WHERE
YOU CAN FIND MORE INFORMATION
We have filed with the SEC a registration
statement on Form S-1 under the Securities Act, with respect to the securities being offered by this prospectus. This prospectus, which
constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits.
For further information with respect to New Silexion and the securities offered by this prospectus, we refer you to the registration statement
and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not
necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration
statement. Each of these statements is qualified in all respects by this reference. You can read our SEC filings, including the registration
statement, over the internet at the SEC's website at
www.sec.gov
.
We are subject to the information reporting
requirements of the Exchange Act, and we file reports, proxy statements and other information with the SEC. These reports, proxy statements
and other information will be available for review at the SEC's website at www.sec.gov. We also maintain a website at https://www.completesolaria.com/,
at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or
furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.
149
INDEX TO FINANCIAL STATEMENTS
TABLE OF CONTENTS
MORINGA ACQUISITION CORP
Page
Moringa Acquisition Corp Condensed Consolidated Financial Statements
Condensed Consolidated Balance Sheets
F-2
Condensed Consolidated Statements of Operations
F-3
Condensed Consolidated Statements of Changes in Capital Deficiency
F-4
Condensed Consolidated Statements of Cash Flows
F-5
Notes to the Condensed Consolidated Financial Statements
F-6
Moringa Acquisition Corp Audited Financial Statements
Report of Independent Registered Public Accounting Firm (PCAOB ID # 1309)
F-22
Balance Sheets
F-23
Statements of Operations
F-24
Statements of Changes in Capital Deficiency
F-25
Statements of Cash Flows
F-26
Notes to Financial Statements
F-27
SILEXION THERAPEUTICS LTD.
CONSOLIDATED FINANCIAL STATEMENTS
Page
Silexion Therapeutics Ltd. Condensed Consolidated Financial Statements
Condensed Consolidated Balance Sheets (unaudited)
F-40
Condensed Consolidated Statements of Operations (unaudited)
F-42
Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred
        Shares and Capital Deficiency (unaudited)
F-43
Condensed Consolidated Statements of Cash Flows (unaudited)
F-45
Notes to Condensed Consolidated Financial Statements (unaudited)
F-47
Silexion Therapeutics Ltd. Audited Financial Statements
Report of Independent Registered Public Accounting Firm
F-58
CONSOLIDATED FINANCIAL STATEMENTS:
Consolidated Balance Sheets
F-59
Consolidated Statements of Operations
F-60
Consolidated Statements of Changes in Redeemable Convertible Preferred Shares
        and Capital Deficiency
F-61
Consolidated Statements of Cash Flows
F-62
Notes to Consolidated Financial Statements
F-63
F-1
MORINGA
ACQUISITION CORP
UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30,
December 31,
Note
2024
2023
U.S.
        Dollars
Assets
ASSETS:
Cash
        and cash equivalents
17,880
108,278
Investments
        held in Trust Account
5,924,118
5,697,632
Prepaid
        expenses
24,808
28,305
TOTAL
        ASSETS
5,966,806
5,834,215
Liabilities
        and shares subject to possible redemption net of capital deficiency
LIABILITIES:
Accrued expenses
55,191
115,560
Related party
4
3,346,000
2,861,000
Private
        warrant liability
27,284
8,531
TOTAL
        LIABILITIES
3,428,475
2,985,091
COMMITMENTS
        AND CONTINGENCIES
5
-
-
CLASS
        A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION:
515,019
shares at redemption value of $
11.50
and $
11.06
as of June 30, 2024 and December 31, 2023, respectively
5,924,118
5,697,632
CAPITAL DEFICIENCY:
7
Class
        A Ordinary Shares, $
0.0001
par value;
500,000,000
shares authorized,
3,354,999
issued and outstanding (excluding 515,019 shares subject to possible redemption) as of June 30, 2024 and December 31, 2023;
336
336
Class
        B Ordinary Shares, $
0.0001
par value;
50,000,000
shares authorized,
1
issued and outstanding as of June 30, 2024 and December 31, 2023;
*
*
Preferred
        Shares, $
0.0001
par value;
5,000,000
shares authorized,
no
shares issued and outstanding as of June 30, 2024 and December 31, 2023.
-
-
Accumulated
        deficit
(
3,386,123
)
(
2,848,844
)
TOTAL
        CAPITAL DEFICIENCY
(
3,385,787
)
(
2,848,508
)
TOTAL
        LIABILITIES AND SHARES SUBJECT TO POSSIBLE REDEMPTION NET OF CAPITAL DEFICIENCY
5,966,806
5,834,215
*
Less than one US dollar
The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements
.
F-2
MORINGA ACQUISITION CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Note
Six months ended
June 30,
Three months ended
June 30,
2024
2023
2024
2023
U.S. Dollars
U.S. Dollars
Except share data
Except share data
INTEREST EARNED ON INVESTMENTS HELD IN TRUST ACCOUNT
149,236
1,063,043
75,305
318,002
GENERAL AND ADMINISTRATIVE
(
441,276
)
(
592,201
)
(
179,135
)
(
155,472
)
CHANGE IN FAIR VALUE OF WARRANT LIABILITY
(
18,753
)
5,301
(
6,745
)
418
NET PROFIT (LOSS) FOR THE PERIOD
(
310,793
)
476,143
(
110,575
)
162,948
WEIGHTED AVERAGE NUMBER OF CLASS A ORDINARY
        SHARES SUBJECT TO POSSIBLE REDEMPTION
8
515,019
5,015,185
515,019
2,589,567
NET PROFIT PER CLASS A ORDINARY SHARE SUBJECT
        TO POSSIBLE REDEMPTION – BASIC AND DILUTED
0.32
$
0.22
0.17
$
0.19
WEIGHTED AVERAGE NUMBER OF NON-REDEEMABLE
        CLASS A AND CLASS B ORDINARY SHARES
8
3,355,000
3,355,000
3,355,000
3,355,000
NET LOSS PER NON-REDEEMABLE CLASS A AND
        CLASS B ORDINARY SHARES – BASIC AND DILUTED
(
0.14
)
$
(
0.19
)
(
0.06
)
$
(
0.10
)
The accompanying notes are
an integral part of these unaudited condensed consolidated financial statements.
F-3
MORINGA ACQUISITION CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES
IN CAPITAL DEFICIENCY
Class A
ordinary shares
Class B
ordinary shares
Total
Number of
shares
Par value
Number of
shares
Par value
Accumulated
deficit
capital
deficiency
BALANCE AT December 31, 2022
480,000
48
2,875,000
288
(
1,203,097
)
(
1,202,761
)
Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of March 31, 2023
(
905,040
)
(
905,040
)
Net profit for the period
313,195
313,195
BALANCE AT March 31, 2023
480,000
48
2,875,000
288
(
1,794,942
)
(
1,794,606
)
Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of June 30, 2023
(
558,002
)
(
558,002
)
Net profit for the period
162,948
162,948
BALANCE AT June 30, 2023
480,000
48
2,875,000
288
(
2,189,996
)
(
2,189,660
)
BALANCE AT December 31, 2023
3,354,999
336
1
*
(
2,848,844
)
(
2,848,508
)
Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of March 31, 2024
(
112,558
)
(
112,558
)
Net loss for the period
(
200,218
)
(
200,218
)
BALANCE AT March 31, 2024
3,354,999
336
1
*
(
3,161,620
)
(
3,161,284
)
Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of June 30, 2024
(
113,928
)
(
113,928
)
Net loss for the period
(
110,575
)
(
110,575
)
BALANCE AT June 30, 2024
3,354,999
336
1
*
(
3,386,123
)
(
3,385,787
)
*
Less than one US dollar
The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.
F-4
MORINGA ACQUISITION CORP
UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Six
        months ended
June 30,
2024
2023
CASH FLOWS
        FROM OPERATING ACTIVITIES:
Net
        profit (loss) for the period
(
310,793
)
476,143
Adjustments
        to reconcile net profit (loss) to net cash provided by (used in) operating activities:
Change
        in the fair value of the private warrant liability
18,753
(
5,301
)
Changes in
        operating assets and liabilities:
Decrease
        in prepaid expenses
3,497
2,023
Increase
        (decrease) in related party
(
20,000
)
30,000
Increase
        (decrease) in accrued expenses
(
60,369
)
14,993
Net
        cash provided by (used in) operating activities
(
368,912
)
517,858
CASH FLOWS
        FROM FINANCING ACTIVITIES:
Partial
        redemption of Class A ordinary shares subject to possible redemption
-
(
90,750,217
)
Proceeds
        from promissory notes – related party
505,000
920,000
Net
        cash provided by (used in) financing activities
505,000
(
89,830,217
)
INCREASE
        (DECREASE) IN CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT
136,088
(
89,312,359
)
CASH,
        CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT BEGINNING OF PERIOD
5,805,910
116,751,752
CASH,
        CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT END OF PERIOD
5,941,998
27,439,393
RECONCILIATION
        OF CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT:
Cash and
        cash equivalents
17,880
34,530
Investments
        held in trust account
5,924,118
27,404,863
Total
        cash, cash equivalents and investments held in a trust account
5,941,998
27,439,393
The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-5
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:
a.
Organization and General
Moringa Acquisition Corp (hereafter – the
Company) is a blank check company, incorporated on September 24, 2020 as a Cayman Islands exempted company, formed for the purpose of
effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination (hereafter –
the Business Combination). The Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as
amended (the "Securities Act"), as modified by the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act").
The Company has selected December 31 as its fiscal
year end.
b.
Sponsor and Financing
The Company's sponsor is Moringa Sponsor,
L.P., a Cayman exempted limited partnership (which is referred to herein, together with its wholly-owned subsidiary, Moringa Sponsor (US)
LP, a Delaware limited partnership, as the "Sponsor").
Refer to Note 7(a) for information regarding the
aggregate withdrawals of approximately $
113
million, due to partial redemptions.
c.
The Trust Account
The proceeds held in the Trust Account are invested
in money market funds registered under the Investment Company Act and compliant with Rule 2a-7 thereof that maintain a stable net asset
value of $
1.00
.
The Company complies with the provisions of ASU
2016-18, under which changes in Investments held in the Trust Account are accounted for as Changes in Cash, Cash Equivalents and Investments
Held in a Trust Account in the Company's Statements of Cash Flows.
Refer to Note 4(a) for information regarding proceeds
received from the Sponsor under the Sixth and Eighth Promissory Notes, deposited into the Trust Account.
F-6
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
(continued)
:
d.
Initial Business Combination
The Company's management has broad discretion
with respect to the specific application of the net proceeds of the Public Offering, although substantially all of the net proceeds of
the Public Offering and the Private Placement are intended to be generally applied toward consummating an initial Business Combination.
The initial Business Combination must occur with one or more operating businesses or assets with a fair market value equal to at least
80
%
of the net assets held in the Trust Account (excluding taxes payable on the income accrued in the Trust Account). There is no assurance
that the Company will be able to successfully consummate an initial Business Combination.
The Company, after signing a definitive agreement
for an Initial Business Combination, will provide its public shareholders the opportunity to redeem all or a portion of their shares upon
the completion of the initial Business Combination, either (i) in connection with a shareholder meeting called to approve the business
combination or (ii) by means of a tender offer.
If the Company holds a shareholder vote or there
is a tender offer for shares in connection with an initial Business Combination, a public shareholder will have the right to redeem its
shares for an amount in cash equal to its pro rata share of the aggregate amount then on deposit in the Trust Account, calculated as of
two days prior to the general meeting or commencement of the Company's tender offer, including interest but less taxes payable.
As a result, the Company's Public Class A ordinary shares are classified as temporary equity upon the completion of the Public Offering,
in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC")
480, "Distinguishing Liabilities from Equity."
Pursuant to the Company's amended and restated
memorandum and articles of association, as amended, if the Company is unable to complete the initial Business Combination within 42 months
from the Closing of the Public Offering, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly
as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash,
equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable,
and less up to $
100,000
of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish
public shareholders' rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii)
as promptly as reasonably possible following such redemption, subject to the approval of the Company's remaining shareholders and
the Company's board of directors, liquidate and dissolve, subject in each case to the Company's obligations under Cayman Islands
law to provide for claims of creditors and the requirements of other applicable law.
The Sponsor and the Company's officers and
directors have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions
from the Trust Account with respect to any Class B ordinary share (as described in Note 7) held by them if the Company fails to complete
the initial Business Combination within 24 months of the Closing of the Public Offering or during any extended time that the Company has
to consummate an initial Business Combination beyond 24 months as a result of a shareholder vote to amend its amended and restated memorandum
and articles of association. However, if the Sponsor or any of the Company's directors or officers acquire any Class A ordinary
shares, they will be entitled to liquidating distributions from the Trust Account with respect to such shares if the Company fails to
complete the Initial Business Combination within the prescribed time period.
F-7
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
(continued)
:
In the event of a liquidation, dissolution or
winding up of the Company after an initial Business Combination, the Company's shareholders are entitled to share ratably in all
assets remaining available for distribution to them after payment of liabilities and after provision is made for each class of stock,
if any, having preference over the ordinary shares. The Company's shareholders have no preemptive or other subscription rights.
There are no sinking fund provisions applicable to the ordinary shares, except that the Company will provide its shareholders with the
opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the Trust
Account, under the circumstances, and, subject to the limitations, described herein.
On February 9, 2023 the Company held an extraordinary
general meeting in lieu of the 2022 annual general meeting of the Company (hereafter – the First Extension Meeting). At the First
Extension Meeting, the Company's shareholders approved the proposal to adopt, by way of special resolution, an amendment to the
Amended and Restated Articles to extend the date by which the Company has to consummate a business combination from the 24 month anniversary
of the Closing of the Public Offering – i.e., February 19, 2023 to August 19, 2023 (hereafter – the Extended Mandatory Liquidation
Date) or such earlier date as may be determined by the Board in its sole discretion.
On August 18, 2023 the Company held an extraordinary
general meeting in lieu of the 2023 annual general meeting of the Company (hereafter – the Second Extension Meeting). At the Second
Extension Meeting, the Company's shareholders approved, among other proposals, an amendment to the Amended and Restated Memorandum
and Articles of Association to further extend the date by which the Company has to consummate a business combination from the Extended
Mandatory Liquidation Date to August 19, 2024 (hereafter – the Second Extended Mandatory Liquidation Date) or such earlier date
as may be determined by the Board in its sole discretion.
Refer to Note 7(a) for information regarding the
partial redemptions of Class A ordinary shares subject to possible redemption, following the First and Second Extensions, and for information
regarding the conversion of Class B ordinary shares into Class A ordinary shares, following the Second Extension Meeting.
e.
Substantial Doubt about the Company's Ability to
        Continue as a Going Concern
As of June 30, 2024, the Company had approximately
$
18
thousand of cash and an accumulated deficit of $
3,386
thousand. In connection with the Company's assessment of going concern considerations in accordance with Financial Accounting Standard
Board's Accounting Standard Codification 205-40, "Going Concern", the Company will need to obtain additional funds in
order to satisfy its liquidity needs in its current endeavors to consummate the Proposed Silexion Merger, as detailed in Note 1(f), or
a different Initial Business Combination, if the former does not occur.
F-8
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
(continued)
:
Since its inception date and through the issuance
date of these unaudited condensed consolidated financial statements, the Company's liquidity needs were satisfied through an initial
capital injection from the Sponsor, followed by net Private Placement proceeds, as well as several withdrawals of the Sponsor promissory
notes. Management has determined that it will need to continue to rely and is significantly dependent on both outstanding and future promissory
notes, or other forms of financial support (all of which the Sponsor is not obligated to provide). Moreover, following the Second Extension
Meeting, the Company has until August 19, 2024 to consummate an Initial Business Combination. If a business combination is not consummated
by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. There can be no assurance that the Company
will be able to consummate any business combination ahead of the Second Extended Mandatory Liquidation Date, nor will it be able to raise
sufficient funds to complete an Initial Business Combination. These matters raise substantial doubt about the Company's ability
to continue as a going concern, for the subsequent twelve months following the issuance date of these unaudited condensed consolidated
financial statements.
In February 2024, the Company entered into a Business
Combination Agreement with Silexion Therapeutics Ltd. (hereafter – Silexion), an Israeli company which is in its developmental stage,
dedicated to the development of innovative treatments for pancreatic cancer. Refer to Note 1(f) for further information regarding the
Proposed Silexion Merger.
No adjustments have been made to the carrying
amounts of assets or liabilities should the company fail to obtain financial support in its pursuit to consummate an Initial Business
Combination, nor if it is required to liquidate after the Second Extended Mandatory Liquidation Date.
f.
Proposed Business Combination
On February 21, 2024, the Company, together with
its wholly-owned Israeli subsidiary
April M.G. Ltd
. – which was incorporated due to the original business combination
structure, entered into a business combination agreement with Silexion (hereafter – the Proposed Silexion Merger).
The Proposed Silexion Merger is expected
to close in the third quarter of 2024, subject to the satisfaction of customary closing conditions under the Business Combination Agreement,
including the approval of the business combination by Silexion's and the Company's shareholders, as well as Nasdaq's
approval of the initial listing of the combined company's securities.
The Proposed Silexion Merger have been unanimously
approved by the boards of directors of the Company and Silexion.
On April 3, 2024, the Proposed Silexion Merger
contemplated under the original Proposed Silexion Merger agreement was restructured pursuant to the Business Combination Agreement, by
and among New Pubco (a newly formed Cayman Islands exempted company), its two newly-formed subsidiaries – Merger Sub 1 and Merger
Sub 2 – the Company and Silexion.
F-9
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
(continued)
:
As contemplated under the Business Combination
Agreement, Merger Sub 2 will merge with and into the Company, with the Company continuing as the surviving company and a wholly-owned
subsidiary of New Pubco, and Merger Sub 1 will merge with and into Silexion, with Silexion continuing as the surviving company and a wholly-owned
subsidiary of New Pubco. The shareholders and other equity holders of each of the Company and Silexion will receive corresponding securities
of New Pubco as consideration in the Prospective Business Combination at set ratios in exchange for their securities of Company and Silexion,
respectively. New Pubco will serve as the public company upon completion of the Proposed Business Combination, with its ordinary
shares and warrants listed for trading on Nasdaq.
The foregoing description of the Proposed Business
Combination, as amended, does not purport to be complete. For further information and access to the full agreement and all other related
agreements, refer to the Company's Current Report on Form 8-K filed with the SEC on April 3, 2024.
In connection with the Proposed Silexion Merger, on May 9,
2024, New Pubco filed with the SEC a Registration Statement on Form S-4, and has subsequently filed amendments on June 24, 2024, July
7, 2024 and July 12, 2024, that include a document that will serve as both a prospectus for the securities to be issued by New Pubco in
the Prospective Business Combination to security holders of the Company and Silexion, as well as a proxy statement of the Company for
the Company's extraordinary general meeting at which the Prospective Business Combination and the Business Combination Agreement
(among other matters) was presented for approval (see note 9). The SEC staff declared the New Pubco Registration Statement effective on
July 16, 2024.
g.
Impact of War in Israel
Israel's current war against the terrorist
organization Hamas continued to rage during the second quarter of 2024. The intensity and duration of the war has varied since it began
on October 7, 2023. Up to the balance sheet date and subsequently, the war has not had a material effect on the Company. However, the
war may cause wider macroeconomic deterioration in Israel, which may have a material adverse effect on the Company's ability to
effectively complete the Proposed Business Combination.
F-10
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:
a.
Basis of Presentation
The condensed consolidated financial statements
herein are unaudited; however, such information reflects all adjustments (consisting of normal, recurring adjustments), which are, in
the opinion of the management, necessary for a fair statement of results for the interim period. The results of the operation for the
six and three-month periods ended June 30, 2024, are not necessarily indicative of the results to be expected for the full year. The year-end
condensed consolidated balance sheet data was derived from audited financial statements for the year ended December 31, 2023 as filed
on April 1, 2024, but does not include all disclosures required by accounting principles generally accepted in the United States of America
("U.S. GAAP"). These unaudited condensed consolidated financial statements should be read in conjunction with the audited
financial statements and related notes thereto of Moringa Acquisition Corp.
b.
Emerging Growth Company
Section 102(b)(1) of the JOBS Act exempts emerging
growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those
that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the
Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect
to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such
election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a
standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth
company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company's
unaudited condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging
growth company which has opted out of using the extended transition period difficult or impossible, because of the potential differences
in accounting standards used.
F-11
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
(continued)
:
c.
Cash and cash
        equivalents
The Company considers as cash equivalents all
short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the
date of purchase that are not restricted as to withdrawal or use by nature of the account and are readily convertible to known amounts
of cash.
d.
Class A Ordinary Shares
        subject to possible redemption
As discussed in Note 1, all of the
11,500,000
shares of Class A ordinary shares sold as parts of the Units in the Public Offering contain a redemption feature. In accordance with
the Accounting Standards Codification 480-10-S99-3A "Classification and Measurement of Redeemable Securities", redemption
provisions not solely within the control of the Company require the security to be classified outside of permanent equity. The Company
has classified all of the shares sold under the Public Units as subject to possible redemption.
Refer to Note 7(a) for information regarding the
partial redemptions of Class A ordinary shares subject to possible redemption, following the First and Second Extensions. Also, refer
to Note 9(c) regarding an additional redemption after the balance sheet date.
e.
Net profit (loss) per share
The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, Earnings Per Share. Net profit (loss) per share is computed by dividing net profit (loss) by the weighted
average number of shares outstanding during the period. The Company applies the two-class method in calculating net profit (loss) per
each class of shares: the non-redeemable shares, which include the Private Class A Ordinary Shares, as defined in Note 7, and the Class
B ordinary shares (hereafter and collectively – Non-Redeemable class A and B ordinary shares); and the Class A ordinary shares subject
to possible redemption.
In order to determine the net profit (loss) attributable
to each class, the Company first considered the total profit (loss) allocable to both sets of shares. This is calculated using the total
net profit (loss) less any interest earned on investments held in trust account. Then, the accretion is fully allocated to the Class A
ordinary shares subject to redemption.
f.
Concentration of credit risk
Financial instruments that potentially
subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed
the Federal Depository Insurance Coverage of $
250,000
.
From the Company's incorporation and through June 30, 2024, the Company has not experienced any losses on these accounts.
As of June 30, 2024, the Company held its cash
and cash equivalents in an SVB bank account, and its investments Held in Trust Account in Goldman Sachs money market funds. Money market
funds are characterized as Level 1 investments within the fair value hierarchy under ASC 820.
F-12
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
(continued)
:
g.
Public Warrants
The Company applied the provisions of ASC 815-40
and classified its public warrants, issued as part of the Public Units as detailed in Note 3, as equity securities.
h.
Private Warrant liability
The Company accounts for the warrants in accordance
with the guidance contained in Accounting Standards Codification 815 ("ASC 815"), "Derivatives and Hedging", under
which the warrants do not meet the criteria for equity treatment and must be recorded as derivative liabilities. Accordingly, the Company
classifies the private warrants as liabilities at their fair value and adjusts the private warrants to fair value at each reporting period.
This liability is subject to re-measurement at each balance sheet date until the private warrants are exercised or expire, and any change
in fair value is recognized in the Company's statements of operations. Refer to Note 6 for information regarding the model used
to estimate the fair value of the Private Warrants (as defined in Note 3).
i.
Financial instruments
The fair value of the Company's assets and
liabilities, which qualify as financial instruments under the FASB ASC 820, "Fair Value Measurements and Disclosures", approximates
the carrying amounts represented in the balance sheet, primarily due to their short-term nature.
j.
Use of estimates in the preparation of financial statements
The preparation of the financial statements in
conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during
the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company's
financial statements.
m.
Income tax
The Company accounts for income taxes in accordance
with ASC 740, "Income Taxes (hereafter – ASC 740). ASC 740 prescribes the use of the liability method whereby deferred
tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and
liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more
likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative
evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU 2015-17.
F-13
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
(continued)
:
n.
Recent accounting pronouncements
Management does not believe that any recently
issued, but not yet effective, accounting pronouncements, if currently adopted would have a material effect on the Company's financial
statements.
NOTE 3 - PUBLIC OFFERING AND PRIVATE PLACEMENTS:
In the Initial Public Offering, the Company issued
and sold
11,500,000
units (including
1,500,000
units sold at a second closing pursuant to the underwriters' exercise of their over-allotment option in full) at an offering price
of $
10.00
per unit (hereafter – the Units). The Sponsor and EarlyBirdCapital, Inc. (the representative of the underwriters) purchased, in
a private placement that occurred simultaneously with the two closings of the initial Public Offering (hereafter – the Private Placement),
an aggregate of
352,857
and
27,143
Units, respectively, at a price of $
10.00
per Unit.
Once the Public Warrants become exercisable, the
Company may redeem them in whole and not in part at a price of $
0.01
per Warrant upon a minimum of 30 days'  prior written notice of redemption, if and only if the last reported sale price of
the Company's Class A ordinary shares equals or exceeds $
18.00
per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which
the Company sends the notice of redemption to the Public Warrant holders.
The Private Warrants are identical to the Public
Warrants except that, for so long as they are held by the Sponsor, EarlyBirdCapital, Inc. or their respective affiliates: (1) will not
be redeemable by the Company; (2) may not (including the Class A ordinary shares issuable upon exercise thereof), subject to certain limited
exceptions, be transferred, assigned or sold by the holders thereof until 30 days after the completion of the Company's Initial
Business Combination; (3) may be exercised by the holders thereof on a cashless basis; and (4) they (including the Class A ordinary shares
issuable upon exercise thereof) are entitled to registration rights.
The Company paid an underwriting commission of
2.0
%
of the gross proceeds of the Public Offering and the full exercise of the underwriters' over-allotment, or $
2,300,000
,
in the aggregate, to the underwriters at the two closings of the Public Offering. Refer to Notes 5(a) and 9(a) for more information regarding
an additional fee payable to the underwriters upon the consummation of an Initial Business Combination, and an amendment to the agreement.
F-14
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 4 - RELATED PARTY TRANSACTIONS:
a.
Promissory Notes
The Company has issued several promissory note
agreements to its Sponsor throughout its life term, in order to fulfil its ongoing operational needs or preparations towards an Initial
Business Combination. All outstanding promissory notes bear no interest and are repayable in full upon the earlier of (a) the date of
the consummation of the Company's Initial Business Combination, or (b) Second Extended Mandatory Liquidation Date (hereafter and
collectively – the Maturity Date).
Second to Fifth Promissory Notes
On August 9, 2021 the Company issued its Second
Promissory Note to the Sponsor, according to which the former may withdraw up to $
1
million – which has been withdrawn in full in several installments up until June 2022.
In December 2022 the Company issued its Third
and Fourth Promissory Notes, according to which the Company may withdraw up to an aggregate amount of $
190
thousand – which were withdrawn in full on the same month.
On February 8, 2023 the Company issued its Fifth
Promissory Note to the Sponsor, in an amount of up to $
310
thousand, which were withdrawn in full in several installments between February and June 2023.
According to the terms of the outstanding Second,
Third, Fourth and Fifth Promissory Notes, which comprise an aggregate principal of $
1.5
million, the Sponsor may elect to convert any portion of the amounts outstanding into private warrants to purchase Class A ordinary shares
at a conversion price of $
1
per private warrant on the Maturity Date. Such private warrants will have an exercise price of $
11.5
and shall be identical to the private warrants included in the private units.
Sixth Promissory Note
On February 9, 2023 the Company issued its Sixth
Promissory Note to the Sponsor, in an amount of $
480
thousand – under which the funds that were loaned by the Sponsor were deposited into the Company's Trust Account, in connection
with the First Extension. The Sponsor provided six monthly injections of $
80
thousand into the Company's Trust Account under the Sixth Promissory Note, starting February 19, 2023.
Seventh Promissory Note
On June 14, 2023 the Company issued its Seventh
Promissory Note to the Sponsor in an amount of up to $
1
million, which were withdrawn in full in several installments between June 2023 and March 2024.
F-15
MORINGA
ACQUISITION CORP
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 4 - RELATED PARTY TRANSACTIONS
(continued)
:
Eighth Promissory Note
On August 18, 2023 the Company issued its Eighth
Promissory Note to the Sponsor, in an amount of approximately $
154
thousand – under which the funds that were loaned by the Sponsor were deposited into the Company's Trust Account, in connection
with the Second Extension. The Sponsor shall make monthly injections of approximately $
13
thousand into the Company's Trust Account, starting August 19, 2023 and up until the earlier of the Second Extended Mandatory Liquidation
Date (or such earlier date that the Board determines to liquidate the Company) or the date on which an Initial Business Combination is
completed. During the six months ended June 30, 2024, approximately $
77
thousand have been injected into the trust account in six monthly installments.
Ninth Promissory Note
On March 27, 2024, the Company issued its Ninth
Promissory Note, according to which the Company may withdraw up to an aggregate amount of $
180
thousand. As of June 30, 2024 the Ninth Promissory Note has been fully withdrawn.
Tenth Promissory Note
On June 27, 2024, the Company issued its Tenth
Promissory Note, according to which the Company may withdraw up to an aggregate amount of $
250
thousand. The Company has made partial withdrawals in June and July 2024.
A&R Promissory Note
Upon the closing of the proposed business combination,
and according to the terms of the amended Silexion Business Combination agreement, all promissory notes shall be converted into one sponsor
promissory note – the A&R Sponsor Promissory Note, which will be subject to a cap of (i) $
5.5
million, minus (ii) any fee that may be paid or owed under the amended Business Marketing Agreement (See Notes 5(a) and 9(a)). Any outstanding
amount loaned by the sponsor to the Company in excess of the cap, will be attributed to the conversion shares issuable under the A&R
Sponsor Promissory Note as additional paid-in capital.
b.
Administrative Services Agreement
On December 16, 2020, the Company signed an agreement
with the Sponsor, under which the Company shall pay the Sponsor a fixed $
10
thousand per month for office space, utilities and other administrative expenses. The monthly payments under this administrative services
agreement commenced on the effective date of the registration statement for the initial Public Offering and will continue until the earlier
of (i) the consummation of the Company's initial Business Combination, or (ii) the Company's liquidation.
The composition of the Related Party balance as
of June 30, 2024 and December 31, 2023 is as follows:
June 30,
2024
December 31,
2023
In U.S. dollars
Promissory notes
3,346,000
2,841,000
Accrual for Administrative Services Agreement
-
20,000
3,346,000
2,861,000
F-16
MORINGA
ACQUISITION CORP
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 5 - COMMITMENTS AND CONTINGENCIES:
a.
Underwriters' deferred discount
Under the Business Combination
Marketing Agreement, the Company shall pay an additional fee (hereafter – the Deferred Commission) of
3.5
%
of the gross proceeds of the Public Offering (or $
4,025,000
)
payable upon the Company's completion of the Initial Business Combination. The Deferred Commission will become payable to the underwriters
from the amounts held in the Trust Account solely in the event the Company completes an Initial Business Combination.
b.
Advisory and Placement Agent Agreement with Cohen & Company
Refer to Note 9(d) for information
regarding the agreement entered into after the balance sheet date.
c.
Nasdaq Deficiency Notice
Third Deficiency Notice
On February 20, 2024, the Company received a notice
from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that unless the Company timely requests
a hearing before the Nasdaq Hearings Panel (hereafter - the Panel), trading of the Company's securities on The Nasdaq Capital Market
would be suspended at the opening of business on February 29, 2024, due to the Company's non-compliance with Nasdaq IM-5101-2, which
requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of
its IPO registration statement.
The Company timely requested a hearing before
the Panel to request sufficient time to complete its previously disclosed proposed business combination with Silexion. The hearing request
has resulted in a stay of any suspension or delisting action pending the hearing, which was held on April 23, 2024.
On April 23, 2024, the Company participated in
a hearing with Nasdaq in which the Company presented its request that Nasdaq provide the Company an additional six months to remedy the
Company's non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business
combinations within 36 months of the effectiveness of its IPO registration statement. The Company's plan for regaining compliance
focused on the Company's efforts to complete its previously disclosed Proposed Business Combination with Silexion. On May 10, 2024,
the Company received the results of the hearing, under which Nasdaq approved the Company's request for a six-month extension—
until the Second Extension Date— to remain listed on Nasdaq and complete its proposed business combination.
F-17
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 6 - FAIR VALUE MEASUREMENTS:
The fair value of a financial instrument is the
amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at
the measurement date (i.e., the exit price).
The fair value hierarchy under ASC 820 prioritizes
the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in
active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
The three levels of the fair value hierarchy are as follows:
Basis for Fair Value Measurement
Level 1: Unadjusted quoted prices in active markets
that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices in markets that are not
active or financial instruments for which significant inputs to models are observable (including but not limited to quoted prices for
similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly or indirectly;
Level 3: Prices or valuations that require significant
unobservable inputs (including the Management's assumptions in determining fair value measurement).
The following table presents information about
the Company's assets and liabilities that are measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023
by level within the fair value hierarchy:
Level
June 30,
2024
December 31,
2023
Assets:
Money market funds held in Trust Account
1
5,924,118
5,697,632
Liabilities:
Private Warrant Liability
3
27,284
8,531
The estimated fair value of the Private Placement
Warrants was determined using a binomial model to extract the market's implied probability for an Initial Business Combination,
using the Public Warrant's market price. Once probability was extracted, a Black-Scholes-Merton model with Level 3 inputs was used
to calculate the Private Warrants' fair value. Inherent in a Black-Scholes-Merton model are assumptions related to expected life
(term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the volatility of its warrants
based on implied volatility from the Company's traded warrants and from historical volatility of selected peer companies'
Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury
zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of
the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which
the Company anticipates remaining at zero.
The following table provides quantitative information
regarding Level 3 fair value measurements inputs:
As of
June 30,
2024
As of
December 31,
2023
Share price
$
10.0
$
10.0
Strike price
$
11.5
$
11.5
Volatility
60
%
60
%
Risk-free interest rate
4.34
%
4.78
%
Dividend yield
0.00
%
0.00
%
Public warrant market price
$
0.08
$
0.03
In U.S dollars
Value of warrant liability measured with Level 3 inputs at December
        31, 2023
8,531
Change in fair value of private warrant liability measured
        with Level 3 inputs
18,753
Value of warrant liability measured with Level 3 inputs at
        June 30, 2024
27,284
F-18
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 7 - CAPITAL DEFICIENCY:
a.
Ordinary Shares
Class A Ordinary Shares
On November 20, 2020 the Company issued
100,000
Class A ordinary shares of $
0.0001
par value each to designees of the Representative (hereafter – the Representative Shares) for a consideration equal to the par value
of the shares. The Representative Shares are deemed to be underwriters' compensation by FINRA pursuant to Rule 5110 of the FINRA
Manual.
The Company accounted for the issuance of the
Representative Shares as compensation expenses amounting to $
860
,
with a corresponding credit to Additional Paid-In Capital, for the excess value over the consideration paid. The Company estimated the
fair value of the issuance based upon the price of Class B Ordinary Shares that were issued to the Sponsor.
Pursuant to the initial Public Offering and the
concurrent Private Placement that were each effected in two closings – on February 19, 2021 and March 3, 2021 – the Company
issued and sold an aggregate of
11,500,000
and
380,000
Class A ordinary shares as part of the Units sold in those respective transactions. The Units (which also included Warrants) were sold
at a price of $
10
per Unit, and for an aggregate consideration of $
115
million and $
3.8
million in the Public Offering and Private Placement, respectively. See Note 3 above for further information regarding those share issuances.
The Company classified its
11,500,000
Public Class A ordinary shares as temporary equity. The remaining
480,000
Private Class A ordinary shares were classified as permanent equity.
In conjunction with the First and Second
Extensions,
8,910,433
and
2,074,548
Class A Ordinary Shares subject to possible redemption were redeemed, respectively, for their redemption value, including accrued interest.
As part of the partial redemptions approximately $
113
million has been withdrawn from the Investments held in Trust Account.
Class B Ordinary Shares
On November 20, 2020, the Company issued
2,875,000
Class B ordinary shares of $
0.0001
par value each for a total consideration of $
25
thousand to the Sponsor's wholly-owned Delaware subsidiary.
Class B ordinary shares are convertible into non-redeemable
Class A ordinary shares, on a one-for-one basis, automatically on the day of the Business Combination or at the election of the holder
thereof at any time prior to the Business Combination. Class B ordinary shares also possess the sole right to vote for the election or
removal of directors, until the consummation of an Initial Business Combination.
Following the Second Extension Meeting, the Sponsor
converted
2,874,999
of its
Class
B ordinary shares into Class A ordinary shares on a one to one basis
.
b.
Preferred shares
The Company is authorized to issue up to
5,000,000
Preferred Shares of $
0.0001
par value each. As of June 30, 2024, the Company has no preferred shares issued and outstanding.
F-19
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(CONTINUED)
NOTE 8 - NET PROFIT (LOSS) PER SHARE:
The following table reflects the calculation
of basic and diluted net profit (loss) per share (in dollars, except share amounts):
Six months ended
June 30,
Three months ended
June 30,
2024
2023
2024
2023
Net profit (loss) for the period
$
(
310,793
)
$
476,143
$
(
110,575
)
$
162,948
Less – interest earned on Investment held in Trust
        Account
(
149,236
)
(
1,063,043
)
(
75,305
)
(
318,002
)
Net loss excluding interest
$
(
460,029
)
$
(
586,900
)
$
(
185,880
)
$
(
155,054
)
Class A ordinary shares subject to possible redemption:
Numerator:
Net loss excluding interest
$
(
61,220
)
$
(
351,654
)
$
(
24,737
)
$
(
67,544
)
Accretion to Class A ordinary shares subject to possible
        redemption to redemption amount ("Accretion")
226,486
1,463,043
113,930
558,002
$
165,266
$
1,111,389
$
89,193
$
490,458
Denominator:
weighted average number of shares
515,019
5,015,185
515,019
2,589,567
Net profit per Class A ordinary share subject
        to possible redemption – basic and diluted
$
0.32
$
0.22
$
0.17
$
0.19
Non-redeemable Class A and B ordinary shares:
Numerator:
Net loss excluding interest
$
(
398,809
)
$
(
235,246
)
$
(
161,143
)
$
(
87,510
)
Accretion
(
77,250
)
(
400,000
)
(
38,625
)
(
240,000
)
(
476,059
)
(
635,246
)
(
199,768
)
(
327,510
)
Denominator:
weighted average number of shares
3,355,000
3,355,000
3,355,000
3,355,000
Net loss per non-redeemable Class A and
        B ordinary share – basic and diluted
$
(
0.14
)
$
(
0.19
)
$
(
0.06
)
$
(
0.10
)
The potential exercise of
5,750,000
Public Warrants and
190,000
Private Warrants sold in the Public Offering and Private Placements as detailed in Note 3 into
5,940,000
shares has not been included in the calculation of diluted net profit (loss) per share, since the exercise of the warrants is contingent
upon the occurrence of a future event.
Additionally, the effect of the conversion
of the Second, Third, Fourth and Fifth Promissory Notes into an aggregate amount of
1,500,000
private warrants (exercisable into
1,500,000
shares) as detailed in Note 4, has not been included in the calculation of diluted net profit (loss) per share, since the conversion of
the abovementioned promissory notes is contingent upon the occurrence of a future event.
As a result, diluted net profit (loss) per
share is the same as basic net profit (loss) per share for each of the periods presented, and for each class.
F-20
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(CONTINUED)
NOTE
9 - SUBSEQUENT EVENTS:
a.
Additional withdrawals under the Promissory Notes
Since the balance sheet date and up until the
filing date of these financial statements, an aggregate amount of $
62
thousand has been withdrawn under the Tenth Promissory Note, and a final injection into the trust account of approximately $
13
thousand has been withdrawn under the Eighth Promissory Note – rendering the latter fully withdrawn.
b.
Extraordinary General Meeting and redemption of Class A ordinary shares subject to possible redemption
On August 6, 2024 the Extraordinary General Meeting
has approved the proposed business combination with Silexion. In connection with the meeting, an additional
427,297
Class A ordinary shares subject to possible redemption have been redeemed. Consequently, $
4.8
million has been withdrawn from the trust account.
c.
Advisory and Placement Agent Agreement with Cohen & Company
On July 29, 2024 the Company has entered into
agreement with Cohen & Company, for providing capital markets advisory and placement agent services, in connection with both (i) the
completion of the proposed business combination with Silexion, and (ii) a private placement of equity, equity-linked, convertible and
/ or debt securities to be consummated with the business combination.
F-21
Report
of Independent Registered Public Accounting Firm
To
the Board of Directors and Shareholders of Moringa Acquisition Corp
Opinion
on the Financial Statements
We
have audited the accompanying balance sheets of Moringa Acquisition Corp (the "Company") as of December 31, 2023 and
2022, and the related statements of operations, changes in capital deficiency and cash flows for each of the two years in the period
ended December 31, 2023, including the related notes (collectively referred to as the "financial statements"). In our
opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31,
2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31,
2023 in conformity with accounting principles generally accepted in the United States of America.
Substantial
Doubt about the Company's Ability to Continue as a Going Concern
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1(e) to
the financial statements, the Company has limited cash and has incurred losses since inception. Moreover, if the Company is unable to
complete a business combination by August 19, 2024 then the Company will cease all operations except for the purpose of liquidating.
These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard
to these matters are also described in Note 1(e). The financial statements do not include any adjustments that might result from
the outcome of this uncertainty.
Basis
for Opinion
These
financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We
conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether
due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the
purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we
express no such opinion.
Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide
a reasonable basis for our opinion.
/s/ Kesselman &
Kesselman
Certified
Public Accountants (Isr.)
A member firm of PricewaterhouseCoopers International Limited
Tel-Aviv,
Israel
April 1, 2024
We
have served as the Company's auditor since 2020.
F-22
MORINGA
ACQUISITION CORP
BALANCE SHEETS
Note
December 31,
2023
December 31,
2022
U.S. Dollars
Assets
ASSETS:
Cash and cash equivalents
108,278
59,714
Investments held in Trust Account
5,697,632
116,692,038
Prepaid expenses
28,305
43,853
TOTAL ASSETS
5,834,215
116,795,605
Liabilities and shares subject to possible redemption
net
        of capital deficiency
LIABILITIES:
Accrued expenses
115,560
86,688
Related party
4
2,861,000
1,190,000
Private warrant liability
8,531
29,640
TOTAL LIABILITIES
2,985,091
1,306,328
COMMITMENTS AND CONTINGENCIES
5
—
—
CLASS A ORDINARY SHARES SUBJECT
        TO POSSIBLE REDEMPTION:
515,019
and
11,500,000
shares
        at redemption value $
11.06
and
        $
10.15
as
        of December 31, 2023 and 2022, respectively
5,697,632
116,692,038
CAPITAL DEFICIENCY:
7
Class A Ordinary Shares, $
0.0001
par
        value;
500,000,000
shares
        authorized,
3,354,999
and
480,000
issued
        and outstanding (excluding 515,019 and 11,500,000 shares subject to possible redemption) as of December 31, 2023 and 2022, respectively;
336
48
Class B Ordinary Shares, $
0.0001
par
        value;
50,000,000
shares
        authorized,
1
and
2,875,000
issued
        and outstanding as of December 31, 2023 and 2022, respectively;
*
288
Preferred Shares, $
0.0001
par
        value;
5,000,000
shares
        authorized,
no
shares
        issued and outstanding as of December 31, 2023 and 2022.
—
—
Additional paid-in capital
—
—
Accumulated deficit
(
2,848,844
)
(
1,203,097
)
TOTAL CAPITAL DEFICIENCY
(
2,848,508
)
(
1,202,761
)
TOTAL LIABILITIES AND SHARES SUBJECT
        TO POSSIBLE REDEMPTION NET OF CAPITAL DEFICIENCY
5,834,215
116,795,605
*
Less than one US dollar.
The
accompanying notes are an integral part of these financial statements
.
F-23
MORINGA
ACQUISITION CORP
STATEMENTS OF OPERATIONS
Note
Year ended
December 31,
2023
Year ended
December 31,
2022
U.S. Dollars
Except share data
Interest earned on investments held in trust account
1,364,444
1,685,666
General and administrative
9
(
1,122,480
)
(
1,232,342
)
Change in fair value of Private Warrant liability
21,109
130,701
Net profit for the year
263,073
584,025
Weighted average number of Class A Ordinary Shares
        subject to Possible Redemption
8
2,774,850
11,500,000
Basic and diluted net profit per
        Class A Ordinary Shares subject to Possible Redemption
$
0.51
0.07
Weighted average number of non-redeemable Class A
        and Class B Ordinary shares
3,355,000
3,355,000
Basic and
        diluted net loss per non-redeemable Class A and Class B Ordinary shares
$
(
0.34
)
(
0.07
)
The
accompanying notes are an integral part of these financial statements.
F-24
MORINGA
ACQUISITION CORP
STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY
Class A
ordinary shares
Class B
ordinary shares
Additional
Number of
shares
Par
value
Number of
shares
Par
value
paid-in
capital
Accumulated
deficit
Total
U.S. Dollars (except share data)
BALANCE AT December 31, 2021
480,000
48
2,875,000
288
855,994
(
951,078
)
(
94,748
)
Subsequent accretion of Class A Ordinary Shares subject to possible
        redemption to amount as of December 31, 2022
—
—
—
—
(
855,994
)
(
836,044
)
(
1,692,038
)
Net profit for the year
—
—
—
—
—
584,025
584,025
BALANCE AT December 31, 2022
480,000
48
2,875,000
288
—
(
1,203,097
)
(
1,202,761
)
Subsequent accretion of Class A Ordinary Shares subject to possible
        redemption to amount as of December 31, 2023
—
—
—
—
—
(
1,908,820
)
(
1,908,820
)
Conversion of Class B ordinary shares into Class A ordinary
        shares
2,874,999
288
(
2,874,999
)
(
288
)
—
—
—
Net profit for the year
—
—
—
—
—
263,073
263,073
BALANCE AT December 31, 2023
3,354,999
336
1
*
—
(
2,848,844
)
(
2,848,508
)
*
Less than one US dollar.
The
accompanying notes are an integral part of these financial statements.
F-25
MORINGA
ACQUISITION CORP
STATEMENTS OF CASH FLOWS
Year ended
December 31,
2023
Year ended
December 31,
2022
U.S. Dollars
CASH FLOWS FROM OPERATING ACTIVITIES:
Net profit for the year
263,073
584,025
Adjustments to reconcile net profit to net cash provided by operating
        activities:
Changes in the fair value of the private warrant liability
(
21,109
)
(
130,701
)
Changes in operating assets and liabilities:
Decrease in prepaid expenses
15,548
325,000
Increase (decrease) in related party
20,000
(
10,000
)
Increase in accrued expenses
28,872
48,112
Net cash provided by operating activities
306,384
816,436
CASH FLOWS FROM FINANCING ACTIVITIES:
Partial redemption of Class A ordinary shares subject to possible
        redemption
(
112,903,226
)
—
Proceeds from a promissory note – related
        party
1,651,000
890,000
Net cash provided by (used in) financing activities
(
111,252,226
)
890,000
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND INVESTMENTS
        HELD IN A TRUST ACCOUNT
(
110,945,842
)
1,706,436
CASH, CASH EQUIVALENTS AND INVESTMENTS
        HELD IN A TRUST ACCOUNT AT BEGINNING OF YEAR
116,751,752
115,045,316
CASH, CASH EQUIVALENTS AND INVESTMENTS
        HELD IN A TRUST ACCOUNT AT END OF YEAR
5,805,910
116,751,752
RECONCILIATION OF CASH, CASH EQUIVALENTS AND INVESTMENTS
        HELD IN A TRUST ACCOUNT:
Cash and cash equivalents
108,278
59,714
Investments held in trust account
5,697,632
116,692,038
Total cash, cash equivalents and investments held
        in a trust account
5,805,910
116,751,752
SUPPLEMENTARY INFORMATION REGARDING NON-CASH ACTIVITIES:
Conversion of Class B ordinary shares into Class A
        ordinary shares
288
—
The
accompanying notes are an integral part of these financial statements.
F-26
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:
a.
Organization and General
Moringa
Acquisition Corp (hereafter — the Company) is a blank check company, incorporated on September 24, 2020 as a Cayman
Islands exempted company, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination (hereafter — the Business Combination). The Company is an emerging growth company, as
defined in Section 2(a) of the Securities Act of 1933, as amended (the "Securities Act"), as modified
by the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act").
All
activity for the year ended December 31, 2023 relates to the Company's search for a target company, as well as attempts to
consummate the Proposed Holisto Merger which was terminated on August 8, 2023 as detailed in Note 1(f).
In
February 2024, the Company entered into a Business Combination Agreement with Silexion. Refer to Note 10(b) for further
information regarding the Proposed Business Combination.
The
Company has selected December 31 as its fiscal year end.
b.
Sponsor and Financing
The
Company's sponsor is Moringa Sponsor, L.P., a Cayman exempted limited partnership (which is referred to herein, together with its
wholly-owned subsidiary, Moringa Sponsor (US) LP, a Delaware limited partnership, as the "Sponsor").
The
registration statement relating to the Company's Public Offering was declared effective by the United States Securities and
Exchange Commission (the "SEC") on February 16, 2021. The initial stage of the Company's Public Offering — the
sale of
10,000,000
Units — closed
on February 19, 2021 (hereafter — the Closing of the Public Offering). Upon that closing and the concurrent closing
of the initial stage of the Private Placement (as defined below in Note 3). $
100,000,000
was
placed in a trust account (the "Trust Account") (discussed in Note 1(c) below). On March 3, 2021 upon the full
exercise by the underwriters of their over-allotment option for the Public Offering, the second stage of the Public Offering — the
sale of
1,500,000
Units — closed.
Upon that closing and the concurrent closing of the second stage of the Private Placement, an additional $
15,000,000
was
placed in the Trust Account. As part of the partial redemptions in conjunction with the First and Second Extensions, approximately $
113
million
have been withdrawn from the Investments held in Trust Account. The Company intends to finance its Initial Business Combination with the
net proceeds from the Public Offering and the Private Placement.
c.
The Trust Account
The
proceeds held in the Trust Account are invested in money market funds registered under the Investment Company Act and compliant with Rule 2a-7
thereof that maintain a stable net asset value of $
1.00
.
The
Company's complies with the provisions of ASU 2016-18, under which changes in proceeds held in the Trust Account are accounted
for as Changes in Cash, Cash Equivalents and Investments Held in a Trust Account in the Company's Statements of Cash Flows.
Refer
to Note 4(a) for information regarding proceeds loaned by the Sponsor under the Sixth and Eighth Promissory Notes, deposited
into the Trust Account.
d.
Initial Business Combination
The
Company's management has broad discretion with respect to the specific application of the net proceeds of the Public Offering, although
substantially all of the net proceeds of the Public Offering and the Private Placement are intended to be generally applied toward consummating
an Initial Business Combination. The Initial Business Combination must occur with one or more operating businesses or assets with a fair
market value equal to at least
80
%
of the net assets held in the Trust Account (excluding taxes payable on the income accrued in the Trust Account) as of the time of entry
into the related definitive agreement for the Initial Business Combination. There is no assurance that the Company will be able to successfully
consummate an Initial Business Combination.
F-27
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:
(cont.)
The
Company, after signing a definitive agreement for an Initial Business Combination, will provide its public shareholders the opportunity
to redeem all or a portion of their shares upon the completion of the Initial Business Combination, either (i) in connection with
a shareholder meeting called to approve the business combination or (ii) by means of a tender offer.
If
the Company holds a shareholder vote or there is a tender offer for shares in connection with an Initial Business Combination, a public
shareholder will have the right to redeem its shares for an amount in cash equal to its pro rata share of the aggregate amount then on
deposit in the Trust Account, calculated as of two days prior to the general meeting or commencement of the Company's tender
offer, including interest but less taxes payable. As a result, the Company's Class A ordinary shares subject to possible redemption
are classified as temporary equity upon the completion of the Public Offering, in accordance with the Financial Accounting Standards Board
("FASB") Accounting Standards Codification ("ASC") 480, "Distinguishing Liabilities from Equity".
Pursuant
to the Company's amended and restated memorandum and articles of association, if the Company is unable to complete the Initial Business
Combination within 24 months (as was subsequently extended, as described below) from the Closing of the Public Offering, the Company
will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than
ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then
on deposit in the Trust Account, including interest (which interest shall be net of taxes payable, and less up to $
100,000
of
interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish
public shareholders' rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as
promptly as reasonably possible following such redemption, subject to the approval of the Company's remaining shareholders and the
Company's board of directors, liquidate and dissolve, subject in each case to the Company's obligations under Cayman Islands
law to provide for claims of creditors and the requirements of other applicable law.
The
Sponsor and the Company's officers and directors have entered into a letter agreement with the Company, pursuant to which they have
waived their rights to liquidating distributions from the Trust Account with respect to any Class B ordinary share, including any
Class A ordinary share issuable upon conversion of such Class B ordinary shares, and Class A ordinary share (as described
in Note 7) held by them if the Company fails to complete the Initial Business Combination within 24 months (as was subsequently
extended) of the Closing of the Public Offering or during any extended time that the Company has to consummate an Initial Business Combination
beyond 24 months as a result of a shareholder vote to amend its amended and restated memorandum and articles of association. However,
if the Sponsor or any of the Company's directors or officers acquire any Class A ordinary shares subject to possible redemption,
they will be entitled to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete
the Initial Business Combination within the prescribed time period.
In
the event of a liquidation, dissolution or winding up of the Company after an Initial Business Combination, the Company's shareholders
are entitled to share ratably in all assets remaining available for distribution to them after payment of liabilities and after provision
is made for each class of stock, if any, having preference over the ordinary shares. The Company's shareholders have no preemptive
or other subscription rights. There are no sinking fund provisions applicable to the ordinary shares, except that the Company will provide
its shareholders with the opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then
on deposit in the Trust Account, under the circumstances, and, subject to the limitations, described herein.
F-28
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:
(cont.)
On
February 9, 2023 the Company held an extraordinary general meeting in lieu of the 2022 annual general meeting of the Company (hereafter — the
First Extension Meeting). At the First Extension Meeting, the Company's shareholders approved the proposal to adopt, by way of special
resolution, an amendment to the Amended and Restated Articles to extend the date by which the Company has to consummate a business combination
from the 24 month anniversary of the Closing of the Public Offering — i.e., February 19, 2023 to August 19,
2023 (hereafter — the Extended Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its
sole discretion.
On
August 18, 2023 the Company held an extraordinary general meeting in lieu of the 2023 annual general meeting of the Company (hereafter — the
Second Extension Meeting). At the Second Extension Meeting, the Company's shareholders approved, among other proposals, an amendment
to the Amended and Restated Memorandum and Articles of Association to further extend the date by which the Company has to consummate a
business combination from the Extended Mandatory Liquidation Date to August 19, 2024 (hereafter — the Second Extended
Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its sole discretion.
Refer
to Note 4(a) for information regarding proceeds received by the Company from the Sponsor under the Sixth and Eighth Promissory
Notes, which were deposited into the Trust Account.
Refer
to Note 7(a) for information regarding the partial redemptions of Class A ordinary shares subject to possible redemption,
following the First and Second Extension Meetings.
Refer
to Note 5(b) for information regarding the conversion of Class B ordinary shares into Class A ordinary shares, following
the Second Extension Meeting.
e.
Substantial Doubt about the
        Company's Ability to Continue as a Going Concern
As
of December 31, 2023 the Company had approximately $
108
thousand
of cash and an accumulated deficit of approximately $
2,848
thousand.
In connection with the Company's assessment of going concern considerations in accordance with Financial Accounting Standard Board's
Accounting Standard Codification 205-40, "Going Concern", the Company will need to obtain additional funds in order to
satisfy its liquidity needs in its endeavors to consummate a business combination.
Since
its inception date and through the issuance date of these financial statements, the Company's liquidity needs were satisfied through
an initial capital injection from the Sponsor, followed by net Private Placement proceeds, as well as several withdrawals of the Sponsor
promissory notes. Management has determined that it will need to continue to rely and is significantly dependent on both outstanding and
future promissory notes, or other forms of financial support (all of which the Sponsor is not obligated to provide). Moreover, following
the Second Extension Meeting, the Company has until August 19, 2024 to consummate an Initial Business Combination. If a business
combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. There can
be no assurance that the Company will be able to consummate any business combination ahead of the Second Extended Mandatory Liquidation
Date, nor will it be able to raise sufficient funds to complete an Initial Business Combination. These matters raise substantial doubt
about the Company's ability to continue as a going concern, for the subsequent twelve months following the issuance date of
these financial statements. In February 2024, the Company entered into a Business Combination Agreement with Silexion Therapeutics
Ltd. (hereafter — Silexion). Refer to Note 10(b) for further information regarding the Proposed Business Combination.
No
adjustments have been made to the carrying amounts of assets or liabilities should the company fail to obtain financial support in its
pursuit to consummate an Initial Business Combination, nor if it is required to liquidate after the Second Extended Mandatory Liquidation
Date.
F-29
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:
(cont.)
f.
Proposed Business Combination
On
June 9, 2022 the Company entered into a Business Combination Agreement for a proposed business combination (hereafter — the
Proposed Holisto Merger) with Holisto Ltd., a company organized under the laws of the State of Israel (hereafter — Holisto)
and Holisto MergerSub, Inc., a Cayman Islands exempted company and wholly-owned subsidiary of Holisto.
On
August 7, 2023 Holisto notified the Company that it was terminating the Proposed Holisto Merger agreement. The termination became
effective as of August 8, 2023. Upon termination of the Proposed Holisto Merger, all rights and obligations of each party to the
agreement ceased, except for those obligations of the parties that are intended to survive such termination and which remain in effect
in accordance with their respective terms. Neither the Company nor Holisto has any remaining substantive obligation to one another following
the above-mentioned termination, as of date of these financial statements.
In
February 2024, the Company entered into a Business Combination Agreement with Silexion. Refer to Note 10(b) for further
information regarding the Proposed Business Combination.
g.
Impact of War in Israel
On
October 7, 2023 Hamas terrorists infiltrated Israel's southern border from the Gaza Strip and conducted a series of attacks
on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along
Israel's border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries
and kidnapping of civilians and soldiers. Following the attack, Israel's security cabinet declared war against Hamas and a military
campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks.
The
intensity and duration of Israel's current war against Hamas is difficult to predict, as are such war's economic implications
on the business and operations on any target company with which the Company may combine, and on Israel's economy in general. These
events may cause wider macroeconomic deterioration in Israel, which may have a material adverse effect on the Company's ability
to effectively complete an Initial Business Combination, or on the operations of an Israel-centered target company with which the Company
may combine.
Refer
to Note 10(b) for further information regarding the Proposed Business Combination.
NOTE
2 — SIGNIFICANT ACCOUNTING POLICIES:
a.
Basis of Presentation
The
Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America ("U.S. GAAP") and the rules and regulations of the SEC.
b.
Emerging Growth Company
Section 102(b)(1) of
the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The
JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply
to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended
transition period which means that
when a standard is issued or revised and it has different application dates for public
or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard.
F-30
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
2 — SIGNIFICANT ACCOUNTING POLICIES:
(cont.)
This
may make comparison of the Company's financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible, because of the potential
differences in accounting standards used.
c.
Cash and cash equivalents
The
Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original
maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use by nature of the account
and are readily convertible to known amounts of cash.
d.
Class A Ordinary Shares
        subject to possible redemption
As
discussed in Note 1(b), all of the
11,500,000
Class A
ordinary shares sold as part of the Units in the Public Offering contained a redemption feature. In accordance with the Accounting
Standards Codification 480-10-S99-3A "Classification and Measurement of Redeemable Securities", redemption provisions
not solely within the control of the Company require the security to be classified outside of permanent equity. The Company has classified
all of the shares sold under the Public Units as subject to possible redemption.
Refer
to Note 7(a) for information regarding the partial redemptions of Class A ordinary shares subject to possible redemption,
following the First Extension Meeting and the Second Extension Meeting.
e.
Net profit (loss) per share
The
Company complies with accounting and disclosure requirements of FASB ASC Topic 260, Earnings Per Share. Net profit (loss) per share
is computed by dividing net profit (loss) by the weighted average number of shares outstanding during the period. The Company applies
the two-class method in calculating net profit (loss) per each class of shares: the non-redeemable shares, which include the Private Class A
Ordinary Shares, as defined in Note 7(a), and the Class B ordinary shares (hereafter and collectively — Non-Redeemable
class A and B ordinary shares); and the Class A ordinary shares subject to possible redemption.
In
order to determine the net profit (loss) attributable to each class, the Company first considered the total profit (loss) allocable to
both sets of shares. This is calculated using the total net profit (loss) less any interest earned on investments held in the Trust Account.
Then, any accretion is fully allocated to the Class A ordinary shares subject to redemption.
f.
Concentration of credit risk
Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which, at times, may exceed the Federal Depository Insurance Coverage of $
250,000
.
From the Company's incorporation and through December 31, 2023 the Company has not experienced any losses on these accounts.
As
of December 31, 2023 the Company held its cash and cash equivalents in an SVB bank account, and its investments Held in Trust Account
in Goldman Sachs money market funds. Money market funds are characterized as Level 1 investments within the fair value hierarchy under
ASC 820.
F-31
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
2 — SIGNIFICANT ACCOUNTING POLICIES:
(cont.)
g.
Public Warrants
The
Company applied the provisions of ASC 815-40 and classified its public warrants, issued as part of the Public Units as detailed
in Note 3, as equity securities.
h.
Private Warrant liability
The
Company accounts for the warrants in accordance with the guidance contained in Accounting Standards Codification 815 ("ASC 815"),
"Derivatives and Hedging", under which the warrants do not meet the criteria for equity treatment and must be recorded as
derivative liabilities. Accordingly, the Company classifies the warrants as liabilities at their fair value and adjusts the warrants to
fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants are exercised
or expire, and any change in fair value is recognized in the Company's statement of operations. Refer to Note 6 for information
regarding the model used to estimate the fair value of the Private Warrants (as defined in Note 3).
i.
Financial instruments
The
fair value of the Company's assets and liabilities, which qualify as financial instruments under the FASB ASC 820, "Fair
Value Measurements and Disclosures", approximates the carrying amounts represented in the balance sheet, primarily due to their
short-term nature.
j.
Use
        of estimates in the preparation of financial statements
The
preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates and such differences
may have a material impact on the Company's financial statements.
k.
Income
        tax
The
Company accounts for income taxes in accordance with ASC 740, "Income Taxes (hereafter — ASC 740). ASC 740
prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences
between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will
be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred
tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not
be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current
in accordance with ASU 2015-17.
l.
Recent accounting pronouncements
Management
does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted would have a material
effect on the Company's financial statements.
NOTE
3 — PUBLIC OFFERING AND PRIVATE PLACEMENTS:
In
the initial Public Offering, the Company issued and sold
11,500,000
units
(including
1,500,000
units
sold at a second closing pursuant to the underwriters' exercise of their over-allotment option in full) at an offering price of
$
10.00
per
unit (hereafter — the Units). The Sponsor and EarlyBirdCapital, Inc. (the representative of the underwriters) purchased,
in a private placement that occurred simultaneously with the two closings of the initial Public Offering (hereafter — the
Private Placement), an aggregate of
352,857
and
27,143
Units,
respectively, at a price of $
10.00
per
Unit.
F-32
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
3 — PUBLIC OFFERING AND PRIVATE PLACEMENTS:
(cont.)
Each
Unit (both those sold in the initial Public Offering and in the Private Placement) consists of one Class A ordinary share, $
0.0001
par
value, and one-half of one warrant, with each whole warrant exercisable for one Class A ordinary share (hereafter — each,
a Public Warrant and a Private Warrant, and collectively, the Warrants). Each Warrant entitles the holder thereof to purchase one whole
Class A ordinary share at a price of $
11.50
per
share, subject to adjustment. No fractional shares will be issued upon exercise of the Warrants and only whole Warrants trade. Each Warrant
will become exercisable 30 days after the completion of the Company's Initial Business Combination and will expire at 5:00 p.m.,
New York City time, five years after the completion of the Initial Business Combination or earlier upon redemption (only in
the case of the Public Warrants) or liquidation.
Once
the Public Warrants become exercisable, the Company may redeem them in whole and not in part at a price of $
0.01
per
Warrant upon a minimum of 30 days' prior written notice of redemption, if and only if the last reported sale price of the Company's
Class A ordinary shares equals or exceeds $
18.00
per
share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the
date on which the Company sends the notice of redemption to the Public Warrant holders.
The
Private Warrants are identical to the Public Warrants except that, for so long as they are held by the Sponsor, EarlyBirdCapital, Inc.
or their respective affiliates: (1) will not be redeemable by the Company; (2) may not (including the Class A ordinary
shares issuable upon exercise thereof), subject to certain limited exceptions, be transferred, assigned or sold by the holders thereof
until 30 days after the completion of the Company's Initial Business Combination; (3) may be exercised by the holders
thereof on a cashless basis; and (4) they (including the Class A ordinary shares issuable upon exercise thereof) are entitled
to registration rights.
The
Company paid an underwriting commission of
2.0
%
of the gross proceeds of the Public Offering and the full exercise of the underwriters' over-allotment, or $
2,300,000
,
in the aggregate, to the underwriters at the two closings of the Public Offering. Refer to Note 5(a) for more information regarding
an additional fee payable to the underwriters upon the consummation of an Initial Business Combination.
NOTE
4 — RELATED PARTY TRANSACTIONS:
a.
Promissory Notes
The
Company has issued several promissory note agreements to its Sponsor throughout its life term, in order to fulfil its ongoing operational
needs or preparations towards an Initial Business Combination. All outstanding promissory notes bear no interest and are repayable in
full upon the earlier of (a) the date of the consummation of the Company's Initial Business Combination, or (b) Second
Extended Mandatory Liquidation Date (hereafter and collectively — the Maturity Date).
First
Promissory Note
The
First Promissory Note withdrawn was borrowed and repaid in full in early 2021 and has subsequently expired.
Second
to Fifth Promissory Notes
On
August 9, 2021 the Company issued its Second Promissory Note to the Sponsor, according to which the former may withdraw up to $
1
million — which
has been withdrawn in full in several installments up until June 2022.
In
December 2022 the Company issued its Third and Fourth Promissory Notes (hereafter — the Third and Fourth Promissory
Notes), according to which the Company may withdraw up to an aggregate amount of $
190
thousand — which
were withdrawn in full on the same month.
F-33
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
4 — RELATED PARTY TRANSACTIONS:
(cont.)
On
February 8, 2023 the Company issued its Fifth Promissory Note to the Sponsor, in an amount of up to $
310
thousand,
which were withdrawn in full in several installments between February and June 2023.
According
to the terms of the outstanding Second, Third, Fourth and Fifth Promissory Notes, which comprise an aggregate principal of $
1.5
million,
the Sponsor may elect to convert any portion of the amounts outstanding into private warrants to purchase Class A ordinary shares
at a conversion price of $
1
per
private warrant on the Maturity Date. Such private warrants will have an exercise price of $
11.5
and
shall be identical to the private warrants included in the private units.
Sixth
Promissory Note
On
February 9, 2023 the Company issued its Sixth Promissory Note to the Sponsor, in an amount of $
480
thousand — under
which the funds that were loaned by the Sponsor were deposited into the Company's Trust Account, in connection with the First Extension.
The Sponsor provided six monthly injections of $
80
thousand
into the Company's Trust Account under the Sixth Promissory Note, starting February 19, 2023.
Seventh
Promissory Note
On
June 14, 2023 the Company issued its Seventh Promissory Note to the Sponsor in an amount of up to $
1
million,
of which $
210
thousand
were withdrawn at the same date; and approximately $
586
thousand
were withdrawn up until December 31, 2023.
Eighth
Promissory Note
On
August 18, 2023 the Company issued its Eighth Promissory Note to the Sponsor, in an amount of approximately $
154
thousand — under
which the funds that were loaned by the Sponsor were deposited into the Company's Trust Account, in connection with the Second Extension.
The Sponsor shall make monthly injections of approximately $
13
thousand
into the Company's Trust Account, starting August 19, 2023 and up until the earlier of the Second Extended Mandatory Liquidation
Date (or such earlier date that the Board determines to liquidate the Company) or the date on which an Initial Business Combination is
completed.
b.
Administrative Services Agreement
On
December 16, 2020 the Company signed an agreement with the Sponsor, under which the Company shall pay the Sponsor a fixed $
10
thousand
per month for office space, utilities and other administrative expenses. The monthly payments under this administrative services agreement
commenced on the effective date of the registration statement for the initial Public Offering and will continue until the earlier of (i) the
consummation of the Company's Initial Business Combination, or (ii) the Company's liquidation.
The
composition of the Related Party balance as of December 31, 2023 and 2022 is as follows:
December 31,
2023
December 31,
2022
U.S. dollars
Promissory notes
2,841,000
1,190,000
Accrual for Administrative Services Agreement
20,000
—
2,861,000
1,190,000
F-34
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
5 — COMMITMENTS AND CONTINGENCIES:
a.
Underwriters' Deferred
        Discount
Under
the Business Combination Marketing Agreement, the Company shall pay an additional fee (hereafter — the Deferred Commission)
of
3.5
%
of the gross proceeds of the Public Offering (or $
4,025,000
)
payable upon the Company's completion of the Initial Business Combination. The Deferred Commission will become payable to the underwriters
from the amounts held in the Trust Account solely in the event the Company completes an Initial Business Combination.
b.
Nasdaq Deficiency Notices
First
Deficiency Notice
On
March 28, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it is not in compliance
with Nasdaq Listing Rule 5550(a)(3) (hereafter — the First Deficiency), according to which the Company must
satisfy the Minimum Public Holders Rule which requires listed companies to have at least 300 public holders. The Company has submitted
its compliance plan on May 11, 2023 which was accepted by Nasdaq, which has then granted an extension of up to 180 calendar days
from the date of the notice — until September 24, 2023 — to evidence compliance with the rule.
On
September 27, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it has regained
compliance with the First Deficiency.
Second
Deficiency Notice
On
June 15, 2023 the Company received another notice from Nasdaq Listing Qualifications Department indicating that it is not in compliance
with Nasdaq Listing Rule 5550(b)(2) (hereafter — the Second Deficiency), according to which the Company must
sustain a market value of listed securities of at least $
35
million,
for continued listing on the Nasdaq Capital Market. The notice was only a notification of deficiency, not of imminent delisting, and has
no current effect on the listing or trading of the Company's securities on the Nasdaq Capital Market.
NOTE
6 — FAIR VALUE MEASUREMENTS:
Following
the Second Extension Meeting, the Sponsor converted
2,874,999
of
its Class B ordinary shares on a one to one basis into Class A ordinary shares, in an effort to regain compliance with the Second
Deficiency.
On
November 24, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it has regained
compliance with the Second Deficiency.
The
fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date (i.e., the exit price).
The
fair value hierarchy under ASC 820 prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives
the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the
lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:
Level
1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
F-35
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
6 — FAIR VALUE MEASUREMENTS:
(cont.)
Level
2: Quoted prices in markets that are not active or financial instruments for which significant inputs to models are observable (including
but not limited to quoted prices for similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly
or indirectly;
Level
3: Prices or valuations that require significant unobservable inputs (including the Management's assumptions in determining fair
value measurement).
Basis
for Fair Value Measurement
The
following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis
at December 31, 2023 by level within the fair value hierarchy:
Level
December 31,
2023
December 31,
2022
Assets:
Money market funds held in Trust Account
1
5,697,632
116,692,038
Liabilities:
Private warrant liability
3
8,531
29,640
The
estimated fair value of the Private Placement Warrants was determined using a binomial model to extract the market's implied probability
for an Initial Business Combination, using the Public Warrant's market price. Once probability was extracted, a Black-Scholes-Merton
model with Level 3 inputs was used to calculate the Private Warrants' fair value. Inherent in a Black-Scholes-Merton model are assumptions
related to expected life (term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the
volatility of its warrants based on implied volatility from the Company's traded warrants and from historical volatility of selected
peer companies' Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate
is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of
the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is
based on the historical rate, which the Company anticipates remaining at zero.
The
following table provides quantitative information regarding Level 3 fair value measurements inputs:
As of
December 31,
2023
As of
December 31,
2022
Share price
$
10.0
$
10.0
Strike price
$
11.5
$
11.5
Volatility
60
%
50
%
Risk-free interest rate
4.78
%
4.00
%
Dividend yield
0.00
%
0.00
%
U.S. dollars
Value of warrant liability measured with Level 3 inputs at December 31, 2022
29,640
Change in fair value of private warrant liability measured with Level 3 inputs
(
21,109
)
Value of warrant liability measured with Level 3 inputs at December 31, 2023
8,531
F-36
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
7 — CAPITAL DEFICIENCY:
a.
Ordinary Shares
Class A
Ordinary Shares
On
November 20, 2020 the Company issued
100,000
Class A
ordinary shares of $
0.0001
par
value each to designees of the Representative (hereafter — the Representative Shares) for a consideration equal to the
par value of the shares. The Representative Shares are deemed to be underwriters' compensation by FINRA pursuant to Rule 5110
of the FINRA Manual.
The
Company accounted for the issuance of the Representative Shares as compensation expenses amounting to $
860
,
with a corresponding credit to Additional Paid-In Capital, for the excess value over the consideration paid. The Company estimated the
fair value of the issuance based upon the price of Class B Ordinary Shares that were issued to the Sponsor.
Pursuant
to the initial Public Offering and the concurrent Private Placement that were each effected in two closings — on February 19,
2021 and March 3, 2021 — the Company issued and sold an aggregate of
11,500,000
and
380,000
Class A
ordinary shares as part of the Units sold in those respective transactions. The Units (which also included Warrants) were sold
at a price of $
10
per
Unit, and for an aggregate consideration of $
115
million
and $
3.8
million
in the Public Offering and Private Placement, respectively. See Note 3 above for further information regarding those share issuances.
The
Company classified its
11,500,000
Class A
ordinary shares subject to possible redemption as temporary equity. The remaining
480,000
Private
Class A ordinary shares were classified as permanent equity.
In
conjunction with the First and Second Extensions,
8,910,433
and
2,074,548
Class A
Ordinary Shares subject to possible redemption were redeemed, respectively, for their redemption value, including accrued interest. As
part of the partial redemptions approximately $
113
million
has been withdrawn from the Investments held in Trust Account.
Class B
Ordinary Shares
On
November 20, 2020 the Company issued
2,875,000
Class B
ordinary shares of $
0.0001
par
value each for a total consideration of $
25
thousand
to the Sponsor's wholly-owned Delaware subsidiary. Out of the
2,875,000
Class B
ordinary shares, up to
375,000
were
subject to forfeiture if the underwriters were to not exercise their over-allotment in full or in part. Because the underwriters exercised
their over-allotment option in full on March 3, 2021 that potential forfeiture did not occur.
Class B
ordinary shares are convertible into non-redeemable Class A ordinary shares, on a one-for-one basis, automatically on the day
of the Business Combination or at the election of the holder thereof at any time prior to the Business Combination. Class B ordinary
shares also possess the sole right to vote for the election or removal of directors, until the consummation of an Initial Business Combination.
Refer
to Note 5(b) for information regarding the conversion of Class B ordinary shares into Class A ordinary shares following
the Second Extension Meeting.
b.
Preferred shares
The
Company is authorized to issue up to
5,000,000
Preferred
Shares of $
0.0001
par
value each. As of December 31, 2023 the Company has
no
preferred shares issued and outstanding.
F-37
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
8 — NET PROFIT (LOSS) PER SHARE:
The
following table reflects the calculation of basic and diluted net profit (loss) per share (in dollars, except share amounts):
Year ended
December 31,
2023
2022
Net profit for the year
$
263,073
$
584,025
Less – interest earned on Investment
        held in Trust Account
(
1,364,444
)
(
1,685,666
)
Net loss excluding interest
$
(
1,101,371
)
$
(
1,101,641
)
Class A ordinary shares subject to possible redemption:
Numerator:
Net loss excluding interest
$
(
498,567
)
$
(
852,835
)
Accretion to Class A ordinary shares subject
        to possible redemption to redemption amount ("Accretion")
1,908,820
1,685,666
$
1,410,253
$
832,831
Denominator:
Weighted average number of shares
2,774,850
11,500,000
Basic and diluted net profit per
        Class A ordinary share subject to possible redemption
$
0.51
$
0.07
Non-redeemable Class A and B ordinary shares:
Numerator:
Net loss excluding interest
$
(
602,804
)
$
(
248,806
)
Accretion
(
544,376
)
—
(1,147,180
)
(248,806
)
Denominator:
Weighted average number of shares
3,355,000
3,355,000
Basic and diluted net loss per non-redeemable
        Class A and B ordinary share
$
(
0.34
)
$
(
0.07
)
The
potential exercise of
5,750,000
Public
Warrants and
190,000
Private
Warrants sold in the Public Offering and Private Placements as detailed in Note 3 into
5,940,000
shares
has not been included in the calculation of diluted net profit (loss) per share, since the exercise of the warrants is contingent upon
the occurrence of a future event.
Additionally,
the effect of the conversion of the Second, Third, Forth and Fifth Promissory Notes into an aggregate amount of
1,500,000
private
warrants (exercisable into 1,500,000 shares) as detailed in Note 4, has not been included in the calculation of diluted net profit
(loss) per share, since the conversion of the abovementioned promissory notes is contingent upon the occurrence of a future event.
As
a result, diluted net profit (loss) per share is the same as basic net profit (loss) per share for each of the periods presented, and
for each class.
F-38
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
9 — GENERAL AND ADMINISTRATIVE:
The
formation and other operating expenses for the years ended December 31, 2023 and 2022 are as follows:
December 31,
2023
December 31,
2022
U.S. dollars
Legal expenses
259,000
398,903
Audit, bookkeeping and accounting
146,600
143,101
Professional services
245,538
115,651
Management fees
120,000
120,000
Insurance
281,044
325,000
Nasdaq fees
70,000
129,500
Other
298
187
1,122,480
1,232,342
NOTE
10 — SUBSEQUENT EVENTS:
a.
Nasdaq Deficiency Note
On
February 20, 2024, the Company received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market
LLC indicating that unless the Company timely requests a hearing before the Nasdaq Hearings Panel (hereafter — the Panel),
trading of the Company's securities on The Nasdaq Capital Market would be suspended at the opening of business on February 29,
2024, due to the Company's non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete
one or more business combinations within 36 months of the effectiveness of its IPO registration statement.
The
Company timely requested a hearing before the Panel to request sufficient time to complete its previously disclosed proposed business
combination with Silexion. The hearing request has resulted in a stay of any suspension or delisting action pending the hearing, which
is scheduled to take place on April 23, 2024.
b.
Proposed Business Combination
On
February 21, 2024, the Company, together with its wholly-owned Israeli subsidiary (hereafter — the Merger Sub), entered
into a business combination agreement (hereafter — the BCA) with Silexion Therapeutics Ltd., an Israeli company (hereafter — Silexion).
The Business
Combination is expected to close in the third quarter of 2024, subject to the satisfaction of customary closing conditions under the BCA,
including the approval of the Business Combination by Silexion's and the Company's shareholders, and Nasdaq approval of the
initial listing of the combined company's securities.
Headquartered
in Israel, Silexion is a clinical-stage, oncology-focused biotechnology company that develops innovative treatments for unsatisfactorily
treated solid tumor cancers which have a mutated KRAS oncogene. The Business Combination values Silexion at a pre-transaction equity value
of $
62.5
million,
based on a $
10
price
per share.
The
BCA and the Business Combination have been unanimously approved by the boards of directors of the Company and Silexion.
F-39
SILEXION
THERAPEUTICS LTD.
UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS
June
        30,
December 31
2024
2023
U.S.
        dollars in thousands
Assets
CURRENT ASSETS:
Cash
        and cash equivalents
$
1,697
$
4,595
Restricted
        cash
25
25
Prepaid
        expenses
527
335
Other
        current assets
66
24
TOTAL
        CURRENT ASSETS
2,315
4,979
NON-CURRENT
        ASSETS:
Restricted
        cash
25
25
Long-term
        deposit
5
5
Property
        and equipment, net
40
49
Operating
        lease right-of-use asset
140
198
TOTAL
        NON-CURRENT ASSETS
210
277
TOTAL
        ASSETS
$
2,525
$
5,256
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
F-40
SILEXION
THERAPEUTICS LTD.
UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS
June
        30,
December 31
2024
2023
U.S.
        dollars in thousands
Liabilities
        and redeemable convertible preferred shares, net of capital deficiency
CURRENT LIABILITIES:
Trade
        payables
$
281
$
319
Current
        maturities of operating lease liability
108
112
Warrants
        to preferred shares (including $
321
and $
186
due to related party, as of June 30, 2024 and December 31, 2023, respectively)
345
200
Employee
        related obligations
251
207
Accrued
        expenses and other account payable
1,379
1,358
TOTAL
        CURRENT LIABILITIES
2,364
2,196
NON-CURRENT
        LIABILITIES:
Long-term
        operating lease liability
8
59
TOTAL
        NON-CURRENT LIABILITIES
$
8
$
59
TOTAL
        LIABILITIES
$
2,372
$
2,255
COMMITMENTS
        AND CONTINGENT LIABILITIES
REDEEMABLE
        CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTERESTS:
Convertible
        Series A Preferred Shares (NIS
0.01
par value,
510,000
shares authorized as of June 30, 2024 and December 31, 2023,
388,088
shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $
8,162
as of June 30, 2024;
Convertible
        Series A-1 Preferred Shares (NIS
0.01
par value per share,
120,000
shares authorized as of June 30, 2024 and December 31, 2023,
91,216
shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $
2,443
as of June 30, 2024;
Convertible
        Series A-2 Preferred Shares (NIS
0.01
par value per share,
200,000
shares authorized as of June 30, 2024 and December 31, 2023,
45,458
shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $
2,763
as of June 30, 2024;
Convertible
        Series A-3 Preferred Shares (NIS
0.01
par value per share,
80,000
shares authorized as of June 30, 2024 and December 31, 2023,
63,331
shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $
2,887
as of June 30, 2024;
Convertible
        Series A-4 Preferred Shares (NIS
0.01
par value per share,
815,000
shares authorized as of June 30, 2024 and December 31, 2023,
21,717
*
        shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $
1,076
as of June 30, 2024;
TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES
15,057
15,057
CONTINGENTLY
        REDEEMABLE NON-CONTROLLING INTERESTS
3,353
3,420
TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS
$
18,410
$
18,477
CAPITAL
        DEFICIENCY:
Ordinary
        shares (NIS
0.01
par value per share,
3,275,000
shares authorized as of June 30, 2024 and December 31, 2023;
250,492
and
219,354
shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively)
1
1
Additional
        paid-in capital
11,398
11,334
Accumulated
        deficit
(
29,656
)
(
26,811
)
TOTAL
        CAPITAL DEFICIENCY
$
(
18,257
)
$
(
15,476
)
TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY
$
153
$
3,001
TOTAL
        LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTEREST NET OF CAPITAL DEFICIENCY
$
2,525
$
5,256
*
Net of 121,119 treasury shares held by the subsidiary
        as of June 30, 2024 and December 31, 2023
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
F-41
SILEXION THERAPEUTICS LTD.
UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Six months ended
June 30
Three months ended
June 30
2024
2023
2024
2023
U.S. dollars in
thousands
U.S. dollars in
thousands
OPERATING EXPENSES:
Research and development (including $
34
from related party for the six months period ended June 30, 2024 and 2023, respectively, and including $
17
from related party for the three months period ended June 30, 2024 and 2023, respectively)
$
1,727
$
1,916
$
766
$
1,235
General and administrative (including $
24
from related party for the six months period ended June 30, 2024 and 2023, respectively, and including $
12
from related party for the three months period ended June 30, 2024 and 2023, respectively)
908
306
619
179
TOTAL OPERATING EXPENSES
2,635
2,222
1,385
1,414
OPERATING LOSS
(
2,635
)
(
2,222
)
(
1,385
)
(
1,414
)
Financial expenses, net (including $
135
and $
0
from related party for the six months period ended June 30, 2024 and 2023, respectively, and including $
60
and $
0
from related party for the three months period ended June 30, 2024 and 2023, respectively)
(
270
)
(
377
)
(
102
)
(
452
)
LOSS BEFORE INCOME TAX
$
(
2,905
)
$
(
2,599
)
$
(
1,487
)
$
(
1,866
)
INCOME TAX
7
20
2
10
NET LOSS
$
(
2,912
)
$
(
2,619
)
$
(
1,489
)
$
(
1,876
)
Attributable to:
Equity holders of the Company
(
2,845
)
(
2,427
)
(
1,472
)
(
1,653
)
Non-controlling interests
(
67
)
(
192
)
(
17
)
(
223
)
$
(
2,912
)
$
(
2,619
)
$
(
1,489
)
$
(
1,876
)
LOSS PER SHARE, BASIC AND DILUTED
$
(
11.31
)
$
(
9.61
)
$
(
5.87
)
$
(
6.54
)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING
        USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
251,655
252,462
250,847
252,462
The accompanying notes are an integral part
of the unaudited condensed consolidated financial statements.
F-42
SILEXION THERAPEUTICS LTD.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES
IN REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY
(U.S. dollars in thousands, except per share data)
Redeemable Convertible
        Preferred Shares
Total
redeemable
convertible
preferred
shares
        and
contingently
redeemable
Series A
preferred
        shares
Series A-1
preferred shares
Series A-2
preferred shares
Series A-3
preferred shares
Series A-4
preferred shares
Contingently
redeemable
non-
controlling
interests
Ordinary shares
Additional
paid-in
Accumulated
Total
capital
non-
controlling
interests,
net of
capital
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Amount
Shares
Amount
Capital
deficit
deficiency
deficiency
BALANCE
        AT JANUARY 1,
2023
388,088
$
7,307
91,216
$
2,392
45,458
$
2,264
63,331
$
2,683
-
-
$
3,586
219,354
$
1
$
11,203
$
(
21,869
)
$
(
10,665
)
$
7,567
CHANGES DURING
        THE SIX MONTHS PERIOD ENDED JUNE 30, 2023
(unaudited):
Issuance
        of Preferred A-4 shares, net of issuance cost
21,717
$
411
1
1
412
Share-based
        compensation
64
64
64
Net loss
(
192
)
(
2,427
)
(
2,427
)
(
2,619
)
BALANCE AS OF JUNE 30,
2023
388,088
$
7,307
91,216
$
2,392
45,458
$
2,264
63,331
$
2,683
21,717
$
411
$
3,394
219,354
$
1
$
11,268
$
(
24,296
)
$
(
13,027
)
$
(
5,424
)
BALANCE AT JANUARY
        1,
2024
388,088
$
7,307
91,216
$
2,392
45,458
$
2,264
63,331
$
2,683
21,717
$
411
$
3,420
219,354
$
1
$
11,334
$
(
26,811
)
$
(
15,476
)
$
3,001
CHANGES DURING
        THE SIX MONTHS PERIOD ENDED JUNE 30, 2024
(unaudited):
Exercise of options
31,138
**
*
*
*
*
Share-based
        compensation
64
64
64
Net loss
(
67
)
(
2845
)
(
2,845
)
(
2,912
)
BALANCE AS OF JUNE 30,
2024
388,088
$
7,307
91,216
$
2,392
45,458
$
2,264
63,331
$
2,683
21,717
$
411
$
3,353
250,492
$
1
$
11,398
$
(
29,656
)
$
(
18,257
)
$
153
*
Represents an amount less than $1
**
Represents fully vested pre-funded options for the Company's ordinary shares at an exercise price of
        $0.01 or 0.01 NIS per share
The accompanying notes are an integral part
of the unaudited condensed consolidated financial statements.
F-43
SILEXION THERAPEUTICS LTD.
UNAUDITED CONDENSED CONSOLIDATED
STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY
(U.S. dollars in thousands, except
per share data)
Redeemable Convertible
        Preferred Shares
Total
redeemable
convertible
preferred
shares
        and
contingently
redeemable
Series A
preferred shares
Series A-1
preferred shares
Series A-2
preferred shares
Series A-3
preferred shares
Series A-4 preferred
        shares
Contingently redeemable non-controlling
interests
Ordinary shares
Additional
paid-in
Accumulated
Total capital
non-
controlling
interests,
net
        of
capital
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Amount
Shares
Amount
Capital
deficit
deficiency
deficiency
BALANCE
        AT MARCH 31,
2023
388,088
$
7,307
91,216
$
2,392
45,458
$
2,264
63,331
$
2,683
-
-
$
3,617
219,354
$
1
$
11,235
$
(
22,643
)
$
(
11,407
)
$
6,856
CHANGES DURING
        THE THREE MONTHS PERIOD ENDED JUNE 30, 2023
(unaudited):
Issuance
        of Preferred A-4 shares, net of issuance cost
21,717
$
411
1
1
412
Share-based
        compensation
32
32
32
Net loss
(
223
)
(
1,653
)
(
1,653
)
(
1,876
)
BALANCE AS OF JUNE 30,
        2023
388,088
$
7,307
91,216
$
2,392
45,458
$
2,264
63,331
$
2,683
21,717
$
411
3,394
219,354
$
1
$
11,268
$
(
24,296
)
$
(
13,027
)
$
(
5,424
)
BALANCE AT MARCH 31,
2024
388,088
$
7,307
91,216
$
2,392
45,458
$
2,264
63,331
$
2,683
21,717
$
411
$
3,370
250,492
$
1
$
11,366
$
(
28,184
)
$
(
16,817
)
$
1,610
CHANGES DURING
        THE THREE MONTHS PERIOD ENDED JUNE 30, 2024
(unaudited):
Share-based
        compensation
32
32
32
Net loss
(
17
)
(
1,472
)
(
1,472
)
(
1,489
)
BALANCE AS OF JUNE 30,
2024
388,088
$
7,307
91,216
$
2,392
45,458
$
2,264
63,331
$
2,683
21,717
$
411
$
3,353
250,492
$
1
$
11,398
$
(
29,656
)
$
(
18,257
)
$
153
*
Represents an amount less than $1
The accompanying notes are an integral part
of the unaudited condensed consolidated financial statements.
F-44
SILEXION THERAPEUTICS LTD.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS
Six months ended
June 30
Three months ended
June 30
2024
2023
2024
2023
U.S. dollars in
thousands
U.S. dollars in
thousands
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
$
(
2,912
)
$
(
2,619
)
$
(
1,489
)
$
(
1,876
)
Adjustments required to reconcile loss to net cash used in operating
        activities:
Depreciation
15
29
7
14
Share-based compensation expenses
64
64
32
32
Non-cash financial expenses
219
257
83
278
Changes in operating assets and liabilities:
Increase (decrease) in prepaid expenses
(
192
)
(
2
)
(
63
)
5
decrease in other receivables
(
42
)
(
9
)
2
(
20
)
Increase (decrease) in trade payable
(
38
)
(
57
)
37
(
52
)
Net change in operating lease
4
(
5
)
2
(
2
)
Increase (decrease) in employee related obligations
44
(
62
)
(
3
)
(
20
)
Increase (decrease) in accrued expenses
21
(
183
)
327
(
35
)
Net cash used in operating activities
(
2,817
)
(
2,587
)
(
1,065
)
(
1,676
)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from short-term deposit
-
507
-
-
Purchase of property and equipment
(
6
)
(
2
)
-
(
2
)
Net cash provided by (used in (investing activities
(
6
)
505
-
(
2
)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of preferred shares and warrants, net of issuance
        costs
-
522
-
522
Exercise of options
*
-
-
-
Net cash provided by financing activities
*
522
-
522
DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED
        CASH
(
2,823
)
(
1,560
)
(
1,065
)
(
1,156
)
EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS
        AND RESTRICTED CASH
(
75
)
(
258
)
(
19
)
(
277
)
BALANCE OF CASH, CASH EQUIVALENTS
        AND RESTRICTED CASH AT BEGINNING OF PERIOD
4,645
8,309
2,831
7,924
BALANCE OF CASH, CASH EQUIVALENTS
        AND RESTRICTED CASH AT END OF PERIOD
$
1,747
$
6,491
$
1,747
$
6,491
*
Represents an amount less than $1
F-45
SILEXION THERAPEUTICS LTD.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS
Six months ended
June 30
Three months ended
June 30
2024
2023
2024
2023
U.S. dollars in thousands
U.S. dollars in thousands
Appendix
        A
–
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED
        CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS:
Cash and cash equivalents
1,697
6,442
1,697
6,442
Restricted cash
50
49
50
49
TOTAL CASH, CASH EQUIVALENTS AND
RESTRICTED
        CASH SHOWN IN STATEMENT OF CASH FLOWS
$
1,747
$
6,491
$
1,747
$
6,491
Appendix B
        - SUPPLEMENTARY INFORMATION:
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest received
$
25
$
78
$
6
$
39
The accompanying notes are an integral part
of the unaudited condensed consolidated financial statements.
F-46
SILEXION LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(U.S. dollars in thousands)
NOTE 1 - GENERAL:
a.
Silexion Therapeutics Ltd. (formerly known as Silenseed Ltd.) (hereinafter -"the Company") was incorporated in
        Israel and began its operations on November 30, 2008. Since its incorporation, the Company has been engaged in
one
operating segment - the research and development of innovative treatments for pancreatic cancer based on siRNAs, aiming to stop the production
        of a specific pancreatic cancer-causing protein known as the KRAS mutation. The Company's long-lived assets are located in Israel.
b.
On April 28, 2021, the Company signed an agreement with Guangzhou Sino-Israel Biotech Investment Fund ("GIBF")
        to establish a new company in China. On June 15, 2021 a company was established in China, named Silenseed (China) Ltd (hereinafter - the
        "Subsidiary"). The Company owns
51
%
        of the shares of the Subsidiary. The Subsidiary has not yet started significant operations as of June 30, 2024. The Company and the Subsidiary,
        together - "the Group".
c.
On February 21, 2024, the Company entered into a business combination agreement with Moringa Acquisition Corp
        (the "SPAC"), a Cayman Islands exempted company whose class A ordinary shares (as well as other instruments) are listed for
        trade on the Nasdaq Capital Market (Nasdaq: MACA), and April M.G. Ltd. (the "April Merger Sub"), an Israeli company and a
        wholly-owned subsidiary of the SPAC (the "Original BCA"). According to the Original BCA, April Merger Sub was to merge with
        and into the Company, with the Company continuing as the surviving entity and a wholly-owned subsidiary of the SPAC, and with the SPAC
        continuing as a public company following the completion of the merger and with its securities continuing to be traded on Nasdaq.
d.
On April 3, 2024, the Company entered into an Amended and Restated Business Combination Agreement (hereinafter,
        "A&R BCA") with the SPAC, Biomotion Sciences, a newly-formed Cayman Islands exempted company ("Biomotion Sciences"
        or "New Pubco"), August M.S. Ltd. an Israeli company and wholly-owned subsidiary of Biomotion Sciences ("Merger Sub
        1"), and Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and wholly-owned subsidiary of Biomotion Sciences
        ("Merger Sub 2") which replaced the Original BCA. The A&R BCA, provided for a technical change in the contemplated transaction
        structure to a "double dummy" structure, as a result of which both the Company and the SPAC will become wholly-owned subsidiaries
        of Biomotion Sciences, which will be the publicly-held, Nasdaq-listed entity, rather than the Company becoming a subsidiary of the Nasdaq-listed
        SPAC, as initially contemplated under the Original BCA.
Pursuant to the transactions
contemplated under the A&R BCA (collectively, the "Business Combination "), Merger Sub 2 was to merge with and into the
SPAC, with the SPAC continuing as the surviving company of such merger and a wholly-owned subsidiary of New Pubco (the "SPAC
Merger"), and Merger Sub 1 was to merge with and into the Company, with the Company continuing as the surviving company of such
merger and a wholly-owned subsidiary of New Pubco (the "Acquisition Merger"). Upon the effectiveness of the SPAC Merger,
each outstanding SPAC Class A ordinary share and the sole outstanding SPAC Class B ordinary share was to convert into an ordinary
share of New Pubco on a one-for-one basis. Each outstanding warrant to purchase one SPAC Class A ordinary share was to convert
into a warrant to purchase one New Pubco ordinary share, at the same exercise price. Upon the effectiveness of the Acquisition Merger,
each outstanding ordinary share and preferred share of the Company was to convert into such number of ordinary shares of New Pubco as
is equal to the quotient obtained by dividing (x) the quotient obtained by dividing (1) $
62,500
by (2) the number of fully diluted Company equity securities, by (y) $
0.01
(the "Silexion Equity Exchange Ratio"). Each outstanding Company warrant and Company option to purchase one Company share,
and Company restricted share unit (RSU) that may be potentially settled for one Company share, was to became exercisable for, or became
subject to settlement for (as applicable), such number of New Pubco ordinary shares as are equal to the Silexion Equity Exchange Ratio.
The exercise price per New Pubco ordinary share of each such converted Company option and Company warrant was to be adjusted based on
dividing the existing per share exercise price by the Silexion Equity Exchange Ratio. The terms of vesting, exercise and/or settlement,
as applicable, of such converted options, warrants and RSUs was to remain the same following such conversion, except that the vesting
of each Company option was to accelerate immediately prior to the Acquisition Merger, such that the New Pubco option into which it was
to be converted was to be fully vested, and all Company warrants were to be exercised (on a cashless basis) immediately prior to the Acquisition
Merger. Immediately prior to the closing of the Business Combination, seven directors were to be elected to New Pubco's board of
directors, of whom five were to designated by the Company and two were to be designated by the SPAC's sponsor (the "Sponsor").
The A&R BCA also required, as a closing condition, the transfer of the remaining outstanding shares of the Subsidiary held by GIBF
to the Company prior to the closing of the Business Combination in exchange for the issuance to GIBF of shares of the Company, which were
to convert into ordinary shares of New Pubco in accordance with the Silexion Equity Exchange Ratio upon the closing.
F-47
SILEXION LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(U.S. dollars in thousands)
NOTE 1 - GENERAL (continued):
e.
In connection with the closing of the Business Combination, the ordinary shares and warrants of Biomotion Sciences
        were expected to be listed on the Nasdaq Global Market and begin trading under the symbols "SLXN" and "SLXNW",
        respectively.
f.
The Business Combination was to be accounted for as a reverse recapitalization in accordance with US GAAP. Under
        this method of accounting, the Company was to be treated as the accounting acquirer and the SPAC was to be treated as the "acquired"
        company for financial reporting purposes. The Company was determined to be the accounting acquirer based on evaluation of the following
        facts and circumstances:
●
the Company's shareholders were to hold approximately
61.55
%
        of the outstanding voting interests in New Pubco upon the closing of the Business Combination;
●
the Company's senior management were to comprise the senior management of New Pubco;
●
the directors nominated by the Company were to constitute a majority of the board of directors of New Pubco (five
        out of seven of the initial directors);
●
the Company's operations were to comprise the ongoing operations of New Pubco; and
●
the Company's name was to be the name used by New Pubco (in replacement of Biomotion Sciences).
Under the reverse recapitalization
accounting method, the Business Combination was to be deemed to be the equivalent of a capital transaction in which the Company will issue
shares for the net assets of the SPAC. The net assets of the SPAC will be stated at fair value, with no goodwill or other intangible assets
recorded. Operations prior to the Business Combination will be those of the Company.
g.
On June 18, 2024 the Company entered into a waiver with the other parties to the A&R BCA (the "Investments
        Waiver"). The Investments Waiver provided, in principal part, that: (i) the conditions to closing under the A&R BCA requiring
        that an equity financing of the Company in an amount of at least $
3,500
(the "Silexion Equity Financing") and an investment by the Sponsor in New Pubco of between $
350
and $
500
(the "Sponsor Investment") shall have occurred, were waived; (ii)
1,382,325
of the Sponsor Investment Shares that were potentially issuable to the Sponsor by New Pubco in respect of the Sponsor Investment under
        the A&R BCA were to be issued to the Sponsor upon the closing notwithstanding that the Sponsor Investment has not taken place; (iii)
        the A&R Sponsor Promissory Note Cap (which sets the maximum dollar amount of Sponsor loans to the SPAC that may be converted by the
        Sponsor into New Pubco ordinary shares, subject to reduction for certain fees payable at the Closing, under an amended and restated promissory
        note to be issued by New Pubco to the Sponsor at the closing (the "A&R Sponsor Promissory Note") was increased from $
5.2
million to $
5.5
million, and (iv) the controlling stakeholder of the Sponsor is to be entitled to a gross monthly fee of $
10
for a period of 36 months following closing under the A&R BCA.
F-48
SILEXION LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(U.S. dollars in thousands)
NOTE 1 - GENERAL: (continued):
h.
On August 15, 2024, the Business Combination was completed (see Note 10).
i.
In October 2023, Hamas terrorists infiltrated Israel's southern border from the Gaza Strip and conducted
        a series of attacks on civilian and military targets. Following the attack, Israel's security cabinet declared war against Hamas
        and commenced a military campaign against Hamas and other terrorist organizations.
The Company's headquarters
are located in Modiin, Israel. As of the issuance date of these consolidated financial statements, the conflict between Israel and Hamas
has not had a material impact on the Company's results of operations or financial position, if at all. The Company cannot currently
predict the intensity or duration of Israel's war against Hamas, however, as most of the Company's trials are not executed
in Israel, the Company does not believe the recent terrorist attack and the subsequent declaration of war by the Israeli government against
the Hamas terrorist organization will have any material impact on its ongoing operations. The Company continues to monitor its ongoing
activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its
employees.
Any hostilities involving Israel,
or the interruption or curtailment of trade within Israel or between Israel and its trading partners could adversely affect the Company's
operations and results of operations and could make it more difficult for the Company to raise capital.
j.
Going concern:
Since its inception,
the Company has devoted substantially all its efforts to research and development, clinical trials, and capital raising activities. The
Company is still in its development and clinical stage and has not yet generated revenues.
The
Company has
incurred losses of $
2,912
and $
5,108
for the six-months period ended on June 30, 2024 and for the year ended December 31, 2023, respectively.
During the
six-month
period ended
on June 30, 2024, the Company had negative operating cash flows of $
2,817
.
As of June 30, 2024, the Company had cash and cash equivalents of $
1,697
.
On August 15, 2024, the Company completed a business combination with the SPAC (see Note 10(f)).
The Company expects to
continue incurring losses, and negative cash flows from operations. Management is in the process of evaluating various financing alternatives,
as the Company will need to finance future research and development activities, general and administrative expenses and working capital
through fund raising. However, there is no assurance that the Company will be successful in obtaining such funding.
Under these circumstances,
in accordance with the requirements of ASC 205-40, management has concluded that there is substantial doubt about the Company's
ability to continue as a going concern for at least 12 months from the date these financial statements are issued. The unaudited condensed
consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going
concern.
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:
a.
Unaudited
        Condensed Financial Statements
The accompanying condensed
financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance
with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial statements and follow
the requirements of the Securities and Exchange Commission ("SEC") for interim financial reporting. Accordingly, they do not
include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited
condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair
statement of the Company's consolidated financial position as of June 30, 2024, and the consolidated results of operations, statements
of changes in redeemable convertible preferred shares and capital deficiency and cash flows for the six-month period ended June 30, 2024
and 2023.
F-49
SILEXION LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(U.S. dollars in thousands)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
The consolidated results
for the six-month ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024.
These unaudited interim
condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company
as of and for the year ended December 31, 2023, which were included in Amendment No. 3 to the registration statement on Form S-4 filed
by Biomotion Sciences with the U.S. Securities and Exchange Commission on July 12, 2024. The significant accounting policies adopted and
used in the preparation of the financial statements are consistent with those of the previous financial year.
b.
Use of estimates
The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the
financial statements and accompanying notes. As applicable to these financial statements, the most significant estimates and assumptions
relate share-based compensation and to fair value of financial instruments. See Note 6 and Notes 4 and 7, respectively. These estimates
and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses
that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.
c.
Restricted cash
As of June 30, 2024 and December
31, 2023, the Company pledged an amount of $
25
in favor of a bank as collateral for guarantees provided to secure the lease payments.
The Company is required to
hold a minimum amount of NIS 85 in its bank account in order to maintain availability of a credit line from its credit card company.
d.
Fair value measurement
Fair value is based on the
price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between
market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance
establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels,
which are described as follows:
Level 1:
Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.
        The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2:
Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active
        market data of similar or identical assets or liabilities.
Level 3
Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest
        priority to Level 3 inputs.
F-50
SILEXION LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(U.S. dollars in thousands)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
In determining fair value,
the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the
extent possible and considers counterparty credit risk in its assessment of fair value.
e.
Concentration of credit risks
Financial instruments that
potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and
short-term deposits. The Company deposits cash and cash equivalents mostly with three low risk financial institution. The Company has
not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.
f.
Loss per share
The Company calculates loss
per share using the two-class method required for participating securities. This method entails allocating income available to ordinary
shareholders for the period between ordinary shares and participating securities based on their respective rights to receive dividends
as if all income for the period had been distributed. Basic loss per share is computed by dividing net loss by the weighted average number
of ordinary shares outstanding during the year, and fully vested pre-funded options for the Company's ordinary shares at an
exercise price of $
0.01
or
0.01
NIS per share. The Company considers these shares to be exercisable for little to no additional consideration. The Company also considers
its redeemable convertible preferred shares to be participating securities as the holders of the redeemable convertible preferred shares
would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis assuming conversion
of all redeemable convertible preferred shares into ordinary shares. However, these participating securities do not contractually require
the holders to participate in the Company's losses. Consequently, net loss for the periods presented was not allocated to the Company's
participating securities.
g.
New accounting pronouncements:
Recently
issued accounting standards not yet adopted:
1)
In November 2023, the FASB issued ASU No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable
        Segment Disclosures. The ASU improves reportable segments disclosure requirements, primarily through enhanced disclosures about significant
        segment expenses.  The ASU also require that a public entity that has a single reportable segment to provide all the disclosures
        required by the amendments and all existing segment disclosures in Topic 280. The ASU is effective for fiscal years beginning after
        December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating
        this ASU to determine its impact on the Company's segment disclosures.
2)
In December, 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disclosure
        of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies
        other income tax-related disclosures. The ASU will be effective for fiscal years beginning after December 15, 2025, and
        allows adoption on a prospective basis, with a retrospective option. The Company is in the process of assessing the impacts and method
        of adoption.
F-51
SILEXION LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(U.S. dollars in thousands)
NOTE 3 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:
Statement of operations:
a.
Research and development expenses:
Six months ended
June 30
Three months ended
June 30
2024
2023
2024
2023
Payroll and related expenses
$
514
$
569
$
235
$
245
Subcontractors and consultants
1,128
1,208
497
910
Materials
3
16
-
6
Rent and maintenance
49
78
18
35
Travel expenses
13
27
13
27
Other
20
18
3
12
$
1,727
$
1,916
$
766
$
1,235
b.
General and administrative expenses:
Payroll and related expenses
$
306
$
145
$
164
$
97
Professional services
448
28
369
10
Depreciation
15
29
7
14
Rent and maintenance
72
42
46
21
Patent registration
25
16
16
7
Travel expenses
16
16
7
16
Other
26
30
10
14
$
908
$
306
$
619
$
179
c.
Financial expense, net:
Change in fair value of financial liabilities measured at
        fair value
$
145
$
(
3
)
$
64
$
(
2
)
Issuance costs
-
3
-
3
Interest income
(
25
)
(
78
)
(
6
)
(
39
)
Foreign currency exchange loss (income), net
148
451
42
487
Other
2
4
2
3
Total financial expense (income), net
$
270
$
377
$
102
$
452
NOTE 4 - WARRANTS TO PURCHASE PREFERRED SHARES:
a.
On January 14, 2022, the Company issued warrants to acquire
47,495
Series A-2 Preferred Shares to various investors, the warrants were issued as part of the converted Simple Agreement for Future Equity
        (SAFE). These warrants feature an exercise price of $
60.783
per share and expired during 2023. As of June 30, 2023, there are
47,495
outstanding warrants. As of June 30, 2024, all warrants are expired.
b.
On May 30, 2023, the Company issued warrants to acquire
21,717
Series A-4 Preferred Shares to various investors, with an exercise price of $
24.769
per share and an expiration date of May 30, 2025. Issuance expenses amounted to $
3
.
As of June 30, 2024, there are outstanding warrants of
21,717
.
The Company classified the warrants for the
purchase of shares of its convertible redeemable preferred shares as a liability in its consolidated balance sheets, as these warrants
were freestanding financial instruments which underlying shares are contingently redeemable and, therefore, may obligate the Company to
transfer assets at some point in the future. The warrant liability was initially recorded at fair value upon the date of issuance and
was subsequently remeasured at fair value at each reporting date. The Company recorded revaluation expenses (income) amounting to $
145
and $(
3
)
for the six months periods ended June 30, 2024 and June 30, 2023 , respectively, and revaluation expenses (income) amounting to $
64
and $(
2
)
for the three months periods ended June 30, 2024 and June 30, 2023 and accounted for such revaluation expenses as part of its financial
(income) expense, net, in the statements of operations (see Note 7).
c.
For conversion of warrants after the reporting period see Note 10(e).
F-52
SILEXION LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(U.S. dollars in thousands)
NOTE
5 - REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY:
a.
As of June 30, 2024 and December 31,
        2023, the share capital is composed of
0.01
NIS par value shares, as follows:
June
        30, 2024
Authorized
Issued
        and
paid
Carrying
Value
Liquidation
Preference
Ordinary Shares
3,275,000
250,492
$
4,685
Preferred A Shares
510,000
388,088
$
7,307
$
8,162
Preferred A-1 Shares
120,000
91,216
$
2,392
$
2,443
Preferred A-2 Shares
200,000
45,458
$
2,264
$
2,763
Preferred A-3 Shares
80,000
63,331
$
2,683
$
2,887
Preferred A-4 Shares
815,000
21,717
$
411
$
1,076
December
        31, 2023
Authorized
Issued
        and
paid
Carrying
Value
Liquidation
Preference
Ordinary Shares
3,275,000
219,354
$
4,685
Preferred A Shares
510,000
388,088
$
7,307
$
8,162
Preferred A-1 Shares
120,000
91,216
$
2,392
$
2,443
Preferred A-2 Shares
200,000
45,458
$
2,264
$
2,763
Preferred A-3 Shares
80,000
63,331
$
2,683
$
2,887
Preferred A-4 Shares
815,000
21,717
$
411
$
1,076
NOTE 6 - SHARE-BASED COMPENSATION:
The Company's options expenses amounted to
a total of $
64
and $
64
in the six months periods ended June 30, 2024 and 2023, respectively. As of June 30, 2024,
39,898
shares remain available for grant under the Company's 2013 and 2023 Incentive Option Plans.
On July 4, 2024, the Company's board of directors
approved granting
178,686
RSUs to the Company's employees and directors.
F-53
SILEXION LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(U.S. dollars in thousands)
NOTE 6 - SHARE-BASED COMPENSATION (continued):
Summary of outstanding and exercisable
options:
Below is a summary of the Company's stock-based
compensation activity and related information with respect to options granted to employees and non-employees for the six months periods
ended June 30, 2024:
Number
of options
Weighted-
average
exercise price
(in
        U.S.
dollars)
Weighted-
average
remaining
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding at January 1, 2024
121,808
$
17.23
4.88
-
Granted
-
-
-
-
Exercised
(
31,138
)
$
0.01
(
0.01
)
$
490
Forfeited
(
735
)
$
26.78
(
6.02
)
-
Expired
(
30,185
)
(
18.08
)
-
-
Outstanding at June 30, 2024
59,750
$
25.66
7.34
-
Exercisable at June 30, 2024
33,554
$
24.78
7.00
-
Vested and expected to vest at June 30, 2024
59,750
$
25.66
7.34
-
Up to June 30, 2024 and for the year ended
December 31, 2023 no options were granted.
On June 30, 2024, there was $
220
of total unrecognized compensation cost related to unvested stock options granted under the Plan. That cost is expected to be recognized
over a weighted-average period of
1.73
years.
The share-based compensation expense by line
item in the accompanying consolidated statements of operations is summarized as follows:
Six months ended
June 30
Three months ended
June 30
2024
2023
2024
2023
Research and development
$
38
$
38
$
19
$
19
General and administrative
26
26
13
13
$
64
$
64
$
32
$
32
NOTE 7 - FAIR VALUE MEASUREMENTS:
Financial instruments measured at fair value on a recurring
basis
The Company's assets and liabilities
that are measured at fair value as of June 30, 2024, and December 31, 2023, are classified in the tables below in one of the six categories
described in "Note 2 – Fair value measurement":
June 30, 2024
Level 3
Total
Financial Liabilities
Warrants to preferred shares
$
345
$
345
December 31, 2023
Level 3
Total
Financial Liabilities
Warrants to preferred shares
$
200
$
200
F-54
SILEXION LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(U.S. dollars in thousands)
NOTE 7 - FAIR VALUE MEASUREMENTS (continued):
The following is a roll forward of the fair
value of liabilities classified under Level 3:
Six months ended
June 30,
Three months ended
June 30,
2024
2023
2024
2023
Warrants
Warrants
Warrants
Warrants
Fair value at the beginning of the period
$
200
$
3
$
281
$
2
Issuance
-
111
-
111
Change in fair value
145
(
3
)
64
(
2
)
Fair value at the end of the period
$
345
$
111
$
345
$
111
The fair value of the Company's warrant
liabilities as of June 30, 2024 and December 31, 2023 was estimated using a hybrid model in order to reflect two scenarios: (1) an IPO
event (including de-SPAC transaction) and (2) other liquidation events. For further details see Note 12 in the annual consolidated financial
statements.
The valuation under the 'other liquidation
events' scenario was assessed using an option pricing model (OPM) by implementing a Monte Carlo Simulation, which treats the financial
instruments in the Company's equity as contingent claims whose future payoff depends on the Company's future equity value.
The Company's entire equity value in 2023 was calculated based, among others, on the financing round closest to the valuation date.
The fair value of the Company's warrant
liabilities as of June 30, 2023 was estimated using only the 'other liquidation events' scenario.
The following table presents the main assumptions
used in the hybrid model for the periods presented:
June 30
2024
2023
Expected volatility
74.82
%
82.80
%
Assumptions regarding the price of the underlying shares:
Probability of an IPO scenario (including de-SPAC transaction)
67
%
-
Expected time to IPO (including de-SPAC transaction) (years)
0.137
-
Probability of other liquidation events
33
%
100
%
Expected time to liquidation (years)
2.25
3
Expected return on Equity
22
%
23
%
A significant increase in the expected volatility,
or in the probability of an IPO (including de-SPAC transaction), could each increase the fair value of the related instruments. A significant
decrease in the expected term of the warrants or expected time to IPO (including de-SPAC transaction), could each decrease the fair value
of related instruments. In combination, changes in these inputs could result in a significantly higher or lower fair value measurement
if the input changes were to be compounding, or could result in a minimally higher or lower fair value measurement if the input changes
were of opposite effects and consequently offset each other.
Financial instruments not measured
at fair value
The carrying amounts of cash and cash equivalents,
restricted cash, receivables, trade payables and other liabilities approximate their fair value due to the short-term maturity of such
instruments.
F-55
SILEXION LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(U.S. dollars in thousands)
NOTE 8 - NET LOSS PER SHARE:
The following table sets forth the computation
of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented (USD in thousands, except per
share data):
Six months ended
June 30
Three months ended
June 30
2024
2023
2024
2023
Numerator:
Net loss
$
2,912
$
2,619
$
1,489
$
1,876
Net loss attributable to ordinary shareholders, basic and diluted:
$
2,845
$
2,427
$
1,472
$
1,653
Denominator:
Weighted-average shares used in computing net loss
        per share attributable to ordinary shareholders, basic and diluted
251,655
252,462
250,847
252,462
Net loss per share attributable to ordinary shareholders,
        basic and diluted
$
11.31
$
9.61
$
5.87
$
6.54
Basic loss per share is computed on the basis
of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the period, including fully
vested pre-funded options for the Company's ordinary shares at an exercise price of $
0.01
or
0.01
NIS per share, as the Company considers these shares to be exercised for little to no additional consideration.
As of June 30, 2024 and June 30, 2023, the
basic loss per share calculation included a weighted average number of
300
and
33,108
,
respectively, of fully vested pre-funded options. As the inclusion of other potential ordinary shares equivalents in the calculation would
be anti-dilutive for all periods presented, diluted net loss per share is the same as basic net loss per share.
The following instruments were not included
in the computation of diluted earnings per share because of their anti-dilutive effect:
-
Redeemable convertible preferred shares;
-
Warrants to purchase redeemable convertible preferred shares;
-
Share-based compensation issuable at substantial consideration.
NOTE 9 - TRANSACTIONS AND BALANCES WITH RELATED PARTIES
:
Transactions with related parties which are
shareholders and directors of the Company:
a.
Transactions:
Six months ended
June 30
Three months ended
June 30
2024
2023
2024
2023
Share-based compensation included in research and development
        expenses
$
34
$
34
$
17
$
17
Share-based compensation included in general and administrative expenses
$
24
$
24
$
12
$
12
Financial expenses
$
135
$
-
$
60
$
-
b.
Balances:
June 30,
2024
December 31,
2023
Non-Current liabilities -
Warrants to preferred shares
$
321
$
186
F-56
SILEXION LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(U.S. dollars in thousands)
NOTE 10 - SUBSEQUENT EVENTS
The Company's management has performed
an evaluation of subsequent events through August 19, 2024, the date the financial statements were available to be issued.
a.
On July 4, 2024, the Company's board of directors approved granting
178,686
Restricted Stock Units (RSUs) to employees, service providers, and directors. These RSUs vest immediately upon the grant date, with
100
%
        vesting at the time of grant.
b.
On July 14, 2024, the Company's shareholders approved, inter alia, the A&R BCA, the Investments Waiver,
        the Business Combination and granting of new RSUs to the Company's directors and certain related parties.
c.
On July 16, 2024, the U.S. Securities and Exchange Commission (SEC) issued an order of effectiveness for the registration
        statement on Form S-4 filed by Biomotion Sciences that registered the issuance of all ordinary shares of Biomotion Sciences issuable pursuant
        to the Business Combination. On July 17, 2024, the SPAC published notice of an extraordinary general meeting at which the Business Combination
        was to be presented for approval, and on July 19, 2024, the SPAC commenced the distribution of proxy materials for that extraordinary
        general meeting. On August 6, 2024, the SPAC held that extraordinary general meeting, and all proposals related to the Business Combination
        were approved by the SPAC's shareholders.
d.
On August 5, 2024, a conversion agreement was signed by and among Biomotion Sciences, GIBF and the Subsidiary,
which implements the transfer of
GIBF's
49
%
holdings
in
the Subsidiary directly
to
Biomotion Sciences (in lieu of to the Company) in exchange for
        the issuance to GIBF of ordinary shares of New Pubco upon the closing of the Business Combination
).
e.
In August 2024, certain Company warrant holders exercised their warrants in a 'cashless' manner for
1,257
A-1 Preferred Shares and
8,320
A-4 Preferred Shares of the Company.
f.
On August 15, 2024, the Business Combination was completed in accordance with the terms of the A&R BCA, as
        modified by the Investments Waiver. As a result of the Business Combination, the Company has become a wholly-owned subsidiary of Biomotion
        Sciences, and its security holders have received securities of Biomotion Sciences in accordance with the Silexion Equity Exchange Ratio.
        On August 16, 2024, the ordinary shares and warrants of Biomotion Sciences begin trading on the Nasdaq Global Market under the symbols
        "SLXN" and "SLXNW", respectively.
F-57
Report of Independent Registered Public Accounting
Firm
To the board of directors and shareholders of Silexion
Therapeutics Ltd.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance
sheets of Silexion Therapeutics Ltd. and its subsidiary (the "Company") as of December 31, 2023 and 2022, and the related
consolidated statements of operations, changes in redeemable convertible preferred shares and capital deficiency and cash flows for the years
then ended, including the related notes (collectively referred to as the "consolidated financial statements"). In our opinion,
the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31,
2023 and 2022, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting
principles generally accepted in the United States of America.
Substantial Doubt about the Company's Ability to Continue as
a Going Concern
The accompanying consolidated financial statements have
been prepared assuming that the Company will continue as a going concern. As discussed in Note 1e to the consolidated financial statements,
the Company has suffered recurring losses from operations and has cash outflows from operating activities that raise substantial doubt
about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1e.
The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These consolidated financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements
based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits of these consolidated financial
statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the
risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable
basis for our opinion.
Tel-Aviv, Israel
/s/ Kesselman & Kesselman
May 9, 2024
Certified Public Accountants (lsr.)
A member firm of PricewaterhouseCoopers International Limited
We have served as the Company's auditor since 2023.
F-58
SILEXION THERAPEUTICS LTD.
CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except share data)
December 31
2023
2022
Assets
CURRENT ASSETS:
Cash and cash equivalents
$
4,595
$
8,259
Restricted cash
25
25
Short term deposits
—
507
Prepaid expenses
335
6
Other current assets
24
42
TOTAL CURRENT ASSETS
4,979
8,839
NON-CURRENT ASSETS:
Restricted cash
25
25
Long-term deposit
5
5
Property and equipment, net
49
159
Operating lease right-of-use asset
198
305
TOTAL NON-CURRENT ASSETS
277
494
TOTAL ASSETS
$
5,256
$
9,333
Liabilities and redeemable convertible preferred
        shares,
net of capital deficiency
CURRENT LIABILITIES:
Trade payables
$
319
$
240
Current maturities of operating lease liability
112
115
Warrants to preferred shares (including $
186
and $
0
due to related party, respectively)
200
3
Employee related obligations
207
253
Accrued expenses
1,358
999
TOTAL CURRENT LIABILITIES
2,196
1,610
NON-CURRENT LIABILITIES:
Long-term operating lease liability
59
156
TOTAL NON-CURRENT LIABILITIES
$
59
$
156
TOTAL LIABILITIES
$
2,255
$
1,766
COMMITMENTS AND CONTINGENT
        LIABILITIES
(Note 6)
REDEEMABLE CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING
        INTERESTS:
Convertible Series A Preferred Shares (NIS
0.01
par value,
510,000
shares authorized as of December 31, 2023 and 2022,
388,088
shares issued and outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $
8,162
as of December 31, 2023;
Convertible Series A-1 Preferred Shares (NIS
0.01
par value per share,
120,000
shares authorized as of December 31, 2023 and 2022,
91,216
shares issued and outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $
2,443
as of December 31, 2023;
Convertible Series A-2 Preferred Shares (NIS
0.01
par value per share,
200,000
shares authorized as of December 31, 2023 and 2022,
45,458
shares issued and outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $
2,763
as of December 31, 2023;
Convertible Series A-3 Preferred Shares (NIS
0.01
par value per share,
80,000
shares authorized as of December 31, 2023 and 2022,
63,331
shares issued and outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $
2,887
as of December 31, 2023;
Convertible Series A-4 Preferred Shares (NIS
0.01
par value per share,
815,000
and
0
shares authorized as of December 31, 2023 and 2022, respectively,
21,717
*
        and
0
shares issued and outstanding as of December 31, 2023 and 2022, respectively); aggregate liquidation preference of $
1,076
as of December 31, 2023;
TOTAL REDEEMABLE CONVERTIBLE PREFERRED
        SHARES
15,057
14,646
CONTINGENTLY REDEEMABLE NON-CONTROLLING
        INTERESTS
3,420
3,586
TOTAL REDEEMABLE CONVERTIBLE PREFERRED
        SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS
$
18,477
$
18,232
CAPITAL DEFICIENCY:
Ordinary shares (NIS
0.01
par value per share,
3,275,000
shares authorized as of December 31, 2023 and 2022;
219,354
shares issued and outstanding as of December 31, 2023 and 2022)
1
1
Additional paid-in capital
11,334
11,203
Accumulated deficit
(
26,811
)
(
21,869
)
TOTAL CAPITAL DEFICIENCY
$
(
15,476
)
$
(
10,665
)
TOTAL REDEEMABLE CONVERTIBLE PREFERRED
        SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY
$
3,001
$
7,567
TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE
        PREFERRED SHARES AND NON-CONTROLLING INTEREST NET OF CAPITAL DEFICIENCY
$
5,256
$
9,333
*
Net of 121,119 treasury shares held by a subsidiary as of December 31, 2023 (see Note 9(b)(2))
The accompanying notes are an integral part
of these consolidated financial statements.
F-59
SILEXION THERAPEUTICS LTD.
CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share data)
Year ended
December 31
2023
2022
OPERATING EXPENSES:
Research and development, net (including $
69
and $
49
from related party, respectively)
$
3,708
$
3,226
General and administrative (including $
48
and $
37
from related party, respectively)
973
634
TOTAL OPERATING EXPENSES
4,681
3,860
OPERATING LOSS
4,681
3,860
Financial expenses (income), net (including $
83
and $
0
from related party, respectively)
395
(
396
)
LOSS BEFORE INCOME TAX
$
5,076
$
3,464
INCOME TAX
32
24
NET LOSS FOR THE YEAR
$
5,108
$
3,488
Attributable to:
Equity holders of the Company
4,942
3,215
Non-controlling interests
166
273
$
5,108
$
3,488
LOSS PER SHARE, BASIC AND DILUTED
$
19.57
$
12.74
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING
        USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
252,462
252,371
The accompanying notes are an integral
part of these consolidated financial statements.
F-60
SILEXION THERAPEUTICS LTD.
CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE
CONVERTIBLE PREFERRED
SHARES AND CAPITAL DEFICIENCY
(U.S. dollars in thousands, except per share data)
Re
deemable
        Convertible Preferred Shares
Total
redeemable
convertible
preferred
shares
        and
contingently
redeemable
Series A
        preferred shares
Series A-1
        preferred shares
Series A-2
        preferred shares
Series A-3
        preferred shares
Series A-4
        preferred shares
Contingently
        redeemable non- controlling interests
Ordinary
        shares
Additional
        paid-in
Accumulated
Total capital
non-
controlling
interests,
net
        of
capital
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Amount
Shares
Amount
Capital
deficit
deficiency
deficiency
BALANCE
        AT JANUARY 1, 2022
388,088
$
7,307
91,216
$
2,392
—
—
—
—
—
—
$
3,859
219,251
$
1
$
11,006
$
(
18,654
)
$
(
7,647
)
$
5,911
CHANGES
        DURING 2022:
Issuance
        of Preferred A-2 shares, net of issuance cost, see Note 9(b)
45,458
2,264
2,264
Conversion
        of simple agreements for future equity (SAFE) to Preferred A-3 shares, see Note 7
63,331
2,683
69
69
2,752
Exercise of options
103
*
3
3
3
Share-based
        compensation
125
125
125
Net
        loss
(
273
)
(
3,215
)
(
3,215
)
(
3,488
)
BALANCE
        AT DECEMBER 31, 2022
388,088
$
7,307
91,216
$
2,392
45,458
$
2,264
63,331
$
2,683
—
—
$
3,586
219,354
$
1
$
11,203
$
(
21,869
)
$
(
10,665
)
$
7,567
CHANGES
        DURING 2023:
Issuance
        of Preferred A-4 shares, net of issuance cost, see Note 9(b)
21,717
411
1
1
412
Share-based
        compensation
130
130
130
Net
        loss
(
166
)
(
4,942
)
(
4,942
)
(
5,108
)
BALANCE
        AT DECEMBER 31, 2023
388,088
$
7,307
91,216
$
2,392
45,458
$
2,264
63,331
$
2,683
21,717
$
411
$
3,420
219,354
$
1
$
11,334
$
(
26,811
)
$
(
15,476
)
$
3,001
*
Represents an amount less than $1
The accompanying notes are an integral part
of these consolidated financial statements.
F-61
SILEXION THERAPEUTICS LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S. dollars in thousands)
Year ended
December 31
2023
2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
$
(
5,108
)
$
(
3,488
)
Adjustments required to reconcile loss to net cash used in operating
        activities:
Depreciation
45
57
Share-based compensation expenses
130
125
Non-cash financial expenses
318
(
268
)
Gain on disposal of property and equipment
(
1
)
—
Changes in operating assets and liabilities:
Increase (decrease) in prepaid expenses
(
329
)
415
Increase (decrease) in other receivables
18
(
40
)
Increase (decrease) in trade payable
79
(
38
)
Net change in operating lease
6
(
34
)
Increase (decrease) in employee related obligations
(
46
)
(
53
)
Increase (decrease) in accrued expenses
359
(
11
)
Net cash used in operating activities
(
4,529
)
(
3,335
)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from long-term deposits
—
16
Investment in short-term deposit
—
(
500
)
Proceeds from short-term deposit
507
—
Purchase of property and equipment
(
12
)
(
40
)
Proceeds from sale of property and equipment
78
—
Net cash provided by (used in) investing activities
573
(
524
)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of preferred shares and warrants, net of issuance
        costs
522
2,749
Exercise of options
—
3
Net cash provided by financing activities
522
2,752
DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED
        CASH
(
3,434
)
(
1,107
)
EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS
        AND RESTRICTED CASH
(
230
)
(
667
)
BALANCE OF CASH, CASH EQUIVALENTS
        AND RESTRICTED CASH AT BEGINNING OF YEAR
8,309
10,083
BALANCE OF CASH, CASH EQUIVALENTS
        AND RESTRICTED CASH AT END OF YEAR
$
4,645
$
8,309
Appendix
        A –
RECONCILIATION OF CASH, CASH EQUIVALENTS
        AND RESTRICTED CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS:
Cash and cash equivalents
4,595
8,259
Restricted cash
50
50
TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH
        FLOWS
$
4,645
$
8,309
Appendix B – SUPPLEMENTARY INFORMATION:
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING
        ACTIVITIES NOT INVOLVING CASH FLOWS:
Transition to ASC 842 – recognition of operating right of use assets
        and operating lease liabilities
$
—
$
391
Conversion of SAFEs to preferred shares and warrants
$
—
$
2,683
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest received
$
153
$
114
The accompanying notes are an integral part
of these consolidated financial statements.
F-62
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 1 — GENERAL:
a.
Silexion Therapeutics Ltd. (formerly known as Silenseed Ltd.) (hereinafter -"the Company") was incorporated
        in Israel and began its operations on November 30, 2008. Since its incorporation, the Company has been engaged in
one
operating segment — the research and development of innovative treatments for pancreatic cancer based on siRNAs, aiming
        to stop the production of a specific pancreatic cancer-causing protein known as the KRAS mutation. The Company's long-lived assets
        are located in Israel.
b.
On April 28, 2021, the Company signed an agreement with Guangzhou Sino-Israel Biotech Investment Fund (GIBF)
        to establish a new company in China. On June 15, 2021 a company was established in China, named Silenseed (China) Ltd (hereinafter — the
        "Subsidiary"). The Company owns
51
%
        of the shares of the Subsidiary. The Subsidiary has not yet started significant operations as of December 31, 2023. The Company and
        Silenseed (China) Ltd., together — "the Group" (see Note 9d).
c.
On April 3, 2024, the Company entered into an Amended and Restated Business Combination Agreement (hereinafter,
        "A&R BCA") with Moringa acquisition Corp (the "SPAC"), Biomotion Sciences, August M.S. Ltd. and Moringa
        Acquisition Merger Sub Corp (hereinafter — the "Business Combination") which replaced an earlier business
        combination agreement, for further information see Note 15.
d.
In October 2023, Hamas terrorists infiltrated Israel's southern border from the Gaza Strip and conducted
        a series of attacks on civilian and military targets. Following the attack, Israel's security cabinet declared war against Hamas
        and commenced a military campaign against Hamas and other terrorist organizations.
The Company's headquarters are located
in Modiin, Israel. As of the issuance date of these consolidated financial statements, the conflict between Israel and Hamas has not had
a material impact on the Company's results of operations or financial position, if at all. The Company cannot currently predict
the intensity or duration of Israel's war against Hamas, however, as most of the Company's trials are not executed in Israel,
the Company does not believe the recent terrorist attack and the subsequent declaration of war by the Israeli government against the Hamas
terrorist organization will have any material impact on its ongoing operations. The Company continues to monitor its ongoing activities
and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employees.
Any hostilities involving Israel, or the interruption
or curtailment of trade within Israel or between Israel and its trading partners could adversely affect the Company's operations
and results of operations and could make it more difficult for the Company to raise capital.
e.
Going concern
:
Since its inception, the Company has devoted
substantially all its efforts to research and development, clinical trials, and capital raising activities. The Company is still in its
development and clinical stage and has not yet generated revenues. The Company has incurred losses of $
5,108
and $
3,488
for the years ended on December 31, 2023 and 2022, respectively. During the years ended on December 31, 2023 and 2022,
the Company had negative operating cash flows of $
4,529
and $
3,335
,
respectively. As of December 31, 2023, the Company had cash and cash equivalents of $
4.6
million. The Company expects to continue incurring losses, and negative cash flows from operations. Management is in the process of evaluating
various financing alternatives, as the Company will need to finance future research and development activities, general and administrative
expenses and working capital through fund raising. However, there is no assurance that the Company will be successful in obtaining such
funding.
Under these circumstances, in accordance with the requirements
of ASC 205-40, management has concluded that it is required to disclose that there is substantial doubt about the Company's
ability to continue as a going concern for at least 12 months from the date these financial statements are issued. The financial statements
do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.
F-63
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES:
a.
Basis of presentation
The Company's consolidated financial statements have
been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP").
b.
Use of estimates
The preparation of the financial statements in conformity with
U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and
accompanying notes. Actual results could differ from those estimates. As applicable to these financial statements, the most significant
estimates and assumptions relate to fair value of financial instruments and share-based compensation see Notes 12 and 11, respectively.
c.
Functional currency
The Company's operations are currently conducted in Israel
and some of the Company's expenses are currently paid in new Israeli shekels ("NIS"); however, the markets for the Company's
future products are located outside of Israel. Financing activities are conducted in U.S. dollar ("dollar" or "$").
The Company's management believes that the US dollar is the currency of the primary economic environment in which the Company operates.
Thus, the functional and reporting currency of the Company is the dollar. The functional currency of the Subsidiary is U.S. dollar,
inter alia, in light of the composition of expenses and expected volume of intercompany transactions with the Company.
Transactions and balances originally denominated in dollars
are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into dollars using historical and
current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the statements
of operations (indicated below), the following exchange rates are used: (i) for transactions — exchange rates at
transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation
and amortization) — historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses,
as appropriate.
d.
Principles of consolidation
The accompanying consolidated financial statements include
the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated in consolidation.
The financial statements of the Company and
of the Subsidiary are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform accounting
policies by all companies in the Group.
e.
Cash and cash equivalents
The Company considers as cash equivalents all
short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from
the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.
Bank balances for which use by the Company
is subject to third party contractual restrictions are included as part of cash unless the restrictions result in a bank balance no longer
meeting the definition of cash. If the contractual restrictions to use the cash extend beyond 12 months after the end of the reporting
period, the related amounts are classified as non-current in Balance sheets.
f.
Restricted cash
As of December 31, 2023 and 2022, the Company pledged
an amount of $
25
in favor of a bank as collateral for guarantees provided to secure the lease payments.
F-64
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 2 — SIGNIFICANT ACCOUNTING
POLICIES:
(cont.)
The Company is required to hold a minimum amount of NIS 85
in its bank account in order to maintain availability of a credit line from its credit card company.
g.
Property and equipment:
Property and equipment are stated at cost, net of accumulated
depreciation.
Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets, at the following annual rates:
%
Computers and software
33
Laboratory and electronic equipment
15
Leasehold improvements*
15
–
40
*
Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter
        than the estimated useful life of the improvements.
h.
Employee rights upon retirement
The Company is required to make severance payments upon dismissal
of an employee or upon termination of employment in certain circumstances.
In accordance with the current employment terms with all of
its employees located in Israel, and pursuant to Section 14 of the Israeli Severance Pay Law, 1963, the Company makes and has been
continuously making, since the beginning of employment of each of its current employees, regular deposits, at a rate of
8.33
%
of their monthly salary, with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee's
full severance pay obligation.
Under these circumstances, the Company is currently relieved
from any severance pay liability with respect to each such employee. Neither the liability in respect of these employees nor the credit
for the amounts funded are reflected on the Company's consolidated balance sheets, as the amounts funded are not under the control
or management of the Company and the severance pay risks have been irrevocably transferred to the applicable insurance companies.
The amounts of severance payment expenses were $
74
and $
82
for the years ended December 31, 2023 and 2022, respectively.
i.
Fair value measurement
Fair value is based on the price that would be received from
the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement
date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that
prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:
Level 1:
Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.
        The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2:
Observable prices that are based on inputs not quoted on active markets, but corroborated by market data
        or active market data of similar or identical assets or liabilities.
Level 3:
Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the
        lowest priority to Level 3 inputs.
F-65
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 2 — SIGNIFICANT ACCOUNTING
POLICIES:
(cont.)
In determining fair value, the Company utilizes valuation techniques
that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty
credit risk in its assessment of fair value.
j.
Financial instruments issued
When the Company issues preferred shares, it first considers
the provisions of ASC 480, Distinguishing Liabilities from Equity ("ASC 480") in order to determine whether the
preferred share should be classified as a liability. If the instrument is not within the scope of ASC 480, the Company further analyzes
the instrument's characteristics in order to determine whether it should be classified within temporary equity (mezzanine) or within
permanent equity in accordance with the provisions of ASC 480-10-S99. The Company's redeemable convertible preferred shares
are not mandatorily or currently redeemable. However, they include clauses that could constitute as in-substance redemption clauses that
are outside of the Company's control. As such, all shares of redeemable convertible preferred shares have been presented outside
of permanent equity.
When the Company issues other freestanding instruments, the
Company first analyzes the provisions of ASC 480 in order to determine whether the instrument should be classified as a liability,
with subsequent changes in fair value recognized in the statements of operations in each period. If the instrument is not within the scope
of ASC 480, the Company further analyzes the provisions of ASC 815-40 in order to determine whether the instrument should be
classified within equity or classified as an asset or liability, with subsequent changes in fair value recognized in the statements of
operations in each period.
The Company's issued financial instruments convertible
to preferred shares are in the scope of ASC 480. For further details see Note 7 and Note 8.
k.
Redeemable Non-controlling Interest
Non-controlling interests with embedded redemption features,
whose settlement is not at the Company's discretion, are considered redeemable non-controlling interest. Redeemable non-controlling
interests are considered to be temporary equity and are therefore presented as a mezzanine section between liabilities and equity on the
Company's consolidated balance sheets. Redeemable non-controlling interests are measured at the greater of the initial carrying
amount adjusted for the non-controlling interest's share of comprehensive income or loss or its redemption value. Subsequent adjustment
of the amount presented in temporary equity is currently not required because the Company's management estimates that it is not
probable that the instrument will become redeemable. Adjustments of redeemable non-controlling interest to its redemption value are recorded
through additional paid-in capital.
l.
Research and development expenses
Research and development costs are charged to the statements
of operations as incurred. Research and development expenses include costs directly attributable to the conduct of research and development
programs, including the cost of payroll and subcontractors, as well as share-based payments. Advance payments for goods or services that
will be used or rendered for future research and development activities are deferred. Such amounts are recognized as an expense as the
related goods are used or the services are rendered.
Grants received from the Israeli Innovation Authority ("IIA")
for approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the
costs incurred and included as a deduction from research and development expenses, see Note 5(a). The Company did not receive any
grants during 2022 and 2023.
F-66
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 2 — SIGNIFICANT ACCOUNTING
POLICIES:
(cont.)
m.
Share-based compensation
The Company's employees and non-employees share-based
payment awards are classified as equity awards. The Company accounts for these awards using the grant-date fair value method. The fair
value of share-based payment transactions is recognized as an expense over the requisite service period using the straight-line method.
The Company elected to recognize compensation costs for awards
conditioned only on continued service that have a graded vesting schedule using the straight-line method based on the multiple-option
award approach. Forfeitures are recognized as they occur.
The Company accounts for its non-employees' equity-classified
share-based payment in a similar manner.
n.
Leases
The Company adopted the ASC 842, Leases accounting guidance.
The Company recognized new right-of-use assets and operating lease liabilities of $
391
as of January 1, 2022. The Company does not have any finance leases.
The Company recognizes operating lease payments in the consolidated
statements of operations on a straight-line basis over the lease term. Right-of-use ("ROU") assets represent the right to
use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum lease payments arising from
the lease. ROU assets are initially measured at amounts representing the discounted present value of the lease payments over the lease,
plus any initial direct costs incurred. The lease liability is initially measured at lease commencement date based on the discounted present
value of minimum lease payments over the lease term. The discount rate for the lease is the rate in the lease unless that rate cannot
readily determined. As the Company's leases do not provide an implicit rate, the Company uses an estimated incremental borrowing
rate ("IBR") based on the information available at commencement date in determining the present value of lease payments. The
Company's IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in
economic environments where the leased asset is located. The lease agreement included an option to extend or terminate the lease. The
Company exercised its option to extend the lease period up to July 2025.
Payments under the Company's lease arrangements are primarily
fixed, however, certain lease agreements contain variable payments, which are expensed as incurred and not included in the operating lease
right-of-use assets and liabilities. The Company elected the practical expedient not to separate lease and non-lease components.
o.
Loss per share
The Company calculates loss per share using the two-class method
required for participating securities. This method entails allocating income available to ordinary shareholders for the period between
ordinary shares and participating securities based on their respective rights to receive dividends as if all income for the period had
been distributed. Basic loss per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding
during the year, and fully vested pre-funded options for the Company's ordinary shares at an exercise price of $
0.01
or
0.01
NIS per share. The Company considers these shares to be exercised for little to no additional consideration. The Company also considers
its redeemable convertible preferred shares to be participating securities as the holders of the redeemable convertible preferred shares
would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis assuming conversion of
all redeemable convertible preferred shares into ordinary shares. However, these participating securities do not contractually require
the holders to participate in the Company's losses. Consequently, net loss for the periods presented was not allocated to the Company's
participating securities.
F-67
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 2 — SIGNIFICANT ACCOUNTING
POLICIES:
(cont.)
p.
Income taxes:
1)
Deferred taxes
Income taxes are computed using the asset and liability method.
Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial
reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance
is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. Given
the Company's losses, the Company has provided a full valuation allowance with respect to its deferred tax assets.
2)
Uncertainty in income tax
The Company follows a two-step approach in recognizing and measuring
uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates
that it is more likely than not that the tax position will be sustained upon examination, including resolution of any related appeals
or litigation processes, based on the technical merits of the position. If this threshold is met, the second step is to measure the tax
position as the largest amount that has more than a 50% likelihood of being realized upon ultimate settlement.
q.
Concentration of credit risks
Financial instruments that potentially subject the Company
to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term deposits. The Company
deposits cash and cash equivalents mostly with three low risk financial institution. The Company has not experienced any material credit
losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.
r.
Operating segments and geographical information:
The Company is managed as one R&D department during its
startup phase that has yet to earn revenues. The Company's Chief Executive Office ("CEO") was identified as the chief
operating decision maker ("CODM"). The CODM reviews the financial information every quarter. Accordingly, the company had
determined to operate under one reportable segment.
All of the Company long-lived assets are located in Israel.
s.
New accounting pronouncements:
The Company qualifies as an emerging growth company ("EGC")
as defined under the Jumpstart Our Business Startups Act (the "JOBS Act"). Using exemptions provided under the JOBS Act for
EGCs, the Company has elected to defer compliance with new or revised ASUs until it is required to comply with such updates, which is
generally consistent with the adoption dates of private companies.
Recently Adopted
accounting pronouncements:
In June 2016, the FASB issued ASU 2016-13, "Financial
Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which replaces
the existing incurred loss model with a current expected credit loss ("CECL") model that requires consideration of a broader
range of reasonable and supportable information to inform credit loss estimates. Subsequent to the issuance of ASU 2016-13, the FASB
issued several additional Accounting Standard Updates to clarify implementation guidance, provide narrow-scope improvements and provide
additional disclosure guidance. Under the ASU, the Company is required to use a forward-looking CECL model for accounts receivables and
other financial instruments. The Company adopted the ASU on January 1, 2023 and it did not have a material impact on its consolidated
financial statement.
F-68
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 2 — SIGNIFICANT ACCOUNTING
POLICIES:
(cont.)
Recently issued
accounting standards not yet adopted:
1)
In June 2022, the FASB issued ASU 2022-03 "Fair Value Measurement of Equity Securities Subject
        to Contractual Sale Restrictions". The ASU clarifies that a contractual restriction on the sale of an equity security is not considered
        part of the unit of account of the equity security and, therefore, is not considered in measuring its fair value. The ASU also clarifies
        that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The ASU also introduces new
        disclosure requirements for equity securities subject to contractual sale restrictions. As an Emerging Growth Company, the ASU is effective
        for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. Early adoption is permitted
        for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is currently
        evaluating the effect that ASU 2022-03 will have on its consolidated financial statements and related disclosures.
2)
In November 2023, the FASB issued ASU No. 2023-07 Segment Reporting (Topic 280): Improvements
        to Reportable Segment Disclosures. The ASU improves reportable segments disclosure requirements, primarily through enhanced disclosures
        about significant segment expenses. The ASU also require that a public entity that has a single reportable segment to provide all the
        disclosures required by the amendments and all existing segment disclosures in Topic 280. The ASU is effective for fiscal years
        beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The
        Company is currently evaluating this ASU to determine its impact on the Company's segment disclosures.
3)
In December, 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disclosure
        of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies
        other income tax-related disclosures. The ASU will be effective for fiscal years beginning after December 15, 2025, and allows
        adoption on a prospective basis, with a retrospective option. The Company is in the process of assessing the impacts and method of adoption.
NOTE 3 — PROPERTY AND EQUIPMENT, NET:
Composition of property and equipment, grouped by major classifications,
is as follows:
December 31
2023
2022
Cost:
$
75
$
67
Computers
Laboratory and electronic equipment
—
274
Office furniture
2
2
Communication equipment
3
3
Leasehold improvements
56
52
$
136
$
398
Accumulated depreciation:
Computers
55
41
Laboratory and electronic equipment
—
179
Office furniture
2
1
Communication equipment
3
3
Leasehold improvements
27
15
$
87
$
239
Property and equipment, net
$
49
$
159
Depreciation expenses were $
45
and $
57
in the years ended December 31, 2023 and 2022, respectively.
F-69
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 4 — LEASES:
The Company leases offices for its facilities in Israel by way
of an operating lease. The lease agreement for such offices is denominated in NIS and linked to the Israeli consumer price index ("CPI").
The Company provided the lessor with a bank guarantee as a rental
security. The bank in turn placed a pledge over restricted cash of $
25
.
The lease for the offices expires on July 31, 2025. The
remaining lease term is up to
1.58
years
as of December 31, 2023.
Operating lease costs for the years ended December 31,
2022 and 2023 are as follows:
Year Ended
December 31,
2023
2022
Fixed payments and variable payments that depend on an index or rate:
Office and operational lease expenses
$
131
$
132
Variable lease cost (included in the operating lease
        costs)
$
9
$
3
Total operating lease costs
$
140
$
135
Operating cash flows, for amounts included in the measurement
of lease liabilities, are as follows:
Year Ended
December 31,
2023
2022
Office and operational spaces lease expenses
$
101
$
119
Supplemental information related to operating leases is as follows:
Year Ended
December 31,
2023
2022
Operating lease right-of-use assets
$
198
$
305
Operating lease liabilities
$
171
$
271
Weighted average remaining lease term (years)
1.58
2.58
Weighted average discount rate
12.69
%
12.69
%
As of December 31, 2023, the Company has not entered into
lease agreements that include options to extend them that are not included in the measurement of the lease liability.
The following table outlines maturities of the Company's
operating lease liabilities as of December 31, 2023:
Operating lease liabilities
2024
$
117
2025
68
Total undiscounted lease payments
$
185
Less – imputed interest
$
14
Present value of lease liabilities
$
171
F-70
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 5 — SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:
Statement of operations:
a.
Research and development expenses, net:
Year ended
December 31,
2023
2022
Payroll and related expenses
$
973
$
1,192
Subcontractors and consultants
2,467
1,595
Materials
13
191
Rent and maintenance
160
175
Travel expenses
37
42
Other
58
31
$
3,708
$
3,226
b.
General and administrative expenses:
Payroll and related expenses
$
356
$
219
Professional services
386
197
Depreciation
45
57
Rent and maintenance
86
71
Patent registration
22
32
Travel expenses
31
—
Other
47
58
$
973
$
634
c.
Financial expense, net:
Change in fair value of financial liabilities measured at fair value
$
86
$
(
1,017
)
Issuance costs
3
84
Interest income
(
153
)
(
114
)
Foreign currency exchange loss, net
453
650
Other
6
1
Total financial expense (income), net
$
395
$
(
396
)
NOTE 6 — COMMITMENTS AND CONTINGENT LIABILITIES:
During 2009 to 2020, the Company received several
approvals from the IIA for participation in research and development activities performed by the Company ("Support Grants")
in a total amount of $
5.8
million.
The Company is obligated to pay royalties to the IIA amounting
to
3
%-
5
%
of the sales of the core products and other related revenues generated from such projects, up to
100
%
of the Support Grants received, linked to the U.S. dollar and bearing interest at the rate of LIBOR. The obligation to pay these
royalties is contingent upon actual sales of the products and, in the absence of such sales, no payment is required. In October 2023,
it was published that the interest rate on the Support Grants will be replaced with the
12
-month
term Secured Overnight Financing Rate (SOFR) published on the first trading day of each calendar year.
As of December 31, 2023, the total royalty amount that
may be payable by the Company is approximately $
5.8
million
($
6.4
million
including interest).
F-71
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 7 — SIMPLE AGREEMENT FOR FUTURE EQUITY:
On
March 15, 2021, a Simple Agreement for Future Equity ("SAFE") was signed between the Company and a group of investors,
for an aggregate amount of up to $
4,000
,
of which $
2,887
were actually raised. The SAFE was for a period of 9 months and was convertible into preferred shares with the most senior class
of rights issued by the Company at the time of conversion.
The
conversion rate and timing were subject to events as determined in the SAFE, the principal amount thereon was to be converted to the most
senior class of shares of the Company in accordance with the terms mentioned in the SAFE, as follows: in an event that the Company consummates
an equity investment of at least $
2,000
,
the principal amount will be converted automatically to the most senior class of equity at the lower of (i) the price per share of
the most senior shares issued in such equity investment less a
25
%
discount, or (ii) a price per share reflecting a fully diluted pre-money Company valuation of $
70,000
.
However, in no event was the price per share to be lower than a price per share reflecting a fully-diluted pre-money valuation of the
Company of $
30,000
.
Total
consideration for the SAFE agreements was $
2,887
.
On
January 14, 2022, the Company converted the SAFE in the total amount of $
3,204
(its fair value as of conversion date) into
63,331
Series A-3 Preferred Shares and
47,495
warrants
exercisable into Series A-2 Preferred Shares. In accordance with ASC 480 the Company recorded financial expenses in amount of
$
317
with respect to the discount on the SAFE conversion.
NOTE 8 — WARRANTS TO PURCHASE PREFERRED SHARES:
a.
In connection with the Series A-2 Preferred Shares (see Note 9(b)), the Company issued warrants to acquire
92,953
Series A-2 Preferred Shares to various investors, including
47,495
warrants
        issued as part of the converted SAFE (see Note 9(b)). These warrants feature an exercise price of $
60.783
per share and expired during 2023. As of December 31, 2022, there are
92,953
outstanding warrants. As of December 31, 2023, all warrants are expired.
b.
Concerning the Series A-4 Preferred Shares (see Note 9(b)), the Company issued warrants to acquire
21,717
Series A-4 Preferred Shares to various investors, with an exercise price of $
24.769
per
        share and an expiration date of May 30, 2025. Issuance expenses amounted to $
3
.
        As of December 31, 2023, there are outstanding warrants of
21,717
.
        Regarding the warrants issued to the Subsidiary see Note 9(b)(2).
The Company classified the warrants for the
purchase of shares of its convertible redeemable preferred shares as a liability in its consolidated balance sheets, as these warrants
were freestanding financial instruments which underlying shares are contingently redeemable and, therefore, may obligate the Company to
transfer assets at some point in the future. The warrant liability was initially recorded at fair value upon the date of issuance and
was subsequently remeasured at fair value at each reporting date. The Company recorded revaluation expenses (income) amounting to $(
86
) and
$
1,017
for
the years ended 2023 and 2022, respectively, and accounted for such revaluation expenses as part of its financial income (expense),
net, in the statements of operations.
For further information in respect of warrants issuance to
service provider see Note 11(1).
F-72
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 9 — REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY:
a.
As of December 31, 2023 and 2022
,
the share capital is composed of
0.01
NIS par value shares, as follows:
December 31, 2023
Authorized
Issued and
paid
Carrying
Value
Liquidation
Preference
Ordinary Shares
3,275,000
219,354
$
4,685
Preferred A Shares
510,000
388,088
$
7,307
$
8,162
Preferred A-1 Shares
120,000
91,216
$
2,392
$
2,443
Preferred A-2 Shares
200,000
45,458
$
2,264
$
2,763
Preferred A-3 Shares
80,000
63,331
$
2,683
$
2,887
Preferred A-4 Shares
815,000
21,717
$
411
$
1,076
December 31, 2022
Authorized
Issued and
paid
Carrying
Value
Liquidation
Preference
Ordinary Shares
4,090,000
219,354
$
4,685
Preferred A Shares
510,000
388,088
$
7,307
$
8,162
Preferred A-1 Shares
120,000
91,216
$
2,392
$
2,443
Preferred A-2 Shares
200,000
45,458
$
2,264
$
2,763
Preferred A-3 Shares
80,000
63,331
$
2,683
$
2,887
b.
Issuance of shares:
1)
On January 14, 2022, the Company signed an agreement to issue shares in consideration for an investment
        in the amount of $
2,763
.
        In return for this investment, the Company issued
45,458
Series A-2 Preferred Shares with a par value of NIS
0.01
.
        Issuance expenses amounted to $
14
.
Following this investment, the Company converted the SAFE in the
total amount of $
3,204
into
63,331
Series A-3 Preferred Shares.
In addition, the Company issued
92,953
warrants
for Series A-2 Preferred Shares NIS
0.01
par value per share, including
47,495
warrants
issued as part of the converted SAFE (see Note 8(a)), each exercisable at a price of $
60.78
per share.
2)
On May 30, 2023, the Company entered into an agreement to receive an investment in a total amount of $
538
.
        In exchange for this investment, the Company issued
21,717
Series A-4 Preferred Shares with a par value of NIS
0.01
.
        Issuance expenses amounted to $
16
.
Additionally, the Company issued
21,717
warrants
for Series A-4 Preferred Shares, each with a par value of NIS
0.01
,
exercisable at a price of $
24.769
per share.
In addition, on May 30, 2023, the Subsidiary made an investment
totaling $
3
million
in the Company. This investment resulted in the acquisition by the Subsidiary of
121,119
Series A-4 Preferred Shares and
121,119
warrants
convertible into series A-4 Preferred Shares. Each warrant is exercisable into one series A-4 Preferred Share at an exercise price of
$
24.769
per share. As the acquisition was eliminated in consolidation, it had no impact on the consolidated financial statement.
F-73
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 9 — REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY:
(cont.)
c.
Shareholders rights:
1)
The Ordinary shares confer upon their holders the right to participate and vote in general shareholders meetings
        of the Company and to share in the distribution of dividends, if any declared by the Company.
The Series A Preferred Shares, Series A-1
Preferred Shares, Series A-2 Preferred Shares, Series A-3 Preferred Shares and Series A-4 Preferred Shares (collectively,
the "Preferred A Shares") confer upon their holders all of the rights conferred upon the holders of Ordinary Shares in the
Company, as well as the following rights:
a)
Distribution Preference
First, the holders of Series A-4 Preferred Shares shall
be entitled to receive, prior and in preference to any holders of Series A-3 Preferred Shares, Series A-2 Preferred Shares,
Series A-1 Preferred Shares, Series A Preferred Shares, Ordinary Shares or any other equity securities of the Company, for each
outstanding Series A-4 Preferred Share held by them, an amount equal to (i)
200
%
of the Original Issue Price per each Series A-4 Preferred Share (in cash, cash equivalents or, if applicable, securities) plus (ii) declared
and unpaid dividend in respect of such share (the "Series A-4 Preference Amount").
In the event that the distributable proceeds are insufficient
for the distribution of the Series A-4 Preference Amount in full to all holders of Series A-4 Preferred Shares, then the Distributable
Proceeds shall be distributed pari passu among such holders of Series A-4 Preferred Shares in proportion to the respective full Series A-4
Preference Amount such holders would otherwise be entitled to receive.
Second, the holders of Series A Preferred Shares, Series A-1
Preferred Shares, Series A-2 Preferred Shares and Series A-3 Preferred Shares, shall be entitled to receive, prior and in preference
to any holders of Ordinary Shares, for each outstanding Preferred A Share held by them, an amount equal to: (a) Series A and
Series A-1 Shares — the issue price paid for such share; (b) Series A-2 preferred share — US$
60.783
per each Series A-2 share, and (c) Series A-3 Preferred Shares — US$
45.587
per each Preferred A-3 share; plus any declared and unpaid dividend in respect of such share (the "Series A, A-1, A-2 and A-3
Preference Amount", and together with the Series A-4 Preference Amount, the "Preference Amounts").
In the event that the distributable proceeds are insufficient
for the distribution of the Series A, A-1, A-2 and A-3 Preference Amount in full to all holders of Preferred A Shares, then the Distributable
Proceeds shall be distributed pari passu among such holders of Series A Preferred Shares, Series A-1 Preferred Shares, Series A-2
Preferred Shares and Series A-3 Preferred Shares in proportion to the respective full Series A, A-1, A-2 and A-3 Preference
Amount such holders would otherwise be entitled to receive.
Third, following the distribution of the Preference Amounts,
any remaining distributable proceeds shall be distributed pro rata among all the holders of Ordinary Shares and Preferred A Shares, based
on their respective holdings of outstanding shares of the Company, on a pari passu and as converted basis.
F-74
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 9 — REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY:
(cont.)
b)
Liquidation Preference:
If the Company is liquidated, dissolved or wound up (including,
without limitation, upon appointment of a receiver or liquidator to all or substantially all of the Company's assets, whether voluntary
or involuntary), then all the assets and funds of the Company available for distribution shall first be distributed in accordance with
the Preference Amounts, and thereafter among all shareholders of the Company pro rata based on the number of Ordinary Shares and Series A
Preferred Shares held by each, on an as-converted basis.
For the purpose of this clause, a liquidation event also includes
(a) a merger of the Company into another corporation(s) in which the holders of the Company's shares do not, immediately
after such merger, represent a majority of the voting power of the surviving corporation (other than a merger with a company in which
the shareholders of the Company receive stock of the surviving company which is publicly traded at the time of such merger); (b) a
sale of all or substantially all of the assets of the Company to entities not controlled by the Company's existing shareholders;
and (c) a grant of an exclusive, irrevocable licensing of all or substantially all of the Company's intellectual property to
a third party
.
c)
Dividend Preference:
In the event that the Company distributes a dividend in respect
of its shares, the holders of Preferred A Shares shall be entitled to receive the Preference Amounts prior to and in preference to the
distribution of dividends to all shareholders of the Company.
d)
Conversion Rights:
Each Preferred A Share is convertible into Ordinary Shares.
Their number is determined by multiplying such Preferred A Share by a quotient equal to (a) the applicable Original Issue Price for
such share divided by (b) the Conversion Price (as defined below) at the time in effect for such share. The Preferred A Shares are
convertible without payment of additional consideration by the holder thereof, upon each of the following events: (i) at the option
of the holder thereof, at any time and from time to time; (ii) upon the consent of, or conversion by, the holders of a majority of
the Preferred A Shares; or (iii) immediately before the consummation of an initial public offering of the Company's securities.
The initial conversion price per each Preferred A Share is
the applicable Original Issue Price for such share (the "Conversion Price"). The Conversion Price per each Preferred A Share
shall be adjusted in the event of a share combination or subdivision, share split, distribution of bonus shares or any other reclassification,
reorganization or recapitalization (each, a "Recapitalization Event"), so that the holder of each Preferred A Share shall
be entitled to receive, upon conversion, such number of Ordinary Shares they would have been entitled to receive following the Recapitalization
Event had each Preferred A Share been converted into Ordinary Shares prior to the Recapitalization Event.
Additionally, in the event that the Company issues Additional
Shares (as such term is defined in the Company's articles of association), for a consideration per share lower than the applicable
Conversion Price for Series A-4 Preferred Shares in effect immediately prior to such issuance (the "Reduced Price"),
then the Conversion Price for Series A-4 Preferred Shares shall be reduced, for no additional consideration, concurrently with such
issuance, to the Reduced Price.
F-75
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 9 — REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY:
(cont.)
d.
Silenseed China Minority Equityholder Rights:
The articles of association of Silenseed (China)
Ltd. (the "Subsidiary's Articles") provide the minority shareholder, Guangzhou Sino-Israel Bio-industry Investment Fund
(LLP) ("GIBF") with the following minority shareholder protections:
a.
Conversion ("Put/Call") Option
:    Either
        GIBF or the Company may elect that the equity rights of GIBF in the Subsidiary shall be exchanged for the most senior shares (i.e., preferred
        shares) of the Company, consequently turning the Subsidiary into a wholly-owned subsidiary of the Company. The number of shares to be
        issued to GIBF upon such exchange shall be calculated by converting the total cash amount invested by GIBF in the Subsidiary (the "Contribution
        Amount"), into the most senior class of shares of the Company as of May 30, 2023, based on a pre-money valuation of the Company
        of US$
20
million
        on a fully diluted basis as of September 1, 2023, or later, as shall be mutually agreed between the parties.
b.
"Company Exit Event" means the consummation of: (i) an initial public offering of Company, in
        a stock exchange, directly or via a SPAC (or similar methods); (ii) the sale of all or substantially all of the securities or assets
        of the Company (or an exclusive license with respect to all or substantially all of the assets of Company); (iii) a merger or acquisition
        of the Company (following which existing shareholders as of immediately prior to such transaction hold less than
50
%
        of the voting power of the surviving or acquiring entity); (iv) sale of at least
50
%
        of the means of control or assets of the Company; (v) liquidation, dissolution or winding up of the Company; or (vi) at any
        time upon a party's written notice, provided, however that the exercise of such right by the Company shall be subject to GIBF's
        written consent, which shall not be unreasonably withheld.
1)
Anti-Dilution Protection
: If the Subsidiary issues any additional
        equity rights in the Subsidiary to a third-party investor in the next two equity investment rounds of the Subsidiary, reflecting a purchase
        price per equity right lower than the purchase price per equity right paid by GIBF, GIBF will be issued additional equity rights of the
        Subsidiary for no consideration, based on a broad based weighted average formula.
2)
Registration Rights
: GIBF shall be entitled to the same rights
        to register its equity rights in the Subsidiary as part of an IPO of the Subsidiary, as granted to Company, on a pro-rata basis.
3)
Liquidation Preference
: In the event of an IPO in which the
        Subsidiary's valuation is at least $
200
million
        or an Exit Event (as defined in the Subsidiary's Articles), GIBF shall be entitled to be paid out of the assets legally available
        for distribution to equity holders of the Subsidiary (the "Distributable Proceeds"), prior to any payment made to any other
        equity holder, an amount in cash equal to the Contribution Amount (the "Preference Amount"). Following payment of the Preference
        Amount, any remaining Distributable Proceeds shall be distributed among all holders of equity rights excluding GIBF, on a pro-rata basis,
        provided that GIBF shall have the right to waive its right to receive the Preference Amount, in which case all Distributable Proceeds
        shall be distributed among all equity holders of the Subsidiary on a pari passu and pro rata basis.
4)
Other rights, such as right of first refusal for GIBF to purchase the Company's equity rights in the Subsidiary
        if the Company proposes to sell or receives an offer to sell its equity rights; a right of co-sale for GIBF to participate in a proposed
        sale of the Company's equity rights in the Subsidiary on a pro-rata basis; a preemptive right for both investors to participate
        in the issuance of new securities by the Subsidiary until the consummation of an IPO or an Exit Event (as defined in the Subsidiary's
        Articles).
F-76
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 10 — INCOME TAXES:
a.
Corporate taxation in Israel
The Company is taxed according to the regular corporate income
tax in Israel. The corporate tax rate is
23
%
in 2023 and 2022.
b.
Income taxes on non-Israeli subsidiary
The Subsidiary is taxed under the tax laws of China and the
corporate tax rate is
25
%.
c.
Tax loss carryforwards
As of December 31, 2023, the expected tax loss carryforwards
of the Company were approximately $
19,151
,
which may be carried forward and offset against taxable income in the future for an indefinite period. The Company has recognized valuation
allowance for the full amount in respect of these tax loss carryforwards since their utilization is not expected in the foreseeable future.
Israel and foreign components of loss from continuing operations,
before income taxes consisted of:
Year ended
December 31
2023
2022
Israel
$
4,769
$
2,929
Subsidiary outside of Israel
307
535
Total
$
5,076
$
3,464
d.
Uncertainty in income tax
As of December 31, 2023 and 2022, no liability for unrecognized
tax benefits was recorded due to immateriality.
e.
Tax rate reconciliation
Income tax expense attributable to income from continuing operations
was $
32
and $
24
for the years ended December 31, 2023 and 2022, respectively, and differed from the amounts computed by applying an Israeli
Statutory income tax rate of
23
%
to pretax income from continuing operations, mainly as a result of changes in valuation allowance of $
922
and $
268
respectively, as well as nondeductible expenses.
The reconciliation of the theoretical tax benefit (expense)
by the Israeli statutory tax rate to the Company's effective benefit (expense) taxes are as follows:
Year ended
December 31
2023
2022
Loss before income taxes
$
(
5,076
)
$
(
3,464
)
Statutory tax rate
23
%
23
%
Computed "expected" tax income
(
1,167
)
(
797
)
Exchange rate differences
120
588
Non-deductible share-based compensation
30
29
Non-deductible financial instruments valuation
21
(
215
)
Effect of other non-deductible differences
112
162
Change in valuation allowance
922
268
Subsidiary tax rate differences
(
6
)
(
11
)
Reported taxes on income
$
32
$
24
F-77
SILEXION LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
U.S. DOLLARS
IN THOUSANDS
NOTE 10 — INCOME TAXES:
(cont.)
f.
Deferred tax
Deferred taxes reflect the net tax effects of temporary differences
between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
Significant components of the Company's deferred tax assets are as follows:
December 31
2023
2022
Deferred tax assets
Operating loss carryforwards
$
4,405
3,752
Research and development
780
592
Accrued expenses
304
219
Lease liability
39
62
Other
25
30
Total deferred tax assets
$
5,553
$
4,655
Deferred tax liabilities
Right of use asset
(
46
)
(
70
)
Total deferred tax liabilities
$
(
46
)
$
(
70
)
Valuation allowance
$
(
5,507
)
$
(
4,585
)
Deferred tax assets, net of valuation
        allowance
$
—
$
—
g.
Roll forward of valuation allowance:
The following table presents a reconciliation of the beginning
and ending valuation allowance:
Balance as of December 31, 2021
$
(
4,317
)
Additions
(
268
)
Balance as of December 31, 2022
$
(
4,585
)
Additions
(
922
)
Balance as of December 31, 2023
$
(
5,507
)
In assessing the realization of deferred tax assets, management
considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. The ultimate realization
of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences
are deductible and net operating losses are utilized. Based on these factors, the Company recorded a full valuation allowance on December 31,
2023 and 2022.
h.
Income tax assessments
The Company has tax assessments that are considered to be final
through tax year 2018. The subsidiary does not have final tax assessments.
F-78
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 11 — SHARE-BASED COMPENSATION:
1)
Warrants to service provider
In conjunction with the issuance of Series A-1 Preferred
Shares, the Company issued warrants to acquire
3,837
Series A-1 Preferred Shares to a service provider who assisted in raising the funds, which warrants were classified as part of the
issue expenses. These warrants carry an exercise price of $
26.78
per share and are set to expire on January 31, 2027. As of December 31, 2023 and 2022, all
3,837
of such warrants remained outstanding.
In conjunction with the issuance of Series A-2 Preferred
Shares, the Company issued warrants to acquire
4,009
Series A-3 Preferred Shares to a service provider who assisted in raising the funds, which were recorded as part of issue expenses.
These warrants carry an exercise price of $
45.587
per share and are set to expire on January 14, 2029. As of December 31, 2023 and 2022, all
4,009
of such warrants remained outstanding.
The warrants for both the Series A-1 Preferred Shares
and Series A-3 Preferred Shares were recognized as issuance costs of the SAFE round and recognized as financial expenses.
In conjunction with the issuance of Series A-4 Preferred
Shares, the Company issued warrants to acquire
107
Series A-4 Preferred Shares to a service provider who assisted in raising the funds, which were recorded as part of issue expenses.
These warrants carry an exercise price as those issued to the investors in such round, and expire on May 30, 2030. As of December 31,
2023, all
107
of such warrants remained outstanding. The warrants were recognized as issuance costs and the portion attributed to the issuance of Series A-4
Preferred Shares was classified as part of the shareholders' equity. The portion attributed to the issuance of the warrants was
recognized as financial expenses.
2)
Employee Stock Option Plan
As of December 31, 2023, the Board of Directors approved
a pool of
130,889
Ordinary
Shares for grant to Company employees, consultants, directors and other service providers.
Under the Company's 2013 and 2023 Incentive Option Plans
(collectively "the Plan"), options to purchase Ordinary Shares may be granted to certain entities and individuals. Each option
granted under the Plan is exercisable until
10
years
from the date of grant, or earlier upon cessation of employment or engagement of the grantee and certain other occurrences.
Grants to employees are made in accordance with the Plan and
are carried out within the provisions of Section 102 of the Israel Income Tax Ordinance, under the capital gains track described
in subsection (b)(2) of Section 102. In accordance with such track selected by the Company and the provisions associated with
it, the Company is not entitled to claim a tax deduction for the employee benefits.
The Company's options expenses amounted to a total of
$
130
and $
125
in 2023 and 2022, respectively. As of December 31, 2023,
9,081
shares remain available for grant under the Plan.
F-79
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 11 — SHARE-BASED COMPENSATION:
(cont.)
Summary of outstanding and exercisable options:
Below is a summary of the Company's stock-based compensation
activity and related information with respect to options granted to employees and non-employees for the year ended December 31, 2023 and
2022:
Number of
options
Weighted-
average
exercise price
(in
        U.S. dollars)
Weighted-
average
remaining
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding at December 31, 2022
122,308
$
17.229
5.88
$
144
Granted
—
$
—
—
$
—
Exercised
—
$
—
—
$
—
Forfeited
—
$
—
—
$
—
Expired
(
500
)
$
(
17
)
—
$
—
Outstanding at December 31, 2023
121,808
$
17.231
4.88
$
316
Exercisable at December 31, 2023
88,895
$
13.696
3.62
$
316
Vested and expected to vest at December 31, 2023
121,808
$
17.231
4.88
$
316
Number of
options
Weighted-
average
exercise price
(in
        U.S. dollars)
Weighted-
average
remaining
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding at December 31, 2021
72,058
$
10.568
4.46
$
493
Granted
54,500
$
26.780
9.98
$
—
Exercised
(
103
)
$
26.771
(
8.22
)
$
—
Forfeited
(
2,548
)
$
26.775
(
9.18
)
$
—
Expired
(
1,599
)
$
(
27
)
—
$
—
Outstanding at December 31, 2022
122,308
$
17.229
5.88
$
144
Exercisable at December 31, 2022
69,318
$
9.939
3.29
$
144
Vested and expected to vest at December 31, 2022
122,308
$
17.229
5.88
$
144
F-80
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 11 — SHARE-BASED COMPENSATION:
(cont.)
The fair value for options granted in 2022 is
estimated at the date of grant using a Black-Scholes option pricing model based on the following assumptions:
Year ended
December 31,
2022
Employees
Expected term (in years)
6.05
–
10.00
Expected volatility
82.97
% –
88.45
%
Risk-free interest rate
2.31
% –
2.90
%
Expected dividend yield
0.00
%
Exercise price
$
26.78
Non-Employees
Expected term (in years)
9.78
Expected volatility
88.46
%
Risk-free interest rate
2.31
%
Expected dividend yield
0.00
%
Exercise price
$
26.78
The option-pricing model requires a number of assumptions, of
which the most significant are the expected stock price volatility and the expected option term. Since the Company is not traded, the
expected volatility was based on the average volatility rate of
8
public companies in the healthcare industry.
The expected term of options granted represents the period during
which options granted are expected to remain outstanding. The risk-free interest rate is based on the yield from U.S. treasury bonds
with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. The Company uses
the simplified method for nonexecutive employees, due to insufficient historical exercise experience".
The fair value of options granted during 2022 was $
529
.
Options granted to employees and non-employees:
In 2023 no options were granted, neither to employees nor to
non-employees.
In the year ended December 31, 2022, the Company granted options
as follows:
Year ended December 31, 2022
Award
amount
Exercise
price
Vesting
period
Expiration
Employees
52,500
26.78
up
        to 4 years
10
years
Non-employees
2,000
26.78
Immediate
10
years
Total granted
54,500
F-81
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 11 — SHARE-BASED COMPENSATION:
(cont.)
Summary of status of the Company's nonvested
employee options:
The following table summarizes the number of
options outstanding for the years ended December 31, 2023 and December 31, 2022, and related information:
Number of
options
Weighted-
average
grant-date
fair
        value
price
Outstanding at December 31, 2022
52,858
$
9.59
Granted
—
$
—
Vested
(
19,945
)
$
9.56
Forfeited
—
$
—
Outstanding at December 31, 2023
32,913
$
9.61
Outstanding at December 31, 2021
4,464
$
7.67
Granted
52,500
$
9.63
Vested
(
1,558
)
$
7.10
Forfeited
(
2,548
)
$
8.56
Outstanding at December 31, 2022
52,858
$
9.59
Summary of status of the Company's
nonvested nonemployee options:
The following table summarizes the number of
options outstanding for the years ended December 31, 2023 and December 31, 2022, and related information:
Number of
options
Weighted-
average
grant-date
fair
        value
price
Outstanding at December 31, 2022
132
$
4.96
Granted
—
$
—
Vested
(
132
)
$
4.96
Forfeited
—
$
—
Outstanding at December 31, 2023
—
$
—
Outstanding at December 31, 2021
304
$
4.91
Granted
2,000
$
11.93
Vested
(
2,172
)
$
11.37
Forfeited
—
$
—
Outstanding at December 31, 2022
132
$
4.96
On December 31, 2023, there was $
284
of total unrecognized compensation cost related to unvested stock options granted under the Plan. That cost is expected to be recognized
over a weighted-average period of
2.22
years.
On December 31, 2022, there was $
414
of total unrecognized compensation cost related to unvested stock options granted under the Plan. That cost is expected to be recognized
over a weighted-average period of
3.20
years.
F-82
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 11 — SHARE-BASED COMPENSATION:
(cont.)
The share-based compensation expense by line item in the accompanying
consolidated statements of operations is summarized as follows:
Year ended
December 31
2023
2022
Research and development
$
78
$
60
General and administrative
52
65
$
130
$
125
NOTE 12 — FAIR VALUE MEASUREMENTS:
Financial instruments measured at fair value on a recurring
basis
The Company's assets and liabilities that are measured
at fair value as of December 31, 2023, and December 31, 2022, are classified in the tables below in one of the three categories
described in "Note 2 — Fair value measurement" above:
December 31, 2023
Level 3
Total
Financial Liabilities
Warrants to preferred shares
$
200
$
200
December 31, 2022
Level 3
Total
Financial Liabilities
Warrants to preferred shares
$
3
$
3
The following is a roll forward of the fair value of liabilities
classified under Level 3:
2023
2022
Warrants
Warrants
SAFE
Fair value at the beginning of the year
$
3
$
—
$
3,204
Issuance
111
1,020
—
Change in fair value
86
(
1,017
)
—
Conversion to equity
—
—
(
3,204
)
Fair value at the end of the year
$
200
$
3
$
—
The fair value of the Company's warrant liabilities as
of December 31, 2023 was estimated using a hybrid model in order to reflect two scenarios: (1) an IPO event (including de-SPAC
transaction) and (2) other liquidation events.
The IPO scenario (including de-SPAC transaction) was based on
management estimation regarding the expected value of the Company's entire equity at the IPO event (including de-SPAC transaction).
Valuation under this scenario was assessed using the probability-weighted expected return method (PWERM).
The valuation under the 'other liquidation events'
scenario was assessed using an option pricing model (OPM) by implementing a Monte Carlo Simulation, which treats the financial instruments
in the Company's equity as contingent claims whose future payoff depends on the Company's future equity value. The Company's
entire equity value in 2023 was calculated based, among others, on the financing round closest to the valuation date.
The fair value of the Company's warrant liabilities as
of December 31, 2022 was estimated using only the 'other liquidation events' scenario.
F-83
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 12 — FAIR VALUE MEASUREMENTS:
(cont.)
Application of these approaches and methodologies involves the
use of estimates, judgments and assumptions that are highly complex and subjective, such as those regarding discount rates, the selection
of comparable public companies, and the probability of and timing associated with possible future events.
The following table presents the main assumptions used in the
hybrid model for the periods presented:
December 31
2023
2022
Expected volatility
73.8
%
87.3
%
Assumptions regarding the price of the underlying shares:
Probability of an IPO scenario (including de-SPAC transaction)
25
%
—
Expected time to IPO (including de-SPAC transaction) (years)
0.414
—
Probability of other liquidation events
75
%
100
%
Expected time to liquidation (years)
2.75
3.00
Expected return on Equity
22
%
23
%
A significant increase in the expected volatility, or in the
probability of an IPO (including de-SPAC transaction) (in 2023), could each increase the fair value of the related instruments. A significant
decrease in the expected term of the warrants or expected time to IPO (including de-SPAC transaction), could each decrease the fair value
of related instruments. In combination, changes in these inputs could result in a significantly higher or lower fair value measurement
if the input changes were to be compounding, or could result in a minimally higher or lower fair value measurement if the input changes
were of opposite effects and consequently offset each other.
Financial instruments not measured at fair value
The carrying amounts of cash and cash equivalents, restricted
cash, receivables, trade payables and other liabilities approximate their fair value due to the short-term maturity of such instruments.
NOTE 13 — NET LOSS PER SHARE:
The following table sets forth the computation of basic and
diluted net loss per share attributable to ordinary shareholders for the periods presented (USD in thousands, except per share data):
Year ended
December 31
2023
2022
Numerator:
Net loss for the year
$
5,108
$
3,488
Net loss attributable to ordinary shareholders, basic and diluted:
$
4,942
$
3,215
Denominator:
Weighted-average shares used in computing net loss
        per share attributable to ordinary shareholders, basic and diluted
252,462
252,371
Net loss per share attributable to ordinary shareholders,
        basic and diluted
$
19.57
$
12.74
Basic loss per share is computed on the basis of the net loss
for the period divided by the weighted average number of ordinary shares outstanding during the period, and fully vested Pre-Funded options
for the Company's ordinary shares at an exercise price of $
0.01
or
0.01
NIS per share, as the Company considers these shares to be exercised for little to no additional consideration.
F-84
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 13 — NET LOSS PER SHARE:
(cont.)
As of December 31, 2023 and 2022, the basic loss per share calculation
included a weighted average number of
33,108
of fully vested Pre-Funded options. As the inclusion of shares of ordinary shares equivalents in the calculation would be anti-dilutive
for all periods presented, diluted net loss per share is the same as basic net loss per share.
The following instruments were not included in the computation
of diluted earnings per share because of their anti-dilutive effect:
●
Redeemable convertible preferred shares (see Note 9);
●
Warrants to purchase redeemable convertible preferred shares (see Note 8);
●
Simple agreements for future equity (see Note 7);
●
Share-based compensation issuable at substantial consideration (see Note 11).
NOTE 14 — TRANSACTIONS AND BALANCES WITH RELATED
PARTIES:
Transactions with related parties which are shareholders and
directors of the Company:
a.
Transactions:
Year ended
December 31
2023
2022
Share-based compensation included in research and development expenses
$
69
$
49
Share-based compensation included in general and administrative expenses
$
48
$
37
Financial expenses
$
83
$
—
b.
Balances:
December 31
2023
2022
Non-Current liabilities –
Warrants to preferred shares
$
186
$
—
NOTE 15 — SUBSEQUENT EVENT:
The Company's management has performed
an evaluation of subsequent events through May 9, 2024, the date the financial statements were available to be issued.
a.
On February 21, 2024, the Company entered into a business combination agreement with Moringa Acquisition
        Corp. (the "SPAC"), an exempted company incorporated under the Laws of the Cayman Islands whose class A ordinary shares (as
        well as other instruments) are listed for trade on the Nasdaq Global Market (NASDAQ: MACA), and April.M.G. Ltd. (the "April
        Merger Sub"), a limited liability company organized under the laws of the State of Israel and a wholly-owned subsidiary of the SPAC
        (the "Original BCA"). According to the Original BCA, April Merger Sub would merge with and into the Company, with the Company
        continuing as the surviving entity and a wholly-owned subsidiary of the SPAC, and with the SPAC continuing as a public company following
        the completion of the merger and with its securities continuing to be traded on Nasdaq.
F-85
SILEXION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
U.S. DOLLARS IN THOUSANDS
NOTE 15 — SUBSEQUENT EVENT
(cont.)
b.
On April 3, 2024, the SPAC and the Company restructured the transactions contemplated under the Original
        BCA by entering into the A&R BCA by and among Biomotion Sciences, a Cayman Islands exempted company (the "New Pubco"),
        August M.S. Ltd., an Israeli company and a wholly owned subsidiary of New Pubco (the "Merger Sub 1"), Moringa Acquisition
        Merger Sub Corp, a Cayman Islands exempted company and a wholly owned subsidiary of New Pubco (the "Merger Sub 2"), the SPAC
        and the Company. The A&R BCA amends and restates, in its entirety, the Original BCA.
Pursuant to the A&R BCA, Merger Sub 2 will merge with and
into the SPAC, with the SPAC continuing as the surviving company of such merger and a wholly-owned subsidiary of New Pubco (the "SPAC
Merger"), and Merger Sub 1 will merge with and into the Company, with the Company continuing as the surviving company of such merger
and a wholly-owned subsidiary of New Pubco (the "Acquisition Merger").
Upon the effectiveness of the SPAC Merger, each outstanding
SPAC Class A ordinary share and the sole outstanding SPAC Class B ordinary share will convert into an ordinary share of New
Pubco on a one-for-one basis, and each outstanding warrant to purchase
one
SPAC Class A ordinary share will convert into a warrant to purchase
one
New Pubco ordinary share, at the same exercise price.
Upon the effectiveness of the Acquisition Merger, each outstanding
ordinary share and preferred share of the Company will convert into such number of ordinary shares of New Pubco as is equal to the quotient
obtained by dividing (x) the quotient obtained by dividing (1) $
62,500,000
by (2) the number of fully diluted Company equity securities, by (y) $
10.00
(the "Company Equity Exchange Ratio"). Each outstanding Company warrant and Company option to purchase one Company share,
and Company restricted share unit (RSU) that may be potentially settled for one Company share, will become exercisable for, or will be
subject to settlement for (as applicable), such number of New Pubco ordinary shares as are equal to the Company Equity Exchange Ratio.
The exercise price per New Pubco ordinary share of each such converted Company options and Company warrants will be adjusted based on
dividing the existing per share exercise price by the Company Equity Exchange Ratio. The terms of vesting, exercise and/or settlement,
as applicable, of such converted options, warrants and RSUs shall remain the same following such conversion, except that the vesting of
each Company option will accelerate immediately prior to the Acquisition Merger, such that the New Pubco option into which it has been
converted will be fully vested.
The completion of the A&R BCA is subject to the satisfaction
of certain conditions, including obtaining the consent of the shareholders of each of the SPAC and the Company and the declaration of
effectiveness of a registration statement on form S-4 by the U.S. Securities and Exchange Commission in relation to issuance of New
Pubco ordinary shares to be issued or issuable to the SPAC's and the Company's respective security holders pursuant to the
A&R BCA. To facilitate the A&R BCA, the parties further entered into certain ancillary agreements.
The A&R BCA further imposes various restrictions on the
total liabilities which the SPAC may incur prior to closing, including the total indebtedness toward the sponsor of the SPAC, and the
terms on which such indebtedness will be repaid or converted, whereas such conversion, if and when it occurs, will further dilute the
holdings of all shareholders of New Pubco at that time, including the former shareholders of the Company.
F-86
Up
to              Ordinary Shares and accompanying
Ordinary
Warrants to Purchase up to              Ordinary Shares
Up
to             Pre-funded Warrants to Purchase up to          Ordinary Shares
and
accompanying Ordinary Warrants to Purchase up to              Ordinary Shares
Placement
Agent Warrants to Purchase up to            Ordinary Shares
Up
to           Ordinary Shares Issuable Upon Exercise of the Ordinary Warrants, Pre-
funded
Warrants and Placement Agent Warrants
,
2024
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item
13. Other Expenses of Issuance and Distribution.
The
following table sets forth all costs and expenses, other than underwriting discounts and commissions, payable by us in connection with
the sale of the securities being registered. All amounts shown are estimates, except for the SEC registration fee and FINRA fee.
Amount
SEC registration fee
$
FINRA fee
$
Accountants' fees
        and expenses
$
Legal fees and expenses
$
Printing fees
$
Miscellaneous expenses
$
Total expenses (other
        than Placement Agent's fees)
$
We
will pay all of the expenses related to the distribution of the securities being offered under this prospectus. Each of the above amounts
(with the exception of the SEC registration fee and FINRA fee) are estimates.
Item
14. Indemnification of Directors and Officers.
Cayman
Islands law does not limit the extent to which a company's memorandum and articles of association may provide for indemnification
of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy,
such as to provide indemnification against willful default, willful neglect, actual fraud or the consequences of committing a crime. our
amended and restated memorandum and articles of association provide for indemnification of its officers and directors to the maximum extent
permitted by law, including for any liability incurred in their capacities as such, except through their own actual fraud, willful default
or willful neglect. we have purchased a policy of directors' and officers' liability insurance that insures its officers and
directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures it against its obligations
to indemnify its officers and directors.
We
believe that these provisions and the insurance are necessary to attract and retain talented and experienced officers and directors.
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us
pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act and is therefore unenforceable.
we
have entered into indemnity agreements with each of its officers and directors. These agreements require New Silexion to indemnify these
individuals and entity to the fullest extent permitted under applicable Cayman Islands law and to hold harmless, exonerate and advance
expenses incurred as a result of any proceeding against them as to which they could be indemnified.
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons
pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense
of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the court of
appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and
will be governed by the final adjudication of such issue.
The
proposed form of securities purchase agreement that we may enter into with certain investors in this offering (which, if entered into,
will be filed as an exhibit to this registration statement) provides for indemnification by the underwriters of the Company and its officers
and directors, and by the Company of the Placement Agent, for certain liabilities arising under the Securities Act or otherwise in connection
with this offering.
II-1
Item
15. Recent Sales of Unregistered Securities.
Since
our formation on April 2, 2024, we have sold securities in transactions not registered under the Securities Act as described below:
Initial
Issuance Upon Formation
Upon
its formation on April 2, 2024, the Company initially sold one ordinary share to its initial shareholder, Maples Corporate Services Limited,
in exchange for corporate services provided by that initial shareholder. That issuance was effected without registration under the Securities
Act in an offshore transaction pursuant to the exemption provided by Regulation S under the Securities Act.
Unregistered
Issuances Upon Closing of Business Combination
Issuance
of EarlyBird Convertible Note and Underlying Ordinary Shares
Prior
to the Closing of the Business Combination, on August 11, 2204, Moringa reached agreement with EarlyBird on the reduction, to $1.6 million,
in the aggregate, of the fee payable to EarlyBird under the Business Combination Marketing Agreement, dated as of February 19, 2021, entered
into by Moringa with EarlyBird at the time of Moringa's initial public offering. As part of that agreement, New Silexion issued
to EarlyBird the EarlyBird Convertible Note, in an amount of $1.25 million to be paid by New Silexion to EarlyBird in cash and/or via
conversion of outstanding amounts into ordinary shares of New Silexion, which convertible note bears interest at a rate of 6% per annum
and is due on December 31, 2025.
EarlyBird
may elect, at its sole discretion, at any time on or prior to the maturity date of the EarlyBird Convertible Note, to convert all or part
of the then outstanding principal and/or accrued interest under the note into New Silexion ordinary shares, at a per share conversion
price equal to 95% of the volume weighted average price of a New Silexion ordinary share for the five trading days immediately prior to
the date of our receipt of a conversion notice, provided, however, that New Silexion is not required to issue, and EarlyBird may not elect
to convert the principal and/or accrued interest into an aggregate number of New Silexion ordinary shares that would exceed the maximum
number of ordinary shares permitted by Section 5635 of the Nasdaq Listing Rules to be issued without the approval of our shareholders,
unless such approval is obtained.
Under
the EarlyBird Convertible Note, New Silexion agreed to promptly file a registration statement with the SEC covering the resale of the
ordinary shares that may be issued upon conversion of the note and use its best efforts to have such registration statement declared effective
as soon thereafter as possible. In the event such registration statement is not declared effective by the SEC within 180 days from the
date hereof, then an event of default shall have occurred under the note, triggering all amounts under the note to become due and payable
immediately and automatically.
The
issuance of the EarlyBird Convertible Note and the potential issuance of New Silexion ordinary shares upon conversion of amounts outstanding
under the EarlyBird Convertible Note, has been, and will be (respectively), effected in reliance upon the exemption from registration
provided under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act in a transaction not requiring registration under
the Securities Act.
II-2
Issuance
of PIPE Financing Shares
As
described under "
Certain Relationships and Related Party Transactions—PIPE Financing
"
above, in connection with, and immediately prior to the Closing of, the Business Combination, Moringa raised $2.0 million via the PIPE
Financing, whereby Moringa sold to the PIPE Investor 200,000 newly issued Moringa Class A ordinary shares at a price of $10.00 per share,
pursuant to the PIPE Agreement. Upon the Closing of the Business Combination, the Company issued 200,000 New Silexion ordinary shares
to the PIPE Investor upon conversion of those 200,000 Moringa Class A ordinary shares.
The
issuance of those 200,000 PIPE Shares by the Company to the PIPE Investor (a Cayman Islands exempted limited partnership) was effected
without registration under the Securities Act in an offshore transaction pursuant to the exemption provided by Regulation S under the
Securities Act.
Issuances
of Equity Line of Credit Financing Shares to White Lion
As
described above in this registration statement under "
Management's Discussion and Analysis
of Financial Condition and Results of Operations— Recent Developments—ELOC Financing
", also in connection with
the Closing of the Business Combination, New Silexion entered into the White Lion Purchase Agreement, under which it will be able to request
to sell to White Lion, and White Lion will be required to purchase, under an equity line of credit, up to $15.0 million of New Silexion
ordinary shares (the "
Purchase Notice Shares
") from time to time after the Closing,
up until December 31, 2025 (unless the agreement is terminated sooner), subject to certain limitations and conditions as described therein.
New Silexion is furthermore required to issue to White Lion ordinary shares having a value equal to $337,500, as a commitment fee under
the White Lion Purchase Agreement (the "
Commitment Shares
"). The issuance of all ordinary
shares to White Lion under the White Lion Purchase Agreement has been and will be effected in reliance upon the exemption from registration
provided under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act in a transaction not requiring registration under
the Securities Act.
Through
October 15, 2024, we have issued and sold an aggregate of 4,059,418 ordinary shares (which includes both the Commitment Shares and some
Purchase Notice Shares) to White Lion under the White Lion Purchase Agreement for aggregate proceeds to us of approximately $2.3 million.
Issuance
of Amended and Restated Sponsor Promissory Note and Underlying Shares to Moringa Sponsor
As
described above in this registration statement under "
Certain Relationships and Related Party Transactions
—
Amended and Restated Sponsor Promissory Note
", upon the Closing of the Business Combination,
New Silexion issued to the Sponsor, in amendment and restatement, and replacement, in their entirety, of all existing promissory notes
issued by Moringa to the Sponsor from Moringa's initial public offering until the Closing, the A&R Sponsor Promissory Note in
an amount of $3,433,000, which matures on February 15, 2027. Amounts outstanding under the A&R Sponsor Promissory Note may be repaid
only by way of conversion by either the Company or the Sponsor into ordinary shares, under various circumstances.
The
issuance by the Company to the Sponsor (a Cayman Islands exempted limited partnership) of the A&R Sponsor Promissory Note, and the
prospective issuance by the Company to the Sponsor of underlying Note Shares, was or will be (as applicable), effected without registration
under the Securities Act in an offshore transaction pursuant to the exemption provided by Regulation S under the Securities Act.
None
of the foregoing transactions described in this "Recent Sales of Unregistered Securities" section involved any underwriters,
underwriting discounts or commissions, or any public offering. The recipients of the securities in each of these transactions represented
their intentions to acquire the securities for investment only and not with a view to or for sale in connection with the distribution
thereof (absent registration under the Securities Act), and appropriate legends were placed on the securities certificates issued in these
transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities
were made without any general solicitation or advertising.
II-3
Item 16.
Exhibits and Financial Statement Schedules
Exhibit
        No.
Description
2.1.1†
Amended
        and Restated Business Combination Agreement, dated as of April 3, 2024, by and among Biomotion Sciences (now known as Silexion Therapeutics
        Corp), August M.S. Ltd., Moringa Acquisition Merger Sub Corp, Silexion Therapeutics Ltd. and Moringa Acquisition Corp (incorporated by
        reference to Exhibit 2.1 to Moringa Acquisition Corp's Current Report on Form 8-K, filed with the SEC on April 3, 2024)
2.1.2
Waiver
        letter, dated June 18, 2024, under Amended and Restated Business Combination Agreement (incorporated by reference to Exhibit 10.1 to Moringa
        Acquisition Corp's Current Report on Form 8-K filed with the SEC on June 24, 2024)
2.2
Plan
        of Merger for merger of Moringa Acquisition Corp and Moringa Acquisition Merger Sub Corp (incorporated by reference to Exhibit 2.2 to
        Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)
3.1
Amended
        and Restated Memorandum and Articles of Association of Silexion Therapeutics Corp (formerly Biomotion Sciences) (incorporated by reference
        to Exhibit 3.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)
4.1
Warrant
        Agreement, dated February 19, 2021, by and between Moringa Acquisition Corp and Continental Stock Transfer & Trust Company,
        as warrant agent (incorporated by reference to Exhibit 4.1 to Moringa Acquisition Corp's Current Report on Form 8-K, filed
        with the SEC on February 22, 2021)
4.2
Assignment,
        Assumption and Amendment Agreement, dated as of August 15, 2024, by and among Moringa Acquisition Corp, Silexion Therapeutics Corp (formerly
        known as Biomotion Sciences) and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 to Silexion
        Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)
4.3**
Form of Ordinary Warrant
        to be sold in the offering
4.4**
Form of Pre-Funded Warrant
        to be sold in the offering
4.5**
Form of Placement Agent
        Warrant
5.1**
Opinion of Conyers Dill &
        Pearman LLP, Cayman legal counsel to Silexion Therapeutics Corp.
5.2**
Opinion of Greenberg
        Traurig, LLP, United States legal counsel to Silexion Therapeutics Corp.
10.1.1
Final
        invoice issued by EarlyBirdCapital, Inc. to Moringa Acquisition Corp under the Business Combination Marketing Agreement, dated February
        16, 2021, by and between EarlyBirdCapital, Inc. and Moringa Acquisition Corp (incorporated by reference to Exhibit 10.1.1 to Silexion
        Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)
10.1.2
Convertible
        Promissory Note, dated August 15, 2024, in an amount of $1,250,000, issued by Silexion Therapeutics Corp (formerly known as Biomotion
        Sciences) to EarlyBirdCapital, Inc. (incorporated by reference to Exhibit 10.1.2 to Silexion Therapeutics Corp's Current Report
        on Form 8-K filed with the SEC on August 21, 2024)
10.2
Subscription
        Agreement, dated August 15, 2024, by and among Moringa Acquisition Corp, Silexion Therapeutics Corp (formerly known as Biomotion Sciences)
        and Greenstar, L.P. (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp's Current Report on Form 8-K filed
        with the SEC on August 21, 2024)
10.3.1
Ordinary
        Share Purchase Agreement, dated August 13, 2024 and effective as of the closing date of the Business Combination, by and between Silexion
        Therapeutics Corp (formerly known as Biomotion Sciences) and White Lion Capital, LLC (incorporated by reference to Exhibit 10.3.1 to Silexion
        Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)
10.3.2
Registration
        Rights Agreement, dated August 13, 2024 and effective as of the closing date of the Business Combination, by and between Silexion Therapeutics
        Corp (formerly known as Biomotion Sciences) and White Lion Capital, LLC (incorporated by reference to Exhibit 10.3.2 to Silexion Therapeutics
        Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)
10.4
Amended
        and Restated Registration Rights and Lock-Up Agreement, dated August 14, 2024 and effective as of the Closing Date, by and among Silexion
        Therapeutics Corp (formerly known as Biomotion Sciences), Moringa Acquisition Corp, Moringa Sponsor, L.P., the distributees of Sponsor
        Investment Shares that were issuable to Moringa Sponsor, L.P., EarlyBirdCapital, Inc., certain of Silexion Therapeutics Ltd.'s pre-Business
        Combination shareholders and Greenstar, L.P. (incorporated by reference to Exhibit 10.4 to Silexion Therapeutics Corp's Current
        Report on Form 8-K filed with the SEC on August 21, 2024)
10.5
Amended
        and Restated Promissory Note, dated August 15, 2024, issued by Silexion Therapeutics Corp (formerly known as Biomotion Sciences) to Moringa
        Sponsor, L.P. (incorporated by reference to Exhibit 10.5 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the
        SEC on August 21, 2024)
10.6
Form
        of Director and Officer Indemnification Agreement, dated August 15, 2024, by and between Silexion Therapeutics Corp (formerly known as
        Biomotion Sciences) and each of its executive officers and directors (incorporated by reference to Exhibit 10.6 to Silexion Therapeutics
        Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)
10.11.1#
Employment
        Agreement, dated April 1, 2022, by and between Silexion Therapeutics Ltd. and Ilan Hadar (incorporated by reference to Exhibit 10.12.1
        to Amendment No. 3 to the Company's Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC on July 12, 2024)
.
10.11.2#
Amendment
        No. 1 to Employment Agreement, dated May 2024, by and between Silexion Therapeutics Ltd. and Ilan Hadar ((incorporated by reference to
        Exhibit 10.12.2 to Amendment No. 3 to the Company's Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC
        on July 12, 2024)
10.12#
Silexion
        Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to Silexion Therapeutics Corp's Current
        Report on Form 8-K filed with the SEC on August 21, 2024)
10.13#
Silexion
        Therapeutics Ltd. 2023 Equity Incentive Plan
(incorporated by reference to Exhibit 10.13 to Silexion Therapeutics Corp's
        Registration Statement on Form S-1 (File No. 333-282017), filed with the SEC on September 10, 2024)
10.14#
Silexion
        Therapeutics Ltd. 2013 Share Option Plan
(incorporated by reference to Exhibit 10.14 to Silexion Therapeutics Corp's
        Registration Statement on Form S-1 (File No. 333-282017), filed with the SEC on September 10, 2024)
10.15**
Form of Securities Purchase
        Agreement
21.1
List
        of Subsidiaries (incorporated by reference to Exhibit 21.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with
        the SEC on August 21, 2024)
23.1*
Consent
        of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting
        firm of Moringa Acquisition Corp
23.2*
Consent
        of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting
        firm of Silexion Therapeutics Ltd.
23.3**
Consent of Conyers Dill
        & Pearman LLP (included in Exhibit 5.1)
23.4**
Consent of Greenberg
        Traurig, LLP  (included in Exhibit 5.2)
24.1*
Power
        of attorney (included on the signature page to this registration statement)
107*
Filing
        fee table
*
Filed
        herewith.
**
To be filed by amendment
†
Certain
        of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees
        to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.
#
Indicates
        management contract or compensatory plan, contract or arrangement.
Item 17.
Undertakings
The
undersigned Registrant hereby undertakes
:
(a)
To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i)
To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
II-4
(ii)
To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration
Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration
Fee" table in the effective registration statement; and
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or
any material change to such information in this Registration Statement.
(b)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment that contains
a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of
such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.
(d)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule
424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than
prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it
is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of
the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus
that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede
or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made
in any such document immediately prior to such date of first use.
(e)
That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications,
(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
424;
(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
the undersigned registrant;
(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and
(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons
of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that
a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director,
officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by them is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.
II-5
SIGNATURES
Pursuant
to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in Ramat Gan, Israel, on October 31, 2024.
SILEXION
        THERAPEUTICS CORP
By:
/s/
        Ilan Hadar
Name:
Ilan
        Hadar
Title:
Chairman
        and Chief Executive Officer
POWER
OF ATTORNEY
KNOW
ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ilan Hadar and Mirit Horenshtein
Hadar, and each of them, as his true and lawful agents, proxies and attorneys-in-fact, with full power of substitution and resubstitution,
for him or her and in his or her name, place and stead, in any and all capacities, to (i) act on, sign and file with the Securities and
Exchange Commission any and all amendments (including post-effective amendments) to this registration statement together with all schedules
and exhibits thereto and any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended,
together with all schedules and exhibits thereto, (ii) act on, sign and file such certificates, instruments, agreements and other documents
as may be necessary or appropriate in connection therewith, (iii) act on and file any supplement to any prospectus included in this registration
statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933,
as amended, and (iv) take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes
as he might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of
his substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities
and on the dates indicated.
Signature
Title
Date
/s/
        Ilan Hadar
Chairman
        and Chief Executive Officer
October 31,
        2024.
Ilan
        Hadar
(Principal
        Executive Officer)
/s/
        Mirit Horenshtein Hadar
Chief
        Financial Officer and Secretary
October
        31, 2024.
Mirit
        Horenshtein Hadar
(Principal
        Financial and Accounting Officer)
/s/
        Dror J. Abramov
Director
October
        31, 2024.
Dror
        J. Abramov
/s/
        Ruth Alon
Director
October
        31
,
2024.
Ruth
        Alon
/s/
        Ilan Levin
Director
October
        31
,
2024.
Ilan
        Levin
/s/
        Avner Lushi
Director
October
        31
,
2024.
Avner
        Lushi
/s/
        Shlomo Noy
Director
October
        31
,
2024.
Shlomo
        Noy
II-6
AUTHORIZED
REPRESENTATIVE
Pursuant
to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative of the Registrant in
the United States, has signed registration statement in Newark, Delaware, on October 31, 2024.
PUGLISI &
        ASSOCIATES
By:
/s/
        Donald J. Puglisi
Name:
Donald
        J. Puglisi
Title:
Authorized
        Representative
II-7